<?xml version="1.0"?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">6011</journal-id>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">29670290</article-id>
      <article-id pub-id-type="pmc">6030568</article-id>
      <article-id pub-id-type="doi">10.1038/s41586-018-0043-0</article-id>
      <article-id pub-id-type="manuscript">NIHMS947517</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Renewing Felsenstein&#x2019;s Phylogenetic Bootstrap in the Era of
Big Data</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lemoine</surname>
            <given-names>F.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Domelevo Entfellner</surname>
            <given-names>J.-B.</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wilkinson</surname>
            <given-names>E.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Correia</surname>
            <given-names>D.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>D&#xE1;vila Felipe</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Oliveira</surname>
            <given-names>T.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gascuel</surname>
            <given-names>O.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A6">6</xref>
          <xref ref-type="author-notes" rid="FN1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
<label>1</label>Unit&#xE9; Bioinformatique Evolutive, C3BI USR 3756, Institut
Pasteur &amp; CNRS, Paris, France</aff>
      <aff id="A2">
<label>2</label>Hub Bioinformatique et Biostatistique, C3BI USR 3756, Institut
Pasteur &amp; CNRS, Paris, France</aff>
      <aff id="A3">
<label>3</label>Department of Computer Science &amp; South African National
Bioinformatics Institute, University of the Western Cape, Bellville 7535, Cape Town,
South Africa</aff>
      <aff id="A4">
<label>4</label>KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP),
School of Laboratory Medicine and Medical Sciences, College of Health Sciences,
University of KwaZulu-Natal, Durban, South Africa</aff>
      <aff id="A5">
<label>5</label>Centre for the AIDS Programme of Research in South Africa (CAPRISA),
University of KwaZulu-Natal, Durban, South Africa</aff>
      <aff id="A6">
<label>6</label>M&#xE9;thodes et Algorithmes pour la Bioinformatique, IBC - LIRMM
UMR 5506, Universit&#xE9; de Montpellier &amp; CNRS, Montpellier,
France</aff>
      <author-notes>
        <corresp id="FN1"><label>*</label><bold>Correspondence and requests for materials should be
addressed to:</bold> Olivier GASCUEL, Unit&#xE9; Bioinformatique
Evolutive, C3BI USR 3756, CNRS &amp; Institut Pasteur, Paris, France,
<ext-link ext-link-type="uri" xlink:href="https://research.pasteur.fr/en/member/">https://research.pasteur.fr/en/member/</ext-link>,
<email>olivier.gascuel@pasteur.fr</email></corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>10</day>
        <month>5</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>4</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>10</month>
        <year>2018</year>
      </pub-date>
      <volume>556</volume>
      <issue>7702</issue>
      <fpage>452</fpage>
      <lpage>456</lpage>
      <!--elocation-id from pubmed: 10.1038/s41586-018-0043-0-->
      <permissions>
        <license>
          <license-p>Users may view, print, copy, and download text and data-mine the
content in such documents, for the purposes of academic research, subject
always to the full Conditions of use: <uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
        </license>
      </permissions>
      <abstract>
        <p id="P1">Felsenstein&#x2019;s article describing the application of the bootstrap
to evolutionary trees is one of the most cited papers of all time. The bootstrap
method, based on resampling and replications, is used extensively to assess the
robustness of phylogenetic inferences. However, increasing numbers of sequences
are now available for a wide variety of species, and phylogenies with hundreds
or thousands of taxa are becoming routine. In that framework,
Felsenstein&#x2019;s bootstrap tends to yield very low supports, especially on
deep branches. We propose a new version of phylogenetic bootstrap, in which the
presence of inferred branches in replications is measured using a gradual
&#x201C;transfer&#x201D; distance, as opposed to the original version using a
binary presence/absence index. The resulting supports are higher, while not
inducing falsely supported branches. Our method is applied to large mammal, HIV,
and simulated datasets, for which it reveals the phylogenetic signal, while
Felsenstein&#x2019;s bootstrap fails to do so.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p id="P2">The bootstrap is a widely used statistical method to study the robustness, bias
and variability of numerical estimates<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup>. It involves resampling with replacement
from the original dataset to obtain replications of the original estimate, and then
typically to compute the variance and distribution of this estimate. In 1985, Joseph
Felsenstein proposed the application of the bootstrap to assess the robustness (or
repeatability) of phylogenetic trees<sup><xref rid="R3" ref-type="bibr">3</xref></sup>.
Given a sequence alignment and a reference tree inferred on it, the procedure is: (i)
resample, with replacement, the sites of the alignment to obtain pseudo-alignments of
the same length, (ii) infer pseudo-trees using the same inference method, and (iii)
measure the support of every branch in the reference tree as the proportion of
pseudo-trees containing that branch. The usefulness, simplicity and interpretability of
this method made it extremely popular in evolutionary studies, to the point that it is
generally required for publication of tree estimates in a wide variety of domains
(molecular biology, genomics, systematics, ecology, epidemiology, etc.).
Felsenstein&#x2019;s article has been cited more than 32,000 times and is ranked in the
top 100 of the most cited scientific papers of all time<sup><xref rid="R4" ref-type="bibr">4</xref></sup>. However, the use of Felsenstein&#x2019;s bootstrap was
questioned on biological grounds, notably regarding the assumptions of site independence
and homogeneity<sup><xref rid="R5" ref-type="bibr">5</xref></sup>. Moreover, the
statistical meaning of Felsenstein&#x2019;s bootstrap proportions (FBPs) has been the
subject of intense debate<sup><xref rid="R6" ref-type="bibr">6</xref></sup>, the main
questions being whether FBPs can be seen as the confidence levels of some test, and
whether or not they are biased<sup><xref rid="R7" ref-type="bibr">7</xref>&#x2013;<xref rid="R10" ref-type="bibr">10</xref></sup>. Several methods<sup><xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R11" ref-type="bibr">11</xref>&#x2013;<xref rid="R12" ref-type="bibr">12</xref></sup> have been
proposed to correct FBP to better agree with standard ideas of confidence levels and
hypothesis testing. These works greatly contributed to the understanding of what
Felsenstein&#x2019;s bootstrap is and what it is not. However, FBP correction methods
are limited to relatively small data sets for mathematical and computational reasons
(e.g. double bootstrapping), and the original method is still highly used
(~2,000 citations in 2016). As stated by Soltis et al.<sup><xref rid="R13" ref-type="bibr">13</xref></sup>: &#x201C;consensus has been reached among
practitioners, if not among statisticians and theoreticians&#x201D;, and &#x201C;many
systematists have adopted Hillis and Bull&#x2019;s &#x201C;70%&#x201D;
value<sup><xref rid="R7" ref-type="bibr">7</xref></sup> as an indication of
support&#x201D;. The alternatives to FBPs are the Bayesian posterior probabilities of
the tree branches<sup><xref rid="R14" ref-type="bibr">14</xref></sup>, which are
difficult to obtain with large datasets for computational reasons, and the approximate
branch supports<sup><xref rid="R15" ref-type="bibr">15</xref>&#x2013;<xref rid="R16" ref-type="bibr">16</xref></sup>, which are fast but provide only a
local view. The bootstrap is also computationally heavy, but is easily parallelized and
fast algorithms have been designed<sup><xref rid="R17" ref-type="bibr">17</xref>&#x2013;<xref rid="R18" ref-type="bibr">18</xref></sup>.</p>
    <p id="P3">It is commonly acknowledged<sup><xref rid="R13" ref-type="bibr">13</xref></sup>
that Felsenstein&#x2019;s bootstrap is not appropriate for large datasets containing
hundreds or thousands of taxonomic units (taxa), which are now common thanks to
high-throughput sequencing technologies. While such datasets generally contain a lot of
phylogenetic information, the bootstrap proportions tend to be low, especially when the
tree is inferred from a single gene, or only a few genes, as illustrated in <xref ref-type="fig" rid="F1">Fig. 1a</xref> with a dataset of ~9,000 HIV-1 group
M <italic>DNA polymerase</italic> (<italic>pol</italic>) sequences. The strongest signal
in such a phylogeny generally corresponds to the deep branching of the subtypes. This
signal is immediately visible here, and in agreement with the common belief about
subtype branching<sup><xref rid="R19" ref-type="bibr">19</xref></sup>, but some of the
subtypes are not supported (A, B, D, G) and their branching is not supported either
(e.g. the grouping of C and H). When using a medium-sized dataset of ~550
randomly selected sequences, the FBPs are higher, with most subtypes supported at
70% or more. However, their deep branching is still unresolved (<xref ref-type="fig" rid="F9">Fig. ED5</xref>).</p>
    <p id="P4">The reason for such degradation is explained by the core methodology of
Felsenstein&#x2019;s bootstrap. A replicated branch must match a reference branch
exactly to be accounted for in the FBP value. A difference of just one taxon (highly
likely with large datasets) is sufficient for the replicated branch to be counted absent
while it is nearly identical to the reference branch<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup>. There are many
biological and computational reasons for the existence of &#x201C;rogue&#x201D; taxa
with unstable phylogenetic positions: convergence, recombination, sequence and tree
errors, etc. The standard approach<sup><xref rid="R20" ref-type="bibr">20</xref>&#x2013;<xref rid="R24" ref-type="bibr">24</xref></sup> is to remove
these taxa and relaunch the analysis, but this is statistically questionable and
computationally expensive. Moreover, with a large number of taxa and a low number of
sites, the phylogenetic signal is weak. Then, the inferred branches are likely to have
errors and a large fraction of taxa may be unstable, even in the absence of model
misspecification of any sort, and without long branches.</p>
    <sec id="S1">
      <title>A statistical approach</title>
      <p id="P5">Our approach has a simple but sound statistical basis, partly inspired by
Sanderson&#x2019;s monophyly index<sup><xref rid="R25" ref-type="bibr">25</xref></sup> and our work on gene clusters obtained from expression
data<sup><xref rid="R26" ref-type="bibr">26</xref></sup> (both are tailored
for rooted trees). We replace the branch presence proportion (<italic>i.e.</italic>
the expectation of a {0,1} indicator function) of Felsenstein&#x2019;s bootstrap,
by the expectation of a refined, gradual function in the [0,1] range, quantifying
the branch presence in the bootstrap trees. In doing so, we admit that the inferred
branch is not simply correct or incorrect (as with FBP), but that it may contain
some errors. Our ultimate aim is to quantify these errors and the presence of the
inferred branch in the true tree, using the plug-in principle (see below). We use
the &#x201C;transfer&#x201D; distance<sup><xref rid="R27" ref-type="bibr">27</xref>&#x2013;<xref rid="R29" ref-type="bibr">29</xref></sup>, where
the distance &#x3B4;(<italic>b,b</italic>*) between a branch <italic>b</italic> of
the reference tree <italic>T</italic> and a branch <italic>b</italic>* of a
bootstrap tree <italic>T</italic>* is equal to the number of taxa that must be
transferred (or removed), in order to make both branches identical
(<italic>i.e.</italic> both split identically the set of taxa). To measure the
presence of <italic>b</italic> in <italic>T</italic>*, we search the branch in
<italic>T</italic>* that is closest to <italic>b</italic> and use the
&#x201C;transfer index&#x201D; &#x3D5;(<italic>b,T</italic>*) =
<italic>Min</italic><sub><italic>b</italic>*&#x2208;<italic>T</italic>*</sub>{&#x3B4;(<italic>b,b</italic>*)}.
This index has several important and useful properties. Let <italic>l</italic> be
the number of taxa. Any branch <italic>b</italic> splits the taxa into two subsets;
let <italic>p</italic> be the size of the smaller subset induced by
<italic>b</italic>. We have (Methods): <list list-type="simple" id="L1"><list-item><p id="P6">&#x3D5;(<italic>b,T</italic>*) = 0 if and only if
<italic>b</italic> belongs to <italic>T</italic>*;</p></list-item><list-item><p id="P7">&#x3D5;(<italic>b,T</italic>*) &#x2264; <italic>p</italic>
&#x2212; 1;</p></list-item><list-item><p id="P8">&#x3D5;(<italic>b,T</italic>*)/(<italic>p</italic> &#x2212; 1)
is very close to 1 when <italic>T</italic>* is random and
<italic>l</italic> is large (say &gt;100);</p></list-item><list-item><p id="P9">&#x3D5;(<italic>b,T</italic>*) is computed recursively in time
proportional to <italic>l</italic>, just as FBP.</p></list-item></list>Based on these properties, we define the transfer bootstrap expectation (TBE)
as: <disp-formula id="FD1"><mml:math id="M1" display="block" overflow="scroll"><mml:mtext>TBE</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:mfrac><mml:mover><mml:mrow><mml:mi mathvariant="normal">&#x3D5;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>T</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:math></disp-formula>where the numerator is the average transfer index
among all bootstrap trees. It is easily seen that TBE ranges from 0 to 1, where 0
means that the bootstrap trees are random regarding <italic>b</italic>, and 1 means
that <italic>b</italic> appears in all bootstrap trees. Moreover, considering the
same set of bootstrap trees, TBE(<italic>b</italic>) is necessarily larger than
FBP(<italic>b</italic>) and the difference is substantial for deep branches,
while TBE(<italic>b</italic>) = FBP(<italic>b</italic>) when <italic>b</italic>
defines a (shallow) &#x201C;cherry&#x201D; (i.e. <italic>p</italic> = 2).
Importantly, we shall see that TBE supports very few branches showing substantial
contradictions with the true tree, when used with common thresholds, typically 70%<sup><xref rid="R7" ref-type="bibr">7</xref></sup> or higher (<xref ref-type="fig" rid="F2">Fig. 2c&#x2013;d</xref>, <xref ref-type="fig" rid="F6">ED2</xref>&#x2013;<xref ref-type="fig" rid="F7">ED3</xref>, <xref ref-type="fig" rid="F11">ED7</xref>&#x2013;<xref ref-type="fig" rid="F12">ED8</xref>).</p>
      <p id="P10">All these properties are highly desirable: easy computation, higher supports
than FBP, low number of falsely supported branches. Moreover, TBE has a simple and
natural interpretation; for instance, with <italic>l</italic> = 1, 000 and
<italic>p</italic> = 200, TBE(<italic>b</italic>) = 95% means that, on
average, (200 &#x2212; 1) &#xD7; 0.05 &#x2248; 10 taxa have to be transferred
to recover <italic>b</italic> in bootstrap replicate trees. Moreover, we can define
an instability score for each taxon, based on the number of times it is transferred
in TBE computations. This interpretation is radically different from that of FBP,
where <italic>b</italic> is assessed globally as correct or erroneous. With TBE,
nearly correct branches will also be likely supported.</p>
      <p id="P11">TBE uses the same resampling with replacement procedure as FBP, and thus
inherits some of its statistical properties<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R6" ref-type="bibr">6,9</xref></sup>, as well as usual
properties of the bootstrap method<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup>. Notably, TBE relies on the same
assumptions as FBP regarding site independence and homogeneity, but these
assumptions can be relaxed<sup><xref rid="R6" ref-type="bibr">6</xref></sup>, for
instance using block bootstrapping<sup><xref rid="R30" ref-type="bibr">30</xref></sup>. Just like FBP<sup><xref rid="R3" ref-type="bibr">3</xref></sup>, TBE(<italic>b</italic>) cannot be interpreted as the
probability for the branch <italic>b</italic> to belong to the true phylogeny. While
deep mathematical approaches<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R9" ref-type="bibr">9</xref>&#x2013;<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> have been
proposed to connect FBP to hypothesis-testing theory, TBE should not be interpreted
as the confidence level of some statistical test (with null and alternative
hypotheses, distribution of test statistics under the null, etc.). TBE is better and
more simply interpreted in terms of repeatability: TBE(<italic>b</italic>) estimates
the extent by which branches identical or similar to <italic>b</italic> would be
recovered when applying the same tree inference method to a new sample of the same
size drawn from the same site distribution as the original sample. With large
samples, the empirical distribution obtained from observed data comes close to the
(unknown) underlying distribution of this data, and sampling with replacement in the
empirical distribution is asymptotically equivalent to drawing samples from the
underlying distribution<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup>. The convergence rate is unknown
with models as complex as the ones used in phylogenetics, but our simulation results
show that moderate sample sizes suffice to obtain good approximations (<xref ref-type="fig" rid="F14">Fig. ED10</xref>). When the sample size is extremely
large, as in phylogenomic studies using genome-scale sequence alignments<sup><xref rid="R32" ref-type="bibr">32</xref></sup>, both FBP and TBE are expected to
be nearly equal to 1 for all branches. Again, this should not be interpreted in
terms of absolute truth regarding the phylogenetic inferences, but it simply
reflects the closeness of the empirical and underlying distributions and the very
small variability of tree estimates. In fact, a high level of repeatability is
necessary to trust phylogenetic inferences, but it may be not sufficient. As quoted
by Felsenstein<sup><xref rid="R3" ref-type="bibr">3</xref></sup>, the bootstrap
&#x201C;may be misleading if the method used to infer phylogenies is
inconsistent&#x201D;. This applies both to FBP and TBE, and typically to inference
methods subject to long-branch attraction. With a consistent, unbiased inference
method, we expect the plug-in principle1<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> to apply,
stating that the distribution of the distance between the true tree and the inferred
tree can be well-approximated by the distribution of the distance between the
inferred and bootstrap trees. Using both real and simulated data, we shall see that
this principle does apply with maximum likelihood estimation, a typically consistent
phylogenetic inference method<sup><xref rid="R33" ref-type="bibr">33</xref></sup>.
In this setting, TBE informs us regarding the (transfer, quartet-based) distance
between the inferred branch and the true tree, and rarely supports poor branches.
Moreover, the ability of TBE to identify rogue taxa makes it possible to study them
further, understand why they are phylogenetically unstable, and revise the branch
supports.</p>
    </sec>
    <sec id="S2">
      <title>Analysis of mammal data</title>
      <p id="P12">We first studied the advantage of TBE on a large phylogeny of 1,449 mammals,
obtained from a usual barcoding marker (COI-5P). The reference and bootstrap trees
were inferred by maximum likelihood from the protein alignment (527 sites) using
both FastTree<sup><xref rid="R34" ref-type="bibr">34</xref></sup> and RAxML with
rapid bootstrap<sup><xref rid="R17" ref-type="bibr">17</xref></sup> to check that
similar conclusions were drawn with different inference methods. To study the impact
of the number of taxa, we randomly selected small (22 taxa) and medium (181 taxa)
datasets and performed the same analyses. The results were compared to the NCBI
taxonomy<sup><xref rid="R35" ref-type="bibr">35</xref></sup>, which
represents current thinking about mammals&#x2019; evolutionary history. To cope
with the low resolution of the NCBI taxonomy, we used a quartet-based topological
distance, rather than the transfer distance. For all inferred branches, we measured
the quartet-based percentage of conflicts with the NCBI taxonomy, and the same
approach was used to assess the topological accuracy of FastTree and RAxML
phylogenies. As expected in this type of study based on a unique marker, the
inferred topologies were relatively poor, and thus challenging for branch support
methods. However, RAxML was more accurate than FastTree, with higher branch
supports, as generally observed with rapid bootstrap<sup><xref rid="R16" ref-type="bibr">16</xref></sup> (<xref ref-type="fig" rid="F6">Fig.
ED2</xref>&#x2013;<xref ref-type="fig" rid="F7">ED3</xref>).</p>
      <p id="P13">Results (<xref ref-type="fig" rid="F2">Fig. 2a&#x2013;c</xref>, <xref ref-type="fig" rid="F6">ED2</xref>&#x2013;<xref ref-type="fig" rid="F7">ED3</xref>) indicate clearly that TBE provides some support for deep branches,
while FBP does not. As expected, the supports of shallow branches are similar, and
the impact of TBE is more pronounced with a large number of taxa, but still of
interest with medium-sized datasets. Comparisons with the NCBI taxonomy show that
TBE supports a larger number of weakly contradicted branches than FBP, which fulfils
one of its objectives (nearly correct branches must be supported), while the number
of supported branches with moderate to high quartet conflicts remains very low.
These results are confirmed by simulations (<xref ref-type="fig" rid="F2">Fig.
2d</xref>, <xref ref-type="fig" rid="F11">ED7</xref>&#x2013;<xref ref-type="fig" rid="F12">ED8</xref>).</p>
      <p id="P14">The advantage of TBE appears clearly when inspecting the tree clades. For
example (<xref ref-type="fig" rid="F3">Fig. 3</xref>), the simian clade inferred by
FastTree has a strong support with TBE, while FBP is nearly null due to a high
number of rogue taxa in the bootstrap trees, and the same holds true for several
sub-clades. This clade includes all simian sequences (152), plus two non-simian
taxa: <italic>Maxomys rajah</italic> and <italic>Canis adustus</italic>. The latter
is not a rogue taxon: its sequence is incomplete and very close to the simian
sequences for the part being available, and its position is very stable in the
bootstrap trees. In contrast, <italic>Maxomys rajah</italic> is a rogue taxon, and
is detected as such by TBE (659/1000 transfers when computing the support of the
simian clade). Similar results were found with other well-established clades and
using RAxML (<xref ref-type="fig" rid="F4">Fig. 4</xref>). Both FBP and TBE support
some small clades, namely the monotremes and elephantidae. However, FBP does not
support any deep branches, except cetaceans (67%), and to some extent,
simians (50%). TBE provides strong supports for these two groups, but also
for five other groups, such as marsupials and insectivores. The latter clade (FBP:
0%, TBE: 78%) contains all insectivores of the NCBI taxonomy, plus
one extra taxon (<italic>Plecotus cf. strelkovi</italic>), which again is detected
by TBE as a rogue taxon (965/1000 transfers). In comparison, the removal of rogue
taxa<sup><xref rid="R24" ref-type="bibr">24</xref></sup> does not
significantly improve FBP (8 and 3 taxa are removed with FastTree and RAxML,
respectively, but the number of branches with FBP &gt;70% remains the
same). This is explained by hundreds of taxa, which are relatively unstable, but not
removed.</p>
    </sec>
    <sec id="S3">
      <title>Analysis of HIV data</title>
      <p id="P15">We applied our method to a large dataset of 9,147 HIV-1 group M
<italic>pol</italic> sequences. Such large datasets are increasingly common in
molecular epidemiology and phylodynamics<sup><xref rid="R36" ref-type="bibr">36</xref></sup>. We only retained sequences annotated as non-recombinant by
the Los Alamos HIV-1 DB using a fast filtering approach. Among these, 48 recombinant
sequences were still detected by jpHMM<sup><xref rid="R37" ref-type="bibr">37</xref></sup>. These 48 sequences were kept in the analyses to study the
impact of recombinant sequences, as their presence is inevitable in any HIV dataset.
In contrast to mammals, the tree topology of HIV-1M strains is essentially unknown.
Moreover, it is intrinsically unstable as reconstructing a tree with so many
relatively short and possibly recombinant sequences is a very hard task. Thus, the
main expectation is to observe a clear separation between the subtypes. We built the
reference and bootstrap trees using FastTree on the DNA sequence alignment (1,043
sites), and performed the same analyses using smaller subsets of 35 and 571
sequences. While the deep branching of the subtypes<sup><xref rid="R19" ref-type="bibr">19</xref></sup> is poorly supported by FBP (<xref ref-type="fig" rid="F1">Fig. 1a</xref>), it becomes apparent with TBE, where all subtypes have
a support larger than 80%, and close to 100% in most cases (<xref ref-type="fig" rid="F1">Fig. 1b</xref>, <xref ref-type="fig" rid="F9">ED5</xref>). For example, the subtype B clade (3,559 taxa) has FBP = 3% and
TBE = 99%. This clade contains all subtype B sequences, plus 2 taxa detected
as recombinant by jpHMM, meaning that both supports are likely right in saying that
this clade is incorrect (FBP), and nearly correct (TBE), but FBP fails to detect any
phylogenetic signal, whereas it is quite strong here. The same holds true with other
well described clades. For example, TBE supports the identification of regional
variants of HIV-1 subtypes that are of epidemiological importance: the East-African,
Indian, and South American subtype C variants, which FBP fails to support. TBE
provides a substantial support to a much larger number of deep branches. Again, the
advantage in using TBE is higher with large data sets (<xref ref-type="fig" rid="F8">Fig. ED4</xref>), but still apparent with 571-taxon datasets, where the deep
subtype branching and C sub-epidemics are supported by TBE but not FBP (<xref ref-type="fig" rid="F9">Fig. ED5</xref>). An important feature of TBE is that
the supports may be non-local, but attached to &#x201C;caterpillar-like&#x201D;
paths (<xref ref-type="fig" rid="F1">Fig. 1b</xref>, e.g. subtype C). With HIV-1M
data, this corresponds to the fact that the subtype roots are usually not well
defined due to recombinant and ancient sequences. Moreover, the instability score
among recombinant sequences is clearly higher than in the sequences not detected as
recombinant (<xref ref-type="fig" rid="F10">Fig. ED6</xref>), supporting the
biological soundness of the approach and its power in detecting recombination and
rogue taxa.</p>
    </sec>
    <sec id="S4">
      <title>Analysis of simulated data</title>
      <p id="P16">To check that TBE does not support erroneous branches, we performed
extensive computer simulations with various tree sizes and phylogenetic signal
levels. We also added unstable taxa having weaker phylogenetic signal than the
others. The results are highly similar to those with real data regarding the support
of deep branches and the tree size (<xref ref-type="fig" rid="F11">Fig.
ED7</xref>&#x2013;<xref ref-type="fig" rid="F12">ED8</xref>). In all the
conditions we examined, TBE supported very few branches showing substantial
contradictions with the true tree, and the rogue taxa exhibited lower stability
(<xref ref-type="fig" rid="F13">Fig. ED9</xref>). In the absence of rogue taxa
(<xref ref-type="fig" rid="F11">Fig. ED7</xref>), the gain of TBE was still
substantial compared to FBP, with almost twice as many branches with support
&gt;70%, thus showing the importance of accounting for the global
instability of the inferred tree. Moreover, we checked the interpretation of TBE as
a measure of repeatability (<xref ref-type="fig" rid="F14">Fig. ED10</xref>) by
comparing TBE to its counterpart computed from simulated alignments, rather than
bootstrap pseudo-alignments; both simulation- and bootstrap-based supports are
highly correlated (0.85) with alignments of moderate length (~500) and have
analogous performance in detecting rogue taxa. Lastly, we checked the validity of
the plug-in principle by comparing TBE to the normalised transfer index measuring
the similarity between the inferred branch and the true tree (<xref ref-type="fig" rid="F14">Fig. ED10</xref>). Again a high correlation (0.74) was found. When
performing the same experiments with FBP, similar or slightly lower correlations
were observed, likely due to the discontinuous nature of FBP.</p>
    </sec>
    <sec sec-type="discussion" id="S5">
      <title>Discussion</title>
      <p id="P17">The transfer bootstrap thus provides a measure of branch repeatability (or
robustness). The results clearly demonstrate its usefulness, especially with deep
branches and large datasets, where branches known to be essentially correct are
supported by TBE but not by FBP. Moreover, when combined with (consistent)
maximum-likelihood tree estimation, TBE rarely supports poor branches. Importantly,
TBE supports are easily interpreted as fractions of unstable taxa. Although our
results suggest that 70% is a reasonable threshold to start with (<xref ref-type="fig" rid="F6">Fig. ED2</xref>, <xref ref-type="fig" rid="F7">ED3</xref>, <xref ref-type="fig" rid="F8">ED4</xref>, and <xref ref-type="fig" rid="F12">ED8</xref>), we do suggest that it is better for users to interpret
the TBE values depending on the data and the phylogenetic question being addressed
(e.g. lower TBE support threshold with HIV and possibly recombinant sequences, than
with mammals). Moreover, our experiments demonstrate the ability of the transfer
index to detect unstable taxa responsible for low supports. Lastly, the approach is
applicable to rapid bootstrap<sup><xref rid="R17" ref-type="bibr">17</xref>&#x2013;<xref rid="R18" ref-type="bibr">18</xref></sup> (<xref ref-type="fig" rid="F4">Fig. 4</xref>, <xref ref-type="fig" rid="F7">ED3</xref>)
and could be extended to parametric bootstrap<sup><xref rid="R2" ref-type="bibr">2</xref></sup> and Bayesian branch supports<sup><xref rid="R14" ref-type="bibr">14</xref></sup>.</p>
    </sec>
    <sec sec-type="methods" id="S6">
      <title>Methods</title>
      <sec id="S7">
        <title>Transfer distance and index: definitions and properties</title>
        <p id="P18">The transfer distance<sup><xref rid="R27" ref-type="bibr">27</xref></sup>, also called R-distance<sup><xref rid="R28" ref-type="bibr">28</xref></sup>, was introduced to compare partitions in cluster
analysis. In this context, the transfer distance is equal to the minimum number
of elements to be transferred (or removed) to transform one partition into the
other. Tree branches are commonly seen as bipartitions or splits, as a branch
divides the taxa into two subsets situated on its two sides. The most used
topological distance between two trees is the Robinson and Foulds
distance<sup><xref rid="R38" ref-type="bibr">38</xref></sup>, which is
equal to the number of bipartitions that belong to one tree but not the other.
As quoted by Lin et al.<sup><xref rid="R29" ref-type="bibr">29</xref></sup>, the
bipartition distance is overly sensitive to some small tree changes, possibly
involving a unique taxon. Those authors proposed using the transfer distance and
designed algorithms to compute a more robust &#x201C;matching&#x201D; distance
between trees, a different task, but related to the aim of this article. In the
following, we first provide basic definitions (see Semple and Steel<sup><xref rid="R39" ref-type="bibr">39</xref></sup> for a text book on
phylogenetic trees), and then demonstrate the properties of the transfer
distance in a bootstrap context.</p>
        <p id="P19">Let X be a fixed set of <italic>l</italic> taxa. An X-tree is a
phylogenetic tree with <italic>l</italic> leaves labelled by the taxa of X. All
(reference, bootstrap) trees discussed here are X-trees, meaning that they are
labelled by the same set of <italic>l</italic> taxa. Any branch of an X-tree
defines a bipartition of X, and the topology of an X-tree can be recovered from
its bipartition set. Thus, we will use both terms (branch, bipartition)
indifferently, depending of the context. Any bipartition <italic>b</italic> of X
can be encoded by a {0,1} vector <bold>v</bold>(<italic>b</italic>) of length
<italic>l</italic>, where the taxa on the same side of the bipartition are
encoded by the same value. Note that <italic>b</italic> is also encoded by <inline-formula><mml:math id="M11" overflow="scroll"><mml:mover><mml:mtext mathvariant="bold">v</mml:mtext><mml:mo>&#xAF;</mml:mo></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:mtext mathvariant="italic">b</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> the negation of
<bold>v</bold>(<italic>b</italic>) (i.e. the 0s are turned into 1s and vice
versa). Moreover, the smaller of the two subsets induced by a bipartition
<italic>b</italic> will be called here the &#x201C;light side&#x201D; of
<italic>b</italic>, and <italic>p</italic> will denote the size of the light
side of <italic>b</italic> (<italic>p</italic> &#x2264; <italic>l &#x2212;
p</italic>). One says that a bipartition is &#x201C;trivial&#x201D; when
it has a unique taxon in its light side (<italic>p</italic> = 1). An X-tree
defines <italic>l</italic> trivial bipartitions corresponding to each of the
taxa. These trivial bipartitions are contained in every X-tree, while the other
non-trivial bipartitions define the core of the tree topology and are the
central subject of phylogenetic studies.</p>
        <p id="P20">The transfer distance &#x3B4;(<italic>b,b</italic>*) between a
bipartition <italic>b</italic> of the reference tree <italic>T</italic> and a
bipartition <italic>b</italic>* of a bootstrap tree <italic>T</italic>* is equal
to the number of taxa that must be transferred (or removed) to make both
bipartitions identical. The transfer distance is easily defined and computed
using the Hamming distance <italic>H</italic> between
<bold>v</bold>(<italic>b</italic>) and <bold>v</bold>(<italic>b</italic>*):
<disp-formula id="FD2"><mml:math id="M2" display="block" overflow="scroll"><mml:mi mathvariant="normal">&#x3B4;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mtext mathvariant="italic">Min</mml:mtext><mml:mo stretchy="false">{</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">v</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi mathvariant="bold">v</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mover><mml:mi mathvariant="bold">v</mml:mi><mml:mo>&#xAF;</mml:mo></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi mathvariant="bold">v</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:math></disp-formula></p>
        <p id="P21">To measure the presence of <italic>b</italic> in <italic>T</italic>*, we
search the bipartition in <italic>T</italic>* that is closest to
<italic>b</italic> and use the transfer index
&#x3D5;(<italic>b,T</italic>*) =
<italic>Min</italic><sub><italic>b</italic>*&#x2208;<italic>T</italic>*</sub>{&#x3B4;(<italic>b,b</italic>*)}.
Based on above definitions, &#x3B4;(<italic>b,b</italic>*) = 0 if and only if
<bold>v</bold>(<italic>b</italic>) and <bold>v</bold>(<italic>b</italic>*)
define the same bipartition of X. Thus, the transfer index satisfies:
<disp-formula id="FD3"><mml:math id="M3" display="block" overflow="scroll"><mml:mi mathvariant="normal">&#x3D5;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>T</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mtext>&#xA0;if and only if&#xA0;</mml:mtext><mml:mi>b</mml:mi><mml:mo>&#x2208;</mml:mo><mml:msup><mml:mi>T</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo>.</mml:mo></mml:math></disp-formula>Moreover, let <italic>b</italic> be any given
bipartition of <italic>T</italic> and <italic>t</italic> be a taxon in the light
side of <italic>b</italic>. The trivial bipartition <italic>b</italic>* =
{<italic>t</italic>}/X &#x2212; {<italic>t</italic>} is found in any
bootstrap tree <italic>T</italic>* and &#x3B4;(<italic>b,b</italic>*) =
<italic>p</italic> &#x2212; 1. There may well be another bipartition closer
to <italic>b</italic> in <italic>T</italic>*, but at least this ensures that:
<disp-formula id="FD4"><mml:math id="M4" display="block" overflow="scroll"><mml:mi mathvariant="normal">&#x3D5;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>T</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x2264;</mml:mo><mml:mi>p</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:math></disp-formula>and thus, the transfer support <italic>TS</italic>
satisfies: <disp-formula id="FD5"><mml:math id="M5" display="block" overflow="scroll"><mml:mtext mathvariant="italic">TS</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>T</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#x3D5;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>T</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac><mml:mo>&#x2208;</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">]</mml:mo><mml:mtext>&#xA0;and</mml:mtext></mml:math></disp-formula>
<disp-formula id="FD6"><mml:math id="M6" display="block" overflow="scroll"><mml:mtext mathvariant="italic">TS</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>T</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mtext>&#xA0;if and only if&#xA0;</mml:mtext><mml:mi>b</mml:mi><mml:mo>&#x2208;</mml:mo><mml:msup><mml:mi>T</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo>.</mml:mo></mml:math></disp-formula></p>
        <p id="P22">Let 1<sub><italic>b</italic></sub>(<italic>T</italic>*) be the indicator
function equal to 1 when <italic>b</italic> &#x2208; <italic>T</italic>* and 0
otherwise. For any bipartition <italic>b</italic> and tree <italic>T</italic>*,
we have 1<sub><italic>b</italic></sub>(<italic>T</italic>*) &#x2264;
<italic>TS</italic>(<italic>b,T</italic>*). The Felsenstein bootstrap
proportion (FBP) is equal to the average of
1<sub><italic>b</italic></sub>(<italic>T</italic>*) over the set of
bootstrap trees, while the transfer bootstrap expectation (TBE) is equal to the
average of <italic>TS</italic>(<italic>b,T</italic>*). Thus, when using the same
set of bootstrap trees, we necessarily have FBP(<italic>b</italic>) &#x2264;
TBE(<italic>b</italic>). When <italic>b</italic> is a
&#x201C;cherry&#x201D; (<italic>p</italic> = 2), we have
1<sub><italic>b</italic></sub>(<italic>T</italic>*) =
<italic>TS</italic>(<italic>b,T</italic>*) and thus FBP(<italic>b</italic>)
= TBE(<italic>b</italic>). With deeper bipartitions, we generally observe that
in the presence of a significant phylogenetic signal, only a small number of
taxa need to be transferred to make <italic>b</italic> identical to a
bipartition in <italic>T</italic>*, while the strict presence of
<italic>b</italic> in <italic>T</italic>* can be relatively rare; the
difference between FBP(<italic>b</italic>) and TBE(<italic>b</italic>) can then
be substantial.</p>
        <p id="P23">The transfer distance and index are related to parsimony. The branch
<italic>b</italic> is equivalent to a binary {0,1} character; assuming that
the tips of <italic>T</italic>* are labelled accordingly, we can define
<italic>PA</italic>(<italic>b,T</italic>*), which is the minimum number of
changes along <italic>T</italic>* branches required to explain the tips labels.
When <italic>b</italic> belongs to <italic>T</italic>*, we have
<italic>PA</italic>(<italic>b,T</italic>*) = 1, and the more shuffled the 0s
and 1s among the tips of <italic>T</italic>*, the higher is
<italic>PA</italic>(<italic>b,T</italic>*). It is easy to see that
<italic>PA</italic>(<italic>b,T</italic>*) &#x2264;
&#x3D5;(<italic>b,T</italic>*)+1. Indeed, let <italic>b</italic>* be a
branch in <italic>T</italic>* such that &#x3D5;(<italic>b,T</italic>*) =
&#x3B4;(<italic>b,b</italic>*) and assume, without loss of generality,
that &#x3B4;(<italic>b,b</italic>*) is equal to the number of tips labelled 1
in the light side of <italic>b</italic>* plus the number of tips labelled 0 in
the heavy side of <italic>b</italic>* (in other words, the light side of
<italic>b</italic>* is mostly 0 and the heavy side is mostly 1). Now
consider that all internal nodes in the light side are 0 and all internal nodes
in the heavy side are 1; this implies a number of changes equal to
&#x3D5;(<italic>b,T</italic>*)+1, which by the definition of parsimony is
larger than or equal to <italic>PA</italic>(<italic>b,T</italic>*). Parsimony is
thus another option to measure branch presence, but it is inappropriate in our
context. For example, consider a reference branch <italic>b</italic> =
<italic>AB</italic>|<italic>CD</italic>, where <italic>A</italic>,
<italic>B</italic>, <italic>C</italic> and <italic>D</italic> are four large
&#x201C;corner&#x201D; subtrees, and a tree <italic>T</italic>* with an
internal branch <italic>b</italic>* grouping the corner subtrees the other way
around (e.g. <italic>b</italic>* = <italic>AC</italic>|<italic>BD</italic>,
meaning that <italic>A</italic> and <italic>C</italic> sit on one side of
<italic>b</italic>*, and <italic>B</italic> and <italic>D</italic> on the
other side). Then, <italic>PA</italic>(<italic>b,T</italic>*) is equal to 2, a
very low value, while <italic>T</italic>* is phylogenetically very different
from <italic>b</italic> since both clades defined by <italic>b</italic> are
mixed. In that case, the transfer index between <italic>b</italic> and
<italic>T</italic>* is much larger and equal to the minimum size of
<italic>A</italic>, <italic>B</italic>, <italic>C</italic> and
<italic>D</italic>.</p>
      </sec>
      <sec id="S8">
        <title>Recursive computation of the transfer index</title>
        <p id="P24">Lin et al.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> describe
a recursive algorithm to compute all transfer distances between any given
bipartition <italic>b</italic> of <italic>T</italic> and all bipartitions of
another tree <italic>T&#x2019;</italic> (see also Br&#xE9;h&#xE9;lin et
al.<sup><xref rid="R26" ref-type="bibr">26</xref></sup>). This algorithm
is easily transformed to compute the transfer index. The principle is as
follows: <list list-type="order" id="L2"><list-item><p id="P25">Map all the leaves of the light side of <italic>b</italic>
to 0, the others to 1, and apply the same mapping to the leaves of
<italic>T</italic>*. Moreover, root <italic>T</italic>* at any
internal node.</p></list-item><list-item><p id="P26">With a single postorder tree traversal, one can compute the
number of leaves labelled 0 and the number of leaves labelled 1 for
every subtree in <italic>T</italic>*.</p></list-item><list-item><p id="P27">Let <italic>l</italic><sub>0</sub> be the number of leaves
labelled 0 and <italic>l</italic><sub>1</sub> be the number of
leaves labelled 1 in the subtree attached below a given bipartition
<italic>b</italic>*. The transfer distance between
<italic>b</italic> and <italic>b</italic>* is given by (think to
the missing 0s and the 1s to be removed in <italic>b</italic>*
subtree, and vice versa): <disp-formula id="FD7"><mml:math id="M7" display="block" overflow="scroll"><mml:mi mathvariant="normal">&#x3B4;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mtext mathvariant="italic">Min&#xA0;</mml:mtext><mml:mo stretchy="false">{</mml:mo><mml:mi>p</mml:mi><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mi>p</mml:mi><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>l</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>.</mml:mo></mml:math></disp-formula>This distance can be computed during
the postorder traversal as well as the transfer index
&#x3D5;(<italic>b,T</italic>*), which is the minimum of
&#x3B4;(<italic>b,b</italic>*) for all bipartitions of
<italic>T</italic>*.</p></list-item></list> This algorithm has linear time complexity, and thus computing TBE for
all bipartitions in <italic>T</italic> with <italic>r</italic> bootstrap
replicates has a time complexity in
<italic>O</italic>(<italic>rl</italic><sup>2</sup>). FBP has the same time
complexity, but very efficient implementations have been developed (e.g. using
bit vectors to encode bipartitions). In practice, computing all TBE supports
with 4,000 taxa and 1,000 replicates requires less than one hour (5 core Intel
Xeon 3.5GHz), which is negligible compared to the time required to infer the
reference and bootstrap trees.</p>
      </sec>
      <sec id="S9">
        <title>Expected transfer index with random trees and TBE distribution</title>
        <p id="P28">We have seen that the transfer index satisfies
&#x3D5;(<italic>b,T</italic>*) &#x2264; <italic>p</italic> &#x2212; 1.
We show in this subsection that the expected transfer index is very close to
this upper-bound with random &#x201C;bootstrap&#x201D; trees, when the number
of taxa is large enough. Consequently, the transfer bootstrap expectation of any
branch
<italic>b</italic> (TBE(<italic>b</italic>)=1&#x2212;<italic>E</italic>(&#x3D5;(<italic>b,T</italic><sup>&#x2217;</sup>))/(<italic>p</italic>&#x2212;1))
is close to 0 when the bootstrap trees seem to
be random and do not contain any signal regarding <italic>b</italic>. This
property explains why moderate supports, for example 70% as used
throughout the article, are sufficient to reject poor branches, as a branch
support of 70% cannot be observed by chance.</p>
        <p id="P29">We first provide a simple argument to explain this result, based on the
expected transfer distance between a fixed bipartition <italic>b</italic> and a
random bipartition <italic>b</italic>* with fixed light-side size
<italic>p</italic>*. Let <italic>x</italic> =
<italic>p</italic>/<italic>l</italic> denote the proportion of taxa in the
light side of <italic>b</italic> (<italic>x</italic> &#x2264; 1 &#x2212;
<italic>x</italic> since <italic>p</italic> &#x2264; <italic>l &#x2212;
p</italic>). Both bipartitions <italic>b</italic> (fixed) and
<italic>b</italic>* (random) define four taxon subsets, the sizes of which
follow hypergeometric distributions with expectations: <list list-type="simple" id="L3"><list-item><p id="P30"><italic>E</italic>(light side of <italic>b</italic>
&#x2229; light side of <italic>b</italic>*) =
<italic>xp</italic>*</p></list-item><list-item><p id="P31"><italic>E</italic>(light side of <italic>b</italic>
&#x2229; heavy side of <italic>b</italic>*) =
<italic>x</italic>(<italic>l</italic> &#x2212;
<italic>p</italic>*)</p></list-item><list-item><p id="P32"><italic>E</italic>(heavy side of <italic>b</italic>
&#x2229; light side of <italic>b</italic>*) = (1 &#x2212;
<italic>x</italic>)<italic>p</italic>*</p></list-item><list-item><p id="P33"><italic>E</italic>(heavy side of <italic>b</italic>
&#x2229; heavy side of <italic>b</italic>*) = (1 &#x2212;
<italic>x</italic>)(<italic>l</italic> &#x2212;
<italic>p</italic>)*</p></list-item></list>It is easily seen that under above assumptions, the expected transfer
distance between <italic>b</italic> and <italic>b</italic>* is equal to the sum
of the second and third (anti-diagonal) terms, that is: <disp-formula id="FD8"><mml:math id="M9" display="block" overflow="scroll"><mml:mi>E</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="normal">&#x3B4;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:mn>2</mml:mn><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mi>p</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:mi>p</mml:mi><mml:mo>.</mml:mo></mml:math></disp-formula>Since <italic>p</italic>* &gt; 0 and (1
&#x2212; 2<italic>x</italic>) &#x2265; 0, we have: <disp-formula id="FD9"><mml:math id="M10" display="block" overflow="scroll"><mml:mi>E</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="normal">&#x3B4;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mo>&#x2217;</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>&#x2265;</mml:mo><mml:mi>p</mml:mi><mml:mo>.</mml:mo></mml:math></disp-formula>This result shows that the expected transfer
distance between <italic>b</italic> and <italic>b</italic>* is larger than or
equal to <italic>p</italic>, for any value of <italic>p</italic> and
<italic>p</italic>*. Moreover, the lower <italic>p</italic>*, the closer the
expected transfer distance is to <italic>p</italic>. As a first approximation,
we thus see that the transfer index should be close to its upper-bound
<italic>p</italic> &#x2212; 1, since it is equal to the minimum of
distances which taken separately are all expected to be larger than
<italic>p</italic>.</p>
        <p id="P34">However, these distances fluctuate around their expected values, and
their minimum may be lower than the minimum of their individual expectations,
especially with small samples (i.e. low number of taxa). We performed computer
simulations to measure the extent of this phenomenon and the validity of the
<italic>E</italic>[&#x3D5;(<italic>b,T</italic>*)] &#x2248;
<italic>p</italic> &#x2212; 1 approximation. We used four tree sizes:
<italic>l =</italic> 16, 128, 1,024 and 8,192 taxa, and four models of
random phylogenetic trees: caterpillars (fully imbalanced), PDA, Yule-Harding,
and perfectly balanced<sup><xref rid="R39" ref-type="bibr">39</xref></sup>. For
the bipartition <italic>b</italic>, all possible integer values of
<italic>p</italic> in the [2, <italic>l</italic>/2] range were used. The
number of random &#x201C;bootstrap&#x201D; trees was equal to 1,000, and we
performed 100 runs per tree size.</p>
        <p id="P35">Results are displayed in <xref ref-type="fig" rid="F5">Fig. ED1</xref>.
With <italic>l</italic> &#x2265; 1,024, the average transfer index with random
trees is surprisingly close to the upper bound <italic>p</italic> &#x2212; 1,
and the approximation is already satisfying with <italic>l</italic> = 128.
Moreover, the results are nearly the same for the four random tree models,
suggesting that the property holds in a number of settings. As expected, the
approximation is better with small <italic>p</italic>. Indeed, remember that the
upper bound <italic>p</italic> &#x2212; 1 is obtained with a trivial
bipartition <italic>b</italic>* made of a unique taxon belonging to the light
side of <italic>b</italic>. When a cherry in <italic>T</italic>* contains two
taxa from the light side of <italic>b</italic>, then
&#x3D5;(<italic>b,T</italic>*) &#x2264; <italic>p</italic> &#x2212; 2.
Similar deviations are observed with subtrees in <italic>T</italic>* containing
a large fraction of taxa belonging to the light side of <italic>b</italic>. The
larger <italic>p</italic>, the higher the probability for such event to occur.
Note, however, that large values of <italic>p</italic> (i.e. <italic>p</italic>
&#x2248; 2) are relatively rare for most tree models (<italic>e.g.</italic>
Yule-Harding). Looking at the distribution of TBE, we see that having TBE larger
than a moderate threshold (say 50%) is very unlikely, even with 16 taxa,
thus explaining that TBE rarely supports poor branches with real and simulated
data (<xref ref-type="fig" rid="F2">Fig. 2c&#x2013;d</xref>, <xref ref-type="fig" rid="F6">ED2</xref>&#x2013;<xref ref-type="fig" rid="F7">ED3</xref>, <xref ref-type="fig" rid="F11">ED7</xref>&#x2013;<xref ref-type="fig" rid="F12">ED8</xref>).</p>
      </sec>
      <sec id="S10">
        <title>Software programs, web server</title>
        <p id="P36">We developed several tools to compute the transfer bootstrap. We first
implemented a command line tool in C, &#x201C;Booster&#x201D;, available at
<ext-link ext-link-type="uri" xlink:href="https://github.com/evolbioinfo/booster">https://github.com/evolbioinfo/booster</ext-link>. This tool computes TBE
as well as FBP supports, and the stability scores of the taxa (globally or per
branch). It takes two files as input: (1) a reference tree file in Newick
format, and (2) a bootstrap tree file in Newick format, containing all bootstrap
trees. A number of software programs can be used to infer trees from MSAs and
produce these reference and bootstrap files in the desired format, such as
RAxML, FastTree and PhyML, as used in this article, and many others (see
examples in Booster GitHub repository).</p>
        <p id="P37">We also developed &#x201C;BoosterWeb&#x201D; (<ext-link ext-link-type="uri" xlink:href="http://booster.c3bi.pasteur.fr">http://booster.c3bi.pasteur.fr</ext-link>), a freely available web
interface, which allows users to compute bootstrap supports (TBE and FBP) easily
without installing any tool on their own computer. Computations are launched on
the Institut Pasteur cluster throughout a Galaxy instance. As for the command
line tool, an option is to input reference and bootstrap trees inferred using
any phylogenetic program. Another option is to upload an MSA and then run
PhyML-SMS<sup><xref rid="R40" ref-type="bibr">40</xref></sup>
(medium-size data sets) or FastTree (large data sets) to infer the trees. We
propose a basic visualization of the resulting tree highlighting highly
supported branches at a given threshold. The resulting tree can be uploaded in
one-click on iTOL<sup><xref rid="R41" ref-type="bibr">41</xref></sup> for
further manipulation. Moreover, BoosterWeb is self-contained and can be easily
installed on any desktop computer (Windows, MacOS, and Linux) by downloading the
BoosterWeb executable.</p>
        <p id="P38">For the sake of reproducibility, all analyses described in this article
were implemented in the NextFlow workflow manager<sup><xref rid="R42" ref-type="bibr">42</xref></sup>, and are accessible along with all our data at
<ext-link ext-link-type="uri" xlink:href="https://github.com/evolbioinfo/booster-workflows">https://github.com/evolbioinfo/booster-workflows</ext-link>. The software
programs that we developed to manipulate data are available for download at
<ext-link ext-link-type="uri" xlink:href="http://github.com/fredericlemoine/goalign">http://github.com/fredericlemoine/goalign</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://github.com/fredericlemoine/gotree">http://github.com/fredericlemoine/gotree</ext-link>, for manipulating
alignments and trees, respectively.</p>
      </sec>
      <sec id="S11">
        <title>Mammal dataset and analyses</title>
        <p id="P39">We downloaded all aligned mammals COI-5P amino-acid sequences from the
Barcode of Life Data System (BOLD - <ext-link ext-link-type="uri" xlink:href="http://www.barcodinglife.org">http://www.barcodinglife.org</ext-link> - date of access: September 2015).
We removed all sequences shown to be identical among several species, kept one
sequence per species (several gene versions are available for some species, but
no paralogs), and converted the resulting multiple alignment (1,449 sequences,
527 sites) into FASTA format. This alignment was sub-sampled to study the impact
of tree size. We randomly drew 8 samples with 1/8th of the sequences (i.e. 181)
and 64 samples with 1/64th of the sequences (i.e. 22). We then generated 1,000
bootstrap alignments for the full alignment and each of the 72 sub-sampled
alignments by drawing sites with replacement.</p>
        <p id="P40">We used FastTree<sup><xref rid="R34" ref-type="bibr">34</xref></sup>
(options: -nopr &#x2013;nosupport &#x2013;wag &#x2013;gamma) to infer trees
from each of these reference (1+8+64=73) and bootstrap (73,000) alignments. To
ensure that the results and conclusions were independent of the tree inference
method, we also performed the same analyses using RAxML with rapid
bootstrap<sup><xref rid="R17" ref-type="bibr">17</xref></sup> (options
&#x2013;f a &#x2013;m PROTGAMMA &#x2013;c 6 &#x2013;T 10 &#x2013;p $RANDOM
&#x2013;x $RANDOM -#1000). The FBP and TBE supports for the (73
&#xD7; 2) reference trees were computed using Booster (command-line version
written in C). All trees were drawn using iTOL and are available on Booster
GitHub repository, along with the sequence alignments. To assess whether rogue
taxa removal improves FBP supports, we ran RAxML rogue-detection tool<sup><xref rid="R24" ref-type="bibr">24</xref></sup> (options &#x2013;J MR_DROP
&#x2013;z bootstrap_trees &#x2013;m PROTGAMMAWAG -c 6 -T 4) and recomputed FBP
supports without the detected taxa.</p>
        <p id="P41">The FastTree and RAxML complete tree topologies were compared to the
NCBI taxonomy (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/taxonomy">https://www.ncbi.nlm.nih.gov/taxonomy</ext-link>), which was converted to
Newick format and reduced to the 1,444 taxa common to both our alignment and the
NCBI taxonomy. This NCBI tree is not fully resolved and summarizes common belief
about the evolutionary history of mammals, resulting from a number of
phylogenetic studies based on numerous markers. The unresolved part of the NCBI
tree (~4.35 descendants per node on average, instead of 2 for a
fully-resolved tree) corresponds to the unknown or uncertain part of that
history. To cope with uncertainty, we used quartets to compare the (fully
resolved) inferred trees to the NCBI tree. A quartet is a tree topology with 4
taxa; AB|CD is the standard notation for quartets, indicating that taxa A and B
form a cherry separated by an internal branch from the cherry formed by C and D;
a quartet is unresolved when the 4 taxa are connected to a single central node.
A bipartition <italic>b</italic> induces a quartet AB|CD when A and B belong to
the same side of <italic>b</italic>, and C and D to the other side. We used
tqDist<sup><xref rid="R43" ref-type="bibr">43</xref></sup> to count the
number of quartets induced by the reference branches, which appeared to be
contradictory with the quartets induced by the NCBI tree and its bipartitions;
for example, AB|CD was found in the studied branch, while AC|BD was found in the
NCBI tree. Unresolved quartets of the NCBI tree were not counted as
contradictory, as they represent an unknown evolutionary truth and the inferred
resolution could be correct. Such an approach would be difficult to implement
with the transfer distance. The number of contradicted quartets was divided by
the total number of quartets induced by the studied branch, to obtain a
normalized measurement in the [0, 1] range (0: no contradiction; 1: all induced
quartets are contradicted). We used the same approach to check the accuracy of
the FastTree and RAxML tree topologies, comparing the whole set of quartets
induced by the inferred tree to those induced by the NCBI tree.</p>
      </sec>
      <sec id="S12">
        <title>HIV dataset and analyses</title>
        <p id="P42">From the HIV database (<ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/index">https://www.hiv.lanl.gov/content/index</ext-link>) we retrieved
<italic>pol</italic> sequences of the nine &#x201C;pure&#x201D; subtypes
of HIV-1 group M, corresponding to positions 2258-3300 relative to the HXB2
reference strain (access date: September 2014). The &#x201C;one sequence per
patient&#x201D; option was used, and we randomly selected samples of the
over-sampled subtypes (A1, B, C, D, and G), resulting in a final dataset of
9,147 sequences. These sequences are annotated as &#x201C;pure&#x201D; (i.e.
non-recombinant) in the database, using a fast filtering approach. However, 48
recombinant sequences were still detected using the standalone version of
jpHMM<sup><xref rid="R37" ref-type="bibr">37</xref></sup> (version:
March 2015; options: -v HIV, with default input and priors). These 48 sequences
were kept in the analyses to study the impact of recombinant sequences, as their
presence is inevitable in any HIV dataset. jpHMM was also used to annotate the
whole set of sequences depending on their subtype or recombinant status.</p>
        <p id="P43">Sequences were aligned using MAFFT<sup><xref rid="R44" ref-type="bibr">44</xref></sup> (version: 7.0; default parameters) along with the HXB2
reference strain. Codon positions associated with major drug resistance
mutations were removed prior to tree inference, resulting in an alignment of
1,043 DNA sites (R source code available at <ext-link ext-link-type="uri" xlink:href="https://github.com/olli0601/big.phylo">https://github.com/olli0601/big.phylo</ext-link>). This alignment was
sub-sampled to study the impact of tree size. We randomly drew 16 samples with
1/16th of the sequences (i.e. 571), and 256 samples with 1/256th of the
sequences (i.e. 35). Then, we generated 1,000 bootstrap alignments for the full
alignment and each of the 272 sub-sampled alignments, by drawing sites with
replacement.</p>
        <p id="P44">We used FastTree<sup><xref rid="R34" ref-type="bibr">34</xref></sup>
(options: -nopr &#x2013;nosupport &#x2013;gtr &#x2013;nt -gamma) to infer
trees from each of these reference (1+16+256=273) and bootstrap (273,000)
alignments. The FBP and TBE supports for the 273 reference trees were computed
using Booster (command-line version written in C). All trees were drawn using
iTOL (<ext-link ext-link-type="uri" xlink:href="http://itol.embl.de/">http://itol.embl.de/</ext-link>) and are available on the Booster-workflows
GitHub repository, along with the sequence alignments. The instability score was
computed considering the reference branches with TBE &gt;70% (the
signal becomes noisy when incorporating branches with lower supports in the
calculation, as these branches may be erroneous and thus non-informative about
taxon stability). For every taxon, the instability score is equal to the average
number of times it has to be transferred to recover these branches from the
bootstrap trees, divided by the number of these branches.</p>
        <p id="P45">The most representative clades for each of the subtypes in the reference
trees (<xref ref-type="fig" rid="F1">Fig. 1</xref>, <xref ref-type="fig" rid="F9">ED5</xref>) were obtained by minimizing the transfer distance. For
example, in <xref ref-type="fig" rid="F1">Fig. 1</xref> with the full dataset,
we obtained a clade very close to subtype B, with 3,559 taxa, 2 wrong taxa (i.e.
non-B), and all B taxa included (i.e. 3,557 taxa, 0 missing).</p>
        <p id="P46">A similar approach was used for the regional variants of subtype C,
which is responsible for approximately 50% of the HIV-1 infections in
the world. Three monophyletic variants of subtype C have been identified by
phylogenetic analysis in East Africa<sup><xref rid="R45" ref-type="bibr">45</xref></sup>, South America<sup><xref rid="R46" ref-type="bibr">46</xref></sup>, and India<sup><xref rid="R47" ref-type="bibr">47</xref></sup>. Moreover, the South American epidemics was shown to
originate from the East African cluster<sup><xref rid="R45" ref-type="bibr">45</xref></sup>. To identify these variants in the inferred trees
(<xref ref-type="fig" rid="F1">Fig. 1</xref>, <xref ref-type="fig" rid="F9">ED5</xref>) we again used the transfer distance. Following previous
references<sup><xref rid="R45" ref-type="bibr">45</xref>&#x2013;<xref rid="R47" ref-type="bibr">47</xref></sup>, we extracted three groups of
C sequences from the whole dataset, based on their geographic origins: East
Africa (EA 440 sequences = Burundi 288 + Djibouti 1 + Ethiopia 9 + Kenya 41 +
Somalia 1 + Sudan 11 + Tanzania 78 + Uganda 11); India (IND 154 sequences =
India 133 + Nepal 13 + Myanmar 8); and South America (SA 14 sequences = Brazil
12 + Uruguay 1 + Argentina 1). We then searched for the tree clades being closer
to these three sets of sequences. The SA sequences were not accounted for in
transfer distance computations when searching for the EA clade, as they
originate from EA. Moreover, we checked that no neighbouring, nearly-optimal
clade was supported by FBP. In all three cases, we found clades closely related
to the sequence sets. As expected, the SA clade was included in the EA clade.
The features of these clades are displayed in <xref ref-type="fig" rid="F1">Fig.
1</xref> and ED5. The fractions correspond to the number of studied
sequences included in these clades, versus the total number of such sequences in
the whole dataset (e.g. 360 EA sequences in the EA clade in <xref ref-type="fig" rid="F1">Fig. 1</xref>, among 440 in the whole tree). The
&#x201C;wrong&#x201D; sequences were expected in most cases. For example, the
IND clade (167 sequences, 143 from IND among 154 in the whole tree) contains 19
sequences from China corresponding to the spread of the virus in Asia via heroin
trafficking routes<sup><xref rid="R47" ref-type="bibr">47</xref></sup>.</p>
      </sec>
      <sec id="S13">
        <title>Simulated data and analyses</title>
        <p id="P47">The aim of these simulation experiments was to check that the results
observed with the mammal and HIV-1 datasets are reproducible and quantifiable
when the simulation conditions and correct tree are known, notably regarding the
support of poor branches and the ability to detect rogue taxa. Simulated data
mimicked the mammal dataset. We used the tree inferred by PhyML<sup><xref rid="R48" ref-type="bibr">48</xref></sup> (options: -b 0 -m WAG -a e
&#x2013;t e -o tlr -d aa) from the full COI-5P protein alignment with 1,449
taxa. Protein sequences were evolved along this tree using INDELible<sup><xref rid="R49" ref-type="bibr">49</xref></sup>, which was launched with
options and parameter values derived from the PhyML analysis, and similar to the
experiments conducted by Aberer et al.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> to assess the accuracy of rogue-taxon detection: <list list-type="bullet" id="L4"><list-item><p id="P48">Length of the root sequence: 250 AAs;</p></list-item><list-item><p id="P49">Substitution model: WAG;</p></list-item><list-item><p id="P50">Amino-acid frequencies estimated from the COI-5P
alignment;</p></list-item><list-item><p id="P51">Rates across-sites model: 4 gamma categories with
&#x2018;alpha&#x2019; = 0.441 and no invariant sites;</p></list-item><list-item><p id="P52">Indel model: &#x2018;power law&#x2019;,
&#x2018;parameter&#x2019; = 1.5, &#x2018;indel max size&#x2019;
= 5, and &#x2018;indel rate&#x2019; = 0.02.</p></list-item></list></p>
        <p id="P53">In this manner, we obtained a first &#x201C;non-noisy&#x201D; MSA of
length ~500 with ~50% gaps. Noise was added to this MSA
to mimic rogue taxa and homoplasy. We shuffled the amino acids vertically for
50% of the sites (MSA columns), thus making these sites homoplasic. For
5% of the sequences (MSA rows), 25% additional sites were
shuffled vertically, thus making these sequences unstable and
&#x201C;rogue&#x201D;, as they contain half of the phylogenetic signal
compared to the 95% others. Both noisy and non-noisy MSAs were used to
compare FBP and TBE. To measure the effect of tree size, both MSAs (comprising
1,449 sequences) were sampled to obtain 8 MSAs with 181 sequences (~1/8
of the full sequence set) and 64 MSAs with 22 sequences (~1/64 of the
full sequence set). For each of these reference MSAs we sampled with replacement
1,000 pseudo-alignments to compare the two bootstrap methods. All trees were
inferred using FastTree (options: -nopr -nosupport -wag -gamma). Just as with
the mammal dataset, we computed, for each of the branches in the reference
trees, the percentage of quartet-based conflicts with the correct (PhyML) tree
used to generate the data. We also computed the instability score of all taxa in
the complete noisy MSA, using only the branches with
TBE&gt;70%.</p>
        <p id="P54">In order to check the repeatability of FBP and TBE, we generated 1,000
noisy MSAs using the same phylogenetic tree, simulation procedure and set of
rogue taxa as the reference noisy MSA (1,449 sequences, ~500 sites,
~50% gaps). We then compared the branch supports of the inferred
branches computed using the pseudo-alignments to those obtained using the
simulated MSAs. The bootstrap theory<sup><xref rid="R2" ref-type="bibr">2</xref></sup> indicates that both types of supports are close when the
sample size is large enough. The goal was thus to check that 500 sites are
enough to obtain a good approximation, and that the bootstrap-based and
simulation-based supports are clearly correlated (Pearson&#x2019;s
coefficients), as well as the instability score (again computed using branches
with TBE&gt;70%). This experiment was performed with FBP and TBE,
with both FastTree (options: -nopr -nosupport -wag &#x2013;gamma) and RAxML
(options: -f d -m PROTGAMMAWAG -c 6). Lastly, the same experiment was used to
check the validity of the plug-in principle: we compared the FBP and TBE
supports of every inferred branch (both FastTree and RAxML), to the
presence/absence (1/0) of that branch in the true tree (FBP), and the normalized
transfer distance between that branch and the true tree (TBE).</p>
      </sec>
    </sec>
    <sec id="S14">
      <title>Data and software availability</title>
      <p id="P55">All our multiple alignments, phylogenetic trees and workflows are available
from the Nature web site, as Source Data. This material, along with a Web interface
and software programs, is also available from Booster web site and GitHub: <ext-link ext-link-type="uri" xlink:href="http://booster.c3bi.pasteur.fr">http://booster.c3bi.pasteur.fr</ext-link> ; <ext-link ext-link-type="uri" xlink:href="https://github.com/evolbioinfo/booster">https://github.com/evolbioinfo/booster</ext-link>. The transfer bootstrap is
available in several phylogenetic programs: PhyML, SeaView, RaXML-NG and others (see
Booster web site).</p>
    </sec>
    <sec id="S15">
      <title>Extended Data</title>
      <fig id="F5" orientation="portrait" position="anchor">
        <label>Fig. ED1</label>
        <caption>
          <title>Transfer index expectation and TBE support with random trees</title>
          <p id="P56">For each number of taxa (panels (a) to (d)) and random tree model,
we compare the transfer index average over 100 runs with the upper-bound
<italic>p</italic>&#x2212;1 (top graphs). We also compare the average
transfer bootstrap support (TBE) to 0, and provide (dashed lines) the
maximum value observed among 100 runs, thus approximating the 1%
quantile of the distribution (bottom graphs). With <italic>l</italic>
&#x2265; 1, 024 (c), the average transfer index with random trees is
surprisingly close to the upper bound <italic>p</italic> &#x2212; 1, and
the approximation is already satisfying with <italic>l</italic> = 128 (b).
Moreover, the results are nearly the same for the four random tree models,
suggesting that the asymptotic behaviour holds in a number of settings. As
expected, the approximation of the transfer index over random bootstrap
trees by <italic>p</italic> &#x2212; 1 is better with small
<italic>p</italic>. These results explain why moderate TBE supports, for
example 70% as used throughout the article, are sufficient to reject
poor branches, as a TBE branch support of 70% cannot be observed by
chance, even with a small number of taxa (e.g. 16, (a)).</p>
        </caption>
        <graphic xlink:href="nihms947517f5"/>
      </fig>
      <fig id="F6" orientation="portrait" position="anchor">
        <label>Fig. ED2</label>
        <caption>
          <title>Comparison of FBP and TBE &#x2013; Mammal dataset &#x2013;
FastTree</title>
          <p id="P57">Both supports are compared regarding branch depth, quartet conflicts
with the NCBI taxonomy, and tree size (see text and notes to <xref ref-type="fig" rid="F1">Fig. 1</xref> and <xref ref-type="fig" rid="F2">2</xref> for explanations). Three support cut-offs are used to select
the branches: 50%, 70%, and 90% (e.g. 28 branches
among 1,446 have TBE &#x2265; 90% and 11 have FBP &#x2265;
90%). The FastTree topology is poor, with 38% of quartets
contradicted by the NCBI taxonomy, and 404/1441 branches with contradiction
&gt;20%. Despite this difficulty, FBP and TBE perform well as
they give supports larger than 70% to a very low number of
moderately (]5,20]%) and highly (&gt;20%) conflictual
branches. FBP supports very few deep branches, while TBE supports a larger
number of them, and is especially useful with large trees. Comparing the
three cut-offs, we see that with 50% the selected branches are still
weakly contradicted, especially with FBP; as expected, with TBE the fraction
of contradicted branches (&gt;5%) is a bit higher but still low
(~7%). With 90%, very few branches are selected
(~2% with TBE), thus justifying the use of the same
70% threshold for TBE as is standard with FBP.</p>
        </caption>
        <graphic xlink:href="nihms947517f6"/>
      </fig>
      <fig id="F7" orientation="portrait" position="anchor">
        <label>Fig. ED3</label>
        <caption>
          <title>Comparison of FBP and TBE &#x2013; Mammal dataset &#x2013; RAxML with
rapid bootstrap</title>
          <p id="P58">Both supports are compared regarding branch depth, quartet conflicts
with the NCBI taxonomy, and tree size (see text and notes to <xref ref-type="fig" rid="F1">Fig. 1</xref> and <xref ref-type="fig" rid="F2">2</xref> for explanations). Three support cut-offs are used to select
the branches: 50%, 70%, and 90% (e.g. 41 branches
among 1,446 have TBE &#x2265; 90% and 19 have FBP &#x2265;
90%). The RAxML topology is closer to the NCBI taxonomy than the
FastTree topology is (27% versus 38% of contradicted
quartets, and 353 versus 404 branches with contradiction
&gt;20%, respectively). However, the RAxML topology is still
relatively poor, as expected in this type of phylogenetic study based on a
unique marker (<xref ref-type="fig" rid="F4">Fig. 4</xref> and text).
Despite this difficulty, FBP and TBE perform well as they give supports
larger than 70% to a very low number of moderately (]5,20]%)
and highly (&gt;20%) conflictual branches. The supports
obtained with RAxML are higher than FastTree&#x2019;s (47 versus 29
branches with FBP&gt;70%, and 158 versus 108 with
TBE&gt;70%, for RAxML and FastTree, respectively). Part of the
explanation could be that the RAxML tree is more accurate than that of
FastTree, and thus better supported. Another factor is that the rapid
bootstrap tends to be more supportive than the standard procedure <sup>(e.g.
16)</sup>. Indeed, the rapid bootstrap uses already inferred trees to
initiate tree searching, and therefore tends to produce less diverse
bootstrap trees than the standard (slower) procedure, which restarts tree
searching from the very beginning for each replicate. Despite these
differences between FastTree and RAxML with rapid bootstrap, similar
conclusions are drawn when comparing FBP and TBE: FBP supports very few deep
branches, while TBE supports a larger number of them; TBE is especially
useful with large trees; both methods support a very low number of
contradicted branches. Comparing the support cut-off, 70% again
appears as a good compromise for both FBP and TBE.</p>
        </caption>
        <graphic xlink:href="nihms947517f7"/>
      </fig>
      <fig id="F8" orientation="portrait" position="anchor">
        <label>Fig. ED4</label>
        <caption>
          <title>Comparison of FBP and TBE &#x2013; HIV dataset &#x2013;
FastTree</title>
          <p id="P59">Both supports are compared regarding branch depth, and tree size
(see text and notes to <xref ref-type="fig" rid="F1">Fig. 1</xref> and <xref ref-type="fig" rid="F2">2</xref> for explanations). Three support
cut-offs are used to select the branches: 50%, 70%, and
90% (e.g. 1,624 branches among 9,144 have TBE&gt;70%
and 1,031 have FBP&gt;70%). Results are mostly similar to those
observed with the mammal dataset. Again, we see a major impact of the depth
on FBP supports: with the full dataset, less than 1% of the deep
(<italic>p</italic> &gt; 16) branches have FBP support larger than
70%, whereas this percentage is higher than 20% with TBE.
The impact of tree size is less pronounced. The fraction of supported
branches decreases when the tree size increases from 35 to 571 taxa, but is
analogous between 571 and 9,147 taxa. Moreover, the gap between FBP and TBE
remains similar, likely due to the very large number of cherries and small
clades, where TBE and FBP are nearly equivalent. Regarding the support
cut-off, 70% again appears as a good compromise for TBE, though
there is no way to evaluate the fraction of supported branches that are
actually erroneous. The interpretability of TBE will be a major asset for
choosing the support level depending on the phylogenetic question being
addressed. Here, as recombinant sequences are inevitable, lower supports
than with mammals will likely be acceptable.</p>
        </caption>
        <graphic xlink:href="nihms947517f8"/>
      </fig>
      <fig id="F9" orientation="portrait" position="anchor">
        <label>Fig. ED5</label>
        <caption>
          <title>Medium-sized HIV datasets, subtype deep branching</title>
          <p id="P60">As the taxa were randomly drawn from the full dataset, the supports
and findings show some fluctuations. We display the trees obtained with two
of the medium-sized datasets in panels (a) and (b); branches with
FBP&gt;70%: yellow dots; branches with TBE&gt;70%:
blue dots; subtype clades: red stars, filled if support &gt;70%
(see Methods and note to <xref ref-type="fig" rid="F1">Fig. 1</xref> for
further details). (c) Deep branching of the subtypes<sup><xref rid="R19" ref-type="bibr">19</xref></sup> and supports obtained on
the full data set (see also <xref ref-type="fig" rid="F1">Fig. 1</xref>).
Rare subtypes (H, J, K) are absent in the medium datasets, and the subtype
clades are almost perfectly recovered (only 1 wrong taxon in A clade for
both trees). FBP supports are higher than with the full dataset (e.g.
58% and 99% for subtype B, versus 3% in <xref ref-type="fig" rid="F1">Fig. 1</xref>). However, some subtype clades
have moderate FBP (e.g. D), though the clade matches the subtype perfectly.
With TBE, all subtype supports are higher than 95%. The deep
branching is the same for all (full, medium) datasets and identical to
Hemelaar<sup><xref rid="R19" ref-type="bibr">19</xref></sup>, but
not supported by FBP, while TBE is larger than 70% for every branch
(or path in <xref ref-type="fig" rid="F1">Fig. 1</xref>). Again, the Indian
and East African sub-epidemics of subtype C are supported by TBE, but not by
FBP.</p>
        </caption>
        <graphic xlink:href="nihms947517f9"/>
      </fig>
      <fig id="F10" orientation="portrait" position="anchor">
        <label>Fig. ED6</label>
        <caption>
          <title>Distribution of the instability score in HIV recombinants</title>
          <p id="P61">We see a clear difference between the distributions of the
instability score for the recombinant and non-recombinant sequences, meaning
that the approach can be used to detect or confirm the recombinant status of
sequences (box quantiles: 25%, 50% and 75%). See
text for details.</p>
        </caption>
        <graphic xlink:href="nihms947517f10"/>
      </fig>
      <fig id="F11" orientation="portrait" position="anchor">
        <label>Fig. ED7</label>
        <caption>
          <title>Comparison of FBP and TBE &#x2013; Simulated, non-noisy and noisy
data</title>
          <p id="P62">Noisy data include rogue taxa and homoplasy, as opposed to non-noisy
data. These graphics display the distribution of branches with FPB/TBE
support &gt;70%. Both supports are compared regarding branch
depth, tree size, and quartet conflicts with the model tree used for
simulations (see text and notes to <xref ref-type="fig" rid="F1">Fig.
1</xref> and <xref ref-type="fig" rid="F2">2</xref> for explanations).
Results are fully congruent with those obtained with real datasets. TBE
supports more deep branches than FBP, especially with noisy data. The effect
of tree size is also more visible with noisy MSA, and the number of
supported branches with moderate (]5,20]%) and high
(&gt;20%) conflict levels is very low, for both FBP and
TBE.</p>
        </caption>
        <graphic xlink:href="nihms947517f11"/>
      </fig>
      <fig id="F12" orientation="portrait" position="anchor">
        <label>Fig. ED8</label>
        <caption>
          <title>Comparison of FBP and TBE at different support cut-offs &#x2013;
Simulated, noisy data</title>
          <p id="P63">Comparison of FBP and TBE regarding branch depth, quartet conflicts,
and tree size, at different support cut-offs (see text and notes to <xref ref-type="fig" rid="F1">Fig. 1</xref> and <xref ref-type="fig" rid="F2">2</xref> for explanations). A cut-off of 50% seems to be
acceptable, as neither FBP nor TBE support highly contradicted branches. But
this could be due to the low level of contradiction, compared to real
datasets (85 branches with contradiction &gt;20%, versus
~400 with the mammal dataset in <xref ref-type="fig" rid="F6">Fig.
ED2</xref>&#x2013;<xref ref-type="fig" rid="F7">ED3</xref>).</p>
        </caption>
        <graphic xlink:href="nihms947517f12"/>
      </fig>
      <fig id="F13" orientation="portrait" position="anchor">
        <label>Fig. ED9</label>
        <caption>
          <title>Distribution of the instability score in rogue taxa &#x2013; Simulated,
noisy data</title>
          <p id="P64">TBE again appears to be useful for detecting and confirming rogue
taxa (box quantiles: 25%, 50% and 75%). See text for
details.</p>
        </caption>
        <graphic xlink:href="nihms947517f13"/>
      </fig>
      <fig id="F14" orientation="portrait" position="anchor">
        <label>Fig. ED10</label>
        <caption>
          <title>Repeatability and accuracy of FBP and TBE &#x2013; Simulated
data</title>
          <p id="P65">The bootstrap theory<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> indicates
that, with large samples, the supports estimated using bootstrap replicates
should be close to supports obtained with datasets of the same size drawn
from the same distribution as the original sample. We used simulated data to
check that this property holds with protein MSAs of 1,449 taxa and
~500 sites (see text for details). Top panels ((a): FBP, (b): TBE)
compare these two supports for all branches in the tree inferred by RAxML
from the original MSA. We observe a clear correlation, which is higher for
TBE (&#x3C1; = 0.85) than for FBP (&#x3C1; = 0.75) using
Pearson&#x2019;s linear correlation coefficient, but identical (0.83) using
Spearman&#x2019;s rank coefficient, which is better suited to the
discontinuous nature of FBP. These results appear to contradict those of
Hillis and Bull<sup><xref rid="R7" ref-type="bibr">7</xref></sup> who
concluded that the bootstrap is a highly imprecise measure of repeatability.
However, they measured the probability to infer the correct tree (not the
supports of inferred branches, as consistent in the bootstrap context), and
their main result was based on 50 sites, which is likely too low for the
bootstrap theory to apply. The bootstrap also relies on the plug-in
principle<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> stating that
the distribution of the distance between the true tree and the inferred tree
can be well-approximated by the distribution of the distance between the
inferred and bootstrap trees. Panel (c) measures for every branch
<italic>b</italic> inferred by RAxML from the original MSA, the accuracy
of TBE in predicting the topological distance between <italic>b</italic> and
the true tree, as measured using the normalized transfer index. Again, we
observe a clear correlation (&#x3C1; = 0.74, Spearman&#x2019;s = 0.70).
We performed the same experiment with FBP, seeking to predict the
presence/absence (1/0) of the inferred branch in the tree true; a lower but
still significant correlation was found (&#x3C1; = 0.59,
Spearman&#x2019;s = 0.54). Panel (d) compares using RAxML the performance
of simulation-based and bootstrap-based instability scores in detecting
rogue taxa; both are nearly identical (TPR: true positive rate; FPR: false
positive rate). Table (e) summarizes the results described above, and those
of FastTree, which are nearly identical to those of RAxML, except regarding
topological accuracy (%correct: fraction of correct branches), where
RAxML is again more accurate than FastTree.</p>
        </caption>
        <graphic xlink:href="nihms947517f14"/>
      </fig>
    </sec>
    <sec sec-type="supplementary-material" id="SM">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>1</label>
        <media xlink:href="NIHMS947517-supplement-1.zip" orientation="portrait" xlink:type="simple" id="d36e2502" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD2">
        <label>2</label>
        <media xlink:href="NIHMS947517-supplement-2.pdf" orientation="portrait" xlink:type="simple" id="d36e2506" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="FN2">
        <p id="P66">
          <bold>Source data:</bold>
        </p>
        <p id="P67">All our data, trees and workflows are available as source data, to be
linked to the online version of the paper at <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/nature">www.nature.com/nature</ext-link>.</p>
      </fn>
      <fn id="FN3" fn-type="con">
        <p id="P68">
          <bold>Author contributions:</bold>
        </p>
        <p id="P69">OG designed the research; FL, JBDE, MDF and OG performed the research;
FL and JBDE implemented the algorithms; FL and DC realized the website and
GitHub repositories; FL performed the analyses and graphics, with the help of EW
and TDO for HIV; OG wrote the paper, with the help of all co-authors.</p>
      </fn>
      <fn fn-type="COI-statement" id="FN4">
        <p id="P70"><bold>Competing interests:</bold> None.</p>
      </fn>
    </fn-group>
    <ack id="S16">
      <p id="P71">We thank Frederic Delsuc, Susan Holmes, Leonid Chindelevitch, Edward Susko,
three anonymous referees, and Nature Editor Dr Henry Gee for help and suggestions.
This work was supported by the EU-H2020 Virogenesis project (grant number 634650
&#x2013; EW, TDO, OG), by the INCEPTION project (PIA/ANR-16-CONV-0005 &#x2013; FL,
DC, MDF, OG), by the &#x201C;Institut Fran&#xE7;ais de Bioinformatique&#x201D;
(IFB - ANR-11-INBS-0013 &#x2013; DC), by the Flagship grant from the South African
Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI &#x2013; TdO, EW, JBDE),
and by the H3ABioNet project (NIH grant number U41HG006941 &#x2013; JBDE).</p>
    </ack>
    <ref-list>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Efron</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Bootstrap Methods: Another Look at the Jackknife</article-title>
          <source>Ann. Stat</source>
          <volume>7</volume>
          <fpage>1</fpage>
          <lpage>26</lpage>
          <year>1979</year>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Efron</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tibshirani</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <source>An introduction to the bootstrap</source>
          <publisher-name>Chapman &amp; Hall, NY</publisher-name>
          <year>1993</year>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Felsenstein</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Confidence limits on phylogenies: an approach using the
bootstrap</article-title>
          <source>Evolution</source>
          <volume>39</volume>
          <fpage>783</fpage>
          <lpage>791</lpage>
          <year>1985</year>
          <pub-id pub-id-type="pmid">28561359</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Noorden</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Maher</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Nuzzo</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The top 100 papers</article-title>
          <source>Nature</source>
          <volume>514</volume>
          <fpage>550</fpage>
          <lpage>553</lpage>
          <year>2014</year>
          <pub-id pub-id-type="pmid">25355343</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanderson</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Objections to bootstrapping phylogenies: A
critique</article-title>
          <source>Syst. Biol</source>
          <volume>44</volume>
          <fpage>299</fpage>
          <lpage>320</lpage>
          <year>1995</year>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holmes</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Bootstrapping Phylogenetic Trees: Theory and
Methods</article-title>
          <source>Stat. Sci</source>
          <volume>18</volume>
          <fpage>241</fpage>
          <lpage>255</lpage>
          <year>2003</year>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hillis</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Bull</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>An empirical test of bootstrapping as a method for assessing
confidence in phyogenetic analysis</article-title>
          <source>Syst. Biol</source>
          <volume>42</volume>
          <fpage>182</fpage>
          <lpage>192</lpage>
          <year>1993</year>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Felsenstein</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kishino</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Is there something wrong with the bootstrap on phylogenies a
reply to hillis and bull</article-title>
          <source>Syst. Biol</source>
          <volume>42</volume>
          <fpage>193</fpage>
          <lpage>200</lpage>
          <year>1993</year>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Efron</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Halloran</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Bootstrap confidence levels for phylogenetic
trees</article-title>
          <source>Proc. Natl. Acad. Sci</source>
          <volume>93</volume>
          <fpage>7085</fpage>
          <lpage>7096</lpage>
          <year>1996</year>
          <pub-id pub-id-type="pmid">8692949</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Susko</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Bootstrap support is not first-order correct</article-title>
          <source>Syst. Biol</source>
          <volume>58</volume>
          <fpage>211</fpage>
          <lpage>223</lpage>
          <year>2009</year>
          <pub-id pub-id-type="pmid">20525579</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zharkikh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Estimation of Confidence in Phylogeny: The Complete-and-Partial
Bootstrap Technique</article-title>
          <source>Mol. Phyl. Evol</source>
          <volume>4</volume>
          <fpage>44</fpage>
          <lpage>63</lpage>
          <year>1995</year>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Susko</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>First-order correct bootstrap support adjustments for splits that
allow hypothesis testing when using maximum likelihood
estimation</article-title>
          <source>Mol. Biol. Evol</source>
          <volume>27</volume>
          <fpage>1621</fpage>
          <lpage>1629</lpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20154180</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soltis</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Soltis</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Applying the Bootstrap in Phylogeny
Reconstruction</article-title>
          <source>Stat. Sci</source>
          <volume>18</volume>
          <fpage>256</fpage>
          <lpage>267</lpage>
          <year>2003</year>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huelsenbeck</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rannala</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Frequentist Properties of Bayesian Posterior Probabilities of
Phylogenetic Trees Under Simple and Complex Substitution
Models</article-title>
          <source>Syst. Biol</source>
          <volume>53</volume>
          <fpage>904</fpage>
          <lpage>913</lpage>
          <year>2004</year>
          <pub-id pub-id-type="pmid">15764559</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anisimova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gascuel</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Approximate Likelihood-Ratio Test for Branches: A Fast, Accurate,
and Powerful Alternative</article-title>
          <source>Syst. Biol</source>
          <volume>55</volume>
          <fpage>539</fpage>
          <lpage>552</lpage>
          <year>2006</year>
          <pub-id pub-id-type="pmid">16785212</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anisimova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gil</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dufayard</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Dessimoz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gascuel</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Survey of branch support methods demonstrates accuracy, power,
and robustness of fast likelihood-based approximation
schemes</article-title>
          <source>Syst. Biol</source>
          <volume>60</volume>
          <fpage>685</fpage>
          <lpage>699</lpage>
          <year>2011</year>
          <pub-id pub-id-type="pmid">21540409</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stamatakis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hoover</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rougemont</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A Rapid Bootstrap Algorithm for the RAxML Web
Servers</article-title>
          <source>Syst. Biol</source>
          <volume>57</volume>
          <fpage>758</fpage>
          <lpage>771</lpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18853362</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minh</surname>
              <given-names>BQ</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>MAT</given-names>
            </name>
            <name>
              <surname>Von Haeseler</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Ultrafast approximation for phylogenetic
bootstrap</article-title>
          <source>Mol. Biol. Evol</source>
          <volume>30</volume>
          <fpage>1188</fpage>
          <lpage>1195</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">23418397</pub-id>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hemelaar</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The origin and diversity of the HIV-1 pandemic</article-title>
          <source>Trends Mol. Med</source>
          <volume>18</volume>
          <fpage>182</fpage>
          <lpage>192</lpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22240486</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanderson</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Shaffer</surname>
              <given-names>HB</given-names>
            </name>
          </person-group>
          <article-title>Troubleshooting Molecular Phylogenetic Analyses</article-title>
          <source>Annu. Rev. Ecol. Syst</source>
          <volume>33</volume>
          <fpage>49</fpage>
          <lpage>72</lpage>
          <year>2002</year>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilkinson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Majority-rule reduced consensus trees and their use in
bootstrapping</article-title>
          <source>Mol. Biol. Evol</source>
          <volume>13</volume>
          <fpage>437</fpage>
          <lpage>444</lpage>
          <year>1996</year>
          <pub-id pub-id-type="pmid">8742632</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thorley</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Testing the Phylogenetic Stability of Early
Tetrapods</article-title>
          <source>J. Theor. Biol</source>
          <volume>200</volume>
          <fpage>343</fpage>
          <lpage>344</lpage>
          <year>1999</year>
          <pub-id pub-id-type="pmid">10527723</pub-id>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomson</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Shaffer</surname>
              <given-names>HB</given-names>
            </name>
          </person-group>
          <article-title>Sparse Supermatrices for Phylogenetic Inference: Taxonomy,
Alignment, Rogue Taxa, and the Phylogeny of Living Turtles</article-title>
          <source>Syst. Biol</source>
          <volume>59</volume>
          <fpage>42</fpage>
          <lpage>58</lpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20525619</pub-id>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aberer</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Krompass</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stamatakis</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Pruning rogue taxa improves phylogenetic accuracy: An efficient
algorithm and webservice</article-title>
          <source>Syst. Biol</source>
          <volume>62</volume>
          <fpage>162</fpage>
          <lpage>166</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">22962004</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanderson</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Confidence limits on phylogenies: the bootstrap
revisited</article-title>
          <source>Cladistics</source>
          <volume>5</volume>
          <fpage>113</fpage>
          <lpage>129</lpage>
          <year>1989</year>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Br&#xE9;h&#xE9;lin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gascuel</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Using repeated measurements to validate hierarchical gene
clusters</article-title>
          <source>Bioinformatics</source>
          <volume>24</volume>
          <fpage>682</fpage>
          <lpage>688</lpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18204054</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Charon</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Denoeud</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gu&#xE9;noche</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hudry</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Maximum transfer distance between partitions</article-title>
          <source>J. Classif</source>
          <volume>23</volume>
          <fpage>103</fpage>
          <lpage>121</lpage>
          <year>2006</year>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Day</surname>
              <given-names>WHE</given-names>
            </name>
          </person-group>
          <article-title>The complexity of computing metric distances between
partitions</article-title>
          <source>Math. Soc. Sci</source>
          <volume>1</volume>
          <fpage>269</fpage>
          <lpage>287</lpage>
          <year>1981</year>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Rajan</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Moret</surname>
              <given-names>BME</given-names>
            </name>
          </person-group>
          <article-title>A Metric for Phylogenetic Trees Based on Matching</article-title>
          <source>IEEE/ACM Trans. Comp. Biol. Bioinf</source>
          <volume>9</volume>
          <fpage>1014</fpage>
          <lpage>1022</lpage>
          <year>2012</year>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>K&#xFC;nsch</surname>
              <given-names>HR</given-names>
            </name>
          </person-group>
          <article-title>The jackknife and the bootstrap for general stationary
observations</article-title>
          <source>Annals of Statistics</source>
          <volume>17</volume>
          <fpage>1217</fpage>
          <lpage>1241</lpage>
          <year>1989</year>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Billera</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Vogtmann</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Geometry of the Space of Phylogenetic Trees</article-title>
          <source>Adv. Appl. Math</source>
          <volume>27</volume>
          <fpage>733</fpage>
          <lpage>767</lpage>
          <year>2001</year>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Filipski</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Battistuzzi</surname>
              <given-names>FU</given-names>
            </name>
            <name>
              <surname>Kosakovsky Pond</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Koichiro</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Statistics and Truth in Phylogenomics</article-title>
          <source>Mol. Biol. Evol</source>
          <volume>29</volume>
          <fpage>457</fpage>
          <lpage>472</lpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">21873298</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Truszkowski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Goldman</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Maximum Likelihood Phylogenetic Inference is Consistent on
Multiple Sequence Alignments, with or without Gaps</article-title>
          <source>Syst Biol</source>
          <volume>65</volume>
          <fpage>328</fpage>
          <lpage>333</lpage>
          <year>2016</year>
          <pub-id pub-id-type="pmid">26615177</pub-id>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Price</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Dehal</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Arkin</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
          <article-title>FastTree 2 - Approximately maximum-likelihood trees for large
alignments</article-title>
          <source>PLoS One</source>
          <volume>5</volume>
          <fpage>e9590</fpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20231880</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <note>
          <p id="P72"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/taxonomy">https://www.ncbi.nlm.nih.gov/taxonomy</ext-link>, date of access: April
2016, available from Booster GitHub repository <ext-link ext-link-type="uri" xlink:href="https://github.com/evolbioinfo/booster">https://github.com/evolbioinfo/booster</ext-link></p>
        </note>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grenfell</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Pybus</surname>
              <given-names>OG</given-names>
            </name>
            <name>
              <surname>Gog</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Daly</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mumford</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
          <article-title>Unifying the Epidemiological and Evolutionary Dynamics of
Pathogens</article-title>
          <source>Science</source>
          <volume>303</volume>
          <fpage>327</fpage>
          <lpage>332</lpage>
          <year>2004</year>
          <pub-id pub-id-type="pmid">14726583</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schultz</surname>
              <given-names>AK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>jpHMM: Improving the reliability of recombination prediction in
HIV-1</article-title>
          <source>Nuc. Acids Res</source>
          <volume>38</volume>
          <fpage>1059</fpage>
          <year>2010</year>
        </element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Foulds</surname>
              <given-names>LR</given-names>
            </name>
          </person-group>
          <article-title>Comparison of phylogenetic trees</article-title>
          <source>Math. Biosci</source>
          <volume>53</volume>
          <fpage>131</fpage>
          <lpage>147</lpage>
          <year>1981</year>
        </element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Semple</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Steel</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <source>Phylogenetics</source>
          <publisher-name>Oxford University Press</publisher-name>
          <publisher-loc>Oxford, UK</publisher-loc>
          <year>2003</year>
        </element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lefort</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Longueville</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Gascuel</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>SMS: Smart Model Selection in PhyML</article-title>
          <source>Mol. Biol. Evol</source>
          <volume>34</volume>
          <fpage>2422</fpage>
          <lpage>2424</lpage>
          <year>2017</year>
          <pub-id pub-id-type="pmid">28472384</pub-id>
        </element-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Letunic</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bork</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Interactive tree of life (iTOL) v3: an online tool for the
display and annotation of phylogenetic and other trees</article-title>
          <source>Nuc. Acids Res</source>
          <volume>44</volume>
          <fpage>W242</fpage>
          <lpage>W245</lpage>
          <year>2016</year>
        </element-citation>
      </ref>
      <ref id="R42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Tommaso</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nextflow enables reproducible computational
workflows</article-title>
          <source>Nat. Biotech</source>
          <volume>35</volume>
          <fpage>316</fpage>
          <lpage>319</lpage>
          <year>2017</year>
        </element-citation>
      </ref>
      <ref id="R43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sand</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TqDist: A library for computing the quartet and triplet distances
between binary or general trees</article-title>
          <source>Bioinformatics</source>
          <volume>30</volume>
          <fpage>2079</fpage>
          <lpage>2080</lpage>
          <year>2014</year>
          <pub-id pub-id-type="pmid">24651968</pub-id>
        </element-citation>
      </ref>
      <ref id="R44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katoh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Standley</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>MAFFT multiple sequence alignment software version 7:
Improvements in performance and usability</article-title>
          <source>Mol. Biol. Evol</source>
          <volume>30</volume>
          <fpage>772</fpage>
          <lpage>780</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">23329690</pub-id>
        </element-citation>
      </ref>
      <ref id="R45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delatorre</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Bello</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Phylodynamics of HIV-1 Subtype C Epidemic in East
Africa</article-title>
          <source>PLoS One</source>
          <volume>7</volume>
          <fpage>e41904</fpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22848653</pub-id>
        </element-citation>
      </ref>
      <ref id="R46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soares</surname>
              <given-names>Ma</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A specific subtype C of human immunodeficiency virus type 1
circulates in Brazil</article-title>
          <source>AIDS</source>
          <volume>17</volume>
          <fpage>11</fpage>
          <lpage>21</lpage>
          <year>2003</year>
          <pub-id pub-id-type="pmid">12478065</pub-id>
        </element-citation>
      </ref>
      <ref id="R47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siddappa</surname>
              <given-names>NB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of subtype C human immunodeficiency virus type 1
by subtype-specific PCR and its use in the characterization of viruses
circulating in the southern parts of India</article-title>
          <source>J. Clin. Microbiol</source>
          <volume>42</volume>
          <fpage>2742</fpage>
          <lpage>2751</lpage>
          <year>2004</year>
          <pub-id pub-id-type="pmid">15184461</pub-id>
        </element-citation>
      </ref>
      <ref id="R48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guindon</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>New Algorithms and Mehtods to Estimate Maximum-Likelihood
Phylogenies: Asessing the Performance of PhyML 3.0</article-title>
          <source>Syst. Biol</source>
          <volume>59</volume>
          <fpage>307</fpage>
          <lpage>321</lpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20525638</pub-id>
        </element-citation>
      </ref>
      <ref id="R49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fletcher</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>INDELible: A flexible simulator of biological sequence
evolution</article-title>
          <source>Mol. Biol. Evol</source>
          <volume>26</volume>
          <fpage>1879</fpage>
          <lpage>1888</lpage>
          <year>2009</year>
          <pub-id pub-id-type="pmid">19423664</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <title>Felsenstein (FBP) and transfer (TBE) bootstrap supports on the same tree with
9,147 HIV-1M pol sequences</title>
        <p id="P73">(a): FBP; (b): TBE. Subtypes are colorized; recombinant sequences are
black; dots correspond to branches with support &gt;70%<sup><xref rid="R7" ref-type="bibr">7</xref></sup>. Supports are given for the tree
clades that are closer to the subtypes (red stars, filled when support
&gt;70%); for each of these clades we provide, using jpHMM
predictions, the number of wrong (<italic>w</italic>) taxa that do not belong to
the corresponding subtype, and the number of missing (<italic>m</italic>) taxa
that belong to the subtype but not to the clade. For the C and the H, these
clades are not supported by FBP, but there exist neighbouring clades with FBP
&gt;70%, and these are shown in brackets. The same approach is
applied to the C sub-epidemics in India (IND) and Eastern Africa (EA); the ratio
provides the coverage of the clade, i.e. the number of studied (e.g. Indian)
taxa in the clade versus the total number of those taxa in the dataset. The
South American clade (SA, not shown, included in EA) is supported by TBE but not
by FBP (73% vs. 14%, 15 taxa, 14/14). The histograms provide the
number of branches with support &gt;70% depending on branch depth,
which is measured by the number of taxa in the smaller of the two clades defined
by the given branch.</p>
      </caption>
      <graphic xlink:href="nihms947517f1"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Fig. 2</label>
      <caption>
        <title>Felsenstein (FBP) and transfer (TBE) bootstrap supports with 1,449 COI-5P
mammal sequences &#x2013; FastTree phylogeny</title>
        <p id="P74">Graphs (a) to (d) refer to branches with supports
&gt;70%<sup><xref rid="R7" ref-type="bibr">7</xref></sup>,
with the vertical axis denoting the percentage of these branches in a given
condition (e.g. (b): 19 internal branches with 22-taxon trees, and 2/19
&#x2248; 10% of branches with FBP &gt;70%). (a) Supports
regarding branch depth (see note to <xref ref-type="fig" rid="F1">Fig.
1</xref>). (b) Supports regarding tree size (i.e. number of taxa). (c) Supports
regarding percentage of quartet conflicts with NCBI taxonomy
(&#x2264;5%: low conflict level;] 5,20]% moderate;
&#x2265;20%: high). (d) Same as (c) but regarding the true tree used
for simulations.</p>
      </caption>
      <graphic xlink:href="nihms947517f2"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Fig. 3</label>
      <caption>
        <title>Felsenstein (FBP) and transfer (TBE) bootstrap supports &#x2013; FastTree
phylogeny using 1,449 COI-5P mammal sequences &#x2013; Focus on the simian
clade</title>
        <p id="P75">All simian sequences are included, but two additional non-simian
sequences are added, one rogue taxon (<italic>Maxomys rajah</italic>, detected
by TBE, see text) and one stable but erroneous taxon with partial sequence
(<italic>Canis adustus</italic>); this simian tree is very close to the NCBI
taxonomy (&lt;2.5% of contradicted quartets, when both erroneous
taxa are pruned).</p>
      </caption>
      <graphic xlink:href="nihms947517f3"/>
    </fig>
    <fig id="F4" orientation="portrait" position="float">
      <label>Fig. 4</label>
      <caption>
        <title>Felsenstein (FBP) and transfer (TBE) supports on the same tree with 1,449
COI-5P mammal sequences &#x2013; RAxML with rapid bootstrap</title>
        <p id="P76">(a): FBP; (b): TBE. This phylogeny is more accurate than the one by
FastTree (27% versus 38% of contradicted quartets,
respectively), but still relatively poor, especially regarding deep nodes and
larger groups. For example, rodents and chiropters are not monophyletic and are
distributed in several subtrees. However, some parts of the tree are more
accurate. A few clades are highlighted, corresponding (almost) exactly to the
NCBI taxonomy. For example, all elephantidae taxa are recovered by RAxML in a
single clade, containing elephantidae only, while insectivores are included in a
clade containing one extra taxon. To select these clades, we minimized the
transfer distance with the NCBI taxonomy, in case of ambiguity. See note to
<xref ref-type="fig" rid="F1">Fig. 1</xref> and Methods for details.</p>
      </caption>
      <graphic xlink:href="nihms947517f4"/>
    </fig>
  </floats-group>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">6011</journal-id>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">29342134</article-id>
      <article-id pub-id-type="pmc">5785464</article-id>
      <article-id pub-id-type="doi">10.1038/nature25432</article-id>
      <article-id pub-id-type="manuscript">NIHMS925648</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Chromosomal instability drives metastasis through a cytosolic DNA response</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bakhoum</surname>
            <given-names>Samuel F.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref rid="FN2" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ngo</surname>
            <given-names>Bryan</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref rid="FN2" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Laughney</surname>
            <given-names>Ashley M.</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cavallo</surname>
            <given-names>Julie-Ann</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Murphy</surname>
            <given-names>Charles J.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ly</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shah</surname>
            <given-names>Pragya</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sriram</surname>
            <given-names>Roshan K</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Watkins</surname>
            <given-names>Thomas B. K.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taunk</surname>
            <given-names>Neil K.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Duran</surname>
            <given-names>Mercedes</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pauli</surname>
            <given-names>Chantal</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shaw</surname>
            <given-names>Christine</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chadalavada</surname>
            <given-names>Kalyani</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rajasekhar</surname>
            <given-names>Vinagolu K.</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Genovese</surname>
            <given-names>Giulio</given-names>
          </name>
          <xref ref-type="aff" rid="A10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Venkatesan</surname>
            <given-names>Subramanian</given-names>
          </name>
          <xref ref-type="aff" rid="A11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Birkbak</surname>
            <given-names>Nicolai J.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
          <xref ref-type="aff" rid="A11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McGranahan</surname>
            <given-names>Nicholas</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
          <xref ref-type="aff" rid="A11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lundquist</surname>
            <given-names>Mark</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>LaPlant</surname>
            <given-names>Quincey</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Healey</surname>
            <given-names>John H.</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Elemento</surname>
            <given-names>Olivier</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chung</surname>
            <given-names>Christine H</given-names>
          </name>
          <xref ref-type="aff" rid="A12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Nancy Y.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Imielenski</surname>
            <given-names>Marcin</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nanjangud</surname>
            <given-names>Gouri</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pe&#x2019;er</surname>
            <given-names>Dana</given-names>
          </name>
          <xref ref-type="aff" rid="A13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cleveland</surname>
            <given-names>Don W.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Powell</surname>
            <given-names>Simon N.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lammerding</surname>
            <given-names>Jan</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Swanton</surname>
            <given-names>Charles</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
          <xref ref-type="aff" rid="A11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cantley</surname>
            <given-names>Lewis C.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
<label>1</label>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA</aff>
      <aff id="A2">
<label>2</label>Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10065, USA</aff>
      <aff id="A3">
<label>3</label>Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA</aff>
      <aff id="A4">
<label>4</label>Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, California 92093, USA</aff>
      <aff id="A5">
<label>5</label>Nancy E. and Peter C. Meinig School of Biomedical Engineering &amp; Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, New York 14850, USA</aff>
      <aff id="A6">
<label>6</label>The Francis Crick Institute, London NW1 1AT, UK</aff>
      <aff id="A7">
<label>7</label>Institute for Pathology and Molecular Pathology, University Hospital Zurich, Zurich 8091, Switzerland</aff>
      <aff id="A8">
<label>8</label>Molecular Cytogenetics Core, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA</aff>
      <aff id="A9">
<label>9</label>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA</aff>
      <aff id="A10">
<label>10</label>The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA</aff>
      <aff id="A11">
<label>11</label>UCL Cancer Institute, London WC1E 6BT, UK</aff>
      <aff id="A12">
<label>12</label>Moffitt Cancer Center, Tampa, Florida 33612, USA</aff>
      <aff id="A13">
<label>13</label>Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA</aff>
      <author-notes>
        <corresp id="FN1">Corresponding author: Lewis C. Cantley, Ph.D., Meyer Director, Sandra and Edward Meyer Cancer Center, Professor of Cancer Biology in Medicine, Weill Cornell Medicine, Belfer Research Building, 413 East 69<sup>th</sup> Street, 13<sup>th</sup> Floor, Box 50, New York, N.Y., 10021, Tel: ++1 (646) 962-632, Fax: ++1 (646) 962-0575, <email>lcantley@med.cornell.edu</email></corresp>
        <fn id="FN2" fn-type="equal">
          <label>*</label>
          <p>Authors contributed equally to this work</p>
        </fn>
        <fn id="FN3">
          <p>Correspondence and requests for materials should be addressed to L.C.C. (<email>lcantley@med.cornell.edu</email>).</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>7</day>
        <month>12</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>1</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>25</day>
        <month>1</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>17</day>
        <month>7</month>
        <year>2018</year>
      </pub-date>
      <volume>553</volume>
      <issue>7689</issue>
      <fpage>467</fpage>
      <lpage>472</lpage>
      <!--elocation-id from pubmed: 10.1038/nature25432-->
      <permissions>
        <license>
          <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:
<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
        </license>
        <license license-type="permissions-link">
          <license-p>Reprints and permissions information is available at <ext-link ext-link-type="uri" xlink:href="www.nature.com/reprints">www.nature.com/reprints</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <p id="P1">Chromosomal instability (CIN) is a hallmark of cancer and it results from ongoing errors in chromosome segregation during mitosis. While CIN is a major driver of tumor evolution, its role in metastasis has not been established. Here we show that CIN promotes metastasis by sustaining a tumor-cell autonomous response to cytosolic DNA. Errors in chromosome segregation create a preponderance of micronuclei whose rupture spills genomic DNA into the cytosol. This leads to the activation of the cGAS-STING cytosolic DNA-sensing pathway and downstream noncanonical NF-&#x3BA;B signaling. Genetic suppression of CIN significantly delays metastasis even in highly aneuploid tumor models, whereas inducing continuous chromosome segregation errors promotes cellular invasion and metastasis in a STING-dependent manner. By subverting lethal epithelial responses to cytosolic DNA, chromosomally unstable tumor cells co-opt chronic activation of innate immune pathways to spread to distant organs.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p id="P2">Chromosomal instability (CIN) correlates with tumor metastasis<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup>, yet it remains unclear whether it is a mere bystander or a driver of metastatic progression. Chromosomally unstable cells exhibit evidence of chromosome missegregation during anaphase<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup>, offering an attractive bottleneck to target CIN and probe its selective contribution in metastasis. Destabilization of microtubule attachments to chromosomes at the kinetochores, through overexpression of the non-motile microtubule depolymerizing kinesin-13 proteins, Kif2b or MCAK/Kif2c, directly suppresses CIN in otherwise chromosomally unstable cells<sup><xref rid="R5" ref-type="bibr">5</xref>&#x2013;<xref rid="R7" ref-type="bibr">7</xref></sup>. Cells overexpressing Kif2b or MCAK continue to propagate abnormal aneuploid karyotypes albeit in a stable manner<sup><xref rid="R7" ref-type="bibr">7</xref></sup>. As such, this approach permits direct experimental interrogation of CIN, as defined by the rate of ongoing chromosome missegregation, independently of aneuploidy, which is defined as a state of abnormal chromosome numbers.</p>
    <sec disp-level="2" id="S2">
      <title>Increased CIN in human metastases</title>
      <p id="P3">First, to determine whether CIN is associated with human metastases, we applied the weighted-genomic integrity index (wGII) as a proxy for CIN<sup><xref rid="R8" ref-type="bibr">8</xref></sup> on 79 primary tumor-brain metastases matched pairs from a recently published cohort<sup><xref rid="R9" ref-type="bibr">9</xref></sup>. Metastases exhibited increased wGII compared to primary tumors (<xref rid="F1" ref-type="fig">Fig. 1a</xref>, <xref rid="F7" ref-type="fig">Extended Data Fig. 1a&#x2013;b</xref>).</p>
      <p id="P4">Next, karyotype analysis of primary breast tumors and metastases archived in the Mitelman Database of chromosomal translocations<sup><xref rid="R10" ref-type="bibr">10</xref></sup> revealed a predilection for near-diploid (2n) karyotypes in primary tumors. Conversely, metastases were enriched for cells with near-triploid (3n) karyotypes and had twice as many structural or numerical chromosomal aberrations per clone. The number of chromosomal aberrations was highest in tumor samples with karyotypes ranging between the diploid and tetraploid (4n) range (<xref rid="F1" ref-type="fig">Fig. 1b&#x2013;c</xref> and <xref rid="F7" ref-type="fig">Extended Data Fig. 1c&#x2013;d</xref>).</p>
      <p id="P5">Finally, histologic analysis of primary tumors from patients with locally advanced head and neck squamous cell carcinoma<sup><xref rid="R11" ref-type="bibr">11</xref></sup> revealed a significant association between anaphase chromosome missegregation and the incidence of lymph node metastasis (<xref rid="F1" ref-type="fig">Fig. 1d</xref>, <xref rid="F7" ref-type="fig">Extended Data Fig. 1e</xref>).</p>
    </sec>
    <sec disp-level="2" id="S3">
      <title>CIN is a driver of metastasis</title>
      <p id="P6">To determine whether CIN is causally involved in metastasis, we used transplantable metastatic tumor models of human (MDA-MB-231) or murine (4T1) triple-negative breast cancer and human lung adenocarcinoma (H2030), in which 47%, 55%, and 67% of anaphase cells, respectively, show evidence of chromosome missegregation. Overexpression of Kif2b or MCAK suppressed chromosome missegregation, whereas overexpression of a dominant negative MCAK mutant<sup><xref rid="R12" ref-type="bibr">12</xref></sup> (dnMCAK) led to a modest increase in chromosome missegregation in MDA-MB-231 cells. Kinesin-13 overexpression did not alter cellular proliferation or the number of centrosomes per cell (<xref rid="F2" ref-type="fig">Fig. 2a&#x2013;b</xref>, <xref rid="F7" ref-type="fig">Extended Data Figs. 1f&#x2013;h</xref> and <xref rid="F9" ref-type="fig">3a</xref>). As a control, we overexpressed Kif2a, a third member of the kinesin-13 proteins that lacks kinetochore and centromere localization domains<sup><xref rid="R13" ref-type="bibr">13</xref></sup>, and observed no effect on CIN despite exhibiting microtubule-depolymerizing activity on interphase microtubules (<xref rid="F2" ref-type="fig">Fig. 2b</xref>, <xref rid="F7" ref-type="fig">Extended Data Fig. 1i&#x2013;j</xref>). We ruled out a direct role for kinesin-13-mediated microtubule depolymerization in activating small GTPases<sup><xref rid="R14" ref-type="bibr">14</xref></sup> by performing RhoA and Rac1 pull-down assays, which revealed low basal levels of activity and no correlation with kinesin-13 overexpression (<xref rid="F8" ref-type="fig">Extended Data Fig. 2a&#x2013;b</xref>). Hereafter, we refer to MCAK and Kif2b-expressing cells as <italic>CIN-low</italic> while denoting control, Kif2a, and dnMCAK-expressing cells as <italic>CIN-high</italic>.</p>
      <p id="P7">Karyotyping of the parental MDA-MB-231 cells revealed a widely aneuploid (~3n) chromosome content with widespread karyotypic heterogeneity (<xref rid="F8" ref-type="fig">Extended Data Fig. 2c</xref>). Suppression of CIN reduced both numerical and structural karyotypic heterogeneity in single-cell derived clones as supported by the presence of fewer chromosomes exhibiting non-clonal structural abnormalities and decreased numerical chromosome heterogeneity in CIN-low cells (<xref rid="F8" ref-type="fig">Extended Data Fig. 2c&#x2013;h</xref>). Importantly, CIN-low cells maintained highly aneuploid karyotypes, yet they faithfully propagated them in a stable manner. Thus, by comparing chromosomally stable aneuploid cells to their chromosomally unstable aneuploid counterparts, we can experimentally examine the role of CIN, independently of aneuploidy, in metastasis.</p>
      <p id="P8">We injected MDA-MB-231 cells into the left cardiac ventricles of athymic mice to enable systemic dissemination while tracking metastatic colonization using a bioluminescence reporter. Altering chromosome missegregation rates had a dramatic effect on colonization, whereby mice harboring CIN-high cells rapidly succumbed to metastatic disease with a median survival of 70 days. Conversely, mice injected with CIN-low cells exhibited lower metastatic burden and a median survival of 207 days. Many metastases from CIN-low cells waxed-and-waned and, at times, spontaneously resolved, whereas metastases from CIN-high cells involved multiple organs and rapidly progressed leading to death. Similar results were obtained after injection of lung adenocarcinoma H2030 cells (<xref rid="F2" ref-type="fig">Fig. 2c&#x2013;e</xref> and <xref rid="F9" ref-type="fig">Extended Data Fig. 3b&#x2013;c</xref>). Overexpression of the spindle assembly checkpoint protein, Mad2 in MCAK-expressing cells partially rescued chromosome missegregation<sup><xref rid="R15" ref-type="bibr">15</xref></sup>, and correspondingly augmented metastasis (<xref rid="F2" ref-type="fig">Fig. 2c</xref> and <xref rid="F9" ref-type="fig">Extended Data Fig. 3f</xref>).</p>
      <p id="P9">We performed orthotopic injections of MDA-MB-231 or 4T1 cells into the mammary fat pad of athymic or immune competent BALB/c mice, respectively, followed by surgical excision of the primary tumor. Suppression of CIN had no effect on primary tumor implantation efficiency and even enhanced primary tumor growth in the 4T1 model. Yet, in both models, suppression of CIN significantly reduced spontaneous metastasis and prolonged survival (<xref rid="F9" ref-type="fig">Extended Data Fig. 3d&#x2013;e</xref>).</p>
      <p id="P10">We then assessed chromosome missegregation in the injected cells as well as cells derived from primary tumors and metastatic colonies (<xref rid="F3" ref-type="fig">Fig. 3a</xref>). We performed this analysis using MDA-MB-231 cells and two metastasis-competent xenografts (PDX) derived from patients with ER+ and TNBC. Regardless of the CIN status of the injected cells, the majority of metastases enriched for higher rates of chromosome missegregation, whereas cells derived from most primary tumors had significantly lower rates of CIN (<xref rid="F3" ref-type="fig">Fig. 3b&#x2013;d</xref>). For instance, when CIN-high cells (<xref rid="F3" ref-type="fig">Fig. 3d</xref>, dnMCAK, blue bars) were injected in the mammary fat pad, chromosome missegregation rates decreased in the primary tumors (green bars) before increasing once more in metastases spontaneously arising within the same animal (orange bars).</p>
    </sec>
    <sec disp-level="2" id="S4">
      <title>CIN enriches for mesenchymal traits</title>
      <p id="P11">Bulk RNA sequencing (RNA-seq) of CIN-low and CIN-high MDA-MB-231 cells revealed 1,584 differentially expressed genes. Principle component analysis (PCA) and unsupervised clustering accurately separated samples according to their CIN status. Metastasis-related and epithelial-to-mesenchymal (EMT) gene sets were relatively enriched in CIN-high cells. The top 23 differentially expressed genes in CIN-high cells (referred to as CIN signature) predicted distant-metastasis-free survival (DMFS) in a meta-analysis<sup><xref rid="R16" ref-type="bibr">16</xref></sup> as well as a validation cohort<sup><xref rid="R17" ref-type="bibr">17</xref></sup> of patients with breast cancer, irrespective of tumor subtype, grade, or lymph node status (<xref rid="F10" ref-type="fig">Extended Data Figs. 4</xref> and <xref rid="F11" ref-type="fig">5</xref>).</p>
      <p id="P12">RNA-seq of primary tumor-derived and metastasis-derived cells revealed pathways that were shared among metastases and CIN-high cells. Yet, metastases contained a large number of differentially upregulated EMT and inflammation-related genes that were disproportionately clustered on chromosome 1, signifying chromosome 1-specific selection. Karyotype analysis revealed that the injected cell lines and most metastases had three copies of chromosome 1, whereas primary tumors consistently had 2 copies. Thus chromosome 1 loss is a recurrent event during primary tumor growth in this model (<xref rid="F10" ref-type="fig">Extended Data Figs. 4c&#x2013;f</xref> and <xref rid="F11" ref-type="fig">5a&#x2013;e</xref>).</p>
      <p id="P13">We then performed single-cell RNA sequencing (scRNA-seq) on two CIN-low (Kif2b and MCAK) and one CIN-high (dnMCAK) MDA-MB-231 cell lines comprising a total of 6,821 cells. Clustering of single cells using EMT genes successfully classified most cells based on their CIN-status and revealed a fraction of cells (primarily CIN-high) that was highly enriched in mesenchymal markers (<xref rid="F4" ref-type="fig">Fig. 4a</xref>). Unsupervised graph-based clustering, based on all expressed genes, identified 12 phenotypically distinct subpopulations. One subpopulation was defined by increased expression of genes involved in EMT and metastasis (referred to as subpopulation &#x2018;M&#x2019;) and was concomitantly enriched for CIN signature genes. This subpopulation comprised 45% of dnMCAK expressing cells compared to 6% of the CIN-low cells (<xref rid="F4" ref-type="fig">Fig. 4b</xref> and <xref rid="F12" ref-type="fig">Extended Data Fig. 6a&#x2013;b</xref>).</p>
      <p id="P14">In line with the scRNA-seq data, CIN-high cells exhibited increased migratory and invasive behavior <italic>in vitro</italic>, and displayed evidence of actin cytoskeletal reorganization, diffuse vimentin staining, and increased cytoplasmic and nuclear localization of &#x3B2;-catenin (<xref rid="F12" ref-type="fig">Extended Data Figs. 6c&#x2013;d</xref> and <xref rid="F13" ref-type="fig">7a&#x2013;d</xref>). Expectedly, Mad2 overexpression rescued invasion and migration of MCAK expressing cells. Furthermore, the ability of Kif2b or MCAK overexpression to suppress invasion <italic>in vitro</italic> was dependent on the cell cycle, as the addition of thymidine after transient transfection of either proteins abrogated this phenotype (<xref rid="F12" ref-type="fig">Extended Data Figs. 6f</xref>, <xref rid="F13" ref-type="fig">7e&#x2013;f</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 2</xref>).</p>
    </sec>
    <sec disp-level="2" id="S5">
      <title>CIN generates cytosolic DNA</title>
      <p id="P15">To better define CIN-responsive pathways, we performed a gene-gene Pearson correlation analysis using scRNA-seq data and identified two large gene modules: module 1 was characterized by proliferative and metabolic pathways, whereas module 2 comprised EMT and inflammation gene sets (<xref rid="F5" ref-type="fig">Fig. 5a</xref>). There was a strong positive correlation between inflammation-related, CIN signature, and EMT genes in the scRNA-seq and bulk RNA-seq data (<xref rid="F4" ref-type="fig">Figs. 4b</xref>, <xref rid="F5" ref-type="fig">5b</xref>, and <xref rid="F10" ref-type="fig">Extended Data Fig. 4b&#x2013;c</xref>).</p>
      <p id="P16">Induction of inflammatory pathways in response to CIN was unexpected and was reminiscent of a viral infection. We asked whether CIN might introduce genomic DNA into the cytosol, thereby eliciting cellular responses normally reserved for anti-viral immunity<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup>. Exposure of genomic DNA to the cytosol can result from either primary nuclear or micronuclear envelope ruptures<sup><xref rid="R20" ref-type="bibr">20</xref>&#x2013;<xref rid="R24" ref-type="bibr">24</xref></sup>. We performed live-cell imaging using a NLS-GFP reporter<sup><xref rid="R25" ref-type="bibr">25</xref></sup> and found no correlation between CIN and the frequency of NLS-GFP leakage into the cytosol in unconfined conditions. There was even a trend for more efficient primary nucleus repair in CIN-high cells. CIN-high nuclei ruptured more frequently only during confined migration, and this was primarily attributed to their increased ability to go through a larger number of small constrictions (<xref rid="F13" ref-type="fig">Extended Data Fig. 7g&#x2013;j</xref>) that mimic confined migration during metastasis<sup><xref rid="R25" ref-type="bibr">25</xref></sup>.</p>
      <p id="P17">Instead, CIN-high cells and those derived from metastases exhibited a higher preponderance of micronuclei compared with CIN-low or primary tumor-derived cells, respectively (<xref rid="F5" ref-type="fig">Fig. 5c&#x2013;e</xref>, <xref rid="F14" ref-type="fig">Extended Data Fig. 8a&#x2013;c</xref>). To examine if rupture-prone<sup><xref rid="R20" ref-type="bibr">20</xref></sup> micronuclei correlated with increased cytosolic DNA, we stained cells using two different anti-dsDNA antibodies after selective plasma membrane permeabilization and found increased cytosolic dsDNA and single-stranded DNA (ssDNA) in CIN-high cells. The dsDNA signal, which was distinct from mitochondrial staining, disappeared after treatment with double-strand-specific &#x2013; but not single-strand-specific &#x2013; nuclease and after overexpression of Dnase2, confirming the specificity of these antibodies (<xref rid="F5" ref-type="fig">Fig. 5f</xref>, <xref rid="F14" ref-type="fig">Extended Data Fig. 8d&#x2013;h</xref>). Quantification of dsDNA levels after subcellular fractionation revealed a four-fold reduction in cytosolic DNA in CIN-low compared to CIN-high cells (<xref rid="F5" ref-type="fig">Fig. 5g</xref>). Whole-genome sequencing of subcellular fractions at 30x coverage confirmed the genomic origin of cytosolic DNA (not shown).</p>
      <p id="P18">To determine whether missegregated chromosomes provide a source of cytosolic DNA, we employed an inducible Y chromosome-specific missegregation system established in chromosomally stable DLD-1 colorectal cancer cells<sup><xref rid="R26" ref-type="bibr">26</xref></sup>. Whole-chromosome FISH probes targeting the Y chromosome or an independent autosome (chr15) revealed selective incorporation of the Y chromosome into micronuclei two days following chromosome missegregation induced by doxycycline and auxin (Dox/IAA) treatment. Strikingly, Y chromosome-specific fragments were found dispersed within the cytosol 2&#x2013;3 days after Dox/IAA addition, whereas the control autosome remained confined to the nucleus (<xref rid="F5" ref-type="fig">Fig. 5h</xref>), demonstrating that cytosolic DNA is generated from chromosomes undergoing high rates of missegregation</p>
      <p id="P19">Suppressing micronuclear envelope rupture through mCherry-Lamin B2 overexpression<sup><xref rid="R20" ref-type="bibr">20</xref></sup> reduced cytosolic dsDNA staining without influencing chromosome segregation errors. Accordingly, it reduced metastasis after intracardiac or tail vein injections (<xref rid="F5" ref-type="fig">Fig. 5i</xref> and <xref rid="F9" ref-type="fig">Extended Data Fig. 3g&#x2013;h</xref>).</p>
    </sec>
    <sec disp-level="2" id="S6">
      <title>Metastasis from cytosolic DNA response</title>
      <p id="P20">In chromosomally stable cells, cytosolic dsDNA is scarce and is sensed by the cGAS-STING pathway<sup><xref rid="R19" ref-type="bibr">19</xref></sup>, leading to induction of type I interferon stimulated genes (ISGs)<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup>. Indeed, induced missegregation of the Y chromosome led to the upregulation of OAS2, an ISG, and increased interferon-&#x3B2; production by DLD-1 cells (<xref rid="F15" ref-type="fig">Extended Data Fig. 9f&#x2013;g</xref>). It is unclear how chromosomally unstable cancer cells cope with the constant presence of cytosolic DNA. We found a striking localization of cGAS to approximately half of all micronuclei as previously observed<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>. Impeding micronuclear rupture through Lamin B2 overexpression<sup><xref rid="R20" ref-type="bibr">20</xref></sup> significantly diminished the relative fraction of cGAS+ micronuclei (<xref rid="F6" ref-type="fig">Fig. 6a&#x2013;b</xref>). Furthermore, CIN-high cells exhibited increased levels and perinuclear localization of STING congruent with pathway activation (<xref rid="F6" ref-type="fig">Fig. 6c</xref>).</p>
      <p id="P21">Interestingly, there was no evidence for robust activation of downstream canonical NF-&#x3BA;B or type I interferon signaling in CIN-high cells as evidenced by the lack of a significant increase in p65 or IRF3 phosphorylation, absence of p65 or IRF3 nuclear translocation, undetectable levels of interferon-&#x3B2;, and failure to induce ISGs (<xref rid="F14" ref-type="fig">Extended Data Figs. 8i&#x2013;j</xref> and <xref rid="F15" ref-type="fig">9</xref>), in line with previous observavtions<sup><xref rid="R28" ref-type="bibr">28</xref>&#x2013;<xref rid="R30" ref-type="bibr">30</xref></sup>.</p>
      <p id="P22">Cytosolic DNA, however, can activate the noncanonical NF-&#x3BA;B pathway in a STING-dependent and TBK1-independent manner<sup><xref rid="R18" ref-type="bibr">18</xref></sup>. We found evidence for noncanonical NF-&#x3BA;B activation in CIN-high cells as revealed by lower levels of the precursor protein, p100, a trend toward higher ratios of p52 and phosphorylated p100 relative to total p100, as well as lower levels of the noncanonical NF-&#x3BA;B pathway inhibitor, TRAF2<sup><xref rid="R31" ref-type="bibr">31</xref></sup> (<xref rid="F14" ref-type="fig">Extended Data Fig. 8i&#x2013;j</xref>). Given the subtle differences seen on the protein level, we assessed the nuclear localization of RelB, the binding partner of p52, and observed increased nuclear localization in CIN-high cells. This was often accompanied by cytosolic staining, indicative of chronic pathway activation. STING depletion reduced RelB nuclear localization and led to downregulation of EMT and inflammatory pathways, whereas the addition of cGAMP or overexpression of Mad2 increased nuclear RelB in MCAK-expressing cells (<xref rid="F6" ref-type="fig">Fig. 6d</xref>, <xref rid="F10" ref-type="fig">Extended Data Figs. 4e</xref> and <xref rid="F15" ref-type="fig">9c&#x2013;e</xref>).</p>
      <p id="P23">Bulk RNA-seq data revealed a number of noncanonical NF-&#x3BA;B target genes that were upregulated in response to CIN (CIN-responsive NC-NF-&#x3BA;B genes). There was a robust correlation between the CIN signature, STING, and the CIN-responsive NC-NF-&#x3BA;B genes in scRNA-seq data, in contrast to a weaker correlation between CIN and type I interferon targets (<xref rid="F5" ref-type="fig">Fig. 5b</xref>, <xref rid="F12" ref-type="fig">Extended Data Fig. 6e</xref>). Similarly, RNA-seq data from primary breast cancer in the TCGA database demonstrated increased expression of CIN-responsive NC-NF-&#x3BA;B genes in tumors with higher CIN signature genes (<xref rid="F6" ref-type="fig">Fig. 6e</xref>) and higher expression of key regulators of the noncanonical NF-&#x3BA;B pathway or its CIN responsive target genes was associated with shorter DMFS and disease-free survival in breast and lung cancers. Conversely, increased canonical NF-&#x3BA;B or type I interferon regulatory factors were associated with an improved prognosis (<xref rid="F16" ref-type="fig">Extended Data Fig. 10a</xref>).</p>
      <p id="P24">cGAS activation by cancer cells has been invoked in brain metastasis through a non-tumor cell-autonomous manner<sup><xref rid="R32" ref-type="bibr">32</xref></sup>. We found that STING and downstream noncanonical NF-&#x3BA;B activity are mediators of metastasis in a tumor cell-autonomous fashion as evidenced by reduction in metastatic dissemination, lifespan extension, and reduction in <italic>in vitro</italic> and <italic>in vivo</italic> invasion in CIN-high cells depleted of STING, RelB, or p100 (<italic>NFKB2</italic>). Conversely, the addition of cGAMP increased invasion and migration of CIN-low cells (<xref rid="F6" ref-type="fig">Fig. 6f&#x2013;g</xref>, <xref rid="F12" ref-type="fig">Extended Data Figs. 6f</xref>, <xref rid="F15" ref-type="fig">9j</xref>, and <xref rid="F16" ref-type="fig">10b-d</xref>). These findings are in line with reported roles for the noncanonical NF-&#x3BA;B pathway in EMT, cellular invasion, and metastasis<sup><xref rid="R33" ref-type="bibr">33</xref>&#x2013;<xref rid="R35" ref-type="bibr">35</xref></sup>.</p>
    </sec>
    <sec sec-type="discussion" id="S7">
      <title>DISCUSSION</title>
      <p id="P25">Our work reveals an unexpected link between CIN, chronic activation of cytosolic DNA sensing pathways, and metastasis. In addition to fueling karyotypic heterogeneity that serves as a substrate for natural selection, ongoing chromosome missegregation is required to replenish cytosolic DNA pools and to maintain cells in a pro-metastatic state. Consequently, suppressing CIN reduces metastasis even in highly aneuploid cells. The repercussions of STING activation are context-dependent and range from senescence to tumorigenesis<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R30" ref-type="bibr">30</xref></sup>. Given that chromosomally unstable cells are awash with cytosolic DNA, we raise the interesting possibility that by suppressing downstream type I interferon signaling<sup><xref rid="R30" ref-type="bibr">30</xref></sup> and instead upregulating the alternative NF-&#x3BA;B pathway, they have substituted a lethal epithelial response to inflammation with that of myeloid-derived cells<sup><xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup>, thereby engaging in some form of immune mimicry. Restoring normal responses to inflammation would constitute a viable therapeutic strategy to target chromosomally unstable cells. The evolutionary benefits of the noncanonical pathway would justify the scarcity of inactivating mutations in cGAS and STING among breast and lung cancers (<xref rid="F16" ref-type="fig">Extended Data Fig. 10e</xref>).</p>
      <p id="P26">The emergence, and subsequent tolerance, of CIN represents an important bottleneck during tumor evolution<sup><xref rid="R38" ref-type="bibr">38</xref>&#x2013;<xref rid="R40" ref-type="bibr">40</xref></sup>. We found that CIN induces a transcriptional shift from a proliferative and highly metabolic state, ideally suited for primary tumor growth, to a mesenchymal state associated with upregulation of inflammatory pathways (<xref rid="F4" ref-type="fig">Figs. 4b</xref> and <xref rid="F5" ref-type="fig">5a</xref>). These two mutually exclusive states, which were recently observed in a pan-cancer genomic analysis of metastatic tumors<sup><xref rid="R41" ref-type="bibr">41</xref></sup>, likely account for the reversibility in chromosome missegregation rates seen in primary tumors and metastases, and provide an explanation for the negative effect of aneuploidy during early tumorigenesis<sup><xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup>. It also leads us to suggest that CIN drives the subset of human metastases characterized by EMT and inflammation<sup><xref rid="R41" ref-type="bibr">41</xref></sup>.</p>
    </sec>
    <sec sec-type="methods" id="S8" specific-use="web-only">
      <title>METHODS</title>
      <sec id="S9">
        <title>Genomic analysis of Primary-metastasis matched pairs</title>
        <p id="P27">Whole exome DNA sequence data from 79 brain metastases with matched primary tumor and normal<sup><xref rid="R9" ref-type="bibr">9</xref></sup> was downloaded from the database of Genotypes and Phenotypes (dbGAP) and processed as described<sup><xref rid="R43" ref-type="bibr">43</xref></sup> to derive allele specific segmented DNA copy number data for each sample. The weighted Genome Instability Index (wGII), describing the proportion of the genome that was classified as aberrant relative to tumor ploidy, was determined as described<sup><xref rid="R8" ref-type="bibr">8</xref></sup>.</p>
      </sec>
      <sec id="S10">
        <title>Mitelman Database analysis</title>
        <p id="P28">All available breast adenocarcinoma cases in the Mitelman database<sup><xref rid="R10" ref-type="bibr">10</xref></sup> were analyzed. Primary literature was reviewed to determine the source of the sample (primary tumor or metastasis). When clonal karyotype was reported as a range, the average value was used for that given clone. Karyotype aberrations included structural aberrations as well as numerical deviations from the overall karyotype of the clone.</p>
      </sec>
      <sec id="S11">
        <title>Analysis of chromosome segregation in HNSCC</title>
        <p id="P29">We analyzed primary tumor specimens for 60 patients with head and neck squamous cell carcinoma (HNSCC)<sup><xref rid="R11" ref-type="bibr">11</xref></sup>. 40 patients had Hematoxylin and Eosin-stained (H&amp;E) primary tumor samples of sufficient quality for high-resolution microscopy analysis. Analysis was restricted to cells fixed while undergoing anaphase as previously described<sup><xref rid="R44" ref-type="bibr">44</xref>,<xref rid="R45" ref-type="bibr">45</xref></sup>. Chromosome missegregation was defined by hematoxylin staining presence in between the remaining segregating chromosomes during anaphase and it was reported as the percentage of cells undergoing anaphase with evidence of chromosome missegregation as previously described<sup><xref rid="R44" ref-type="bibr">44</xref></sup>. Clinical lymph node status was defined on the basis of clinical examination or radiographic evidence of lymph node tumor involvement<sup><xref rid="R11" ref-type="bibr">11</xref></sup>.</p>
      </sec>
      <sec id="S12">
        <title>Single-cell karyotyping</title>
        <p id="P30">Cultures were treated with colcemid at a final concentration of 0.1&#x3BC;g ml<sup>&#x2212;1</sup>. Following 45 min incubation at 37&#xB0;C, the cultures were trypsinized, resuspended in pre-warmed 0.075M KCl, incubated for an additional 10 minutes at 37&#xB0;C and fixed in methanol-acetic acid (3:1). The fixed cell suspension was then dropped onto slides, stained in 0.08&#x3BC;g/ml DAPI in 2xSSC for 5 minutes and mounted in antifade solution (Vectashield, Vector Labs). Metaphase spreads were captured using the Nikon Eclipse E800 epifluorescence microscope equipped with GenASI Cytogenetic suite (Applied Spectral Imaging, Carlsbad). For each sample a minimum of 20 inverted DAPI-stained metaphases were fully karyotyped and analyzed according to the International System of Human Cytogenetic Nomenclature (ISCN) 2013.</p>
      </sec>
      <sec id="S13">
        <title>Fluorescence in situ hybridization (FISH) analysis</title>
        <p id="P31">FISH analysis was performed on fixed-cells prepared for single-cell karyotyping. Based on karyotype data, a total of four chromosomes were selected to further evaluate numerical instability. Probes specific for Centromere 3 (Red), Centromere 4 (Orange), and Centromere 9 (Green) were purchased form Abbott-Vysis (Des Plaines, IL). Chromosome 6 centromeric probe was home-brew (PAC clone P308; labeled with Green dUTP, MSKCC Molecular Cytogenetics Core Facility. Probe labeling, hybridization, post-hybridization washing, and fluorescence detection were performed according to standard laboratory procedures. For each probe, three normal peripheral blood samples (GM07535, GM06875 and GM00558), obtained from Coriell Institute (Camden, New Jersey) were also analyzed to derive cut-off values (false-positive).</p>
      </sec>
      <sec id="S14">
        <title>RhoA and Rac1 pull-down assays</title>
        <p id="P32">The activity of RhoA and Rac1 was determined according to the bead-based pull-down assay kits (Cytoskeleton Inc., RhoA: BK036S, Rac1: BK035S). Cells were lysed on the tissue culture dish and rapidly snap frozen until further processing. cGAMP was added for 18 hours prior to lysis. In addition to His-tagged RhoA and Rac1, the positive and negative controls were total cell lysates supplanted with non-hydrolysable GTP or GDP, respectively.</p>
      </sec>
      <sec id="S15">
        <title>Cell culture</title>
        <p id="P33">Cell lines were purchased from the American Type Culture Collection (ATCC). Tumor (MDA-MB-231, 4T1, HEK293, and H2030), cells were cultured in DMEM or RPMI (4T1) supplemented with 10% FBS and 2mM of L-Glutamine in the presence of penicillin (50 Uml<sup>&#x2212;1</sup>) and streptomycin (50 &#x3BC;gml<sup>&#x2212;1</sup>). All cells tested negative for mycoplasma. Cell confluence was measured using IncuCyte live-cell analysis system (Essen Bioscience).</p>
      </sec>
      <sec id="S16">
        <title>Immunofluorescence microscopy</title>
        <p id="P34">Cell fixation and antibody staining were performed as previously described<sup><xref rid="R7" ref-type="bibr">7</xref></sup>. Briefly, cells were fixed with ice-cold (&#x2212;30 C) methanol for 15 minutes &#x2013; when staining for centromeres, centrosomes, cGAS, Vimentin, &#x3B2;-actin, IRF3, or a-tubulin &#x2013; or 4% paraformaldehyde &#x2013; when staining for RelB, p65, STING, ssDNA, dsDNA, CoxIV, or &#x3B2;-catenin. Subsequently, cells were permeabilized using 1% triton for 4 minutes. See <xref rid="SD1" ref-type="supplementary-material">supplementary Table 1</xref> for antibody information. For selective plasma membrane permeabilization used for cytosolic dsDNA and ssDNA staining, cells were treated with 0.02% saponin for 5 minutes after fixation. For single-stranded (Thermo Fisher FEREN0321) and double stranded (Life Technologies &#x2013; EN0771)-specific nuclease treatment, cells were also permeabilized with 0.02% saponin for 2 minutes and treated with either nucleases for 10 minutes before fixation using 4% paraformaldehyde. TBS-BSA was used as a blocking agent during antibody staining. DAPI was added together with secondary antibodies. Cells were mounted with Prolong Diamond Antifade Mountant (Life Technologies &#x2013; P36961). cGAMP (Invivogen &#x2013; tlrl-nacga23) was transfected into cells at a concentration of 4&#x3BC;g/ml using lipofectamine2000 that was added for 3&#x2013;4 hours and then replaced with regular serum containing medium.</p>
      </sec>
      <sec id="S17">
        <title>Immunoblotting</title>
        <p id="P35">Cells were pelleted and lysed using RIPA buffer. Protein concentration was determined using BCA protein assay and 20&#x2013;30&#x3BC;g of total protein were loaded in each lane. Proteins were separated by gradient SDS-PAGE and transferred to PVDF or nitrocellulose membranes. Full blots are shown in <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 1</xref>. See <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref> for antibody information. Band intensities on immunoblots were obtained using ImageJ (<ext-link ext-link-type="uri" xlink:href="www.imagej.nih.gov/ij">www.imagej.nih.gov/ij</ext-link>) or the LI-COR Odyssey software, normalized to loading control and background was subtracted. Ratios were normalized to control cells. Interferon-&#x3B2; levels from conditioned media were measured using the Human IFN beta Array 1-plex (Eve Technologies &#x2013; HIFNB-01-31).</p>
      </sec>
      <sec id="S18">
        <title>Y chromosome missegregation and fluorescent in situ hybridization (FISH)</title>
        <p id="P36">Flp-In T-REx DLD-1 cells were engineered to express the TIR1 auxin-dependent plant E3 ligase, an auxin-inducible degron (AID)-tagged CENP-A modified at the endogenous allele (CENP-A<sup>AID/&#x2013;</sup>), and a doxycycline-inducible CENP-A<sup>C&#x2013;H3</sup> rescue gene integrated into the Flp-In locus as previously described<sup><xref rid="R26" ref-type="bibr">26</xref></sup>. 4.0 &#xD7; 10<sup>4</sup> cells were seeded into 4-well chamber slides and treated with doxycycline (DOX, Sigma) and indole-3-acetic acid (IAA, Sigma) for up to 3 days to induce Y chromosome missegregation and micronuclei. Slides were washed in PBS, fixed in 3:1 methanol:acetic acid for 15 minutes at room temperature, and dehydrated with 80% ethanol. Chromosome paint FISH probes targeting chromosome Y and 15 (MetaSystems) were mixed at equal ratios, applied to cells, sealed with a coverslip, and co-denatured at 75&#xB0;C for 2 minutes followed by overnight hybridization at 37&#xB0;C in a humidified chamber. Slides were washed in 0.4x saline&#x2013;sodium citrate (SSC) buffer for 2 minutes at 72&#xB0;C, followed by a 30 second wash in 2x SCC, 0.05% Tween-20 buffer at room temperature. Cells were counterstained with DAPI and captured on a DeltaVision Elite (GE Healthcare) microscope system at 60x magnification (25 &#xD7; 0.2 &#x3BC;m <italic>z</italic>-stacks) followed by image deconvolution and maximum intensity quick projection.</p>
      </sec>
      <sec id="S19">
        <title>Knockdown and overexpression constructs</title>
        <p id="P37">Luciferase expression was achieved using pLVX plasmid (expressing tdTomato) and cells stably expressing luciferase were selected using hygromycin and sorted for tdTomato expression. Kinesin-13 expression was achieved using plasmid (pEGFP) transfection or lentiviral (pLenti-GIII-CMV-GFP-2A-Puro) expression where cells were selected using G418 (0.5mgml<sup>&#x2212;1</sup>) or puromycin (5&#x3BC;gml<sup>&#x2212;1</sup>), respectively. Dnase2 overexpression was achieved using a pLenti-GIII-CMV-RFP-2A-Puro plasmid with puromycin used for selection. Plasmids containing kinesin-13 or Lamin B2 (pQCXIB-mCherry-lmnb2) constructs were kindly offered by the Compton and Hetzer Laboratories, respectively. Blasticidin was used to select for <italic>lmnb2</italic> expressing cells at 10&#x3BC;gml<sup>&#x2212;1</sup>. All other plasmids were purchased from Applied Biological Materials Inc. (<ext-link ext-link-type="uri" xlink:href="www.abmgood.com">www.abmgood.com</ext-link>). Stable knockdown of STING, NFKB2, RelB, and cGAS were achieved using shRNAs in pRRL (SGEP or SGEN) plasmids and were obtained from the MSKCC RNA Interference Core. 2&#x2013;4 distinct shRNA hairpins were screened per target. Targeted shRNA sequences are listed in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3</xref>. To visualize primary nuclear rupture, cells were stably modified with retroviral construct expressing both NLS-GFP<sup><xref rid="R25" ref-type="bibr">25</xref></sup> and H2B-Tdtomato (3xNLScopGFP-P2A-H2BtdTomato-IRES-Puromycin). Cells were cultured for 24 hours after viral transduction before selection with 1&#x3BC;g ml<sup>&#x2212;1</sup> of Puromycin and subsequently sorted to select for NLS-GFP and H2B-TdTomato expression.</p>
      </sec>
      <sec id="S20">
        <title>Cell migration in microfluidic devices</title>
        <p id="P38">Microfluidic migration devices with precisely defined constrictions were prepared as described previously<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R46" ref-type="bibr">46</xref></sup>. Devices were coated with 50 &#x3BC;g/mL of type-I rat tail collagen (BD Biosciences) in 0.02N acetic acid overnight at 4&#xB0;C. Approximately 80,000 cells were seeded (in DMEM supplemented with 10% FBS and 1% PenStrep) per migration chamber. Devices were placed in a tissue-culture incubator (37&#xB0;C) for 5&#x2013;6 hours to allow the cells to adhere. Subsequently, media was changed to phenol-red free Leibovitz L15 media supplemented with 10% FBS and 1% PenStrep before mounting the device on an inverted microscope (Zeiss Observer Z1) equipped with temperature-controlled stage (37&#xB0;C) for live-cell imaging. The media reservoirs of the device were covered with glass coverslips to minimize evaporation during live-cell imaging. Cells were imaged for 14&#x2013;16 hours at 10 minute intervals with a CCD camera (Photometrics CoolSNAP KINO) using a Zeiss 20&#x2032;/NA 0.8 air objective. Acquired image sequences were analyzed for nuclear rupture frequency, duration, and transit time of cells through 1&#xD7;5&#x3BC;m<sup>2</sup>, 2&#xD7;5&#x3BC;m<sup>2</sup>, and 15&#xD7;5&#x3BC;m<sup>2</sup> constrictions using Zen (Zeiss) software and a custom-written MATLAB 2016a script for automated image analysis.</p>
      </sec>
      <sec id="S21">
        <title>Animal studies</title>
        <p id="P39">Animal experiments were performed in accordance with protocols approved by the Weill Cornell Medicine Institutional Animal Care and Use Committee. For disease-specific survival in MDA-MB-231 experiments, power analysis indicated that 10 mice per group will be sufficient to detect a difference at relative hazard ratios of &lt;0.2 or &gt;5 with 80% power and 95% confidence, given a median disease-specific survival of 3 months in the control group and a total follow up period of 250 days. For the 4T1 experiments, Power analysis indicates that 10 mice per group will be sufficient to detect a difference at relative hazard ratios of &lt;0.25 or &gt;4.0 with 80% power and 95% confidence, given a median survival of 58 days in the control group and a total follow up period of 180 days. There was no need to randomize animals. Investigators were not blinded to group allocation. Intracardiac injection was performed as previously described<sup><xref rid="R32" ref-type="bibr">32</xref></sup>. Briefly, cells were trypsinized and washed with PBS and a 1&#xD7;10<sup>5</sup> cells (in 100 &#x3BC;l of PBS) were injected into the left cardiac ventricle of female athymic 6&#x2013;7 week old athymic nude (nu/nu) mice (Jackson Laboratory strain 002019). 2&#xD7;10<sup>5</sup> cells were injected into the tail vein cohort of animals. Mice were then immediately injected with D-luciferin (150 mgkg<sup>&#x2212;1</sup>) and subjected to bioluminescence imaging (BLI) using tan IVIS Spectrum Xenogen instrument (Caliper Life Sciences) to ensure systemic dissemination of tumor cells. Metastatic burden was measured 5&#x2013;7 weeks after injection using BLI. BLI images were analyzed using Living Image Software v.2.50. Disease-specific survival endpoint was met when the mice died or met the criteria for euthanasia under the IACUC protocol and had radiographic evidence of metastatic disease. For orthotopic tumor implantation, 2.5&#xD7;10<sup>5</sup> cells in 50&#x3BC;l of PBS were mixed 1:1 with Matrigel (BD Biosciences) and injected into the fourth mammary fat pad. Only one tumor was implanted per animal. MDA-MB-231 primary tumors were surgically excited before they reached ~1.5 cm in the largest dimension (which was the maximum allowable under our IACUC protocol) and metastatic dissemination was assessed using BLI imaging at 1&#x2013;3 week intervals for up to 30 weeks. Distant metastasis-free survival endpoint was met when BLI signal was seen outside of site of primary tumor transplantation. 4T1 tumors were excised 8&#x2013;9 days after implantation. To derive short-term culture from primary tumors and metastases, anesthetized animals (isofluorane) were imaged then sacrificed. <italic>Ex-vivo</italic> BLI was subsequently performed on harvested organs to define the precise location of the metastatic lesion. Primary tumors and metastases were subsequently mechanically dissociated and cultured in DMEM with selection media (G418 or hygromycin) to select for tumor cells and exclude host cells. All subsequent assays (karyotyping, RNAseq, immunofluorescence, and subcellular fractionation) were performed after a single passage from the primary sample. To assess chromosome missegregation from primary tumor-derived and metastases-derived cells, we performed high-resolution immunofluorescence analysis on passage #1 cells, staining for DNA (DAPI) and centromeres (ACA). Cells with DNA or centromere staining in the middle of the anaphase plate was taken as evidence of chromosome missegregation.</p>
      </sec>
      <sec id="S22">
        <title>Patient-derived xenografts (PDX) assays</title>
        <p id="P40">PDX models of human metastatic breast cancers were generated by transplanting the freshly obtained surgically excised tumor specimens from patients consented under the IRB approved protocol (MSKCC IRB #97-094) in female NOD-<italic>scid</italic> IL2Rgamma<sup>null</sup> (NSG) (Jackson Laboratories strain 005557). All relevant ethical regulations were followed. The estrogen receptor-positive PDX was derived from breast cancer metastatic to the bone. The TNBC PDX was established out of an axillary lymph node metastasis from a patient with inflammatory breast cancer. PDXs were maintained for a maximum of three serial passages. Briefly, freshly obtained tumor tissue specimens were either directly transplanted in the mammary fat-pad of the mice or minced into 1&#x2013;2 mm pieces in serum free MEM medium with nonessential amino acids (Cat# 41500018, Thermofisher) transduced with lentiviral vectors expressing either GFP-luciferase or pUltra-Chili-Luc plasmid (Addgene plasmid: 48688) followed by transplantation into mice. Typically PDX tumor growth became evident during the first 1&#x2013;3 weeks post engrafting and tumor continued to grow for additional 4&#x2013;8 weeks. Primary tumor growth and metastases were followed using BLI or spectrum CT imaging. At the time of harvesting of primary tumors and metastases, we derived primary cell cultures directly from primary tumors as well as lung and liver metastases. Briefly, 500 mg of fresh bulk tumor tissues were chopped into 1&#x2013;2 mm<sup>3</sup> sized pieces and incubated in Accutase (AT104; Innovative Cell Technologies) for cell detachment and separation over 1&#x2013;2 hours. The dissociated tissues were sieved through 100-&#x3BC;m cell strainers and pelleted the cells by centrifugation at 1200 RPM. The pellets were washed and resuspended in the above MEM buffer with 3% FBS. Cells were analyzed for chromosome missegregation after one passage.</p>
      </sec>
      <sec id="S23">
        <title>RNA sequencing and analysis</title>
        <p id="P41">Bulk RNA was extracted from cells using the QIAShredder (Qiagen &#x2013; 79654) and the RNA extraction kit (Qiagen &#x2013; 74106) and sequenced using HiSeq2500 or HiSeq4000 (Illumina Inc.). The quality of the raw FASTQ files were checked with FastQC (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>). For samples originating from mouse xenografts, FASTQ reads were classified as originating from either mouse (GRCm38) or human (GRCh38) genomes using xenome<sup><xref rid="R47" ref-type="bibr">47</xref></sup>, and human-specific reads were used for mapping. Reads were mapped to human reference GRCh38 using STAR (v2.4.1d, 2-pass mode)<sup><xref rid="R48" ref-type="bibr">48</xref></sup>. Gene expression was estimated using cufflinks (v2.2.1, default parameters) and HTSeq (v0.6.1)<sup><xref rid="R49" ref-type="bibr">49</xref>,<xref rid="R50" ref-type="bibr">50</xref></sup>. Differential expression analyses were performed using DESeq2 (v1.14.1)<sup><xref rid="R51" ref-type="bibr">51</xref></sup>. Pre-ranked gene set enrichment analyses (GSEA) was performed on the DESeq2 log2 fold changes<sup><xref rid="R52" ref-type="bibr">52</xref></sup>. Prior to any unsupervised analyses, expression counts were transformed using variance stabilizing transformation using the DESeq2 R package. Gene signatures used in the study are listed in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 5</xref>. Differentially expressed gene sets and their associated statistics are listed in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 6</xref>. To detect potential copy number changes, positional gene enrichment analysis (PGE) was performed on the up-regulated and down-regulated differentially expressed genes, separately (padj &#x2264; 0.1)<sup><xref rid="R53" ref-type="bibr">53</xref></sup>. Only significant regions with 4 or more genes and with p-value &#x2264; 0.01 were kept for further analysis. Circos plots were made using the circlize R package<sup><xref rid="R54" ref-type="bibr">54</xref></sup>.</p>
      </sec>
      <sec id="S24">
        <title>Reverse-transcriptase quantitative polymerize chain reaction (RT-qPCR)</title>
        <p id="P42">Cells were collected into trizol&#xAE; reagent (thermofisher) and total RNA was extracted using &#x2018;Pureling RNA mini kit&#x2019; (thermofisher) according to manufacturer&#x2019;s instructions. 5ug of total RNA was used in reverse transcriptase polymerase chain reaction performed using &#x2018;RNA to cDNA Ecodry<sup>&#x2122;</sup> premix (oligo dT)&#x2019; cDNA synthesis kit (Clontech) according to manufacturers instructions. Resulting cDNA corresponding to 50ng of total RNA was used in each 20ul of quantitative real time PCR reaction. qRT-PCR was performed using SybrGreen master mix (Biorad) and the relative expression of each gene was calculated after normalizing to &#x3B2;-Actin endogenous control and using comparative &#x394;Ct method. A list of the primers used is in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 4</xref>.</p>
      </sec>
      <sec id="S25">
        <title>Single-cell RNA sequencing</title>
        <p id="P43">Cells were trypsinized and resuspended in PBS. 21&#x3BC;l of a cellular suspension at 400 cells/ul, &gt;95% viability, were loaded onto to the 10X Genomics Chromium platform to generate barcoded single-cell GEMs. Single-cell RNA sequencing (scRNA-seq) libraries were prepared according to 10X Genomics specifications (Single Cell 3&#x2032; Reagent Kits User Guide PN-120233, 10x Genomics, Pleasanton, CA, USA). GEM-Reverse Transcription (RT) (55&#xB0;C for 2h, 85&#xB0;C for 5min; held at 4&#xB0;C) was performed in a C1000 Touch Thermal cycler with 96-Deep Well Reaction Module (Bio-Rad, Hercules). After RT, GEMs were broken and the single-strand cDNA was cleaned up with DynaBeads MyOne Silane Beads (Thermo Fisher Scientific, Waltham, MA) and SPRIselect Reagent Kit (0.6 &#xD7; SPRI; Beckman Coulter). cDNA was amplified for 14 cycles using the C1000 Touch Thermal cycler with 96-Deep Well Reaction Module (98&#xB0;C for 3min; 98&#xB0;C for 15s, 67&#xB0;C for 20s, and 72&#xB0;C for 1min &#xD7; 14 cycles; 72&#xB0;C for 1min; held at 4&#xB0;C). Quality of the cDNA was analysed using an Agilent Bioanalyzer 2100 (Santa Clara, CA). The resulting cDNA was sheared to ~200bp using a Covaris S220 instrument (Covaris, Woburn, MA) and cleaned using 0.6 x SPRI beads. The products were end-repaired, &#x2018;A&#x2019;-tailed and ligated to adaptors provided in the kit. A unique sample index for each library was introduced through 10 cycles of PCR amplification using the indexes provided by in the kit (98&#xB0;C for 45 s; 98&#xB0;C for 20s, 60&#xB0;C for 30s, and 72&#xB0;C for 20 s x 14 cycles; 72&#xB0;C for 1min; held at 4&#xB0;C). After two SPRI cleanups, libraries were quantified using Qubit fluorometric quantification (Thermo Fisher Scientific, Waltham, MA) and the quality assessed on an Agilent Bioanalyzer 2100. Four libraries were pooled and clustered on a HiSeq2500 rapid mode at 10pM on a pair end read flow cell and sequenced for 98 cycles R1, followed by 14bp I7 Index (10X Barcode), 8bp I5 Index (sample Index) and 10bp on R2 (UMI). Primary processing of sequencing images was done using Illumina&#x2019;s Real Time Analysis software (RTA). Demultiplexing and post processing was done using the 10X Genomics Cell Ranger pipeline as per the manufacturer recommendations. Single cell RNA sequencing data (scRNA-seq) was processed from raw reads to a molecule count array using the Cell Ranger pipeline<sup><xref rid="R55" ref-type="bibr">55</xref></sup>. Additionally, to minimize the effects of experimental artifacts on the analysis, data was pre-processed to filter out cells with low total molecule counts (library size), low complexity and high mitochondrial content, identified by a bimodal fit. Remaining cells were normalized by dividing the expression level of each gene in a cell by its total library size and then scaling by the median library size of all cells). After normalizing by library size; we performed principal component analysis (PCA) to improve robustness of the constructed Markov Matrix generated when computing diffusion eigenvalues for imputation of dropout noise<sup><xref rid="R56" ref-type="bibr">56</xref></sup>. We chose the number of principle components to retain approximately 80% of variance in the data and excluded the first principal component, which was highly correlated with library size. Imputation of both he normalized and unnormalized count matrix was performed using a Markov matrix raised to the power of 3 (power corresponds the approximate number of weighted nearest neighbors) and with a gene expression distribution computed according to 21 nearest neighboring cells as described<sup><xref rid="R56" ref-type="bibr">56</xref></sup>. Our analysis was robust to imputation and we obtained similar results without imputed data (not shown). Subpopulations were identified using Phenograph<sup><xref rid="R57" ref-type="bibr">57</xref></sup> and genes differentially expressed in at least one subpopulation were identified by the Kruskal-Wallis rank statistic using a bootstrapping method for random downsampling of matched molecule and cell counts from each subpopulation. t-Distributed Stochastic Neighbor Embedding (t-SNE) was used to visualize subpopulation structure based on the first 20 principle components of the imputed count matrix, subsetted by the top 5,150 differentially expressed genes (FDR q of Kruskal Wallis rank statistic &lt; 0.05). Mean expression of key gene signatures in population M versus other subpopulations were z-normalized and visualized by violin plots. All gene signatures are annotated in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 5</xref>. The correlation between gene signatures was computed using the Spearman Rank Correlation Coefficient according to mean expression of all genes per signature per cell. Ward&#x2019;s minimum variance method was applied to hierarchically cluster cells by their normalized expression of differentially expressed EMT genes.</p>
      </sec>
      <sec id="S26">
        <title>Patient survival analysis</title>
        <p id="P44">Genes used for survival analysis are listed in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 5</xref>. For the meta-analysis cohort, we used aggregate data from KMPlot (<ext-link ext-link-type="uri" xlink:href="www.kmplot.com">www.kmplot.com</ext-link>)<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R58" ref-type="bibr">58</xref></sup> using only JetSet best probe set and auto-selection for best cutoff between the 25<sup>th</sup> and 75<sup>th</sup> percentile. For the validation cohort in which DMFS data was available<sup><xref rid="R17" ref-type="bibr">17</xref></sup>, we used the z-normalized expression data for a dataset and the median value was used as a cutoff. DMFS curves were compared using the log-rank test.</p>
      </sec>
      <sec id="S27">
        <title><italic>In vitro</italic> invasion and migration assays</title>
        <p id="P45">For the invasion and migration/chemotaxis assays we used the CytoSelect cell invasion (CBA-110) and cell migration (CBA-100) kits, respectively. Briefly, 3&#xD7;10<sup>5</sup> cells were suspended in serum-free media and placed on top of the membrane. Media containing serum was placed at the bottom and cells, which have invaded to the inferior surface of the collagen membrane, were stained and counted 18&#x2013;24 hours later. For experiments involving transient transfection, cells were transfected, and thymidine (2mM) was added 18 later. Cells were plated on the membrane 3 days after transfection. For the chemotaxis assay, we used a colorimetric approach (OD 560nm) for quantification. For the scratch assay, cells were treated with mitomycin C (10 &#x3BC;gml<sup>&#x2212;1</sup>) for 1 hour when they reached &gt;90% confluence and then placed in DMEM containing 1% FBS. Wounds were applied using p200 pipette tip and images of the wound were taken immediately and at subsequent regular intervals. ImageJ was used for quantification of wound surface area.</p>
      </sec>
      <sec id="S28">
        <title>Quantification of cytosolic DNA</title>
        <p id="P46">Approximately 1&#xD7;10<sup>7</sup> cells were lysed and the nuclear, cytosolic, and mitochondrial fractions were obtained using the mitochondrial isolation kit (Thermo Fisher &#x2013; 89874). Protease inhibitors were not used to enable subsequent DNA purification. Mitochondria were purified at 12,000x<italic>g</italic> to minimize their contamination in the cytosolic fraction. DNA was subsequently isolated from the nuclear, cytosolic, mitochondrial fractions using the Qiagen DNeasy blood and tissue kit (Qiagen &#x2013; 69506) and dsDNA was quantified using Qubit 2.0 (Invitrogen) using Qubit dsDNA HS Reagent.</p>
      </sec>
      <sec id="S29">
        <title>Code availability</title>
        <p id="P47">All custom code, statistical analysis, and visualizations were performed in Python or R, and used Nextflow to manage some of the computational pipelines<sup><xref rid="R59" ref-type="bibr">59</xref></sup>. Code for the RNA sequencing analysis is available online at: <ext-link ext-link-type="uri" xlink:href="https://github.com/murphycj/manuscripts/tree/master/BakhoumEtAl2017">https://github.com/murphycj/manuscripts/tree/master/BakhoumEtAl2017</ext-link>. The live-cell tracking MATLAB 2016a code can be found at <ext-link ext-link-type="uri" xlink:href="https://github.com/Lammerding/MATLAB-CellTracking">https://github.com/Lammerding/MATLAB-CellTracking</ext-link></p>
      </sec>
      <sec id="S30">
        <title>Data availability</title>
        <p id="P48">Source data for <xref rid="F1" ref-type="fig">figures 1</xref>&#x2013;<xref rid="F3" ref-type="fig">3</xref>, <xref rid="F5" ref-type="fig">5</xref>&#x2013;<xref rid="F6" ref-type="fig">6</xref>, and <xref rid="F7" ref-type="fig">Extended Data figures 1</xref>&#x2013;<xref rid="F9" ref-type="fig">3</xref> and <xref rid="F11" ref-type="fig">5</xref>&#x2013;<xref rid="F16" ref-type="fig">10</xref> are provided with the paper. Single-cell RNA sequencing data (shown in <xref rid="F4" ref-type="fig">figures 4</xref>&#x2013;<xref rid="F5" ref-type="fig">5</xref> and <xref rid="F12" ref-type="fig">Extended Data figure 6</xref>) was deposited in the Sequence Read Archive under the following accession number: SRP104750 (<ext-link ext-link-type="ftp" xlink:href="ftp://ftp-trace.ncbi.nlm.nih.gov/sra/review/SRP104750_20170426_131604_b0888d686e89bf883fe90b85c9220b47">ftp://ftp-trace.ncbi.nlm.nih.gov/sra/review/SRP104750_20170426_131604_b0888d686e89bf883fe90b85c9220b47</ext-link>). Bulk RNAseq data (shown in <xref rid="F10" ref-type="fig">Extended Data figures 4</xref>&#x2013;<xref rid="F11" ref-type="fig">5</xref>) was deposited in Gene Expression Omnibus under accession number GSE98183 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98183">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98183</ext-link>)</p>
      </sec>
    </sec>
    <sec id="S31">
      <title>Extended Data</title>
      <fig id="F7" orientation="portrait" position="anchor">
        <label>Extended Data Figure 1</label>
        <caption>
          <title>Generation of isogenic tumor models of CIN</title>
          <p id="P49"><bold>a</bold>, Weighted genomic instability index (wGII) of brain metastases as a function of the wGII of the matched primary tumor. Red line represents linear regression, <italic>n</italic> = 79 patients. <bold>b</bold>, Differences in wGII between metastases and matched primary tumors. RCC, renal cell carcinoma, the &#x201C;Other&#x201D; category includes melanoma, sarcoma, ovarian, thyroid, and salivary gland cancers. <bold>c</bold>, Number of clones (based on single-cell karyotypes) in primary breast tumors (<italic>n</italic> = 637) or metastases (Mets, <italic>n</italic> = 131) found in the Mitelman Database, boxes represent median &#xB1; interquartile range and bars span the 10<sup>th</sup> and 90<sup>th</sup> percentile, significance tested using two-sided Mann Whitney test. <bold>d</bold>, The number of chromosome aberrations per clone as a function of the total number of chromosomes in a given clone in samples derived from primary breast tumor clones (<italic>n</italic> = 983) and metastatic clones (<italic>n</italic> = 186), data points represent average &#xB1; SD. <bold>e</bold>, Percentage of N&#x2212; or N+ patients as a function of chromosome missegregation frequency (<italic>n</italic> = 20 patients per condition), significance tested using two-sided Fisher Exact test. <bold>f</bold>, Immunoblots of cells expressing various GFP-tagged kinesin-13 proteins stained using anti-GFP antibody, &#x3B2;-actin used as a loading control, 2 independent experiments. <bold>g</bold>, Cellular confluence as a function of time of MDA-MB-231 cells expressing various kinesin-13 proteins or dnMCAK expressing cells depleted of components of the cytosolic DNA-sensing machinery or the noncanonical NF-&#x3BA;B pathway, data points represent mean &#xB1; SD, <italic>n</italic> = 4 independent experiments. <bold>h</bold>, <italic>Left</italic>, MCAK and dnMCAK expressing cells stained for microtubules (DM1A), centrosomes (pericentrin) and DNA (DAPI), scale bar 5-&#x3BC;m, 2 independent experiments. <italic>Right</italic>, Frequency distribution of the number of pericentrin foci per cells. Significance tested using ANOVA. <italic>n</italic> = 100 cells per condition, 2 independent experiments. <bold>i</bold>, Cells expressing kinesin-13 proteins stained for microtubules (DM1A), centrosomes (pericentrin) and DNA (DAPI), scale bar 50-&#x3BC;m, 2 independent experiments. <italic>Bottom-right</italic>, Fluorescence normalized to cell count of MDA-MB0-231 cells expressing kinesin-13 proteins, bars represent mean &#xB1; s.e.m., * <italic>p</italic> &lt; 0.05, two-sided t-test, <italic>n</italic> = 10 high-power fields encompassing 477&#x2013;612 cells, 2 independent experiments.</p>
        </caption>
        <graphic xlink:href="nihms925648f7"/>
      </fig>
      <fig id="F8" orientation="portrait" position="anchor">
        <label>Extended Data Figure 2</label>
        <caption>
          <title>Karyotype analysis of human tumor cells</title>
          <p id="P50"><bold>a&#x2013;b</bold>, Immunoblots showing total Rac1 (a) or RhoA (b) levels as well as Rac1 or RhoA that were pulled-down using antibodies that were specific to the GTP-bound form of Rac1 (a) or RhoA (b). Positive and negative controls were total MDA-MB-231 cell lysates supplanted with non-hydrolysable GTP (nhGTP) or GDP, respectively. &#x3B2;-actin was used as a loading control, 2 independent experiments. <bold>c&#x2013;e</bold>, Representative karyotypes (DAPI-banding) from parental MDA-MB-231 cells (c), or populations derived from single MCAK (d) or Kif2a (e) expressing cells that were allowed to divide for 30 days. <bold>f</bold>, The number of non-clonal (present in &lt;25% of the cells in a single clone) structurally abnormal chromosomes in CIN-low or CIN-high MDA-MB-231 cells. &#x2018;Mar&#x2019; denotes chromosomes so structurally abnormal that precludes their unambiguous identification by conventional banding, bars represent mean &#xB1; SD, <italic>n</italic> = 140 cells from 7 clonal populations, significance tested using two-way ANOVA test. <bold>g</bold>, Examples taken from 4 distinct cells belonging to the same clonal population &#x2013; derived from a single Kif2a-expressing cell &#x2013; showing convergent translocations involving chromosome 22 with four other chromosomes. <bold>h</bold>, Deviation from modal chromosome number in single-cell-derived clones grown for 30 days. Four chromosomes were assayed for each clone using centromere-specific probes, *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.005 compared to control clone 4, two-sided c<sup>2</sup>-test, n = 300 cells per clone. Diploid controls were used to determine false positive rate of the centromeric probes.</p>
        </caption>
        <graphic xlink:href="nihms925648f8"/>
      </fig>
      <fig id="F9" orientation="portrait" position="anchor">
        <label>Extended Data Figure 3</label>
        <caption>
          <title>CIN promotes formation and maintenance of metastasis</title>
          <p id="P51"><bold>a</bold>, Chromosome missegregation in H2030 and 4T1 cells expressing kinesin-13 proteins. Bars represent mean &#xB1; SD, <italic>n</italic> = 150 cells, 3 independent experiments, significance tested using two-sided t-test. <bold>b</bold>, <italic>Left</italic>, Normalized photon flux over time of whole animals injected with MDA-MB-231 cells expressing kinesin-13 proteins Bars represent mean &#xB1; s.e.m. <italic>n</italic> = 8 (MCAK), 7 (Kif2b), 5 (Control), 4 (Kif2a), and 9 (dnMCAK) mice per group, 3 independent experiments. <italic>Right</italic>, Mice injected with MDA-MB-231 cells expressing dnMCAK (<italic>above</italic>) or Kif2b (<italic>below</italic>) where disease burden was tracked using BLI, 3 independent experiments. <bold>c,</bold> Photon flux (p/s) of whole animals imaged 5 weeks after intracardiac injection with control or MCAK expressing H2030 cells. Bars represent the mean, significance tested using two-sided Mann Whitney test, <italic>n</italic> = 10 mice in the MCAK group and 5 mice in the control group. <bold>d</bold>, <italic>Left</italic>, Representative BLI images from two independent experiments of mice orthotopically transplanted with MDA-MB-231 cells before (Day 33) and after (Day 90) tumor excision. Metastasis can be detected in the mouse transplanted with dnMCAK expressing cells at day 90. <italic>Middle</italic>, Total flux (p/s) emitted from primary tumors 52 days after transplantation. Bars represent mean &#xB1; SD, n = 5 (CIN-low) and 14 (CIN-high) mice, <italic>p</italic> = 0.13, two-sided Mann Whitney test. <italic>Right</italic>, Distant metastasis-free survival (DMFS) of mice orthotopically transplanted with MDA-MB-231 cells with various levels of CIN. <italic>n</italic> = 15 (CIN-low) and 29 (CIN-high) mice, pairwise significance tested with two-sided log-rank test. <bold>e</bold>, Tumor volume at 8 days (top) and survival (bottom) of mice transplanted with murine 4T1 cells in the mammary fat pad. Bars represent median &#xB1; interquartile range, pairwise significance tested with two-sided t-test (top) and two-sided log-rank test (bottom). n = 20 (CIN-low) and 30 (CIN-high) mice. <bold>f</bold>, <italic>Top</italic>, immunoblots of MCAK or MCAK and mad2 overexpressing MDA-MB-231 cells stained for mad2 using anti-mad2 antibody with a-tubulin used as a loading control, 3 independent experiments. <italic>Bottom</italic>, Percentage of anaphase cells exhibiting evidence of chromosome missegregation in MCAK or MCAK and mad2 overexpressing cells, bars represent mean &#xB1; SD, <italic>n</italic> = 150 cells, 3 experiments, significance tested using two-sided t-test. <bold>g</bold>, <italic>Top</italic>, immunoblots of dnMCAK or dnMCAK and Lamin B2 overexpressing MDA-MB-231 cells stained for Lamin B2 using anti-Lamin B2 antibody with &#x3B2;-actin used as a loading control, 2 experiments. <italic>Bottom</italic>, Percentage of anaphase cells exhibiting evidence of chromosome missegregation in dnMCAK or dnMCAK and Lamin B2 overexpressing cells, bars represent mean &#xB1; SD, <italic>n</italic> = 150 cells, 3 experiments, significance tested using two-sided t-test. <bold>h</bold>, Photon flux (p/s) of whole animals after intracardiac (left) or tail vein (right) injection with dnMCAK or dnMCAK and Lamin B2 expressing MDA-MB-231 cells. Bars represent the median, significance tested using two-sided Mann Whitney test, <italic>n</italic> = 9 (dnMCAK), 15 (dnMCAK and Lamin B2) mice in the intracardiac injection cohort and 5 mice per group in the tail vein injection cohort.</p>
        </caption>
        <graphic xlink:href="nihms925648f9"/>
      </fig>
      <fig id="F10" orientation="portrait" position="anchor">
        <label>Extended Data Figure 4</label>
        <caption>
          <title>Transcriptional consequences of CIN in cancer cells</title>
          <p id="P52"><bold>a&#x2013;b</bold>, Principle component analysis (PCA) (left) and unsupervised clustering (right) of 5 MDA-MB-231 cell lines expressing different kinesin-13 proteins based on bulk RNA expression data. <bold>b&#x2013;e</bold>, Gene set enrichment analysis (GSEA) results showing HALLMARK gene sets that are highly enriched in CIN-high (control, Kif2a, and dnMCAK) compared with CIN-low cells (MCAK and Kif2b) cells (b&#x2013;c) or STING-depleted cells (e), or after comparing metastases with primary tumors (d), significance tested using one-sided Weighted Smirnov-Kolmogorov test corrected for multiple tests. <bold>f</bold>, Heatmap of consensus chromosomal karyotypes of cells derived from primary tumors and metastases showing selective increase in chromosome 1 copy number in metastases compared with primary tumors.</p>
        </caption>
        <graphic xlink:href="nihms925648f10"/>
      </fig>
      <fig id="F11" orientation="portrait" position="anchor">
        <label>Extended Data Figure 5</label>
        <caption>
          <title>Prognostic impact of the CIN signature</title>
          <p id="P53"><bold>a</bold>, Volcano plot showing differentially expressed genes between CIN-high and CIN-low MDA-MB-231 cells. Red data points denote genes subsequently used for determining the CIN signature. <bold>b&#x2013;e</bold>, Enrichment plots for all differentially expressed genes (a) or those on Chromosome 1 (d&#x2013;e). Circos plot (c) showing genomic location (outer circle), log<sub>2</sub>-fold expression of genes significantly differentially expressed in metastases compared to primary tumors (middle circles), and the log<sub>10</sub>(<italic>p</italic> value, inner circle) for genomic amplifications (red) or deletions (blue) in metastases relative to primary tumors. <italic>n</italic> = 2 (CIN-low), 3 (CIN-high), 11 (primary tumors), 28 (metastases). Significance tested using two-sided Wald test (a), one-sided Weighted Smirnov-Kolmogorov test (b, d, e), and one-sided hypergeometric test (c) all corrected for multiple testing. <bold>f&#x2013;g</bold>, DMFS of breast cancer patients stratified by lymph node status, grade, and receptor status, from a meta-analysis (f, <italic>n</italic> = 664 patients) or a validation cohort (g, <italic>n</italic> = 171 patients) divided based on their average expression of the CIN gene expression. Significance tested using two-sided log-rank test.</p>
        </caption>
        <graphic xlink:href="nihms925648f11"/>
      </fig>
      <fig id="F12" orientation="portrait" position="anchor">
        <label>Extended Data Figure 6</label>
        <caption>
          <title>Single-cell sequencing and population detection</title>
          <p id="P54"><bold>a</bold>, The cellular composition of every subpopulation presented <xref rid="F4" ref-type="fig">Figure 4b</xref>. <bold>b</bold>, Violin plots showing expression probability density of key metastasis and invasion genes in a subpopulation of cells (<italic>n</italic> = 1273 cells) enriched for EMT and CIN genes (subpopulation &#x2018;M&#x2019;) compared with the remaining subpopulations (<italic>n</italic> = 5548 cells) that were identified using graph-based unsupervised K-nearest neighbor embedding. <bold>c</bold>, Representative low-power field images (<italic>left</italic>) and numbers (<italic>right</italic>) of MDA-MB-231 cells which invaded through a collagen membrane within 18 hours of culture. Bars represent mean &#xB1; SD, Significance tested using two-sided Mann Whitney test, <italic>n</italic> = 10 high-power fields, 2 independent experiments. <bold>d</bold>, Representative images of MDA-MB-231 cells expressing MCAK or dnMCAK stained for &#x3B2;-actin, Vimentin, and DNA scale bar 50-&#x3BC;m, <italic>n</italic> = 2 independent experiments. <bold>e</bold>, Single-cell correlation plots between CIN signature genes, canonical NF-&#x3BA;B and type I interferon target genes, <italic>n</italic> = 6,821 cells. <bold>e</bold>, Representative phase-contrast images of a wound-healing assay of cells MCAK, MCAK+mad2 or dnMCAK expressing MDA-MB-231 cells and MCAK cells treated with cGAMP, scale bar 800-&#x3BC;m, 4 experiments.</p>
        </caption>
        <graphic xlink:href="nihms925648f12"/>
      </fig>
      <fig id="F13" orientation="portrait" position="anchor">
        <label>Extended Data Figure 7</label>
        <caption>
          <title>CIN promotes in vitro invasion and migration</title>
          <p id="P55"><bold>a</bold>, <italic>Left</italic>, representative phase contrast images of MDA-MB-231 cells in the wound area, 36-hours after wound creation, 4 experiments. <italic>Right</italic>, length-to-width ratio of cells expressing different kinesin-13 proteins. Bars span the interquartile range, <italic>n</italic> = 100 cells, 2 independent experiments, significance tested using two-sided Mann Whitney test. <bold>b</bold>, Representative MDA-MB-231 cells stained for &#x3B2;-catenin (anti-&#x3B2;-catenin antibody) or DNA (DAPI). Changes in &#x3B2;-catenin are seen upon alteration of CIN; enriched at cell-to-cell junctions in MCAK expressing cells but cytoplasmic and nuclear in dnMCAK expressing cells, scale bar 30-&#x3BC;m, 2 experiments. <bold>c</bold>, <italic>Above</italic>, Phase-contrast images of a wound-healing assay of cells expressing kinesin-13 proteins, scale bar 800-&#x3BC;m, 2 experiments. <italic>Bottom</italic>, Wound area (normalized to the 0h time point) 24h and 45h after wound creation, bars represent mean &#xB1; SD, n = 4 experiments, significance tested using two-sided t-test. <bold>d</bold>, <italic>Above</italic>, Low-power field images of MDA-MB-231 cells that have migrated through a polycarbonate membrane containing 8-&#x3BC;m pores within 18 hours of culture. <italic>Below</italic>, Normalized O.D. of cells scraped from the bottom of the membrane, bars represent mean &#xB1; s.e.m., significance tested using two-sided t-test, <italic>n</italic> = 3 experiments. <bold>e&#x2013;f</bold>, <italic>Left</italic>, Number of MDA-MB-231 cells that have successfully invaded through a collagen basement membrane 24 hours after plating. Bars represent mean &#xB1; SD, n = 20 high power fields from 2 independent experiments, significance tested using two-sided Mann-Whitney test. <italic>Right</italic>, representative images from high-power fields, 2 independent experiments. <bold>g, i</bold>, Representative time-lapse fluorescence and phase-contract image sequences of control cells expressing NLS-GFP undergoing unconfined migration (g) or going through 1&#xD7;5 &#x3BC;m<sup>2</sup> constrictions (i). Scale bar 20-&#x3BC;m. Arrows in (g) indicate cytoplasmic NLS-GFP. Arrows in (i) indicate formation of nuclear protrusion and subsequently fragment during confined migration, 3 independent experiments. <bold>h</bold>, <bold>j</bold>, The probability of primary nuclear rupture during unconfined conditions (h, <italic>top</italic>) or after migration through 1&#xD7;5 &#x3BC;m<sup>2</sup> wide constrictions (j, <italic>top</italic>). The number of cells migrating through more than one 1-&#x3BC;m wide constrictions (j, <italic>bottom</italic>) and the duration of nuclear rupture (h, <italic>bottom</italic>) as measured by the length of time in which NLS-GFP signal is observed in the cytosol. Bars represent mean &#xB1; s.e.m., <italic>n</italic> = 3 independent experiments (except for unconfined rupture probability &#x2013; 2 independent experiments) encompassing 390&#x2013;665 (h) and 150&#x2013;336 (j) cells observed during unconfined and confined migration, respectively, significance tested using two-sided t-test.</p>
        </caption>
        <graphic xlink:href="nihms925648f13"/>
      </fig>
      <fig id="F14" orientation="portrait" position="anchor">
        <label>Extended Data Figure 8</label>
        <caption>
          <title>CIN generates micronuclei and cytosolic DNA</title>
          <p id="P56"><bold>a&#x2013;b</bold>, Percentage of micronuclei in samples depicted in <xref rid="F3" ref-type="fig">Figure 3c&#x2013;d</xref>: injected cells (blue), first-passage cells derived from primary tumors (green), or metastases (orange denotes spontaneous metastases arising from primary tumors, red denotes metastases obtained from direct intracardiac implantation). Bars represent mean &#xB1; s.e.m., <italic>n</italic> = 10 high-power fields encompassing 500&#x2013;1500 cells/sample, 3 independent experiments, * <italic>p</italic> &lt; 0.05 and denotes samples with higher missegregation rates than the injected lines, # <italic>p</italic> &lt; 0.05 and denotes samples with lower missegregation rates than the injected lines, ** <italic>p</italic> &lt; 0.05 and it denotes significant differences between metastases and matched primary tumors from the same animals, two-tailed t-test. <bold>c</bold>, Correlation between the percentage of cells exhibiting evidence of chromosome missegregation and percentage of micronuclei in all injected cell lines as well as cells derived from primary tumors and metastases. Data points represent mean &#xB1; s.e.m., <italic>n</italic> = 44 samples. <bold>d&#x2013;f</bold>, Representative images of cells stained for DNA (DAPI), cytosolic single-stranded DNA (ssDNA) (d), Dnase2 (RFP reporter) (e), or cytosolic double-stranded DNA (dsDNA) (f), scale bar 20-&#x3BC;m, arrows in e denote Dnase2 expressing cell, 2 independent experiments. <bold>g</bold>, Representative images of dnMCAK expressing cells treated with ssDnase or dsDnase for 10 min. after selective plasma membrane permeabilization (using 0.02% saponin) stained for DNA (DAPI) and cytosolic dsDNA, scale bar 20-&#x3BC;m, one experiment. <bold>h</bold>, Representative images of dnMCAK expressing cells stained for mitochondria (using anti-CoxIV antibody), DNA (DAPI) or for cytosolic DNA (using anti-dsDNA antibody), scale bar 20-&#x3BC;m, 2 independent experiments. <bold>i</bold>, Immunoblots of lysates from cells expressing different kinesin-13 proteins, control or STING shRNA, &#x3B2;-actin used as a loading control. <bold>j</bold>, Normalized ratio of phosphorylated p52-to-p100 (left) and p100-to-total p100 (right) protein levels. Bars represent mean &#xB1; s.e.m., <italic>n</italic> = 5 independent experiments.</p>
        </caption>
        <graphic xlink:href="nihms925648f14"/>
      </fig>
      <fig id="F15" orientation="portrait" position="anchor">
        <label>Extended Data Figure 9</label>
        <caption>
          <title>Alternative response to cytosolic DNA in cancer cells</title>
          <p id="P57"><bold>a&#x2013;d</bold>, Representative images of MDA-MB-231 cells stained for DNA (DAPI), and for p65 (a), IRF3 (b), or RelB (c&#x2013;d). Images were individually contrast-enhanced to emphasize nuclear versus cytosolic localization of p65, IRF3, and RelB. For quantitative comparisons of the identical images, please refer to <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3</xref>. Arrows (c&#x2013;d) point to RelB-positive nuclei, scale bars, 20-&#x3BC;m, 3 independent experiments. <bold>e</bold>, Immunoblots of fractionated lysates. a-tubulin and Lamin B2 were used as loading controls for the cytoplasmic and nuclear fractions, respectively, 3 independent experiments. <bold>f</bold>, <bold>h</bold>, Interferon-&#x3B2; levels in conditioned media from DLD-1 cells (f) MDA-MB-231 or HEK293 cells with and without cGAMP addition (h). Bars represent mean &#xB1; s.e.m. n = 3 experiments, significance tested using one-sided Mann-Whitney test. <bold>g</bold>, <bold>i</bold>, Relative levels of interferon responsive genes obtained by RT-qPCR, DLD-1 cells (g) normalized to untreated conditions or MDA-MB-231 cells (i) normalized to control cells. Bars represent mean &#xB1; SD n = 3 experiments, significance tested using 2-sided t-test. <bold>j</bold>, Immunoblots of lysates of dnMCAK expressing cells that also co-express control shRNA or shRNAs targeting components of cytosolic DNA sensing or the noncanonical NF-&#x3BA;B pathway. shRNA hairpins are numbered in ascending order based on the efficiency of the protein knockdown, 2 independent experiments.</p>
        </caption>
        <graphic xlink:href="nihms925648f15"/>
      </fig>
      <fig id="F16" orientation="portrait" position="anchor">
        <label>Extended Data Figure 10</label>
        <caption>
          <title>Effect of cytosolic DNA sensing pathways on prognosis</title>
          <p id="P58"><bold>a</bold>, Distant metastasis-free survival (DMFS), Relapse-free survival (RFS) and Progression-free survival (PFS) of breast and lung cancer patients, respectively stratified based on their expression of NF-&#x3BA;B and interferon pathways, significance tested using two-sided log-rank test. <bold>b</bold>, Disease-specific survival of mice injected with dnMCAK expressing MDA-MB-231 cells co-expressing either control shRNA, STING shRNA, NFKB2 shRNA, or RelB shRNA <italic>n</italic> = 35, 16, 19, and 20 mice in the control, STING shRNA, NFKB2 shRNA, and RelB shRNA groups respectively, significance tested using two-sided log-rank test. <bold>c</bold>, Number of MDA-MB-231 cells expressing shRNA targeting genes belonging to the DNA sensing or noncanonical NF-&#x3BA;B pathways that invaded through a collagen membrane within 24 hours of culture. Bars represent mean &#xB1; SD, ** <italic>p</italic> &lt; 0.0001, two-sided Mann Whitney test, <italic>n</italic> = 20 high-power fields, 2 independent experiments. <bold>d</bold>, Number of different normal tissues (vascular, neuronal, or soft tissues) invaded by orthotopically transplanted tumors. Bars represent mean &#xB1; s.e.m., *<italic>p</italic> &lt; 0.05, two-tailed t-test, n = 13 tumors (CIN-high), 20 tumors (noncanonical NF-&#x3BA;B depleted), 19 tumors (cGAS-STING depleted). <bold>e</bold>, Oncoprints showing genomic alterations in STING (TMEM173) and cGAS (MB21D1) in breast and lung cancers from the TCGA database.</p>
        </caption>
        <graphic xlink:href="nihms925648f16"/>
      </fig>
    </sec>
    <sec sec-type="supplementary-material" id="S32">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>1</label>
        <media xlink:href="NIHMS925648-supplement-1.pdf" orientation="portrait" xlink:type="simple" id="d36e1898" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S33">
      <p>We thank Joan Massagu&#xE9;, Robert Benezra, Xin Cai, Jonathan Leeman, Mathieu Bakhoum, Benjamin Hopkins, and Dan Landau for critical feedback. Grant support: SFB (DoD Breast Cancer Research Breakthrough Award (BCRBA) W81XWH-16-1-0315, Elsa Pardee Foundation, MSKCC Cytogenetics Core (P30-CA008748) and core (P30-CA008748) grants, BN (NSF Graduate Research Fellowship DGE1257284), JL (NIH R01-HL082792, U54-CA210184, DoD BCRBA BC150580, NSF CBET-1254846), PL (NCI K99-CA218871), LCC (NIH R35-CA197588, U54-CA210184, Breast Cancer Research Foundation, Gray Foundation Basser Initiative).</p>
    </ack>
    <fn-group>
      <fn id="FN4">
        <p><xref rid="SD1" ref-type="supplementary-material">Supplementary information</xref> is available in the online version of this paper.</p>
      </fn>
      <fn id="FN5" fn-type="con">
        <p><bold>Author Contributions</bold> SFB and LCC conceived of the project, SFB, BN, JACF, RKS performed animal experiments, VKR derived PDX models, PL performed experiments using DLD-1 cells, SFB, BN, JAC, RKS, MD, SV, QL performed immunostaining, immunoblotting, microscopy, qPCR, PS performed live-cell imaging, TBKW, NJB, NM analyzed matched primary tumors-metastases data, NKT, CHC, SFB performed data analysis of the HNSCC data, SFB analyzed breast cancer karyotype data, CP performed histological analysis, CS, KC, GN performed cytogenetic analysis, AML analyzed scRNSseq data, ML, SFB analyzed survival data, CJM analyzed bulk RNAseq data, MI analyzed whole-genome sequence data, GG, ML, QL, JH, OE, CHC, NYL, DP, DWC, SNP, JL, CS, LCC assisted with data interpretation. All authors contributed to the writing and editing of the manuscript.</p>
      </fn>
      <fn id="FN6">
        <p>L.C.C. owns equity in, receives compensation from, and serves on the board of directors and scientific advisory board of Agios Pharmaceuticals. He is also a founder of and receives laboratory support from Petra Pharmaceuticals.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jamal-Hanjani</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tracking the Evolution of Non-Small-Cell Lung Cancer</article-title>
          <source>N Engl J Med</source>
          <volume>376</volume>
          <fpage>2109</fpage>
          <lpage>2121</lpage>
          <year>2017</year>
          <pub-id pub-id-type="pmid">28445112</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turajlic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Swanton</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Metastasis as an evolutionary process</article-title>
          <source>Science</source>
          <volume>352</volume>
          <fpage>169</fpage>
          <lpage>175</lpage>
          <year>2016</year>
          <pub-id pub-id-type="pmid">27124450</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Compton</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Examining the link between chromosomal instability and aneuploidy in human cells</article-title>
          <source>J Cell Biol</source>
          <volume>180</volume>
          <fpage>665</fpage>
          <lpage>672</lpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18283116</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cimini</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Merotelic kinetochore orientation is a major mechanism of aneuploidy in mitotic mammalian tissue cells</article-title>
          <source>J Cell Biol</source>
          <volume>153</volume>
          <fpage>517</fpage>
          <lpage>527</lpage>
          <year>2001</year>
          <pub-id pub-id-type="pmid">11331303</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakhoum</surname>
              <given-names>SF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The mitotic origin of chromosomal instability</article-title>
          <source>Curr Biol</source>
          <volume>24</volume>
          <fpage>R148</fpage>
          <lpage>9</lpage>
          <year>2014</year>
          <pub-id pub-id-type="pmid">24556433</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakhoum</surname>
              <given-names>SF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Numerical chromosomal instability mediates susceptibility to radiation treatment</article-title>
          <source>Nat Commun</source>
          <volume>6</volume>
          <fpage>5990</fpage>
          <year>2015</year>
          <pub-id pub-id-type="pmid">25606712</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakhoum</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Manning</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Compton</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Genome stability is ensured by temporal control of kinetochore-microtubule dynamics</article-title>
          <source>Nat Cell Biol</source>
          <volume>11</volume>
          <fpage>27</fpage>
          <lpage>35</lpage>
          <year>2009</year>
          <pub-id pub-id-type="pmid">19060894</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burrell</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Replication stress links structural and numerical cancer chromosomal instability</article-title>
          <source>Nature</source>
          <volume>494</volume>
          <fpage>492</fpage>
          <lpage>496</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">23446422</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brastianos</surname>
              <given-names>PK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets</article-title>
          <source>Cancer Discovery</source>
          <volume>5</volume>
          <fpage>1164</fpage>
          <lpage>1177</lpage>
          <year>2015</year>
          <pub-id pub-id-type="pmid">26410082</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="web">
          <person-group person-group-type="author">
            <name>
              <surname>Mitelman</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mertens</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer</article-title>
          <source>cgapncinihgov</source>
          <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://cgap.nci.nih.gov/Chromosomes/Mitelman">http://cgap.nci.nih.gov/Chromosomes/Mitelman</ext-link></comment>
          <date-in-citation>Accessed: 24 October 2014</date-in-citation>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chung</surname>
              <given-names>CH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression</article-title>
          <source>Cancer Cell</source>
          <volume>5</volume>
          <fpage>489</fpage>
          <lpage>500</lpage>
          <year>2004</year>
          <pub-id pub-id-type="pmid">15144956</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>AT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>MCAK associates with the tips of polymerizing microtubules</article-title>
          <source>J Cell Biol</source>
          <volume>169</volume>
          <fpage>391</fpage>
          <lpage>397</lpage>
          <year>2005</year>
          <pub-id pub-id-type="pmid">15883193</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ems-McClung</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Walczak</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Kinesin-13s in mitosis: Key players in the spatial and temporal organization of spindle microtubules</article-title>
          <source>Semin Cell Dev Biol</source>
          <volume>21</volume>
          <fpage>276</fpage>
          <lpage>282</lpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20109574</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waterman-Storer</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Worthylake</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Burridge</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Salmon</surname>
              <given-names>ED</given-names>
            </name>
          </person-group>
          <article-title>Microtubule growth activates Rac1 to promote lamellipodial protrusion in fibroblasts</article-title>
          <source>Nat Cell Biol</source>
          <volume>1</volume>
          <fpage>45</fpage>
          <lpage>50</lpage>
          <year>1999</year>
          <pub-id pub-id-type="pmid">10559863</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sotillo</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mad2 overexpression promotes aneuploidy and tumorigenesis in mice</article-title>
          <source>Cancer Cell</source>
          <volume>11</volume>
          <fpage>9</fpage>
          <lpage>23</lpage>
          <year>2007</year>
          <pub-id pub-id-type="pmid">17189715</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gy&#xF6;rffy</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients</article-title>
          <source>Breast Cancer Res Treat</source>
          <volume>123</volume>
          <fpage>725</fpage>
          <lpage>731</lpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20020197</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hatzis</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer</article-title>
          <source>JAMA</source>
          <volume>305</volume>
          <fpage>1873</fpage>
          <lpage>1881</lpage>
          <year>2011</year>
          <pub-id pub-id-type="pmid">21558518</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Barber</surname>
              <given-names>GN</given-names>
            </name>
          </person-group>
          <article-title>Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-&#x3BA;B activation through TBK1</article-title>
          <source>J Virol</source>
          <volume>88</volume>
          <fpage>5328</fpage>
          <lpage>5341</lpage>
          <year>2014</year>
          <pub-id pub-id-type="pmid">24600004</pub-id>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway</article-title>
          <source>Science</source>
          <volume>339</volume>
          <fpage>786</fpage>
          <lpage>791</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">23258413</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hatch</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Deerinck</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Hetzer</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Catastrophic nuclear envelope collapse in cancer cell micronuclei</article-title>
          <source>Cell</source>
          <volume>154</volume>
          <fpage>47</fpage>
          <lpage>60</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">23827674</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahn</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inflammation-driven carcinogenesisis mediated through STING</article-title>
          <source>Nat Commun</source>
          <volume>5</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <year>1AD</year>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harding</surname>
              <given-names>SM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mitotic progression following DNA damage enables pattern recognition within micronuclei</article-title>
          <source>Nature</source>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1038/nature23470</pub-id>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mackenzie</surname>
              <given-names>KJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>cGAS surveillance of micronuclei links genome instability to innate immunity</article-title>
          <source>Nature</source>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1038/nature23449</pub-id>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lan</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Londo&#xF1;o</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bouley</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rooney</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Hacohen</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Dnase2a deficiency uncovers lysosomal clearance of damaged nuclear DNA via autophagy</article-title>
          <source>Cell Rep</source>
          <volume>9</volume>
          <fpage>180</fpage>
          <lpage>192</lpage>
          <year>2014</year>
          <pub-id pub-id-type="pmid">25284779</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Denais</surname>
              <given-names>CM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nuclear envelope rupture and repair during cancer cell migration</article-title>
          <source>Science</source>
          <volume>352</volume>
          <fpage>353</fpage>
          <lpage>358</lpage>
          <year>2016</year>
          <pub-id pub-id-type="pmid">27013428</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ly</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Selective Y centromere inactivation triggers chromosome shattering in micronuclei and repair by non-homologous end joining</article-title>
          <source>Nat Cell Biol</source>
          <volume>19</volume>
          <fpage>68</fpage>
          <lpage>75</lpage>
          <year>2017</year>
          <pub-id pub-id-type="pmid">27918550</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ren</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>ZJ</given-names>
            </name>
          </person-group>
          <article-title>cGAS is essential for cellular senescence</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>114</volume>
          <fpage>E4612</fpage>
          <lpage>E4620</lpage>
          <year>2017</year>
          <pub-id pub-id-type="pmid">28533362</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stetson</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Ko</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Heidmann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Medzhitov</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Trex1 Prevents Cell-Intrinsic Initiation of Autoimmunity</article-title>
          <source>Cell</source>
          <volume>134</volume>
          <fpage>587</fpage>
          <lpage>598</lpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18724932</pub-id>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lau</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Brunette</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Stetson</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway</article-title>
          <source>Science</source>
          <volume>350</volume>
          <fpage>568</fpage>
          <lpage>571</lpage>
          <year>2015</year>
          <pub-id pub-id-type="pmid">26405230</pub-id>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dou</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cytoplasmic chromatin triggers inflammation in senescence and cancer</article-title>
          <source>Nature</source>
          <volume>550</volume>
          <fpage>402</fpage>
          <lpage>406</lpage>
          <year>2017</year>
          <pub-id pub-id-type="pmid">28976970</pub-id>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>S-C</given-names>
            </name>
          </person-group>
          <article-title>Controlling the fate of NIK: a central stage in noncanonical NF-kappaB signaling</article-title>
          <source>Sci Signal</source>
          <volume>3</volume>
          <fpage>pe18</fpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20501935</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer</article-title>
          <source>Nature</source>
          <volume>533</volume>
          <fpage>493</fpage>
          <lpage>498</lpage>
          <year>2016</year>
          <pub-id pub-id-type="pmid">27225120</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2</article-title>
          <source>Nat Cell Biol</source>
          <volume>9</volume>
          <fpage>470</fpage>
          <lpage>478</lpage>
          <year>2007</year>
          <pub-id pub-id-type="pmid">17369819</pub-id>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>The NF-&#x3BA;B subunit RelB regulates the migration and invasion abilities and the radio-sensitivity of prostate cancer cells</article-title>
          <source>Int J Oncol</source>
          <volume>49</volume>
          <fpage>381</fpage>
          <lpage>392</lpage>
          <year>2016</year>
          <pub-id pub-id-type="pmid">27121503</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation</article-title>
          <source>Cancer Discovery</source>
          <volume>3</volume>
          <fpage>212</fpage>
          <lpage>223</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">23269702</pub-id>
        </element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gulen</surname>
              <given-names>MF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Signalling strength determines proapoptotic functions of STING</article-title>
          <source>Nat Commun</source>
          <volume>8</volume>
          <fpage>427</fpage>
          <year>2017</year>
          <pub-id pub-id-type="pmid">28874664</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kis-Toth</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Szanto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thai</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Tsokos</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
          <article-title>Cytosolic DNA-activated human dendritic cells are potent activators of the adaptive immune response</article-title>
          <source>J Immunol</source>
          <volume>187</volume>
          <fpage>1222</fpage>
          <lpage>1234</lpage>
          <year>2011</year>
          <pub-id pub-id-type="pmid">21709148</pub-id>
        </element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheltzer</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Single-chromosome Gains Commonly Function as Tumor Suppressors</article-title>
          <source>Cancer Cell</source>
          <volume>31</volume>
          <fpage>240</fpage>
          <lpage>255</lpage>
          <year>2017</year>
          <pub-id pub-id-type="pmid">28089890</pub-id>
        </element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weaver</surname>
              <given-names>BAA</given-names>
            </name>
            <name>
              <surname>Silk</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Montagna</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Verdier-Pinard</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cleveland</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>Aneuploidy acts both oncogenically and as a tumor suppressor</article-title>
          <source>Cancer Cell</source>
          <volume>11</volume>
          <fpage>25</fpage>
          <lpage>36</lpage>
          <year>2007</year>
          <pub-id pub-id-type="pmid">17189716</pub-id>
        </element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="joural">
          <person-group person-group-type="author">
            <name>
              <surname>Rowald</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth</article-title>
          <source>Cell Rep</source>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.048</pub-id>
        </element-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>DR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Integrative clinical genomics of metastatic cancer</article-title>
          <source>Nature</source>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1038/nature23306</pub-id>
        </element-citation>
      </ref>
      <ref id="R42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheltzer</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>A transcriptional and metabolic signature of primary aneuploidy is present in chromosomally unstable cancer cells and informs clinical prognosis</article-title>
          <source>Cancer Res</source>
          <volume>73</volume>
          <fpage>6401</fpage>
          <lpage>6412</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">24041940</pub-id>
        </element-citation>
      </ref>
      <ref id="R43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McGranahan</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade</article-title>
          <source>Science</source>
          <volume>351</volume>
          <fpage>1463</fpage>
          <lpage>1469</lpage>
          <year>2016</year>
          <pub-id pub-id-type="pmid">26940869</pub-id>
        </element-citation>
      </ref>
      <ref id="R44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakhoum</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Danilova</surname>
              <given-names>OV</given-names>
            </name>
            <name>
              <surname>Kaur</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Compton</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma</article-title>
          <source>Clin Cancer Res</source>
          <volume>17</volume>
          <fpage>7704</fpage>
          <lpage>7711</lpage>
          <year>2011</year>
          <pub-id pub-id-type="pmid">22184286</pub-id>
        </element-citation>
      </ref>
      <ref id="R45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zaki</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Suriawinata</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Eastman</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Garner</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Bakhoum</surname>
              <given-names>SF</given-names>
            </name>
          </person-group>
          <article-title>Chromosomal instability portends superior response of rectal adenocarcinoma to chemoradiation therapy</article-title>
          <source>Cancer</source>
          <volume>120</volume>
          <fpage>1733</fpage>
          <lpage>1742</lpage>
          <year>2014</year>
          <pub-id pub-id-type="pmid">24604319</pub-id>
        </element-citation>
      </ref>
      <ref id="R46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davidson</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Denais</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bakshi</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Lammerding</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Nuclear deformability constitutes a rate-limiting step during cell migration in 3-D environments</article-title>
          <source>Cell Mol Bioeng</source>
          <volume>7</volume>
          <fpage>293</fpage>
          <lpage>306</lpage>
          <year>2014</year>
          <pub-id pub-id-type="pmid">25436017</pub-id>
        </element-citation>
      </ref>
      <ref id="R47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conway</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Xenome--a tool for classifying reads from xenograft samples</article-title>
          <source>Bioinformatics</source>
          <volume>28</volume>
          <fpage>i172</fpage>
          <lpage>8</lpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22689758</pub-id>
        </element-citation>
      </ref>
      <ref id="R48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dobin</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>
          <source>Bioinformatics</source>
          <volume>29</volume>
          <fpage>15</fpage>
          <lpage>21</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">23104886</pub-id>
        </element-citation>
      </ref>
      <ref id="R49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trapnell</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation</article-title>
          <source>Nat Biotechnol</source>
          <volume>28</volume>
          <fpage>511</fpage>
          <lpage>515</lpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20436464</pub-id>
        </element-citation>
      </ref>
      <ref id="R50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anders</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pyl</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>HTSeq--a Python framework to work with high-throughput sequencing data</article-title>
          <source>Bioinformatics</source>
          <volume>31</volume>
          <fpage>166</fpage>
          <lpage>169</lpage>
          <year>2015</year>
          <pub-id pub-id-type="pmid">25260700</pub-id>
        </element-citation>
      </ref>
      <ref id="R51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Love</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Anders</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>
          <source>Genome Biol</source>
          <volume>15</volume>
          <fpage>550</fpage>
          <year>2014</year>
          <pub-id pub-id-type="pmid">25516281</pub-id>
        </element-citation>
      </ref>
      <ref id="R52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Subramanian</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>102</volume>
          <fpage>15545</fpage>
          <lpage>15550</lpage>
          <year>2005</year>
          <pub-id pub-id-type="pmid">16199517</pub-id>
        </element-citation>
      </ref>
      <ref id="R53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Preter</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Barriot</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Speleman</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Vandesompele</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moreau</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Positional gene enrichment analysis of gene sets for high-resolution identification of overrepresented chromosomal regions</article-title>
          <source>Nucleic Acids Research</source>
          <volume>36</volume>
          <fpage>e43</fpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18346969</pub-id>
        </element-citation>
      </ref>
      <ref id="R54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Eils</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schlesner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brors</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>circlize Implements and enhances circular visualization in R</article-title>
          <source>Bioinformatics</source>
          <volume>30</volume>
          <fpage>2811</fpage>
          <lpage>2812</lpage>
          <year>2014</year>
          <pub-id pub-id-type="pmid">24930139</pub-id>
        </element-citation>
      </ref>
      <ref id="R55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>GXY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Massively parallel digital transcriptional profiling of single cells</article-title>
          <source>Nat Commun</source>
          <volume>8</volume>
          <fpage>14049</fpage>
          <year>2017</year>
          <pub-id pub-id-type="pmid">28091601</pub-id>
        </element-citation>
      </ref>
      <ref id="R56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Dijk</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nainys</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kathail</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Carr</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>MAGIC: A diffusion-based imputation method reveals gene-gene interactions in single-cell RNA-sequencing data</article-title>
          <comment>BioRxiv</comment>
          <year>2017</year>
        </element-citation>
      </ref>
      <ref id="R57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levine</surname>
              <given-names>JH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis</article-title>
          <source>Cell</source>
          <volume>162</volume>
          <fpage>184</fpage>
          <lpage>197</lpage>
          <year>2015</year>
          <pub-id pub-id-type="pmid">26095251</pub-id>
        </element-citation>
      </ref>
      <ref id="R58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gy&#xF6;rffy</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Surowiak</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Budczies</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lanczky</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer</article-title>
          <source>PLoS ONE</source>
          <volume>8</volume>
          <fpage>e82241</fpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">24367507</pub-id>
        </element-citation>
      </ref>
      <ref id="R59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Tommaso</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nextflow enables reproducible computational workflows</article-title>
          <source>Nat Biotechnol</source>
          <volume>35</volume>
          <fpage>316</fpage>
          <lpage>319</lpage>
          <year>2017</year>
          <pub-id pub-id-type="pmid">28398311</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <title>Human metastases enrich for CIN</title>
        <p><bold>a</bold>, wGII of matched primary tumors (P) and brain metastases (M), <italic>n</italic> = 79 patients. <bold>b&#x2013;c</bold>, Karyotype probability density (b) and chromosomal aberrations (c) in 983 primary tumor and 186 metastatic breast cancer clones. <bold>d</bold>, Images of a head and neck squamous cell carcinoma cells undergoing anaphase. Arrows point to chromosome missegregation, scale bar 5-&#x3BC;m. <italic>Right,</italic> Chromosome missegregation in tumors from patients with (N+, <italic>n</italic> = 22 patients) or without (N-, <italic>n</italic> = 18 patients) clinically detectable lymph node metastases. Boxes represent median &#xB1; interquartile range, confidence intervals denote 10<sup>th</sup>&#x2013;90<sup>th</sup> percentile (a, c&#x2013;d), significance tested using two-sided Wilcoxon matched-pairs signed rank test (a) and two-sided Mann Whitney test (b&#x2013;d).</p>
      </caption>
      <graphic xlink:href="nihms925648f1"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <title>CIN is a driver of metastasis</title>
        <p><bold>a</bold>, Anaphase cells stained for centromeres and DNA, scale bar 5-&#x3BC;m. <bold>b</bold>, Chromosome missegregation in cells expressing kinesin-13 proteins. Bars represent mean &#xB1; SD, <italic>n</italic> = 150 cells. <bold>c,</bold> Whole animal bioluminescence (BLI) 7 weeks after intracardiac injection of MDA-MB-231 cells. Bars represent the median, <italic>n</italic> = 12 (MCAK+Mad2), 20 (MCAK), 7 (Kif2b), 9 (control), 9 (Kif2a), 8 (dnMCAK) mice. <bold>d</bold>, Ex-vivo BLI of organs with metastases from MDA-MB-231 cells expressing dnMCAK. <bold>e</bold>, Disease-specific survival of mice injected with CIN-high (<italic>n</italic> = 33) or CIN-low (<italic>n</italic> = 20) MDA-MB-231. Significance tested using two-sided t-test (b), two-sided Mann Whitney test (c), and two-sided log-rank test (e) <italic>n</italic> = 3 (a&#x2013;b) and 5 (d) independent experiments. Throughout the manuscript, pairwise comparisons between individual CIN-low and CIN-high conditions are smaller than the stated <italic>p</italic> value.</p>
      </caption>
      <graphic xlink:href="nihms925648f2"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <title>Opposing roles for CIN in primary tumors and metastases</title>
        <p><bold>a</bold>, Experimental schema. <bold>b&#x2013;d</bold>, Chromosome missegregation in injected cells (blue), cells derived from primary tumors (green), metastases (met) arising spontaneously (orange) or after intracardiac injection (red). ST, soft tissue. Bars represent mean &#xB1; SD, <italic>n</italic> = 150 cells, 3 independent experiments, *<italic>p</italic> &lt; 0.05, #<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.05 denote samples with higher or lower chromosome missegregation than the injected lines, and spontaneous metastases with higher missegregation than matched primary tumors, respectively. Significance tested using two-sided t-test (b&#x2013;d).</p>
      </caption>
      <graphic xlink:href="nihms925648f3"/>
    </fig>
    <fig id="F4" orientation="portrait" position="float">
      <label>Figure 4</label>
      <caption>
        <title>CIN enriches for mesenchymal cell traits</title>
        <p><bold>a</bold>, Heatmap showing expression of EMT genes in 6,821 MCAK, Kif2b, and dnMCAK expressing MDA-MB-231 cells. <bold>b</bold>, <italic>Above</italic>, t-stochastic neighbor embedding (tSNE) projection of all cells in a. <italic>Below</italic>, Heatmap of normalized enrichment score (NES) for pathways with an FDRq &lt; 0.05 based on GSEA using one-sided Weighted Smirnov-Kolmogorov test on subpopulations identified using Phenograph. Boxes outline populations with mutually exclusive transcriptional profiles.</p>
      </caption>
      <graphic xlink:href="nihms925648f4"/>
    </fig>
    <fig id="F5" orientation="portrait" position="float">
      <label>Figure 5</label>
      <caption>
        <title>CIN generates cytosolic DNA</title>
        <p><bold>a</bold>, Heatmap showing gene-gene correlations in 6,821 cells and HALLMARK gene sets significantly enriched in Module 2, one-sided Weighted Smirnov-Kolmogorov test. <bold>b</bold>, <italic>Top right</italic>, normalized expression level of key gene signatures in 6,821 MCAK, Kif2b, and dnMCAK expressing MDA-MB-231 cells. <italic>Bottom left</italic>, Correlation plots for key gene signatures. <bold>c</bold>, A primary nucleus and a micronucleus stained for centromeres and DNA, scale bar 5-&#x3BC;m. <bold>d&#x2013;e</bold>, Percentage of micronuclei cells expressing various kinesin-13 proteins (d) or in cells derived from 10 primary tumors and 28 metastases (e). <italic>n</italic> = 20 high-power fields per sample (d) or average values derived from 10 high-power fields per sample (e). <bold>f</bold>, MCAK and dnMCAK expressing MDA-MB-231 cells stained using DAPI and anti-dsDNA antibody, scale bar 20-&#x3BC;m. <bold>g</bold>, Cytosolic-to-nuclear DNA ratios in CIN-high (<italic>n</italic> = 5) and CIN-low (<italic>n</italic> = 4) MDA-MB-231 (<italic>n</italic> = 5) and H2030 (<italic>n</italic> = 4) cells. <bold>h</bold>, <italic>Left</italic>, DLD-1 cells stained for DNA and hybridized to chromosome-specific FISH probes, scale bar 5-&#x3BC;m. <italic>Right</italic>, Percentage of cells containing micronuclei or small cytosolic DNA fragments (<italic>n</italic> &gt;500 cells per condition). <bold>i</bold>, MDA-MB-231 cells stained using DAPI, anti-dsDNA antibody, or mCherry-Lamin B2 (arrow), scale bar 10-&#x3BC;m. Bars represent median &#xB1; inter-quartile range (d&#x2013;e), mean &#xB1; SD (g), mean &#xB1; sem (h). <italic>n</italic> = 6 (c&#x2013;d), 3 (e&#x2013;f, h), 1 (g) and 2 (i) independent experiments. Significance tested using two-sided Mann-Whitney test (d&#x2013;e) or two-sided t-test (g&#x2013;h), * <italic>p</italic> &lt;0.05.</p>
      </caption>
      <graphic xlink:href="nihms925648f5"/>
    </fig>
    <fig id="F6" orientation="portrait" position="float">
      <label>Figure 6</label>
      <caption>
        <title>Metastasis from a cytosolic DNA response</title>
        <p><bold>a</bold>, MDA-MB-231 cells stained for DNA and cGAS, scale bar 5-&#x3BC;m. <bold>b</bold><italic>,</italic> Percentage of micronuclei with (cGAS+) or without (cGAS-) cGAS localization, <italic>n</italic> = 200 cells. <bold>c</bold>, Cells stained for DNA and STING, scale bar 20-&#x3BC;m. <bold>d</bold>, Percentage of MDA-MB-231 cells with nuclear RelB, <italic>n</italic> = 150 cells. <bold>e</bold>, Average z-normalized expression of CIN-responsive noncanonical NF-&#x3BA;B target genes in breast cancer patients with low (&lt;30<sup>th</sup> percentile, <italic>n</italic> = 330) or high (&gt;30<sup>th</sup> percentile, <italic>n</italic> = 332) CIN gene expression signature. <bold>f&#x2013;g</bold>, Photon flux (p/s) of whole animals after intracardiac injection with MDA-MB-231 cells expressing control shRNA, STING shRNA (f), RelB shRNA (g) or NFKB2 shRNA (g), <italic>n</italic> = 9, 7, and 9 mice for the control, STING shRNA1, and STING shRNA2 groups, respectively (f), n = 22, 10, 10, 10, and 9 mice for the control, RelB shRNA1, RelB shRNA2, NFKB2 shRNA1, and NFKB2 shRNA2 groups, respectively (g). Bars represent mean &#xB1; SD (b, d), median &#xB1; interquartile range with bars spanning 10<sup>th</sup>&#x2013;90<sup>th</sup> percentile (e), median (f&#x2013;g), significance tested using two-sided t-test (b, d), two-sided Mann Whitney test (e&#x2013;g), <italic>n</italic> = 4 (a&#x2013;b), and 3 (c&#x2013;d) independent experiments.</p>
      </caption>
      <graphic xlink:href="nihms925648f6"/>
    </fig>
  </floats-group>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0404511</journal-id>
      <journal-id journal-id-type="nlm-ta">Science</journal-id>
      <journal-id journal-id-type="iso-abbrev">Science</journal-id>
      <journal-title-group>
        <journal-title>Science (New York, N.Y.)</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0036-8075</issn>
      <issn pub-type="epub">1095-9203</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32943498</article-id>
      <article-id pub-id-type="pmc">7116327</article-id>
      <article-id pub-id-type="manuscript">EMS101650</article-id>
      <article-id pub-id-type="doi">10.1126/science.aba7667</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Species-specific developmental timing is associated with differences in protein stability in mouse and human</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rayon</surname>
            <given-names>Teresa</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="corresp" rid="CR1">*</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Stamataki</surname>
            <given-names>Despina</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Perez-Carrasco</surname>
            <given-names>Ruben</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garcia-Perez</surname>
            <given-names>Lorena</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barrington</surname>
            <given-names>Christopher</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Melchionda</surname>
            <given-names>Manuela</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Exelby</surname>
            <given-names>Katherine</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lazaro</surname>
            <given-names>Jorge</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tybulewicz</surname>
            <given-names>Victor L. J.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fisher</surname>
            <given-names>Elizabeth M. C.</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Briscoe</surname>
            <given-names>James</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="corresp" rid="CR1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
<label>1</label>The Francis Crick Institute, London, United Kingdom</aff>
      <aff id="A2">
<label>2</label>Department of Mathematics, University College London, London WC1E 6BT, UK</aff>
      <aff id="A3">
<label>3</label>Department of Life Sciences, Imperial College London, London SW7 2AZ, UK</aff>
      <aff id="A4">
<label>4</label>Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK</aff>
      <aff id="A5">
<label>5</label>UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK</aff>
      <author-notes>
        <corresp id="CR1"><label>*</label>Correspondence to: <email>james.briscoe@crick.ac.uk</email>, <email>teresa.rayon@crick.ac.uk</email></corresp>
        <fn fn-type="COI-statement" id="FN2">
          <p id="P25">
<bold>Competing Interests</bold>
</p>
          <p id="P26">The authors declare no competing or financial interests.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>28</day>
        <month>10</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>3</month>
        <year>2021</year>
      </pub-date>
      <volume>369</volume>
      <issue>6510</issue>
      <elocation-id>eaba7667</elocation-id>
      <abstract>
        <p id="P1">Although many molecular mechanisms controlling developmental processes are evolutionarily conserved, the speed at which the embryo develops can vary substantially between species. For example, the same genetic program, comprising sequential changes in transcriptional states, governs the differentiation of motor neurons in mouse and human, but the tempo at which it operates differs between species. Using in vitro directed differentiation of embryonic stem cells to motor neurons, we show that the program runs more than twice as fast in mouse as in human. This is not due to differences in signaling, nor the genomic sequence of genes or their regulatory elements. Instead, there is an approximately two-fold increase in protein stability and cell cycle duration in human cells compared to mouse. This can account for the slower pace of human development and suggests that differences in protein turnover play a role in interspecies differences in developmental tempo.</p>
      </abstract>
    </article-meta>
  </front>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <?properties manuscript?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0404511</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">7473</journal-id>
      <journal-id journal-id-type="nlm-ta">Science</journal-id>
      <journal-id journal-id-type="iso-abbrev">Science</journal-id>
      <journal-title-group>
        <journal-title>Science (New York, N.Y.)</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0036-8075</issn>
      <issn pub-type="epub">1095-9203</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">35239393</article-id>
      <article-id pub-id-type="pmc">8944923</article-id>
      <article-id pub-id-type="doi">10.1126/science.abk2432</article-id>
      <article-id pub-id-type="manuscript">NIHMS1788050</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fly Cell Atlas: a single-nucleus transcriptomic atlas of the adult fruit fly</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Hongjie</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="FN1" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Janssens</surname>
            <given-names>Jasper</given-names>
          </name>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A4" ref-type="aff">4</xref>
          <xref rid="FN1" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Waegeneer</surname>
            <given-names>Maxime</given-names>
          </name>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kolluru</surname>
            <given-names>Sai Saroja</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Davie</surname>
            <given-names>Kristofer</given-names>
          </name>
          <xref rid="A3" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gardeux</surname>
            <given-names>Vincent</given-names>
          </name>
          <xref rid="A6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Saelens</surname>
            <given-names>Wouter</given-names>
          </name>
          <xref rid="A6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>David</surname>
            <given-names>Fabrice</given-names>
          </name>
          <xref rid="A6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brbi&#x107;</surname>
            <given-names>Maria</given-names>
          </name>
          <xref rid="A7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Spanier</surname>
            <given-names>Katina</given-names>
          </name>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leskovec</surname>
            <given-names>Jure</given-names>
          </name>
          <xref rid="A7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McLaughlin</surname>
            <given-names>Colleen N.</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Xie</surname>
            <given-names>Qijing</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jones</surname>
            <given-names>Robert C.</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brueckner</surname>
            <given-names>Katja</given-names>
          </name>
          <xref rid="A8" ref-type="aff">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shim</surname>
            <given-names>Jiwon</given-names>
          </name>
          <xref rid="A9" ref-type="aff">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tattikota</surname>
            <given-names>Sudhir Gopal</given-names>
          </name>
          <xref rid="A10" ref-type="aff">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schnorrer</surname>
            <given-names>Frank</given-names>
          </name>
          <xref rid="A11" ref-type="aff">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rust</surname>
            <given-names>Katja</given-names>
          </name>
          <xref rid="A12" ref-type="aff">12</xref>
          <xref rid="A13" ref-type="aff">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nystul</surname>
            <given-names>Todd G.</given-names>
          </name>
          <xref rid="A13" ref-type="aff">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho-Santos</surname>
            <given-names>Zita</given-names>
          </name>
          <xref rid="A14" ref-type="aff">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Carlos</given-names>
          </name>
          <xref rid="A14" ref-type="aff">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pal</surname>
            <given-names>Soumitra</given-names>
          </name>
          <xref rid="A15" ref-type="aff">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mahadevaraju</surname>
            <given-names>Sharvani</given-names>
          </name>
          <xref rid="A24" ref-type="aff">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Przytycka</surname>
            <given-names>Teresa M.</given-names>
          </name>
          <xref rid="A15" ref-type="aff">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Allen</surname>
            <given-names>Aaron M.</given-names>
          </name>
          <xref rid="A16" ref-type="aff">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goodwin</surname>
            <given-names>Stephen F.</given-names>
          </name>
          <xref rid="A16" ref-type="aff">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Berry</surname>
            <given-names>Cameron W.</given-names>
          </name>
          <xref rid="A17" ref-type="aff">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fuller</surname>
            <given-names>Margaret T.</given-names>
          </name>
          <xref rid="A17" ref-type="aff">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>White-Cooper</surname>
            <given-names>Helen</given-names>
          </name>
          <xref rid="A18" ref-type="aff">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matunis</surname>
            <given-names>Erika L.</given-names>
          </name>
          <xref rid="A19" ref-type="aff">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>DiNardo</surname>
            <given-names>Stephen</given-names>
          </name>
          <xref rid="A20" ref-type="aff">20</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Galenza</surname>
            <given-names>Anthony</given-names>
          </name>
          <xref rid="A21" ref-type="aff">21</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>O&#x2019;Brien</surname>
            <given-names>Lucy Erin</given-names>
          </name>
          <xref rid="A21" ref-type="aff">21</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dow</surname>
            <given-names>Julian A. T.</given-names>
          </name>
          <xref rid="A22" ref-type="aff">22</xref>
        </contrib>
        <contrib contrib-type="author">
          <collab>FCA Consortium</collab>
          <xref rid="A25" ref-type="aff">25</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jasper</surname>
            <given-names>Heinrich</given-names>
          </name>
          <xref rid="A23" ref-type="aff">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Oliver</surname>
            <given-names>Brian</given-names>
          </name>
          <xref rid="A24" ref-type="aff">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Perrimon</surname>
            <given-names>Norbert</given-names>
          </name>
          <xref rid="A10" ref-type="aff">10</xref>
          <xref rid="CR1" ref-type="corresp">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Deplancke</surname>
            <given-names>Bart</given-names>
          </name>
          <xref rid="A6" ref-type="aff">6</xref>
          <xref rid="CR1" ref-type="corresp">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Quake</surname>
            <given-names>Stephen R.</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
          <xref rid="CR1" ref-type="corresp">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>Liqun</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="CR1" ref-type="corresp">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aerts</surname>
            <given-names>Stein</given-names>
          </name>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A4" ref-type="aff">4</xref>
          <xref rid="CR1" ref-type="corresp">&#x2020;</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Biology, Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305, USA</aff>
      <aff id="A2"><label>2</label>Huffington Center on Aging and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA</aff>
      <aff id="A3"><label>3</label>VIB-KU Leuven Center for Brain &amp; Disease Research, KU Leuven, Leuven 3000, Belgium</aff>
      <aff id="A4"><label>4</label>Laboratory of Computational Biology, Department of Human Genetics, KU Leuven, Leuven 3000, Belgium</aff>
      <aff id="A5"><label>5</label>Departments of Bioengineering and Applied Physics, Stanford University, Stanford CA USA, and Chan Zuckerberg Biohub, San Francisco CA, USA</aff>
      <aff id="A6"><label>6</label>Laboratory of Systems Biology and Genetics, Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique F&#xE9;d&#xE9;rale de Lausanne (EPFL) and Swiss Institute of Bioinformatics, CH-1015 Lausanne, Switzerland</aff>
      <aff id="A7"><label>7</label>Department of Computer Science, Stanford University, Stanford, CA 94305, USA, and Chan Zuckerberg Biohub, San Francisco CA, USA</aff>
      <aff id="A8"><label>8</label>Department of Cell and Tissue Biology, University of California, San Francisco, CA 94143, USA</aff>
      <aff id="A9"><label>9</label>Department of Life Science, College of Natural Science, Hanyang University, Seoul, Republic of Korea 04763</aff>
      <aff id="A10"><label>10</label>Department of Genetics, Blavatnik Institute, Harvard Medical School, Harvard University, Boston, MA 02115; Howard Hughes Medical Institute, Boston, MA, USA</aff>
      <aff id="A11"><label>11</label>Aix-Marseille University, CNRS, IBDM (UMR 7288), Turing Centre for Living systems, 13009 Marseille, France</aff>
      <aff id="A12"><label>12</label>Institute of Physiology and Pathophysiology, Department of Molecular Cell Physiology, Philipps-University, Marburg, Germany</aff>
      <aff id="A13"><label>13</label>Department of Anatomy, University of California, San Francisco, CA 94143, USA</aff>
      <aff id="A14"><label>14</label>Behavior and Metabolism Laboratory, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal</aff>
      <aff id="A15"><label>15</label>National Center of Biotechnology Information, National Library of Medicine, NIH, Bethesda, MD 20894, USA</aff>
      <aff id="A16"><label>16</label>Centre for Neural Circuits &amp; Behaviour, University of Oxford, Tinsley Building, Mansfield road, Oxford, OX1 3SR, UK</aff>
      <aff id="A17"><label>17</label>Department of Developmental Biology and Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA</aff>
      <aff id="A18"><label>18</label>Molecular Biosciences Division, Cardiff University, Cardiff, CF10 3AX UK</aff>
      <aff id="A19"><label>19</label>Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA</aff>
      <aff id="A20"><label>20</label>Perelman School of Medicine, The University of Pennsylvania, and The Penn Institute for Regenerative Medicine Philadelphia, PA 19104, USA</aff>
      <aff id="A21"><label>21</label>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford CA 94305, USA</aff>
      <aff id="A22"><label>22</label>Institute of Molecular, Cell &amp; Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.</aff>
      <aff id="A23"><label>23</label>Immunology Discovery, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA</aff>
      <aff id="A24"><label>24</label>Laboratory of Cellular and Developmental Biology, National Institute of Diabetes and Kidney and Digestive Diseases, National Institutes of Health, Bethesda, MD 20892, USA</aff>
      <aff id="A25"><label>25</label>FCA Consortium: All authors listed before Acknowledgements, and all contributions and affiliations listed in the <xref rid="SD1" ref-type="supplementary-material">Supplementary Materials</xref></aff>
      <author-notes>
        <fn fn-type="equal" id="FN1">
          <label>*</label>
          <p id="P1">equal contribution</p>
        </fn>
        <fn fn-type="con" id="FN2">
          <p id="P2"><bold>Author contributions:</bold> See FCA Consortium Contributions in <xref rid="SD1" ref-type="supplementary-material">Supplementary Materials</xref>.</p>
        </fn>
        <fn fn-type="con" id="FN3">
          <p id="P40">FCA Consortium authors (last name, A&#x2013;Z):</p>
          <p id="P41">Stein Aerts, Devika Agarwal, Yasir Ahmed-Braimah, Aaron M. Allen, Michelle Arbeitman, Majd M. Ariss, Jordan Augsburger, Kumar Ayush, Catherine C. Baker, Torsten Banisch, Cameron W. Berry, Katja Birker, Rolf Bodmer, Benjamin Bolival, Susanna E. Brantley, Maria Brbic, Julie A. Brill, Nora C. Brown, Katja Brueckner, Norene A. Buehner, Xiaoyu Tracy Cai, Rita Cardoso-Figueiredo, Zita Carvalho-Santos, Fernando Casares, Amy Chang, Thomas R. Clandinin, Sheela Crasta, Fabrice PA David, Kristofer Davie, Bart Deplancke, Claude Desplan, Angela M. Detweiler, Darshan B. Dhakan, Stephen DiNardo, Erika Don&#xE0;, Julian A. T. Dow, Stefanie Engert, Swann Floc&#x2019;hlay, Margaret T. Fuller, Anthony Galenza, Vincent Gardeux, Nancy George, Amanda J Gonz&#xE1;lez-Segarra, Stephen F Goodwin, Andrew K. Groves, Samantha Gumbin, Yanmeng Guo, Devon E. Harris, Yael Heifetz, Stephen L. Holtz, Felix Horns, Bruno Hudry, Ruei-Jiun Hung, Yuh Nung Jan, Jasper Janssens, Heinrich Jasper, Jacob S. Jaszczak, Gregory S.X.E. Jefferis, Robert C. Jones, Jim Karkanias, Timothy L. Karr, Nadja Sandra Katheder, James Kezos, Anna A. Kim, Seung K. Kim, Lutz Kockel, Sai Saroja Kolluru, Nikolaos Konstantinides, Thomas B Kornberg, Henry M. Krause, Andrew Thomas Labott, Meghan Laturney, Ruth Lehmann, Sarah Leinwand, Jure Leskovec, Hongjie Li, Jiefu Li, Joshua Shing Shun Li, Kai Li, Ke Li, Liying Li, Tun Li, Maria Litovchenko, Han-Hsuan Liu, Yifang Liu, Tzu-Chiao Lu, Liqun Luo, Sharvani Mahadevaraju, Jonathan Manning, Anjeli Mase, Mikaela Matera-Vatnick, Neuza Reis Matias, Erika L. Matunis, Caitlin E. McDonough-Goldstein, Aaron McGeever, Alex D. McLachlan, Colleen N McLaughlin, Paola Moreno-Roman, Norma Neff, Megan Neville, Sang Ngo, Tanja Nielsen, Todd G. Nystul, Caitlin E. O&#x2019;Brien, Lucy Erin O&#x2019;Brien, Brian Oliver, David Osumi-Sutherland, Mehmet Neset &#xD6;zel, Soumitra Pal, Irene Papatheodorou, Norbert Perrimon, Maja Petkovic, Clare Pilgrim, Angela Oliveira Pisco, Teresa M Przytycka, Stephen R. Quake, Carolina Reisenman, Carlos Ribeiro, Katja Rust, Wouter Saelens, Erin Nicole Sanders, Gilberto dos Santos, Frank Schnorrer, Kristin Scott, Aparna Sherlekar, Jiwon Shim, Philip Shiu, David Sims, Rene V. Sit, Maija Slaidina, Harold E. Smith, Katina Spanier, Gabriella Sterne, Yu-Han Su, Daniel Sutton, Marco Tamayo, Michelle Tan, Ibrahim Tastekin, Sudhir Gopal Tattikota, Christoph Treiber, David Vacek, Georg Vogler, Scott Waddell, Maxime De Waegeneer, Wanpeng Wang, Helen White-Cooper, Rachel I. Wilson, Mariana F. Wolfner, Yiu-Cheung E. Wong, Anthony Xie, Qijing Xie, Jun Xu, Shinya Yamamoto, Jia Yan, Zepeng Yao, Kazuki Yoda, Ruijun Zhu, Robert P Zinzen</p>
        </fn>
        <corresp id="CR1"><label>&#x2020;</label>corresponding authors: <email>perrimon@genetics.med.harvard.edu</email> (N.P.), <email>bart.deplancke@epfl.ch</email> (B.D.), <email>steve@quake-lab.org</email> (S.R.Q.), <email>lluo@stanford.edu</email> (L.L.), <email>stein.aerts@kuleuven.be</email> (S.A.)</corresp>
        <fn fn-type="COI-statement" id="FN4">
          <p id="P42"><bold>Competing interests:</bold> H. Jasper, N.S. Katheder and X.T. Cai are employees of Genentech, Inc. Other authors declare no competing interests.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>12</day>
        <month>3</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>04</day>
        <month>3</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>04</day>
        <month>3</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>24</day>
        <month>3</month>
        <year>2022</year>
      </pub-date>
      <volume>375</volume>
      <issue>6584</issue>
      <fpage>eabk2432</fpage>
      <lpage>eabk2432</lpage>
      <abstract id="ABS1">
        <p id="P3">For over 100 years, the fruit fly <italic toggle="yes">Drosophila melanogaster</italic> has been one of the most studied model organisms. Here we present a single cell atlas of the adult fly, Tabula <italic toggle="yes">Drosophilae</italic>, that includes 580k nuclei from 15 individually dissected sexed tissues as well as the entire head and body, annotated to &gt;250 distinct cell types. We provide an in-depth analysis of cell type-related gene signatures and transcription factor markers, as well as sexual dimorphism, across the whole animal. Analysis of common cell types between tissues, such as blood and muscle cells, reveals rare cell types and tissue-specific subtypes. This atlas provides a valuable resource for the entire <italic toggle="yes">Drosophila</italic> community and serves as a reference to study genetic perturbations and disease models at single-cell resolution.</p>
      </abstract>
      <abstract id="ABS2" abstract-type="summary">
        <title>One Sentence Summary:</title>
        <p id="P4">A single-nucleus transcriptomic map of the entire adult <italic toggle="yes">Drosophila melanogaster</italic></p>
      </abstract>
    </article-meta>
  </front>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Science</journal-id>
      <journal-id journal-id-type="iso-abbrev">Science</journal-id>
      <journal-id journal-id-type="publisher-id">science</journal-id>
      <journal-title-group>
        <journal-title>Science (New York, N.y.)</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0036-8075</issn>
      <issn pub-type="epub">1095-9203</issn>
      <publisher>
        <publisher-name>American Association for the Advancement of Science</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">34344823</article-id>
      <article-id pub-id-type="pmc">9268357</article-id>
      <article-id pub-id-type="publisher-id">abj3321</article-id>
      <article-id pub-id-type="doi">10.1126/science.abj3321</article-id>
      <article-categories>
        <subj-group subj-group-type="article-type">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
        <subj-group subj-group-type="legacy-article-type">
          <subject>R-Articles</subject>
        </subj-group>
        <subj-group subj-group-type="field">
          <subject>Biochem</subject>
          <subject>Microbio</subject>
        </subj-group>
        <subj-group subj-group-type="overline">
          <subject>Coronavirus</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Broad betacoronavirus neutralization by a stem helix&#x2013;specific human antibody</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Pinto</surname>
            <given-names>Dora</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
          <xref rid="afn1" ref-type="author-notes">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0908-0775</contrib-id>
          <name>
            <surname>Sauer</surname>
            <given-names>Maximilian M.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
          <xref rid="afn1" ref-type="author-notes">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3146-4110</contrib-id>
          <name>
            <surname>Czudnochowski</surname>
            <given-names>Nadine</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
          <xref rid="afn1" ref-type="author-notes">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1775-0778</contrib-id>
          <name>
            <surname>Low</surname>
            <given-names>Jun Siong</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref>
          <xref rid="afn1" ref-type="author-notes">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2260-2577</contrib-id>
          <name>
            <surname>Tortorici</surname>
            <given-names>M. Alejandra</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Housley</surname>
            <given-names>Michael P.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9113-8181</contrib-id>
          <name>
            <surname>Noack</surname>
            <given-names>Julia</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9636-8330</contrib-id>
          <name>
            <surname>Walls</surname>
            <given-names>Alexandra C.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3590-9727</contrib-id>
          <name>
            <surname>Bowen</surname>
            <given-names>John E.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3759-3252</contrib-id>
          <name>
            <surname>Guarino</surname>
            <given-names>Barbara</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8030-0219</contrib-id>
          <name>
            <surname>Rosen</surname>
            <given-names>Laura E.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9343-127X</contrib-id>
          <name>
            <surname>di Iulio</surname>
            <given-names>Julia</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5358-5055</contrib-id>
          <name>
            <surname>Jerak</surname>
            <given-names>Josipa</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3991-7401</contrib-id>
          <name>
            <surname>Kaiser</surname>
            <given-names>Hannah</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Islam</surname>
            <given-names>Saiful</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jaconi</surname>
            <given-names>Stefano</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3258-5552</contrib-id>
          <name>
            <surname>Sprugasci</surname>
            <given-names>Nicole</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0956-0018</contrib-id>
          <name>
            <surname>Culap</surname>
            <given-names>Katja</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9771-7312</contrib-id>
          <name>
            <surname>Abdelnabi</surname>
            <given-names>Rana</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6380-4917</contrib-id>
          <name>
            <surname>Foo</surname>
            <given-names>Caroline</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7888-4534</contrib-id>
          <name>
            <surname>Coelmont</surname>
            <given-names>Lotte</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3360-1999</contrib-id>
          <name>
            <surname>Bartha</surname>
            <given-names>Istvan</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5100-8905</contrib-id>
          <name>
            <surname>Bianchi</surname>
            <given-names>Siro</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silacci-Fregni</surname>
            <given-names>Chiara</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4723-6892</contrib-id>
          <name>
            <surname>Bassi</surname>
            <given-names>Jessica</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6025-6735</contrib-id>
          <name>
            <surname>Marzi</surname>
            <given-names>Roberta</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vetti</surname>
            <given-names>Eneida</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8674-4294</contrib-id>
          <name>
            <surname>Cassotta</surname>
            <given-names>Antonino</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4308-0405</contrib-id>
          <name>
            <surname>Ceschi</surname>
            <given-names>Alessandro</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref>
          <xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref>
          <xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref>
          <xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9619-3104</contrib-id>
          <name>
            <surname>Ferrari</surname>
            <given-names>Paolo</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref>
          <xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref>
          <xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cipp&#xE0;</surname>
            <given-names>Pietro E.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref>
          <xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2306-0498</contrib-id>
          <name>
            <surname>Giannini</surname>
            <given-names>Olivier</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref>
          <xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4146-3434</contrib-id>
          <name>
            <surname>Ceruti</surname>
            <given-names>Samuele</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0832-2376</contrib-id>
          <name>
            <surname>Garzoni</surname>
            <given-names>Christian</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <xref rid="aff14" ref-type="aff">
<sup>14</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3171-3049</contrib-id>
          <name>
            <surname>Riva</surname>
            <given-names>Agostino</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <xref rid="aff15" ref-type="aff">
<sup>15</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1974-5606</contrib-id>
          <name>
            <surname>Benigni</surname>
            <given-names>Fabio</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cameroni</surname>
            <given-names>Elisabetta</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Piccoli</surname>
            <given-names>Luca</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pizzuto</surname>
            <given-names>Matteo S.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smithey</surname>
            <given-names>Megan</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hong</surname>
            <given-names>David</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Telenti</surname>
            <given-names>Amalio</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lempp</surname>
            <given-names>Florian A.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Neyts</surname>
            <given-names>Johan</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Havenar-Daughton</surname>
            <given-names>Colin</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lanzavecchia</surname>
            <given-names>Antonio</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sallusto</surname>
            <given-names>Federica</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref>
          <xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Snell</surname>
            <given-names>Gyorgy</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Virgin</surname>
            <given-names>Herbert W.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
          <xref rid="aff17" ref-type="aff">
<sup>17</sup>
</xref>
          <xref rid="aff18" ref-type="aff">
<sup>18</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Beltramello</surname>
            <given-names>Martina</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Corti</surname>
            <given-names>Davide</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &amp; editing</role>
          <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
          <xref rid="cor1" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Veesler</surname>
            <given-names>David</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.casrai.org/Contributor_Roles/Visualization">Visualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role>
          <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
          <xref rid="cor1" ref-type="corresp">*</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.</aff>
        <aff id="aff2"><label>2</label>Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.</aff>
        <aff id="aff3"><label>3</label>Vir Biotechnology, San Francisco, CA 94158, USA.</aff>
        <aff id="aff4"><label>4</label>Institute for Research in Biomedicine, Universit&#xE0; della Svizzera italiana, 6500 Bellinzona, Switzerland.</aff>
        <aff id="aff5"><label>5</label>Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.</aff>
        <aff id="aff6"><label>6</label>Clinical Trial Unit, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.</aff>
        <aff id="aff7"><label>7</label>Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.</aff>
        <aff id="aff8"><label>8</label>Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.</aff>
        <aff id="aff9"><label>9</label>Faculty of Biomedical Sciences, Universit&#xE0; della Svizzera italiana, 6900 Lugano, Switzerland.</aff>
        <aff id="aff10"><label>10</label>Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.</aff>
        <aff id="aff11"><label>11</label>Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.</aff>
        <aff id="aff12"><label>12</label>Faculty of Medicine, University of Zurich, 8057 Zurich, Switzerland.</aff>
        <aff id="aff13"><label>13</label>Intensive Care Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.</aff>
        <aff id="aff14"><label>14</label>Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.</aff>
        <aff id="aff15"><label>15</label>III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy.</aff>
        <aff id="aff16"><label>16</label>Institute of Microbiology, ETH Zurich, 8093 Zurich, Switzerland.</aff>
        <aff id="aff17"><label>17</label>UT Southwestern Medical Center, Dallas, TX 75390, USA.</aff>
        <aff id="aff18"><label>18</label>Washington University School of Medicine, St. Louis, MO 63110, USA.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>*</label>Corresponding author. Email: <email xlink:href="dveesler@uw.edu">dveesler@uw.edu</email> (D.V.); dcorti@vir.bio (D.C.)</corresp>
        <fn id="afn1" fn-type="equal">
          <label>&#x2020;</label>
          <p>These authors contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date publication-format="print" date-type="pub">
        <day>03</day>
        <month>9</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>03</day>
        <month>8</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>03</day>
        <month>8</month>
        <year>2021</year>
      </pub-date>
      <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
      <volume>373</volume>
      <issue>6559</issue>
      <fpage>1109</fpage>
      <lpage>1116</lpage>
      <history>
<date date-type="received"><day>06</day><month>5</month><year>2021</year></date>
<date date-type="accepted"><day>29</day><month>7</month><year>2021</year></date>
</history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).</copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder>The Authors</copyright-holder>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2021-09-03">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution license</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="science.abj3321.pdf"/>
      <abstract abstract-type="key-image-no-article-view">
        <fig position="float" id="d64e1386">
          <alt-text>Description</alt-text>
          <graphic xlink:href="keyimage" position="float"/>
        </fig>
      </abstract>
      <abstract abstract-type="editor">
        <title>Targeting a range of betacoranaviruses</title>
        <p>In the past 20 years, three highly pathogenic &#x3B2;-coronaviruses have crossed from animals to humans, including the most recent: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A spike protein that decorates these viruses has an S1 domain that binds host cell receptors and an S2 domain that fuses the viral and cell membranes to allow cell entry. The S1 domain is the target of many neutralizing antibodies but is more genetically variable than S2, and antibodies can exert selective pressure, leading to resistant variants. Pinto <italic toggle="yes">et al</italic>. identified five monoclonal antibodies that interact with a helix in the S2 domain. The most broadly neutralizing antibody inhibited all &#x3B2;-coronavirus subgenera and reduced viral burden in hamsters infected with SARS-CoV-2. &#x2014;VV</p>
      </abstract>
      <abstract abstract-type="teaser">
        <p>A broadly neutralizing monoclonal antibody targeting the conserved viral spike stem helix reduces SARS-CoV-2 burden in hamsters.</p>
      </abstract>
      <abstract>
        <p>The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants highlight the need for broad coronavirus countermeasures. We describe five monoclonal antibodies (mAbs) cross-reacting with the stem helix of multiple betacoronavirus spike glycoproteins isolated from COVID-19 convalescent individuals. Using structural and functional studies, we show that the mAb with the greatest breadth (S2P6) neutralizes pseudotyped viruses from three different subgenera through the inhibition of membrane fusion, and we delineate the molecular basis for its cross-reactivity. S2P6 reduces viral burden in hamsters challenged with SARS-CoV-2 through viral neutralization and Fc-mediated effector functions. Stem helix antibodies are rare, oftentimes of narrow specificity, and can acquire neutralization breadth through somatic mutations. These data provide a framework for structure-guided design of pan-betacoronavirus vaccines eliciting broad protection.</p>
      </abstract>
      <funding-group>
        <award-group id="award880186">
          <funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap>
</funding-source>
        </award-group>
        <award-group id="award880183">
          <funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000015</institution-id><institution>U.S. Department of Energy</institution></institution-wrap>
</funding-source>
          <award-id>DE-AC02-76SF00515</award-id>
        </award-group>
        <award-group id="award880184">
          <funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000015</institution-id><institution>U.S. Department of Energy</institution></institution-wrap>
</funding-source>
          <award-id>P30GM133894</award-id>
        </award-group>
        <award-group id="award880185">
          <funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap>
</funding-source>
        </award-group>
        <award-group id="award880178">
          <funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap>
</funding-source>
          <award-id>DP1AI158186</award-id>
        </award-group>
        <award-group id="award880179">
          <funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap>
</funding-source>
          <award-id>HHSN272201700059C</award-id>
        </award-group>
        <award-group id="award880180">
          <funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap>
</funding-source>
          <award-id>U01 AI151698-01</award-id>
        </award-group>
        <award-group id="award880177">
          <funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002066</institution-id><institution>GlaxoSmithKline foundation</institution></institution-wrap>
</funding-source>
          <award-id>V2 CHO-K1</award-id>
        </award-group>
        <award-group id="award880181">
          <funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Swiss National Science Foundation</institution></institution-wrap>
</funding-source>
          <award-id>P400PB</award-id>
        </award-group>
        <award-group id="award880182">
          <funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Swiss National Science Foundation</institution></institution-wrap>
</funding-source>
          <award-id>183942</award-id>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>Number-color-figs</meta-name>
          <meta-value>5</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>Number-figs</meta-name>
          <meta-value>5</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Coronaviruses are zoonotic pathogens responsible for several epidemics and a pandemic in the past two decades. All three highly pathogenic coronaviruses belong to the betacoronavirus genus: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV cluster within the <italic toggle="yes">sarbecovirus</italic> subgenus and originated in bats, whereas Middle East respiratory syndrome coronavirus (MERS-CoV) belongs to the <italic toggle="yes">merbecovirus</italic> subgenus and is transmitted to humans through dromedary camels. Moreover, HCoV-HKU1 and HCoV-OC43 (<italic toggle="yes">embecovirus</italic> subgenus, betacoronaviruses) as well as NL63 and 229E (<italic toggle="yes">setracovirus</italic> and <italic toggle="yes">duvinacovirus</italic> subgenera, alphacoronaviruses) are endemic and cause common colds in humans.</p>
    <p>The coronavirus spike (S) glycoprotein promotes viral entry into host cells through an S<sub>1</sub> subunit that engages host receptors and an S<sub>2</sub> subunit mediating membrane fusion (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>). The S<sub>1</sub> subunit is the major target of (neutralizing) antibodies (Abs) and is more genetically variable than the S<sub>2</sub> subunit (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>&#x2013;<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>). Accordingly, Abs binding to the S<sub>1</sub> subunit receptor-binding domain (RBD) and N-terminal domain (NTD) exert a selective pressure that results in the emergence of new variants (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>&#x2013;<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>). SARS-CoV-2 S comprises 22 N-linked glycans (13 and 9 of them in the S<sub>1</sub> and S<sub>2</sub> subunits, respectively) participating in folding as well as modulating access to host proteases and antibodies (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>, <xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>, <xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>&#x2013;<xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>). Monoclonal antibodies (mAbs) binding to the S<sub>2</sub> fusion machinery can neutralize distantly related coronaviruses (<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>&#x2013;<xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>), as observed for other viruses such as influenza and HIV-1 (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>, <xref rid="R18" ref-type="bibr"><italic toggle="yes">18</italic></xref>).</p>
    <sec sec-type="results" disp-level="1">
      <title>Results</title>
      <sec disp-level="2">
        <title>Isolation of a broadly neutralizing betacoronavirus mAb from a convalescent SARS-CoV-2&#x2013;exposed individual</title>
        <p>To identify mAbs targeting highly conserved regions of the S glycoprotein, we interrogated human immunoglobulin G<sup>+</sup> (IgG<sup>+</sup>) memory B cells from three COVID-19 convalescent donors. Five mAbs bound to the prefusion-stabilized S ectodomain trimers of SARS-CoV and SARS-CoV-2 (<italic toggle="yes">sarbecovirus</italic>), MERS-CoV (<italic toggle="yes">merbecovirus</italic>), and OC43 and HKU1 (<italic toggle="yes">embecovirus</italic>), but not to the human alphacoronaviruses 229E and NL63 (<xref rid="F1" ref-type="fig">Fig. 1, A to C</xref>, and fig. S1, A and B). S2P6 and S2S43 mAbs were each derived from a separate donor and use VH1-46*01 and D5-12*01 genes, whereas P34D10, P34G12, and P34E3 mAbs were derived from a third donor, are clonally related, and use the VH3-30 gene (fig. S1A). These five mAbs share nucleotide sequence identities with their respective germline genes ranging from 86 to 97% (fig. S1A), which correspond to a higher level of mutations than that observed for RBD- and NTD-specific mAbs isolated early after SARS-CoV-2 infection or vaccination (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>, <xref rid="R19" ref-type="bibr"><italic toggle="yes">19</italic></xref>&#x2013;<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>). The mAbs bound to all prefusion-stabilized human-infecting betacoronavirus S trimers (<xref rid="F1" ref-type="fig">Fig. 1, A to C</xref>, and fig. S1B), and they all neutralize SARS-CoV-2 S vesicular stomatitis virus (VSV) pseudotypes (fig. S1C).</p>
        <fig position="float" id="F1" fig-type="image" specific-use="distribute">
          <label>Fig. 1.</label>
          <caption>
            <title>The S2P6 cross-reactive mAb broadly neutralizes betacoronaviruses from three subgenera.</title>
            <p>(<bold>A</bold>) Binding avidity (EC<sub>50</sub>) of five mAbs to prefusion coronavirus S trimer ectodomains as determined by ELISA. (<bold>B</bold>) S2P6 ELISA binding curves showing the full titration. One representative experiment out of two is shown. OD, optical density. (<bold>C</bold>) Cladogram of representative alpha- (black) and betacoronavirus (red) S glycoprotein amino acid sequences inferred through maximum likelihood analysis. (<bold>D</bold>) Flow cytometry analysis of S2P6 binding (from 10 to 0.22 &#x3BC;g/ml) to a panel of 26 S glycoproteins representative of all <italic toggle="yes">sarbecovirus</italic> clades (left) and eight SARS-CoV-2 variants (right) displayed as EC<sub>50</sub> values. (<bold>E</bold>) Neutralization of authentic SARS-CoV-2 by S2P6 determined using VeroE6-TMPRSS2 (left) or Vero-E6 (right) cells. The S309 mAb that binds RBD site IV (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>) is included for comparison. The mean &#xB1; SD of triplicates from one representative experiment out of three is shown. (<bold>F</bold>) S2P6-mediated neutralization of SARS-CoV-2 B.1.1.7 (Alpha) S, B.1.351 (Beta) S, P.1 (Gamma) S, and B1.617.1 (Kappa) S VSV pseudotypes (mut) represented as IC<sub>50</sub> fold change relative to wild-type (WT) (D614G) S VSV pseudotype. Individual values for each of the two replicates are shown as open circles, the mean as a colored bar, and the SD as error bars. (<bold>G</bold>) S2P6-mediated neutralization of VSV pseudotyped with various betacoronavirus S glycoproteins. Error bars indicate standard deviation of triplicates. IC<sub>50</sub> values are 2.4 &#x3BC;g/ml, 1.4 &#x3BC;g/ml, 17.1 &#x3BC;g/ml, 1.3 &#x3BC;g/ml, and 0.02 &#x3BC;g/ml for SARS-CoV, SARS-CoV-2, MERS-CoV, OC43, and PANG/GD, respectively. pp, pseudoparticles. (<bold>H</bold>) Alignment of betacoronavirus stem helix amino acid sequences with the S2P6 epitope boxed. Residue numbering is shown according to SARS-CoV-2 S. The sequences of the peptides used in this study are shown in blue, and N-linked glycosylation sequons are highlighted in yellow. (<bold>I</bold>) Competition assay for S2P6 or B6 binding to the SARS-CoV-2 or SARS-CoV stem helix peptide (herein defined as SARS-CoV/-2). B6 binding in the presence of S2P6 (red line), B6 binding in the absence of S2P6 (black line), and the control lacking the SARS-CoV/-2 stem helix peptide (gray line) are shown. (<bold>J</bold>) Kinetics of S2P6 binding to a panel of biotinylated betacoronavirus stem helix peptides immobilized at the surface of biolayer interferometry biosensors.</p>
          </caption>
          <graphic xlink:href="science.abj3321-f1" position="float"/>
        </fig>
        <p>S2P6 was selected for further in-depth characterization because it exhibited the overall greatest cross-reactivity and neutralization breadth. S2P6 bound both prefusion and postfusion SARS-CoV-2 S with comparable avidities, which indicates that its epitope might be (at least partially) accessible in both conformational states (<xref rid="F1" ref-type="fig">Fig. 1, A and B</xref>, and fig. S1D). S2P6 bound to all full-length SARS-CoV-2 S variants tested and to 25 S glycoproteins representative of all <italic toggle="yes">sarbecovirus</italic> clades (<xref rid="F1" ref-type="fig">Fig. 1D</xref> and fig. S1, E and F). Using surface plasmon resonance (SPR), we found that the S2P6 Fab fragment had the highest affinity for SARS-CoV-2 S and SARS-CoV S followed by MERS-CoV S and OC43 S with equilibrium dissociation constants (K<sub>D</sub>) of 7, 7, 12, and 16 nM, respectively (fig. S1, G and H). S2P6 also bound to HKU1 S, albeit with reduced affinity (K<sub>D</sub> ~120 nM) (fig. S1G). Collectively, these data demonstrate that S2P6 cross-reacts with all human-infecting betacoronaviruses.</p>
        <p>To evaluate the neutralization potency and breadth of S2P6, we investigated its ability to inhibit entry of authentic SARS-CoV-2 into Vero-E6 cells in the presence or absence of TMPRSS2, as this protease activates fusion with the cytoplasmic membrane in cultured lung cells (<xref rid="R22" ref-type="bibr"><italic toggle="yes">22</italic></xref>&#x2013;<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>). S2P6 completely neutralized infection of TMPRSS2-positive Vero-E6 cells but was less effective in inhibiting infection of Vero-E6 cells lacking TMPRSS2 (<xref rid="F1" ref-type="fig">Fig. 1E</xref>), which suggests that S2P6 binding might be reduced at endosomal pH. The recognition of prefusion SARS-CoV-2 S by S2P6 is pH dependent, with higher binding affinity at pH 7, relative to pH 5, in both IgG and Fab formats (fig. S1H). We subsequently assessed S2P6-mediated neutralization of VSV (<xref rid="R25" ref-type="bibr"><italic toggle="yes">25</italic></xref>) pseudotyped with SARS-CoV-2 S of several variants of concern (VOCs), including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B1.617.1 (Kappa), and we observed similar potency to that found against the parental SARS-CoV-2 D614G S (<xref rid="F1" ref-type="fig">Fig. 1F</xref> and fig. S1I). Moreover, S2P6 inhibited SARS-CoV S, Pangolin Guangdong 2019 (PANG/GD) S, MERS-CoV S, and OC43 S VSV pseudotypes with median inhibitory concentration (IC<sub>50</sub>) values ranging from 0.02 to 17 &#x3BC;g/ml (<xref rid="F1" ref-type="fig">Fig. 1G</xref>). S2P6 is therefore a broadly neutralizing betacoronavirus mAb with activity against SARS-CoV-2 and SARS-CoV&#x2013;related viruses as well as members of the <italic toggle="yes">merbecovirus</italic> and <italic toggle="yes">embecovirus</italic> subgenera.</p>
        <p>Peptide mapping experiments using 15-nucleotide oligomer linear overlapping peptides revealed that all five mAbs bound to peptides containing the SARS-CoV-2 motif F<sub>1148</sub>KEELDKYF<sub>1156</sub> located in the S<sub>2</sub> subunit stem helix (<xref rid="F1" ref-type="fig">Fig. 1H</xref> and fig. S2A). This region is strictly conserved in SARS-CoV, is highly conserved among other betacoronaviruses, and overlaps with the epitopes of the B6 (<xref rid="F1" ref-type="fig">Fig. 1I</xref>) and 28D9 mouse mAbs (<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>, <xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>). S2P6 bound efficiently to the stem helix peptides of the five betacoronaviruses that infect humans (albeit with a faster off-rate for HKU1) as well as those of the MERS-CoV&#x2013;related bat viruses (HKU4 and HKU5) and murine hepatitis virus (MHV) (<xref rid="F1" ref-type="fig">Fig. 1J</xref> and fig. S2B). S2S43 exhibited similar overall binding to that of S2P6, with markedly weaker reactivity toward the HKU1, HKU4, and HKU5 peptides, whereas the three clonally related P34D10, P34G12, and P34E3 mAbs exhibited weaker or no binding to HKU4 and HKU5 peptides (fig. S2B).</p>
      </sec>
      <sec disp-level="2">
        <title>Structural basis for S2P6 binding to the conserved S glycoprotein stem helix</title>
        <p>To determine the molecular basis of the S2P6 neutralization breadth, we determined a cryo&#x2013;electron microscopy (cryo-EM) structure of the SARS-CoV-2 S ectodomain trimer in complex with the Fab fragments of S2P6 and S2M11 [to lock the RBDs in the closed state (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>)] at 4.2-&#xC5; overall resolution. The marked conformational dynamics of the region recognized by S2P6 limited the local resolution of the stem helix&#x2013;Fab to ~12 &#xC5;, and three-dimensional classification of the cryo-EM data revealed incomplete Fab saturation (<xref rid="F2" ref-type="fig">Fig. 2A</xref>; table S1; and fig. S3, A to F). Our cryo-EM structure confirms that S2P6 recognizes the stem helix and suggests that the mAb disrupts its quaternary structure, which is presumed to form a three-helix bundle in prefusion SARS-CoV-2 S (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>, <xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>, <xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>). To overcome the limited resolution of the stem helix&#x2013;Fab interface in the cryo-EM structure, we determined a crystal structure of the S2P6 Fab in complex with the SARS-CoV-2 S stem helix peptide (residues 1146 to 1159) at 2.67-&#xC5; resolution (<xref rid="F2" ref-type="fig">Fig. 2, B to D</xref>; fig. S4A; and table S2). The peptide folds as an amphipathic &#x3B1; helix resolved for residues 1146 to 1159. S2P6 buries ~600 &#xC5;<sup>2</sup> upon binding to its epitope using shape-complementarity and hydrogen bonding involving complementarity-determining regions (CDRs) H1 to H3, L1, and L3. The light chain residues Y33, Y92, G93, S94, P96, P97, and F99 as well as heavy chain residues Y33, I50, H57, T58, S59, P101, K102, and G103 form a deep groove in which the hydrophobic side of the stem helix docks through residues F1148, L1152, Y1155, and F1156. Binding specificity is provided through backbone hydrogen bonding of residues F1148<sub>SARS-CoV-2</sub> and K1149<sub>SARS-CoV-2</sub> with CDRH3 P101 and side chain hydrogen bonding of residues E1151<sub>SARS-CoV-2</sub> with CDRL1 Y33 and CDRL3 S94, D1153<sub>SARS-CoV-2</sub> with CDRH1 Y33 side chains, as well as Y1155<sub>SARS-CoV-2 S</sub> with CDRH2 S59 through a water molecule and F1156<sub>SARS-CoV-2 S</sub> with CDRH2 H57, also through a water molecule (<xref rid="F2" ref-type="fig">Fig. 2, C and D</xref>). The contribution of each epitope residue was validated by single-substitution scan analysis with most mutations at positions 1148, 1151 to 1153, and 1155 to 1156 abolishing S2P6 binding, which highlights the importance of these residues for mAb recognition (fig. S5A). A substitution scan analysis performed on the P34D10, P34G12, and P34E3 mAbs revealed a similar pattern of key interacting residues (fig. S5A). Residue Y1155 is conservatively substituted to F1238<sub>MERS-CoV</sub> or W1237/1240<sub>HKU1/OC43</sub>, and residue D1153 is conserved in MERS-CoV and OC43 but mutated to S1235 for HKU1 (fig. S5B). The residue scan and structural results suggest that the reduced binding affinity of S2P6 for HKU1 S is at least partially a result of the D1153 <sub>SARS-CoV-2</sub>&#x2013;S1235<sub>HKU1</sub> substitution, which is expected to dampen electrostatic interactions with the CDRH1 Y33 side chain hydroxyl (<xref rid="F2" ref-type="fig">Fig. 2, C and D</xref>).</p>
        <fig position="float" id="F2" fig-type="image" specific-use="distribute">
          <label>Fig. 2.</label>
          <caption>
            <title>Structural basis for the broad S2P6 cross-reactivity with the conserved coronavirus stem helix peptide.</title>
            <p>(<bold>A</bold>) Composite model of the S2P6-bound SARS-CoV-2 S cryo-EM structure and of the S2P6-bound stem helix peptide crystal structure docked in the cryo-EM map (semitransparent gray surface). SARS-CoV-2 S protomers are colored pink, cyan, and gold; the S2P6 Fab heavy and light chains are colored purple and magenta; and the S2M11 Fab heavy and light chains are colored dark and light gray, respectively. (<bold>B</bold>) Crystal structure of the S2P6 Fab (surface rendering) in complex with the SARS-CoV-2 S stem helix peptide (yellow ribbon with side chains rendered as sticks). (<bold>C</bold> and <bold>D</bold>) Ribbon diagram in two orthogonal orientations of the S2P6 Fab bound to the SARS-CoV-2 S stem helix peptide showing the network of interactions. Only key interface residues and the S2P6 CDR loops are shown for clarity. Residues Q32 and H57, which are mutated during affinity maturation of the S2P6 heavy chain, are colored blue. Hydrogen bonds are indicated with dashed lines. Residues substituted in the escape mutants isolated are underlined. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.</p>
          </caption>
          <graphic xlink:href="science.abj3321-f2" position="float"/>
        </fig>
        <p>Although S2P6 and B6 recognize a similar epitope (fig. S4, B and C), they bind with opposite orientations of the heavy and light chains relative to the stem helix and the S2P6-bound structure resolves three additional C-terminal peptide residues (1146 to 1159) compared with the B6-bound structure (1147 to 1156) (fig. S4, B and C). Superposition of both structures based on the stem helix reveals that B6 CDRH2 would sterically clash with H1159<sub>SARS-CoV-2</sub>, putatively explaining the broader cross-reactivity of S2P6 over B6 (fig. S4, B and C).</p>
        <p>To further validate our structural data, we carried out viral escape mutant selection in vitro in the presence of S2P6 using a replication-competent VSV&#x2013;SARS-CoV-2 S virus (<xref rid="R26" ref-type="bibr"><italic toggle="yes">26</italic></xref>). After two passages, virus neutralization by S2P6 was abrogated, and deep sequencing revealed the emergence of five distinct resistance mutations&#x2014;L1152F, D1153N/G/A, and F1156L, which are consistent with the structural data and substitution scan analysis (fig. S5A). Although these mutations have been detected with very low frequencies in circulating SARS-CoV-2 isolates (146 out of 1,217,814 sequences as of 30 April 2021), the subdominant immunogenicity of this cryptic site, likely because of its limited exposure, might result in low Ab pressure limiting accumulation of mutations in this epitope.</p>
      </sec>
      <sec disp-level="2">
        <title>Stem helix&#x2013;targeting mAbs inhibit S-mediated membrane fusion</title>
        <p>The S stem helix forms a three-helix bundle in many prefusion cryo-EM structures of SARS-CoV-2 S and SARS-CoV S although it is not fully resolved (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>, <xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>, <xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>, <xref rid="R27" ref-type="bibr"><italic toggle="yes">27</italic></xref>&#x2013;<xref rid="R29" ref-type="bibr"><italic toggle="yes">29</italic></xref>). By contrast, the S2P6&#x2013;S2M11&#x2013;SARS-CoV-2 S cryo-EM structure suggests that the quaternary organization of the stem is disrupted (<xref rid="F2" ref-type="fig">Fig. 2A</xref>), consistent with S2P6 binding to the hydrophobic face of the stem helix. This face is mostly buried through homo-oligomeric interactions in prefusion S and may be only transiently available for Ab binding. Although we observed S2P6 binding to postfusion SARS-CoV-2 S (fig. S1D), the epitope recognized is buried at the interface with the other two protomers of the rod-shaped trimer and therefore might become accessible as a result of conformational dynamics, as is the case for the prefusion state (fig. S4D) (<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>, <xref rid="R30" ref-type="bibr"><italic toggle="yes">30</italic></xref>&#x2013;<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>). On the basis of these data, we propose that S2P6 binding to S sterically interferes with the conformational changes leading to membrane fusion, as observed for B6 (<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>) and 27D9 (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>).</p>
        <p>To validate the inferred mechanism of S2P6-mediated broad coronavirus neutralization, we first showed that S2P6 binding did not block engagement of SARS-CoV-2 S by angiotensin-converting enzyme 2 (ACE2)&#x2014;using enzyme-linked immunosorbent assay (ELISA)&#x2014;as expected based on the distance of its epitope from the RBD (<xref rid="F3" ref-type="fig">Fig. 3A</xref>). S2P6, however, blocked cell-cell fusion between Vero-E6 cells transfected with full-length SARS-CoV-2 S as effectively as the S2M11 mAb, which locks SARS-CoV-2 S in the closed state (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>) (<xref rid="F3" ref-type="fig">Fig. 3B</xref>). We previously described mAbs targeting RBD antigenic sites Ia (e.g., S2E12) and IIa (e.g., S2X259 or S2X35), which can mimic receptor attachment and prematurely trigger fusogenic S conformational changes (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>, <xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>, <xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>). Accordingly, S2P6 at concentrations as low as 1 ng/ml abrogated the formation of syncytia mediated by S2E12 (<xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>). Collectively, these results suggest that the main mechanism of S2P6 neutralization is to prevent viral entry by impeding S fusogenic rearrangements, thereby inhibiting membrane fusion (<xref rid="F3" ref-type="fig">Fig. 3C</xref>).</p>
        <fig position="float" id="F3" fig-type="image" specific-use="distribute">
          <label>Fig. 3.</label>
          <caption>
            <title>S2P6 binding disrupts the stem helix bundle and sterically inhibits membrane fusion.</title>
            <p>(<bold>A</bold>) SARS-CoV-2 S binding to ACE2 in the presence of mAb S2P6 analyzed by ELISA. S2E12 was included as a positive control. (<bold>B</bold>) S2P6 inhibition of cell-cell fusion using VeroE6 cells transfected with SARS-CoV-2 S. S2M11 was included as a positive control. Inhibition of fusion values are normalized to the percentage of fusion without mAb (100%) and to that of fusion of nontransfected cells (0%). (<bold>C</bold>) Proposed mechanism of inhibition mediated by the S2P6 mAb. S2P6 binds to the hydrophobic core of the stem helix bundle and disrupts its quaternary structure. S2P6 binding likely prevents S<sub>2</sub> subunit refolding from the pre- to the postfusion state and blocks viral entry.</p>
          </caption>
          <graphic xlink:href="science.abj3321-f3" position="float"/>
        </fig>
      </sec>
      <sec disp-level="2">
        <title>S2P6-mediated protection in hamsters is enhanced by Fc-mediated effector functions</title>
        <p>Functions mediated by the constant (Fc) region of Abs can contribute to in vivo protection by promoting viral clearance and antiviral immune responses (<xref rid="R34" ref-type="bibr"><italic toggle="yes">34</italic></xref>&#x2013;<xref rid="R37" ref-type="bibr"><italic toggle="yes">37</italic></xref>). We analyzed the ability of S2P6 to trigger activation of the Fc receptors, Fc&#x3B3;RIIa and Fc&#x3B3;RIIIa, as well as to exert Fc effector functions in vitro. S2P6 promoted moderate dose-dependent Fc&#x3B3;RIIa- and Fc&#x3B3;RIIIa-mediated signaling using a luciferase reporter assay (<xref rid="F4" ref-type="fig">Fig. 4A</xref>). However, S2P6 promoted robust activation of Ab-dependent cell cytotoxicity (ADCC), to levels comparable to those observed with the S309 mAb (<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>), after incubation of SARS-CoV-2 S&#x2013;expressing CHO-K1 target cells with human peripheral blood mononuclear cells (PBMCs) (<xref rid="F4" ref-type="fig">Fig. 4B</xref>). S2P6 also triggered measurable Ab-dependent cellular phagocytosis (ADCP) activity using cell trace violet&#x2013;labeled PBMCs as phagocytic cells and SARS-CoV-2 S&#x2013;expressing CHO (CHO-S) as target cells (<xref rid="F4" ref-type="fig">Fig. 4C</xref>). Finally, S2P6 did not promote complement-dependent cytotoxicity (CDC) (<xref rid="F4" ref-type="fig">Fig. 4D</xref>), indicating that S2P6 Fc&#x2013;mediated effector functions, but not CDC, might participate in viral control in vivo.</p>
        <fig position="float" id="F4" fig-type="image" specific-use="distribute">
          <label>Fig. 4.</label>
          <caption>
            <title>S2P6 activates effector functions and reduces SARS-CoV-2 lung burden in Syrian hamsters.</title>
            <p>(<bold>A</bold>) NFAT (nuclear factor of activated T cells)&#x2013;driven luciferase signal induced in Jurkat cells stably expressing Fc&#x3B3;RIIIa (V158, left) or Fc&#x3B3;RIIa (V131, right) upon S2P6 binding to full-length wild-type SARS-CoV-2 S expressed at the surface of CHO target cells. S309 is included as positive control. RLU, relative luminescence unit. (<bold>B</bold>) mAb-mediated ADCC using SARS-CoV-2 CHO-K1 cells (genetically engineered to stably express a HaloTag-HiBit) as target cells and PBMC as effector cells. The magnitude of natural killer cell&#x2013;mediated killing is expressed as a percentage of specific lysis. (<bold>C</bold>) mAb-mediated ADCP using cell trace violet&#x2013;labeled PBMCs as a source of phagocytic cells (monocytes) and PKH67&#x2013;fluorescently labeled S-expressing CHO cells as target cells. The <italic toggle="yes">y</italic> axis indicates the percentage of monocytes double-positive for anti-CD14 (monocyte) marker and PKH67. (<bold>D</bold>) Lysis of SARS-CoV-2 S stably transfected CHO cells by mAbs in the presence of complement. S309 was included as positive control; S309-GRLR with diminished Fc&#x3B3;R binding capacity and an unrelated mAb (neg mAb) were used as negative controls. (<bold>E</bold>) Syrian hamsters were administered with the indicated amount of S2P6 mAb harboring either a hamster (Hm-S2P6) or a human (Hu-S2P6) constant region before intranasal challenge with prototypic SARS-CoV-2 (Wuhan-1 related). An irrelevant mAb (MGH2 against <italic toggle="yes">Plasmodium falciparum</italic> CSP) at 20 mg/kg was used as negative control (CTRL) (<xref rid="R60" ref-type="bibr"><italic toggle="yes">60</italic></xref>). Viral RNA loads and replicating virus titers are shown on the left and right, respectively. TCID<sub>50</sub>, median tissue culture infectious dose. (<bold>F</bold>) Prophylactic administration of Hu-S2P6 at 20 mg/kg in hamsters challenged with SARS-CoV-2 B.1.351 (Beta) VOC. Viral RNA loads and replicating virus titers are shown on the left and right, respectively. *<italic toggle="yes">P</italic> &lt; 0.05; **<italic toggle="yes">P</italic> &lt; 0.01; Mann-Whitney test.</p>
          </caption>
          <graphic xlink:href="science.abj3321-f4" position="float"/>
        </fig>
        <p>We evaluated the prophylactic activity of S2P6 against challenge with the prototypic (Wuhan-1 related) SARS-CoV-2 in a Syrian hamster model (<xref rid="R39" ref-type="bibr"><italic toggle="yes">39</italic></xref>). As we previously showed that the human IgG1 Fc fragment poorly recognizes hamster Fc&#x3B3;Rs (<xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>), we compared S2P6 harboring a human IgG1 constant region (Hu-S2P6) with S2P6 harboring a hamster IgG2a constant region (Hm-S2P6), the latter enabling optimal interactions with hamster Fc&#x3B3;Rs. Two different doses of Hu-S2P6 or Hm-S2P6 were administered 24 hours before intranasal SARS-CoV-2 challenge, and the lungs of the animals were assessed 4 days after infection for viral RNA load and replicating virus. Hm-S2P6 administered at 20 mg/kg reduced lung viral RNA copies and replicating viral titers by two orders of magnitude relative to a control mAb but did not exert any antiviral effect at 2 mg/kg (<xref rid="F4" ref-type="fig">Fig. 4E</xref> and fig. S6). Hm-S2P6 at 20 mg/kg reduced lung viral RNA load to levels statistically significantly lower than those observed with Hu-S2P6 at 20 mg/kg, suggesting a beneficial effect of S2P6 effector functions in vivo. On the basis of the comparable S2P6 neutralization potencies toward SARS-CoV-2 VOCs observed in vitro (<xref rid="F1" ref-type="fig">Fig. 1F</xref>), we assessed the protective efficacy of S2P6 in hamsters challenged with SARS-CoV-2 B.1.351 (Beta VOC). Prophylactic administration of Hu-S2P6 at 20 mg/kg reduced replicating viral titers in the lungs (but not RNA copy numbers) by ~1.5 orders of magnitude relative to the control group. Although this difference was not statistically significant, the observed efficacy against this VOC is in line with the strict conservation of the stem helix epitope in all VOCs identified to date (<xref rid="F4" ref-type="fig">Fig. 4F</xref>). Collectively, these findings demonstrate that Abs targeting a highly conserved epitope in the S fusion machinery can trigger Fc-mediated ADCC and ADCP in vitro and that their in vivo antiviral activity may rely on both neutralization and effector functions.</p>
      </sec>
      <sec disp-level="2">
        <title>Natural infection or vaccination predominantly elicit stem helix&#x2013;directed Abs of narrow specificities</title>
        <p>To understand how frequently stem helix&#x2013;specific Abs are elicited, we analyzed plasma samples from prepandemic, COVID-19&#x2013;convalescent, and COVID-19&#x2013;vaccinated individuals to determine IgG binding titers to the SARS-CoV-2&#x2013;SARS-CoV (SARS-CoV/-2), OC43, MERS-CoV, HKU1, HKU4, and HKU5 stem helix peptides (<xref rid="F5" ref-type="fig">Fig. 5A</xref> and fig. S7). In prepandemic samples, we only observed binding to the HKU1 stem helix peptide, probably reflecting prior infection with this virus in the cohort. Stem helix&#x2013;specific Abs were found at low frequencies in individuals previously infected with SARS-CoV-2 or those who had received two doses of mRNA vaccines (<xref rid="F5" ref-type="fig">Fig. 5A</xref>). The highest frequencies of stem helix&#x2013;specific serum Abs were observed for vaccinated individuals who were previously infected (ranging from 22 to 78% against the different stem helix peptides). Overall, these data show that plasma Ab responses to the stem helix are elicited upon SARS-CoV-2 infection or vaccination, although they are relatively rare. Evaluation of the prevalence of mAbs targeting other fusion machinery epitopes will reveal whether this trend holds true for the overall S<sub>2</sub> subunit or whether it is a specificity of the cryptic stem helix epitope.</p>
        <fig position="float" id="F5" fig-type="image" specific-use="distribute">
          <label>Fig. 5.</label>
          <caption>
            <title>Stem helix&#x2013;directed Abs are rare, of narrow specificities, and enhance their binding affinity and cross-reactivity through somatic mutations.</title>
            <p>(<bold>A</bold>) Binding of prepandemic (P; <italic toggle="yes">n</italic> = 88), COVID-19 convalescent (C; <italic toggle="yes">n</italic> = 72), vaccinees immune (VI; <italic toggle="yes">n</italic> = 9), and vaccinees na&#xEF;ve (VN; <italic toggle="yes">n</italic> = 37) plasma Abs (diluted 1:10) to immobilized betacoronavirus stem helix peptides analyzed by ELISA. A cutoff of 0.7 was determined on the basis of the signal of prepandemic samples and binding to uncoated ELISA plates (horizontal dashed line). The fraction of samples for which binding above the cutoff was detected is indicated. (<bold>B</bold> to <bold>G</bold>) Analysis of memory B cell specificities for betacoronavirus stem helix peptides. Each dot represents a well containing oligoclonal B cell supernatant screened for the presence of stem helix peptide binding IgG Abs using ELISA. Samples obtained from 21 COVID-19 convalescent individuals [(B) to (D)] and 16 vaccinees [(E) to (G)]. Pairwise reactivity comparison is shown for SARS-CoV/-2 and OC43 [(C) and (F)] and SARS-CoV/-2 and HKU1 [(D) and (G)]. Cultures cross-reactive with at least three peptides are highlighted in color. A cutoff of 0.4 is indicated by a horizontal dashed line. The fraction of wells for which binding above the cutoff was detected is indicated. (<bold>H</bold> and <bold>I</bold>) Binding to stem helix peptides of S2P6 (H) harboring mature (SH/SK), fully germline-reverted (UCA/UCA), germline-reverted heavy chain paired with mature light chain (UCA/SK), mature heavy chain paired with germline-reverted light chain (SH/UCA), and of P34D10, P34G12, and P34E3 (I) harboring either mature (SH/SK) or germline-reverted (UCA/UCA) sequences.</p>
          </caption>
          <graphic xlink:href="science.abj3321-f5" position="float"/>
        </fig>
        <p>Next, we investigated the frequencies of stem helix&#x2013;specific memory B cells among 21 convalescent and 17 vaccinated individuals using a clonal analysis based on in vitro polyclonal stimulation (<xref rid="R40" ref-type="bibr"><italic toggle="yes">40</italic></xref>) (<xref rid="F5" ref-type="fig">Fig. 5, B to G</xref>, and figs. S7 to S9). In both cohorts, we observed frequencies of culture positive for stem helix&#x2013;specific IgGs ranging from 0 to 2.5%, except for one individual (infected and vaccinated with a single dose of mRNA vaccine) for which 99.6% of culture supernatants were binding to the SARS-CoV/-2 stem helix (fig. S9). Most SARS-CoV-2 stem helix&#x2013;specific memory B cells were cross-reactive with OC43, consistent with the high sequence identity of the stem helices of these two viruses (<xref rid="F5" ref-type="fig">Fig. 5, C and F</xref>, and <xref rid="F1" ref-type="fig">Fig. 1H</xref>). Abs specific for the HKU1 S stem helix were found, but they were not cross-reactive with other betacoronaviruses except for one convalescent and one vaccinated individual (<xref rid="F5" ref-type="fig">Fig. 5, D and G</xref>). This analysis revealed a single example of cross-reactivity to all stem helix betacoronavirus peptides tested (<xref rid="F5" ref-type="fig">Fig. 5E</xref>), whereas most other Abs show limited cross-reactivity among betacoronaviruses.</p>
      </sec>
      <sec disp-level="2">
        <title>Broadly reactive betacoronavirus Abs enhance their binding affinity and cross-reactivity through somatic mutations</title>
        <p>To define the ontogeny of the broadly reactive betacoronavirus mAbs presented here, we generated a panel of germline variants of S2P6, P34D10, P34E3, and P34G12. Two out of seven S2P6 heavy chain residues that are mutated relative to germline contribute to epitope recognition (Q32 and H57), whereas none of the five light chain mutated residues participate in S binding (<xref rid="F2" ref-type="fig">Fig. 2, C and D</xref>). To address the role of VH and VK somatic mutations, we generated a panel of S2P6 germline variants for the heavy or the light chain, or both variable regions (VH and VK). The fully germline-reverted S2P6 [unmutated common ancestor (UCA)] bound to OC43 and MERS-CoV stem helix peptides [with approximately one order of magnitude higher median effective concentration (EC<sub>50</sub>) compared with that of the mature mAb] but did not bind to SARS-CoV/-2 or HKU1 stem helix peptides or spike trimers (<xref rid="F5" ref-type="fig">Fig. 5H</xref> and fig. S10, A to C). Somatic mutations in VH were sufficient for high-avidity binding to SARS-CoV/-2, whereas both VH and VK mutations were required for optimal binding to HKU1. The presence of residue G103 in CDRH3 was essential for binding to all betacoronaviruses (fig. S10, A to C). These findings indicate that the S2P6 mAb likely arose in response to OC43 infection, and its specificity was broadened toward SARS-CoV-2 and HKU1 through somatic mutations selected upon natural infection with one or both of these betacoronaviruses. By contrast, analysis of UCA binding of the clonally related P34D10, P34G12, and P34E3 mAbs suggests that they were likely primed by HKU1 infection rather than OC43 infection and acquired cross-reactivity toward the other human betacoronaviruses primarily through somatic mutations in VH (<xref rid="F5" ref-type="fig">Fig. 5I</xref> and fig. S10, D to F). Collectively, these findings demonstrate that broadly reactive betacoronavirus Abs may result from priming of virus-specific B cells gaining affinity and cross-reactivity through somatic mutations in response to heterotypic coronavirus exposures.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" disp-level="1">
      <title>Discussion</title>
      <p>The coronavirus S<sub>2</sub> subunit (fusion machinery) contains several conserved antigenic sites, including the fusion peptide and the heptad-repeat 2 regions (<xref rid="R41" ref-type="bibr"><italic toggle="yes">41</italic></xref>&#x2013;<xref rid="R46" ref-type="bibr"><italic toggle="yes">46</italic></xref>). The recent identification of four cross-reactive mAbs targeting the stem helix in the S<sub>2</sub> subunit highlighted the importance of this epitope, which is conserved among betacoronavirus but not alphacoronavirus S glycoproteins (<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>&#x2013;<xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>, <xref rid="R47" ref-type="bibr"><italic toggle="yes">47</italic></xref>), although none of these mAbs inhibit members of all three betacoronavirus subgenera. Here, we identified five stem helix&#x2013;specific human mAbs cross-reacting with human and animal betacoronaviruses and showed that S2P6 broadly neutralized all sarbecoviruses, merbecoviruses, and embecoviruses pseudotypes evaluated through the inhibition of membrane fusion.</p>
      <p>We show that an S<sub>2</sub> subunit&#x2013;directed mAb reduces lung viral burden in hamsters challenged with SARS-CoV-2 with a key contribution of Fc-mediated effector functions, as described for some SARS-CoV-2 RBD-specific mAbs (<xref rid="R34" ref-type="bibr"><italic toggle="yes">34</italic></xref>, <xref rid="R37" ref-type="bibr"><italic toggle="yes">37</italic></xref>) and influenza virus hemagglutinin stem mAbs (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>, <xref rid="R48" ref-type="bibr"><italic toggle="yes">48</italic></xref>, <xref rid="R49" ref-type="bibr"><italic toggle="yes">49</italic></xref>). Although this study showcases the stem helix as a target of pan-betacoronavirus Abs, the existence of other cross-reactive S<sub>2</sub> epitopes with neutralizing potential remains a subject of investigation. Stem helix&#x2013;targeted Abs are elicited upon natural infection by endemic (OC43 or HKU1) or pandemic (SARS-CoV-2) coronaviruses as well as by COVID-19 mRNA vaccines. Similarly to the subdominance of Abs recognizing the conserved hemagglutinin stem region of influenza A viruses (<xref rid="R48" ref-type="bibr"><italic toggle="yes">48</italic></xref>, <xref rid="R50" ref-type="bibr"><italic toggle="yes">50</italic></xref>), stem helix&#x2013;specific Abs are present at low titers in convalescent or vaccinee plasma and at low frequencies in their memory B cell repertoires, possibly as a result of limited epitope exposure. These findings along with the moderate neutralization potency of these mAbs indicate that eliciting high-enough titers of stem helix&#x2013;targeted mAbs through vaccination will be a key challenge to overcome to develop pan-betacoronavirus vaccines. We propose that harnessing recent advances in computational protein design, such as epitope-focused vaccine design approaches as described for the respiratory syncytial virus fusion protein (<xref rid="R51" ref-type="bibr"><italic toggle="yes">51</italic></xref>&#x2013;<xref rid="R53" ref-type="bibr"><italic toggle="yes">53</italic></xref>) and multivalent display as described for influenza virus (<xref rid="R54" ref-type="bibr"><italic toggle="yes">54</italic></xref>&#x2013;<xref rid="R59" ref-type="bibr"><italic toggle="yes">59</italic></xref>) to target the S stem helix or the fusion peptide regions, might enable elicitation of broad betacoronavirus immunity.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material position="float" content-type="local-data">
        <label>20210803-1</label>
        <media xlink:href="science.abj3321.v1.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank J. C. Nix for x-ray data collection, T. I. Croll for assistance in refinement of the crystal structure, A. Arvin for her insightful comments, M. Meury for help with protein production, and H. Tani (University of Toyama) for providing the reagents necessary for preparing VSV pseudotyped viruses. The authors would also like to thank C. Castado and N. Blais (GSK Vaccines) for their help in the selection of the genetically divergent sarbecoviruses used in this study. We thank Promega Corporation for kindly providing SARS-CoV-2 CHO-K1 cells (genetically engineered to stably express a HaloTag-HiBit-tagged). <bold>Funding:</bold> This study was supported by the National Institute of Allergy and Infectious Diseases (DP1AI158186 and HHSN272201700059C to D.V. and U01 AI151698-01 to WCVV), a Pew Biomedical Scholars Award (D.V.), Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund (D.V.), Fast Grants (D.V.), the Swiss National Science Foundation (P400PB_183942 to M.M.S.), the University of Washington Arnold and Mabel Beckman cryo-EM center, Vir Biotechnology, and the Helmut Horten Foundation (to F.S. and the Institute for Research in Biomedicine). The project was also partially funded by the Swiss Kidney Foundation. Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, is supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under contract no. DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research and by the National Institutes of Health, National Institute of General Medical Sciences (P30GM133894). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH. <bold>Author contributions:</bold> Experiment design: D.P., M.M.S., J.S.L., M.A.T., M.S.P., H.W.V., M.B., D.C., and D.V.; Donors&#x2019; recruitment and sample collection: E.C., F.B., B.G., A.Ce., P.F., P.E.C., O.G., S.C., C.G., A.R., L.P., M.S., D.V., and C.H.-D.; Antibody discovery: D.P., M.B., J.S.L., J.J., S.J., N.S., K.C., E.C., and D.C.; Antigen-specific memory B cell repertoire analysis preparation: C.S.-F., J.B., and A.Ca.; Expression and purification of proteins: A.C.W., J.E.B., and J.J.; Antibody functional experiments: D.P., M.M.S., N.C., J.S.L., M.A.T., A.C.W., F.A.L., J.No., S.B., and R.M.; Bioinformatic analysis of virus diversity and variants: J.d.I., I.B., and A.T.; Evaluation of effector functions: B.G.; SPR binding assays: L.E.R.; Neutralization assay: D.P., M.A.T., F.A.L., J.No., and M.P.H.; Escape mutants selection and sequencing: H.K., S.I., F.A.L., and J.d.I.; Effects in the hamster model and data analysis: R.A., C.F., L.C., J.Ne., E.V., and F.B.; Cryo-EM data collection, processing, and model building: M.M.S. and D.V.; Crystallization, x-ray crystallography data collection, processing, and model building: M.M.S., N.C., G.S., and D.V.; Serological assays: D.P. and R.M.; Data analysis: D.P., M.M.S., M.B., J.S.L., J.J., F.A.L., J.No., N.C., A.T., A.C.W., G.S., D.C., and D.V.; Manuscript writing: D.P., M.M.S., J.S.L., M.B., G.S., F.S., A.L., H.W.V., D.C., and D.V. <bold>Competing interests:</bold> D.P., N.C., M.P.H., J.No., B.G., L.E.R., J.d.I., H.K., S.I., S.J., N.S., K.C., I.B., S.B., C.S.-F., J.B., R.M., E.V., F.B., E.C., L.P., M.S.P., M.S., D.H., A.T., F.A.L., C.H.-D., A.L., G.S., H.W.V., M.B., and D.C. are employees of Vir Biotechnology and may hold shares in Vir Biotechnology. D.C., J.S.L., F.S., A.Ca., and A.L. are currently listed as inventors on multiple patent applications, which disclose the subject matter described in this manuscript. D.V. is a consultant for Vir Biotechnology Inc. The Veesler laboratory and the Sallusto laboratory have received sponsored research agreements from Vir Biotechnology Inc. The other authors declare no competing interests. <bold>Data and materials availability:</bold> The crystal structure of S2P6-bound SARS-CoV-2 stem helix peptide was deposited to the Protein Data Bank (PDB) with accession no. 7RNJ. The cryo-EM structure of SARS-CoV-2 spike protein bound to the S2P6 and S2M11 Fab fragments was deposited to the Electron Microscopy Data Bank with accession no. EMD-24533. Materials generated in this study will be made available on request but may require a completed materials transfer agreement signed with Vir Biotechnology or the University of Washington. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <ext-link xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by/4.0/</ext-link>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</p>
    </ack>
    <sec sec-type="supplementary-material">
      <title>Supplementary Materials</title>
      <sec>
        <title>This PDF file includes:</title>
        <supplementary-material position="float" content-type="local-data">
          <caption>
            <p>Materials and Methods</p>
            <p>Figs. S1 to S10</p>
            <p>Tables S1 and S2</p>
            <p>References (<xref rid="R61" ref-type="bibr"><italic toggle="yes">61</italic></xref>&#x2013;<xref rid="R86" ref-type="bibr"><italic toggle="yes">86</italic></xref>)</p>
          </caption>
          <media xlink:href="science.abj3321_sm.pdf">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
      </sec>
      <sec>
        <title>Other Supplementary Material for this manuscript includes the following:</title>
        <supplementary-material position="float" content-type="local-data">
          <caption>
            <p>MDAR Reproducibility Checklist</p>
          </caption>
          <media xlink:href="science.abj3321_mdar_reproducibility_checklist.pdf">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
      </sec>
    </sec>
    <sec>
      <p>
<ext-link xlink:href="https://en.bio-protocol.org/cjrap.aspx?eid=10.1126/science.abj3321" ext-link-type="uri">View/request a protocol for this paper from <italic toggle="yes">Bio-protocol</italic>.</ext-link>
</p>
    </sec>
    <ref-list>
      <title>References and Notes</title>
      <ref id="R1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Structural insights into coronavirus entry</article-title>. <source>Adv. Virus Res.</source>
<volume>105</volume>, 
<fpage>93</fpage>&#x2013;<lpage>116</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1016/bs.aivir.2019.08.002</pub-id><pub-id pub-id-type="pmid">31522710</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>Y. J.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Wall</surname></string-name>, <string-name><given-names>A. T.</given-names>
<surname>McGuire</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title>. <source>Cell</source>
<volume>181</volume>, 
<fpage>281</fpage>&#x2013;<lpage>292.e6</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Wrapp</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>K. S.</given-names>
<surname>Corbett</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Goldsmith</surname></string-name>, <string-name><given-names>C. L.</given-names>
<surname>Hsieh</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Abiona</surname></string-name>, <string-name><given-names>B. S.</given-names>
<surname>Graham</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>McLellan</surname></string-name></person-group>, 
<article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>. <source>Science</source>
<volume>367</volume>, 
<fpage>1260</fpage>&#x2013;<lpage>1263</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E. C.</given-names>
<surname>Thomson</surname></string-name>, <string-name><given-names>L. E.</given-names>
<surname>Rosen</surname></string-name>, <string-name><given-names>J. G.</given-names>
<surname>Shepherd</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Spreafico</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>da Silva Filipe</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Wojcechowskyj</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Davis</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Piccoli</surname></string-name>, <string-name><given-names>D. J.</given-names>
<surname>Pascall</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Dillen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Lytras</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Czudnochowski</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Shah</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Meury</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Jesudason</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>De Marco</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Bassi</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>O&#x2019;Toole</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pinto</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Colquhoun</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Culap</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Jackson</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zatta</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Rambaut</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jaconi</surname></string-name>, <string-name><given-names>V. B.</given-names>
<surname>Sreenu</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Nix</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>R. F.</given-names>
<surname>Jarrett</surname></string-name>, <string-name><given-names>W. G.</given-names>
<surname>Glass</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Beltramello</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Nomikou</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Pizzuto</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Tong</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cameroni</surname></string-name>, <string-name><given-names>T. I.</given-names>
<surname>Croll</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Johnson</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Di Iulio</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Wickenhagen</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Ceschi</surname></string-name>, <string-name><given-names>A. M.</given-names>
<surname>Harbison</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Mair</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Ferrari</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Smollett</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Sallusto</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Carmichael</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Garzoni</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Nichols</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Galli</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Hughes</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Riva</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Ho</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Schiuma</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Semple</surname></string-name>, <string-name><given-names>P. J. M.</given-names>
<surname>Openshaw</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Fadda</surname></string-name>, <string-name><given-names>J. K.</given-names>
<surname>Baillie</surname></string-name>, <string-name><given-names>J. D.</given-names>
<surname>Chodera</surname></string-name>, <collab>ISARIC4C Investigators</collab>, <collab>COVID-19 Genomics UK (COG-UK) Consortium</collab>, <string-name><given-names>S. J.</given-names>
<surname>Rihn</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Lycett</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Telenti</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>D. L.</given-names>
<surname>Robertson</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Snell</surname></string-name></person-group>, 
<article-title>Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity</article-title>. <source>Cell</source>
<volume>184</volume>, 
<fpage>1171</fpage>&#x2013;<lpage>1187.e20</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2021.01.037</pub-id><pub-id pub-id-type="pmid">33621484</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>McCallum</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>De Marco</surname></string-name>, <string-name><given-names>F. A.</given-names>
<surname>Lempp</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pinto</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Beltramello</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zatta</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Zepeda</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>di Iulio</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Bowen</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Montiel-Ruiz</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>L. E.</given-names>
<surname>Rosen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bianchi</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Guarino</surname></string-name>, <string-name><given-names>C. S.</given-names>
<surname>Fregni</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Abdelnabi</surname></string-name>, <string-name><given-names>S.-Y. C.</given-names>
<surname>Foo</surname></string-name>, <string-name><given-names>P. W.</given-names>
<surname>Rothlauf</surname></string-name>, <string-name><given-names>L.-M.</given-names>
<surname>Bloyet</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Benigni</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cameroni</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Neyts</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Riva</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Snell</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Telenti</surname></string-name>, <string-name><given-names>S. P. J.</given-names>
<surname>Whelan</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Pizzuto</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2</article-title>. <source>Cell</source>
<volume>184</volume>, 
<fpage>2332</fpage>&#x2013;<lpage>2347.e16</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2021.03.028</pub-id><pub-id pub-id-type="pmid">33761326</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. R.</given-names>
<surname>McCarthy</surname></string-name>, <string-name><given-names>L. J.</given-names>
<surname>Rennick</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Nambulli</surname></string-name>, <string-name><given-names>L. R.</given-names>
<surname>Robinson-McCarthy</surname></string-name>, <string-name><given-names>W. G.</given-names>
<surname>Bain</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Haidar</surname></string-name>, <string-name><given-names>W. P.</given-names>
<surname>Duprex</surname></string-name></person-group>, 
<article-title>Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape</article-title>. <source>Science</source>
<volume>371</volume>, 
<fpage>1139</fpage>&#x2013;<lpage>1142</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1126/science.abf6950</pub-id><pub-id pub-id-type="pmid">33536258</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Choi</surname></string-name>, <string-name><given-names>M. C.</given-names>
<surname>Choudhary</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Regan</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Sparks</surname></string-name>, <string-name><given-names>R. F.</given-names>
<surname>Padera</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Qiu</surname></string-name>, <string-name><given-names>I. H.</given-names>
<surname>Solomon</surname></string-name>, <string-name><given-names>H. H.</given-names>
<surname>Kuo</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Boucau</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Bowman</surname></string-name>, <string-name><given-names>U. D.</given-names>
<surname>Adhikari</surname></string-name>, <string-name><given-names>M. L.</given-names>
<surname>Winkler</surname></string-name>, <string-name><given-names>A. A.</given-names>
<surname>Mueller</surname></string-name>, <string-name><given-names>T. Y.</given-names>
<surname>Hsu</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Desjardins</surname></string-name>, <string-name><given-names>L. R.</given-names>
<surname>Baden</surname></string-name>, <string-name><given-names>B. T.</given-names>
<surname>Chan</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Walker</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Lichterfeld</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Brigl</surname></string-name>, <string-name><given-names>D. S.</given-names>
<surname>Kwon</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kanjilal</surname></string-name>, <string-name><given-names>E. T.</given-names>
<surname>Richardson</surname></string-name>, <string-name><given-names>A. H.</given-names>
<surname>Jonsson</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Alter</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Barczak</surname></string-name>, <string-name><given-names>W. P.</given-names>
<surname>Hanage</surname></string-name>, <string-name><given-names>X. G.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>G. D.</given-names>
<surname>Gaiha</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Seaman</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Cernadas</surname></string-name>, <string-name><given-names>J. Z.</given-names>
<surname>Li</surname></string-name></person-group>, 
<article-title>Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host</article-title>. <source>N. Engl. J. Med.</source>
<volume>383</volume>, 
<fpage>2291</fpage>&#x2013;<lpage>2293</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1056/NEJMc2031364</pub-id><pub-id pub-id-type="pmid">33176080</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Z.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>VanBlargan</surname></string-name>, <string-name><given-names>L.-M.</given-names>
<surname>Bloyet</surname></string-name>, <string-name><given-names>P. W.</given-names>
<surname>Rothlauf</surname></string-name>, <string-name><given-names>R. E.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Stumpf</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Errico</surname></string-name>, <string-name><given-names>E. S.</given-names>
<surname>Theel</surname></string-name>, <string-name><given-names>M. J.</given-names>
<surname>Liebeskind</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Alford</surname></string-name>, <string-name><given-names>W. J.</given-names>
<surname>Buchser</surname></string-name>, <string-name><given-names>A. H.</given-names>
<surname>Ellebedy</surname></string-name>, <string-name><given-names>D. H.</given-names>
<surname>Fremont</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Diamond</surname></string-name>, <string-name><given-names>S. P. J.</given-names>
<surname>Whelan</surname></string-name></person-group>, 
<article-title>Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization</article-title>. <source>Cell Host Microbe</source>
<volume>29</volume>, 
<fpage>477</fpage>&#x2013;<lpage>488.e4</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1016/j.chom.2021.01.014</pub-id><pub-id pub-id-type="pmid">33535027</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Weisblum</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>DaSilva</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Poston</surname></string-name>, <string-name><given-names>J. C. C.</given-names>
<surname>Lorenzi</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Muecksch</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Rutkowska</surname></string-name>, <string-name><given-names>H.-H.</given-names>
<surname>Hoffmann</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Michailidis</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Gaebler</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Agudelo</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Cho</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Gazumyan</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Cipolla</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Luchsinger</surname></string-name>, <string-name><given-names>C. D.</given-names>
<surname>Hillyer</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Caskey</surname></string-name>, <string-name><given-names>D. F.</given-names>
<surname>Robbiani</surname></string-name>, <string-name><given-names>C. M.</given-names>
<surname>Rice</surname></string-name>, <string-name><given-names>M. C.</given-names>
<surname>Nussenzweig</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Hatziioannou</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Bieniasz</surname></string-name></person-group>, 
<article-title>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</article-title>. <source>eLife</source>
<volume>9</volume>, 
<elocation-id>e61312</elocation-id> (<year>2020</year>). <pub-id pub-id-type="doi">10.7554/eLife.61312</pub-id><pub-id pub-id-type="pmid">33112236</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>McCallum</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Bassi</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>De Marco</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Di Iulio</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>M.-J.</given-names>
<surname>Navarro</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Silacci-Fregni</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Saliba</surname></string-name>, <string-name><given-names>K. R.</given-names>
<surname>Sprouse</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Agostini</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pinto</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Culap</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bianchi</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jaconi</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cameroni</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Bowen</surname></string-name>, <string-name><given-names>S. W.</given-names>
<surname>Tilles</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Pizzuto</surname></string-name>, <string-name><given-names>S. B.</given-names>
<surname>Guastalla</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Bona</surname></string-name>, <string-name><given-names>A. F.</given-names>
<surname>Pellanda</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Garzoni</surname></string-name>, <string-name><given-names>W. C.</given-names>
<surname>Van Voorhis</surname></string-name>, <string-name><given-names>L. E.</given-names>
<surname>Rosen</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Snell</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Telenti</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Piccoli</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern</article-title>. <source>Science</source>
<volume>373</volume>, 
<fpage>648</fpage>&#x2013;<lpage>654</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1126/science.abi7994</pub-id><pub-id pub-id-type="pmid">34210893</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Xiong</surname></string-name>, <string-name><given-names>Y. J.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Snijder</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Quispe</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cameroni</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Gopal</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Dai</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Zambon</surname></string-name>, <string-name><given-names>F. A.</given-names>
<surname>Rey</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion</article-title>. <source>Cell</source>
<volume>176</volume>, 
<fpage>1026</fpage>&#x2013;<lpage>1039.e15</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2018.12.028</pub-id><pub-id pub-id-type="pmid">30712865</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Watanabe</surname></string-name>, <string-name><given-names>J. D.</given-names>
<surname>Allen</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Wrapp</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>McLellan</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Crispin</surname></string-name></person-group>, 
<article-title>Site-specific glycan analysis of the SARS-CoV-2 spike</article-title>. <source>Science</source>
<volume>369</volume>, 
<fpage>330</fpage>&#x2013;<lpage>333</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1126/science.abb9983</pub-id><pub-id pub-id-type="pmid">32366695</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Du</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jiang</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Baric</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Li</surname></string-name></person-group>, 
<article-title>Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus</article-title>. <source>J. Virol.</source>
<volume>89</volume>, 
<fpage>9119</fpage>&#x2013;<lpage>9123</lpage> (<year>2015</year>). <pub-id pub-id-type="doi">10.1128/JVI.01279-15</pub-id><pub-id pub-id-type="pmid">26063432</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <mixed-citation publication-type="webpage">M. M. Sauer, M. A. Tortorici, Y.-J. Park, A. C. Walls, L. Homad, O. Acton, J. Bowen, C. Wang, X. Xiong, W. de van der Schueren, J. Quispe, B. G. Hoffstrom, B.-J. Bosch, A. T. McGuire, D. Veesler, Structural basis for broad coronavirus neutralization. bioRxiv 2020.12.29.424482 [Preprint] (2021). <pub-id pub-id-type="doi">10.1101/2020.12.29.424482</pub-id>.<pub-id pub-id-type="doi">10.1101/2020.12.29.424482</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>van Haperen</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Guti&#xE9;rrez-&#xC1;lvarez</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>N. M. A.</given-names>
<surname>Okba</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Albulescu</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Widjaja</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>van Dieren</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Fernandez-Delgado</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Sola</surname></string-name>, <string-name><given-names>D. L.</given-names>
<surname>Hurdiss</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Daramola</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Grosveld</surname></string-name>, <string-name><given-names>F. J. M.</given-names>
<surname>van Kuppeveld</surname></string-name>, <string-name><given-names>B. L.</given-names>
<surname>Haagmans</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Enjuanes</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Drabek</surname></string-name>, <string-name><given-names>B.-J.</given-names>
<surname>Bosch</surname></string-name></person-group>, 
<article-title>A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies</article-title>. <source>Nat. Commun.</source>
<volume>12</volume>, 
<fpage>1715</fpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1038/s41467-021-21968-w</pub-id><pub-id pub-id-type="pmid">33731724</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names>
<surname>Song</surname></string-name>, <string-name><given-names>W.-t.</given-names>
<surname>He</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Callaghan</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Anzanello</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Ricketts</surname></string-name>, <string-name><given-names>J. L.</given-names>
<surname>Torres</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Beutler</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Peng</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Vargas</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Cassell</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Parren</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Ignacio</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Smith</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Voss</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Nemazee</surname></string-name>, <string-name><given-names>A. B.</given-names>
<surname>Ward</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Rogers</surname></string-name>, <string-name><given-names>D. R.</given-names>
<surname>Burton</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Andrabi</surname></string-name></person-group>, 
<article-title>Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection</article-title>. <source>Nat. Commun.</source>
<volume>12</volume>, 
<fpage>2938</fpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1038/s41467-021-23074-3</pub-id><pub-id pub-id-type="pmid">34011939</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N. L.</given-names>
<surname>Kallewaard</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Collins</surname></string-name>, <string-name><given-names>U.</given-names>
<surname>Neu</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>McAuliffe</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Benjamin</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Wachter-Rosati</surname></string-name>, <string-name><given-names>F. J.</given-names>
<surname>Palmer-Hill</surname></string-name>, <string-name><given-names>A. Q.</given-names>
<surname>Yuan</surname></string-name>, <string-name><given-names>P. A.</given-names>
<surname>Walker</surname></string-name>, <string-name><given-names>M. K.</given-names>
<surname>Vorlaender</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bianchi</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Guarino</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>De Marco</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Vanzetta</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Agatic</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Foglierini</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pinna</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Fernandez-Rodriguez</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Fruehwirth</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Silacci</surname></string-name>, <string-name><given-names>R. W.</given-names>
<surname>Ogrodowicz</surname></string-name>, <string-name><given-names>S. R.</given-names>
<surname>Martin</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Sallusto</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Suzich</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Zhu</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Gamblin</surname></string-name>, <string-name><given-names>J. J.</given-names>
<surname>Skehel</surname></string-name></person-group>, 
<article-title>Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes</article-title>. <source>Cell</source>
<volume>166</volume>, 
<fpage>596</fpage>&#x2013;<lpage>608</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2016.05.073</pub-id><pub-id pub-id-type="pmid">27453466</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B. F.</given-names>
<surname>Haynes</surname></string-name>, <string-name><given-names>D. R.</given-names>
<surname>Burton</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Mascola</surname></string-name></person-group>, 
<article-title>Multiple roles for HIV broadly neutralizing antibodies</article-title>. <source>Sci. Transl. Med.</source>
<volume>11</volume>, 
<elocation-id>eaaz2686</elocation-id> (<year>2019</year>). <pub-id pub-id-type="doi">10.1126/scitranslmed.aaz2686</pub-id><pub-id pub-id-type="pmid">31666399</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Z.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Weisblum</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Muecksch</surname></string-name>, <string-name><given-names>C. O.</given-names>
<surname>Barnes</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Finkin</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Schaefer-Babajew</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Cipolla</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Gaebler</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Lieberman</surname></string-name>, <string-name><given-names>T. Y.</given-names>
<surname>Oliveira</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>M. E.</given-names>
<surname>Abernathy</surname></string-name>, <string-name><given-names>K. E.</given-names>
<surname>Huey-Tubman</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Hurley</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Turroja</surname></string-name>, <string-name><given-names>K. A.</given-names>
<surname>West</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Gordon</surname></string-name>, <string-name><given-names>K. G.</given-names>
<surname>Millard</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Ramos</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Da Silva</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Xu</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Colbert</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Patel</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Dizon</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Unson-O&#x2019;Brien</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Shimeliovich</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Gazumyan</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Caskey</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Bjorkman</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Casellas</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Hatziioannou</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Bieniasz</surname></string-name>, <string-name><given-names>M. C.</given-names>
<surname>Nussenzweig</surname></string-name></person-group>, 
<article-title>mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants</article-title>. <source>Nature</source>
<volume>592</volume>, 
<fpage>616</fpage>&#x2013;<lpage>622</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1038/s41586-021-03324-6</pub-id><pub-id pub-id-type="pmid">33567448</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>Piccoli</surname></string-name>, <string-name><given-names>Y. J.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Czudnochowski</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Beltramello</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Silacci-Fregni</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pinto</surname></string-name>, <string-name><given-names>L. E.</given-names>
<surname>Rosen</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Bowen</surname></string-name>, <string-name><given-names>O. J.</given-names>
<surname>Acton</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jaconi</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Guarino</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Minola</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zatta</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Sprugasci</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Bassi</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Peter</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>De Marco</surname></string-name>, <string-name><given-names>J. C.</given-names>
<surname>Nix</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Mele</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jovic</surname></string-name>, <string-name><given-names>B. F.</given-names>
<surname>Rodriguez</surname></string-name>, <string-name><given-names>S. V.</given-names>
<surname>Gupta</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Jin</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Piumatti</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Lo Presti</surname></string-name>, <string-name><given-names>A. F.</given-names>
<surname>Pellanda</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Biggiogero</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Tarkowski</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Pizzuto</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cameroni</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Havenar-Daughton</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Smithey</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Hong</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Lepori</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Albanese</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Ceschi</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Bernasconi</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Elzi</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Ferrari</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Garzoni</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Riva</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Snell</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Sallusto</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Fink</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology</article-title>. <source>Cell</source>
<volume>183</volume>, 
<fpage>1024</fpage>&#x2013;<lpage>1042.e21</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2020.09.037</pub-id><pub-id pub-id-type="pmid">32991844</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Beltramello</surname></string-name>, <string-name><given-names>F. A.</given-names>
<surname>Lempp</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pinto</surname></string-name>, <string-name><given-names>H. V.</given-names>
<surname>Dang</surname></string-name>, <string-name><given-names>L. E.</given-names>
<surname>Rosen</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>McCallum</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Bowen</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Minola</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jaconi</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zatta</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>De Marco</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Guarino</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bianchi</surname></string-name>, <string-name><given-names>E. J.</given-names>
<surname>Lauron</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Tucker</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Peter</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Havenar-Daughton</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Wojcechowskyj</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Case</surname></string-name>, <string-name><given-names>R. E.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Kaiser</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Montiel-Ruiz</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Meury</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Czudnochowski</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Spreafico</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Dillen</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Ng</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Sprugasci</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Culap</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Benigni</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Abdelnabi</surname></string-name>, <string-name><given-names>S. C.</given-names>
<surname>Foo</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Schmid</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cameroni</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Riva</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Gabrieli</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Galli</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Pizzuto</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Neyts</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Diamond</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Snell</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Fink</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms</article-title>. <source>Science</source>
<volume>370</volume>, 
<fpage>950</fpage>&#x2013;<lpage>957</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1126/science.abe3354</pub-id><pub-id pub-id-type="pmid">32972994</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Hoffmann</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>M&#xF6;sbauer</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Hofmann-Winkler</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Kaul</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Kleine-Weber</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Kr&#xFC;ger</surname></string-name>, <string-name><given-names>N. C.</given-names>
<surname>Gassen</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>M&#xFC;ller</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Drosten</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>P&#xF6;hlmann</surname></string-name></person-group>, 
<article-title>Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2</article-title>. <source>Nature</source>
<volume>585</volume>, 
<fpage>588</fpage>&#x2013;<lpage>590</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1038/s41586-020-2575-3</pub-id><pub-id pub-id-type="pmid">32698190</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Hoffmann</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Kleine-Weber</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Schroeder</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Kr&#xFC;ger</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Herrler</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Erichsen</surname></string-name>, <string-name><given-names>T. S.</given-names>
<surname>Schiergens</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Herrler</surname></string-name>, <string-name><given-names>N. H.</given-names>
<surname>Wu</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Nitsche</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>M&#xFC;ller</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Drosten</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>P&#xF6;hlmann</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>. <source>Cell</source>
<volume>181</volume>, 
<fpage>271</fpage>&#x2013;<lpage>280.e8</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Hoffmann</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Kleine-Weber</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>P&#xF6;hlmann</surname></string-name></person-group>, 
<article-title>A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells</article-title>. <source>Mol. Cell</source>
<volume>78</volume>, 
<fpage>779</fpage>&#x2013;<lpage>784.e5</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1016/j.molcel.2020.04.022</pub-id><pub-id pub-id-type="pmid">32362314</pub-id></mixed-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Kaname</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Tani</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Kataoka</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Shiokawa</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Taguwa</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Abe</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Moriishi</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Kinoshita</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Matsuura</surname></string-name></person-group>, 
<article-title>Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64</article-title>. <source>J. Virol.</source>
<volume>84</volume>, 
<fpage>3210</fpage>&#x2013;<lpage>3219</lpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1128/JVI.02519-09</pub-id><pub-id pub-id-type="pmid">20071581</pub-id></mixed-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. B.</given-names>
<surname>Case</surname></string-name>, <string-name><given-names>P. W.</given-names>
<surname>Rothlauf</surname></string-name>, <string-name><given-names>R. E.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>L. M.</given-names>
<surname>Bloyet</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Zeng</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Tahan</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Droit</surname></string-name>, <string-name><given-names>M. X. G.</given-names>
<surname>Ilagan</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tartell</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Amarasinghe</surname></string-name>, <string-name><given-names>J. P.</given-names>
<surname>Henderson</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Miersch</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Ustav</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Sidhu</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ding</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>E. S.</given-names>
<surname>Theel</surname></string-name>, <string-name><given-names>D. H.</given-names>
<surname>Fremont</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Diamond</surname></string-name>, <string-name><given-names>S. P. J.</given-names>
<surname>Whelan</surname></string-name></person-group>, 
<article-title>Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2</article-title>. <source>Cell Host Microbe</source>
<volume>28</volume>, 
<fpage>475</fpage>&#x2013;<lpage>485.e5</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1016/j.chom.2020.06.021</pub-id><pub-id pub-id-type="pmid">32735849</pub-id></mixed-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Gui</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Song</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Xu</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Xiang</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Wang</surname></string-name></person-group>, 
<article-title>Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding</article-title>. <source>Cell Res.</source>
<volume>27</volume>, 
<fpage>119</fpage>&#x2013;<lpage>129</lpage> (<year>2017</year>). <pub-id pub-id-type="doi">10.1038/cr.2016.152</pub-id><pub-id pub-id-type="pmid">28008928</pub-id></mixed-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. N.</given-names>
<surname>Kirchdoerfer</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Pallesen</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Wrapp</surname></string-name>, <string-name><given-names>H. L.</given-names>
<surname>Turner</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Cottrell</surname></string-name>, <string-name><given-names>K. S.</given-names>
<surname>Corbett</surname></string-name>, <string-name><given-names>B. S.</given-names>
<surname>Graham</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>McLellan</surname></string-name>, <string-name><given-names>A. B.</given-names>
<surname>Ward</surname></string-name></person-group>, 
<article-title>Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis</article-title>. <source>Sci. Rep.</source>
<volume>8</volume>, 
<fpage>15701</fpage> (<year>2018</year>). <pub-id pub-id-type="doi">10.1038/s41598-018-34171-7</pub-id><pub-id pub-id-type="pmid">30356097</pub-id></mixed-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Yuan</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Cao</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Ma</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Qi</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Lu</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wu</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yan</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>G. F.</given-names>
<surname>Gao</surname></string-name></person-group>, 
<article-title>Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains</article-title>. <source>Nat. Commun.</source>
<volume>8</volume>, 
<fpage>15092</fpage> (<year>2017</year>). <pub-id pub-id-type="doi">10.1038/ncomms15092</pub-id><pub-id pub-id-type="pmid">28393837</pub-id></mixed-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Snijder</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Xiong</surname></string-name>, <string-name><given-names>B. J.</given-names>
<surname>Bosch</surname></string-name>, <string-name><given-names>F. A.</given-names>
<surname>Rey</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>114</volume>, 
<fpage>11157</fpage>&#x2013;<lpage>11162</lpage> (<year>2017</year>). <pub-id pub-id-type="doi">10.1073/pnas.1708727114</pub-id><pub-id pub-id-type="pmid">29073020</pub-id></mixed-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Cai</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Xiao</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Peng</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Sterling</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Walsh</surname>
<suffix>Jr</suffix></string-name>., <string-name><given-names>S.</given-names>
<surname>Rawson</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Rits-Volloch</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Chen</surname></string-name></person-group>, 
<article-title>Distinct conformational states of SARS-CoV-2 spike protein</article-title>. <source>Science</source>
<volume>369</volume>, 
<fpage>1586</fpage>&#x2013;<lpage>1592</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1126/science.abd4251</pub-id><pub-id pub-id-type="pmid">32694201</pub-id></mixed-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>X.</given-names>
<surname>Fan</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Cao</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Kong</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Zhang</surname></string-name></person-group>, 
<article-title>Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein</article-title>. <source>Nat. Commun.</source>
<volume>11</volume>, 
<fpage>3618</fpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1038/s41467-020-17371-6</pub-id><pub-id pub-id-type="pmid">32681106</pub-id></mixed-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <mixed-citation publication-type="webpage">F. A. Lempp, L. Soriaga, M. Montiel-Ruiz, F. Benigni, J. Noack, Y.-J. Park, S. Bianchi, A. C. Walls, J. E. Bowen, J. Zhou, H. Kaiser, M. Agostini, M. Meury, E. Dellota Jr., S. Jaconi, E. Cameroni, H. W. Virgin, A. Lanzavecchia, D. Veesler, L. Purcell, A. Telenti, D. Corti, Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies. bioRxiv 2021.04.03.438258 [Preprint] (2021). <pub-id pub-id-type="doi">10.1101/2021.04.03.438258</pub-id>.<pub-id pub-id-type="doi">10.1101/2021.04.03.438258</pub-id></mixed-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Sch&#xE4;fer</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Muecksch</surname></string-name>, <string-name><given-names>J. C. C.</given-names>
<surname>Lorenzi</surname></string-name>, <string-name><given-names>S. R.</given-names>
<surname>Leist</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Cipolla</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bournazos</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Maison</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Gazumyan</surname></string-name>, <string-name><given-names>D. R.</given-names>
<surname>Martinez</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Baric</surname></string-name>, <string-name><given-names>D. F.</given-names>
<surname>Robbiani</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Hatziioannou</surname></string-name>, <string-name><given-names>J. V.</given-names>
<surname>Ravetch</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Bieniasz</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Bowen</surname></string-name>, <string-name><given-names>M. C.</given-names>
<surname>Nussenzweig</surname></string-name>, <string-name><given-names>T. P.</given-names>
<surname>Sheahan</surname></string-name></person-group>, 
<article-title>Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo</article-title>. <source>J. Exp. Med.</source>
<volume>218</volume>, 
<elocation-id>e20201993</elocation-id> (<year>2021</year>). <pub-id pub-id-type="doi">10.1084/jem.20201993</pub-id><pub-id pub-id-type="pmid">33211088</pub-id></mixed-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Bournazos</surname></string-name>, <string-name><given-names>T. T.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>J. V.</given-names>
<surname>Ravetch</surname></string-name></person-group>, 
<article-title>The Role and Function of Fc&#x3B3; Receptors on Myeloid Cells</article-title>. <source>Microbiol. Spectr.</source>
<volume>4</volume>, 
<elocation-id>4.6.20</elocation-id> (<year>2016</year>). <pub-id pub-id-type="doi">10.1128/microbiolspec.MCHD-0045-2016</pub-id><pub-id pub-id-type="pmid">28087938</pub-id></mixed-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Bournazos</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>J. V.</given-names>
<surname>Ravetch</surname></string-name></person-group>, 
<article-title>Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection</article-title>. <source>Nature</source>
<volume>588</volume>, 
<fpage>485</fpage>&#x2013;<lpage>490</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1038/s41586-020-2838-z</pub-id><pub-id pub-id-type="pmid">33032297</pub-id></mixed-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E. S.</given-names>
<surname>Winkler</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Gilchuk</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>A. L.</given-names>
<surname>Bailey</surname></string-name>, <string-name><given-names>R. E.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Chong</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Zost</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Jang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>J. D.</given-names>
<surname>Allen</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Case</surname></string-name>, <string-name><given-names>R. E.</given-names>
<surname>Sutton</surname></string-name>, <string-name><given-names>R. H.</given-names>
<surname>Carnahan</surname></string-name>, <string-name><given-names>T. L.</given-names>
<surname>Darling</surname></string-name>, <string-name><given-names>A. C. M.</given-names>
<surname>Boon</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Mack</surname></string-name>, <string-name><given-names>R. D.</given-names>
<surname>Head</surname></string-name>, <string-name><given-names>T. M.</given-names>
<surname>Ross</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Crowe</surname>
<suffix>Jr.</suffix></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Diamond</surname></string-name></person-group>, 
<article-title>Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection</article-title>. <source>Cell</source>
<volume>184</volume>, 
<fpage>1804</fpage>&#x2013;<lpage>1820.E16</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2021.02.026</pub-id><pub-id pub-id-type="pmid">33691139</pub-id></mixed-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Pinto</surname></string-name>, <string-name><given-names>Y. J.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Beltramello</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bianchi</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jaconi</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Culap</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zatta</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>De Marco</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Peter</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Guarino</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Spreafico</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cameroni</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Case</surname></string-name>, <string-name><given-names>R. E.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Havenar-Daughton</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Snell</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Telenti</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Diamond</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Fink</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name></person-group>, 
<article-title>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</article-title>. <source>Nature</source>
<volume>583</volume>, 
<fpage>290</fpage>&#x2013;<lpage>295</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1038/s41586-020-2349-y</pub-id><pub-id pub-id-type="pmid">32422645</pub-id></mixed-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Boudewijns</surname></string-name>, <string-name><given-names>H. J.</given-names>
<surname>Thibaut</surname></string-name>, <string-name><given-names>S. J. F.</given-names>
<surname>Kaptein</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Vergote</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Seldeslachts</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Van Weyenbergh</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>De Keyzer</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Bervoets</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Sharma</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Liesenborghs</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Ma</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jansen</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Van Looveren</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Vercruysse</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Jochmans</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Martens</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Roose</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>De Vlieger</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Schepens</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Van Buyten</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jacobs</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Mart&#xED;-Carreras</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Vanmechelen</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Wawina-Bokalanga</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Delang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Rocha-Pereira</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Coelmont</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Chiu</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Leyssen</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Heylen</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Schols</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Close</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Matthijnssens</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Van Ranst</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Compernolle</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Schramm</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Van Laere</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Saelens</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Callewaert</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Opdenakker</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Maes</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Weynand</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Cawthorne</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Vande Velde</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Neyts</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Dallmeier</surname></string-name></person-group>, 
<article-title>STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters</article-title>. <source>Nat. Commun.</source>
<volume>11</volume>, 
<fpage>5838</fpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1038/s41467-020-19684-y</pub-id><pub-id pub-id-type="pmid">33203860</pub-id></mixed-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Pinna</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Jarrossay</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Sallusto</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name></person-group>, 
<article-title>Clonal dissection of the human memory B-cell repertoire following infection and vaccination</article-title>. <source>Eur. J. Immunol.</source>
<volume>39</volume>, 
<fpage>1260</fpage>&#x2013;<lpage>1270</lpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1002/eji.200839129</pub-id><pub-id pub-id-type="pmid">19404981</pub-id></mixed-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Daniel</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Anderson</surname></string-name>, <string-name><given-names>M. J.</given-names>
<surname>Buchmeier</surname></string-name>, <string-name><given-names>J. O.</given-names>
<surname>Fleming</surname></string-name>, <string-name><given-names>W. J.</given-names>
<surname>Spaan</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Wege</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Talbot</surname></string-name></person-group>, 
<article-title>Identification of an immunodominant linear neutralization domain on the S2 portion of the murine coronavirus spike glycoprotein and evidence that it forms part of complex tridimensional structure</article-title>. <source>J. Virol.</source>
<volume>67</volume>, 
<fpage>1185</fpage>&#x2013;<lpage>1194</lpage> (<year>1993</year>). <pub-id pub-id-type="doi">10.1128/jvi.67.3.1185-1194.1993</pub-id><pub-id pub-id-type="pmid">7679743</pub-id></mixed-citation>
      </ref>
      <ref id="R42">
        <label>42</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Nie</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Lian</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Yin</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Qu</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Ding</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Deng</surname></string-name></person-group>, 
<article-title>Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies</article-title>. <source>J. Virol.</source>
<volume>78</volume>, 
<fpage>6938</fpage>&#x2013;<lpage>6945</lpage> (<year>2004</year>). <pub-id pub-id-type="doi">10.1128/JVI.78.13.6938-6945.2004</pub-id><pub-id pub-id-type="pmid">15194770</pub-id></mixed-citation>
      </ref>
      <ref id="R43">
        <label>43</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. M.</given-names>
<surname>Poh</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Carissimo</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>S. N.</given-names>
<surname>Amrun</surname></string-name>, <string-name><given-names>C. Y.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Chee</surname></string-name>, <string-name><given-names>S. W.</given-names>
<surname>Fong</surname></string-name>, <string-name><given-names>N. K.</given-names>
<surname>Yeo</surname></string-name>, <string-name><given-names>W. H.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Torres-Ruesta</surname></string-name>, <string-name><given-names>Y. S.</given-names>
<surname>Leo</surname></string-name>, <string-name><given-names>M. I.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>S. Y.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>L. Y. A.</given-names>
<surname>Chai</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kalimuddin</surname></string-name>, <string-name><given-names>S. S. G.</given-names>
<surname>Kheng</surname></string-name>, <string-name><given-names>S. Y.</given-names>
<surname>Thien</surname></string-name>, <string-name><given-names>B. E.</given-names>
<surname>Young</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Lye</surname></string-name>, <string-name><given-names>B. J.</given-names>
<surname>Hanson</surname></string-name>, <string-name><given-names>C. I.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Renia</surname></string-name>, <string-name><given-names>L. F. P.</given-names>
<surname>Ng</surname></string-name></person-group>, 
<article-title>Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients</article-title>. <source>Nat. Commun.</source>
<volume>11</volume>, 
<fpage>2806</fpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1038/s41467-020-16638-2</pub-id><pub-id pub-id-type="pmid">32483236</pub-id></mixed-citation>
      </ref>
      <ref id="R44">
        <label>44</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H. A.</given-names>
<surname>Elshabrawy</surname></string-name>, <string-name><given-names>M. M.</given-names>
<surname>Coughlin</surname></string-name>, <string-name><given-names>S. C.</given-names>
<surname>Baker</surname></string-name>, <string-name><given-names>B. S.</given-names>
<surname>Prabhakar</surname></string-name></person-group>, 
<article-title>Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing</article-title>. <source>PLOS ONE</source>
<volume>7</volume>, 
<elocation-id>e50366</elocation-id> (<year>2012</year>). <pub-id pub-id-type="doi">10.1371/journal.pone.0050366</pub-id><pub-id pub-id-type="pmid">23185609</pub-id></mixed-citation>
      </ref>
      <ref id="R45">
        <label>45</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Z.</given-names>
<surname>Zheng</surname></string-name>, <string-name><given-names>V. M.</given-names>
<surname>Monteil</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Maurer-Stroh</surname></string-name>, <string-name><given-names>C. W.</given-names>
<surname>Yew</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Leong</surname></string-name>, <string-name><given-names>N. K.</given-names>
<surname>Mohd-Ismail</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Cheyyatraivendran Arularasu</surname></string-name>, <string-name><given-names>V. T. K.</given-names>
<surname>Chow</surname></string-name>, <string-name><given-names>R. T. P.</given-names>
<surname>Lin</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Mirazimi</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Hong</surname></string-name>, <string-name><given-names>Y. J.</given-names>
<surname>Tan</surname></string-name></person-group>, 
<article-title>Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2</article-title>. <source>Euro Surveill.</source>
<volume>25</volume>, 
<elocation-id>2000291</elocation-id> (<year>2020</year>). <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.28.2000291</pub-id><pub-id pub-id-type="pmid">32700671</pub-id></mixed-citation>
      </ref>
      <ref id="R46">
        <label>46</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>B. J.</given-names>
<surname>Bosch</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Frenz</surname></string-name>, <string-name><given-names>P. J. M.</given-names>
<surname>Rottier</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>DiMaio</surname></string-name>, <string-name><given-names>F. A.</given-names>
<surname>Rey</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer</article-title>. <source>Nature</source>
<volume>531</volume>, 
<fpage>114</fpage>&#x2013;<lpage>117</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1038/nature16988</pub-id><pub-id pub-id-type="pmid">26855426</pub-id></mixed-citation>
      </ref>
      <ref id="R47">
        <label>47</label>
        <mixed-citation publication-type="webpage">P. Zhou, M. Yuan, G. Song, N. Beutler, N. Shaabani, D. Huang, W.-t. He, X. Zhu, S. Callaghan, P. Yong, F. Anzanello, L. Peng, J. Ricketts, M. Parren, E. Garcia, S. A. Rawlings, D. M. Smith, D. Nemazee, J. R. Teijaro, T. F. Rogers, I. A. Wilson, D. R. Burton, R. Andrabi, A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes. bioRxiv 2021.03.30.437769 [Preprint] (2021). <pub-id pub-id-type="doi">10.1101/2021.03.30.437769</pub-id>.<pub-id pub-id-type="doi">10.1101/2021.03.30.437769</pub-id></mixed-citation>
      </ref>
      <ref id="R48">
        <label>48</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Voss</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Gamblin</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Codoni</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Macagno</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Jarrossay</surname></string-name>, <string-name><given-names>S. G.</given-names>
<surname>Vachieri</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pinna</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Minola</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Vanzetta</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Silacci</surname></string-name>, <string-name><given-names>B. M.</given-names>
<surname>Fernandez-Rodriguez</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Agatic</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bianchi</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Giacchetto-Sasselli</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Calder</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Sallusto</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Collins</surname></string-name>, <string-name><given-names>L. F.</given-names>
<surname>Haire</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Temperton</surname></string-name>, <string-name><given-names>J. P.</given-names>
<surname>Langedijk</surname></string-name>, <string-name><given-names>J. J.</given-names>
<surname>Skehel</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name></person-group>, 
<article-title>A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins</article-title>. <source>Science</source>
<volume>333</volume>, 
<fpage>850</fpage>&#x2013;<lpage>856</lpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1126/science.1205669</pub-id><pub-id pub-id-type="pmid">21798894</pub-id></mixed-citation>
      </ref>
      <ref id="R49">
        <label>49</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. J.</given-names>
<surname>DiLillo</surname></string-name>, <string-name><given-names>G. S.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Palese</surname></string-name>, <string-name><given-names>J. V.</given-names>
<surname>Ravetch</surname></string-name></person-group>, 
<article-title>Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc&#x3B3;R interactions for protection against influenza virus in vivo</article-title>. <source>Nat. Med.</source>
<volume>20</volume>, 
<fpage>143</fpage>&#x2013;<lpage>151</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1038/nm.3443</pub-id><pub-id pub-id-type="pmid">24412922</pub-id></mixed-citation>
      </ref>
      <ref id="R50">
        <label>50</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>A. L.</given-names>
<surname>Suguitan</surname>
<suffix>Jr</suffix></string-name>., <string-name><given-names>D.</given-names>
<surname>Pinna</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Silacci</surname></string-name>, <string-name><given-names>B. M.</given-names>
<surname>Fernandez-Rodriguez</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Vanzetta</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Santos</surname></string-name>, <string-name><given-names>C. J.</given-names>
<surname>Luke</surname></string-name>, <string-name><given-names>F. J.</given-names>
<surname>Torres-Velez</surname></string-name>, <string-name><given-names>N. J.</given-names>
<surname>Temperton</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Weiss</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Sallusto</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Subbarao</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name></person-group>, 
<article-title>Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine</article-title>. <source>J. Clin. Invest.</source>
<volume>120</volume>, 
<fpage>1663</fpage>&#x2013;<lpage>1673</lpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1172/JCI41902</pub-id><pub-id pub-id-type="pmid">20389023</pub-id></mixed-citation>
      </ref>
      <ref id="R51">
        <label>51</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>F.</given-names>
<surname>Sesterhenn</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Bonet</surname></string-name>, <string-name><given-names>J. T.</given-names>
<surname>Cramer</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Wen</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>C. I.</given-names>
<surname>Chiang</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>Abriata</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Kucharska</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Castoro</surname></string-name>, <string-name><given-names>S. S.</given-names>
<surname>Vollers</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Galloux</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Dheilly</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Rosset</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Corth&#xE9;sy</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Georgeon</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Villard</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Richard</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Descamps</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Delgado</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Oricchio</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Rameix-Welti</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>M&#xE1;s</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ervin</surname></string-name>, <string-name><given-names>J. F.</given-names>
<surname>El&#xE9;ou&#xEB;t</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Riffault</surname></string-name>, <string-name><given-names>J. T.</given-names>
<surname>Bates</surname></string-name>, <string-name><given-names>J. P.</given-names>
<surname>Julien</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Jardetzky</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Krey</surname></string-name>, <string-name><given-names>B. E.</given-names>
<surname>Correia</surname></string-name></person-group>, 
<article-title>De novo protein design enables the precise induction of RSV-neutralizing antibodies</article-title>. <source>Science</source>
<volume>368</volume>, 
<elocation-id>eaay5051</elocation-id> (<year>2020</year>). <pub-id pub-id-type="doi">10.1126/science.aay5051</pub-id><pub-id pub-id-type="pmid">32409444</pub-id></mixed-citation>
      </ref>
      <ref id="R52">
        <label>52</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. L.</given-names>
<surname>Azoitei</surname></string-name>, <string-name><given-names>B. E.</given-names>
<surname>Correia</surname></string-name>, <string-name><given-names>Y. E.</given-names>
<surname>Ban</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Carrico</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Kalyuzhniy</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Schroeter</surname></string-name>, <string-name><given-names>P. S.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>McLellan</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Kwong</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Baker</surname></string-name>, <string-name><given-names>R. K.</given-names>
<surname>Strong</surname></string-name>, <string-name><given-names>W. R.</given-names>
<surname>Schief</surname></string-name></person-group>, 
<article-title>Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold</article-title>. <source>Science</source>
<volume>334</volume>, 
<fpage>373</fpage>&#x2013;<lpage>376</lpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1126/science.1209368</pub-id><pub-id pub-id-type="pmid">22021856</pub-id></mixed-citation>
      </ref>
      <ref id="R53">
        <label>53</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B. E.</given-names>
<surname>Correia</surname></string-name>, <string-name><given-names>J. T.</given-names>
<surname>Bates</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Loomis</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Baneyx</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Carrico</surname></string-name>, <string-name><given-names>J. G.</given-names>
<surname>Jardine</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Rupert</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Correnti</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Kalyuzhniy</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Vittal</surname></string-name>, <string-name><given-names>M. J.</given-names>
<surname>Connell</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Stevens</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Schroeter</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Macpherson</surname></string-name>, <string-name><given-names>A. M.</given-names>
<surname>Serra</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Adachi</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Holmes</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>R. E.</given-names>
<surname>Klevit</surname></string-name>, <string-name><given-names>B. S.</given-names>
<surname>Graham</surname></string-name>, <string-name><given-names>R. T.</given-names>
<surname>Wyatt</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Baker</surname></string-name>, <string-name><given-names>R. K.</given-names>
<surname>Strong</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Crowe</surname>
<suffix>Jr</suffix></string-name>., <string-name><given-names>P. R.</given-names>
<surname>Johnson</surname></string-name>, <string-name><given-names>W. R.</given-names>
<surname>Schief</surname></string-name></person-group>, 
<article-title>Proof of principle for epitope-focused vaccine design</article-title>. <source>Nature</source>
<volume>507</volume>, 
<fpage>201</fpage>&#x2013;<lpage>206</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1038/nature12966</pub-id><pub-id pub-id-type="pmid">24499818</pub-id></mixed-citation>
      </ref>
      <ref id="R54">
        <label>54</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Fiala</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Sch&#xE4;fer</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Wrenn</surname></string-name>, <string-name><given-names>M. N.</given-names>
<surname>Pham</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Murphy</surname></string-name>, <string-name><given-names>L. V.</given-names>
<surname>Tse</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Shehata</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>O&#x2019;Connor</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>M. J.</given-names>
<surname>Navarro</surname></string-name>, <string-name><given-names>M. C.</given-names>
<surname>Miranda</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pettie</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Ravichandran</surname></string-name>, <string-name><given-names>J. C.</given-names>
<surname>Kraft</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Ogohara</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Palser</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Chalk</surname></string-name>, <string-name><given-names>E. C.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Guerriero</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Kepl</surname></string-name>, <string-name><given-names>C. M.</given-names>
<surname>Chow</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Sydeman</surname></string-name>, <string-name><given-names>E. A.</given-names>
<surname>Hodge</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Brown</surname></string-name>, <string-name><given-names>J. T.</given-names>
<surname>Fuller</surname></string-name>, <string-name><given-names>K. H.</given-names>
<surname>Dinnon</surname>
<suffix>3rd</suffix></string-name>, <string-name><given-names>L. E.</given-names>
<surname>Gralinski</surname></string-name>, <string-name><given-names>S. R.</given-names>
<surname>Leist</surname></string-name>, <string-name><given-names>K. L.</given-names>
<surname>Gully</surname></string-name>, <string-name><given-names>T. B.</given-names>
<surname>Lewis</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Guttman</surname></string-name>, <string-name><given-names>H. Y.</given-names>
<surname>Chu</surname></string-name>, <string-name><given-names>K. K.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>D. H.</given-names>
<surname>Fuller</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Baric</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Kellam</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Carter</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Pepper</surname></string-name>, <string-name><given-names>T. P.</given-names>
<surname>Sheahan</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name>, <string-name><given-names>N. P.</given-names>
<surname>King</surname></string-name></person-group>, 
<article-title>Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2</article-title>. <source>Cell</source>
<volume>183</volume>, 
<fpage>1367</fpage>&#x2013;<lpage>1382.e17</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2020.10.043</pub-id><pub-id pub-id-type="pmid">33160446</pub-id></mixed-citation>
      </ref>
      <ref id="R55">
        <label>55</label>
        <mixed-citation publication-type="webpage">A. C. Walls, M. C. Miranda, M. N. Pham, A. Sch&#xE4;fer, A. Greaney, P. S. Arunachalam, M.-J. Navarro, M. A. Tortorici, K. Rogers, M. A. O&#x2019;Connor, L. Shireff, D. E. Ferrell, N. Brunette, E. Kepl, J. Bowen, S. K. Zepeda, T. Starr, C.-L. Hsieh, B. Fiala, S. Wrenn, D. Pettie, C. Sydeman, M. Johnson, A. Blackstone, R. Ravichandran, C. Ogohara, L. Carter, S. W. Tilles, R. Rappuoli, D. T. O&#x2019;Hagan, R. Van Der Most, W. C. Van Voorhis, J. S. McLellan, H. Kleanthous, T. P. Sheahan, D. H. Fuller, F. Villinger, J. Bloom, B. Pulendran, R. Baric, N. King, D. Veesler, Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. bioRxiv 2021.03.15.435528 [Preprint] (2021). <pub-id pub-id-type="doi">10.1101/2021.03.15.435528</pub-id>.<pub-id pub-id-type="doi">10.1101/2021.03.15.435528</pub-id></mixed-citation>
      </ref>
      <ref id="R56">
        <label>56</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Boyoglu-Barnum</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Ellis</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Gillespie</surname></string-name>, <string-name><given-names>G. B.</given-names>
<surname>Hutchinson</surname></string-name>, <string-name><given-names>Y.-J.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Moin</surname></string-name>, <string-name><given-names>O. J.</given-names>
<surname>Acton</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Ravichandran</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Murphy</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pettie</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Matheson</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Carter</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Creanga</surname></string-name>, <string-name><given-names>M. J.</given-names>
<surname>Watson</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kephart</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ataca</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Vaile</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Ueda</surname></string-name>, <string-name><given-names>M. C.</given-names>
<surname>Crank</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Stewart</surname></string-name>, <string-name><given-names>K. K.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Guttman</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Baker</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Mascola</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name>, <string-name><given-names>B. S.</given-names>
<surname>Graham</surname></string-name>, <string-name><given-names>N. P.</given-names>
<surname>King</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Kanekiyo</surname></string-name></person-group>, 
<article-title>Quadrivalent influenza nanoparticle vaccines induce broad protection</article-title>. <source>Nature</source>
<volume>592</volume>, 
<fpage>623</fpage>&#x2013;<lpage>628</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1038/s41586-021-03365-x</pub-id><pub-id pub-id-type="pmid">33762730</pub-id></mixed-citation>
      </ref>
      <ref id="R57">
        <label>57</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Kanekiyo</surname></string-name>, <string-name><given-names>C. J.</given-names>
<surname>Wei</surname></string-name>, <string-name><given-names>H. M.</given-names>
<surname>Yassine</surname></string-name>, <string-name><given-names>P. M.</given-names>
<surname>McTamney</surname></string-name>, <string-name><given-names>J. C.</given-names>
<surname>Boyington</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Whittle</surname></string-name>, <string-name><given-names>S. S.</given-names>
<surname>Rao</surname></string-name>, <string-name><given-names>W. P.</given-names>
<surname>Kong</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>G. J.</given-names>
<surname>Nabel</surname></string-name></person-group>, 
<article-title>Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies</article-title>. <source>Nature</source>
<volume>499</volume>, 
<fpage>102</fpage>&#x2013;<lpage>106</lpage> (<year>2013</year>). <pub-id pub-id-type="doi">10.1038/nature12202</pub-id><pub-id pub-id-type="pmid">23698367</pub-id></mixed-citation>
      </ref>
      <ref id="R58">
        <label>58</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Kanekiyo</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Joyce</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Gillespie</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Gallagher</surname></string-name>, <string-name><given-names>S. F.</given-names>
<surname>Andrews</surname></string-name>, <string-name><given-names>H. M.</given-names>
<surname>Yassine</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Wheatley</surname></string-name>, <string-name><given-names>B. E.</given-names>
<surname>Fisher</surname></string-name>, <string-name><given-names>D. R.</given-names>
<surname>Ambrozak</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Creanga</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Leung</surname></string-name>, <string-name><given-names>E. S.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Boyoglu-Barnum</surname></string-name>, <string-name><given-names>I. S.</given-names>
<surname>Georgiev</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Tsybovsky</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Prabhakaran</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Andersen</surname></string-name>, <string-name><given-names>W. P.</given-names>
<surname>Kong</surname></string-name>, <string-name><given-names>U.</given-names>
<surname>Baxa</surname></string-name>, <string-name><given-names>K. L.</given-names>
<surname>Zephir</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Ledgerwood</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Koup</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Kwong</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Harris</surname></string-name>, <string-name><given-names>A. B.</given-names>
<surname>McDermott</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Mascola</surname></string-name>, <string-name><given-names>B. S.</given-names>
<surname>Graham</surname></string-name></person-group>, 
<article-title>Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses</article-title>. <source>Nat. Immunol.</source>
<volume>20</volume>, 
<fpage>362</fpage>&#x2013;<lpage>372</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1038/s41590-018-0305-x</pub-id><pub-id pub-id-type="pmid">30742080</pub-id></mixed-citation>
      </ref>
      <ref id="R59">
        <label>59</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Marcandalli</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Fiala</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ols</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Perotti</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>de van der Schueren</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Snijder</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Hodge</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Benhaim</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Ravichandran</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Carter</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Sheffler</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Brunner</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Lawrenz</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Dubois</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Sallusto</surname></string-name>, <string-name><given-names>K. K.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name>, <string-name><given-names>C. E.</given-names>
<surname>Correnti</surname></string-name>, <string-name><given-names>L. J.</given-names>
<surname>Stewart</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Baker</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Lor&#xE9;</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Perez</surname></string-name>, <string-name><given-names>N. P.</given-names>
<surname>King</surname></string-name></person-group>, 
<article-title>Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus</article-title>. <source>Cell</source>
<volume>176</volume>, 
<fpage>1420</fpage>&#x2013;<lpage>1431.e17</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2019.01.046</pub-id><pub-id pub-id-type="pmid">30849373</pub-id></mixed-citation>
      </ref>
      <ref id="R60">
        <label>60</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>B. K.</given-names>
<surname>Sack</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Oyen</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Zenklusen</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Piccoli</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Barbieri</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Foglierini</surname></string-name>, <string-name><given-names>C. S.</given-names>
<surname>Fregni</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Marcandalli</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jongo</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Abdulla</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Perez</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Corradin</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Varani</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Sallusto</surname></string-name>, <string-name><given-names>B. K. L.</given-names>
<surname>Sim</surname></string-name>, <string-name><given-names>S. L.</given-names>
<surname>Hoffman</surname></string-name>, <string-name><given-names>S. H. I.</given-names>
<surname>Kappe</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Daubenberger</surname></string-name>, <string-name><given-names>I. A.</given-names>
<surname>Wilson</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name></person-group>, 
<article-title>A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein</article-title>. <source>Nat. Med.</source>
<volume>24</volume>, 
<fpage>401</fpage>&#x2013;<lpage>407</lpage> (<year>2018</year>). <pub-id pub-id-type="doi">10.1038/nm.4513</pub-id><pub-id pub-id-type="pmid">29554084</pub-id></mixed-citation>
      </ref>
      <ref id="R61" specific-use="online-only">
        <label>61</label>
        <mixed-citation publication-type="webpage">M. A. Tortorici, N. Czudnochowski, T. N. Starr, R. Marzi, A. C. Walls, F. Zatta, J. E. Bowen, S. Jaconi, J. di Iulio, Z. Wang, A. De Marco, S. K. Zepeda, D. Pinto, Z. Liu, M. Beltramello, I. Bartha, M. P. Housley, F. A. Lempp, L. E. Rosen, E. Dellota Jr., H. Kaiser, M. Montiel-Ruiz, J. Zhou, A. Addetia, B. Guarino, K. Culap, N. Sprugasci, C. Saliba, E. Vetti, I. Giacchetto-Sasselli, C. S. Fregni, R. Abdelnabi, S.-Y. C. Foo, C. Havenar-Daughton, M. A. Schmid, F. Benigni, E. Cameroni, J. Neyts, A. Telenti, G. Snell, H. W. Virgin, S. P. J. Whelan, J. D. Bloom, D. Corti, D. Veesler, M. S. Pizzuto, Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody. bioRxiv 2021.04.07.438818 [Preprint] (2021). .<pub-id pub-id-type="doi">10.1101/2021.04.07.438818</pub-id></mixed-citation>
      </ref>
      <ref id="R62">
        <label>62</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Lang</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Koerhuis</surname></string-name>, <string-name><given-names>G. J.</given-names>
<surname>Boons</surname></string-name>, <string-name><given-names>B. J.</given-names>
<surname>Bosch</surname></string-name>, <string-name><given-names>F. A.</given-names>
<surname>Rey</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>de Groot</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Structural basis for human coronavirus attachment to sialic acid receptors</article-title>. <source>Nat. Struct. Mol. Biol.</source>
<volume>26</volume>, 
<fpage>481</fpage>&#x2013;<lpage>489</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1038/s41594-019-0233-y</pub-id><pub-id pub-id-type="pmid">31160783</pub-id></mixed-citation>
      </ref>
      <ref id="R63">
        <label>63</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y. J.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>M. M.</given-names>
<surname>Sauer</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>B. J.</given-names>
<surname>Bosch</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>DiMaio</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors</article-title>. <source>Nat. Struct. Mol. Biol.</source>
<volume>26</volume>, 
<fpage>1151</fpage>&#x2013;<lpage>1157</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1038/s41594-019-0334-7</pub-id><pub-id pub-id-type="pmid">31792450</pub-id></mixed-citation>
      </ref>
      <ref id="R64">
        <label>64</label>
        <mixed-citation publication-type="webpage">T. N. Starr, N. Czudnochowski, F. Zatta, Y.-J. Park, Z. Liu, A. Addetia, D. Pinto, M. Beltramello, P. Hernandez, A. J. Greaney, R. Marzi, W. G. Glass, I. Zhang, A. S. Dingens, J. E. Bowen, J. A. Wojcechowskyj, A. De Marco, L. E. Rosen, J. Zhou, M. Montiel-Ruiz, H. Kaiser, H. Tucker, M. P. Housley, J. di Iulio, G. Lombardo, M. Agostini, N. Sprugasci, K. Culap, S. Jaconi, M. Meury, E. Dellota, E. Cameroni, T. I. Croll, J. C. Nix, C. Havenar-Daughton, A. Telenti, F. A. Lempp, M. S. Pizzuto, J. D. Chodera, C. M. Hebner, S. P. J. Whelan, H. W. Virgin, D. Veesler, D. Corti, J. D. Bloom, G. Snell, Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape. bioRxiv 2021.04.06.438709 [Preprint] (2021). .<pub-id pub-id-type="doi">10.1101/2021.04.06.438709</pub-id></mixed-citation>
      </ref>
      <ref id="R65">
        <label>65</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. M.</given-names>
<surname>Bolger</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Lohse</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Usadel</surname></string-name></person-group>, 
<article-title>Trimmomatic: A flexible trimmer for Illumina sequence data</article-title>. <source>Bioinformatics</source>
<volume>30</volume>, 
<fpage>2114</fpage>&#x2013;<lpage>2120</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id></mixed-citation>
      </ref>
      <ref id="R66">
        <label>66</label>
        <mixed-citation publication-type="webpage">H. Li, Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. <ext-link xlink:href="https://arxiv.org/abs/1303.3997" ext-link-type="uri">arXiv:1303.3997</ext-link> [q-bio.GN] (2013).</mixed-citation>
      </ref>
      <ref id="R67">
        <label>67</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Wilm</surname></string-name>, <string-name><given-names>P. P. K.</given-names>
<surname>Aw</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Bertrand</surname></string-name>, <string-name><given-names>G. H. T.</given-names>
<surname>Yeo</surname></string-name>, <string-name><given-names>S. H.</given-names>
<surname>Ong</surname></string-name>, <string-name><given-names>C. H.</given-names>
<surname>Wong</surname></string-name>, <string-name><given-names>C. C.</given-names>
<surname>Khor</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Petric</surname></string-name>, <string-name><given-names>M. L.</given-names>
<surname>Hibberd</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Nagarajan</surname></string-name></person-group>, 
<article-title>LoFreq: A sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets</article-title>. <source>Nucleic Acids Res.</source>
<volume>40</volume>, 
<fpage>11189</fpage>&#x2013;<lpage>11201</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1093/nar/gks918</pub-id><pub-id pub-id-type="pmid">23066108</pub-id></mixed-citation>
      </ref>
      <ref id="R68">
        <label>68</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Cingolani</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Platts</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Coon</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Nguyen</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Land</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Lu</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Ruden</surname></string-name></person-group>, 
<article-title>A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff</article-title>. <source>Fly</source>
<volume>6</volume>, 
<fpage>80</fpage>&#x2013;<lpage>92</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.4161/fly.19695</pub-id><pub-id pub-id-type="pmid">22728672</pub-id></mixed-citation>
      </ref>
      <ref id="R69">
        <label>69</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B. S.</given-names>
<surname>Pedersen</surname></string-name>, <string-name><given-names>A. R.</given-names>
<surname>Quinlan</surname></string-name></person-group>, 
<article-title>Mosdepth: Quick coverage calculation for genomes and exomes</article-title>. <source>Bioinformatics</source>
<volume>34</volume>, 
<fpage>867</fpage>&#x2013;<lpage>868</lpage> (<year>2018</year>). <pub-id pub-id-type="doi">10.1093/bioinformatics/btx699</pub-id><pub-id pub-id-type="pmid">29096012</pub-id></mixed-citation>
      </ref>
      <ref id="R70">
        <label>70</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Danecek</surname></string-name>, <string-name><given-names>J. K.</given-names>
<surname>Bonfield</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Liddle</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Marshall</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Ohan</surname></string-name>, <string-name><given-names>M. O.</given-names>
<surname>Pollard</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Whitwham</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Keane</surname></string-name>, <string-name><given-names>S. A.</given-names>
<surname>McCarthy</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Davies</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Li</surname></string-name></person-group>, 
<article-title>Twelve years of SAMtools and BCFtools</article-title>. <source>Gigascience</source>
<volume>10</volume>, 
<elocation-id>giab008</elocation-id> (<year>2021</year>). <pub-id pub-id-type="doi">10.1093/gigascience/giab008</pub-id><pub-id pub-id-type="pmid">33590861</pub-id></mixed-citation>
      </ref>
      <ref id="R71">
        <label>71</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Ewels</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Magnusson</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Lundin</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>K&#xE4;ller</surname></string-name></person-group>, 
<article-title>MultiQC: Summarize analysis results for multiple tools and samples in a single report</article-title>. <source>Bioinformatics</source>
<volume>32</volume>, 
<fpage>3047</fpage>&#x2013;<lpage>3048</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1093/bioinformatics/btw354</pub-id><pub-id pub-id-type="pmid">27312411</pub-id></mixed-citation>
      </ref>
      <ref id="R72">
        <label>72</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Di Tommaso</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Chatzou</surname></string-name>, <string-name><given-names>E. W.</given-names>
<surname>Floden</surname></string-name>, <string-name><given-names>P. P.</given-names>
<surname>Barja</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Palumbo</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Notredame</surname></string-name></person-group>, 
<article-title>Nextflow enables reproducible computational workflows</article-title>. <source>Nat. Biotechnol.</source>
<volume>35</volume>, 
<fpage>316</fpage>&#x2013;<lpage>319</lpage> (<year>2017</year>). <pub-id pub-id-type="doi">10.1038/nbt.3820</pub-id><pub-id pub-id-type="pmid">28398311</pub-id></mixed-citation>
      </ref>
      <ref id="R73">
        <label>73</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Gr&#xFC;ning</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Dale</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Sj&#xF6;din</surname></string-name>, <string-name><given-names>B. A.</given-names>
<surname>Chapman</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Rowe</surname></string-name>, <string-name><given-names>C. H.</given-names>
<surname>Tomkins-Tinch</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Valieris</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>K&#xF6;ster</surname></string-name>, <collab>Bioconda Team</collab></person-group>, 
<article-title>Bioconda: Sustainable and comprehensive software distribution for the life sciences</article-title>. <source>Nat. Methods</source>
<volume>15</volume>, 
<fpage>475</fpage>&#x2013;<lpage>476</lpage> (<year>2018</year>). <pub-id pub-id-type="doi">10.1038/s41592-018-0046-7</pub-id><pub-id pub-id-type="pmid">29967506</pub-id></mixed-citation>
      </ref>
      <ref id="R74">
        <label>74</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Emsley</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Lohkamp</surname></string-name>, <string-name><given-names>W. G.</given-names>
<surname>Scott</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Cowtan</surname></string-name></person-group>, 
<article-title>Features and development of <italic toggle="yes">Coot</italic></article-title>. <source>Acta Cryst.</source>
<volume>D66</volume>, 
<fpage>486</fpage>&#x2013;<lpage>501</lpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></mixed-citation>
      </ref>
      <ref id="R75">
        <label>75</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. I.</given-names>
<surname>Croll</surname></string-name></person-group>, 
<article-title><italic toggle="yes">ISOLDE</italic>: A physically realistic environment for model building into low-resolution electron-density maps</article-title>. <source>Acta Cryst.</source>
<volume>D74</volume>, 
<fpage>519</fpage>&#x2013;<lpage>530</lpage> (<year>2018</year>). <pub-id pub-id-type="doi">10.1107/S2059798318002425</pub-id><pub-id pub-id-type="pmid">29872003</pub-id></mixed-citation>
      </ref>
      <ref id="R76">
        <label>76</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G. N.</given-names>
<surname>Murshudov</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Skub&#xE1;k</surname></string-name>, <string-name><given-names>A. A.</given-names>
<surname>Lebedev</surname></string-name>, <string-name><given-names>N. S.</given-names>
<surname>Pannu</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Steiner</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Nicholls</surname></string-name>, <string-name><given-names>M. D.</given-names>
<surname>Winn</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Long</surname></string-name>, <string-name><given-names>A. A.</given-names>
<surname>Vagin</surname></string-name></person-group>, 
<article-title><italic toggle="yes">REFMAC5</italic> for the refinement of macromolecular crystal structures</article-title>. <source>Acta Cryst.</source>
<volume>D67</volume>, 
<fpage>355</fpage>&#x2013;<lpage>367</lpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1107/S0907444911001314</pub-id><pub-id pub-id-type="pmid">21460454</pub-id></mixed-citation>
      </ref>
      <ref id="R77">
        <label>77</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Liebschner</surname></string-name>, <string-name><given-names>P. V.</given-names>
<surname>Afonine</surname></string-name>, <string-name><given-names>M. L.</given-names>
<surname>Baker</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Bunk&#xF3;czi</surname></string-name>, <string-name><given-names>V. B.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>T. I.</given-names>
<surname>Croll</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Hintze</surname></string-name>, <string-name><given-names>L. W.</given-names>
<surname>Hung</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jain</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>McCoy</surname></string-name>, <string-name><given-names>N. W.</given-names>
<surname>Moriarty</surname></string-name>, <string-name><given-names>R. D.</given-names>
<surname>Oeffner</surname></string-name>, <string-name><given-names>B. K.</given-names>
<surname>Poon</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Prisant</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Read</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Richardson</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Richardson</surname></string-name>, <string-name><given-names>M. D.</given-names>
<surname>Sammito</surname></string-name>, <string-name><given-names>O. V.</given-names>
<surname>Sobolev</surname></string-name>, <string-name><given-names>D. H.</given-names>
<surname>Stockwell</surname></string-name>, <string-name><given-names>T. C.</given-names>
<surname>Terwilliger</surname></string-name>, <string-name><given-names>A. G.</given-names>
<surname>Urzhumtsev</surname></string-name>, <string-name><given-names>L. L.</given-names>
<surname>Videau</surname></string-name>, <string-name><given-names>C. J.</given-names>
<surname>Williams</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Adams</surname></string-name></person-group>, 
<article-title>Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in <italic toggle="yes">Phenix</italic></article-title>. <source>Acta Cryst.</source>
<volume>D75</volume>, 
<fpage>861</fpage>&#x2013;<lpage>877</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1107/S2059798319011471</pub-id><pub-id pub-id-type="pmid">31588918</pub-id></mixed-citation>
      </ref>
      <ref id="R78">
        <label>78</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Suloway</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Pulokas</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Fellmann</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Cheng</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Guerra</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Quispe</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Stagg</surname></string-name>, <string-name><given-names>C. S.</given-names>
<surname>Potter</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Carragher</surname></string-name></person-group>, 
<article-title>Automated molecular microscopy: The new Leginon system</article-title>. <source>J. Struct. Biol.</source>
<volume>151</volume>, 
<fpage>41</fpage>&#x2013;<lpage>60</lpage> (<year>2005</year>). <pub-id pub-id-type="doi">10.1016/j.jsb.2005.03.010</pub-id><pub-id pub-id-type="pmid">15890530</pub-id></mixed-citation>
      </ref>
      <ref id="R79">
        <label>79</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Tegunov</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Cramer</surname></string-name></person-group>, 
<article-title>Real-time cryo-electron microscopy data preprocessing with Warp</article-title>. <source>Nat. Methods</source>
<volume>16</volume>, 
<fpage>1146</fpage>&#x2013;<lpage>1152</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1038/s41592-019-0580-y</pub-id><pub-id pub-id-type="pmid">31591575</pub-id></mixed-citation>
      </ref>
      <ref id="R80">
        <label>80</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Punjani</surname></string-name>, <string-name><given-names>J. L.</given-names>
<surname>Rubinstein</surname></string-name>, <string-name><given-names>D. J.</given-names>
<surname>Fleet</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Brubaker</surname></string-name></person-group>, 
<article-title>cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination</article-title>. <source>Nat. Methods</source>
<volume>14</volume>, 
<fpage>290</fpage>&#x2013;<lpage>296</lpage> (<year>2017</year>). <pub-id pub-id-type="doi">10.1038/nmeth.4169</pub-id><pub-id pub-id-type="pmid">28165473</pub-id></mixed-citation>
      </ref>
      <ref id="R81">
        <label>81</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Zivanov</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Nakane</surname></string-name>, <string-name><given-names>S. H. W.</given-names>
<surname>Scheres</surname></string-name></person-group>, 
<article-title>A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis</article-title>. <source>IUCrJ</source>
<volume>6</volume>, 
<fpage>5</fpage>&#x2013;<lpage>17</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1107/S205225251801463X</pub-id><pub-id pub-id-type="pmid">30713699</pub-id></mixed-citation>
      </ref>
      <ref id="R82">
        <label>82</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>McMullan</surname></string-name>, <string-name><given-names>A. R.</given-names>
<surname>Faruqi</surname></string-name>, <string-name><given-names>G. N.</given-names>
<surname>Murshudov</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Short</surname></string-name>, <string-name><given-names>S. H.</given-names>
<surname>Scheres</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Henderson</surname></string-name></person-group>, 
<article-title>High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy</article-title>. <source>Ultramicroscopy</source>
<volume>135</volume>, 
<fpage>24</fpage>&#x2013;<lpage>35</lpage> (<year>2013</year>). <pub-id pub-id-type="doi">10.1016/j.ultramic.2013.06.004</pub-id><pub-id pub-id-type="pmid">23872039</pub-id></mixed-citation>
      </ref>
      <ref id="R83">
        <label>83</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E. F.</given-names>
<surname>Pettersen</surname></string-name>, <string-name><given-names>T. D.</given-names>
<surname>Goddard</surname></string-name>, <string-name><given-names>C. C.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>G. S.</given-names>
<surname>Couch</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Greenblatt</surname></string-name>, <string-name><given-names>E. C.</given-names>
<surname>Meng</surname></string-name>, <string-name><given-names>T. E.</given-names>
<surname>Ferrin</surname></string-name></person-group>, 
<article-title>UCSF Chimera&#x2014;A visualization system for exploratory research and analysis</article-title>. <source>J. Comput. Chem.</source>
<volume>25</volume>, 
<fpage>1605</fpage>&#x2013;<lpage>1612</lpage> (<year>2004</year>). <pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></mixed-citation>
      </ref>
      <ref id="R84">
        <label>84</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. J.</given-names>
<surname>Reed</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Muench</surname></string-name></person-group>, 
<article-title>A Simple Method of Estimating Fifty Per Cent Endpoints</article-title>. <source>Am. J. Epidemiol.</source>
<volume>27</volume>, 
<fpage>493</fpage>&#x2013;<lpage>497</lpage> (<year>1938</year>). <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a118408</pub-id></mixed-citation>
      </ref>
      <ref id="R85">
        <label>85</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Abdelnabi</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Boudewijns</surname></string-name>, <string-name><given-names>C. S.</given-names>
<surname>Foo</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Seldeslachts</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Sanchez-Felipe</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Delang</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Maes</surname></string-name>, <string-name><given-names>S. J. F.</given-names>
<surname>Kaptein</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Weynand</surname></string-name>, <string-name><given-names>G. V.</given-names>
<surname>Velde</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Neyts</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Dallmeier</surname></string-name></person-group>, 
<article-title>Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters</article-title>. <source>EBioMedicine</source>
<volume>68</volume>, 
<elocation-id>103403</elocation-id> (<year>2021</year>). <pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103403</pub-id><pub-id pub-id-type="pmid">34049240</pub-id></mixed-citation>
      </ref>
      <ref id="R86" specific-use="online-only">
        <label>86</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Foglierini</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Pappas</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Perez</surname></string-name></person-group>, 
<article-title>AncesTree: An interactive immunoglobulin lineage tree visualizer</article-title>. <source>PLOS Comput. Biol.</source>
<volume>16</volume>, 
<elocation-id>e1007731</elocation-id> (<year>2020</year>). <pub-id pub-id-type="doi">10.1371/journal.pcbi.1007731</pub-id><pub-id pub-id-type="pmid">32649725</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">6011</journal-id>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33429418</article-id>
      <article-id pub-id-type="pmc">7987233</article-id>
      <article-id pub-id-type="doi">10.1038/s41586-020-03148-w</article-id>
      <article-id pub-id-type="manuscript">NIHMS1656482</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Grant</surname>
            <given-names>Rogan A.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="FN1" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Morales-Nebreda</surname>
            <given-names>Luisa</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="FN1" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Markov</surname>
            <given-names>Nikolay S.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="FN1" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Swaminathan</surname>
            <given-names>Suchitra</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Querrey</surname>
            <given-names>Melissa</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guzman</surname>
            <given-names>Estefany R.</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abbott</surname>
            <given-names>Darryl A.</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Donnelly</surname>
            <given-names>Helen K.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Donayre</surname>
            <given-names>Alvaro</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goldberg</surname>
            <given-names>Isaac A.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Klug</surname>
            <given-names>Zasu M.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Borkowski</surname>
            <given-names>Nicole</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>Ziyan</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kihshen</surname>
            <given-names>Hermon</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Politanska</surname>
            <given-names>Yuliya</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sichizya</surname>
            <given-names>Lango</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kang</surname>
            <given-names>Mengjia</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shilatifard</surname>
            <given-names>Ali</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Qi</surname>
            <given-names>Chao</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lomasney</surname>
            <given-names>Jon W.</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Argento</surname>
            <given-names>A. Christine</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kruser</surname>
            <given-names>Jacqueline M.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Malsin</surname>
            <given-names>Elizabeth S.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pickens</surname>
            <given-names>Chiagozie O.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>Sean B.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Walter</surname>
            <given-names>James M.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pawlowski</surname>
            <given-names>Anna E.</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schneider</surname>
            <given-names>Daniel</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nannapaneni</surname>
            <given-names>Prasanth</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abdala-Valencia</surname>
            <given-names>Hiam</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bharat</surname>
            <given-names>Ankit</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gottardi</surname>
            <given-names>Cara J.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Budinger</surname>
            <given-names>GR Scott</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="CR1" ref-type="corresp">**</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Misharin</surname>
            <given-names>Alexander V.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A6">6</xref>
          <xref rid="CR1" ref-type="corresp">**</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Singer</surname>
            <given-names>Benjamin D.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A5">5</xref>
          <xref ref-type="aff" rid="A6">6</xref>
          <xref rid="CR1" ref-type="corresp">**</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wunderink</surname>
            <given-names>Richard G.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A6">6</xref>
          <xref rid="CR1" ref-type="corresp">**</xref>
        </contrib>
        <contrib contrib-type="author">
          <collab>The NU SCRIPT Study Investigators</collab>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University</aff>
      <aff id="A2"><label>2</label>Division of Rheumatology, Department of Medicine, Feinberg School of Medicine, Northwestern University</aff>
      <aff id="A3"><label>3</label>Robert H Lurie Comprehensive Cancer Research Center, Feinberg School of Medicine, Northwestern University</aff>
      <aff id="A4"><label>4</label>Division of Thoracic Surgery, Department of Surgery, Feinberg School of Medicine, Northwestern University</aff>
      <aff id="A5"><label>5</label>Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University</aff>
      <aff id="A6"><label>6</label>Simpson Querrey Institute for Epigenetics, Feinberg School of Medicine, Northwestern University</aff>
      <aff id="A7"><label>7</label>Department of Pathology, Feinberg School of Medicine, Northwestern University</aff>
      <aff id="A8"><label>8</label>Clinical and Translational Sciences Institute, Feinberg School of Medicine, Northwestern University</aff>
      <author-notes>
        <fn fn-type="equal" id="FN1">
          <label>*</label>
          <p id="P1">These authors contributed equally to this work and will list themselves first on their CVs.</p>
        </fn>
        <fn fn-type="con" id="FN2">
          <p id="P2">Consortia: The NU SCRIPT Study Investigators:</p>
          <p id="P3">Rogan A. Grant<sup>1</sup>, Luisa Morales-Nebreda<sup>1</sup>, Nikolay S. Markov<sup>1</sup>, Suchitra Swaminathan<sup>2,3</sup>, Melissa Querrey<sup>4</sup>, Estefany R. Guzman<sup>3</sup>, Darryl A. Abbott<sup>3</sup>, Helen K. Donnelly<sup>1</sup>, Alvaro Donayre<sup>1</sup>, Isaac A. Goldberg<sup>1</sup>, Zasu M. Klug<sup>1</sup>, Nicole Borkowski<sup>1</sup>, Ziyan Lu<sup>1</sup>, Hermon Kihshen<sup>1</sup>, Yuliya Politanska<sup>1</sup>, Lango Sichizya<sup>1</sup>, Mengjia Kang<sup>1</sup>, Ali Shilatifard<sup>5,6</sup>, Chao Qi<sup>7</sup>, Jon W. Lomasney<sup>7</sup>, A. Christine Argento<sup>1</sup>, Jacqueline M. Kruser<sup>1</sup>, Elizabeth S. Malsin<sup>1</sup>, Chiagozie O. Pickens<sup>1</sup>, Sean B. Smith<sup>1</sup>, James M. Walter<sup>1</sup>, Anna E. Pawlowski<sup>8</sup>, Daniel Schneider<sup>8</sup>, Prasanth Nannapaneni<sup>8</sup>, Hiam Abdala-Valencia<sup>1</sup>, Ankit Bharat<sup>1,4</sup>, Cara J. Gottardi<sup>1</sup>, GR Scott Budinger<sup>1</sup>, Alexander V. Misharin<sup>1,6</sup>, Benjamin D. Singer<sup>1,5,6</sup>, Richard G. Wunderink<sup>1,6</sup>, Ajay A. Wagh<sup>1</sup>, Alan R. Hauser<sup>9</sup>, Alexis Rose Wolfe<sup>1</sup>, Anjali Thakrar<sup>2</sup>, Anjana V. Yeldandi<sup>7</sup>, Ann A. Wang<sup>1</sup>, Anne R. Levenson<sup>1</sup>, Anthony M. Joudi<sup>1</sup>, Betty Tran<sup>1</sup>, Catherine A. Gao<sup>1</sup>, Chitaru Kurihara<sup>4</sup>, Clara J. Schroedl<sup>1</sup>, Curt M. Horvath<sup>9,10</sup>, Daniel Meza<sup>1</sup>, David D. Odell<sup>4</sup>, David W. Kamp<sup>1</sup>, Deborah R. Winter<sup>2</sup>, Egon A. Ozer<sup>9</sup>, Elisheva D. Shanes<sup>7</sup>, Elizabeth T. Bartom<sup>5,6</sup>, Emily J. Rendleman<sup>5</sup>, Emily M. Leibenguth<sup>1</sup>, Firas Wehbe<sup>8</sup>, Gabrielle Y. Liu<sup>1</sup>, Gaurav T. Gadhvi<sup>2</sup>, Heliodoro Tejedor Navarro<sup>11</sup>, Jacob I. Sznajder<sup>1</sup>, Jane E. Dematte<sup>1</sup>, Jasmine Le<sup>1</sup>, Jason M. Arnold<sup>1</sup>, Joanne C. Du<sup>1</sup>, John Coleman<sup>1</sup>, Joseph I. Bailey<sup>1</sup>, Joseph S. Deters<sup>1</sup>, Justin A. Fiala<sup>1</sup>, Justin Starren<sup>8</sup>, Karen M. Ridge<sup>1</sup>, Katharine Secunda<sup>1</sup>, Kathleen Aren<sup>2</sup>, Khalilah L. Gates<sup>1</sup>, Kristy Todd<sup>1</sup>, Lindsey D. Gradone<sup>1</sup>, Lindsey N. Textor<sup>1</sup>, Lisa F. Wolfe<sup>1</sup>, Lorenzo L. Pesce<sup>4</sup>, Lu&#xED;s A. Nunes Amaral<sup>11</sup>, Madeline L. Rosenbaum<sup>1</sup>, Manoj Kandpal<sup>8</sup>, Manu Jain<sup>1</sup>, Marc A. Sala<sup>1</sup>, Mark Saine<sup>4</sup>, Mary Carns<sup>2</sup>, Michael J. Alexander<sup>1</sup>, Michael J. Cuttica<sup>1</sup>, Michelle H. Prickett<sup>1</sup>, Nabiha H. Khan<sup>5</sup>, Navdeep S. Chandel<sup>1,6</sup>, Nicholas D. Soulakis<sup>8</sup>, Orlyn R. Rivas<sup>1</sup>, Patrick C. Seed<sup>12</sup>, Paul A. Reyfman<sup>1</sup>, Pearl D. Go<sup>8</sup>, Peter H. S. Sporn<sup>1</sup>, Phillip R. Cooper<sup>1</sup>, Rade Tomic<sup>1</sup>, Radhika Patel<sup>1</sup>, Rafael Garza-Castillon<sup>4</sup>, Ravi Kalhan<sup>1</sup>, Richard I. Morimoto<sup>10</sup>, Ruben J. Mylvaganam<sup>1</sup>, Samuel S. Kim<sup>4</sup>, Samuel W.M. Gatesy<sup>13</sup>, Sanket Thakkar<sup>4</sup>, Sarah Ben Maamar<sup>8</sup>, SeungHye Han<sup>1</sup>, Sharon R. Rosenberg<sup>1</sup>, Sophia Nozick<sup>9</sup>, Stefan J. Green<sup>14</sup>, Susan R. Russell<sup>1</sup>, Taylor A. Poor<sup>1</sup>, Taylor J. Zak<sup>7</sup>, Theresa A. Lombardo<sup>8</sup>, Thomas Stoeger<sup>11</sup>, Todd Shamaly<sup>8</sup>, Ziyou Ren<sup>1</sup>.</p>
          <p id="P4"><sup>9</sup> Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University</p>
          <p id="P5"><sup>10</sup> Department of Molecular Biosciences, Weinberg College of Art and Sciences, Northwestern University</p>
          <p id="P6"><sup>11</sup> Department of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University</p>
          <p id="P7"><sup>12</sup> Division of Pediatric Infectious Diseases, Stanley Manne Research Institute, Ann and Robert H. Lurie Children&#x2019;s Hospital</p>
          <p id="P8"><sup>13</sup> Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University</p>
          <p id="P9"><sup>14</sup> Genome Research Core, University of Illinois at Chicago.</p>
        </fn>
        <fn fn-type="con" id="FN5">
          <p id="P10">Authors contribution:</p>
          <p id="P11">G.R.S.B., A.V.M., B.D.S. and R.G.W. conceived and designed the project and provided funding. R.A.G., L.M.-N., N.S.M., G.R.S.B., A.V.M., B.D.S. and R.G.W. curated and analyzed the data and wrote the manuscript. C.O.P., J.M.K., J.M.W., B.D.S. and R.G.W. performed adjudication of clinical outcomes. A.D., H.K.D., I.A.G., N.B. and Z.M.K. recruited patients into the study and coordinated interactions between clinical and research teams. A.C.A., A.B., B.D.S., C.O.P., E.S.M., G.R.S.B., J.M.K., J.M.W., L.M.-N., R.G.W. and S.B.S. performed BAL procedures and sample collection. A.S. contributed equipment. C.Q. performed clinical microbiological assessment of BAL fluid. J.W.L. performed autopsies on patients who died from COVID-19 and provided biological materials. M.Q. performed RNAscope assay, imaging and analysis. A.E.P., D.S., M.K., P.N., performed programmatic extraction of clinical data and data curation. C.J.G. and E.S.M. coordinated and performed sample collection from healthy volunteers and provided biological materials. D.A.A., E.R.G., A.V.M. and S.S. processed BAL fluid samples and performed flow cytometry and cell sorting. D.A.A., H.K., L.S., R.A.G. and Z.L. performed post-sorting sample processing including RNA isolation for RNA-seq. B.D.S., A.V.M. and S.S. analyzed flow cytometry data. A.V.M. and Z.L. performed single-cell RNA-seq. H.A.-V. and Y.P. performed bulk RNA-seq. All authors provided edits and feedback on the manuscript.</p>
        </fn>
        <corresp id="CR1"><label>**</label>These corresponding authors jointly supervised this work and are listed in alphabetical order.</corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>28</day>
        <month>12</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>1</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>11</day>
        <month>7</month>
        <year>2021</year>
      </pub-date>
      <volume>590</volume>
      <issue>7847</issue>
      <fpage>635</fpage>
      <lpage>641</lpage>
      <!--elocation-id from pubmed: 10.1038/s41586-020-03148-w-->
      <permissions>
        <license>
          <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<uri xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
        </license>
      </permissions>
      <abstract id="ABS1">
        <p id="P12">Some patients infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) develop severe pneumonia and the acute respiratory distress syndrome (ARDS)<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. Distinct clinical features in these patients have led to speculation that the immune response to virus in the SARS-CoV-2-infected alveolus differs from other types of pneumonia<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. We collected bronchoalveolar lavage fluid samples from 88 patients with SARS-CoV-2-induced respiratory failure and 211 patients with known or suspected pneumonia from other pathogens and subjected them to flow cytometry and bulk transcriptomic profiling. We performed single-cell RNA-seq on 10 bronchoalveolar lavage fluid samples collected from patients with severe COVID-19 within 48 hours of intubation. In the majority of patients with SARS-CoV-2 infection, the alveolar space was persistently enriched in T cells and monocytes. Bulk and single-cell transcriptomic profiling suggested that SARS-CoV-2 infects alveolar macrophages, which in turn respond by producing T cell chemoattractants. These T cells produce interferon-gamma to induce inflammatory cytokine release from alveolar macrophages and further promote T cell activation. Collectively, our results suggest that SARS-CoV-2 causes a slowly-unfolding, spatially limited alveolitis in which alveolar macrophages harboring SARS-CoV-2 and T cells form a positive feedback loop that drives persistent alveolar inflammation.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p id="P13">A minority of patients infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) develop severe pneumonia requiring mechanical ventilation and these patients account for almost all of the morbidity and mortality associated with the infection<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R3" ref-type="bibr">3</xref>&#x2013;<xref rid="R5" ref-type="bibr">5</xref></sup>. The reported 20&#x2013;40% mortality among patients with severe SARS-CoV-2 pneumonia, combined with a severe systemic inflammatory response in some patients, have led to speculation that the pathobiology of SARS-CoV-2 pneumonia is distinct from pneumonia caused by other respiratory viral and bacterial pathogens<sup><xref rid="R2" ref-type="bibr">2</xref></sup>.</p>
    <p id="P14">We obtained bronchoalveolar lavage (BAL) samples from 88 patients with respiratory failure secondary to severe SARS-CoV-2 pneumonia and compared them with BAL samples prospectively collected before and during the pandemic from 211 patients with pneumonia secondary to other pathogens and 42 intubated patients without pneumonia. For many patients, we were able to obtain samples within 48 hours of intubation and sequentially over the course of the illness, allowing us to gain insights about the early pathogenesis and progression of COVID-19-induced respiratory failure. We profiled BAL samples using flow cytometry and performed bulk transcriptomic profiling of alveolar macrophages. Additionally, we performed single-cell RNA-sequencing on BAL fluid collected less than 48 hours after intubation from 10 patients with severe SARS-CoV-2 pneumonia. We used these data to develop a testable hypothesis to explain SARS-CoV-2 pathobiology (<xref rid="F1" ref-type="fig">Fig. 1a</xref>).</p>
    <sec disp-level="2" id="S1">
      <title>Demographics of the cohort:</title>
      <p id="P15">Samples were collected as part of the Successful Clinical Response in Pneumonia Therapy (SCRIPT) Systems Biology Center, an observational study of patients with severe pneumonia, defined as those requiring mechanical ventilation. We prospectively enrolled 88 of the 179 patients with SARS-CoV-2-induced pneumonia and respiratory failure requiring mechanical ventilation in our intensive care unit (ICU) (<xref rid="F1" ref-type="fig">Fig. 1b</xref>, <xref ref-type="fig" rid="F5">Extended Data Fig. 1a</xref>&#x2013;<xref ref-type="fig" rid="F5">c</xref>; <xref rid="T1" ref-type="table">Extended Data Table 1</xref>).</p>
      <p id="P16">We compared patients with COVID-19 with 253 mechanically ventilated patients enrolled in the two years before and during the pandemic. These included patients intubated for reasons other than pneumonia (non-pneumonia control), patients diagnosed with severe non-SARS-CoV-2 viral pneumonia (other viral pneumonia), or patients with severe pneumonia secondary to bacterial or fungal pathogens (other pneumonia). Compared with these patients, patients with SARS-CoV-2 pneumonia were similar in age, race, and sex, but had a significantly higher self-reported Hispanic or Latino ethnicity and body mass index (<xref rid="F1" ref-type="fig">Fig. 1c</xref>&#x2013;<xref rid="F1" ref-type="fig">f</xref>, <xref rid="T1" ref-type="table">Extended Data Table 1</xref>).</p>
      <p id="P17">Severity of illness estimated using the sequential organ failure assessment (SOFA) score and the acute physiology score (APS) was similar in patients with SARS-CoV-2 pneumonia compared with other pneumonia and was comparable to that observed in a recent study of ARDS<sup><xref rid="R6" ref-type="bibr">6</xref></sup> (<xref rid="F1" ref-type="fig">Fig. 1g</xref>,<xref rid="F1" ref-type="fig">h</xref>, <xref rid="T1" ref-type="table">Extended Data Table 1</xref>). Patients with severe SARS-CoV-2 pneumonia had longer lengths of stay in the ICU and required longer periods of ventilation compared with all pneumonia and non-pneumonia controls (<xref rid="F1" ref-type="fig">Fig. 1i</xref>,<xref rid="F1" ref-type="fig">j</xref>). On the day of their first BAL, patients with severe SARS-CoV-2 pneumonia had increased levels of C-reactive protein compared with patients with other pneumonias, while other biomarkers of inflammation were similar (<xref ref-type="fig" rid="F5">Extended Data Fig. 1d</xref>&#x2013;<xref ref-type="fig" rid="F5">i</xref>). The BAL sampling rate per day among patients with COVID-19 was not higher than the sampling rate among patients with other pneumonias (see <xref ref-type="fig" rid="F5">Extended Data Fig. 1j</xref>&#x2013;<xref ref-type="fig" rid="F5">l</xref>). Mortality was not different between patients with SARS-CoV-2 pneumonia compared with the entire cohort (<xref rid="F1" ref-type="fig">Fig. 1k</xref>).</p>
    </sec>
    <sec disp-level="2" id="S2">
      <title>BAL fluid composition in SARS-CoV-2 pneumonia.</title>
      <p id="P18">We began by performing flow cytometry on BAL samples collected within 48 hours of intubation (<xref rid="F2" ref-type="fig">Fig. 2a</xref>,<xref rid="F2" ref-type="fig">b</xref>, <xref ref-type="fig" rid="F6">Extended Data Fig. 2a</xref>&#x2013;<xref ref-type="fig" rid="F6">e</xref>). We found that, despite severe pneumonia requiring mechanical ventilation, only 31% of patients with severe COVID-19 exhibited neutrophilia in BAL fluid (<xref rid="F2" ref-type="fig">Fig. 2a</xref>,<xref rid="F2" ref-type="fig">b</xref>). Instead, we found that in patients with severe SARS-CoV-2 pneumonia, the alveolar space was significantly enriched for CD4+ and CD8+ T cells and monocytes (<xref rid="F2" ref-type="fig">Fig. 2a</xref>,<xref rid="F2" ref-type="fig">b</xref>, <xref ref-type="fig" rid="F7">Extended Data Fig. 3a</xref>).</p>
    </sec>
    <sec disp-level="2" id="S3">
      <title>Distinct macrophage response in COVID-19.</title>
      <p id="P19">As macrophages respond to alterations in their micro-environment<sup><xref rid="R7" ref-type="bibr">7</xref></sup>, we reasoned that changes in the alveolar macrophage transcriptome may reflect unique features of the SARS-CoV-2-infected alveolus. We isolated alveolar macrophages from BAL fluid collected within the first 48 hours after intubation from patients with severe SARS-CoV-2 pneumonia and compared them with alveolar macrophages from patients with pneumonia secondary to other pathogens, non-pneumonia controls, and healthy volunteers. k-means clustering of the 1,194 significantly variable genes (q &lt; 0.05, likelihood-ratio test) across diagnosis identified 5 clusters (<xref rid="F2" ref-type="fig">Fig. 2c</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplemental Data Files 1</xref>&#x2013;<xref rid="SD4" ref-type="supplementary-material">3</xref>). Notably, the majority of patients with COVID-19 clustered together. Cluster 1 contained genes specifically upregulated in patients with COVID-19 and was characterized by genes involved in the response to interferon (IFN). Cluster 1 also included genes encoding the chemokines <italic>CCL7</italic>, <italic>CCL8</italic>, and <italic>CCL13,</italic> which drive recruitment of monocytes and T cells.</p>
      <p id="P20">To detect viruses in alveolar macrophages we aligned RNA-seq reads to a hybrid genome including the human, SARS-CoV-2, and Influenza A/California/07/2009 reference genomes. An additional negative-strand SARS-CoV-2 transcript, which is transiently formed during its replication, was added to the SARS-CoV-2 genome to detect replicating virus<sup><xref rid="R8" ref-type="bibr">8</xref></sup>. We detected SARS-CoV-2 transcripts in alveolar macrophage transcriptomes from 67% of samples with PCR-confirmed SARS-CoV-2 infection. In 38% of these samples, we detected both positive- and negative-strand SARS-CoV-2 transcripts (<xref ref-type="fig" rid="F7">Extended Data Fig. 3b</xref>,<xref ref-type="fig" rid="F7">c</xref>).</p>
    </sec>
    <sec disp-level="2" id="S4">
      <title>SARS-CoV-2 pneumonia persists over time.</title>
      <p id="P21">Unlike other types of pneumonia, SARS-CoV-2 pneumonia is characterized by a long duration between symptom onset and the development of respiratory failure (6&#x2013;12 days) and a prolonged course of mechanical ventilation (<xref rid="F1" ref-type="fig">Fig. 1b</xref>,<xref rid="F1" ref-type="fig">i</xref>,<xref rid="F1" ref-type="fig">j</xref>)<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup>. To determine whether the unique cellular composition of the BAL fluid and the interferon response signature in alveolar macrophages persists over the course of the disease, we analyzed samples obtained early after intubation (&lt;48 hours) and all samples obtained &gt;48 hours after intubation. Hierarchical clustering of BAL samples from all time points from serially sampled patients as well as direct pairwise comparison of early (&lt;48 hours after intubation) versus late (&gt;48 hours after intubation) samples between groups demonstrated that, in comparison with BAL samples from other pneumonia, samples from patients with COVID-19 were persistently enriched for T cells (<xref rid="F3" ref-type="fig">Fig. 3a</xref>,<xref rid="F3" ref-type="fig">b</xref>; <xref ref-type="fig" rid="F8">Extended Data Fig. 4a</xref>,<xref ref-type="fig" rid="F8">b</xref>). These findings persisted in the 40% of patients with severe SARS-CoV-2 pneumonia who had a superinfecting pathogen detected over the course of mechanical ventilation (<xref rid="T2" ref-type="table">Extended Data Table 2</xref>). Nevertheless, BAL fluid neutrophils were increased in samples collected after 48 hours of mechanical ventilation in patients with COVID-19, likely attributable to the duration of mechanical ventilation and the attendant risk of bacterial superinfection (<xref ref-type="fig" rid="F8">Extended Data Fig. 4c</xref>).</p>
      <p id="P22">We then performed RNA-seq on alveolar macrophages isolated early (&lt;48 hours) and later over the course of mechanical ventilation. k-means clustering of the 2,323 significantly variable genes (q &lt; 0.05, likelihood-ratio test) across diagnoses identified five clusters (<xref rid="F3" ref-type="fig">Fig. 3c</xref>; <xref ref-type="fig" rid="F9">Extended Data Fig. 5a</xref>; <xref rid="SD2" ref-type="supplementary-material">Supplemental Data Files 1</xref>&#x2013;<xref rid="SD4" ref-type="supplementary-material">3</xref>). Of note, genes and related GO biological processes associated with these clusters were remarkably similar to those identified in samples collected within 48 hours after intubation (<xref rid="F2" ref-type="fig">Fig. 2c</xref>). Specifically, samples from patients with COVID-19 continued to cluster together and were differentiated by increased expression of genes in Cluster 1, which was enriched for interferon-response genes and T cell chemokines (<xref rid="F3" ref-type="fig">Fig. 3c</xref>, <xref ref-type="fig" rid="F9">Extended Data Fig. 5a</xref>,<xref ref-type="fig" rid="F9">b</xref>).</p>
      <p id="P23">In order to identify gene modules in alveolar macrophages that distinguish pneumonia type and outcome, we performed weighted gene co-expression network analysis (WGCNA) (<xref ref-type="fig" rid="F9">Extended Data Fig. 5c</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplemental Data File 1</xref>). Module 15 was enriched for interferon-responsive genes and correlated with the detection of SARS-CoV-2 transcripts, levels of C-reactive protein, CD8+ T cell abundance, and COVID-19 diagnosis (R = 0.28, 0.30, 0.28, 0.25, respectively). Notably, all SARS-CoV-2 genes included in this analysis were assigned to this module, further underscoring the relevance of the disease diagnosis category. Consistent with the results of k-means clustering, module 15 was enriched for type I and type II interferon response genes (GO:0060337, GO:0060333). We observed a significant negative correlation between interferon signaling and the duration of mechanical ventilation (<xref ref-type="fig" rid="F9">Extended Data Fig. 5d</xref>&#x2013;<xref ref-type="fig" rid="F9">f</xref>). In addition, we identified modules related to macrophage maturation, including Module 4, which exhibited a positive correlation with the percentage of CD206<sup>hi</sup> alveolar macrophages (R = 0.61), and Module 12, which exhibited a negative correlation with percentage of CD206<sup>hi</sup> macrophages (R = &#x2212;0.62) (<xref ref-type="fig" rid="F9">Extended Data Fig. 5c</xref>). The unique features of SARS-CoV-2 pneumonia are further illustrated by a UMAP projection of all bulk RNA-seq samples, which separated largely by diagnosis, module 15 gene expression, and abundance of T cells (<xref ref-type="fig" rid="F9">Extended Data Fig. 5g</xref>).</p>
      <p id="P24">We took advantage of the serial samples collected from the same patients with COVID-19 and explored the relationship between expression of canonical interferon-response genes and patient outcomes. Analysis of the serial samples from patients with COVID-19 who were discharged home (5 patients) or to an inpatient facility (2 patients) demonstrated decreased expression of interferon-response genes as the disease progressed, while in patients who were discharged to a long-term acute care facility (LTAC, 5 patients) or died (2 patients) the expression of interferon-response genes was largely unchanged (<xref ref-type="fig" rid="F9">Extended Data Fig. 5h</xref>). Consistent with these findings, we observed a significant negative correlation between abundance of SARS-CoV-2 transcripts in patients with confirmed COVID-19 and the time since intubation (&#x3C1; = &#x2212;0.49, Spearman correlation; <xref ref-type="fig" rid="F9">Extended Data Fig. 5i</xref>).</p>
    </sec>
    <sec disp-level="2" id="S5">
      <title>Immune cell circuits in SARS-CoV-2 pneumonia.</title>
      <p id="P25">We performed single-cell RNA-seq on 10 patients with COVID-19 from whom BAL samples were collected within 48 hours of intubation (<xref rid="F4" ref-type="fig">Fig. 4a</xref>, <xref ref-type="fig" rid="F10">Extended Data Fig. 6a</xref>&#x2013;<xref ref-type="fig" rid="F10">d</xref>). We included two additional patients, one with bacterial pneumonia and one non-pneumonia control (<xref ref-type="fig" rid="F10">Extended Data Fig. 6e</xref>&#x2013;<xref ref-type="fig" rid="F10">h</xref>). Analysis of an integrated object resolved multiple clusters corresponding to macrophages and other cell types (<xref rid="SD5" ref-type="supplementary-material">Supplemental Data File 4</xref>). Alveolar macrophages contained six clusters. Four clusters of monocyte-derived alveolar macrophages (MoAM) were characterized by <italic>CCL2</italic> expression and gradually increasing expression of genes associated with alveolar macrophage maturation. The other two clusters expressed markers of tissue-resident alveolar macrophages (TRAM) (<xref rid="F4" ref-type="fig">Fig. 4b</xref>, <xref ref-type="fig" rid="F10">Extended Data Fig. 6a</xref>). We did not detect expression of type I interferons in our single-cell dataset or in other publicly available single-cell RNA-seq datasets<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> obtained from BAL fluid later in the clinical course of patients with COVID-19 (data not shown). In contrast, expression of type II interferon (<italic>IFNG</italic>) was detected in T cells from all 10 patients with COVID-19 (<xref rid="F4" ref-type="fig">Fig. 4c</xref>, <xref ref-type="fig" rid="F10">Extended Data Fig. 6b</xref>). These results suggest that the interferon-response gene signature we observed in alveolar macrophages may be in response to IFN&#x3B3; released from activated T cells.</p>
      <p id="P26">As expected, positive- and negative-strand SARS-CoV-2 transcripts were detected in epithelial cells. Surprisingly, we also detected SARS-CoV-2 transcripts in migratory <italic>CCR7</italic>+ dendritic cells, MoAM2 and TRAM2, which do not express <italic>ACE2</italic> (<xref rid="F4" ref-type="fig">Fig. 4d</xref>, <xref ref-type="fig" rid="F10">Extended Data Fig. 6c</xref>). Coronaviruses generate large numbers of positive-strand transcripts from a single negative-strand template<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R11" ref-type="bibr">11</xref></sup>. Consistent with this known biology, we detected more transcripts for positive compared with negative strands in both our single-cell and bulk RNA-seq data (<xref ref-type="fig" rid="F7">Extended Data Fig. 3c</xref>, <xref ref-type="fig" rid="F10">Extended Data Fig. 6d</xref> and <xref rid="F4" ref-type="fig">Fig. 4d</xref>). These results suggest that alveolar macrophages harbor SARS-CoV-2 and that they may support viral replication as has been reported for SARS-CoV and MERS-CoV<sup><xref rid="R12" ref-type="bibr">12</xref>&#x2013;<xref rid="R14" ref-type="bibr">14</xref></sup>.</p>
      <p id="P27">TRAM2 harboring SARS-CoV-2 exhibited a distinct transcriptional program compared with uninfected TRAM1 (<xref rid="F4" ref-type="fig">Fig. 4b</xref>,<xref rid="F4" ref-type="fig">h</xref>, <xref ref-type="fig" rid="F10">Extended Data Fig. 6g</xref>,<xref ref-type="fig" rid="F10">h</xref>, <xref rid="SD6" ref-type="supplementary-material">Supplemental Data File 5</xref>). In patients with COVID-19, genes distinguishing infected TRAM2 from non-infected TRAM1 included several chemokines and cytokines important for T cell and monocyte recruitment, such as <italic>CCL4, CCL20</italic>, <italic>CXCL10</italic> and <italic>CXCL11.</italic> TRAM2 also expressed genes <italic>IL1B, TNFSF10</italic>, and <italic>DEFB1</italic> (<xref rid="F4" ref-type="fig">Fig. 4b</xref>,<xref rid="F4" ref-type="fig">e</xref>&#x2013;<xref rid="F4" ref-type="fig">h</xref>, <xref rid="SD7" ref-type="supplementary-material">Supplemental Data File 6</xref>). Finally, infected TRAM2 were marked by increased expression of interferon-response genes compared with non-infected TRAM1 (<xref rid="F4" ref-type="fig">Fig. 4b</xref>,<xref rid="F4" ref-type="fig">h</xref>).</p>
      <p id="P28">IL-6 induces the transcription of clotting factors in the liver and tissue factor in the endothelium to promote thrombosis, and elevated levels of IL-6 predict mortality in patients with COVID-19<sup><xref rid="R15" ref-type="bibr">15</xref>&#x2013;<xref rid="R17" ref-type="bibr">17</xref></sup>. Because single-cell RNA-seq analyses of peripheral blood from patients with COVID-19 failed to identify circulating cells producing IL-6<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup>, some have suggested that IL-6 is produced by inflammatory cells in the alveolus<sup><xref rid="R17" ref-type="bibr">17</xref></sup>. In our dataset, the overall expression of <italic>IL6</italic> was low and was primarily restricted to very immature MoAM1 originating from two patients (<xref ref-type="fig" rid="F11">Extended Data Fig. 7a</xref>). Furthermore, the expression of <italic>IL6</italic> in BAL fluid cells from patients with COVID-19 was comparable to previously reported <italic>IL6</italic> expression in alveolar macrophages from patients with later-stage COVID-19<sup><xref rid="R9" ref-type="bibr">9</xref></sup> and lower than <italic>IL6</italic> expression observed in stromal and endothelial cells from a published single-cell RNA-seq dataset describing the healthy or fibrotic lung<sup><xref rid="R20" ref-type="bibr">20</xref></sup>. Consistently, in our bulk RNA-seq data from flow cytometry-sorted alveolar macrophages, <italic>IL6</italic> expression was not different between patients with pneumonia secondary to SARS-CoV-2 compared with other respiratory pathogens, although it was higher than in healthy controls, in whom <italic>IL6</italic> transcripts were never detected (<xref ref-type="fig" rid="F9">Extended Data Fig. 5b</xref>). While we did not sample neutrophils, Liao et al. and Chua et al. did not detect increased neutrophil <italic>IL6</italic> expression in their single-cell RNA-seq datasets of BAL fluid from patients with SARS-CoV-2 pneumonia<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup>.</p>
      <p id="P29">In murine models of influenza A viral pneumonia, IFN&#x3B3; drives apoptosis of tissue-resident alveolar macrophages<sup><xref rid="R21" ref-type="bibr">21</xref></sup>. We therefore wondered whether the CD206<sup>hi</sup> alveolar macrophages in patients with severe SARS-CoV-2 pneumonia were truly tissue-resident alveolar macrophages or maturing monocyte-derived alveolar macrophages. We performed cell-type deconvolution of our bulk RNA-seq data and found that in patients with SARS-CoV-2 pneumonia only a small fraction of alveolar macrophages were tissue-resident alveolar macrophages. Instead, the majority of alveolar macrophages were monocyte-derived alveolar macrophages (MoAM3) (<xref ref-type="fig" rid="F11">Extended Data Fig. 7b</xref>,<xref ref-type="fig" rid="F11">c</xref>).</p>
      <p id="P30">The BAL procedure samples cells from a lung segment, which includes many thousands of alveoli. Therefore, the detection of infected and non-infected alveolar macrophages in the same BAL fluid sample in our single cell RNA-seq data suggests infected and uninfected alveoli will co-exist within a single lung segment. To test this prediction, we examined lung tissue from a patient who died from SARS-CoV-2 pneumonia while forgoing treatments, save comfort measures. Using smFISH we detected positive- and negative-strand SARS-CoV-2 transcripts in the lung epithelium and alveolar macrophages (<xref rid="F4" ref-type="fig">Fig. 4i</xref> and <xref rid="SD10" ref-type="supplementary-material">Supplemental Data File 7</xref>, <xref rid="SD12" ref-type="supplementary-material">Supplemental Data Video 1</xref>). Positive-strand SARS-CoV-2 transcripts exhibited diffuse cytoplasmic staining, and the number of punctae exceeded that of negative transcripts. As predicted from our model of lung infection, cells containing SARS-CoV-2 transcripts were also detected in a spatially-restricted manner, as regions of the lung containing the virus were adjacent to the regions with nearly-normal architecture where viral particles were absent.</p>
    </sec>
    <sec id="S6">
      <title>Discussion:</title>
      <p id="P31">A minority of patients with severe SARS-CoV-2 pneumonia develop respiratory failure, but it is these patients who account for almost all of the morbidity, mortality, and socioeconomic cost associated with the COVID-19 pandemic. We systematically sampled the alveolar space in patients with new-onset respiratory failure secondary to SARS-CoV-2 pneumonia and compared these samples with those from a large comparison cohort of patients with pneumonia from other respiratory pathogens collected before and during the pandemic. We used these data to develop a model for the unique pathobiology of SARS-CoV-2 pneumonia (<xref rid="F1" ref-type="fig">Fig. 1a</xref>). Our model proposes that SARS-CoV-2 initially infects and replicates in epithelial cells in the nasopharynx, which express relatively high levels of <italic>ACE2</italic> in comparison with epithelial cells in lower airways or the distal lung<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>. Whether by progressive movement distally in the tracheobronchial tree or via aspiration of nasopharyngeal contents, some virus gains access to the distal alveolar space. In the alveolar space, SARS-CoV-2 infects alveolar epithelial cells and tissue-resident alveolar macrophages<sup><xref rid="R24" ref-type="bibr">24</xref></sup>. A transcriptional program is activated within infected tissue-resident alveolar macrophages that promotes the recruitment of memory T cells to the alveolar space. There, memory T cells become activated, releasing IFN&#x3B3;, which activates tissue-resident alveolar macrophages harboring SARS-CoV-2. Eventually, these tissue-resident alveolar macrophages die and monocyte-derived alveolar macrophages are recruited, which in turn become infected with SARS-CoV-2 to sustain the inflammatory signaling loop with T cells. These infected alveolar macrophages may act as a Trojan horse, transferring the virus to adjacent lung regions, slowly propagating SARS-CoV-2 infection across the lung.</p>
      <p id="P32">Our model is informed by a wealth of causal data generated in cell and animal models of SARS-CoV-2 and the related coronaviruses SARS-CoV and MERS-CoV. SARS-CoV-2 proteins have been shown to suppress type I interferon responses<sup><xref rid="R24" ref-type="bibr">24</xref>&#x2013;<xref rid="R26" ref-type="bibr">26</xref></sup>, and we did not detect ongoing expression of type I interferons in our bulk or single-cell RNA-seq data<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup>. Our data suggesting that SARS-CoV-2 replicates in alveolar macrophages are consistent with reports that SARS-CoV, MERS-CoV, and SARS-CoV-2 can infect macrophages <italic>in vitro</italic><sup><xref rid="R12" ref-type="bibr">12</xref>&#x2013;<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup>, and the detection of SARS-CoV-2 in alveolar macrophages in autopsy studies of patients with SARS-CoV-2 pneumonia<sup><xref rid="R29" ref-type="bibr">29</xref></sup>.</p>
      <p id="P33">Alveolar macrophage infection might result from phagocytosis of infected alveolar epithelial cells followed by viral escape from the lysosome. Alternatively, alveolar macrophages might be directly infected, as was shown for SARS-CoV and MERS-CoV<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup>. Finally, antibody-dependent enhancement has been suggested from cell and animal models of SARS-CoV and MERS-CoV infection<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup>.</p>
      <p id="P34">Activation of memory T cells leads to IFN&#x3B3; production, local proliferation of activated memory T cells, mounting of inflammatory responses, and recruitment of monocytes and T cells. We observed enrichment of CD4+ and CD8+ T cells in the alveolar space of patients with SARS-CoV-2 pneumonia relative to pneumonia secondary to other pathogens. Furthermore, our single-cell RNA-seq data confirmed production of IFN&#x3B3; by both CD4+ and CD8+ T cells. These results raise the question of how T cells in the alveolar space become activated following SARS-CoV-2 infection. While tissue-resident alveolar macrophages are poor antigen-presenting cells and do not convert na&#xEF;ve T cells into effector T cells<sup><xref rid="R32" ref-type="bibr">32</xref></sup>, a low level of antigen presentation by alveolar macrophages might be sufficient to activate pre-existing memory T cells that cross-react with SARS-CoV-2. Existence of such cross-reactive memory T cells has been reported for SARS-CoV<sup><xref rid="R33" ref-type="bibr">33</xref></sup> and for SARS-CoV-2<sup><xref rid="R34" ref-type="bibr">34</xref>&#x2013;<xref rid="R38" ref-type="bibr">38</xref></sup>. A larger number of SARS-CoV-2 cross-reactive memory T cells was observed independently in elderly people and in patients with severe COVID-19, compared with those with mild COVID-19<sup><xref rid="R38" ref-type="bibr">38</xref></sup>. These cross-reactive T cells exhibited lower avidity and reduced antiviral responses in response to stimulation with SARS-CoV-2 peptides compared with T cells from patients who recovered from COVID-19. This mechanism might explain the epidemiology of severe SARS-CoV-2 pneumonia, which disproportionately affects elderly individuals.</p>
      <p id="P35">Single-cell RNA-seq atlases and smFISH studies of the normal human lung show that only a small number of alveolar epithelial cells express <italic>ACE2</italic>, the gene encoding the receptor for SARS-CoV-2 entry<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>. In contrast, the sialic acid residues that serve as receptors for influenza A virus are abundantly expressed in alveolar type 2 cells<sup><xref rid="R22" ref-type="bibr">22</xref></sup>. Thus, while influenza A infects large numbers of cells leading to rapid viral replication, widespread injury, robust antiviral responses, and death of infected epithelial cells, infection by SARS-CoV-2 is likely to lead to spatially localized areas of infection. This could explain the localized areas of ground glass infiltrates observed in chest computed tomography in minimally symptomatic patients with COVID-19<sup><xref rid="R39" ref-type="bibr">39</xref></sup>. We speculate that alveolar macrophages harboring SARS-CoV-2 might spread virus between alveoli. For example, tissue-resident alveolar macrophages, once thought to be sessile, were recently shown to travel between alveoli through pores of Kohn, particularly during viral infection<sup><xref rid="R40" ref-type="bibr">40</xref></sup>. In each new area of infection, positive feedback loops between alveolar macrophages harboring the virus and activated T cells could promote persistent injury and inflammation.</p>
      <p id="P36">Our model of SARS-CoV-2 pneumonia as a slowly-progressive, spatially-restricted infection explains some of the unusual clinical features of COVID-19. Most notably, the clinical course of severe SARS-CoV-2 pneumonia is much longer than that of other respiratory viruses. The time from the onset of symptoms to respiratory failure in patients with SARS-CoV-2 infection is 6&#x2013;12 days, compared with 1&#x2013;3 days or even less in patients with influenza A virus infection<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R41" ref-type="bibr">41</xref></sup>. Furthermore, in our cohort the duration of mechanical ventilation and ICU stay were much longer in patients with severe SARS-CoV-2 pneumonia, compared with other respiratory pathogens causing pneumonia, despite a similar severity of illness and mortality. This longer clinical course might also explain some of the systemic complications of the disease. Although sparsely sampled, the levels of inflammatory biomarkers in the blood were similar in patients with COVID-19 and those with other etiologies of pneumonia in our cohort, confirming more recent systematic reports<sup><xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup>. This observation raises the intriguing possibility that the increased number of systemic complications observed in patients with SARS-CoV-2 pneumonia are related to prolonged, rather than higher level, exposure to circulating inflammatory cytokines.</p>
      <p id="P37">In summary, we present a dataset that supports a testable model, in which alveolar macrophages harboring SARS-CoV-2 form positive feedback loops with IFN&#x3B3;-secreting T cells to promote alveolitis in patients with severe COVID-19.</p>
    </sec>
    <sec id="S7">
      <title>Methods:</title>
      <sec id="S8">
        <title>Human subjects:</title>
        <p id="P38">All human subjects research was approved by the Northwestern University Institutional Review Board. Samples from patients with COVID-19, viral pneumonia, other pneumonia, and non-pneumonia controls were collected from participants enrolled in the Successful Clinical Response In Pneumonia Therapy (SCRIPT) study STU00204868. Alveolar macrophages from healthy volunteers were obtained under study STU00206783. Autopsy tissues were obtained per usual protocols and analyzed under study STU00079445. All study participants or their surrogates provided informed consent.</p>
        <p id="P39">Patients &#x2265; 18 years of age with suspicion of pneumonia based on clinical criteria (including but not limited to fever, radiographic infiltrate, and respiratory secretions) were screened for enrollment into the SCRIPT study. Inability to safely perform BAL or NBBAL were considered exclusion criteria<sup><xref ref-type="supplementary-material" rid="SD13">44</xref></sup>. In our center, patients with respiratory failure are intubated based on the judgement of bedside clinicians for worsening hypoxemia, hypercapnia, or work of breathing refractory to high-flow oxygen or non-invasive ventilation modes. Extubation occurs based on the judgement of bedside clinicians following a protocol-driven trial of spontaneous breathing in patients demonstrating physiologic improvement in their cardiorespiratory status during their period of mechanical ventilation.</p>
        <p id="P40">We collected data and samples from patients enrolled in SCRIPT from June 15, 2018 to July 6, 2020 in our intensive care unit (ICU) at Northwestern Memorial Hospital in Chicago. We prospectively enrolled 88 of the 179 patients with SARS-CoV-2-induced pneumonia and respiratory failure requiring mechanical ventilation in our intensive care unit (<xref rid="F1" ref-type="fig">Fig. 1b</xref>, <xref rid="F5" ref-type="fig">Extended Data Fig. 1a</xref>, <xref rid="F5" ref-type="fig">b</xref>; <xref rid="T1" ref-type="table">Extended Data Table 1</xref>), all but one of whom had been discharged at the time of our submission. Management of patients with COVID-19 was guided by protocols published and updated on the Northwestern Medicine intranet as new information became available over the pandemic. Clinical laboratory testing including studies ordered on BAL fluid was at the discretion of the care team; however, quantitative cultures, multiplex PCR (BioFire Film Array Respiratory 2 panel), and automated cell count and differential were recommended by local ICU protocols. Most patients also underwent urinary antigen testing for <italic>Streptococcus pneumoniae</italic> and <italic>Legionella pneumophilia</italic> serogroup 1 on admission. Clinicians were encouraged to manage all patients, including those with COVID-19, according to ARDSNetwork protocols including the use of a higher PEEP/lower FiO<sub>2</sub> strategy for those with severe hypoxemia<sup><xref ref-type="supplementary-material" rid="SD13">45</xref>, <xref ref-type="supplementary-material" rid="SD13">46</xref></sup>. Prone positioning (16 hours per day) was performed in all patients with a PaO<sub>2</sub>/FiO<sub>2</sub> &lt;150 who did not have contraindications<sup><xref ref-type="supplementary-material" rid="SD13">47</xref></sup>. In those who had a response to prone positioning evidenced by improved oxygenation, prone positioning was repeated. Esophageal balloon catheters (Cooper Surgical) were placed at the discretion of the care team to estimate transpulmonary pressure and optimize PEEP, particularly in patients with a higher-than-normal BMI.</p>
        <p id="P41">Autopsy specimen used for sm-FISH (RNAscope) (<xref rid="F4" ref-type="fig">Fig. 4i</xref>): An 81-year old woman with end-stage renal disease and cirrhosis was admitted for a fever of 38.5&#xB0;C. She had a positive nasopharyngeal swab for SARS-CoV-2. The patient developed increased O<sub>2</sub> requirements and was subsequently transferred to the COVID ICU. In the ICU, the decedent developed hypotension to 60s/40s and after discussion with the clinical team, the decedent&#x2019;s family elected to focus on comfort care. The patient died 8 days after admission.</p>
      </sec>
      <sec id="S9">
        <title>NBBAL and BAL procedures:</title>
        <p id="P42">Consent was obtained from patients or their surrogates for bronchoscopic procedures. Bronchoscopic BAL was performed in intubated ICU patients with flexible, single-use Ambu aScope (Ambu) devices. Patients were given sedation and topical anesthetic at the physician proceduralist&#x2019;s discretion. Vital signs were monitored continuously throughout the procedure. The bronchoscope was wedged in the segment of interest based on available chest imaging or intra-procedure observations, aliquots of 30 ml of normal saline at a time, generally 90&#x2013;120 ml total, were instilled and aspirated back. The fluid returned following the first aliquot was routinely discarded. Samples were split (if sufficient return volume was available) and sent for clinical studies and an aliquot reserved for research. A similar procedure was applied to non-bronchoscopic BAL (NBBAL); however, NBBAL was performed with directional (lateral) but not visual guidance, and as usual procedural care by a respiratory therapist rather than a pulmonologist<sup><xref ref-type="supplementary-material" rid="SD13">44</xref></sup>.</p>
        <p id="P43">For bronchoscopies performed in COVID-19 patients, additional precautions were taken to minimize the risk to healthcare workers including only having essential providers present in the room, clamping of the endotracheal tube, transient disconnection of the inspiratory limb from the ventilator, and preloading of the bronchoscope through the adapter<sup><xref ref-type="supplementary-material" rid="SD13">48</xref></sup>. Sedation and neuromuscular blockade to prevent cough, was administered for these procedures at the physician&#x2019;s discretion. In most cases of early bronchoscopy, the procedure was performed immediately after intubation, taking advantage of neuromuscular blockade administered for the intubation procedure.</p>
        <p id="P44">For all patients with COVID-19, samples were collected from regions of greatest chest radiograph abnormality by a critical care physician using a disposable bronchoscope. The majority of samples prior to the pandemic were collected by respiratory therapists using a non-bronchoscopic bronchoalveolar lavage (NBBAL) catheter that is the same diameter as a standard bronchoscope with the catheter directed to the most radiographically affected lung. For both bronchoscopic and NBBAL, the recommended instillate volume was 120 ml and the initial aliquot was discarded if adequate return was obtained<sup><xref ref-type="supplementary-material" rid="SD13">44</xref></sup>.</p>
      </sec>
      <sec id="S10">
        <title>Pneumonia adjudication:</title>
        <p id="P45">Five critical care physicians (JMK, COP, BDS, JMW, RGW) retrospectively adjudicated patients as COVID-19 pneumonia, non-COVID-19 viral pneumonia, pneumonia secondary to other pathogens, or non-pneumonia controls (intubated for reasons other than pneumonia), according to a standardized adjudication procedure (the adjudication protocol can be found in <xref rid="SD8" ref-type="supplementary-material">Supplemental Data File 8</xref>). Non-pneumonia controls were defined as patients who underwent BAL to exclude pneumonia but had negative quantitative cultures, a negative multiplex PCR for viral and bacterial pathogens (when available) and negative urine antigens for <italic>Streptococcus pneumoniae</italic> and <italic>Legionella pneumophilia</italic> serogroup 1, as well as an alternative diagnosis. The treating clinician&#x2019;s impression was considered, but concordance was not required. Subsequent course and the entirety of the clinical record was used for adjudication. Some of the patients adjudicated as non-pneumonia controls developed ventilator-associated pneumonia later in their clinical course. Viral pneumonia was diagnosed based on detection of a respiratory viral pathogen from either a nasopharyngeal swab or BAL fluid in the appropriate clinical setting. Bacterial pneumonia was defined as positive quantitative cultures with &gt; 10^2 colony forming units/ml, detection of a bacterial pathogen by PCR analysis of BAL fluid or a positive urine antigen. Over the course of the study, BAL fluid was analyzed using an MRSA PCR (MRSA/SA SSTI) and the BioFire FilmArray Respiratory 2 (RP2) Panel and Pneumonia panels. SARS-CoV-2 was detected with a variety of assay platforms including the Cepheid Gene Expert, Abbott ID NOW, Becton-Dickinson, and a locally-developed and validated PCR. For some patients without COVID-19, the diagnosis of pneumonia was made based on clinical suspicion, radiographic findings, and response to antimicrobial therapy in the absence of an identified pathogen. Ventilator-associated pneumonia was diagnosed as detection of a new respiratory pathogen using quantitative culture or PCR more than 48 hours after intubation, the detection of a new respiratory pathogen on serial BAL samples, or the reappearance of a respiratory pathogen after a negative BAL on a subsequent study. Clinical laboratory data were obtained from the Northwestern Medicine Enterprise Data Warehouse using Structured Query Language (SQL). APS and SOFA scores were generated from the Electronic Health Record using previously validated programming.</p>
      </sec>
      <sec id="S11">
        <title>Flow cytometry and cell sorting:</title>
        <p id="P46">NBBAL and BAL samples were filtered through a 70-&#x3BC;m cell strainer, pelleted by centrifugation at 300 rcf for 10 min at 4&#xB0;C, followed by hypotonic lysis of red blood cells with 2 ml of BD PharmLyse reagent for 2 minutes. Lysis was stopped by adding 13 ml of MACS buffer (Miltenyi Biotech). Cells were pelleted again and resuspended in 100 &#x3BC;l of 1:10 Fc-Block (Human TruStain FcX, Biolegend) in MACS buffer, and a 10-&#x3BC;l aliquot was taken for counting using K2 Cellometer (Nexcelom) with AO/PI reagent. The volume of Fc-Block was adjusted so the concentration of cells was always less than 5&#xD7;10<sup>7</sup> cells/ml and the fluorophore-conjugated antibody cocktail was added in 1:1 ratio (<xref rid="T3" ref-type="table">Extended Data Table 3</xref>). After incubation at 4&#xB0;C for 30 minutes, cells were washed with 5 ml of MACS buffer, pelleted by centrifugation, and resuspended in 500 &#x3BC;l of MACS buffer with 2 &#x3BC;l of SYTOX Green viability dye (ThermoFisher). Cells were sorted on a FACS Aria III SORP instrument using a 100-&#x3BC;m nozzle at 20 psi. Cells were sorted into 300 &#x3BC;l of MACS buffer for bulk RNA-seq or 300 &#x3BC;l of 2% BSA in PBS for single-cell RNA-seq. Sample processing was performed in BSL-2 facility using BSL-3 practices. Analysis of the flow cytometry data was performed using FlowJo 10.6.2. using uniform sequential gating strategy (<xref rid="F6" ref-type="fig">Extended Data Fig. 2</xref>) reviewed by three investigators (SS, BDS, AVM). Immune populations were defined using canonical markers as shown in <xref rid="F6" ref-type="fig">Extended Data Fig. 2</xref><sup><xref ref-type="supplementary-material" rid="SD13">44</xref>, <xref ref-type="supplementary-material" rid="SD13">49</xref></sup>. Alveolar macrophages were defined by the expression of CD206 (mannose receptor). We further subdivided alveolar macrophages into CD206<sup>lo</sup> alveolar macrophages, which represent differentiating monocyte-derived alveolar macrophages, and CD206<sup>hi</sup> alveolar macrophages, which include both tissue-resident alveolar macrophages, present in the lung prior to the onset of pneumonia, and mature monocyte-derived alveolar macrophages. Since CD206<sup>hi</sup> alveolar macrophages can be found in BAL fluid from both healthy volunteers and patients across different types of pneumonia, and the presence of CD206<sup>lo</sup> alveolar macrophages varies across the patients with pneumonia<sup><xref ref-type="supplementary-material" rid="SD13">49</xref>&#x2013;<xref ref-type="supplementary-material" rid="SD13">51</xref></sup>, we focused our transcriptomic analysis on CD206<sup>hi</sup> alveolar macrophages. Abundance of specific populations in individual BAL fluid samples can be found in <xref rid="SD9" ref-type="supplementary-material">Supplemental Data File 9</xref>.</p>
      </sec>
      <sec id="S12">
        <title>Bulk RNA-seq of flow cytometry-sorted alveolar macrophages:</title>
        <p id="P47">Immediately after sorting, cells were pelleted by centrifugation and lysed in 350 &#x3BC;l of RLT Plus lysis buffer (Qiagen) supplemented with 2-mercaptoethanol. Lysates were stored at &#x2212;80&#xB0;C until RNA isolation using the AllPrep DNA/RNA Micro kit according to the manufacturer&#x2019;s protocol (Qiagen). RNA quality and quantity were assessed using TapeStation 4200 High Sensitivity RNA tapes (Agilent), and RNA-seq libraries were prepared from 250 pg of total RNA using SMARTer Stranded Total RNA-seq Kit v2 (Takara Bio). Libraries were pooled using dual indexing and sequenced on a NextSeq 500 instrument (Illumina), 75 cycles, single-end, to an average sequencing depth of 19.55M reads.</p>
        <p id="P48">FASTQ files were generated using bcl2fastq (Illumina). To enable detection of viral RNA, a custom hybrid genome was prepared by joining FASTA, GFF, and GTF files for GRCh37.87, SARS-CoV-2 (NC_045512.2), and Influenza A/California/07/2009 (GCF_001343785.1), which was the dominant strain of influenza throughout BAL fluid collection at our hospital<sup><xref ref-type="supplementary-material" rid="SD13">52</xref></sup>. An additional negative strand transcript spanning the entirety of the SARS-CoV-2 genome was then added to the GTF and GFF files to enable detection of SARS-CoV-2 replication. Normalized counts tables later revealed high enrichment of SARS-CoV-2 transcripts in diagnosed COVID-19 patients, and enrichment of IAV genes in patients marked as other viral pneumonia. Of note, since our alveolar macrophage sorting strategy for bulk RNA-seq (<xref rid="F6" ref-type="fig">Extended Data Fig. 2a</xref>,<xref rid="F6" ref-type="fig">b</xref>) only focused on CD206<sup>hi</sup> cells, our bulk RNA-seq data likely underestimate infection of alveolar macrophages infected with SARS-CoV-2 (<xref rid="F2" ref-type="fig">Fig. 2d</xref>).</p>
        <p id="P49">To facilitate reproducible analysis, samples were processed using the publicly available nf-core/RNA-seq pipeline version 1.4.2 implemented in Nextflow 19.10.0 using Singularity 3.2.1&#x2013;1 with the minimal command nextflow run nf-core/rnaseq -r 1.4.2 &#x2013;singleEnd -profile singularity &#x2013;reverseStranded --three_prime_clip_r2 3<sup><xref ref-type="supplementary-material" rid="SD13">53</xref>&#x2013;<xref ref-type="supplementary-material" rid="SD13">55</xref></sup>. Briefly, lane-level reads were trimmed using trimGalore! 0.6.4 and aligned to the hybrid genome described above using STAR 2.6.1d<sup><xref ref-type="supplementary-material" rid="SD13">56</xref></sup>. Gene-level assignment was then performed using featureCounts 1.6.4<sup><xref ref-type="supplementary-material" rid="SD13">57</xref></sup>. Putative sample swaps were identified first by comparing known patient sex with sex determined by levels of <italic>XIST</italic> and <italic>RPS4Y1</italic> expression, followed by single nucleotide polymorphism analysis with NGSCheckMate version 1.0.0 in FASTQ mode using default settings<sup><xref ref-type="supplementary-material" rid="SD13">58</xref></sup>. Samples exhibiting unexpected correlation were excluded from analysis.</p>
      </sec>
      <sec id="S13">
        <title>Bulk differential expression analysis:</title>
        <p id="P50">All analysis was performed using custom scripts in R version 3.6.3 using the DESeq2 version 1.26.0 framework<sup><xref ref-type="supplementary-material" rid="SD13">59</xref></sup>. Correspondence between lanes was first confirmed by principal component analysis before merging counts using the command collapseReplicates(). One outlier sample from the Other Pneumonia group with low RIN score and exhibiting extreme deviation on PCA and poor alignment and assignment metrics was excluded from downstream analysis. For differential expression analysis (DEA), both proportion of alveolar macrophage from flow cytometry data and diagnosis were used as explanatory factors. A &#x201C;local&#x201D; model of gene dispersion was employed as this better fit dispersion trends without obvious overfitting, and gene outlier replacement was disabled; otherwise default settings were used. See code for details.</p>
      </sec>
      <sec id="S14">
        <title>k-means clustering of bulk samples.</title>
        <p id="P51">A custom-built function was used (available at <ext-link ext-link-type="uri" xlink:href="https://github.com/NUPulmonary/utils/blob/master/R/k_means_Figure.R">https://github.com/NUPulmonary/utils/blob/master/R/k_means_Figure.R</ext-link>) for k-means clustering. Briefly, variable genes were identified using a likelihood-ratio test (LRT) with local estimates of gene dispersion in DESeq2 with diagnosis as the full model as well as a reduced model corresponding to intercept alone. Genes with q &#x2265; 0.05 were discarded. Extant genes were then clustered using the Hartigan-Wong method with 25 random sets and a maximum of 1000 iterations using the kmeans function in R stats 3.6.3. Samples were then clustered using Ward&#x2019;s method and plotted using pheatmap version 1.0.12. GO term enrichment was then determined using Fisher&#x2019;s exact test in topGO version 2.38.1, with org.Hs.eg.db version 3.10.0 and GO.db version 3.10.0 as references.</p>
      </sec>
      <sec id="S15">
        <title>Weighted gene coexpression network analysis (WGCNA).</title>
        <p id="P52">WGCNA was performed manually using WGCNA version 1.69 with default settings unless otherwise noted<sup><xref ref-type="supplementary-material" rid="SD13">60</xref></sup>. Genes with counts &gt; 5 and detection in at least 10% of samples were included in the analysis. To best capture patterns of co-regulation, a signed network was used. Using the pickSoftThreshold function, we empirically determined a soft threshold of 7 to best fit the network structure. A minimum module size of 30 was chosen to isolate relatively large gene modules. Module eigengenes were then related back to patient and sample metadata using biweight midcorrelation. Module GO enrichment was then determined as above using Fisher&#x2019;s exact test in topGO version 2.38.1, with org.Hs.eg.db version 3.10.0 as a reference. UMAP plotting was performed using uwot version 0.1.8 using the first 20 principal components of the same genes used in WGCNA analysis after Z-scaling and centering, with a minimum distance of 0.2<sup><xref ref-type="supplementary-material" rid="SD13">61</xref></sup>. Default parameters were otherwise used.</p>
      </sec>
      <sec id="S16">
        <title>Single-cell RNA-seq of flow cytometry-sorted BAL cells:</title>
        <p id="P53">For patients with COVID-19 we limited our analysis to samples in which flow cytometry identified distinct populations of CD206<sup>hi</sup> and CD206<sup>lo</sup> macrophages (Patient 1, 2, 3, 4, 5, 7, 8, 9, A and B). We included two additional patients, one with bacterial pneumonia secondary to infection with <italic>Pseudomonas aeruginosa</italic> and <italic>Acinetobacter baumannii</italic> (assigned as &#x201C;other pneumonia&#x201D;, Patient 6) and one intubated for airway protection to facilitate endoscopy for severe gastrointestinal bleeding without pneumonia (assigned as a &#x201C;non-pneumonia control&#x201D;, Patient C) to examine nonspecific effects of inflammation and mechanical ventilation, respectively, on transcriptomic signatures.</p>
        <p id="P54">Samples were enriched via flow cytometry sorting for live cells, excluding granulocytes. Cells were sorted into 2% BSA in DPBS, pelleted by centrifugation at 400 rcf for 5 min at 4&#xB0;C, resuspended in 0.1% BSA in DPBS to ~1000 cells/&#x3BC;l concentration. Concentration was confirmed using K2 Cellometer (Nexcelom) with AO/PI reagent and cells were loaded on 10x Genomics Chip A with Chromium Single Cell 5&#x2019; gel beads and reagents (10x Genomics) aiming to capture ~5,000&#x2013;10,000 cells per library. Libraries were prepared according to the manufacturer&#x2019;s protocol (10x Genomics, CG000086_RevM). After quality checks, single-cell RNA-seq libraries were pooled and sequenced on a NovaSeq 6000 instrument.</p>
        <p id="P55">Data was processed using the Cell Ranger 3.1.0 pipeline (10x Genomics). To enable detection of viral RNA, reads were aligned to a custom hybrid genome containing GRCh38.93 and SARS-CoV-2 (NC_045512.2). An additional negative-strand transcript spanning the entirety of the SARS-CoV-2 genome was then added to the GTF and GFF files to enable detection of SARS-CoV-2 replication. Data were processed using Scanpy v1.5.1<sup><xref ref-type="supplementary-material" rid="SD13">62</xref></sup>, doublets were detected with scrublet v0.2.1<sup><xref ref-type="supplementary-material" rid="SD13">63</xref></sup> and removed, ambient RNA was corrected with FastCAR (<ext-link ext-link-type="uri" xlink:href="https://github.com/LungCellAtlas/FastCAR">https://github.com/LungCellAtlas/FastCAR</ext-link>), and multisample integration was performed with BBKNN v1.3.12<sup><xref ref-type="supplementary-material" rid="SD13">64</xref></sup>. Only human transcripts were used during integration, selection of highly variable genes and clustering, SARS-CoV-2 transcripts did not influence clustering. Gene set enrichment analysis was performed with signatures retrieved from the <ext-link ext-link-type="uri" xlink:href="https://gsea-msigdb.org">gsea-msigdb.org</ext-link> website<sup><xref ref-type="supplementary-material" rid="SD13">65</xref></sup> using following terms: HALLMARK_INTERFERON_GAMMA_RESPONSE M5913, HALLMARK_INTERFERON_ALPHA_RESPONSE M5911. Computations were automated with snakemake v5.5.4<sup><xref ref-type="supplementary-material" rid="SD13">66</xref></sup>.</p>
        <p id="P56">With exclusion of patients A and B, single-cell RNA-seq was performed without multiplexing, using cells from a single patient per single 10x Genomics chip channel. Cells from patients A and B were split into three 10x Genomics chip channels: sample 14 contained cells from patient A, sample 15 contained cells from patient B and sample 16 contained cells from patients A and B multiplexed together. To assign cells from this sample to patients, we used souporcell v2.0<sup><xref ref-type="supplementary-material" rid="SD13">67</xref></sup> (commit 34eade2ad3a361f045a31f53fee58c2e0c49423f) with the list of common variants for GRCh38 genome, provided on the souporcell page. We ran souporcell for samples 14, 15 and 16 with the number of clusters k=2. We computed Pearson correlation between integer-coded single-nucleotide polymorphisms in genotypic clusters in sample pairs 14&#x2013;16 and 15&#x2013;16 to determine which genotypic clusters come from the same patients. Genotypic doublets and unassigned cells were discarded. See code for details.</p>
      </sec>
      <sec id="S46">
        <title>Deconvolution of bulk RNA-seq alveolar macrophage signatures</title>
        <p id="P57">Deconvolution of bulk RNA-seq alveolar macrophage signatures was performed using AutoGeneS v1.0.3<sup><xref ref-type="supplementary-material" rid="SD13">68</xref></sup> and signatures derived from the integrated single-cell RNA-seq object. We used an integrated single-cell RNA-seq object containing the first six subjects included into analysis (patients 1&#x2013;6) to train the AutoGeneS model. Signatures were automatically identified from 4500 highly variable genes with function optimize(ngen=200, seed=0, nfeatures=2000, mode=&#x201D;fixed&#x201D;) (see code at <ext-link ext-link-type="uri" xlink:href="https://github.com/NUPulmonary/2020_Grant">https://github.com/NUPulmonary/2020_Grant</ext-link>). The model was then applied to bulk RNA-seq data to estimate the proportion of specific cell types using regression. We used bulk RNA-seq samples from healthy volunteers (which contain only tissue-resident alveolar macrophages and do not contain inflammatory monocyte-derived alveolar macrophages) to validate and optimize selection of the cluster-specific genes and deconvolution results.</p>
      </sec>
      <sec id="S17">
        <title>RNAscope of paraffin lung slices:</title>
        <p id="P58">RNAscope Multiplex V2 manual assay from ACDbio was performed on paraffin-embedded 5 &#x3BC;m slices of lung tissue using mild digest times according to manufacturer instructions as we have described. Probes used were RNAscope Probe-V-nCoV2019-S-C3 (catalog number 848561) with Akoya Bio Opal Dye 520 using the 488 nm laser line and RNAscope Probe-nCoV2019-orf1ab-sense-C2 (catalog number 859151) with Opal Dye 690 using 640 nm laser line. After RNAscope assay was complete, slides were washed in TBST (1X TBS pH 7.6 with 0.1% Tween-20) for 2 minutes with agitation twice. Slides were incubated in the dark at room temperature for 30 minutes with 10% normal goat serum in 1X TBS with 1% bovine serum albumin (BSA). The blocking solution was removed from slides via gentle flicking. Slides were then incubated in primary antibody solution containing anti-CD206 antibody (clone C-10) conjugated to AF546 (Santa Cruz Biotechnology Cat# sc-376232, RRID:AB_10989352) at 1:100 dilutions in TBS 1% BSA for 1 h at room temperature in the dark. Slides were rinsed using TBST for 5 minutes with agitation twice. Slides were rinsed in TBST buffer for 5 minutes twice. Slides were then mounted and dried overnight. Images were acquired at the Center for Advanced Microscopy at Northwestern University Feinberg School of Medicine using the Nikon W1-Spinning Disk Confocal microscope. Nucleus was added to the images using machine-based learning network trained on one patient using DAPI and brightfield images in Nikon Elements. Final images were rendered using Fiji.</p>
      </sec>
      <sec id="S18">
        <title>Statistical analysis:</title>
        <p id="P59">Statistical analysis was performed using base R version 3.6.3 with tidyverse version 1.3.0<sup><xref ref-type="supplementary-material" rid="SD13">69</xref></sup> and Python 3.6. For all comparisons, normality was first assessed using a Shapiro-Wilk test and manual examination of distributions. For parameters exhibiting a clear lack of normality, nonparametric tests were employed. In cases of multiple testing, P-values were corrected using false-discovery rate (FDR) correction. In Python, we used the mannwhitneyu function from scipy package version 1.3.1<sup><xref ref-type="supplementary-material" rid="SD13">70</xref></sup> for nonparametric tests, and corrected for multiple testing with the statsmodels package version 0.10.1<sup><xref ref-type="supplementary-material" rid="SD13">71</xref></sup>. Adjusted P-values &lt; 0.05 were considered significant. Two-sided statistical tests were performed in all cases.</p>
      </sec>
      <sec id="S19">
        <title>Visualization:</title>
        <p id="P60">Plotting was performed in <xref rid="F1" ref-type="fig">figures 1</xref>, <xref rid="F2" ref-type="fig">2</xref>, <xref rid="F3" ref-type="fig">3</xref>, <xref rid="F5" ref-type="fig">extended data figures 1</xref>, <xref rid="F6" ref-type="fig">2</xref>, and <xref rid="F7" ref-type="fig">3</xref> using ggplot2 version 3.3.1 unless otherwise noted. Comparisons for these figures were added using ggsignif version 0.6.0. Heatmaps on <xref rid="F2" ref-type="fig">figures 2</xref> and <xref rid="F3" ref-type="fig">3</xref> were generated using pheatmap version 1.0.12. Sankey/Alluvial plots on <xref rid="F5" ref-type="fig">Extended Data Fig. 1</xref> were generated using ggalluvial version 0.12.0<sup><xref ref-type="supplementary-material" rid="SD13">72</xref></sup>. Figure layouts for <xref rid="F1" ref-type="fig">Figures 1</xref>, <xref rid="F2" ref-type="fig">2</xref>, <xref rid="F3" ref-type="fig">3</xref>, <xref rid="F4" ref-type="fig">4</xref>, and <xref rid="F5" ref-type="fig">Extended Data Figures 1</xref>, and <xref rid="F7" ref-type="fig">3</xref> were generated using patchwork version 1.01 and edited in Adobe Illustrator 2021. <xref rid="F4" ref-type="fig">Figure 4</xref> and <xref rid="F8" ref-type="fig">extended data figures 4</xref> and <xref rid="F9" ref-type="fig">5</xref> were generated with matplotlib v3.2.1<sup><xref ref-type="supplementary-material" rid="SD13">73</xref></sup>. For all boxplots shown, box limitsq represent the interquartile range (IQR) with a centerline at the median. Whiskers represent the largest point &#x2264; 1.5 * IQR. All points are overlaid.</p>
      </sec>
      <sec id="S20">
        <title>Study limitations:</title>
        <p id="P61">First, this is an observational study, and in the absence of a specific intervention targeting a necessary component of our model, our data are hypothesis-generating. Moreover, our observational cohorts are heterogeneous with respect to treatments received and other processes of care. Second, while we made every attempt to standardize BAL fluid volumes, the number of alveoli sampled and the return volume during both bronchoscopic and non-bronchoscopic BAL is variable. Hence, our observations are relative rather than quantitative. Third, our flow cytometry panels, while rigorous, were limited by the number of antibodies that could be used for high volume characterization of clinical samples. Fourth, our BAL samples were collected as part of clinical care; therefore, sicker patients were more likely to be sampled. Finally, while we made every effort to standardize care for patients with SARS-CoV-2 pneumonia in our ICU, some of our patients were enrolled in clinical trials of remdesivir or sarilumab, many patients received unproven therapies off label including hydroxychloroquine and tocilizumab, and our study largely preceded reports on the use of steroids in patients with severe SARS-CoV-2 pneumonia (<xref rid="T1" ref-type="table">Extended Data Table 1</xref>). Despite these limitations, our systems approach to understand SARS-CoV-2 pathobiology provides a model with testable predictions that can serve as a template for the design of targeted interventions in patients with severe disease.</p>
      </sec>
    </sec>
    <sec sec-type="extended-data" id="S21">
      <title>Extended Data</title>
      <fig id="F5" orientation="portrait" position="anchor">
        <label>Extended Data Fig. 1:</label>
        <caption>
          <title>Overview of the study and biomarkers.</title>
          <p id="P62">We compared BAL fluid obtained sequentially from 88 patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation with 38 patients with confirmed pneumonia secondary to other respiratory viruses (other viral pneumonia), 173 patients with non-viral pneumonia (other pneumonia) and 42 mechanically ventilated patients without pneumonia undergoing BAL (non-pneumonia controls). <bold>a</bold>. Sankey diagram illustrating steps in analysis performed for at least one BAL sample for participants with COVID-19, other viral pneumonia, non-viral pneumonia (other pneumonia), non-pneumonia controls, and healthy controls. This includes samples from patients 1) enrolled in the SCRIPT study (346 patients), 2) analyzed via flow cytometry (241 patients), 3) for whom bulk RNA-seq was performed on flow cytometry-sorted alveolar macrophages (181 patients) and 4) for whom single-cell RNA-seq was performed on cells from BAL fluid (10 patients with SARS-CoV-2 pneumonia, 1 patient with bacterial pneumonia and 1 patient intubated for reasons other than pneumonia (gastrointestinal bleeding requiring endoscopy, a non-pneumonia control)). Some samples were cryopreserved and sorted post-cryorecovery. Because cryopreservation affects the number of neutrophils, these samples were not included in flow cytometric analysis but were used for bulk RNA-seq profiling of flow cytometry-sorted alveolar macrophages. Samples for which flow or bulk RNA-seq analysis was skipped are represented by alluvia flowing over the grouping bars. <bold>b</bold>. Sankey diagram illustrating steps in analysis performed for all BAL samples from participants with COVID-19, other viral pneumonia, non-viral pneumonia (other pneumonia) and non-pneumonia controls. This includes samples from patients 1) enrolled in the SCRIPT study (564 samples), 2) analyzed via flow cytometry (352 samples), 3) for whom bulk RNA-seq was performed on flow cytometry-sorted alveolar macrophages (232 samples) and 4) for whom single-cell RNA-seq was performed on cells from BAL fluid (12 samples). <bold>c</bold>. Self-reported smoking status. Significantly fewer active smokers were observed in the COVID-19 cohort as compared with all control groups (q &lt; 0.05, pairwise Chi-square tests of proportions with continuity and FDR correction). <bold>d&#x2013;i.</bold> Biomarkers: C-reactive protein (CRP), D-dimer, ferritin, procalcitonin, creatine phosphokinase (CPK), lactate dehydrogenase (LDH). The green-shaded area indicates the normal range. <bold>j</bold>. Number of patients remaining on mechanical ventilation. <bold>k</bold>. Number of BAL per day of mechanical ventilation. <bold>l</bold>. The BAL sampling rate per day among patients with COVID-19 was not higher than the sampling rate among patients with other pneumonias.</p>
        </caption>
        <graphic xlink:href="nihms-1656482-f0005"/>
      </fig>
      <fig id="F6" orientation="portrait" position="anchor">
        <label>Extended Data Fig. 2:</label>
        <caption>
          <title>Representative gating strategy to identify immune cell subsets in BAL samples.</title>
          <p id="P63"><bold>a</bold>. We developed a gating strategy that allowed us to quantify immune cell populations including monocytes, alveolar macrophage subsets, and T cell subsets. Importantly, we defined alveolar macrophages by their expression of CD206, subdividing them into early monocyte-derived alveolar macrophages (CD206<sup>lo</sup>) and more mature (CD206<sup>hi</sup>) alveolar macrophages. T cells were identified as CD3-positive and further subdivided into CD4+ and CD8+ T cells. Tregs were identified as CD3+CD4+CD25+CD127&#x2212;. Neutrophils were identified as CD15+ cells. Monocytes were identified as HLA-DR+CD4+CD206&#x2212; cells. Of note, only CD206<sup>hi</sup> alveolar macrophages were flow cytometry-sorted for bulk RNA-seq analysis (<xref rid="F2" ref-type="fig">Figs. 2</xref> and <xref rid="F3" ref-type="fig">3</xref>); hence, early monocyte-derived alveolar macrophages (MoAM1 and MoAM2 in our single-cell RNA-seq data, <xref rid="F4" ref-type="fig">Fig. 4a</xref>&#x2013;<xref rid="F4" ref-type="fig">h</xref>) were not captured in bulk RNA-seq. Representative sample from a patient without neutrophilia is shown. Solid red arrows indicate direct sequential gating, dashed blue arrows indicate Boolean &#x201C;not&#x201D; gates. Numbers on plots indicate the percentage of the parent population. Axis labels indicate laser line (UV &#x2013; 355 nm, V &#x2013; 405 nm, B &#x2013; 488 nm, YG &#x2013; 552 nm, R &#x2013; 640 nm), bandpass filter, fluorochrome and antigen/dye. <bold>b</bold>. Representative sample from a patient with neutrophilia illustrates loss of CD206<sup>hi</sup> alveolar macrophages and influx of monocyte-derived CD206<sup>lo</sup> alveolar macrophages. <bold>c&#x2013;d</bold>. Contour plot and histogram overlays illustrating forward (FSC) and side scatter (SSC) properties of the CD3+ T cells (CD3), CD15+ neutrophils (CD15), monocytes, CD206<sup>lo</sup> alveolar macrophages (CD206<sup>lo</sup>), and CD206<sup>hi</sup> alveolar macrophages (CD206<sup>hi</sup>) in the representative sample from a patient without neutrophilia (<bold>c.</bold>) and with neutrophilia (<bold>d.</bold>). Note that neutrophils have higher side scatter than monocytes. <bold>e</bold>. Representative contour plots illustrating a sample with two distinct populations of CD206<sup>hi</sup> alveolar macrophages. Single-cell RNA-seq analysis (<xref rid="F4" ref-type="fig">Fig. 4a</xref>&#x2013;<xref rid="F4" ref-type="fig">h</xref>) suggests that CD206<sup>hi</sup> alveolar macrophages (double-head arrow) are <italic>bona fide</italic> tissue-resident alveolar macrophages.</p>
        </caption>
        <graphic xlink:href="nihms-1656482-f0006"/>
      </fig>
      <fig id="F7" orientation="portrait" position="anchor">
        <label>Extended Data Fig. 3.</label>
        <caption>
          <title>At the time of intubation, the alveolar space in patients with severe SARS-CoV-2 pneumonia is enriched for T cells and monocytes and contains alveolar macrophages harboring SARS-CoV-2 RNA.</title>
          <p id="P64"><bold>a</bold>. Proportions of cells detected within 48 hours of intubation (q &lt; 0.05, pairwise Wilcoxon rank-sum tests with FDR correction). Comparisons are not significant unless otherwise noted. <bold>b</bold>. Hierarchical clustering of viral reads for SARS-CoV-2 and influenza A/California/07/2009 virus using Ward&#x2019;s method. Log<sub>10</sub>(DESeq2-normalized counts) are shown. <bold>c</bold>. Cumulative coverage plot of RNA-seq reads from flow cytometry-sorted alveolar macrophages aligned to the SARS-CoV-2 genome.</p>
        </caption>
        <graphic xlink:href="nihms-1656482-f0007"/>
      </fig>
      <fig id="F8" orientation="portrait" position="anchor">
        <label>Extended Data Fig. 4.</label>
        <caption>
          <title>The BAL fluid from patients with SARS-CoV-2 pneumonia is persistently enriched for T cells irrespective of superinfection status.</title>
          <p id="P65"><bold>a</bold>. Heatmap of flow cytometry data demonstrating composition of BAL samples from all time points, grouped by diagnosis and ordered by the duration of mechanical ventilation. Column headers are color-coded by the diagnosis, duration of mechanical ventilation (white color indicates chronically ventilated patients), and presence or absence of superinfection (&#x201C;Infection Status&#x201D;). &#x201C;Infection Status&#x201D; refers only to the &#x201C;COVID-19&#x201D; and &#x201C;Other Viral Pneumonia&#x201D; groups; blanks in these groups refer to samples for which microbiology data were incomplete and infectious status could not be determined. &#x201C;Viral infection only&#x201D; refers to viral pathogens as the only detected pathogen in a sample and &#x201C;Viral infection with bacterial/fungal superinfection&#x201D; refers to detection of a viral pathogen with one or more bacterial or fungal co-pathogens. <bold>b.</bold> Comparison of percentage of CD206<sup>lo</sup> and CD206<sup>hi</sup> alveolar macrophages between early (&lt;48 hours after intubation) and late (&gt;48 hours of mechanical ventilation) samples (q &lt; 0.05, pairwise Wilcoxon rank-sum tests with FDR correction). <bold>c</bold>. Comparison of CD4+ and CD8+ T cell and neutrophil abundance in the COVID-19 group, with and without superinfection in early and late sampling. Superinfection is represented by lighter bars. Differences between groups are not significant after FDR correction.</p>
        </caption>
        <graphic xlink:href="nihms-1656482-f0008"/>
      </fig>
      <fig id="F9" orientation="portrait" position="anchor">
        <label>Extended Data Fig. 5.</label>
        <caption>
          <title>SARS-CoV-2 pneumonia is characterized by a persistent interferon-response signature in alveolar macrophages.</title>
          <p id="P66"><bold>a</bold>. k-means clustering of the 2,323 significantly variable genes (q &lt; 0.05, likelihood-ratio test) across diagnosis, columns represent each individual patient, grouped by diagnosis and ordered by day from first intubation. &#x201C;Infection Status&#x201D; refers only to the &#x201C;COVID-19&#x201D; and &#x201C;Other Viral Pneumonia&#x201D; groups; blanks in these groups refer to samples for which microbiology data were incomplete and infectious status could not be determined. &#x201C;Viral infection only&#x201D; refers to viral pathogens as the only detected pathogen in a sample and &#x201C;Viral infection with bacterial/fungal superinfection&#x201D; refers to detection of a viral pathogen with one or more bacterial or fungal co-pathogens. Representative genes and GO biological processes are shown for each cluster. Column headers are color-coded by diagnosis and duration of mechanical ventilation (white color indicates chronically ventilated patients). <bold>b</bold>. Expression of selected genes between the groups. Note that expression of <italic>IL6</italic> is not increased in any group. All significant comparisons are shown (q &lt; 0.05, Wald test with FDR correction in DESeq2). <bold>c</bold>. Weighted gene co-expression network analysis (WGCNA). <bold>d&#x2013;f</bold>. Interferon-response signatures in alveolar macrophages from patients with COVID-19 gradually decrease over the course of disease. Correlation between average expression of genes from GO:0060337 &#x201C;type I interferon signaling pathway&#x201D; (R = &#x2212;0.51, P = 5.7&#xD7;10<sup>&#x2212;6</sup>, Pearson correlation; panel <bold>d</bold>.), GO:0060333 &#x201C;interferon-gamma-mediated signaling pathway&#x201D; (R = &#x2212;0.22, P = 0.06, Pearson correlation; panel <bold>e</bold>.), module 15 of WGCNA (R = &#x2212;0.40, P = 5.5&#xD7;10<sup>&#x2212;4</sup>, Pearson correlation; panel <bold>f.</bold>) and time on mechanical ventilation. Gray boundaries represent 95% confidence intervals. <bold>g</bold>. UMAP projections of all bulk RNA-seq samples. Average expression of WGCNA module 15 (left) and percent of CD3+ T cells in BAL (right) are shown by point area. <bold>h</bold>. Heatmap demonstrating time-dependent changes in gene expression of the canonical interferon-response genes from module 15 from patients with positive outcomes (discharged home or inpatient facility) or poor outcomes (discharged to a long-term acute care facility (LTAC) or deceased. <bold>i</bold>. Correlation between detection of SARS-CoV-2 reads and disease progression (&#x3C1; = &#x2212;0.49, p = 8.3&#xD7;10<sup>&#x2212;4</sup>, Spearman correlation).</p>
        </caption>
        <graphic xlink:href="nihms-1656482-f0009"/>
      </fig>
      <fig id="F10" orientation="portrait" position="anchor">
        <label>Extended Data Fig. 6.</label>
        <caption>
          <title>Single-cell RNA-seq identifies a positive feedback loop between IFN&#x3B3;-producing T cells and SARS-CoV-2-infected alveolar macrophages.</title>
          <p id="P67"><bold>a</bold>. Subsets of alveolar macrophages and T cells are represented by the cells from all 10 patients with COVID-19. <bold>b</bold>. <italic>IFNG</italic> expression is detected in T cells from all 10 patients with COVID-19, T cells with at least one count of <italic>IFNG</italic> were used for analysis. <bold>c</bold>. Detection of the SARS-CoV-2 negative strand. Density projection plot, with expression averaged within hexagonal areas on UMAP. <bold>d</bold>. Coverage plot of single-cell RNA-seq reads aligned to the SARS-CoV-2 genome. Cumulative data from 10 patients. Reads were aligned to genes on the positive strand or to the entire negative strand. <bold>e</bold>. UMAP plot showing integrative analysis of 105,715 cells isolated from 10 patients with severe COVID-19 within 48 hours after intubation (see <xref rid="F4" ref-type="fig">Fig. 4a</xref>&#x2013;<xref rid="F4" ref-type="fig">h</xref>), one intubated patient with bacterial pneumonia and one intubated non-pneumonia control patient. AT1 &#x2013; alveolar epithelial type 1 cells; AT2 &#x2013; alveolar epithelial type 2 cells; DC1 &#x2013; conventional dendritic cells type 1, <italic>CLEC9A</italic>+; DC2 &#x2013; conventional dendritic cells type 2, <italic>CD1C</italic>+; Migratory DC &#x2013; migratory dendritic cells, <italic>CCR7</italic>+; pDC &#x2013; plasmacytoid dendritic cells, <italic>CLEC4C</italic>+; Mixed myeloid &#x2013; mixed cluster containing transitory dendritic cells and very immature monocyte-derived macrophages; TRAM &#x2013; tissue-resident alveolar macrophages; MoAM &#x2013; monocyte-derived alveolar macrophages; iNKT cells &#x2013; invariant natural killer T cells; Treg &#x2013; regulatory T cells, <italic>FOXP3</italic>+. <bold>f</bold>. Cells from non-pneumonia control (patient 6) and a patient with bacterial pneumonia (Patient C) primarily contribute to the TRAM1 cluster and have limited contribution to MoAM clusters. <bold>g</bold>. UMAP plot showing cells from non-pneumonia control (patient 6) and a patient with bacterial pneumonia (Patient C) from the integrative analysis on <xref ref-type="fig" rid="F9">Extended Data Fig. 5e</xref>. <xref ref-type="fig" rid="F9">h</xref>. Presence of co-infection does not affect clustering. UMAP plot showing cells from patients with and without co-infection from the integrative analysis in <xref rid="F4" ref-type="fig">Fig. 4</xref>.</p>
        </caption>
        <graphic xlink:href="nihms-1656482-f0010"/>
      </fig>
      <fig id="F11" orientation="portrait" position="anchor">
        <label>Extended Data Fig. 7.</label>
        <caption>
          <title>Deconvolution of bulk RNA-seq demonstrates loss of tissue-resident alveolar macrophages and persistence of mature monocyte-derived alveolar macrophages in patients with severe COVID-19.</title>
          <p id="P68"><bold>a</bold>. Dot plot showing <italic>IL6</italic> expression across cell types. Dot size is proportional to the number of cells expressing <italic>IL6</italic> in the corresponding cluster. Data from this study (G.) are presented per patient, data from Liao et al. 2020 (L.) and Haberman et al. 2020 (H.) are averaged by condition. <bold>b</bold>. Heatmap demonstrating proportion of alveolar macrophage subsets predicted from deconvolution analysis. Data are grouped by condition and ordered by proportion of CD206<sup>hi</sup> alveolar macrophages. <bold>c</bold>. Proportion of alveolar macrophage cell types in patients with COVID-19 in comparison to other types of pneumonia obtained from deconvolution analysis (pairwise Wilcoxon rank-sum tests with FDR correction, * q &lt; 0.05, ** q &lt; 0.01, *** q &lt; 0.001).</p>
        </caption>
        <graphic xlink:href="nihms-1656482-f0011"/>
      </fig>
      <table-wrap id="T1" position="anchor" orientation="portrait">
        <label>Extended Data Table 1:</label>
        <caption>
          <p id="P69">Demographics of the SCRIPT cohort, grouped by diagnosis. All patients were admitted to Northwestern Memorial Hospital in Chicago between June 15, 2018 and July 6, 2020. Bronchoscopy was most commonly performed as part of routine clinical care to guide antimicrobial therapy. Patients with ARDS were managed using a high PEEP, low tidal volume ventilation strategy and were ventilated prone when suggested by ARDSnet guidelines. Patients received steroids and off label IL-6 receptor antagonists (tocilizumab or sarilumab) at the discretion of the clinical team. Any hydroxychloroquine use is reported, but hydroxychloroquine was routinely stopped upon ICU admission. Some patients were enrolled in multicenter placebo-controlled trials of remdesivir or sarilumab, treatment assignment is blinded.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" valign="top" rowspan="1" colspan="1"/>
              <th align="center" valign="top" rowspan="1" colspan="1">COVID-19 (N = 88)</th>
              <th align="center" valign="top" rowspan="1" colspan="1">Non-Pneumonia Control (N = 42)</th>
              <th align="center" valign="top" rowspan="1" colspan="1">Other Pneumonia (N = 173)</th>
              <th align="center" valign="top" rowspan="1" colspan="1">Other Viral Pneumonia (N = 38)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Ethnicity</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Hispanic or Latino</td>
              <td align="left" valign="top" rowspan="1" colspan="1">38/ 88 (43.2%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6/ 42 (14.3%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">13/ 173 (7.5%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">8/ 38 (21.1%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Not Hispanic or Latino</td>
              <td align="left" valign="top" rowspan="1" colspan="1">39/ 88 (44.3%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">33/ 42 (78.6%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">148/ 173 (85.5%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">27/ 38 (71.1%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Unknown or Not Reported</td>
              <td align="left" valign="top" rowspan="1" colspan="1">11/ 88 (12.5%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">3/ 42 (7.1%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">12/ 173 (6.9%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">3/ 38 (7.9%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Race</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;American Indian/ Alaska Native</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 88 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 42 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1/ 173 (0.6%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1/ 38 (2.6%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Asian</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1/ 88 (1.1%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2/ 42 (4.8%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7/ 173 (4.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1/ 38 (2.6%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Black/ African American</td>
              <td align="left" valign="top" rowspan="1" colspan="1">20/ 88 (22.7%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7/ 42 (16.7%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">38/ 173 (22.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7/ 38 (18.4%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Unknown or Not Reported</td>
              <td align="left" valign="top" rowspan="1" colspan="1">33/ 88 (37.5%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">5/ 42 (11.9%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">13/ 173 (7.5%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">4/ 38 (10.5%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;White</td>
              <td align="left" valign="top" rowspan="1" colspan="1">34/ 88 (38.6%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">28/ 42 (66.7%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">114/ 173 (65.9%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">25/ 38 (65.8%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Age</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Minimum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">21</td>
              <td align="left" valign="top" rowspan="1" colspan="1">19</td>
              <td align="left" valign="top" rowspan="1" colspan="1">22</td>
              <td align="left" valign="top" rowspan="1" colspan="1">34</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Median (IQR)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">59.50 (46.00, 68.25)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">62.00 (46.75, 71.50)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">65.00 (51.00, 73.00)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">59.50 (52.25, 69.00)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Mean (SD)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">57.09 &#xB1; 14.64</td>
              <td align="left" valign="top" rowspan="1" colspan="1">59.14 &#xB1; 17.89</td>
              <td align="left" valign="top" rowspan="1" colspan="1">61.44 &#xB1; 16.06</td>
              <td align="left" valign="top" rowspan="1" colspan="1">60.66 &#xB1; 13.64</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Maximum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">86</td>
              <td align="left" valign="top" rowspan="1" colspan="1">90</td>
              <td align="left" valign="top" rowspan="1" colspan="1">99</td>
              <td align="left" valign="top" rowspan="1" colspan="1">88</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Sex</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Female</td>
              <td align="left" valign="top" rowspan="1" colspan="1">30/ 88 (34.1%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">19/ 42 (45.2%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">69/ 173 (39.9%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">17/ 38 (44.7%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Male</td>
              <td align="left" valign="top" rowspan="1" colspan="1">58/ 88 (65.9%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">23/ 42 (54.8%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">104/ 173 (60.1%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">21/ 38 (55.3%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Discharge Status</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Deceased</td>
              <td align="left" valign="top" rowspan="1" colspan="1">22/ 88 (25.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">15/ 42 (35.7%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">60/ 173 (34.7%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">14/ 38 (36.8%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Home</td>
              <td align="left" valign="top" rowspan="1" colspan="1">38/ 88 (43.2%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">18/ 42 (42.9%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">37/ 173 (21.4%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">8/ 38 (21.1%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Inpatient Facility</td>
              <td align="left" valign="top" rowspan="1" colspan="1">16/ 88 (18.2%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7/ 42 (16.7%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">53/ 173 (30.6%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">14/ 38 (36.8%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;LTAC</td>
              <td align="left" valign="top" rowspan="1" colspan="1">11/ 88 (12.5%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2/ 42 (4.8%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">22/ 173 (12.7%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2/ 38 (5.3%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Other</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1/ 88 (1.1%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 42 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1/ 173 (0.6%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 38 (0.0%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Smoking Status</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Current Smoker</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 88 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6/ 42 (14.3%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">23/ 173 (13.3%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">5/ 38 (13.2%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Never Smoker</td>
              <td align="left" valign="top" rowspan="1" colspan="1">41/ 88 (46.6%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">25/ 42 (59.5%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">73/ 173 (42.2%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">17/ 38 (44.7%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Past Smoker</td>
              <td align="left" valign="top" rowspan="1" colspan="1">14/ 88 (15.9%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">9/ 42 (21.4%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">62/ 173 (35.8%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">15/ 38 (39.5%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Unknown or Not Reported</td>
              <td align="left" valign="top" rowspan="1" colspan="1">33/ 88 (37.5%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2/ 42 (4.8%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">15/ 173 (8.7%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1/ 38 (2.6%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Days of Intubation</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Minimum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Median (IQR)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">18.00 (10.00, 33.00)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">4.00 (2.00, 8.75)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7.00 (3.00, 13.00)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7.00 (3.00, 13.00)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Mean (SD)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">25.48 &#xB1; 25.06</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7.93 &#xB1; 11.48</td>
              <td align="left" valign="top" rowspan="1" colspan="1">10.62 &#xB1; 10.98</td>
              <td align="left" valign="top" rowspan="1" colspan="1">9.79 &#xB1; 8.91</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Maximum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">153</td>
              <td align="left" valign="top" rowspan="1" colspan="1">58</td>
              <td align="left" valign="top" rowspan="1" colspan="1">68</td>
              <td align="left" valign="top" rowspan="1" colspan="1">34</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Unknown/ Missing</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1 (0.58%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Length of ICU Stay</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Minimum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">3</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Median (IQR)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">21.00 (12.75, 31.50)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">5.50 (3.00, 11.50)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">9.00 (5.00, 18.00)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">10.50 (4.50, 13.75)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Mean (SD)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">24.49 &#xB1; 16.96</td>
              <td align="left" valign="top" rowspan="1" colspan="1">10.17 &#xB1; 12.87</td>
              <td align="left" valign="top" rowspan="1" colspan="1">13.87 &#xB1; 13.41</td>
              <td align="left" valign="top" rowspan="1" colspan="1">11.39 &#xB1; 8.10</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Maximum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">85</td>
              <td align="left" valign="top" rowspan="1" colspan="1">68</td>
              <td align="left" valign="top" rowspan="1" colspan="1">84</td>
              <td align="left" valign="top" rowspan="1" colspan="1">33</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Unknown/ Missing</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2 (1.16%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">BMI</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Minimum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">20.62</td>
              <td align="left" valign="top" rowspan="1" colspan="1">16.56</td>
              <td align="left" valign="top" rowspan="1" colspan="1">12.46</td>
              <td align="left" valign="top" rowspan="1" colspan="1">17.34</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Median (IQR)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">31.21 (26.76, 37.09)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">27.41 (24.59, 33.83)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">25.89 (21.90, 32.32)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">26.78 (23.19, 32.75)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Mean (SD)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">33.17 &#xB1; 9.14</td>
              <td align="left" valign="top" rowspan="1" colspan="1">30.77 &#xB1; 9.78</td>
              <td align="left" valign="top" rowspan="1" colspan="1">27.48 &#xB1; 8.15</td>
              <td align="left" valign="top" rowspan="1" colspan="1">28.73 &#xB1; 8.37</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Maximum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">81.81</td>
              <td align="left" valign="top" rowspan="1" colspan="1">70.6</td>
              <td align="left" valign="top" rowspan="1" colspan="1">70.25</td>
              <td align="left" valign="top" rowspan="1" colspan="1">55.76</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Unknown/ Missing</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1 (2.38%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1 (0.58%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">SOFA</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Minimum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.83</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1.75</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Median (IQR)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7.02 (5.49, 9.33)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6.58 (4.87, 10.49)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6.54 (4.47, 9.66)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6.04 (4.03, 8.88)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Mean (SD)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7.44 &#xB1; 2.65</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7.38 &#xB1; 3.31</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7.35 &#xB1; 3.62</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6.54 &#xB1; 3.02</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Maximum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">15.84</td>
              <td align="left" valign="top" rowspan="1" colspan="1">13.75</td>
              <td align="left" valign="top" rowspan="1" colspan="1">18.5</td>
              <td align="left" valign="top" rowspan="1" colspan="1">13.17</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Unknown/ Missing</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2 (1.16%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0 (0.00%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">APS</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Minimum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">33</td>
              <td align="left" valign="top" rowspan="1" colspan="1">28.25</td>
              <td align="left" valign="top" rowspan="1" colspan="1">21.2</td>
              <td align="left" valign="top" rowspan="1" colspan="1">26.33</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Median (IQR)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">70.27 (57.75, 82.11)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">60.67 (46.31, 80.88)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">64.22 (51.14, 80.55)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">70.60 (51.20, 78.77)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Mean (SD)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">69.54 &#xB1; 16.98</td>
              <td align="left" valign="top" rowspan="1" colspan="1">65.08 &#xB1; 21.89</td>
              <td align="left" valign="top" rowspan="1" colspan="1">66.85 &#xB1; 23.08</td>
              <td align="left" valign="top" rowspan="1" colspan="1">66.68 &#xB1; 19.89</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Maximum</td>
              <td align="left" valign="top" rowspan="1" colspan="1">103.36</td>
              <td align="left" valign="top" rowspan="1" colspan="1">115.5</td>
              <td align="left" valign="top" rowspan="1" colspan="1">161</td>
              <td align="left" valign="top" rowspan="1" colspan="1">106.5</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Unknown/ Missing</td>
              <td align="left" valign="top" rowspan="1" colspan="1">13 (14.77%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1 (2.38%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">19 (10.98%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1 (2.63%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Remdesivir Study</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Enrolled</td>
              <td align="left" valign="top" rowspan="1" colspan="1">17/ 88 (19.3%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 42 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 173 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 38 (0.0%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Not Enrolled</td>
              <td align="left" valign="top" rowspan="1" colspan="1">71/ 88 (80.7%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">42/ 42 (100.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">173/ 173 (100.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">38/ 38 (100.0%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Sarilumab Study</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Enrolled</td>
              <td align="left" valign="top" rowspan="1" colspan="1">30/ 88 (34.1%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 42 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 173 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 38 (0.0%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Not Enrolled</td>
              <td align="left" valign="top" rowspan="1" colspan="1">58/ 88 (65.9%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">42/ 42 (100.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">173/ 173 (100.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">38/ 38 (100.0%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Steroids</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Treated</td>
              <td align="left" valign="top" rowspan="1" colspan="1">30/ 88 (34.1%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 42 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 173 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 38 (0.0%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Unreated</td>
              <td align="left" valign="top" rowspan="1" colspan="1">58/ 88 (65.9%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">42/ 42 (100.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">173/ 173 (100.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">38/ 38 (100.0%)</td>
            </tr>
            <tr>
              <td colspan="5" align="left" valign="top" rowspan="1">Hydroxychloroquine</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Treated</td>
              <td align="left" valign="top" rowspan="1" colspan="1">17/ 88 (19.3%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 42 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 173 (0.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0/ 38 (0.0%)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;Unreated</td>
              <td align="left" valign="top" rowspan="1" colspan="1">71/ 88 (80.7%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">42/ 42 (100.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">173/ 173 (100.0%)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">38/ 38 (100.0%)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="T2" position="anchor" orientation="portrait">
        <label>Extended Data Table 2:</label>
        <caption>
          <p id="P70">Pneumonia-causing pathogens detected in the SCRIPT cohort.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" valign="top" rowspan="1" colspan="1"/>
              <th align="left" valign="top" rowspan="1" colspan="1">Pathogen</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Achromobacter species</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">2</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Acinetobacter baumannii</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">3</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Acinetobacter ursingii</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">4</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Elizabethkingia meningoseptica</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">5</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Enterobacter aerogenes</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">6</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Enterobacter cloacae complex</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">7</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Enterococcus faecalis</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">8</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Enterococcus faecium</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">9</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Escherichia coli</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">10</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Klebsiella oxytoca</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">11</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Klebsiella pneumoniae</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">12</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Staphylococcus aureus</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">13</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Proteus mirabilis</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">14</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Providencia stuartii</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">15</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Pseudomonas aeruginosa</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">16</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Serratia marcescens</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">17</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Stenotrophomonas maltophilia</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">18</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Stomatococcus species</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">19</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Streptococcus agalactiae (Group B)</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">20</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Streptococcus pneumoniae</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">21</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Streptococcus pseudopneumoniae</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">22</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Viridans streptococcus</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="T3" position="anchor" orientation="portrait">
        <label>Extended Data Table 3:</label>
        <caption>
          <p id="P71">Flow cytometry panels, reagents and instruments configuration.</p>
        </caption>
        <table frame="box" rules="all">
          <colgroup span="1">
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
          </colgroup>
          <tbody>
            <tr>
              <th colspan="8" align="left" valign="middle" rowspan="1">Panel 1: Used in original SCRIPT study prior to March 13, 2020</th>
            </tr>
            <tr>
              <th align="left" valign="top" rowspan="1" colspan="1"/>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Laser</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Filter</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Dye</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Antigen</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Clone</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Final dilution</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Catalog #/Identifier</th>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">355 nm</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">379/28</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BUV395</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD4</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">RPA-T4</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:40</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences Cat# 564724, RRID:AB_2738917</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">2</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1"/>
              <td align="left" valign="bottom" rowspan="1" colspan="1">750/50</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BUV737</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD25</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">2A3</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences Cat# 564385, RRID:AB_2744342</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">3</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">405 nm</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">450/50</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">eFluor450</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">HLA-DR</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">L243</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:40</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific Cat# 48-9952-42, RRID:AB_1603291</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">4</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1"/>
              <td align="left" valign="bottom" rowspan="1" colspan="1">780/60</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BV786</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD15</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">HI98</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences Cat# 563838, RRID:AB_2738444</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">5</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">488 nm</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">530/30</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">SYTOX Green</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">L/D</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">na</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:250</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific Cat# S34860</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">6</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">561 nm</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">585/15</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">PE</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD3</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">SK7</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:40</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific Cat# 12-0036-42, RRID:AB_10805512</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">7</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1"/>
              <td align="left" valign="bottom" rowspan="1" colspan="1">610/20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">PECF594</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD127</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">HIL-7R</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences Cat# 562397, RRID:AB_11154212</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">8</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1"/>
              <td align="left" valign="bottom" rowspan="1" colspan="1">780/60</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">PECy7</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD206</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">19.2</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:40</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific Cat# 25-2069-42, RRID:AB_2573426</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">9</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">640 nm</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">670/30</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">APC</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD8</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">SK1</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend Cat# 344721, RRID:AB_2075390</td>
            </tr>
            <tr>
              <td colspan="8" align="left" valign="top" style="border-right-style: hidden;border-left-style: hidden" rowspan="1"/>
            </tr>
          </tbody>
          <tbody>
            <tr>
              <th colspan="8" align="left" valign="middle" rowspan="1">Panel 2: Used on all samples starting March 13, 2020</th>
            </tr>
            <tr>
              <th align="left" valign="top" rowspan="1" colspan="1"/>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Laser</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Filter</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Dye</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Antigen</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Clone</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Final dilution</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Catalog #/Identifier</th>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">355 nm</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">379/28</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BUV395</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD4</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">RPA-T4</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:40</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences Cat# 564724, RRID:AB_2738917</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">2</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1"/>
              <td align="left" valign="bottom" rowspan="1" colspan="1">750/50</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BUV737</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD25</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">2A3</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences Cat# 564385, RRID:AB_2744342</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">3</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">405 nm</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">450/50</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">eFluor450</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">HLA-DR</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">L243</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:40</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific Cat# 48-9952-42, RRID:AB_1603291</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">4</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1"/>
              <td align="left" valign="bottom" rowspan="1" colspan="1">520/50</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BV510</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD45</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">HI30</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend Cat# 304036, RRID:AB_2561940</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">5</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1"/>
              <td align="left" valign="bottom" rowspan="1" colspan="1">780/60</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BV786</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD15</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">HI98</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences Cat# 563838, RRID:AB_2738444</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">6</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">488 nm</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">530/30</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">SYTOX Green</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">L/D</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">na</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:250</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific Cat# S34860</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">7</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">561 nm</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">585/15</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">PE</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD3</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">SK7</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:40</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific Cat# 12-0036-42, RRID:AB_10805512</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">8</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1"/>
              <td align="left" valign="bottom" rowspan="1" colspan="1">610/20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">PECF594</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD127</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">HIL-7R</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BD Biosciences Cat# 562397, RRID:AB_11154212</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">9</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1"/>
              <td align="left" valign="bottom" rowspan="1" colspan="1">780/60</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">PECy7</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD206</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">19.2</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:40</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">Thermo Fisher Scientific Cat# 25-2069-42, RRID:AB_2573426</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">10</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">640 nm</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">670/30</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">APC</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">CD8</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">SK1</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:20</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend Cat# 344721, RRID:AB_2075390</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" rowspan="1" colspan="1">11</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1"/>
              <td align="left" valign="bottom" rowspan="1" colspan="1">670/30</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">APC</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">EpCAM</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">9C4</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">1:40</td>
              <td align="left" valign="bottom" rowspan="1" colspan="1">BioLegend Cat# 324208, RRID:AB_756082</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec sec-type="supplementary-material" id="SM1">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>1</label>
        <media xlink:href="NIHMS1656482-supplement-1.docx" orientation="portrait" id="d40e3406" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD2">
        <label>1656482_Supp_Data1</label>
        <media xlink:href="NIHMS1656482-supplement-1656482_Supp_Data1.xlsx" orientation="portrait" id="d40e3410" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD3">
        <label>1656482_Supp_Data2</label>
        <media xlink:href="NIHMS1656482-supplement-1656482_Supp_Data2.csv" orientation="portrait" id="d40e3414" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD4">
        <label>1656482_Supp_Data3</label>
        <media xlink:href="NIHMS1656482-supplement-1656482_Supp_Data3.csv" orientation="portrait" id="d40e3418" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD5">
        <label>1656482_Supp_Data4</label>
        <media xlink:href="NIHMS1656482-supplement-1656482_Supp_Data4.csv" orientation="portrait" id="d40e3422" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD6">
        <label>1656482_Supp_Data5</label>
        <media xlink:href="NIHMS1656482-supplement-1656482_Supp_Data5.csv" orientation="portrait" id="d40e3426" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD7">
        <label>1656482_Supp_Data6</label>
        <media xlink:href="NIHMS1656482-supplement-1656482_Supp_Data6.csv" orientation="portrait" id="d40e3430" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD8">
        <label>1656482_Supp_Data8</label>
        <media xlink:href="NIHMS1656482-supplement-1656482_Supp_Data8.pdf" orientation="portrait" id="d40e3434" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD9">
        <label>1656482_Supp_Data9</label>
        <media xlink:href="NIHMS1656482-supplement-1656482_Supp_Data9.csv" orientation="portrait" id="d40e3438" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD10">
        <label>1656482_Supp_Data7</label>
        <media xlink:href="NIHMS1656482-supplement-1656482_Supp_Data7.tif" orientation="portrait" id="d40e3442" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD11">
        <label>12</label>
        <media xlink:href="NIHMS1656482-supplement-12.pdf" orientation="portrait" id="d40e3447" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD12">
        <label>Supp_Vid1</label>
        <media xlink:href="NIHMS1656482-supplement-Supp_Vid1.mp4" orientation="portrait" id="d40e3451" position="anchor" mimetype="video"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD13">
        <label>13</label>
        <media xlink:href="NIHMS1656482-supplement-13.pdf" orientation="portrait" id="d40e3455" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S22">
      <title>Acknowledgments and funding:</title>
      <p id="P72">Northwestern University Flow Cytometry Core Facility is supported by NCI Cancer Center Support Grant P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. Cell sorting was performed on BD FACSAria SORP cell sorter purchased through the support of NIH 1S10OD011996-01. Imaging work was performed at the Northwestern University Center for Advanced Microscopy supported by NCI Cancer Center Support Grant P30 CA060553 awarded to the Robert H Lurie Comprehensive Cancer Center. This research was supported in part through the computational resources and staff contributions provided by the Genomics Compute Cluster which is jointly supported by the Feinberg School of Medicine, the Center for Genetic Medicine, and Feinberg&#x2019;s Department of Biochemistry and Molecular Genetics, the Office of the Provost, the Office for Research, and Northwestern Information Technology. The Genomics Compute Cluster is part of Quest, Northwestern University&#x2019;s high-performance computing facility, with the purpose to advance research in genomics. We would like to thank the Office for Research Safety and Institutional Biosafety Committee at Northwestern University for their help and guidance in setting up protocols and workflows for safe processing of samples from patients with COVID-19. Single-cell RNA sequencing was performed with support from Simpsons Querrey Institute for Epigenetics.</p>
      <p id="P73">Rogan Grant was supported by NIH grant T32AG020506-18. Luisa Morales-Nebreda was supported by T32HL076139 and F32HL151127. Ankit Bharat was supported by NIH grants HL145478, HL147290, and HL147575. Cara J. Gottardi was supported by NIH grants GM129312 and HL134800. GR Scott Budinger was supported by NIH grants U19AI135964, P01AG049665, P01AG04966506S1, R01HL147575 and Veterans Affairs grant I01CX001777. Alexander V. Misharin was supported by NIH grants U19AI135964, P01AG049665, R56HL135124, R01HL153312 and NUCATS COVID-19 Rapid Response Grant. Benjamin D. Singer was supported by NIH awards K08HL128867, U19AI135964, R01HL149883, and P01AG049665. Richard G. Wunderink was supported by NIH grant U19AI135964 and a GlaxoSmithKline Distinguished Scholar in Respiratory Health grant from the CHEST Foundation.</p>
    </ack>
    <fn-group>
      <fn fn-type="COI-statement" id="FN6">
        <p id="P74">Authors do not declare conflict of interest.</p>
      </fn>
      <fn id="FN7">
        <p id="P75">Data availability:</p>
        <p id="P76">Bulk RNA-seq counts tables and metadata are included as <xref rid="SD3" ref-type="supplementary-material">Supplemental Data Files 2</xref> and <xref rid="SD4" ref-type="supplementary-material">3</xref>. Single-cell RNA-seq counts tables and integrated objects are available through GEO with accession number GSE155249. Raw data are available through SRA/dbGaP phs002300.v1.p1.</p>
      </fn>
      <fn id="FN8">
        <p id="P77">Code availability:</p>
        <p id="P78">All code used for analysis is available at: <ext-link ext-link-type="uri" xlink:href="https://github.com/NUPulmonary/2020_Grant">https://github.com/NUPulmonary/2020_Grant</ext-link>. High-level bulk and single-cell RNA-seq data can be explored via our in-house data browsers at <ext-link ext-link-type="uri" xlink:href="https://www.nupulmonary.org/covid-19/">https://www.nupulmonary.org/covid-19/</ext-link>.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>X</given-names></name>
<etal/>
<article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title>. <source>Lancet Respir Med</source>
<volume>8</volume>, <fpage>475</fpage>&#x2013;<lpage>481</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32105632</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><name><surname>Gattinoni</surname><given-names>L</given-names></name>
<etal/>
<article-title>COVID-19 Does Not Lead to a &#x201C;Typical&#x201D; Acute Respiratory Distress Syndrome</article-title>. <source>American Journal of Respiratory and Critical Care Medicine</source> vol. <volume>201</volume>
<fpage>1299</fpage>&#x2013;<lpage>1300</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32228035</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><name><surname>Baud</surname><given-names>D</given-names></name>
<etal/>
<article-title>Real estimates of mortality following COVID-19 infection</article-title>. <source>Lancet Infect. Dis</source>
<volume>20</volume>, <fpage>773</fpage> (<year>2020</year>).</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>F</given-names></name>
<etal/>
<article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>. <source>Lancet</source>
<volume>395</volume>, <fpage>1054</fpage>&#x2013;<lpage>1062</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><collab>RECOVERY Collaborative Group</collab>
<etal/>
<article-title>Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report</article-title>. <source>N. Engl. J. Med</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2021436</pub-id><comment>.</comment></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><collab>National Heart, Lung, and Blood Institute PETAL Clinical Trials Network</collab>
<etal/>
<article-title>Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome</article-title>. <source>N. Engl. J. Med</source>
<volume>380</volume>, <fpage>1997</fpage>&#x2013;<lpage>2008</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31112383</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><name><surname>Watanabe</surname><given-names>S</given-names></name>, <name><surname>Alexander</surname><given-names>M</given-names></name>, <name><surname>Misharin</surname><given-names>AV</given-names></name>, <name><surname>Budinger</surname><given-names>GRS</given-names></name> &amp; <comment>Others.</comment>
<article-title>The role of macrophages in the resolution of inflammation</article-title>. <source>J. Clin. Invest</source>
<volume>129</volume>, <fpage>2619</fpage>&#x2013;<lpage>2628</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31107246</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>D</given-names></name>
<etal/>
<article-title>The Architecture of SARS-CoV-2 Transcriptome</article-title>. <source>Cell</source>
<volume>181</volume>, <fpage>914</fpage>&#x2013;<lpage>921.e10</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32330414</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><name><surname>Liao</surname><given-names>M</given-names></name>
<etal/>
<article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title>. <source>Nat. Med</source>
<volume>26</volume>, <fpage>842</fpage>&#x2013;<lpage>844</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32398875</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><name><surname>Chua</surname><given-names>RL</given-names></name>
<etal/>
<article-title>COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis</article-title>. <source>Nat. Biotechnol</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1038/s41587-020-0602-4</pub-id><comment>.</comment></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><name><surname>Sola</surname><given-names>I</given-names></name>, <name><surname>Almaz&#xE1;n</surname><given-names>F</given-names></name>, <name><surname>Z&#xFA;&#xF1;iga</surname><given-names>S</given-names></name> &amp; <name><surname>Enjuanes</surname><given-names>L</given-names></name>
<article-title>Continuous and Discontinuous RNA Synthesis in Coronaviruses</article-title>. <source>Annu Rev Virol</source>
<volume>2</volume>, <fpage>265</fpage>&#x2013;<lpage>288</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26958916</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>J</given-names></name>
<etal/>
<article-title>Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis</article-title>. <source>J. Infect. Dis</source>
<volume>209</volume>, <fpage>1331</fpage>&#x2013;<lpage>1342</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24065148</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><name><surname>Yip</surname><given-names>MS</given-names></name>
<etal/>
<article-title>Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus</article-title>. <source>Virol. J</source>
<volume>11</volume>, <fpage>82</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24885320</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><name><surname>Cheung</surname><given-names>CY</given-names></name>
<etal/>
<article-title>Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis</article-title>. <source>J. Virol</source>
<volume>79</volume>, <fpage>7819</fpage>&#x2013;<lpage>7826</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15919935</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><name><surname>Soberanes</surname><given-names>S</given-names></name>
<etal/>
<article-title>Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis</article-title>. <source>Cell Metab</source>. <volume>29</volume>, <fpage>503</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30726761</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><name><surname>Price</surname><given-names>LC</given-names></name>, <name><surname>McCabe</surname><given-names>C</given-names></name>, <name><surname>Garfield</surname><given-names>B</given-names></name> &amp; <name><surname>Wort</surname><given-names>SJ</given-names></name>
<article-title>Thrombosis and COVID-19 pneumonia: the clot thickens!</article-title>
<source>The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology</source> vol. <volume>56</volume> (<year>2020</year>).</mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><name><surname>Vabret</surname><given-names>N</given-names></name>
<etal/>
<article-title>Immunology of COVID-19: Current State of the Science</article-title>. <source>Immunity</source>
<volume>52</volume>, <fpage>910</fpage>&#x2013;<lpage>941</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32505227</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><name><surname>Wilk</surname><given-names>AJ</given-names></name>
<etal/>
<article-title>A single-cell atlas of the peripheral immune response in patients with severe COVID-19</article-title>. <source>Nat. Med</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1038/s41591-020-0944-y</pub-id><comment>.</comment></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name>
<etal/>
<article-title>Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment</article-title>. <source>Cell</source>
<volume>182</volume>, <fpage>1419</fpage>&#x2013;<lpage>1440.e23</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32810438</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><name><surname>Habermann</surname><given-names>AC</given-names></name>
<etal/>
<article-title>Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis</article-title>. <source>Science Advances</source>
<volume>6</volume>, <fpage>eaba1972</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32832598</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><name><surname>Califano</surname><given-names>D</given-names></name>, <name><surname>Furuya</surname><given-names>Y</given-names></name> &amp; <name><surname>Metzger</surname><given-names>DW</given-names></name>
<article-title>Effects of Influenza on Alveolar Macrophage Viability Are Dependent on Mouse Genetic Strain</article-title>. <source>J. Immunol</source>
<volume>201</volume>, <fpage>134</fpage>&#x2013;<lpage>144</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29760191</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><name><surname>Sungnak</surname><given-names>W</given-names></name>
<etal/>
<article-title>SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes</article-title>. <source>Nat. Med</source>
<volume>26</volume>, <fpage>681</fpage>&#x2013;<lpage>687</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32327758</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><name><surname>Hou</surname><given-names>YJ</given-names></name>
<etal/>
<article-title>SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract</article-title>. <source>Cell</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.05.042</pub-id><comment>.</comment></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><name><surname>Chu</surname><given-names>H</given-names></name>
<etal/>
<article-title>Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19</article-title>. <source>Clin. Infect. Dis</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1093/cid/ciaa410</pub-id><comment>.</comment></mixed-citation>
      </ref>
      <ref id="R25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><name><surname>Blanco-Melo</surname><given-names>D</given-names></name>
<etal/>
<article-title>Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19</article-title>. <source>Cell</source>
<volume>181</volume>, <fpage>1036</fpage>&#x2013;<lpage>1045.e9</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32416070</pub-id></mixed-citation>
      </ref>
      <ref id="R26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><name><surname>Konno</surname><given-names>Y</given-names></name>
<etal/>
<article-title>SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant</article-title>. <source>Cell Rep</source>. <volume>32</volume>, <fpage>108185</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32941788</pub-id></mixed-citation>
      </ref>
      <ref id="R27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><name><surname>Hadjadj</surname><given-names>J</given-names></name>
<etal/>
<article-title>Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients</article-title>. <source>Science</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1126/science.abc6027</pub-id><comment>.</comment></mixed-citation>
      </ref>
      <ref id="R28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><name><surname>Jaume</surname><given-names>M</given-names></name>
<etal/>
<article-title>Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent Fc&#x3B3;R pathway</article-title>. <source>J. Virol</source>
<volume>85</volume>, <fpage>10582</fpage>&#x2013;<lpage>10597</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21775467</pub-id></mixed-citation>
      </ref>
      <ref id="R29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><name><surname>Martines</surname><given-names>RB</given-names></name>
<etal/>
<article-title>Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States</article-title>. <source>Emerg. Infect. Dis</source>
<volume>26</volume>, <fpage>2005</fpage>&#x2013;<lpage>2015</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32437316</pub-id></mixed-citation>
      </ref>
      <ref id="R30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><name><surname>Sariol</surname><given-names>A</given-names></name> &amp; <name><surname>Perlman</surname><given-names>S</given-names></name>
<article-title>Lessons for COVID-19 Immunity from Other Coronavirus Infections</article-title>. <source>Immunity</source>
<volume>53</volume>, <fpage>248</fpage>&#x2013;<lpage>263</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32717182</pub-id></mixed-citation>
      </ref>
      <ref id="R31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>L</given-names></name>
<etal/>
<article-title>Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection</article-title>. <source>JCI Insight</source>
<volume>4</volume>, (<year>2019</year>).</mixed-citation>
      </ref>
      <ref id="R32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><name><surname>Guilliams</surname><given-names>M</given-names></name>, <name><surname>Lambrecht</surname><given-names>BN</given-names></name> &amp; <name><surname>Hammad</surname><given-names>H</given-names></name>
<article-title>Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections</article-title>. <source>Mucosal Immunol</source>. <volume>6</volume>, <fpage>464</fpage>&#x2013;<lpage>473</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23549447</pub-id></mixed-citation>
      </ref>
      <ref id="R33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><name><surname>Gioia</surname><given-names>C</given-names></name>
<etal/>
<article-title>T-Cell response profiling to biological threat agents including the SARS coronavirus</article-title>. <source>Int. J. Immunopathol. Pharmacol</source>
<volume>18</volume>, <fpage>525</fpage>&#x2013;<lpage>530</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16164833</pub-id></mixed-citation>
      </ref>
      <ref id="R34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><name><surname>Grifoni</surname><given-names>A</given-names></name>
<etal/>
<article-title>Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals</article-title>. <source>Cell</source>
<volume>181</volume>, <fpage>1489</fpage>&#x2013;<lpage>1501.e15</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32473127</pub-id></mixed-citation>
      </ref>
      <ref id="R35">
        <label>35.</label>
        <mixed-citation publication-type="journal"><name><surname>Le Bert</surname><given-names>N</given-names></name>
<etal/>
<article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title>. <source>Nature</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1038/s41586-020-2550-z</pub-id><comment>.</comment></mixed-citation>
      </ref>
      <ref id="R36">
        <label>36.</label>
        <mixed-citation publication-type="journal"><name><surname>Mateus</surname><given-names>J</given-names></name>
<etal/>
<article-title>Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans</article-title>. <source>Science</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1126/science.abd3871</pub-id><comment>.</comment></mixed-citation>
      </ref>
      <ref id="R37">
        <label>37.</label>
        <mixed-citation publication-type="journal"><name><surname>Braun</surname><given-names>J</given-names></name>
<etal/>
<article-title>SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19</article-title>. <source>Nature</source>
<volume>587</volume>, <fpage>270</fpage>&#x2013;<lpage>274</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32726801</pub-id></mixed-citation>
      </ref>
      <ref id="R38">
        <label>38.</label>
        <mixed-citation publication-type="journal"><name><surname>Bacher</surname><given-names>P</given-names></name>
<etal/>
<article-title>Low avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19</article-title>. <source>Immunity</source>
<volume>0</volume>, (<year>2020</year>).</mixed-citation>
      </ref>
      <ref id="R39">
        <label>39.</label>
        <mixed-citation publication-type="journal"><name><surname>Oran</surname><given-names>DP</given-names></name> &amp; <name><surname>Topol</surname><given-names>EJ</given-names></name>
<article-title>Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review</article-title>. <source>Ann. Intern. Med</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.7326/M20-3012</pub-id><comment>.</comment></mixed-citation>
      </ref>
      <ref id="R40">
        <label>40.</label>
        <mixed-citation publication-type="journal"><name><surname>Neupane</surname><given-names>AS</given-names></name>
<etal/>
<article-title>Patrolling Alveolar Macrophages Conceal Bacteria from the Immune System to Maintain Homeostasis</article-title>. <source>Cell</source>
<volume>183</volume>, <fpage>110</fpage>&#x2013;<lpage>125.e11</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32888431</pub-id></mixed-citation>
      </ref>
      <ref id="R41">
        <label>41.</label>
        <mixed-citation publication-type="journal"><name><surname>Louie</surname><given-names>JK</given-names></name>
<etal/>
<article-title>Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California</article-title>. <source>JAMA</source>
<volume>302</volume>, <fpage>1896</fpage>&#x2013;<lpage>1902</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19887665</pub-id></mixed-citation>
      </ref>
      <ref id="R42">
        <label>42.</label>
        <mixed-citation publication-type="journal"><name><surname>Leisman</surname><given-names>DE</given-names></name>
<etal/>
<article-title>Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes</article-title>. <source>Lancet Respir Med</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30404-5</pub-id><comment>.</comment></mixed-citation>
      </ref>
      <ref id="R43">
        <label>43.</label>
        <mixed-citation publication-type="journal"><name><surname>Kox</surname><given-names>M</given-names></name>, <name><surname>Waalders</surname><given-names>NJB</given-names></name>, <name><surname>Kooistra</surname><given-names>EJ</given-names></name>, <name><surname>Gerretsen</surname><given-names>J</given-names></name> &amp; <name><surname>Pickkers</surname><given-names>P</given-names></name>
<article-title>Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions</article-title>. <source>JAMA</source> (<year>2020</year>) doi:<pub-id pub-id-type="doi">10.1001/jama.2020.17052</pub-id><comment>.</comment></mixed-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1.</label>
      <caption>
        <title>Schematic and demographics of the SCRIPT cohort.</title>
        <p id="P79"><bold>a</bold>. Schematic illustrating the interpretation of the main findings. 1. The normal alveolus contains <italic>ACE2</italic>-expressing alveolar type 1 and type 2 cells (AT1 and AT2, respectively) and tissue-resident alveolar macrophages (TRAM). 2. SARS-CoV-2 infects AT1 and AT2 cells and TRAM. Infected TRAM express T cell chemokines. 3. Cross-reactive or <italic>de novo</italic>-generated effector-memory T cells recognize SARS-CoV-2 antigens presented by TRAM and produce IFN&#x3B3;, further activating TRAM to produce cytokines and chemokines. 4. Activated T cells proliferate and continue to produce IFN&#x3B3;, eventually leading to death of infected TRAM and recruitment of monocytes, which rapidly differentiate into monocyte-derived alveolar macrophages (MoAM). 5. Recruited MoAM become infected with SARS-CoV-2, continuing to present antigens to T cells and maintaining the feedback loop until viral clearance is achieved. <bold>b.</bold> Timing of hospital admission (square), BAL fluid collection (diamonds), length of mechanical ventilation (bold red line), and hospital stay (thin grey line) in patients with severe COVID-19 grouped by outcomes (crossed open red circles &#x2013; death; green circles &#x2013; discharged). Day 0 is defined as the day of the first intubation. <bold>c</bold>. Distribution of patient age. Differences not significant by pairwise t-test with FDR correction. <bold>d</bold>. Proportions of females (red) and males (blue) (pairwise Chi-square tests of proportions with continuity and FDR correction). <bold>e</bold>. Self-reported ethnicity (pairwise Chi-square tests of proportions with continuity and FDR correction). <bold>f</bold>. Body mass index (BMI) (t-test with FDR correction). <bold>g</bold>. The Sequential Organ Failure Assessment (SOFA) score (pairwise Wilcoxon rank-sum tests with FDR correction). <bold>h</bold>. The Acute Physiology Score (APS) (pairwise Wilcoxon rank-sum tests with FDR correction). <bold>i</bold>. ICU length of stay (pairwise t-tests with FDR correction). <bold>j</bold>. The duration of mechanical ventilation (pairwise t-tests with FDR correction). <bold>k</bold>. Mortality in patients with COVID-19 was similar to patients in other groups (25% vs. 35%, P = 0.10, &#x3C7;<sup>2</sup> = 2.63, Chi-square tests of proportions).</p>
      </caption>
      <graphic xlink:href="nihms-1656482-f0001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Fig. 2.</label>
      <caption>
        <title>At the time of intubation, the alveolar space in patients with severe SARS-CoV-2 pneumonia is enriched for T cells and monocytes and contains alveolar macrophages harboring SARS-CoV-2 RNA and expressing interferon response genes.</title>
        <p id="P80"><bold>a.</bold> Hierarchical clustering of flow cytometry data from BAL samples collected within 48 hours of intubation. Column headers are color-coded by the diagnosis and presence or absence of co-infection (&#x201C;Infection Status&#x201D;). &#x201C;Infection Status&#x201D; refers only to the &#x201C;COVID-19&#x201D; and &#x201C;Other Viral Pneumonia&#x201D; groups. &#x201C;Viral infection only&#x201D; refers to viral pathogens as the only detected pathogen in a sample and &#x201C;Viral infection with bacterial/fungal co-infection&#x201D; refers to detection of a viral pathogen with one or more bacterial or fungal co-pathogens. Samples were clustered by Euclidean distance using Ward&#x2019;s method. <bold>b.</bold> Proportions of cells detected within 48 hours of intubation (q &lt; 0.05, pairwise Wilcoxon rank-sum tests with FDR correction). Comparisons are not significant unless otherwise noted. <bold>c</bold>. k-means clustering of the 1,194 significantly variable genes (q &lt; 0.05, likelihood-ratio test) across diagnosis. Columns represent each individual sample and are clustered using Ward&#x2019;s method. Column headers are color-coded by the diagnosis and presence or absence of a co-infecting pathogen (&#x201C;Infection Status&#x201D;). &#x201C;Infection Status&#x201D; refers only to the &#x201C;COVID-19&#x201D; and &#x201C;Other Viral Pneumonia&#x201D; groups; blanks in these groups refer to samples for which microbiology data were incomplete and infectious status could not be determined. &#x201C;Viral infection only&#x201D; refers to viral pathogens as the only detected pathogen in a sample and &#x201C;Viral infection with bacterial/fungal co-infection&#x201D; refers to detection of a viral pathogen with one or more bacterial or fungal co-pathogens. Representative genes and GO biological processes are shown for each cluster.</p>
      </caption>
      <graphic xlink:href="nihms-1656482-f0002"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Fig. 3.</label>
      <caption>
        <title>The BAL fluid from patients with SARS-CoV-2 pneumonia is persistently enriched for T cells and characterized by an interferon-response signature in alveolar macrophages.</title>
        <p id="P81"><bold>a.</bold> Hierarchical clustering of flow cytometry analysis of BAL samples from all time points from patients with serial sampling (n &gt; 1) based on their composition. Column headers are color-coded by the diagnosis, patient, duration of mechanical ventilation, and presence or absence of superinfection (&#x201C;Infection Status&#x201D;). &#x201C;Infection Status&#x201D; refers only to the &#x201C;COVID-19&#x201D; and &#x201C;Other Viral Pneumonia&#x201D; groups; blanks in these groups refer to samples for which microbiology data were incomplete and infectious status could not be determined. &#x201C;Viral infection only&#x201D; refers to viral pathogens as the only detected pathogen in a sample and &#x201C;Viral infection with bacterial/fungal superinfection&#x201D; refers to detection of a viral pathogen with one or more bacterial or fungal co-pathogens. Samples were clustered by Euclidean distance using Ward&#x2019;s method. <bold>b.</bold> Comparison of percentage of CD4+ and CD8+ T cells and neutrophils between early (&lt;48 hours after intubation) and late (&gt;48 hours of mechanical ventilation) samples (q &lt; 0.05, pairwise Wilcoxon rank-sum tests with FDR correction). <bold>c.</bold> k-means clustering of the 2,323 significantly variable genes (q &lt; 0.05, likelihood-ratio test) across diagnosis, columns represent each individual patient and clustered using Ward&#x2019;s method. Representative genes and GO biological processes are shown for each cluster. Column headers are color-coded by the diagnosis, duration of mechanical ventilation (white color indicates chronically ventilated patients), and presence or absence of superinfection (&#x201C;Infection Status&#x201D;). &#x201C;Infection Status&#x201D;, &#x201C;Viral infection only&#x201D; and &#x201C;Viral infection with bacterial/fungal superinfection&#x201D; are as in panel <bold>a.</bold></p>
      </caption>
      <graphic xlink:href="nihms-1656482-f0003"/>
    </fig>
    <fig id="F4" orientation="portrait" position="float">
      <label>Fig. 4.</label>
      <caption>
        <title>Single-cell RNA-seq identifies a positive feedback loop between IFN&#x3B3;-producing T cells and SARS-CoV-2-infected alveolar macrophages.</title>
        <p id="P82"><bold>a</bold>. UMAP plot showing integrated analysis of 77,146 cells isolated from 10 patients with severe COVID-19 within 48 hours after intubation. AT1 &#x2013; alveolar epithelial type 1 cells; AT2 &#x2013; alveolar epithelial type 2 cells; DC1 &#x2013; conventional dendritic cells type 1, <italic>CLEC9A</italic>+; DC2 &#x2013; conventional dendritic cells type 2, <italic>CD1C</italic>+; Migratory DC &#x2013; migratory dendritic cells, <italic>CCR7</italic>+; pDC &#x2013; plasmacytoid dendritic cells, <italic>CLEC4C</italic>+; Mixed myeloid &#x2013; mixed cluster containing transitory dendritic cells and very immature monocyte-derived macrophages; TRAM &#x2013; tissue-resident alveolar macrophages; MoAM &#x2013; monocyte-derived alveolar macrophages; iNKT cells &#x2013; invariant natural killer T cells; Treg &#x2013; regulatory T cells, <italic>FOXP3</italic>+. <bold>b.</bold> Heatmap demonstrating expression of the selected genes of interest in two subsets of tissue-resident (TRAM1 and TRAM2) and four subsets of monocyte-derived (MoAM1, MoAM2, MoAM3, MoAM4) alveolar macrophages. Each column represents a single patient with COVID-19. <bold>c</bold>. Expression of <italic>IFNG</italic> is restricted to T cells. <bold>d</bold>. Detection of SARS-CoV-2 transcripts. Plot shows cumulative number of SARS-CoV-2 genes plus negative strand. <bold>e-g</bold>. Specific upregulation of selected cytokines and chemokines in TRAM2: <italic>CXCL10</italic> (<bold>e.</bold>), <italic>CCL4</italic> (<bold>f.</bold>), <italic>IL1B</italic> (<bold>g.</bold>). Density projection plots, expression averaged within hexagonal areas on UMAP. <bold>h</bold>. Heatmap demonstrating selected differentially expressed genes between two subsets of tissue-resident alveolar macrophages (TRAM1 and TRAM2). <bold>i</bold>. SARS-CoV-2 infection is spatially restricted. Combined immunofluorescence microscopy for CD206, a marker of mature macrophages (red arrows), and smFISH (RNAscope) for positive- (yellow arrowheads) and negative-strand (cyan doublehead arrows) SARS-CoV-2 transcripts. Inserts show infected and non-infected CD206-positive alveolar macrophages in the adjacent alveoli.</p>
      </caption>
      <graphic xlink:href="nihms-1656482-f0004"/>
    </fig>
  </floats-group>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32968280</article-id>
      <article-id pub-id-type="pmc">7116725</article-id>
      <article-id pub-id-type="manuscript">EMS114563</article-id>
      <article-id pub-id-type="doi">10.1038/s41586-020-2744-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Conformation of sister chromatids in the replicated human genome</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mitter</surname>
            <given-names>Michael</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="corresp" rid="CR1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gasser</surname>
            <given-names>Catherina</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takacs</surname>
            <given-names>Zsuzsanna</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Langer</surname>
            <given-names>Christoph C. H.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>Wen</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jessberger</surname>
            <given-names>Gregor</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Beales</surname>
            <given-names>Charlie T.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Neuner</surname>
            <given-names>Eva</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ameres</surname>
            <given-names>Stefan L.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Peters</surname>
            <given-names>Jan-Michael</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goloborodko</surname>
            <given-names>Anton</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Micura</surname>
            <given-names>Ronald</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gerlich</surname>
            <given-names>Daniel W.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="corresp" rid="CR1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
<label>1</label>Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCenter, Vienna, Austria</aff>
      <aff id="A2">
<label>2</label>Institute of Organic Chemistry and Center for Molecular Biosciences (CMBI), Leopold-Franzens University, Innsbruck, Austria</aff>
      <aff id="A3">
<label>3</label>Research Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria</aff>
      <aff id="A4">
<label>4</label>Department of Physics, Massachusetts Institute of Technology, Cambridge, MA, USA</aff>
      <author-notes>
        <corresp id="CR1"><label>*</label>Correspondence to: <email>michael.mitter@imba.oeaw</email> and <email>daniel.gerlich@imba.oeaw.ac.at</email></corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>01</day>
        <month>2</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>01</day>
        <month>10</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>23</day>
        <month>3</month>
        <year>2021</year>
      </pub-date>
      <volume>586</volume>
      <issue>7827</issue>
      <fpage>139</fpage>
      <lpage>144</lpage>
      <permissions>
        <license>
          <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p>
        </license>
      </permissions>
      <abstract>
        <p id="P1">The three-dimensional organization of the genome supports regulated gene expression, recombination, DNA repair, and chromosome segregation during mitosis. Chromosome conformation capture (Hi-C)<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> has revealed a complex genomic landscape of internal chromosome structures in vertebrate cells<sup><xref rid="R3" ref-type="bibr">3</xref>&#x2013;<xref rid="R7" ref-type="bibr">7</xref></sup> yet how sister chromatids topologically interact in replicated chromosomes has remained elusive due to their identical sequences. Here, we present sister-chromatid-sensitive Hi-C (scsHi-C) based on nascent DNA labeling with 4-thio-thymidine and nucleoside conversion chemistry. Genome-wide conformation maps of human chromosomes revealed that sister chromatid pairs interact most frequently at the boundaries of topologically associating domains (TADs). Continuous loading of a dynamic cohesin pool separates sister-chromatid pairs inside TADs and is required to focus sister chromatid contacts at TAD boundaries. We identified a subset of TADs that are overall highly paired, characterized by facultative heterochromatin, as well as insulated topological domains that form separately within individual sister chromatids. The rich pattern of sister chromatid topologies and our scsHi-C technology will make it possible to dissect how physical interactions between identical DNA molecules contribute to DNA repair, gene expression, chromosome segregation, and potentially other biological processes.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p id="P2">Expression, maintenance, and inheritance of genetic information relies on highly regulated topological interactions within and between huge chromosomal DNA molecules. For instance, intramolecular contacts between promoters and distant enhancers activate gene transcription<sup><xref rid="R8" ref-type="bibr">8</xref></sup>, whereas intermolecular contacts between homologous DNA sequences of replicated sister chromatids enable error-free DNA damage repair<sup><xref rid="R9" ref-type="bibr">9</xref></sup>. During cell cycle progression, conformational changes of chromosomes shape mechanical bodies that can be segregated by the mitotic spindle<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup>. In vertebrates, intramolecular DNA loops are dynamically formed by the Structural Maintenance of Chromosomes complex cohesin<sup><xref rid="R11" ref-type="bibr">11</xref>&#x2013;<xref rid="R17" ref-type="bibr">17</xref></sup> within boundaries established by the CCCTC-binding factor (CTCF), thereby structuring chromosomes into topologically associating domains (TADs)<sup><xref rid="R3" ref-type="bibr">3</xref>&#x2013;<xref rid="R5" ref-type="bibr">5</xref></sup>. This organization contributes to transcriptional control<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup>, and misregulated chromosome conformations have been associated with developmental disorders<sup><xref rid="R19" ref-type="bibr">19</xref></sup> and cancer<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup>. A distinct pool of cohesin links sister chromatids<sup><xref rid="R22" ref-type="bibr">22</xref></sup> topologically to enable homology-directed DNA repair<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> and chromosome segregation in subsequent mitosis<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup>. However, it is not known how cohesive linkages distribute on the genome to support these important functions, and how they are coordinated with dynamic loop formation and TADs.</p>
    <p id="P3">The complex organization of vertebrate genomes has been revealed by chromosome conformation capture technology (Hi-C)<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup>, which maps DNA contacts genome-wide. However, Hi-C technology cannot currently be used to explore topological interactions between the sister chromatids of replicated chromosomes, as the identical DNA sequences in replicated chromosomes make it impossible to distinguish between intra-molecular and inter-molecular contacts. To overcome this limitation, we have developed sister-chromatid-sensitive Hi-C (scsHi-C) for genome-wide conformation analysis of replicated human chromosomes.</p>
    <sec id="S1">
      <title>Sister-chromatid-sensitive Hi-C</title>
      <p id="P4">To distinguish between cis and trans sister chromatid contacts, it would be necessary to introduce a sister-chromatid-specific label. This could be achieved by culturing cells for one round of DNA replication in the presence of a DNA nucleotide analogue to label the Watson strand on one sister chromatid and the Crick strand on the other (<xref ref-type="fig" rid="F1">Fig. 1a</xref>). If the nucleotide analogue can be detected by DNA sequencing, then standard Hi-C procedures could be used to categorize chromatid contacts as either cis, which would be labelled on the same strand, or trans, which would be labelled on different strands (<xref ref-type="fig" rid="F1">Fig. 1b</xref>).</p>
      <fig id="F1" orientation="portrait" position="anchor">
        <label>Figure 1</label>
        <caption>
          <title>scsHi-C methodology based on nascent DNA labeling in live cells.</title>
          <p id="P01">(a) Sister chromatid-specific labeling using synthetic nucleotides. During DNA replication, a synthetic nucleotide analogue incorporates into different strands (Watson or Crick) within each sister chromatid. Labelled DNA, dashed line; unlabelled DNA, solid line. (b) Strategy to distinguish cis from trans sister contacts in a Hi-C experiment based on 4sT-mediated DNA labeling. After progression through S-Phase in the presence of 4sT, each sister chromatid contains one labelled DNA strand of opposing strandedness (see panel a). Chromatin is crosslinked in cells and Hi-C samples are prepared using standard procedures, followed by chemical conversion to induce 4sT signature mutations and Illumina-based sequencing. Half-reads are classified as labelled if at least two signature mutations are present. If a ligation junction contains two labelled half-reads that map to the same strand, it is classified as cis sister contact; if it contains two labelled halves that map to opposing strands, it is classified as a trans sister contact (see <xref ref-type="fig" rid="F8">Extended Data Fig. 4a</xref> for details). (c) Conversion of 4-thio-thymidine (4sT) to the point-mutation inducing 5-methyl-cytosine (5mC) by treating DNA with OsO<sub>4</sub> and NH<sub>4</sub>Cl at elevated temperatures. Functional groups that are changed in the course of the reaction are highlighted in red. (d) Point-mutation rates of genomic DNA from HeLa cells grown in medium containing 4sT relative to control DNA from cells grown in the absence of 4sT, before and after OsO<sub>4</sub>/NH<sub>4</sub>Cl-mediated conversion. Bar graphs indicate the mean of n = 3 biologically independent experiments.</p>
        </caption>
        <graphic xlink:href="EMS114563-f001"/>
      </fig>
      <p id="P5">To establish a sister-chromatid-specific DNA label, we considered 4-thio-thymidine (4sT), because its RNA-analogue 4-thio-uridine is used to label nascent RNA without compromising cell viability<sup><xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup>. ThioUridine-to-Cytidine-sequencing (TUC-seq)<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> employs 4-thio-uridine labeling combined with post-extraction OsO<sub>4</sub> / NH<sub>4</sub>Cl conversion chemistry to generate distinct point mutations. If this chemistry could be adapted to convert 4sT into 5-methyl-cytosine (5mC) after genomic DNA purification (<xref ref-type="fig" rid="F1">Fig. 1c</xref>), then 4sT-labelled DNA would also generate signature mutations that could be detected by high-throughput sequencing. We tested whether 4sT within synthetic DNA oligonucleotides can be converted into 5mC by OsO<sub>4</sub> / NH<sub>4</sub>Cl chemistry and found that, after 3 hours, virtually all 4sT was converted into 5mC (<xref ref-type="fig" rid="F5">Extended Data Fig. 1a-d</xref>). To assess toxicity, we cultured HeLa cells in medium containing 4sT and found no activation of DNA damage response nor compromised cell viability up to 6 mM 4sT (<xref ref-type="fig" rid="F6">Extended Data Fig. 2a-c</xref>). Furthermore, 2 mM 4sT only slightly prolonged S-phase, and almost all cells progressed through mitosis to the following G1 phase (<xref ref-type="fig" rid="F6">Extended Data Fig. 2d</xref>). Thus, 4sT fulfils key requirements for sister-chromatid-specific labelling of genomic DNA in live cells.</p>
      <p id="P6">Next, we assessed how efficiently 4sT labels genomic DNA. We cultured cells in the presence or absence of 2 mM 4sT for 5 days to establish fully labelled and unlabelled conditions, respectively. We then purified genomic DNA, treated with OsO<sub>4</sub> / NH<sub>4</sub>Cl, amplified, and sequenced. Conversion of 4sT to 5mC should yield reads with signature A-to-G and T-to-C point mutations depending on whether the forward or reverse strand of a PCR amplicon is sequenced. Indeed, these signature mutations were elevated almost 50-fold in DNA isolated from 4sT-treated cells compared to controls, whereas other point mutations were not affected (<xref ref-type="fig" rid="F1">Fig. 1d</xref>). The overall frequency of signature mutations was 2.5%, in agreement with mass spectrometry-based detection of 4sT in genomic DNA (<xref ref-type="fig" rid="F7">Extended Data Fig. 3a, b</xref>). Importantly, 4sT-labelled DNA that was not chemically converted had a similar point mutation distribution to that of unlabelled DNA (<xref ref-type="fig" rid="F1">Fig. 1d</xref>). Thus, chemical conversion of 4sT-labelled genomic DNA produces a strong and specific mutation signature that can be detected by high-throughput sequencing.</p>
      <p id="P7">To implement an scsHi-C procedure (<xref ref-type="fig" rid="F7">Extended Data Fig. 3c</xref>), we synchronized HeLa cells to the G1/S boundary, released them into medium containing 4sT for one S-Phase, and arrested them in the subsequent G2 phase using the Cdk1 inhibitor RO3306<sup><xref rid="R29" ref-type="bibr">29</xref></sup> (<xref ref-type="fig" rid="F7">Extended Data Fig. 3d, e</xref>). We cross-linked chromatin, digested, tagged with biotin, ligated and purified, as per standard Hi-C procedures adapted from<sup><xref rid="R30" ref-type="bibr">30</xref></sup>; we then converted 4sT to 5mC and prepared DNA libraries for high-throughput sequencing. Hi-C maps from all contacts closely resembled those from similarly processed cells grown without 4sT treatment (<xref ref-type="fig" rid="F7">Extended Data Fig. 3f, g</xref>), indicating that 4sT labelling does not perturb genome conformation. To construct sister-chromatid-resolved contact maps, we used reads that contained 4sT-specific point mutations on both sides of the contact (&#x201C;double-labelled reads&#x201D;). Reads were classified as cis sister contacts if the labels mapped to the same chromosomal DNA strand on both sides, and as trans sister contacts if the labels mapped to different chromosomal DNA strands on each side (<xref ref-type="fig" rid="F1">Fig. 1b</xref>; <xref ref-type="fig" rid="F8">Extended Data Fig. 4a</xref>). Statistical analyses of various labeling conditions indicate that less than 2 % of trans sister contacts are wrongly assigned (<xref ref-type="fig" rid="F8">Extended Data Fig. 4b-f</xref>). Thus, scsHi-C enables accurate discrimination between cis- and trans sister contacts.</p>
      <p id="P8">To assess whether scsHi-C can detect resolution and segregation of sister chromatids, we analyzed cells progressing from G2 through mitosis to the following G1 (<xref ref-type="fig" rid="F7">Extended Data Fig. 3d, e</xref>). Sister chromatids resolve during mitotic entry, which should reduce trans sister contacts. In the following G1, each daughter cell inherits only one labelled sister chromatid per homologous chromosome and trans sister contacts should not be present. scsHi-C analysis indeed showed that trans sister contacts dropped from 23.7 % in G2 to 9.8 % in prometaphase and 2.7 % in the following G1 (<xref ref-type="fig" rid="F8">Extended Data Fig. 4g</xref>), whereby residual trans sister contacts in the G1 sample are most likely due to incomplete synchronization (<xref ref-type="fig" rid="F7">Extended Data Fig. 3e</xref>). Thus, scsHi-C enables genome-wide analysis of sister chromatid interactions in human cells.</p>
    </sec>
    <sec id="S2">
      <title>Conformation of replicated chromosomes</title>
      <p id="P9">To determine where sister chromatids contact each other during interphase and to measure the extent of sister chromatid resolution during mitosis, we constructed genome-wide scsHi-C maps of cells synchronized to G2 or mitotic prometaphase (<xref ref-type="fig" rid="F2">Fig. 2a, b</xref>; <xref ref-type="fig" rid="F7">Extended Data Fig. 3d, e</xref>; <xref ref-type="supplementary-material" rid="SD1">Table S1, 2</xref>). G2 maps were constructed based on 1.7 billion Hi-C reads, which yielded 195 million unique sister-chromatid-specific contacts of 11 highly reproducible replicates (<xref ref-type="fig" rid="F9">Extended Data Fig. 5a, b</xref>; <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). In low-magnification views, trans sister contacts were highly enriched along the diagonal (<xref ref-type="fig" rid="F2">Fig. 2a</xref>), indicating that sister chromatids were overall aligned. In scsHi-C maps of prometaphase cells, trans sister contacts were very scarce and not substantially enriched along the diagonal (<xref ref-type="fig" rid="F2">Fig. 2b</xref>; <xref ref-type="fig" rid="F9">Extended Data Figure 5c, d</xref>). scsHi-C thus reveals globally paired organization of sister chromatids in interphase and almost complete separation in mitosis.</p>
      <fig id="F2" orientation="portrait" position="anchor">
        <label>Figure 2</label>
        <caption>
          <title>Genome-wide conformation maps of replicated human chromosomes.</title>
          <p id="P02">(a) Hi-C interaction matrices of the long arm of chromosome 1 of all contacts, cis sister-, and trans sister contacts merged G2 samples from n = 11 biologically independent experiments. The all-contacts matrix was normalized to the total number of corrected contacts in the region of interest (ROI), whereas cis sister and trans sister contacts were normalized to the total amount of cis sister and trans sister contacts in the ROI. Bin size of the matrix is 500 kb. (b) Hi-C interaction matrix of the long arm of chromosome 1 of all, cis sister, and trans sister contacts of merged prometaphase samples from n = 2 biologically independent experiments. Contacts were normalized as in (a). Bin size of the matrix is 500 kb. (c) Average contact probability over different genomic distances for cis sister and trans sister contacts of the G2 sample shown in (a). (d) Average contact probability as in (c) of the prometaphase sample shown in (b). (e) All-contacts, cis sister and trans sister contacts, as well as the ratio of trans sister observed/expected to cis sister observed/expected of merged G2 samples from n = 11 biologically independent experiments at a representative region on chromosome 8 is displayed alongside the location of TAD boundaries and the trans sister pairing score within a sliding diamond of 400 kb (see <xref ref-type="sec" rid="S6">Method section</xref> for details). Bin size of the matrix is 20 kb. (f) Stack-up of trans sister pairing score (see <xref ref-type="sec" rid="S6">Method section</xref> for details) along TADs that are highly paired or highly unpaired (see <xref ref-type="fig" rid="F10">Extended Data Fig. 6d</xref>), sorted by the size of TADs. Shown are windows of 6 Mb around the center of the respective TADs. Pairing scores were calculated within a sliding window of 200 kb on a Hi-C matrix with 20 kb bin size. Data shown is from merged G2 samples from n = 11 biologically independent experiments. (g) Visualization of enrichment analysis that was done on TADs that exhibit high pairing (see <xref ref-type="fig" rid="F10">Extended Data Fig. 6d</xref>) using LOLA<sup><xref rid="R33" ref-type="bibr">33</xref></sup>. The panel shows all chromatin modification datasets in the extended LOLA database for HeLa cells with their respective p-value. P-value cut-off (p &lt; 0.01) is displayed as a dashed line. (h) Quantification of H3K27me3 enrichment at highly paired (n = 490) and highly unpaired (n = 570) TADs, displaying the average fold-enrichment of H3K27me3 within the respective intervals. P-value was calculated using a two-sided Mann-Whitney U test. P = 7 * 10<sup>-100</sup>.</p>
        </caption>
        <graphic xlink:href="EMS114563-f002"/>
      </fig>
      <p id="P10">To investigate sister chromatid organization in more detail, we calculated average contact frequencies over distinct genomic intervals. In G2 cells, cis sister contacts were more frequent than trans sister contacts over genomic distances up to ~3 Mb (<xref ref-type="fig" rid="F2">Fig. 2c</xref>), indicating local sister separation and register shift within the globally paired arrangement. Above genomic distances of 3 Mb, cis and trans sister-contact frequencies were indistinguishable, suggesting an overall intermixed arrangement of sister chromatids in G2 nuclei. In prometaphase cells, cis sister contacts dominated trans sister contacts even at 100 Mb genomic intervals (<xref ref-type="fig" rid="F2">Fig. 2d</xref>). Thus, locally separated but globally entangled sister chromatids of interphase nuclei convert into almost completely resolved bodies during mitosis.</p>
      <p id="P11">We next explored how trans sister contacts are coordinated with intra-chromatid conformations. High-magnification scsHi-C maps of G2 chromosomes showed a highly structured pattern of trans sister contacts along the diagonal, which to some extent corresponded to the positions of TADs in cis sister contact maps (<xref ref-type="fig" rid="F2">Fig. 2e</xref>). However, trans and cis sister contact distributions were highly divergent, with some TADs densely filled with trans sister contacts, indicating extensive pairing, whereas others were virtually devoid of trans sister contacts, indicating loose association (<xref ref-type="fig" rid="F2">Fig. 2e</xref>, <xref ref-type="fig" rid="F10">Extended Data Fig. 6a</xref>). Regions with low frequencies of trans sister contacts detected by scsHi-C correlated well with a high propensity of replicated sister loci to split, as previously observed in the same cell type by fluorescence in situ hybridization and live-cell imaging<sup><xref rid="R31" ref-type="bibr">31</xref></sup> (<xref ref-type="fig" rid="F10">Extended Data Fig. 6b, c</xref>), validating our scsHi-C measurements. TADs thus demarcate discrete domains with variable degrees of sister chromatid pairing.</p>
      <p id="P12">To understand the molecular basis of pairing domains, we annotated TADs in our scsHi-C maps using OnTAD<sup><xref rid="R32" ref-type="bibr">32</xref></sup>. We then calculated a pairing score for each TAD based on average trans sister contact frequency (<xref ref-type="fig" rid="F2">Fig. 2e</xref>, <xref ref-type="fig" rid="F10">Extended Data Fig. 6d</xref>), which revealed 490 TADs that were highly paired, as well as 570 highly unpaired TADs (<xref ref-type="fig" rid="F2">Fig. 2f</xref>, <xref ref-type="fig" rid="F10">Extended Data Fig. 6e</xref>). While the highly paired TADs were apparently smaller in size than the unpaired TADs, we also aimed to identify potential differences in chromatin composition. We therefore correlated the pairing score of individual TADs with different chromatin features using Locus Overlap Analysis (LOLA)<sup><xref rid="R33" ref-type="bibr">33</xref></sup>. This analysis showed that highly paired TADs were markedly enriched in H3K27me3 (<xref ref-type="fig" rid="F2">Fig. 2g, h</xref>, <xref ref-type="fig" rid="F10">Extended Data Fig. 6f</xref>), a mark for polycomb-repressed facultative heterochromatin<sup><xref rid="R34" ref-type="bibr">34</xref></sup>. The overall degree of sister chromatid pairing within TADs is thus defined by characteristic chromatin modifications.</p>
    </sec>
    <sec id="S3">
      <title>TADs in replicated chromosomes</title>
      <p id="P13">We next investigated how chromatin fibers fold within individual TADs. Cis sister contacts were most prominently enriched along the diagonal throughout TADs, indicating frequent short-range intra-molecular contacts (<xref ref-type="fig" rid="F3">Fig. 3a</xref>; <xref ref-type="fig" rid="F11">Extended Data Fig. 7a-c</xref>). In contrast, trans sister contacts filled TAD areas without substantial accumulation along the diagonal (<xref ref-type="fig" rid="F3">Fig. 3a</xref>; <xref ref-type="fig" rid="F11">Extended Data Fig. 7a-c</xref>), indicating that sister DNAs are not strictly aligned in a &#x201C;railroad&#x201D; configuration<sup><xref rid="R35" ref-type="bibr">35</xref></sup> within TADs. Trans sister contacts were particularly enriched at many TAD boundaries (<xref ref-type="fig" rid="F3">Fig. 3b</xref>), indicating that these might be sites where sister chromatids contact most frequently. Aggregated contact probability maps of TADs confirmed trans sister contact enrichment at TAD boundaries, also at corner positions connecting the neighboring TAD boundaries (<xref ref-type="fig" rid="F3">Fig. 3c</xref>). This is consistent with an overall registration of TADs, where a given TAD boundary is in proximity to the same TAD boundary on its sister chromatid, as well as the neighboring TAD boundary of the sister chromatid (<xref ref-type="fig" rid="F3">Fig. 3d</xref>). Trans sister contacts further enriched along the edges of many TADs (<xref ref-type="fig" rid="F3">Fig. 3a, c</xref>; <xref ref-type="fig" rid="F11">Extended Data Fig. 7a-c</xref>), consistent with a dynamic interaction of TAD boundaries with TAD internal chromatin regions. Contact density line profiles of all 5801 TADs confirmed that trans sister contacts enriched at the boundaries of most TADs (<xref ref-type="fig" rid="F3">Fig. 3e</xref>), on average 2-fold compared to the genome-wide average (<xref ref-type="fig" rid="F3">Fig. 3f</xref>). As TAD boundaries are marked by CTCF, we investigated how sister chromatid contacts distribute relative to 60,929 ChIP-seq peaks of CTCF of HeLa cells<sup><xref rid="R36" ref-type="bibr">36</xref></sup> overlapping annotated CTCF motifs<sup><xref rid="R37" ref-type="bibr">37</xref></sup>. Trans sister contacts indeed enriched at most CTCF sites (<xref ref-type="fig" rid="F11">Extended Data Fig. 7d, e</xref>). Thus, sister chromatids are predominantly linked at TAD boundaries, whereas they separate extensively inside TADs.</p>
      <fig id="F3" orientation="portrait" position="anchor">
        <label>Figure 3</label>
        <caption>
          <title>TAD topologies in replicated chromosomes.</title>
          <p id="P03">(a) Cis sister and trans sister contacts of merged G2 samples from n = 11 biologically independent experiments at a representative region on chromosome 1 are displayed alongside the location of TAD boundaries (see <xref ref-type="sec" rid="S6">Method section</xref> for details). Bin size of the matrix is 40 kb. (b) Average trans sister and cis sister contact amount (&#x201C;contact density&#x201D;; see <xref ref-type="sec" rid="S6">Methods</xref> for details) within a sliding window of 200 kb at the region shown in (a). (c) Average cis sister and trans sister contact environment around TAD centers of TADs between 300 and 500 kb. The panel shows ICE-normalized contacts binned at 10 kb. Filled arrows indicate positions where the same TAD boundaries are connected across sister chromatids, whereas the hollow arrow indicates the connection of neighboring TAD boundaries across sister chromatids. Data shown is from merged G2 samples from n=11 biologically independent experiments. (d) Model of sister-chromatid configuration around TAD boundaries. (e) Stack-up of average trans sister and cis sister contacts within sliding windows of 100 kb along TADs sorted by size. The panel shows windows of 6 Mb around the center of the respective TADs. Data shown is from merged G2 samples from n = 11 biologically independent experiments. (f) Quantification of trans-contact enrichment at TAD boundaries. The average observed/expected values for cis sister and trans sister contacts within a 80 kb window surrounding all (n = 5801) annotated TAD-boundaries (see <xref ref-type="sec" rid="S6">Method section</xref> for details) are displayed as a histogram. P-value was calculated using a two-sided Mann-Whitney U test. P &lt; 10<sup>-308</sup> (precision limit of floating point representation.)</p>
        </caption>
        <graphic xlink:href="EMS114563-f003"/>
      </fig>
    </sec>
    <sec id="S4">
      <title>Control of sister-chromatid topologies</title>
      <p id="P14">The conformation of TADs in replicated chromosomes is organized by at least two functionally distinct types of cohesin complexes. During G2, about half of all chromatin-bound cohesin dynamically turns over<sup><xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R39" ref-type="bibr">39</xref></sup> to form cis-chromatid loops that shape TADs<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup>, whereas the other half binds Sororin<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R40" ref-type="bibr">40</xref></sup> and persistently links sister chromatids. Trans sister contacts might concentrate at TAD boundaries because of motor-driven loop extrusion<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> or via a mechanism involving cohesin independently of DNA loops. To investigate these possibilities, we aimed to selectively deplete the pool of cohesin that forms chromatin loops without disrupting sister-chromatid cohesion. The cohesin loading factor NIPBL is required to extrude and maintain cis-chromatid loops formed by cohesin<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup>, but it is not expected to be required to maintain cohesion, given that this is mediated by persistently bound cohesin<sup><xref rid="R38" ref-type="bibr">38</xref></sup>. To test this hypothesis, we homozygously tagged NIPBL with auxin-inducible degrons (AID)<sup><xref rid="R41" ref-type="bibr">41</xref></sup>, synchronized cells to G2 and added auxin to induce NIPBL degradation (<xref ref-type="fig" rid="F12">Extended Data Fig. 8a, b</xref>). Conventional Hi-C analysis showed a reduction of contact probability between ~200 kb and 3 Mb (<xref ref-type="fig" rid="F12">Extended Data Fig. 8c</xref>), indicating suppression of cohesin-mediated loop formation. Moreover, live imaging showed that NIPBL-degraded cells efficiently congressed chromosomes (<xref ref-type="fig" rid="F12">Extended Data Fig. 8d</xref>), confirming the presence of functional cohesion at centromeres. Thus, NIPBL degradation during G2 selectively removes the pool of cohesin that forms loops and TADs while maintaining a pool of cohesin that mediates cohesion.</p>
      <p id="P15">To determine how loop-forming cohesin affects sister-chromatid organization in G2 cells, we analyzed NIPBL-depleted cells by scsHi-C. TAD structures were much less pronounced and cis sister contacts were substantially reduced between ~200 kb and 3 Mb (<xref ref-type="fig" rid="F4">Fig. 4a-c</xref>; <xref ref-type="fig" rid="F12">Extended Data Fig. 8e, f</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S3</xref>); trans sister contacts were overall much more abundant compared to unperturbed control cells and particularly enriched along the diagonal throughout entire TADs (<xref ref-type="fig" rid="F4">Fig. 4a-c</xref>, compare <xref ref-type="fig" rid="F3">Fig. 3a-c</xref>), validating that NIPBL-AID cells establish functional cohesion. The overall number of trans sister contacts was greatly increased throughout the entire TAD region, but the local enrichment at TAD boundaries was less pronounced (<xref ref-type="fig" rid="F4">Fig. 4d, e</xref>; <xref ref-type="fig" rid="F13">Extended Data Fig. 9a, b</xref>). Highly paired and especially unpaired domains (<xref ref-type="fig" rid="F2">Fig. 2f</xref>) were also less pronounced in NIPBL-depleted cells compared to wildtype cells, while trans sister contacts were globally increased also in these domains (<xref ref-type="fig" rid="F13">Extended Data Fig. 9c, d</xref>). Thus, loop-forming cohesin is necessary to separate sister chromatids within TADs, resulting in locally enriched sister chromatid contacts at TAD boundaries. Loop-forming cohesin further contributes to the formation of discrete highly paired domains.</p>
      <fig id="F4" orientation="portrait" position="anchor">
        <label>Figure 4</label>
        <caption>
          <title>Organization of sister chromatids by distinct pools of cohesin complexes.</title>
          <p id="P04">(a) Cis sister and trans sister contacts of merged G2 wildtype samples (from n = 11 biologically independent experiments), merged G2 NIPBL-degraded samples (from n = 4 biologically independent experiments) and merged Sororin-degraded samples (from n = 3 biologically independent experiments) at a representative region on chromosome 1 are displayed alongside the location of TAD boundaries (see <xref ref-type="sec" rid="S6">Method section</xref> for details). Bin size of the matrix is 40 kb. (b) Average contact probability over different genomic distances for cis sister and trans sister contacts of the different G2 sample shown in (a). (c) Average cis sister and trans sister contact environment around TAD centers of TADs between 300 and 500 kb in G2 synchronized cells with either degraded NIPBL or Sororin. The panel shows ICE-normalized contacts binned at 10 kb in a window of 900 kb. (d) Stack-up of average observed/expected values within sliding windows of 100 kb around TAD boundaries of G2 wildtype samples, G2 NIPBL-degraded samples and Sororin-degraded samples. The panel shows windows of 900 kb. The rows are sorted based on the center enrichment of the G2 wildtype condition. P-values were calculated using a two-sided Mann-Whitney U test performed on the n = 5801 values in the center columns of the respective stack-up matrix. WT-Nipbl P-value = 2 * 10<sup>-77</sup>; WT-Sororin P &lt; 10<sup>-308</sup> (precision limit of floating point representation.) (e) Quantification of trans sister contact density at TAD boundaries. The average ICE-corrected trans sister contact amount within a 400 kb window surrounding all annotated (n = 5801) TAD boundaries (see <xref ref-type="sec" rid="S6">Methods section</xref> for details) is shown for G2 wildtype samples, G2 NIPBL-degraded samples and Sororin-degraded samples. P-values were calculated using a two-sided Mann-Whitney U test. P &lt; 10<sup>-308</sup> (precision limit of floating point representation.) (f) Model of sister chromatid organization by two distinct cohesin complexes.</p>
        </caption>
        <graphic xlink:href="EMS114563-f004"/>
      </fig>
      <p id="P16">We next addressed how the pool of cohesin mediating sister chromatid cohesion affects the conformation of replicated chromosomes. To this end, we suppressed maintenance of cohesion while maintaining the pool of cohesin that forms loops by acutely degrading Sororin prior to DNA replication in cells in which endogenous Sororin was homozygously tagged with AID (<xref ref-type="fig" rid="F12">Extended Data Fig. 8a</xref>). We then released cells to the subsequent G2 and performed scsHi-C (<xref ref-type="fig" rid="F12">Extended Data Fig. 8b</xref>; <xref ref-type="supplementary-material" rid="SD1">Table S4</xref>). In Sororin-depleted cells, trans sister contacts were globally reduced and not enriched along the diagonal (<xref ref-type="fig" rid="F4">Fig. 4a, b</xref>, <xref ref-type="fig" rid="F12">Extended Data Fig. 8e</xref>), indicating loss of global sister chromatid alignment. Consistently, trans sister contacts were not enriched at TAD boundaries (<xref ref-type="fig" rid="F4">Fig. 4d, e</xref>). However, the cis sister contact distribution was indistinguishable from that of unperturbed cells (<xref ref-type="fig" rid="F4">Fig. 4a-c</xref>; <xref ref-type="fig" rid="F12">Extended Data Fig. 8e</xref>). The Sororin-stabilized pool of cohesin is thus not required to form intra-chromatid loops or TADs in G2, but it is required to prevent the separation of sister chromatids and to maintain their global alignment during G2.</p>
    </sec>
    <sec sec-type="conclusions" id="S5">
      <title>Conclusions</title>
      <p id="P17">Our scsHi-C analysis shows that a pool of cohesin mediating linkage between replicated DNA molecules maintains global alignment of sister chromatids after DNA replication, while a pool of cohesin that dynamically forms loops locally separates sister chromatids within TADs during G2. An independent implementation of sister-chromatid-sensitive Hi-C based on a distinct labeling strategy showed that sister chromatids of the fungus <italic>S. cerevisiae</italic> are also globally aligned and locally separated<sup><xref rid="R42" ref-type="bibr">42</xref></sup>, indicating common principles of chromosome organization in evolutionary distant organisms.</p>
      <p id="P18">Our data support a model where CTCF imposes a boundary both for loop-extruding cohesin as well as cohesive cohesin, and where loop-extruding cohesin might push cohesive cohesin towards these boundaries (<xref ref-type="fig" rid="F4">Fig. 4f</xref>). Furthermore, sister chromatids remain highly paired in H3K27me3-enriched domains, which might be mediated by locally reduced rates of dynamic loop extrusion, or by cohesin-independent association of polycomb-repressed chromatin, as observed in mouse embryonic stem cells<sup><xref rid="R43" ref-type="bibr">43</xref></sup>. The organization of sister chromatids has implications for the maintenance, expression, and mechanical transport of the genome.</p>
      <p id="P19">The global alignment of sister chromatid arms by Sororin-stabilized cohesin favors interactions between homologous genome regions, as required for error-free homology-directed DNA damage repair<sup><xref rid="R9" ref-type="bibr">9</xref></sup>. Local variations of sister chromatid pairing along chromosome arms might explain how the genomic context affects the efficiency of homology-directed DNA repair<sup><xref rid="R44" ref-type="bibr">44</xref></sup>. Tight sister chromatid pairing observed in TADs containing facultative heterochromatin might facilitate transcriptional co-repression and transfer of epigenetic information between distinct DNA molecules, as previously observed between paired homologous chromosomes in <italic>D. melanogaster</italic>
<sup><xref rid="R45" ref-type="bibr">45</xref></sup>.</p>
      <p id="P20">When cells enter mitosis, they resolve whole chromosome arms. This involves sequential binding of two distinct condensin complexes and dissociation of cohesin from chromosome arms<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup>, but how these activities are coordinated to promote sister chromatid resolution remains unknown. ScsHi-C provides a versatile tool to investigate this complex topological reorganization, as well as interactions between DNA molecules in other biological contexts, such as pairing and recombination of homologous chromosomes during meiosis.</p>
    </sec>
    <sec sec-type="methods" id="S6" specific-use="web only">
      <title>Methods</title>
      <sec id="S7">
        <title>Cell culture</title>
        <p id="P21">All cell lines used in this study have been regularly tested negatively for mycoplasm contamination. The parental HeLa cell line (&#x2018;Kyoto strain&#x2019;) was obtained from S. Narumiya (Kyoto University, Japan) and validated by a Multiplex human Cell line Authentication test (MCA). Cells were cultured in WT medium (DMEM high-glucose [Sigma], buffered with HEPES [Applichem] and Sodium bicarbonate [Sigma], adjusted to pH 7.1-7.3 and supplemented with 10 % [v/v] FCS [Gibco], 1 % [v/v] Penicillin/Streptomycin [Gibco] and 1 % [v/v] GlutaMAX [Gibco]) in a humidified incubator at 37 &#xB0;C and 5 % CO<sub>2</sub>. For culturing HeLa Sororin-AID and HeLa NIPBL-AID cells, medium was supplemented with 0.5 &#x3BC;g/ml Puromycin (Calbiochem). Cells were passaged every 48 h by dissociation using Trypsin/EDTA-Solution (Gibco).</p>
      </sec>
      <sec id="S8">
        <title>Generation of cell lines</title>
        <p id="P22">All cell lines used in this study are listed in <xref ref-type="supplementary-material" rid="SD1">Table S6</xref> and the plasmid used in their generation are listed in <xref ref-type="supplementary-material" rid="SD1">Table S7</xref>. The HeLa Kyoto N-terminally-tagged Sororin auxin-inducible degron (AID) cell line was created by CRISPR/Cas9-mediated genome editing as described previously<sup><xref rid="R12" ref-type="bibr">12</xref></sup>. The gRNA sequences that were used for generating EGFP-AID-Sororin were CACCGCGCTCACCGGAGCGCTGAG, and CACCGACGTGAGGTCGAGCCGTTT together with the repair template &#x2018;EGFP-AID-Sororin-HR&#x2019;. The primers used for genotyping were CTGCGGGGGACAATACCAAT and CCGATCTCAGATTCCTGCCC. Subsequently, Tir1 expression was introduced by transducing a homozygous cell clone with lentiviruses using pRRL containing the constitutive promotor from spleen focus forming virus (SFFV) followed by <italic>Oryza sativa</italic> Tir1-3xMyc-T2A-Puro. Cells expressing Tir1 were selected by culturing in medium containing 2.5 &#x3BC;g/ml Puromycin (Sigma-Aldrich).</p>
        <p id="P23">HeLa Kyoto N-terminally tagged AID-GFP-NIPBL cells were generated using CRISPR/Cas9-mediated genome editing based on a double nickase strategy<sup><xref rid="R49" ref-type="bibr">49</xref></sup>. The template for homologous recombination introduced sequences coding for monomeric EGFP (L221K) and the <italic>Arabidopsis thaliana</italic> IAA17 71-114 (AID*) mini-degron<sup><xref rid="R50" ref-type="bibr">50</xref></sup>. The gRNAs used for CRISPR/Cas9-mediated genome editing were CACCGCCCATTCATCCTGAATTTC and CACCGCCCCATTACTACTCTTGCG together with the repair template &#x2018;AID-GFP-NIPBL-HR&#x2019;. Single clones were obtained by sorting into 96-well plates on a BD FACS Aria III machine (BD Biosciences) and homozygous tagging was confirmed by PCR using the forward primer ATCGTGGGAACGTGCTTTGGA and reverse primer GCTCAGCCTCAATAGGTACCAACA. Subsequently, Tir1 expression was introduced as for HeLa Sororin-AID described above.</p>
        <p id="P24">HeLa Kyoto RIEP H2B-mCherry cells were derived from HeLa Kyoto RIEP cells<sup><xref rid="R51" ref-type="bibr">51</xref></sup> using a lentiviral delivery system<sup><xref rid="R51" ref-type="bibr">51</xref></sup> to stably integrate a plasmid carrying H2B-mCherry (Lenti-H2B-mCherry). Cells were sorted into 96-wells to derive single clones using a BD Aria III instrument (BD Biosciences).</p>
      </sec>
      <sec id="S9">
        <title>FACS analysis of cell cycle stage</title>
        <p id="P25">For S-Phase release experiment (<xref ref-type="fig" rid="F6">ED Fig. 2d</xref>), cells were trypsinized, washed with phosphate buffered saline (PBS; made in-house) and fixed using 70 % MeOH (Sigma) for at least 1 h at -20 &#xB0;C. Cells were spun down (1100 x g; 1 min) and stained using 50 &#x3BC;g/ml Propidium Iodide (Sigma) in a solution with 10 mM TRIS-HCl (Sigma; adjusted to pH 7.5), 5 mM MgCl<sub>2</sub> (Sigma) and 200 &#x3BC;g/ml RNaseA (Qiagen) at 37 &#xB0;C for 20 min. Samples were then measured on a FACSCanto II instrument (BD Biosiences). Analysis was performed using FlowJo(v10.6.0) as follows: Gate for cells in FSC-A/SSC-A, for single cells in FSC-A/SSC-H, histogram of PI-intensity. For all other FACS experiments, cells were trypsinized, washed with phosphate buffered saline (PBS; made in-house) and fixed using 70 % EtOH (Sigma) for at least 1 h at 4 &#xB0;C. Cells were spun down (1100 x g; 1 min) and permeabilized using 0.25 % Triton-X100 (Sigma) in PBS for 15 min on ice. Cells were spun down again and stained using 0.25 &#x3BC;g <italic>&#x3B1;</italic>-H3S10p (Merck Millipore 04-817) in 1 % Bovine serum albumin (BSA; Sigma) for 1 h at room temperature (RT). Cells were washed once with 1 % BSA and then stained using 1:300 <italic>&#x3B1;</italic>-mouse-AF488 (Molecular Probes A11001) in 1 % BSA for 30 min at RT in the dark. Cells were washed once with 1 % BSA and incubated with a solution containing 200 &#x3BC;g/ml RNase A (Qiagen) and 50 &#x3BC;g/ml Propidium Iodide (Sigma) in PBS for 30 min at RT in the dark. Samples were then measured on a FACSCanto II instrument (BD Biosiences). Analysis was performed using FlowJo(v10.6.0) as follows: Gate for cells in FSC-A/SSC-A, for single cells in PE-A/PE-H, scatterplot of FITC and PI intensity (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2</xref> for the exact gating strategy).</p>
      </sec>
      <sec id="S10">
        <title>DNA damage assay</title>
        <p id="P26">WT HeLa Kyoto cells were seeded into an 8-well Lab-Tek (Thermo Scientific) and grown for 16 h. Then, different concentrations of 4sT (2mM-10mM; Carbosynth) and 50 &#x3BC;M etoposide (Sigma) were added and cells were incubated for 24 h. For immunofluorescence (IF), cells were washed two times with PBS and fixed using 4 % formaldehyde (Sigma) in PBS for 5 min. Formaldehyde was quenched using 20 mM TRIS-HCl (Sigma; adjusted to pH 7.5) in PBS for 3 min and washed with PBS. Cells were permeabilized using 0.5 % Triton-X100 (Sigma) in PBS for 10 min. Then, cells were blocked using 2 % BSA in PBS for 30 min at RT, followed by incubation with 1:500 <italic>&#x3B1;</italic>-phospho-<italic>&#x3B3;</italic>-H2A.X (ABCAM ab2893) in 2 % BSA [PBS] for 1.5 h at RT. Then, cells were washed 3x for 5 min using PBS, followed by incubation with 1:1000 <italic>&#x3B1;</italic>-mouse-AF488 (Molecular Probes A11001) in 2 % BSA [PBS] for 30 min at RT in the dark. Then, cells were washed one time using PBS for 5 min, followed by staining using 1 &#x3BC;g/ml 4,6-diamidino-2-phenylindole (DAPI; Thermo Scientific) for 5 min. Then, cells were washed again for 5 min in PBS. Samples were imaged on a customized Zeiss LSM780 microscope using a 20x, 0.8 NA, Oil DIC Plan-Apochromat objective (Zeiss). Images were analyzed using CellCognitionExplorer 1.0.2<sup><xref rid="R52" ref-type="bibr">52</xref></sup> for segmentation and intensity extraction and Python scripts to visualize the data.</p>
      </sec>
      <sec id="S11">
        <title>Viability assay</title>
        <p id="P27">Cells carrying a stable H2B-mCherry integration were seeded into a 96 well imaging plate (Greiner) in imaging medium (custom; DMEM High-glucose [Gibco] without Riboflavin and Phenolred containing 10% [w/w] FCS [Gibco], 1% [w/w] P/S [Gibco] and 1 % [w/w] Glutamax [Gibco]) supplemented with 1 &#x3BC;M TO-PRO<sup>&#xAE;</sup>-3 (Thermo Fisher Scientific). After 16 h, compounds to be tested were added and imaging was started on a Molecular Devices ImageXpressMicro XL screening microscope with a reflection-based laser auto focus and a 10x, 0.75 NA, S Fluor dry objective (Nikon). Cells were maintained for 24 h in a microscopic stage incubator at 37 &#xB0;C in a humidified atmosphere at 5 % CO<sub>2</sub> and images in the mCherry and TO-PRO<sup>&#xAE;</sup>-3 channel were recorded every 2 h. Images were analyzed using CellCognition<sup><xref rid="R53" ref-type="bibr">53</xref></sup> for segmentation and intensity extraction and Python scripts to visualize the data.</p>
      </sec>
      <sec id="S12">
        <title>Western Blot</title>
        <p id="P28">Cell suspension (1 million cells/ml) was mixed with 6x SDS loading buffer and 10 mM DTT (Roche) and incubated at 95 &#xB0;C for 10 min. Samples were separated on a NuPage 4-12% Bis-Tris Gel (Invitrogen) and transferred onto a Hybond P 0.45 polyvinylidene difluoride (PVDF) membrane (GE life sciences) using wet blotting. Sororin was probed using a custom antibody kindly provided by Jan-Michael Peters (1:500). GAPDH was probed using a polyclonal antibody (1: 2000; Abcam ab9485) and NIPBL was probed using a monoclonal antibody (1:1000; Absea 010702F01). Horseradish peroxidase-conjugated secondary antibodies were used (anti-rat Amersham NA935 at 1:2000; anti-rabbit Biorad 170-6515 at 1:5000), and blots were visualized using ECL Plus Western Blotting Substrate (Thermo Fisher Scientific). Western blots were imaged on a Biorad Imager operated by ImageLab.</p>
      </sec>
      <sec id="S13">
        <title>Metaphase congression assay</title>
        <p id="P29">Cells were synchronized to G2 as explained in the cell synchronization section (<xref ref-type="fig" rid="F7">Extended Data Fig. 3d</xref>). Then, 1 h before RO3306 wash-out, cells were supplemented with 250 ng/ml SIR-DNA (Spirochrome). Then, cells were washed 2x with imaging medium containing 250 ng/ml SIR-DNA, followed by imaging every 3 min for 120 min on a customized Zeiss LSM780 microscope at 37 &#xB0;C and 5 % CO<sub>2</sub> using a 20x, 0.8 NA, Oil DIC Plan-Apochromat objective (Zeiss). Congression time was measured by visual inspection using Fiji and ImageJ<sup><xref rid="R54" ref-type="bibr">54</xref></sup> for all cells that entered mitosis in the indicated time frame. Results were visualized using Python.</p>
      </sec>
      <sec id="S14">
        <title>Cell synchronization for scsHi-C</title>
        <p id="P30">Cells were seeded into 25 cm<sup>2</sup> flasks and grown for 3 h, then supplemented with 2 mM Thymidine (Sigma). Cells were released 16 h later by washing 2 times with prewarmed WT medium. 8 h later, cells were supplemented with 3 &#x3BC;g/ml aphidicolin (Sigma) and 2 mM 4sT (Carbosynth). Cells were released 16 h later by washing 2 times with PBS and addition of medium containing 2 mM 4sT (Carbosynth). For Sororin-AID experiments, 500 &#x3BC;M Indole-3-acetic acid (Sigma) was added 1 h prior to S-phase release. For S-phase release experiments, samples were taken at the indicated time-points. For synchronization to G2 and prometaphase, after 4 h release, 9 &#x3BC;g RO-3306 (Sigma) or 200 ng/ml nocodazole (Sigma) were added respectively. For NIPBL-AID experiments, 500 &#x3BC;M Indole-3-acetic acid (Sigma) was added 8 h after released. Samples were processed 16 h later. Cells were harvested by washing with PBS, followed by trypsinisation and resuspension in WT medium. Cells were then spun down, washed again with PBS, followed by fixation for 4 min in 1 % formaldehyde (Sigma). Cell pellets were stored at -20 &#xB0;C or processed immediately.</p>
      </sec>
      <sec id="S15">
        <title>Hi-C sample preparation</title>
        <p id="P31">Fixed cells were permeabilized using ice-cold Hi-C lysis buffer (10 mM TRIS-HCl pH 8 [Sigma], 10 mM NaCl [Sigma], 0.2 % Nonidet P-40 substitute [Sigma], 1x Complete EDTA-free Protease inhibitor [Roche]) for 30 min at 4 &#xB0;C. Then, cells were spun down (2500 x g for 5 min), supernatant was discarded, and digestion mix was added (375 U DpnII [NEB] in 1x DpnII buffer [NEB]) and cells incubated for 16 h at 37 &#xB0;C under rotation. Then, cells were spun down, supernatant was discarded and fill-in mix was added (38 &#x3BC;M Biotin-14-dATP [Thermo Fisher Scientific], 38 &#x3BC;M dCTP, dGTP and dCTP [Thermo Fisher Scientific], 50 U Klenow Polymerase [NEB], 1x NEB 2 buffer) and cells incubated for 1 h at 37 &#xB0;C under rotation. Then, cells were spun down again, and ligation mix was added (1x T4 DNA ligase buffer [Thermo Fisher Scientific], 0.1 % Triton X-100 [Sigma], 100 &#x3BC;g/ml BSA [Sigma], 50 U T4 DNA ligase [Thermo Fisher Scientific]) and incubated at RT for 4 h. Then, cells were spun down, resuspended in 200 &#x3BC;l PBS and gDNA was purified using the DNeasy Blood and Tissue kit (Quiagen). DNA was transferred to a Covaris microTUBE (Covaris) and sheared on a Covaris S2 instrument (Duty cycle 10 %, Intensity 5.0, Cycles/burst 200) for 25 s. Double size selection was performed by employing AMPure XP beads (Beckman Coulter) first at 0.8-fold sample volume according to the standard protocol, followed by transfer of the supernatant and bead application at 0.12-fold sample volume. The resulting DNA was bound to Dynabeads MyOne Streptavidin C1 beads (Thermo Fisher Scientific) in Biotin binding buffer (5 mM Tris-HCl pH 7.5 [Sigma], 0.5 mM EDTA [AppliChem], 1 M NaCl [Merck]) for 1 h at RT. Beads were then washed 2x in Tween wash buffer (5 mM Tris-HCl [Sigma], 0.5 mM EDTA [AppliChem], 1 M NaCl [Merck], 0.05 % Tween-20 [Sigma]) and 1x in H<sub>2</sub>O. Beads were resuspended in H<sub>2</sub>O and library preparation was performed using the NEBNext Ultra II DNA library prep kit for Illumina [NEB] according to the standard protocol. After this, beads were washed 4x using Tween wash buffer and DNA was eluted using 95 % formamide (Sigma), 10 mM EDTA (AppliChem) at 65 &#xB0;C for 2 min. DNA was then precipitated using 80 % EtOH (Sigma), washed with 75 % EtOH and resuspended in H<sub>2</sub>O. Then, 4sT was converted to methyl-cytosine using OsO<sub>4</sub> / NH<sub>4</sub>Cl (see below), followed by qPCR according the NEBUltra Ultra II DNA library prep kit for Illumina [NEB]. The finished libraries were purified using AMPure XP beads (Beckman Coulter) at 0.9x sample volume following the standard protocol.</p>
      </sec>
      <sec id="S16">
        <title>Sequencing</title>
        <p id="P32">Sequencing of all samples was performed either on an Illumina NovaSeq 6000 instrument using patterned SP flowcells using read-mode PE250 or on an Illumina MiSeq instrument using a Nanoflowcell using read-mode PE250 (v2).</p>
      </sec>
      <sec id="S17">
        <title>Quantification of 4sT incorporation into gDNA</title>
        <p id="P33">HeLa Kyoto cells were cultured for 24 h after splitting and supplemented with either H<sub>2</sub>0 or 2 mM 4sT (Carbosynth) and then cultured for 5 days. DNA was extracted using the DNeasy Blood and Tissue kit (Quiagen). Extracted DNA was digested using 1 U DNA Degradase Plus (Zymo Research) in 1x DNA Degradase buffer (Zymo Research) for 2 h at 37 &#xB0;C. Deoxyribonucleosides were quantified by injecting 1 &#x3BC;l of the acidified digest on a RSLC ultimate 3000 (Thermo Fisher Scientific) directly coupled to a TSQ Vantage mass spectrometer (Thermo Fisher Scientific) via electrospray ionization. A Kinetex C18 column was used (100 &#xC5;, 150 x 2.1 mm), employing a flow rate of 100 &#x3BC;l/min. An 8-minute-long linear gradient was used from 0% A (1 % acetonitrile, 0.1 % formic acid in water) to 60% B (0.1 % formic acid in acetonitrile). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed by employing the selected reaction monitoring (SRM) mode of the instrument. Thymidine and 4-thio-thymidine were quantified by analyzing the in-source fragments of the respective nucleotides at an elevated declustering potential. For thymidine the transition 127.1 m/z &#x2192; 54.1 m/z (CE 23 V) and for 4-thio-thymidine the transition 143.1 m/z &#x2192; 126.1 m/z (CE 25 V) were used. A calibration curve of synthetic standard nucleosides was used to quantify the relative percentage of 4-thio-thymidine in total thymidine in the biological samples. Each sample was measured in duplicate.</p>
      </sec>
      <sec id="S18">
        <title>Conversion analysis of 4sT on synthetic oligos</title>
        <p id="P34">Conversion was done similarly as described in<sup><xref rid="R55" ref-type="bibr">55</xref></sup>: A 4sT-containing oligonucleotide was synthesized as described below. The molecular weight of the oligonucleotide with and without OsO<sub>4</sub> / NH<sub>4</sub>Cl treatment (see below) was analyzed on a Finnigan LCQ Advantage MAX ion trap instrument connected to an Amersham Ettan micro LC system in the negative-ion mode with a potential of -4 kV applied to the spray needle. LC: Sample (200 pmol RNA dissolved in 30 &#x3BC;l of 20 mM EDTA solution; average injection volume: 30 &#x3BC;l), column (Waters XTerra<sup>&#xAE;</sup> MS, C18 2.5 m; 2.1 &#xD7; 50 mm) at 21 &#xB0;C; flow rate: 30 &#x3BC;l min<sup>-1</sup>; eluent A: Et<sub>3</sub>N (8.6 mM), 1,1,1,3,3,3-hexafluoroisopropanol (100 mM) in H<sub>2</sub>O (pH 8.0); eluent B: MeOH; gradient: 0&#x2013;100% B in A within 30 min; UV detection at 254 nm.</p>
      </sec>
      <sec id="S19">
        <title>Conventional sequencing library preparation to estimate 4sT mutation rates</title>
        <p id="P35">Cells were harvested by trypsinization, spun down at 1100 x g for 1 min and the supernatant was discarded. Then, cells were spun down, resuspended in 200 &#x3BC;l PBS and gDNA was purified using the DNeasy Blood and Tissue kit (Quiagen). DNA was transferred to Covaris microTUBE (Covaris) and sheared on a Covaris S2 instrument (Duty cycle 10 %, Intensity 5.0, Cycles/burst 200) for 25 s. Double size selection was performed by employing AMPure XP beads (Beckman Coulter) first at 0.8-fold sample volume according to the standard protocol, followed by transfer of the supernatant and bead application at 0.12-fold sample volume. DNA library preparation was performed with the resulting DNA using the NEBNext Ultra II DNA library prep kit for Illumina [NEB] according to the standard protocol. The unamplified libraries were then treated using OsO<sub>4</sub> (see below) and amplified according the NEBNext Ultra II DNA library prep kit for Illumina [NEB]. The finished libraries were purified using AMPure XP beads (Beckman Coulter) at 0.9x sample volume following the standard protocol.</p>
      </sec>
      <sec id="S20">
        <title>OsO<sub>4</sub> / NH<sub>4</sub>Cl-mediated conversion of 4sT</title>
        <p id="P36">For synthetic oligos, lyophilized DNA (1 nmol) was dissolved in water (10 &#x3BC;l) and denatured for 2 min at 90 &#xB0;C. Then, the solution was heated to 60 &#xB0;C and NH<sub>4</sub>Cl buffer (2 &#x3BC;l, 2 M, pH 8.88) and OsO<sub>4</sub> solution (10 &#x3BC;l, 1 mM) were added to yield final concentrations of 0.45 mM OsO<sub>4</sub> and 180 mM NH<sub>4</sub>Cl in a total volume of 22 &#x3BC;l. The reaction mixture was incubated for three hours at 60 &#xB0;C. The DNA was precipitated by adding 90 &#x3BC;l of precipitation solution (made of water (650 &#x3BC;l), aqueous NaOAc solution (150 &#x3BC;l; 1 M, pH 5.2), and glycogen (10 &#x3BC;l; 20 mg/ml)) and 250 &#x3BC;l of cold ethanol. The mixture was kept at &#x2013;20 &#xB0;C for 30 minutes, followed by centrifugation (13,000 rpm, 4 &#xB0;C, 30 min). The supernatant was discarded, and the precipitated DNA analyzed by anion exchange HPLC and mass spectrometry (see above). Genomic DNA was incubated with 0.45 mM OsO<sub>4</sub> (Sigma) and 200 mM NH<sub>4</sub>Cl (Sigma) adjusted with NH<sub>3</sub> (Honeywell Fluka) to pH 8.88 first for 5 min at 95 &#xB0;C followed by 60 &#xB0;C for 3 h on a T100 Thermal Cycler (Bio-Rad) with the heated lid set to 105 &#xB0;C. DNA was then precipitated using 80 % EtOH, washed with 75 % EtOH and resuspended in H<sub>2</sub>O.</p>
      </sec>
      <sec id="S21">
        <title>Melting curve analysis of hairpin oligo</title>
        <p id="P37">The absorbance versus temperature profiles were recorded at 260 nm on a Varian Cary 100 spectrophotometer equipped with a multiple cell holder and a Peltier temperature-control device. The 4sT containing DNA hairpins and their reference oligonucleotides were measured at a concentration of 2 &#x3BC;M in melting buffer (150 mM NaCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub> at pH 7.0). Three cycles of cooling and heating between 30 &#xB0;C to 95 &#xB0;C and a rate of 0.7 &#xB0;C min<sup>-1</sup> were recorded. Sample preparation: An aliquot of oligonucleotide stock solution was lyophilized, dissolved in 1 ml of melting buffer to give the desired final concentration. The solution was transferred into a quartz cuvette and degassed. A layer of silicon oil was placed on the surface of the solution to minimize evaporation during the measurements.</p>
      </sec>
      <sec id="S22">
        <title>Statistical analysis and sample number</title>
        <p id="P38">All Hi-C datasets that are presented in this paper are merges of at least two independent replicates. For a detailed listing of all datasets, see <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>&#x2013;<xref ref-type="supplementary-material" rid="SD1">S4</xref>. All statistical tests were performed using scipy<sup><xref rid="R56" ref-type="bibr">56</xref></sup>.</p>
      </sec>
      <sec id="S23">
        <title>Data Reporting</title>
        <p id="P39">No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments.</p>
      </sec>
      <sec id="S24">
        <title>Synthesis of a 4-thiothymidine (4sT) phosphoramidite building block</title>
        <p id="P40">General information: Chemical reagents and solvents were purchased from commercial suppliers and used without further purification. Thymidine phosphoramidite was purchased from ChemGenes. Organic solvents for reactions were dried overnight over freshly activated molecular sieves (3 &#xC5;). All reactions were carried out under argon atmosphere. Analytical thin-layer chromatography (TLC) was carried out on Marchery-Nagel (Polygram SIL G/UV254, 0.2 mm silica gel) plates. Flash column chromatography was carried out on silica gel 60 (70-230 mesh). <sup>1</sup>H and <sup>31</sup>P NMR spectra were recorded on Bruker 400 and 700 MHz spectrometers. The chemical shifts are referenced to the residual proton signal of the deuterated solvents: CDCl<sub>3</sub> (7.26 ppm), d6-DMSO (2.50 ppm) for <sup>1</sup>H NMR spectra; <sup>31</sup>P-shifts are relative to external 85% phosphoric acid. <sup>1</sup>H assignments were based on COSY experiments. Mass spectrometric analysis of low molecular weight compounds was performed on a Thermo Scientific Q Exactive Orbitrap mass spectrometer in the positive ion mode. Procedure: Thymidine phosphoramidite (229 mg, 0.307 mmol) was dissolved in dry dichloromethane (3 ml). Then, triethylamine (37 mg, 51 &#x3BC;l, 0.366 mmol), 4-dimethylaminopyridine (1 mg) and 2-mesitylensulfonyl chloride (56 mg, 0.256 mmol) were added. The solution was stirred at room temperature for 2 hours. In the meantime, 3,3&#x2032;-dithiobis(propionitrile) (200 mg, 1.16 mmol) was suspended in aqueous 2 M HCl solution, followed by slow addition of zinc powder (220 mg, 3.36 mmol). The mixture was stirred at room temperature for one hour, extracted three times with dichloromethane, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The 3-mercaptopropionitrile was obtained as slightly yellow oil. Then, <italic>N</italic>-methylpyrrolidine (261 mg, 319 &#x3BC;l, 3.07 mmol) and the freshly prepared 3-mercaptopropionitrile (133 mg, 1.54 mmol) were mixed in dry dichloromethane (1 ml) and added to the reaction mixture containing the activated nucleoside. Stirring was continued at 0 &#xB0;C (ice bath) for one hour. Finally, the solution was diluted with dichloromethane, washed with saturated NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated (<xref ref-type="fig" rid="F13">Extended Data Fig. 9a</xref>). The crude product was purified by column chromatography on silica gel (ethyl acetate/cyclohexane, 15:100 &#x2013; 75:25). Yield: 172 mg (69%) white foam. TLC (ethyl acetate/cyclohexane, 1:1): R<sub>f</sub> = 0.1. HR-ESI-MS (m/z): [M+Na]<sup>+</sup> calculated: [836.3217]; found: [836.3110]. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): &#x3B4; 1.15 &#x2013; 1.18 (m, 12 H, 2x (H<sub>3</sub>C)<sub>2</sub>CHN); 1.43 (s, 3H, H<sub>3</sub>C(5)); 2.22 &#x2013; 2.28 (1H, HaC(2&#x2032;)); 2.33 &#x2013; 2.35 (1H, HC(N)); 2.53 &#x2013; 2.56 (1H, HC(N)); 2.60 &#x2013; 2.66 (1H, HbC(2&#x2032;)); 2.78 &#x2013; 2.88 (2H, H<sub>2</sub>CCN); 3.26 &#x2013; 3.34 (m, 4H, H<sub>2</sub>CS, H<sub>2</sub>C(5&#x2032;)); 3.44 &#x2013; 3.54 (m, 4H, H<sub>2</sub>CCN, H<sub>2</sub>CO); 3.73 (s, 6H, 2x H<sub>3</sub>CO(DMT)); 4.13 (m, 1H, HC(4&#x2032;)); 4.58 (m, 1H, HC(3&#x2032;)); 6.21 (m, 1H, HC(1&#x2032;)); 6.73 &#x2013; 6.78 (m, 4H, HC(DMT)); 7.27 &#x2013; 7.41 (m, 9H, HC(DMT)); 7.87 (s, 1H, HC(6)) ppm. <sup>31</sup>P-NMR (282 MHz, CDCl<sub>3</sub>): &#x3B4; 148.64; 149.33 ppm (<xref ref-type="fig" rid="F13">Extended Data Fig. 9b-c</xref>).</p>
      </sec>
      <sec id="S25">
        <title>Solid-phase synthesis of 4sT containing DNA</title>
        <p id="P41">CCGGAAGGTATGAACC(4sT)TCCG was synthesized by automated solid-phase synthesis (ABI 392 Nucleic Acids Synthesizer) using standard DNA nucleoside phosphoramidites (ChemGenes), the 4-thiothymidine phosphoramidite (as described above), and polystyrene support (GE Healthcare, Primer Support 80s, 80 &#x3BC;mol per g; PS 200). The following set-up was applied: detritylation (80 s) with dichloroacetic acid/1,2-dichloroethane (4/96); coupling (2.0 min) with phosphoramidites/acetonitrile (0.1 M, 130 &#x3BC;l) and 5-(benzylthio)-1<italic>H</italic>-tetrazole/acetonitrile (0.3 M, 360 &#x3BC;l); capping (0.4 min, three cycles) with Cap A: 4-(dimethylamino)pyridine in acetonitrile (0.5 M) and Cap B: Ac<sub>2</sub>O/sym-collidine/acetonitrile (2/3/5); oxidation (1.0 min) with I<sub>2</sub> (20 mM) in THF/pyridine/H<sub>2</sub>O (35/10/5). Acetonitrile (DNA synthesis grade) was purchased from Anteris Systems GmbH. Acetonitrile, acetonitrile solutions of amidites, and acetonitrile solution of 5-(benzylthio)-1<italic>H</italic>-tetrazole were dried over activated molecular sieves (3 &#xC5;) overnight.</p>
      </sec>
      <sec id="S26">
        <title>Deprotection of 4sT containing DNA</title>
        <p id="P42">After DNA strand assembly, the beads were treated with 1,8-diazabicyclo[5.4.0]undec-7-en (DBU) in anhydrous acetonitrile (5 ml, 1 M) for three hours. Subsequently, the beads were incubated with <italic>tert</italic>.-butyl amine/ethanol/water (1/1/2, v/v/v) and dithiothreitol (50 mM) for five hours at 55 &#xB0;C. Then, the supernatant was removed and the beads were washed three times with 1 ml ethanol/water (1/1). The combined phases were evaporated to dryness. The crude DNA was dissolved in water (1 ml).</p>
      </sec>
      <sec id="S27">
        <title>Analysis and purification of 4sT containing DNA</title>
        <p id="P43">After the deprotection, the crude DNA was analyzed by anion-exchange chromatography on a Dionex DNAPac PA-100 column (4 mm &#xD7; 250 mm) at 80 &#xB0;C. Flow rate: 1 ml min<sup>-1</sup>, eluant A: 25 mM Tris&#xB7;HCl (pH 8.0), 6 M urea; eluant B: 25 mM Tris&#xB7;HCl (pH 8.0), 0.5 M NaClO<sub>4</sub>, 6 M urea; gradient: 0 &#x2013; 60% B in A within 50 min, UV detection at 260 nm. The DNA was purified on a semipreparative Dionex DNAPac PA-100 column (9 mm &#xD7; 250 mm) at 80 &#xB0;C with flow rate 2 ml min<sup>-1</sup>, using the same eluents A and B as for analytical analysis, but with flat gradients that were optimized according to the length of the oligonucleotide. DNA containing fractions were loaded on a C18 SepPak Plus cartridge (Waters/Millipore), washed with 0.1 &#x2212; 0.15 M (Et<sub>3</sub>NH)<sup>+</sup>HCO<sub>3</sub>
<sup>&#x2212;</sup>, H<sub>2</sub>O and eluted with H<sub>2</sub>O/CH<sub>3</sub>CN (1/1). DNA containing fractions were evaporated to dryness and then dissolved in 1 ml water (stock solutions for storage at &#x2013;20 &#xB0;C). The quality of purified DNA was again analyzed by anion-exchange chromatography. The molecular weight of the DNA was analyzed by LC-ESI MS. Yields were determined by UV photometrical analysis of oligonucleotide solutions.</p>
      </sec>
    </sec>
    <sec id="S28">
      <title>Sequencing data analysis</title>
      <sec id="S29">
        <title>Published datasets used</title>
        <p id="P44">All published datasets used in the sequencing data analysis are listed in <xref ref-type="supplementary-material" rid="SD1">Table S5</xref>.</p>
      </sec>
      <sec id="S30">
        <title>Calling HeLa single-nucleotide polymorphisms</title>
        <p id="P45">In order to discriminate between 4sT-introduced mutations and single-nucleotide polymorphisms (SNPs), HeLa Kyoto SNPs were called on DNA-seq data from WT HeLa cells and a new consensus genome based on hg19 was constructed using bcftools (<ext-link ext-link-type="uri" xlink:href="https://github.com/samtools/bcftools">https://github.com/samtools/bcftools</ext-link>).</p>
      </sec>
      <sec id="S31">
        <title>Mutation rate analysis</title>
        <p id="P46">First, sequencing data was aligned to the hg19 genome containing HeLa SNPs using bowtie2. Then, relative point mutation rates for all possible point mutations were calculated using a custom Python script as follows: Absolute point mutation rates were counted and normalized to the total covered amount of the source base (e.g. for T-to-C normalization was done to T in the reference genome). These values were then normalized to an unlabelled control sample that had undergone OsO<sub>4</sub> / NH<sub>4</sub>Cl treatment. The incorporated amount of 4sT was determined by sequencing analysis, based on calculating the ratio of the sum of T-to-C and the A-to-G absolute mutation rates to the sum of all Ts and all As, respectively. The fraction of read pairs being labelled in samples derived from DNA-seq libraries was calculated as follows: Only high-quality read-pairs (alignment score &gt; 20, longer than 240 bp, no more than one non-signature mutation [other than T-to-C or A-to-G]) were counted. Only point mutations that had a Phred-score higher than 30 were counted. The number of T-to-C and A-to-G mutations were counted on both read-pairs of a paired-end read. The read halves were then assigned to be labelled if they contained 2 or more signature point mutations. A read-pair was classified as double labelled if both halves were labelled. To calculate a histogram of signature mutations per read, the number of T-to-C and A-to-G mutations per read was counted and plotted for control samples (not treated with 4sT) and samples treated with 4sT for 5 days.</p>
      </sec>
      <sec id="S32">
        <title>Correlation analysis of loci splitting frequency and FISH with scsHi-C</title>
        <p id="P47">The average number of trans sister contacts (balanced as described in &#x201C;Hi-C data preprocessing&#x201D;) was extracted at target sites of the 16 gRNAs from Stanyte et al.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> within a 600 kb window and 1&#x2212;<italic>average</italic>(<italic>trans&#x2212;sister contacts</italic>) was calculated and converted to a Z-score by subtracting the mean and dividing by the standard deviation. The resulting value correlated with the average frequency of split loci 1.2 h before G2 phase<sup><xref rid="R31" ref-type="bibr">31</xref></sup> for 11 WT G2 replicates. A similar analysis was performed for the 5 loci for which both gRNA splitting data and FISH data was available.</p>
      </sec>
      <sec id="S33">
        <title>Hi-C data preprocessing</title>
        <p id="P48">Hi-C samples were preprocessed using a custom nextflow pipeline (<ext-link ext-link-type="uri" xlink:href="https://github.com/gerlichlab/scshic_pipeline">https://github.com/gerlichlab/scshic_pipeline</ext-link>). Briefly, bcl2 files were first demultiplexed using bcl2tofastq. Then, fastq files were aligned to hg19 with HeLa SNPs using bwa, aligning read pairs independently. Then, pairsam files were constructed using pairtools (<ext-link ext-link-type="uri" xlink:href="https://github.com/mirnylab/pairtools">https://github.com/mirnylab/pairtools</ext-link>), followed by sorting and deduplicating. Then, reads were split into cis sister and trans sister contacts based on the presence of signature mutations using pairtools select: A read was assigned to the Watson strand if it contained two or more A-to-G mutations and no T-to-C mutations. Similarly, if a read contained two or more T-to-C mutations, but no A-to-G mutations it was assigned to the Crick strand. Then, contacts were classified as cis sister contacts if (after correcting for the opposite read-strandedness of Illumina sequencing of the two mates) both mates mapped to the same strand. Conversely, contacts were classified as trans sister contacts if the two mates mapped to opposing strands. Then, cooler (<ext-link ext-link-type="uri" xlink:href="https://github.com/mirnylab/cooler">https://github.com/mirnylab/cooler</ext-link>;<sup><xref rid="R57" ref-type="bibr">57</xref></sup>) was used to construct. cool files, and binned at multiple resolutions. After completion of the nextflow pipeline, cis sister and trans sister contacts were merged, and the resulting file balanced using cooler<sup><xref rid="R58" ref-type="bibr">58</xref></sup>. Balancing was done as described in<sup><xref rid="R58" ref-type="bibr">58</xref></sup>, excluding the 0<sup>th</sup>-diagonal to avoid Hi-C artefacts. Bins that had marginal read-count with a median absolute deviation (MAD) &gt; 5 based on the genome-wide distribution were excluded from balancing and further analysis. Then, the resulting weights were transferred to the individual cooler files containing the cis sister and trans sister contacts. Hi-C matrices containing all contacts (not stratified into cis sister and trans sister contacts) were balanced similarly. Human centromeres have repetitive sequences and were thus not included in our analysis.</p>
      </sec>
      <sec id="S34">
        <title>Hi-C genome scaling plots</title>
        <p id="P49">Scaling plots were calculated separately for cis sister and trans sister contacts using pairlib (<ext-link ext-link-type="uri" xlink:href="https://github.com/mirnylab/pairlib">https://github.com/mirnylab/pairlib</ext-link>). Briefly, contacts were binned into geometrically spaced bins from 10 kb to 100 Mb with a total of 64 bins. Then, the number of contacts in each bin was divided by the number of covered base pairs. When multiple samples were compared on the same plot, they were down sampled to contain an equal number of combined cis sister- and trans sister contacts that are separated further than 1 kb using the NGS package (<ext-link ext-link-type="uri" xlink:href="https://github.com/gerlichlab/ngs">https://github.com/gerlichlab/ngs</ext-link>).</p>
      </sec>
      <sec id="S35">
        <title>Observed-over-expected transformation of Hi-C matrices</title>
        <p id="P50">The expected number of Hi-C contacts <italic>e</italic> at a given genomic separation <italic>k</italic> in Hi-C bin units was calculated using the cooltools (<ext-link ext-link-type="uri" xlink:href="https://github.com/mirnylab/cooltools">https://github.com/mirnylab/cooltools</ext-link>) package: <disp-formula id="FD1"><mml:math id="M1"><mml:mi>e</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>v</mml:mi></mml:mfrac><mml:munder><mml:mi>&#x2211;</mml:mi><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#x2264;</mml:mo><mml:mi>i</mml:mi><mml:mo>&#x2264;</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:munder><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></disp-formula> with <italic>e</italic>(<italic>k</italic>) being the expected number of Hi-C contacts separated by <italic>k</italic> Hi-C bins, <italic>v</italic> being the number of valid bin-interactions with separation <italic>k</italic> (interactions between bins that were assigned valid balancing weights during the ICE-procedure) and <italic>M</italic> being the ICE-corrected Hi-C interaction matrix containing <italic>m</italic> bins. Note that the expected number of contacts is obtained from the upper-triangular part of the Hi-C matrix only since the matrix is symmetric. The observed-over-expected Hi-C matrix <italic>OE</italic> was then obtained as follows: <disp-formula id="FD2"><mml:math id="M2"><mml:mi>O</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>e</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>|</mml:mo><mml:mi>j</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mi>i</mml:mi><mml:mo>|</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></disp-formula>
</p>
      </sec>
      <sec id="S36">
        <title>Hi-C aggregate maps at TAD-centers</title>
        <p id="P51">Aggregate maps of Hi-C submatrices around TAD-centers of genomic neighborhoods were calculated within a custom ipython notebook using the cooltools package (<ext-link ext-link-type="uri" xlink:href="https://github.com/mirnylab/cooltools">https://github.com/mirnylab/cooltools</ext-link>). First, 900 kb-sized submatrices centered around TAD-centers were extracted and the pixel-wise average of the ICE-corrected contacts over all the windows was calculated. In order to avoid Hi-C artefacts, the main diagonal as well as the neighboring diagonals were blanked out in the plot.</p>
      </sec>
      <sec id="S37">
        <title>Extraction of sample regions</title>
        <p id="P52">Sample regions of ICE-corrected Hi-C-matrices were extracted using the cooler Python API. For calculations of ratio maps, the observed/expected values were calculated for the respective ROI using the cooltools (<ext-link ext-link-type="uri" xlink:href="https://github.com/mirnylab/cooltools">https://github.com/mirnylab/cooltools</ext-link>) package as described above and then trans/cis ratios were calculated. Before plotting, a pseudocount of 0.01 was added to avoid removal of 0-bins from the image during log-transformation.</p>
      </sec>
      <sec id="S38">
        <title>TAD-calling</title>
        <p id="P53">TAD-calling was done using OnTAD<sup><xref rid="R32" ref-type="bibr">32</xref></sup> on a G2 WT Hi-C matrix construct from all generated contacts merged over all replicates. OnTAD calls TADs based on the insulation score, which was shown previously to correlate with enrichment of known boundary factors such as CTCF and SMC3<sup><xref rid="R59" ref-type="bibr">59</xref></sup>. We note that this approach does not discriminate between TADs with and without corner dot that have been described previously<sup><xref rid="R5" ref-type="bibr">5</xref></sup>. The bin size for TAD-calling was 50 kb and the only parameter that was changed from the standard set was the maximum TAD-size, which was restricted to 6 Mb. The TADs used for all analysis in this paper can be found here <ext-link ext-link-type="uri" xlink:href="https://github.com/gerlichlab/scsHiCanalysis/blob/master/data/TADs_final.bedpe">https://github.com/gerlichlab/scsHiCanalysis/blob/master/data/TADs_final.bedpe</ext-link>.</p>
      </sec>
      <sec id="S39">
        <title>Pairing-score and contact-density calculation</title>
        <p id="P54">We defined the contact density as the average contact frequency within a sliding window of half-length <italic>w</italic> in Hi-C bin units: <disp-formula id="FD3"><mml:math id="M3"><mml:mi>C</mml:mi><mml:mi>D</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>v</mml:mi></mml:mfrac><mml:munder><mml:mi>&#x2211;</mml:mi><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mi>w</mml:mi><mml:mo>&#x2264;</mml:mo><mml:mi>m</mml:mi><mml:mo>&#x2264;</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mi>w</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mi>w</mml:mi><mml:mo>&#x2264;</mml:mo><mml:mi>n</mml:mi><mml:mo>&#x2264;</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mi>w</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:munder><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math></disp-formula> with <italic>CD</italic>(<italic>i</italic>) denoting the contact density at bin <italic>i</italic>, <italic>M</italic> the Hi-C matrix (either ICE-corrected or observed-over-expected transformed), <italic>v</italic> being the number of valid Hi-C pixels within the window of summation (interactions between bins that were assigned valid balancing weights during the ICE-procedure; Note that the main diagonal does not contain valid pixels) within the sliding window. We then defined the pairing-score to be the contact density subtracted by the genome-wide average and converted to a Z-score by dividing by the genome-wide standard deviation: <disp-formula id="FD4"><mml:math id="M4"><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>C</mml:mi><mml:mi>D</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x2212;</mml:mo><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>C</mml:mi><mml:mi>D</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>d</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>C</mml:mi><mml:mi>D</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula> with <italic>PS</italic>(<italic>i</italic>) referring to the pairing score at genomic bin <italic>i</italic>, <italic>median</italic>(<italic>CD</italic>) referring to the genome-wide median of <italic>CD</italic> and <italic>std</italic>(<italic>CD</italic>) referring to the genome wide standard deviation of <italic>CD</italic>.</p>
      </sec>
      <sec id="S40">
        <title>Stack-up analysis of line profiles</title>
        <p id="P55">Stack-ups of line profiles along a set of regions was calculated as follows: <list list-type="order" id="L1"><list-item><p id="P56">The contact density within a sliding diamond of half-length <italic>w</italic> was calculated along each region within the set of regions as described above (either for ICE-corrected matrices or observed-expected-transformed matrices), resulting in a vector of size <italic>n</italic> for each region.</p></list-item><list-item><p id="P57">Then, these vectors were stacked into an <italic>m x n</italic> matrix with <italic>m</italic> denoting the number of regions and <italic>n</italic> denoting the length of the line profile along each region as described in 1.</p></list-item><list-item><p id="P58">Finally, the rows of the matrix were sorted based either on the size of TADs within the regions of interest for analyses in <xref ref-type="fig" rid="F2">Fig.2f</xref> and <xref ref-type="fig" rid="F3">Fig.3e</xref> or based on the average line profile signal within the center bins &#x2013; bins with index in the interval [&#x230A;<italic>median</italic>(0,<italic>n</italic>)&#x230B; &#x2212; 5, &#x230A;<italic>median</italic>(0,<italic>n</italic>)&#x230B; + 5] - for analysis in <xref ref-type="fig" rid="F4">Fig.4d</xref>.</p></list-item></list>
</p>
        <p id="P59">For display of observed-over-expected transformed values, a pseudocount of 0.01 was added before log-transformation. Moreover, line profiles that only contained invalid Hi-C bins were removed from the stack-up.</p>
      </sec>
      <sec id="S41">
        <title>LOLA-analysis of highly paired and highly unpaired TADs</title>
        <p id="P60">LOLA<sup><xref rid="R33" ref-type="bibr">33</xref></sup> probes whether genomic features like ChIP-seq peaks are significantly enriched in a &#x2018;query&#x2019; set of regions compared to all possible regions. The probability of observing a given number of ChIP-seq peaks (or a greater number) by chance (p-value) is then calculated using Fisher&#x2019;s exact test. LOLA enrichment analysis was done for TADs with high trans sister contact density and low trans sister contact density as follows: The average contact density (see above for details) for every annotated TAD (see above for details) was calculated for a window with size <italic>w</italic> that corresponded to the size of the respective TAD centered on the TAD-center <inline-formula><mml:math id="M5"><mml:mrow><mml:mo>&#x230A;</mml:mo><mml:mfrac><mml:mrow><mml:mo>&#xA0;</mml:mo><mml:mi>T</mml:mi><mml:mi>A</mml:mi><mml:mi>D</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>A</mml:mi><mml:mi>D</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mo>&#xA0;</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mo>&#x230B;</mml:mo></mml:mrow></mml:math></inline-formula> for a Hi-C contact matrix binned at 10 kb and containing ICE-corrected trans sister contacts. The 90th and 10th percentile of trans sister contact density within these TADs was calculated and the TADs that showed a trans sister contact density larger than the 90th percentile were denoted &#x201C;highly paired&#x201D;, whereas TADs that had a trans sister contact density smaller than the 10th percentile were denoted &#x201C;highly unpaired&#x201D;. LOLA was then run using the LOLA Extended dataset<sup><xref rid="R33" ref-type="bibr">33</xref></sup> for the highly paired and highly unpaired TAD regions using all TADs as the region universe. Only chromatin datasets that were from HeLa cells are shown. A pseudocount of 0.05 was added to be able to display datasets that were very close to 0.</p>
      </sec>
      <sec id="S42">
        <title>HiCRep analysis</title>
        <p id="P61">HiCRep<sup><xref rid="R46" ref-type="bibr">46</xref></sup> was run using the python wrapper <italic>hicreppy</italic> (<ext-link ext-link-type="uri" xlink:href="https://github.com/cmdoret/hicreppy">https://github.com/cmdoret/hicreppy</ext-link>) for all conditions tested using a Hi-C matrix with bin size 100 kb, a smoothing parameter <italic>v</italic> = 10, a maximum distance of <italic>maxdist</italic> = 10<sup>6</sup>
<italic>bp</italic> without subsampling.</p>
      </sec>
      <sec id="S43">
        <title>False-positive rate estimation of double labelled reads and trans sister contacts</title>
        <p id="P62">To estimate the false-positive rate of double labelled Hi-C contact, a Hi-C sample from cells that were grown in the absence of 4sT was analyzed. The reasoning was that all reads that were classified as double labelled in this condition would be false positives. A Hi-C contact was annotated as double labelled, if both half-reads exhibited more than a threshold amount of signature mutations (A to G or T to C). Then, the false-positive rate <disp-formula id="FD5"><mml:math id="M6"><mml:mo>&#xA0;</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>D</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>b</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#xA0;</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>&#xA0;</mml:mo><mml:mi>D</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>b</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>s</mml:mi><mml:mo>&#xA0;</mml:mo></mml:mrow><mml:mrow><mml:mo>&#xA0;</mml:mo><mml:mi>A</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>s</mml:mi><mml:mo>&#xA0;</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula> was calculated for different thresholds of signature mutations. To estimate the false-positive rate of trans sister contact assignment, an approach developed in<sup><xref rid="R35" ref-type="bibr">35</xref></sup> was adapted. We assumed that all contacts of a G2 WT Hi-C sample that exhibited a genomic separation below 1 kb were Hi-C artefacts, namely uncut DNA. Such contacts should be exclusively classified as cis sister contacts since a successful digestion and re-ligation is needed to generate a trans sister contact. The false-positive rate of trans sister contacts was therefore defined as <disp-formula id="FD6"><mml:math id="M7"><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>&#xA0;</mml:mo><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mo>&#x2212;</mml:mo><mml:mo>&#xA0;</mml:mo><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>&#xA0;</mml:mo><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mo>&#x2212;</mml:mo><mml:mo>&#xA0;</mml:mo><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mn>1</mml:mn><mml:mi>k</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>&#xA0;</mml:mo><mml:mi>D</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>b</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mn>1</mml:mn><mml:mi>k</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula>
</p>
        <p id="P63">To estimate the number of wrongly assigned trans sister Hi-C contacts we assumed that the false-positive rate of trans sister assignment is independent of genomic separation and that the amount of wrongly assigned cis sister contacts is negligible. We further assumed that contacts with genomic separation larger than 1 kb constitute true Hi-C contacts. We therefore defined the fraction of wrong trans sister Hi-C contacts <italic>WTC</italic> as <disp-formula id="FD7"><mml:math id="M8"><mml:mi>W</mml:mi><mml:mi>T</mml:mi><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>&#xA0;</mml:mo><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mo>&#x2212;</mml:mo><mml:mo>&#xA0;</mml:mo><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mi>x</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mo>&#x2212;</mml:mo><mml:mo>&#xA0;</mml:mo><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>a</mml:mi><mml:mi>b</mml:mi><mml:mi>o</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mn>1</mml:mn><mml:mi>k</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>&#xA0;</mml:mo><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mo>&#x2212;</mml:mo><mml:mo>&#xA0;</mml:mo><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>a</mml:mi><mml:mi>b</mml:mi><mml:mi>o</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mo>&#xA0;</mml:mo><mml:mn>1</mml:mn><mml:mi>k</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula> and calculated this value for different signature mutation thresholds.</p>
      </sec>
      <sec id="S44">
        <title>H3K27me3 enrichment analysis</title>
        <p id="P64">In order to calculate the enrichment of H3K27me3 Chip-seq signal at highly paired and highly unpaired TADs, ChIP-seq data from<sup><xref rid="R60" ref-type="bibr">60</xref></sup> was downloaded and the average enrichment of H3K27me3 with respect to the control dataset calculated for both region sets</p>
      </sec>
    </sec>
    <sec sec-type="extended-data" id="S45">
      <title>Extended Data</title>
      <fig id="F5" orientation="portrait" position="anchor">
        <label>Extended Data Figure 1</label>
        <caption>
          <title>Characterization of 4sT.</title>
          <p id="P65">(a) Synthetic hairpin-oligonucleotide used to probe 4sT conversion by OsO<sub>4</sub>. The theorized reaction educts and products are highlighted in red. (b) High performance liquid chromatography (HPLC) trace at 260 nm of the oligos depicted in (a) before and after the conversion by OsO<sub>4</sub>/NH<sub>4</sub>Cl. The peak position of the oligo before conversion is indicated by a dashed line. (c) Melting point analysis of a synthetic DNA hairpins containing 4sT or thymidine in the Watson&#x2013;Crick base-paired stem (see Material and Methods for details). (d) Native mass spectrum of the oligonucleotide shown in (a) before and after OsO<sub>4</sub>/NH<sub>4</sub>Cl conversion measured in negative ion mode.</p>
        </caption>
        <graphic xlink:href="EMS114563-f005"/>
      </fig>
      <fig id="F6" orientation="portrait" position="anchor">
        <label>Extended Data Figure 2</label>
        <caption>
          <title>Characterization of the cellular response to 4sT.</title>
          <p id="P66">(a) Percentage of live cells determined via Topro-3-Iodide staining of dead cells after 24 h incubation with the indicated compounds. Bars indicate mean of live cell percentages of individual wells from n = 2 biologically independent experiments. (b) DNA damage assay performed after 24 h incubation with the indicated compounds. Scale bars indicate 5 &#x3BC;m. (c) Quantification of mean fluorescence in cell nuclei stained by anti-p-&#x3B3;-H2A.X antibody shown in (b). Bars indicate mean of individual cells from n = 2 biologically independent experiments. (d) Flow cytometry (FACS) analysis of cells progressing through S-phase in the presence or absence of 2 mM 4sT. DNA was stained using propidium iodide and kernel density estimation of signal in the PE-channel is shown. Cells were pre-synchronized to G1/S by thymidine and released into S-phase by removal of thymidine. The G2 sample was arrested by RO3306 and the G1 sample was arrested after progression through mitosis using aphidicolin. This experiment was repeated one more time with similar results.</p>
        </caption>
        <graphic xlink:href="EMS114563-f006"/>
      </fig>
      <fig id="F7" orientation="portrait" position="anchor">
        <label>Extended Data Figure 3</label>
        <caption>
          <title>Preparation of cell cycle stage-specific scsHi-C samples.</title>
          <p id="P67">(a) Quantification of 4sT incorporation into genomic DNA of HeLa cells using mass spectrometry. Cells were grown in medium containing 4sT for 5 days and purified genomic DNA digested to single nucleotides. Indicated values reflect the percentage of 4sT in total measured thymidine. Bars indicate mean of n = 6 biologically independent experiments. (b) Quantification of 4sT incorporation using DNA sequencing. Cells were 4sT labelled as in (a) and purified genomic DNA chemically converted as in <xref ref-type="fig" rid="F1">Fig. 1c</xref>. Indicated values are the sum of the A-to-G-mutation rate and the T-to-C mutation rate, normalized to the total amount of adenosine and thymidine measured respectively. Bars indicate mean of n = 3 biologically independent experiments. (c) Overview of experimental procedure for differential labeling of sister chromatids using 4sT. (d) Procedure of cell synchronization for scsHi-C sample preparation of cells synchronized to G2, prometaphase and the subsequent G1 phase. The different compounds were added to the cell culture medium as indicated by the colored bars. (e) Cell cycle analysis of WT HeLa cells synchronized to G2, prometaphase and G1 as indicated in (d). Anti-pH3S10 antibody was used to detect the mitotic state and propidium iodide to measure DNA content. Gates for different cell cycle stages are shown and the indicated numbers reflect percentage of cells that were measured. This experiment was repeated one time with similar results. See <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2</xref> for the exact gating strategy. (f) Average contact probability over different genomic distances of HeLa cells synchronized to G2 that were either labelled with 4sT or unlabelled. Experiment was repeated one time with similar results. (g) Hi-C interaction matrices at example regions of HeLa cells synchronized to G2 that were either labelled with 4sT or unlabelled.</p>
        </caption>
        <graphic xlink:href="EMS114563-f007"/>
      </fig>
      <fig id="F8" orientation="portrait" position="anchor">
        <label>Extended Data Figure 4</label>
        <caption>
          <title>scsHi-C classification procedure.</title>
          <p id="P68">(a) Depiction of all possible Hi-C ligation products of a sample where one strand of each sister chromatid has been labelled with a synthetic nucleotide. Only ligation products that carry two continuous halves that are labelled (&#x201C;double-labelled&#x201D;) can be used to discriminate cis sister contacts from trans sister contacts. This is because 4sT incorporation density is not high enough to allow detection of unlabelled reads based on the absence of signature mutations. If a given read exhibits signature mutations, however, it is possible to know with high confidence (see panel b and c) that it comes from the labelled strand. The ligation products that do not contain two halves with signature mutations are thus discarded during analysis. (b) Histograms of signature point mutations per read (AG or TC) of conventional sequencing libraries constructed from cells that were grown for 5 days in the presence (&#x201C;4sT-labelled&#x201D;) or absence (&#x201C;unlabelled&#x201D;) of 4sT and treated with OsO<sub>4</sub> as described in <xref ref-type="fig" rid="F1">Fig. 1c</xref>. Note that at sites of 4sT-incorporation only 50% of PCR amplicons will contain the signature mutations, as 4sT base-pairs with unmodified A on the opposing DNA strand. Bar indicates mean of n = 3 biologically independent experiments. (c) To assess how many signature mutations are required to confidently detect double-labelled reads, we analyzed Hi-C libraries from cells grown in the absence of 4sT and calculated the false-positive rate of double-labelled read detection. Double-labelled reads were assigned based on different required signature point mutations on both read-halves. The samples shown was grown without 4sT, suggesting that every detected double-labelled read should be a false positive. Points indicate mean of n = 2 biologically independent experiments. When considering reads that contained at least two signature mutations, less than 0.2% were classified as &#x201C;double-labelled&#x201D;, indicating very low rates of misclassification. When cells were released into S-Phase in the presence of 4sT, the percentage of double-labelled reads increased to 12% in the subsequent G2 phase (panel f). Thus, double-labelled reads are detected with a very low false positive rate and at sufficient yield to construct Hi-C-maps. (d) Percentage of Hi-C contacts in HeLa wildtype cells synchronized to G2 in the presence of 4sT that can be used to assign sister chromatid identity (&#x201C;double-labelled reads&#x201D;) based on a classification scheme that requires an equal amount or more than the shown number of signature mutation thresholds. The number used in this paper (2) is highlighted in red. Points indicate mean of n = 9 biologically independent experiments. (e) Quantification of wrongly assigned trans sister contacts based on different signature mutation thresholds. To calculate the false-positive rate with which a cis sister contact is wrongly assigned as a trans sister contact, we adapted the scheme used to quantify the false-positive rate of trans-homolog contact assignment from Erceg et al<sup><xref rid="R35" ref-type="bibr">35</xref></sup>. Briefly, all contacts that exhibit a genomic separation smaller than 1 kb are assumed to be Hi-C artifacts that arise from uncut continuous pieces of chromatin. Such contacts should be exclusively classified as cis sister contacts and thus all trans sister contacts in this range are assumed to be false positives. To then quantify the percentage of incorrect trans sister Hi-C contacts among all trans sister Hi-C contacts, the calculated false-positive rate was multiplied by the number of cis sister contacts exhibiting separation larger than 1 kb and the resulting percentage of all trans sister contacts exhibiting separation larger than 1 kb plotted in this figure. Points indicate mean of n = 9 biologically independent experiments. We thus estimate that - at the number of required point mutations used in this paper (2) - the wrongly assigned trans sister contacts are below 2 %. (f) Quantification of Hi-C reads that are labelled on both sides for sister-specific contact classification, as a percentage of all reads. Cells were synchronized to the G1/S boundary and released into S-Phase in the presence of 4sT for the indicated times. The G2 sample was arrested using RO3306; the prometaphase sample was arrested using nocodazole; the control sample refers to unlabelled DNA and the G1/S 4sT sample refers to a sample that was treated with 4sT, but not released into S-Phase. Bars show the mean of n = 2 biologically independent replicates. (g) Percentage of trans sister contacts based on all double-labelled reads that exhibit a genomic separation larger than 10 kb. Cells were released from G1/S block into medium containing 4sT and then arrested in G2 using RO3306, in prometaphase using nocodazole, or the following G1 using thymidine. Bars show mean of n = 2 biologically independent replicates.</p>
        </caption>
        <graphic xlink:href="EMS114563-f008"/>
      </fig>
      <fig id="F9" orientation="portrait" position="anchor">
        <label>Extended Data Figure 5</label>
        <caption>
          <title>Reproducibility of scsHi-C.</title>
          <p id="P69">(a) Hi-C interaction matrices of the long arm of chromosome 1 of all contacts, cis sister, and trans sister contacts shown for two of the 11 G2 WT replicates. The all-contacts matrix was normalized to the total number of corrected contacts in the region of interest (ROI), whereas cis sister and trans sister contacts were normalized to the total amount of cis sister contacts and trans sister contacts in the ROI. Bin size of the matrix is 500 kb. (b) HiCrep<sup><xref rid="R46" ref-type="bibr">46</xref></sup> analysis of all, cis sister and trans sister contacts of all n = 11 biologically independent G2 replicates. Bars show the mean of all comparisons. (c) Hi-C interaction matrix of the long arm of chromosome 1 of all, cis sister, and trans sister contacts of the two prometaphase replicates. Contacts were normalized as in (a). (d) HiCrep<sup><xref rid="R46" ref-type="bibr">46</xref></sup> analysis of all, cis sister and trans sister contacts of n = 2 biologically independent prometaphase replicates. Bars show the mean of all comparisons.</p>
        </caption>
        <graphic xlink:href="EMS114563-f009"/>
      </fig>
      <fig id="F10" orientation="portrait" position="anchor">
        <label>Extended Data Figure 6</label>
        <caption>
          <title>Sister chromatid conformation analysis by scsHi-C and microscopy.</title>
          <p id="P70">(a) All contacts, cis sister and trans sister contacts, as well as the ratio of trans sister observed/expected to cis sister observed/expected of n = 11 biologically independent, merged G2 samples at a representative region on chromosome 3 is displayed alongside the location of TAD boundaries and the trans sister pairing score (see <xref ref-type="sec" rid="S6">Method section</xref> for details). Bin size is 30 kb. (b) Comparison of sister chromatid separation at 5 genomic loci measured by fluorescence in situ hybridization (FISH) and scsHi-C. Microscopy image shows examples for split and unsplit genomic sister loci, from G2-synchronized HeLa cell data reported in Stanyte et al<sup><xref rid="R31" ref-type="bibr">31</xref></sup>. scsHi-C quantification of sister locus distance was done by calculating (1 &#x2013; average trans sister contacts) in a region spanning 600 kb around each FISH target site and standardizing the resulting value (see <xref ref-type="sec" rid="S6">Method section</xref> for more details). Each dot indicates one target locus, measured in n = 11 biologically independent HeLa WT G2 samples by scsHi-C. The points indicate the mean and the error indicates the standard deviation of the Hi-C measurements. Two-sided p-value for a Wald-test with t-distribution of the test statistic is shown with the null hypothesis being a zero slope (calculated using the scipy.stats.linregress function). P-value = 1 * 10<sup>-14</sup>. (c) Comparison of sister chromatid separation at 16 genomic loci measured by live cell microscopy and scsHi-C. Microscopy analysis was by live-cell imaging of 16 HeLa cell lines expressing dCas9-EGFP with different locus-specific gRNAs, using automated detection of merged or split sister loci in G2 cells, as reported in Stanyte et al<sup><xref rid="R31" ref-type="bibr">31</xref></sup>. scsHi-C quantification of sister locus distance was done by calculating (1 &#x2013; average trans sister contacts) in a region spanning 600 kb around each gRNA target site and standardizing the resulting value. Each dot indicates one target locus, measured in n = 11 biologically independent HeLa WT G2 samples by scsHi-C. The points indicate the mean and the error indicates the standard deviation of the Hi-C measurements. Two-sided p-value for a Wald-test with t-distribution of the test statistic is shown with the null hypothesis being a zero slope (calculated using the scipy.stats.linregress function). P-value = 3 * 10<sup>-27</sup>. (d) Histogram of average trans sister contact frequency for annotated TADs (see <xref ref-type="sec" rid="S6">Method section</xref> for details). Vertical lines indicate the cut-offs for &#x201C;highly paired&#x201D; and &#x201C;highly unpaired&#x201D; TADs. (e) Average contact probability over different genomic distances for cis sister and trans sister contacts at &#x201C;highly paired&#x201D;, &#x201C;highly unpaired&#x201D; regions as well as the genome-wide average for the n = 11 biologically independent HeLa WT G2 samples. Trans sister contacts were evenly increased or decreased over variable genomic distances in these highly paired or unpaired domains, respectively. Curves were normalized to the contact frequency of doubly labelled reads below 1 kb. (f) Average H3K27me3 ChIP-seq signal (fold-control) at &#x201C;highly paired&#x201D; domains. Within highly paired domains, H3K27me3 distributed relatively evenly, without marked enrichment at the edges. The domains of different size were scaled to range from arbitrary genomic units -0.5 to 0.5. The bars represent average ChIP-seq signal (fold-control). TAD boundaries are marked with dashed, grey vertical lines.</p>
        </caption>
        <graphic xlink:href="EMS114563-f010"/>
      </fig>
      <fig id="F11" orientation="portrait" position="anchor">
        <label>Extended Data Figure 7</label>
        <caption>
          <title>TAD conformations in G2 chromosomes.</title>
          <p id="P71">(a) Cis sister- and trans sister contacts of n = 11 biologically independent, merged G2 samples at a representative region on chromosome 1 are displayed alongside the location of TAD boundaries (see <xref ref-type="sec" rid="S6">Method section</xref> for details) and average trans sister and cis sister contact amount within a sliding window of 200 kb (see <xref ref-type="sec" rid="S6">Method section</xref> for details). Bin size of matrix is 40 kb. (b) Cis sister and trans sister contacts of n = 11 biologically independent, merged G2 samples at a representative region on chromosome 3 are displayed alongside the location of TAD boundaries (see <xref ref-type="sec" rid="S6">Method section</xref> for details) and average trans sister and cis sister contact amount within a sliding window of 200 kb (see <xref ref-type="sec" rid="S6">Method section</xref> for details). Bin size of matrix is 40 kb. (c) Cis sister and trans sister contacts of n = 11 biologically independent, merged G2 samples at a representative region on chromosome 5 are displayed alongside the location of TAD boundaries (see <xref ref-type="sec" rid="S6">Method section</xref> for details) and average trans sister and cis sister contact amount within a sliding window of 200 kb (see <xref ref-type="sec" rid="S6">Method section</xref> for details). Bin size of matrix is 40 kb. These examples show that the high-resolution maps of G2 chromosomes reveal many fine structures inside TADs, which we currently cannot attribute to specific genomic features. (d) Stack-up of corrected interaction frequency within sliding windows of 100 kb around CTCF Chip-seq peaks overlapping CTCF motifs of n = 11 biologically independent, merged G2 wildtype samples. The panel shows windows of 900 kb. The rows are sorted based on the center enrichment. (e) Quantification of trans-contact enrichment at CTCF Chip-seq peaks. The average observed/expected values for cis sister and trans sister contacts within a 80 kb window surrounding all (n = 60,929) annotated CTCF Chip-seq peaks overlapping a CTCF motif are displayed as a histogram. P-value was calculated using a two-sided Mann-Whitney U test. P-value = 2 * 10<sup>-296</sup>.</p>
        </caption>
        <graphic xlink:href="EMS114563-f011"/>
      </fig>
      <fig id="F12" orientation="portrait" position="anchor">
        <label>Extended Data Figure 8</label>
        <caption>
          <title>Characterization of HeLa Sororin-AID and HeLa NIPBL-AID cells.</title>
          <p id="P72">(a) Western blot for Sororin and GAPDH of HeLa Sororin-AID cells synchronized to G2 and either treated with auxin (+) or H<sub>2</sub>0 (-) as well as Western blot for NIPBL and GAPDH of HeLa NIPBL-AID cells synchronized to G2 and either treated with auxin (+) or H<sub>2</sub>O (-). This experiment was repeated two (Sororin-AID samples) and three (NIPBL-AID samples) more times with similar results. Uncropped images are displayed in <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>. (b) Cell cycle analysis of HeLa Sororin-AID and HeLa NIPBL-AID cells synchronized to G2 as indicated in <xref ref-type="fig" rid="F7">Extended Data Fig. 3d</xref>, treated with auxin. Panel shows a FACS plot of cells stained for pH3S10 to mark mitotic cells and propidium iodide to measure DNA content. Gates for different cell cycle stages are shown and the indicated numbers reflect percentage of cells that were measured. This experiment was repeated three more times with similar results. (c) Contact probability of all contacts at different genomic distances of HeLa NIPBL-AID cells synchronized to G2 (n = 4 biologically independent experiments) that were treated with auxin and HeLa WT cells synchronized to G2 (n = 11 biologically independent experiments). (d) Chromosome congression analysis of NIPBL- and Sororin-depleted cells. AID-tagging often reduces protein levels already prior to the addition of auxin<sup><xref rid="R47" ref-type="bibr">47</xref>,<xref rid="R48" ref-type="bibr">48</xref></sup>, which for NIPBL might impair sister chromatid cohesion establishment during S-phase. We therefore performed metaphase congression analysis by time-lapse microscopy of WT HeLa cells, HeLa Sororin-AID cells and HeLa NIPBL-AID cells stained with SiR-DNA. HeLa Sororin-AID cells were treated with auxin before the final S-phase and HeLa NIPBL-AID cells were treated with auxin after the final S-phase. Panel shows the cumulative frequency of cells congressing their chromosomes in metaphase after entering mitosis in a RO3306 wash-out. Pooled replicates are shown from n = 2 biologically independent experiments. (e) Cis sister and trans sister contacts of n = 11 biologically independent, merged G2 wildtype samples, n = 4 biologically independent, merged G2 NIPBL-degraded samples and n = 3 biologically independent, merged Sororin-degraded samples at a representative region on chromosome 5 are displayed alongside the location of TAD boundaries (see <xref ref-type="sec" rid="S6">Method section</xref> for details). The strong accumulation of trans sister contacts close to the diagonal in NIPBL-depleted cells indicates frequent contacts between sister chromatids and a tighter alignment. Owing to normalization of contacts to the marginal count per row, trans sister contacts appear less frequent at larger genomic distances. Bin size of matrix is 150 kb. (f) HiCrep<sup><xref rid="R46" ref-type="bibr">46</xref></sup> analysis of all, cis sister and trans sister contacts of all replicates of HeLa NIPBL-AID (n = 4 biologically independent experiments) or Sororin-AID (n = 3 biologically independent experiments) cells treated with auxin. Bars show the mean of all comparisons.</p>
        </caption>
        <graphic xlink:href="EMS114563-f012"/>
      </fig>
      <fig id="F13" orientation="portrait" position="anchor">
        <label>Extended Data Figure 9</label>
        <caption>
          <title>Effect of NIPBL degradation on distribution of trans sister contacts.</title>
          <p id="P73">(a) Stack-up of average cis sister and trans sister contacts for NIPBL-degraded cells (n = 4 biologically independent, merged experiments) within sliding windows of 100 kb along TADs; lines represent 6 Mb genomic windows of individual TADs, aligned at the center and sorted by size. Compare <xref ref-type="fig" rid="F3">Fig. 3e</xref> for WT data. (b) Stack-up of average trans sister observed/expected values for NIPBL-degraded (n = 4 biologically independent, merged experiments) and WT cells (n = 11 biologically independent, merged experiments) within sliding windows of 100 kb along TADs, individual TADs aligned at center and sorted by size. (c) Stack-up of trans sister corrected interaction frequency (see <xref ref-type="sec" rid="S6">Method section</xref> for details) along TADs that are defined as highly paired or highly unpaired in WT cells (see <xref ref-type="fig" rid="F2">Fig. 2f</xref>; <xref ref-type="fig" rid="F10">Extended Data Fig. 6d</xref>), sorted by the size of TADs for NIPBL-degraded cells (n = 4 biologically independent, merged experiments) an WT cells (n = 11 biologically independent, merged experiments). Shown are windows of 6 Mb around the center of the respective TADs. Pairing scores were calculated within a sliding window of 200 kb on a Hi-C matrix with 20 kb bin size. (d) Stack-up of trans sister pairing score (see <xref ref-type="sec" rid="S6">Method section</xref> for details) along TADs that are highly paired or highly unpaired in WT cells (see <xref ref-type="fig" rid="F2">Fig. 2f</xref>; <xref ref-type="fig" rid="F10">Extended Data Fig. 6d</xref>), sorted by the size of TADs for NIPBL-degraded cells (n = 4 biologically independent, merged experiments). Shown are windows of 6 Mb around the center of the respective TADs. Pairing scores were calculated within a sliding window of 200 kb on a Hi-C matrix with 20 kb bin size.</p>
        </caption>
        <graphic xlink:href="EMS114563-f013"/>
      </fig>
      <fig id="F14" orientation="portrait" position="anchor">
        <label>Extended Data Figure 10</label>
        <caption>
          <title>Synthesis of a 4sT-phosphoramidite building block.</title>
          <p id="P74">(a) Synthesis of 5&#x2032;-<italic>O</italic>-(4,4&#x2032;-Dimethoxytrityl)-<italic>S</italic>-(2-cyanoethyl)-4-thiothymidine 3&#x2032;-<italic>O</italic>-[(2-cyanoethyl)-(<italic>N</italic>,<italic>N</italic>-diisopropyl)]-phosphoramidite. (b) <sup>1</sup>H-NMR (700 MHz, CDCl<sub>3</sub>) of 4sT phosphoramidite (diastereomeric mixture). (c) <sup>31</sup>P-NMR (282 MHz, CDCl<sub>3</sub>) of 4sT phosphoramidite (diastereomeric mixture).</p>
        </caption>
        <graphic xlink:href="EMS114563-f014"/>
      </fig>
    </sec>
    <sec sec-type="supplementary-material" id="SM">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>Supplementary Material</label>
        <media xlink:href="EMS114563-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" id="d40e2639" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S46">
      <title>Acknowledgments</title>
      <p>The authors acknowledge technical support by the IMBA/IMP/GMI BioOptics and Molecular Biology Services facilities, and the Vienna BioCenter Metabolomics and Next Generation Sequencing facilities. We thank I. Patten, P. Batty, M.W.G. Schneider, M. Voichek for comments on the manuscript, and Life Science Editors for editing assistance. Research in the laboratory of D.W.G. is supported by the Austrian Academy of Sciences, an ERC Starting (Consolidator) Grant (nr. 281198), the Austrian Science Fund (FWF; Doktoratskolleg &#x201C;Chromosome Dynamics&#x201D; DK W1238), and the Vienna Science and Technology Fund (WWTF; project nr. LS17-003). Research in the laboratory of R.M. is supported by the Austrian Science Fund (P27947, P31691, F8011), the Austrian Research Promotion Agency FFG (West-Austrian BioNMR 858017), and the Vienna Science and Technology Fund (WWTF; project nr. LS17-003). Research in the laboratory of S.L.A. is supported by the Austrian Academy of Sciences, the European Research Council (ERC-CoG-866166 and ERC-PoC-825710), the Vienna Science and Technology Fund (WWTF; project nr. LS17-003), and the Austrian Science Fund (FWF; SFB F8002). Research in the laboratory of J.-M.P. is supported by Boehringer Ingelheim, the Austrian Research Promotion Agency (Headquarter grant FFG-852936), the European Research Council (ERC) under the European Union&#x2019;s Horizon 2020 research and innovation programme GA No 693949, the Human Frontiers Science Programme (RGP0057/2018) and the Vienna Science and Technology Fund (WWTF; grant LS19-029). M.M. received a PhD fellowship from the Boehringer Ingelheim Fonds. The VBCF Metabolomics Facility is funded by the City of Vienna through the Vienna Business Agency.</p>
    </ack>
    <fn-group>
      <fn id="FN1" fn-type="con">
        <p id="P77">
<bold>Author contributions</bold>
</p>
        <p id="P78">Michael Mitter, Daniel W. Gerlich, and Ronald Micura conceived the project and designed experiments. Catherina Gasser, Eva Neuner, and Ronald Micura developed the chemistry to convert 4sT into 5mC. Michael Mitter developed the scsHi-C methodology and together with Zsuzsanna Takacs performed all experiments of this study, except some scsHi-C experiments that were performed by Charlie T. Beales. Stefan L. Ameres provided advice on DNA labeling methodology. Christoph C. H. Langer developed the computational pipeline for DNA sequencing pre-processing. Michael Mitter developed computational procedures for scsHi-C analysis, with help from Christoph C. H. Langer. Michael Mitter and Daniel Gerlich analyzed and interpreted the data, with help from Jan-Michael Peters and Anton Goloborodko. Wen Tang and Gregor Jessberger generated AID-tagged cell lines. Daniel W. Gerlich, Ronald Micura, Stefan L. Ameres, Jan-Michael Peters, and Michael Mitter acquired funding. Daniel W. Gerlich and Ronald Micura supervised the project. Daniel W. Gerlich and Michael Mitter wrote the manuscript.</p>
      </fn>
      <fn fn-type="COI-statement" id="FN2">
        <p id="P79">
<bold>Competing interests</bold>
</p>
        <p id="P80">C.G. and R.M. declare a competing financial interest. A patent application related to this work has been filed.</p>
      </fn>
      <fn id="FN3">
        <p id="P81">
<bold>Additional information</bold>
</p>
        <p id="P82">
<bold>Supplementary information</bold> is available for this paper.</p>
        <p id="P83">
<bold>Correspondence and requests for materials</bold> should be addressed D.W.G. and M.M..</p>
      </fn>
    </fn-group>
    <sec id="S47" sec-type="data-availability">
      <title>Data availability</title>
      <p id="P75">All scsHi-C datasets generated in this study were made available via the Gene Expression Omnibus (GEO) database under the Series accession number GSE152373 and are also available from the authors upon request.</p>
    </sec>
    <sec id="S48" sec-type="data-availability">
      <title>Code availability</title>
      <p id="P76">The ipython notebooks used to perform all the sequencing data analysis of data generated within this work are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/gerlichlab/scshic_analysis">https://github.com/gerlichlab/scshic_analysis</ext-link>, alongside with a detailed description of each script and the figures they produce. The programing environment used to perform this analysis is provided as a docker container (<ext-link ext-link-type="uri" xlink:href="https://hub.docker.com/repository/docker/gerlichlab/scshic_docker">https://hub.docker.com/repository/docker/gerlichlab/scshic_docker</ext-link>) under the tag &#x201C;release-1.0&#x201D;. All the versions of the software packages used are noted within the dockerfile.</p>
    </sec>
    <ref-list>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dekker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rippe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dekker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kleckner</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Capturing chromosome conformation</article-title>
          <source>Science</source>
          <year>2002</year>
          <volume>295</volume>
          <fpage>1306</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">11847345</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lieberman-Aiden</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comprehensive mapping of long-range interactions reveals folding principles of the human genome</article-title>
          <source>Science</source>
          <year>2009</year>
          <volume>326</volume>
          <fpage>289</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">19815776</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dixon</surname>
              <given-names>JR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Topological domains in mammalian genomes identified by analysis of chromatin interactions</article-title>
          <source>Nature</source>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1038/nature11082</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nora</surname>
              <given-names>EP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Spatial partitioning of the regulatory landscape of the X-inactivation centre</article-title>
          <source>Nature</source>
          <year>2012</year>
          <volume>485</volume>
          <fpage>381</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="pmid">22495304</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rao</surname>
              <given-names>SSP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>159</volume>
          <fpage>1665</fpage>
          <lpage>1680</lpage>
          <pub-id pub-id-type="pmid">25497547</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagano</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cell-cycle dynamics of chromosomal organization at single-cell resolution</article-title>
          <source>Nature</source>
          <year>2017</year>
          <volume>547</volume>
          <fpage>61</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="pmid">28682332</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gibcus</surname>
              <given-names>JH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A pathway for mitotic chromosome formation</article-title>
          <source>Science</source>
          <year>2018</year>
          <volume>359</volume>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schoenfelder</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Long-range enhancer&#x2013;promoter contacts in gene expression control</article-title>
          <source>Nat Rev Genet</source>
          <year>2019</year>
          <volume>20</volume>
          <fpage>437</fpage>
          <lpage>455</lpage>
          <pub-id pub-id-type="pmid">31086298</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hustedt</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Durocher</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>The control of DNA repair by the cell cycle</article-title>
          <source>Nature Cell Biology</source>
          <year>2017</year>
          <volume>19</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Batty</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gerlich</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>Mitotic Chromosome Mechanics: How Cells Segregate Their Genome</article-title>
          <source>Trends in Cell Biology</source>
          <year>2019</year>
          <volume>29</volume>
          <fpage>717</fpage>
          <lpage>726</lpage>
          <pub-id pub-id-type="pmid">31230958</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwarzer</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Two independent modes of chromatin organization revealed by cohesin removal</article-title>
          <source>Nature</source>
          <year>2017</year>
          <volume>551</volume>
          <fpage>51</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">29094699</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wutz</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Topologically associating domains and chromatin loops depend on cohesin and are regulated by CTCF, WAPL, and PDS5 proteins</article-title>
          <source>EMBO J</source>
          <year>2017</year>
          <volume>36</volume>
          <fpage>3573</fpage>
          <lpage>3599</lpage>
          <pub-id pub-id-type="pmid">29217591</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rao</surname>
              <given-names>SSP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cohesin Loss Eliminates All Loop Domains</article-title>
          <source>Cell</source>
          <year>2017</year>
          <volume>171</volume>
          <fpage>305</fpage>
          <lpage>320.e24</lpage>
          <pub-id pub-id-type="pmid">28985562</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gassler</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A mechanism of cohesin-dependent loop extrusion organizes zygotic genome architecture</article-title>
          <source>EMBO J</source>
          <year>2017</year>
          <volume>36</volume>
          <fpage>3600</fpage>
          <lpage>3618</lpage>
          <pub-id pub-id-type="pmid">29217590</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Ruiten</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Rowland</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>SMC Complexes: Universal DNA Looping Machines with Distinct Regulators</article-title>
          <source>Trends in Genetics</source>
          <year>2018</year>
          <volume>34</volume>
          <fpage>477</fpage>
          <lpage>487</lpage>
          <pub-id pub-id-type="pmid">29606284</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davidson</surname>
              <given-names>IF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>DNA loop extrusion by human cohesin</article-title>
          <source>Science</source>
          <year>2019</year>
          <volume>366</volume>
          <fpage>1338</fpage>
          <lpage>1345</lpage>
          <pub-id pub-id-type="pmid">31753851</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Finkelstein</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Human cohesin compacts DNA by loop extrusion</article-title>
          <source>Science (80-)</source>
          <year>2019</year>
          <volume>366</volume>
          <fpage>1345</fpage>
          <lpage>1349</lpage>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kagey</surname>
              <given-names>MH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mediator and cohesin connect gene expression and chromatin architecture</article-title>
          <source>Nature</source>
          <year>2010</year>
          <volume>467</volume>
          <fpage>430</fpage>
          <lpage>435</lpage>
          <pub-id pub-id-type="pmid">20720539</pub-id>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ay</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Analysis methods for studying the 3D architecture of the genome</article-title>
          <source>Genome Biol</source>
          <year>2015</year>
          <volume>16</volume>
          <fpage>183</fpage>
          <pub-id pub-id-type="pmid">26328929</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Northcott</surname>
              <given-names>PA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma</article-title>
          <source>Nature</source>
          <year>2014</year>
          <volume>511</volume>
          <fpage>428</fpage>
          <lpage>434</lpage>
          <pub-id pub-id-type="pmid">25043047</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gr&#xF6;schel</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>157</volume>
          <fpage>369</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="pmid">24703711</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rankin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ayad</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Kirschner</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Sororin, a Substrate of the Anaphase-Promoting Complex, Is Required for Sister Chromatid Cohesion in Vertebrates</article-title>
          <source>Mol Cell</source>
          <year>2005</year>
          <volume>18</volume>
          <fpage>185</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="pmid">15837422</pub-id>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watrin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>J-M</given-names>
            </name>
          </person-group>
          <article-title>Cohesin and DNA damage repair</article-title>
          <source>Exp Cell Res</source>
          <year>2006</year>
          <volume>312</volume>
          <fpage>2687</fpage>
          <lpage>2693</lpage>
          <pub-id pub-id-type="pmid">16876157</pub-id>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sj&#xF6;gren</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nasmyth</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Sister chromatid cohesion is required for postreplicative double-strand break repair in Saccharomyces cerevisiae</article-title>
          <source>Curr Biol</source>
          <year>2001</year>
          <volume>11</volume>
          <fpage>991</fpage>
          <lpage>995</lpage>
          <pub-id pub-id-type="pmid">11448778</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nasmyth</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Haering</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Cohesin: Its Roles and Mechanisms</article-title>
          <source>Annu Rev Genet</source>
          <year>2009</year>
          <volume>43</volume>
          <fpage>525</fpage>
          <lpage>558</lpage>
          <pub-id pub-id-type="pmid">19886810</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herzog</surname>
              <given-names>VA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thiol-linked alkylation of RNA to assess expression dynamics</article-title>
          <source>Nat Methods</source>
          <year>2017</year>
          <volume>14</volume>
          <fpage>1198</fpage>
          <lpage>1204</lpage>
          <pub-id pub-id-type="pmid">28945705</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riml</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Osmium-Mediated Transformation of 4-Thiouridine to Cytidine as Key To Study RNA Dynamics by Sequencing</article-title>
          <source>Angew Chem Int Ed Engl</source>
          <year>2017</year>
          <volume>56</volume>
          <fpage>13479</fpage>
          <lpage>13483</lpage>
          <pub-id pub-id-type="pmid">28817234</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gasser</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thioguanosine Conversion Enables mRNA&#x2010;Lifetime Evaluation by RNA Sequencing Using Double Metabolic Labeling (TUC&#x2010;seq DUAL)</article-title>
          <source>Angew Chem Int Ed Engl</source>
          <year>2020</year>
          <volume>59</volume>
          <fpage>6881</fpage>
          <lpage>6886</lpage>
          <pub-id pub-id-type="pmid">31999864</pub-id>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vassilev</surname>
              <given-names>LT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1</article-title>
          <source>Proc Natl Acad Sci</source>
          <year>2006</year>
          <volume>103</volume>
          <fpage>10660</fpage>
          <lpage>10665</lpage>
          <pub-id pub-id-type="pmid">16818887</pub-id>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mumbach</surname>
              <given-names>MR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HiChIP: efficient and sensitive analysis of protein-directed genome architecture</article-title>
          <source>Nat Methods</source>
          <year>2016</year>
          <volume>13</volume>
          <fpage>919</fpage>
          <lpage>922</lpage>
          <pub-id pub-id-type="pmid">27643841</pub-id>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stanyte</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dynamics of sister chromatid resolution during cell cycle progression</article-title>
          <source>J Cell Biol</source>
          <year>2018</year>
          <volume>217</volume>
          <fpage>1985</fpage>
          <lpage>2004</lpage>
          <pub-id pub-id-type="pmid">29695489</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>An</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>OnTAD: hierarchical domain structure reveals the divergence of activity among TADs and boundaries</article-title>
          <source>Genome Biol</source>
          <year>2019</year>
          <volume>20</volume>
          <fpage>282</fpage>
          <pub-id pub-id-type="pmid">31847870</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheffield</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Bock</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>LOLA: enrichment analysis for genomic region sets and regulatory elements in R and Bioconductor</article-title>
          <source>Bioinformatics</source>
          <year>2016</year>
          <volume>32</volume>
          <fpage>587</fpage>
          <pub-id pub-id-type="pmid">26508757</pub-id>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jambhekar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dhall</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Roles and regulation of histone methylation in animal development</article-title>
          <source>Nature Reviews Molecular Cell Biology</source>
          <year>2019</year>
          <volume>20</volume>
          <fpage>625</fpage>
          <lpage>641</lpage>
          <pub-id pub-id-type="pmid">31267065</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Erceg</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The genome-wide multi-layered architecture of chromosome pairing in early Drosophila embryos</article-title>
          <source>Nat Commun</source>
          <year>2019</year>
          <volume>10</volume>
          <fpage>1</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">30602773</pub-id>
        </element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Consortium</surname>
              <given-names>TEP</given-names>
            </name>
          </person-group>
          <article-title>An integrated encyclopedia of DNA elements in the human genome</article-title>
          <source>Nature</source>
          <year>2012</year>
          <volume>489</volume>
          <fpage>57</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="pmid">22955616</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sandelin</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>JASPAR: an open-access database for eukaryotic transcription factor binding profiles</article-title>
          <source>Nucleic Acids Res</source>
          <year>2004</year>
          <volume>32</volume>
          <fpage>91</fpage>
          <lpage>94</lpage>
        </element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ladurner</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sororin actively maintains sister chromatid cohesion</article-title>
          <source>EMBO J</source>
          <year>2016</year>
          <volume>35</volume>
          <fpage>635</fpage>
          <lpage>653</lpage>
          <pub-id pub-id-type="pmid">26903600</pub-id>
        </element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerlich</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dupeux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>J-M</given-names>
            </name>
            <name>
              <surname>Ellenberg</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Live-cell imaging reveals a stable cohesin-chromatin interaction after but not before DNA replication</article-title>
          <source>Curr Biol</source>
          <year>2006</year>
          <volume>16</volume>
          <fpage>1571</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">16890534</pub-id>
        </element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmitz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Watrin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>L&#xE9;n&#xE1;rt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mechtler</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>J-M</given-names>
            </name>
          </person-group>
          <article-title>Sororin Is Required for Stable Binding of Cohesin to Chromatin and for Sister Chromatid Cohesion in Interphase</article-title>
          <source>Curr Biol</source>
          <year>2007</year>
          <volume>17</volume>
          <fpage>630</fpage>
          <lpage>636</lpage>
          <pub-id pub-id-type="pmid">17349791</pub-id>
        </element-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishimura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fukagawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takisawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kakimoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kanemaki</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>An auxin-based degron system for the rapid depletion of proteins in nonplant cells</article-title>
          <source>Nat Methods</source>
          <year>2009</year>
          <volume>6</volume>
          <fpage>917</fpage>
          <lpage>922</lpage>
          <pub-id pub-id-type="pmid">19915560</pub-id>
        </element-citation>
      </ref>
      <ref id="R42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oomen</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Hedger</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Watts</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Dekker</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Detecting chromatin interactions along and between sister chromatids with SisterC</article-title>
          <source>bioRxiv</source>
          <year>2020</year>
          <comment>2020.03.10.986208</comment>
          <pub-id pub-id-type="doi">10.1101/2020.03.10.986208</pub-id>
        </element-citation>
      </ref>
      <ref id="R43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rhodes</surname>
              <given-names>JDP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cohesin Disrupts Polycomb-Dependent Chromosome Interactions in Embryonic Stem Cells Correspondence</article-title>
          <source>CellReports</source>
          <year>2020</year>
          <volume>30</volume>
          <fpage>820</fpage>
          <lpage>835.e10</lpage>
        </element-citation>
      </ref>
      <ref id="R44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Altmeyer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lukas</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>To spread or not to spread&#x2014;chromatin modifications in response to DNA damage</article-title>
          <source>Curr Opin Genet Dev</source>
          <year>2013</year>
          <volume>23</volume>
          <fpage>156</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="pmid">23312207</pub-id>
        </element-citation>
      </ref>
      <ref id="R45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bantignies</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Polycomb-dependent regulatory contacts between distant hox loci in drosophila</article-title>
          <source>Cell</source>
          <year>2011</year>
          <volume>144</volume>
          <fpage>214</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="pmid">21241892</pub-id>
        </element-citation>
      </ref>
      <ref id="R46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HiCRep: assessing the reproducibility of Hi-C data using a stratum-adjusted correlation coefficient</article-title>
          <source>Genome Res</source>
          <year>2017</year>
          <volume>27</volume>
          <fpage>1939</fpage>
          <lpage>1949</lpage>
          <pub-id pub-id-type="pmid">28855260</pub-id>
        </element-citation>
      </ref>
      <ref id="R47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sathyan</surname>
              <given-names>KM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An improved auxin-inducible degron system preserves native protein levels and enables rapid and specific protein depletion</article-title>
          <source>Genes Dev</source>
          <year>2019</year>
          <volume>33</volume>
          <fpage>1441</fpage>
          <lpage>1455</lpage>
          <pub-id pub-id-type="pmid">31467088</pub-id>
        </element-citation>
      </ref>
      <ref id="R48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yesbolatova</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Natsume</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kanemaki</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Generation of conditional auxin-inducible degron (AID) cells and tight control of degron-fused proteins using the degradation inhibitor auxinole</article-title>
          <source>Methods</source>
          <year>2019</year>
          <volume>164&#x2013;165</volume>
          <fpage>73</fpage>
          <lpage>80</lpage>
        </element-citation>
      </ref>
      <ref id="R49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ran</surname>
              <given-names>FA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity</article-title>
          <source>Cell</source>
          <year>2013</year>
          <volume>154</volume>
          <fpage>1380</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">23992846</pub-id>
        </element-citation>
      </ref>
      <ref id="R50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morawska</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ulrich</surname>
              <given-names>HD</given-names>
            </name>
          </person-group>
          <article-title>An expanded tool kit for the auxin-inducible degron system in budding yeast</article-title>
          <source>Yeast</source>
          <year>2013</year>
          <volume>30</volume>
          <fpage>341</fpage>
          <lpage>351</lpage>
          <pub-id pub-id-type="pmid">23836714</pub-id>
        </element-citation>
      </ref>
      <ref id="R51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Samwer</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>DNA Cross-Bridging Shapes a Single Nucleus from a Set of Mitotic Chromosomes</article-title>
          <source>Cell</source>
          <year>2017</year>
          <volume>170</volume>
          <fpage>956</fpage>
          <lpage>972.e23</lpage>
          <pub-id pub-id-type="pmid">28841419</pub-id>
        </element-citation>
      </ref>
      <ref id="R52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sommer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hoefler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Samwer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gerlich</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>A deep learning and novelty detection framework for rapid phenotyping in high-content screening</article-title>
          <source>Mol Biol Cell</source>
          <year>2017</year>
          <volume>28</volume>
          <fpage>3428</fpage>
          <lpage>3436</lpage>
          <pub-id pub-id-type="pmid">28954863</pub-id>
        </element-citation>
      </ref>
      <ref id="R53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Held</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CellCognition: time-resolved phenotype annotation in high-throughput live cell imaging</article-title>
          <source>Nat Methods</source>
          <year>2010</year>
          <volume>7</volume>
          <fpage>747</fpage>
          <lpage>754</lpage>
          <pub-id pub-id-type="pmid">20693996</pub-id>
        </element-citation>
      </ref>
      <ref id="R54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schindelin</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fiji: an open-source platform for biological-image analysis</article-title>
          <source>Nat Methods</source>
          <year>2012</year>
          <volume>9</volume>
          <fpage>676</fpage>
          <lpage>682</lpage>
          <pub-id pub-id-type="pmid">22743772</pub-id>
        </element-citation>
      </ref>
      <ref id="R55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lusser</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thiouridine-to-Cytidine Conversion Sequencing (TUC-Seq) to Measure mRNA Transcription and Degradation Rates</article-title>
          <source>Methods Mol Biol</source>
          <year>2020</year>
          <volume>2062</volume>
          <fpage>191</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="pmid">31768978</pub-id>
        </element-citation>
      </ref>
      <ref id="R56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Virtanen</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SciPy 1.0: fundamental algorithms for scientific computing in Python</article-title>
          <source>Nat Methods</source>
          <year>2020</year>
          <volume>7</volume>
          <fpage>1</fpage>
          <lpage>12</lpage>
        </element-citation>
      </ref>
      <ref id="R57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdennur</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mirny</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Cooler: scalable storage for Hi-C data and other genomically-labeled arrays</article-title>
          <source>bioRxiv</source>
          <pub-id pub-id-type="doi">10.1101/557660</pub-id>
        </element-citation>
      </ref>
      <ref id="R58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Imakaev</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Iterative correction of Hi-C data reveals hallmarks of chromosome organization</article-title>
          <source>Nat Methods</source>
          <year>2012</year>
          <volume>9</volume>
          <fpage>999</fpage>
          <lpage>1003</lpage>
          <pub-id pub-id-type="pmid">22941365</pub-id>
        </element-citation>
      </ref>
      <ref id="R59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zufferey</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tavernari</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Oricchio</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ciriello</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Comparison of computational methods for the identification of topologically associating domains</article-title>
          <source>Genome Biol</source>
          <year>2018</year>
          <volume>19</volume>
          <fpage>217</fpage>
          <pub-id pub-id-type="pmid">30526631</pub-id>
        </element-citation>
      </ref>
      <ref id="R60">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhong</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Purification of nanogram-range immunoprecipitated DNA in ChIP-seq application</article-title>
          <source>BMC Genomics</source>
          <year>2017</year>
          <volume>18</volume>
          <fpage>985</fpage>
          <pub-id pub-id-type="pmid">29268714</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">34649268</article-id>
      <article-id pub-id-type="pmc">8674138</article-id>
      <article-id pub-id-type="publisher-id">4069</article-id>
      <article-id pub-id-type="doi">10.1038/s41586-021-04069-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Genomic reconstruction of the SARS-CoV-2 epidemic in England</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>V&#xF6;hringer</surname>
            <given-names>Harald S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sanderson</surname>
            <given-names>Theo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3054-7846</contrib-id>
          <name>
            <surname>Sinnott</surname>
            <given-names>Matthew</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Maio</surname>
            <given-names>Nicola</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nguyen</surname>
            <given-names>Thuy</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9954-841X</contrib-id>
          <name>
            <surname>Goater</surname>
            <given-names>Richard</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schwach</surname>
            <given-names>Frank</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4117-961X</contrib-id>
          <name>
            <surname>Harrison</surname>
            <given-names>Ian</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2683-0849</contrib-id>
          <name>
            <surname>Hellewell</surname>
            <given-names>Joel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ariani</surname>
            <given-names>Cristina V.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gon&#xE7;alves</surname>
            <given-names>Sonia</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8090-9462</contrib-id>
          <name>
            <surname>Jackson</surname>
            <given-names>David K.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Johnston</surname>
            <given-names>Ian</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jung</surname>
            <given-names>Alexander W.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8720-9736</contrib-id>
          <name>
            <surname>Saint</surname>
            <given-names>Callum</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sillitoe</surname>
            <given-names>John</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suciu</surname>
            <given-names>Maria</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8486-2211</contrib-id>
          <name>
            <surname>Goldman</surname>
            <given-names>Nick</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7720-1121</contrib-id>
          <name>
            <surname>Panovska-Griffiths</surname>
            <given-names>Jasmina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author" id="IAu1">
          <collab>The Wellcome Sanger Institute COVID-19 Surveillance Team<contrib-group><contrib contrib-type="author"><name><surname>Abnizova</surname><given-names>Irina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Aigrain</surname><given-names>Louise</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Alderton</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ali</surname><given-names>Mozam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Allen</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Amato</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Ralph</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ariani</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Austin-Guest</surname><given-names>Siobhan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bala</surname><given-names>Sendu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Barrett</surname><given-names>Jeffrey</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bassett</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Battleday</surname><given-names>Kristina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Beal</surname><given-names>James</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Beale</surname><given-names>Mathew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Beaver</surname><given-names>Charlotte</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bellany</surname><given-names>Sam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bellerby</surname><given-names>Tristram</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bellis</surname><given-names>Katie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Berger</surname><given-names>Duncan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Berriman</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Betteridge</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bevan</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Binley</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bishop</surname><given-names>Jason</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Blackburn</surname><given-names>Kirsty</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bonfield</surname><given-names>James</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Boughton</surname><given-names>Nick</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bowker</surname><given-names>Sam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Brendler-Spaeth</surname><given-names>Timothy</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bronner</surname><given-names>Iraad</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Brooklyn</surname><given-names>Tanya</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Buddenborg</surname><given-names>Sarah Kay</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bush</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Caetano</surname><given-names>Catarina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cagan</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Carter</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cartwright</surname><given-names>Joanna</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Monteiro</surname><given-names>Tiago Carvalho</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chapman</surname><given-names>Liz</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chillingworth</surname><given-names>Tracey-Jane</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Clapham</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Clarke</surname><given-names>Adrian</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Clarke</surname><given-names>Catriona</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cole</surname><given-names>Daryl</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cook</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Coppola</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cornell</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cornwell</surname><given-names>Clare</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Corton</surname><given-names>Craig</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Crackett</surname><given-names>Abby</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cranage</surname><given-names>Alison</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Craven</surname><given-names>Harriet</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Craw</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Crawford</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cutts</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dabrowska</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dawson</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Day</surname><given-names>Callum</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Densem</surname><given-names>Aiden</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dibling</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dockree</surname><given-names>Cat</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dodd</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dogga</surname><given-names>Sunil</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dorman</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dougan</surname><given-names>Gordon</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dougherty</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dove</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Drummond</surname><given-names>Lucy</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Drury</surname><given-names>Eleanor</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dudek</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Durham</surname><given-names>Jillian</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Durrant</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Easthope</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Eckert</surname><given-names>Sabine</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ellis</surname><given-names>Pete</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Farr</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fenton</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ferrero</surname><given-names>Marcella</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Flack</surname><given-names>Neil</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fordham</surname><given-names>Howerd</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Forsythe</surname><given-names>Grace</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Foulser</surname><given-names>Luke</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Francis</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fraser</surname><given-names>Audrey</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Freeman</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Galvin</surname><given-names>Anastasia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Garcia-Casado</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gedny</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Girgis</surname><given-names>Sophia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Glover</surname><given-names>James</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Goncalves</surname><given-names>Sonia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Goodwin</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gould</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gourtovaia</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gray</surname><given-names>Andy</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gray</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Griffiths</surname><given-names>Coline</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Guerin</surname><given-names>Florence</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hamilton</surname><given-names>Will</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hanks</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Harrison</surname><given-names>Ewan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Harrott</surname><given-names>Alexandria</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Harry</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Harvison</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Heath</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hernandez-Koutoucheva</surname><given-names>Anastasia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hobbs</surname><given-names>Rhiannon</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Holland</surname><given-names>Dave</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Holmes</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hornett</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hough</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Huckle</surname><given-names>Liz</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hughes-Hallet</surname><given-names>Lena</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hunter</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Inglis</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Iqbal</surname><given-names>Sameena</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>James</surname><given-names>Keith</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jamrozy</surname><given-names>Dorota</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Verdejo</surname><given-names>Carlos Jimenez</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kallepally</surname><given-names>Kalyan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kane</surname><given-names>Leanne</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kay</surname><given-names>Keely</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kay</surname><given-names>Sally</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Keatley</surname><given-names>Jon</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Keith</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>King</surname><given-names>Alison</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kitchin</surname><given-names>Lucy</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kleanthous</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Klimekova</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Korlevic</surname><given-names>Petra</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Krasheninnkova</surname><given-names>Ksenia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lane</surname><given-names>Greg</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Langford</surname><given-names>Cordelia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Laverack</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Law</surname><given-names>Katharine</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lawniczak</surname><given-names>Mara</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lensing</surname><given-names>Stefanie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Leonard</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Letchford</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lewis-Wade</surname><given-names>Amanah</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liddle</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Quan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lindsay</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Linsdell</surname><given-names>Sally</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Livett</surname><given-names>Rich</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lo</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Long</surname><given-names>Rhona</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lovell</surname><given-names>Jamie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lovell</surname><given-names>Jon</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ludden</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mack</surname><given-names>James</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Maddison</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Makunin</surname><given-names>Aleksei</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mamun</surname><given-names>Irfan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mansfield</surname><given-names>Jenny</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Marriott</surname><given-names>Neil</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mayho</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>McCarthy</surname><given-names>Shane</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>McClintock</surname><given-names>Jo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>McGuigan</surname><given-names>Samantha</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>McHugh</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>McMinn</surname><given-names>Liz</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Meadows</surname><given-names>Carl</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mobley</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Moll</surname><given-names>Robin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Morra</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Morrow</surname><given-names>Leanne</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Murie</surname><given-names>Kathryn</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nash</surname><given-names>Sian</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nathwani</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Naydenova</surname><given-names>Plamena</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Neaverson</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nelson</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nerou</surname><given-names>Ed</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nicholson</surname><given-names>Jon</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nimz</surname><given-names>Tabea</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Noell</surname><given-names>Guillaume G.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>O&#x2019;Meara</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ohan</surname><given-names>Valeriu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Oliver</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Olney</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ormond</surname><given-names>Doug</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Oszlanczi</surname><given-names>Agnes</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Palmer</surname><given-names>Steve</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pang</surname><given-names>Yoke Fei</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pardubska</surname><given-names>Barbora</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Naomi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Parmar</surname><given-names>Aaron</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Gaurang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Minal</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Payne</surname><given-names>Maggie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Peacock</surname><given-names>Sharon</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Petersen</surname><given-names>Arabella</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Plowman</surname><given-names>Deborah</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Preston</surname><given-names>Tom</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Prestwood</surname><given-names>Liam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Puethe</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Quail</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rajan</surname><given-names>Diana</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rajatileka</surname><given-names>Shavanthi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rance</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rawlings</surname><given-names>Suzannah</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Redshaw</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Reynolds</surname><given-names>Joe</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Reynolds</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rice</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Richardson</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>Connor</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>Katrina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>Melanie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rogers</surname><given-names>Hazel</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rojo</surname><given-names>Eduardo Martin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Roopra</surname><given-names>Daljit</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rose</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rudd</surname><given-names>Luke</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sadri</surname><given-names>Ramin</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Salmon</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Saul</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schwach</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Scott</surname><given-names>Carol</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Seekings</surname><given-names>Phil</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shirley</surname><given-names>Lesley</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Simms</surname><given-names>Alison</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sinnott</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sivadasan</surname><given-names>Shanthi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Siwek</surname><given-names>Bart</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sizer</surname><given-names>Dale</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Skeldon</surname><given-names>Kenneth</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Skelton</surname><given-names>Jason</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Slater-Tunstill</surname><given-names>Joanna</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sloper</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smerdon</surname><given-names>Nathalie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Christen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>James</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Katie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Sean</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Tina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sneade</surname><given-names>Leighton</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Soria</surname><given-names>Carmen Diaz</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sousa</surname><given-names>Catarina</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Souster</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sparkes</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Spencer-Chapman</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Squares</surname><given-names>Janet</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stanley</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Steed</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stickland</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Still</surname><given-names>Ian</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stratton</surname><given-names>Michael R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Strickland</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Swann</surname><given-names>Allen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Swiatkowska</surname><given-names>Agnieszka</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sycamore</surname><given-names>Neil</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Swift</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Symons</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Szluha</surname><given-names>Suzanne</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Taluy</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tao</surname><given-names>Nunu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Katy</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Sam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>Stacey</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Thomson</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Thomson</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Thurston</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tonkin-Hill</surname><given-names>Gerry</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Toombs</surname><given-names>Dee</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Topping</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tovar-Corona</surname><given-names>Jaime</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ungureanu</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Uphill</surname><given-names>James</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Urbanova</surname><given-names>Jana</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Van Vuuren</surname><given-names>Philip Jansen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Vancollie</surname><given-names>Valerie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Voak</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Danielle</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Waller</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ward</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Weatherhogg</surname><given-names>Charlie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Webb</surname><given-names>Niki</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Weldon</surname><given-names>Danni</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wells</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wells</surname><given-names>Eloise</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Westwood</surname><given-names>Luke</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Whipp</surname><given-names>Theo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Whiteley</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Whitton</surname><given-names>Georgia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Whitwham</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Widaa</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Mia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wright</surname><given-names>Sean</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib></contrib-group></collab>
        </contrib>
        <contrib contrib-type="author">
          <collab>The COVID-19 Genomics UK (COG-UK) Consortium*<contrib-group><contrib contrib-type="author"><name><surname>Robson</surname><given-names>Samuel C.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, metadata curation, project administration, samples and logistics, sequencing and analysis, software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Connor</surname><given-names>Thomas R.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Loman</surname><given-names>Nicholas J.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, metadata curation, project administration, samples and logistics, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Golubchik</surname><given-names>Tanya</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, project administration, samples and logistics, sequencing and analysis, software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Martinez Nunez</surname><given-names>Rocio T.</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, metadata curation, samples and logistics, sequencing and analysis, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Bonsall</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, project administration, samples and logistics, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rambaut</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, project administration, sequencing and analysis, software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Snell</surname><given-names>Luke B.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><on-behalf-of>for the Funding acquisition, metadata curation, project administration, samples and logistics, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><on-behalf-of>for the Leadership and supervision, metadata curation, project administration, samples and logistics, software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ludden</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, metadata curation, project administration, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Corden</surname><given-names>Sally</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Nastouli</surname><given-names>Eleni</given-names></name><xref ref-type="aff" rid="Aff19">19</xref><xref ref-type="aff" rid="Aff20">20</xref><xref ref-type="aff" rid="Aff21">21</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, metadata curation, samples and logistics, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Nebbia</surname><given-names>Gaia</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, metadata curation, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><on-behalf-of>for the Funding acquisition, leadership and supervision, project administration, samples and logistics, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Lythgoe</surname><given-names>Katrina</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Torok</surname><given-names>M. Estee</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Goodfellow</surname><given-names>Ian G.</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, project administration, samples and logistics, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Prieto</surname><given-names>Jacqui A.</given-names></name><xref ref-type="aff" rid="Aff24">24</xref><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name><surname>Saeed</surname><given-names>Kordo</given-names></name><xref ref-type="aff" rid="Aff24">24</xref><xref ref-type="aff" rid="Aff26">26</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, project administration, samples and logistics, and visualization</on-behalf-of></contrib-group><contrib-group><on-behalf-of>for the Leadership and supervision, metadata curation, project administration, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Houlihan</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="Aff19">19</xref><xref ref-type="aff" rid="Aff27">27</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, samples and logistics, sequencing and analysis, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Frampton</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="Aff20">20</xref><xref ref-type="aff" rid="Aff27">27</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, sequencing and analysis, software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Hamilton</surname><given-names>William L.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Witney</surname><given-names>Adam A.</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><on-behalf-of>for the Metadata curation, project administration, samples and logistics, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Bucca</surname><given-names>Giselda</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><on-behalf-of>for the Funding acquisition, samples and logistics, sequencing and analysis, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Pope</surname><given-names>Cassie F.</given-names></name><xref ref-type="aff" rid="Aff29">29</xref><xref ref-type="aff" rid="Aff30">30</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, metadata curation and project administration</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Moore</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, metadata curation, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Thomson</surname><given-names>Emma C.</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, metadata curation, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Harrison</surname><given-names>Ewan M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff32">32</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, project administration, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Colin P.</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, sequencing and analysis, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rogan</surname><given-names>Fiona</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, project administration, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Beckwith</surname><given-names>Shaun M.</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>Murray</surname><given-names>Abigail</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>Singleton</surname><given-names>Dawn</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>Eastick</surname><given-names>Kirstine</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>Sheridan</surname><given-names>Liz A.</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name><surname>Randell</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>Leigh M.</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Gon&#xE7;alves</surname><given-names>S&#xF3;nia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, project administration, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Fairley</surname><given-names>Derek J.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><name><surname>Loose</surname><given-names>Matthew W.</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name><surname>Watkins</surname><given-names>Joanne</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, samples and logistics, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Moses</surname><given-names>Samuel</given-names></name><xref ref-type="aff" rid="Aff41">41</xref><xref ref-type="aff" rid="Aff42">42</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, samples and logistics, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Nicholls</surname><given-names>Sam</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Bull</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Darren L.</given-names></name><xref ref-type="aff" rid="Aff43">43</xref><xref ref-type="aff" rid="Aff44">44</xref><xref ref-type="aff" rid="Aff45">45</xref></contrib><on-behalf-of>for the Leadership and supervision, project administration, samples and logistics, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Aanensen</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff46">46</xref></contrib><on-behalf-of>for the Leadership and supervision, sequencing and analysis, software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Aggarwal</surname><given-names>Dinesh</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Shepherd</surname><given-names>James G.</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Curran</surname><given-names>Martin D.</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name><surname>Parmar</surname><given-names>Surendra</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><on-behalf-of>for the Metadata curation, project administration, samples and logistics, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Parker</surname><given-names>Matthew D.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><on-behalf-of>for the Metadata curation, project administration, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Catryn</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><on-behalf-of>for the Metadata curation, samples and logistics, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Glaysher</surname><given-names>Sharon</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><on-behalf-of>for the Metadata curation, samples and logistics, sequencing and analysis, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Underwood</surname><given-names>Anthony P.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff46">46</xref></contrib><contrib contrib-type="author"><name><surname>Bashton</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff43">43</xref><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name><surname>Pacchiarini</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Loveson</surname><given-names>Katie F.</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Byott</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff19">19</xref><xref ref-type="aff" rid="Aff20">20</xref></contrib><on-behalf-of>for the Metadata curation, sequencing and analysis, software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Carabelli</surname><given-names>Alessandro M.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><on-behalf-of>for the Project administration, sequencing and analysis, software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Templeton</surname><given-names>Kate E.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref><xref ref-type="aff" rid="Aff50">50</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, and metadata curation</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>de Silva</surname><given-names>Thushan I.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Dennis</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Langford</surname><given-names>Cordelia F.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, and project administration</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Gunson</surname><given-names>Rory N.</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Cottrell</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>O&#x2019;Grady</surname><given-names>Justin</given-names></name><xref ref-type="aff" rid="Aff52">52</xref><xref ref-type="aff" rid="Aff53">53</xref></contrib><contrib contrib-type="author"><name><surname>Kwiatkowski</surname><given-names>Dominic</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff54">54</xref></contrib><on-behalf-of>for the Funding acquisition, leadership and supervision, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Lillie</surname><given-names>Patrick J.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation and project administration</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Cortes</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name><surname>Moore</surname><given-names>Nathan</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name><surname>Burns</surname><given-names>Phillipa J.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>Mahungu</surname><given-names>Tabitha W.</given-names></name><xref ref-type="aff" rid="Aff56">56</xref></contrib><contrib contrib-type="author"><name><surname>Liggett</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="Aff57">57</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Beckett</surname><given-names>Angela H.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name><surname>Holden</surname><given-names>Matthew T. G.</given-names></name><xref ref-type="aff" rid="Aff59">59</xref></contrib><on-behalf-of>for the Leadership and supervision, metadata curation, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Levett</surname><given-names>Lisa J.</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name><surname>Osman</surname><given-names>Husam</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff61">61</xref></contrib><contrib contrib-type="author"><name><surname>Hassan-Ibrahim</surname><given-names>Mohammed O.</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><on-behalf-of>for the Leadership and supervision, project administration, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Simpson</surname><given-names>David A.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><on-behalf-of>for the Leadership and supervision, project administration, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Chand</surname><given-names>Meera</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Ravi K.</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Darby</surname><given-names>Alistair C.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Paterson</surname><given-names>Steve</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><on-behalf-of>for the Leadership and supervision, samples and logistics, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Pybus</surname><given-names>Oliver G.</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name><surname>Volz</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>de Angelis</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="Aff64">64</xref></contrib><contrib contrib-type="author"><name><surname>Robertson</surname><given-names>David L.</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Page</surname><given-names>Andrew J.</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><on-behalf-of>for the Leadership and supervision, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Bassett</surname><given-names>Andrew R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Leadership and supervision, sequencing and analysis, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Nick</given-names></name><xref ref-type="aff" rid="Aff65">65</xref></contrib><contrib contrib-type="author"><name><surname>Taha</surname><given-names>Yusri</given-names></name><xref ref-type="aff" rid="Aff66">66</xref></contrib><contrib contrib-type="author"><name><surname>Erkiert</surname><given-names>Michelle J.</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Spencer Chapman</surname><given-names>Michael H.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff32">32</xref></contrib><on-behalf-of>for the Metadata curation, project administration, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Dewar</surname><given-names>Rebecca</given-names></name><xref ref-type="aff" rid="Aff50">50</xref></contrib><contrib contrib-type="author"><name><surname>McHugh</surname><given-names>Martin P.</given-names></name><xref ref-type="aff" rid="Aff50">50</xref><xref ref-type="aff" rid="Aff67">67</xref></contrib><on-behalf-of>for the Metadata curation, project administration, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mookerjee</surname><given-names>Siddharth</given-names></name><xref ref-type="aff" rid="Aff68">68</xref><xref ref-type="aff" rid="Aff69">69</xref></contrib><on-behalf-of>for the Metadata curation, project administration, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Aplin</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Harvey</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Sass</surname><given-names>Thea</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Umpleby</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Wheeler</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><on-behalf-of>for the Metadata curation, project administration and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>McKenna</surname><given-names>James P.</given-names></name><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><name><surname>Warne</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="Aff70">70</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Joshua F.</given-names></name><xref ref-type="aff" rid="Aff71">71</xref></contrib><contrib contrib-type="author"><name><surname>Chaudhry</surname><given-names>Yasmin</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Izuagbe</surname><given-names>Rhys</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Jahun</surname><given-names>Aminu S.</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Gregory R.</given-names></name><xref ref-type="aff" rid="Aff43">43</xref><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name><surname>McMurray</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>McCann</surname><given-names>Clare M.</given-names></name><xref ref-type="aff" rid="Aff44">44</xref><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author"><name><surname>Nelson</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff44">44</xref><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author"><name><surname>Elliott</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><on-behalf-of>for the Metadata curation, samples and logistics, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Lowe</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="Aff41">41</xref></contrib><on-behalf-of>for the Metadata curation, samples and logistics, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Price</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Crown</surname><given-names>Matthew R.</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name><surname>Rey</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Roy</surname><given-names>Sunando</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Temperton</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><on-behalf-of>for the Metadata curation, sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Shaaban</surname><given-names>Sharif</given-names></name><xref ref-type="aff" rid="Aff59">59</xref></contrib><contrib contrib-type="author"><name><surname>Hesketh</surname><given-names>Andrew R.</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><on-behalf-of>for the Metadata curation, sequencing and analysis, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Laing</surname><given-names>Kenneth G.</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name><surname>Monahan</surname><given-names>Irene M.</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name><surname>Heaney</surname><given-names>Judith</given-names></name><xref ref-type="aff" rid="Aff19">19</xref><xref ref-type="aff" rid="Aff20">20</xref><xref ref-type="aff" rid="Aff60">60</xref></contrib><on-behalf-of>for the Project administration, samples and logistics, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Pelosi</surname><given-names>Emanuela</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Silviera</surname><given-names>Siona</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Wilson-Davies</surname><given-names>Eleri</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><on-behalf-of>for the Project administration, samples and logistics, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Fryer</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><on-behalf-of>for the Samples and logistics, software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Adams</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="Aff72">72</xref></contrib><contrib contrib-type="author"><name><surname>du Plessis</surname><given-names>Louis</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Rob</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Harvey</surname><given-names>William T.</given-names></name><xref ref-type="aff" rid="Aff31">31</xref><xref ref-type="aff" rid="Aff73">73</xref></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Orton</surname><given-names>Richard J.</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Spurgin</surname><given-names>Lewis G.</given-names></name><xref ref-type="aff" rid="Aff74">74</xref></contrib><contrib contrib-type="author"><name><surname>Bourgeois</surname><given-names>Yann</given-names></name><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name><surname>Ruis</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>O&#x2019;Toole</surname><given-names>&#xC1;ine</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Sanderson</surname><given-names>Theo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Sequencing and analysis, software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Fraser</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Edgeworth</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Breuer</surname><given-names>Judith</given-names></name><xref ref-type="aff" rid="Aff19">19</xref><xref ref-type="aff" rid="Aff75">75</xref></contrib><contrib contrib-type="author"><name><surname>Michell</surname><given-names>Stephen L.</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Todd</surname><given-names>John A.</given-names></name><xref ref-type="aff" rid="Aff76">76</xref></contrib><on-behalf-of>for the Funding acquisition, and leadership and supervision</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>John</surname><given-names>Michaela</given-names></name><xref ref-type="aff" rid="Aff77">77</xref></contrib><contrib contrib-type="author"><name><surname>Buck</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff76">76</xref></contrib><on-behalf-of>for the Funding acquisition and project administration</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Gajee</surname><given-names>Kavitha</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>Kay</surname><given-names>Gemma L.</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><on-behalf-of>for the Leadership and supervision, and metadata curation</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Peacock</surname><given-names>Sharon J.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Heyburn</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><on-behalf-of>for the Leadership and supervision, and project administration</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Kitchman</surname><given-names>Katie</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>McNally</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff78">78</xref></contrib><contrib contrib-type="author"><name><surname>Pritchard</surname><given-names>David T.</given-names></name><xref ref-type="aff" rid="Aff65">65</xref></contrib><contrib contrib-type="author"><name><surname>Dervisevic</surname><given-names>Samir</given-names></name><xref ref-type="aff" rid="Aff79">79</xref></contrib><contrib contrib-type="author"><name><surname>Muir</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff61">61</xref></contrib><contrib contrib-type="author"><name><surname>Vipond</surname><given-names>Barry B.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ramadan</surname><given-names>Newara A.</given-names></name><xref ref-type="aff" rid="Aff80">80</xref></contrib><contrib contrib-type="author"><name><surname>Jeanes</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="Aff81">81</xref></contrib><contrib contrib-type="author"><name><surname>Catalan</surname><given-names>Jana</given-names></name><xref ref-type="aff" rid="Aff82">82</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Neil</given-names></name><xref ref-type="aff" rid="Aff82">82</xref></contrib><on-behalf-of>for the Leadership and supervision, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>da Silva Filipe</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Fuchs</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Miskelly</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Jeffries</surname><given-names>Aaron R.</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Naomi R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Leadership and supervision, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ash</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="Aff83">83</xref></contrib><contrib contrib-type="author"><name><surname>Koshy</surname><given-names>Cherian</given-names></name><xref ref-type="aff" rid="Aff83">83</xref></contrib><contrib contrib-type="author"><name><surname>Barrow</surname><given-names>Magdalena</given-names></name><xref ref-type="aff" rid="Aff84">84</xref></contrib><contrib contrib-type="author"><name><surname>Buchan</surname><given-names>Sarah L.</given-names></name><xref ref-type="aff" rid="Aff84">84</xref></contrib><contrib contrib-type="author"><name><surname>Mantzouratou</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff84">84</xref></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Gemma</given-names></name><xref ref-type="aff" rid="Aff85">85</xref></contrib><contrib contrib-type="author"><name><surname>Holmes</surname><given-names>Christopher W.</given-names></name><xref ref-type="aff" rid="Aff86">86</xref></contrib><contrib contrib-type="author"><name><surname>Campbell</surname><given-names>Sharon</given-names></name><xref ref-type="aff" rid="Aff87">87</xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff88">88</xref></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Ngee Keong</given-names></name><xref ref-type="aff" rid="Aff71">71</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Julianne R.</given-names></name><xref ref-type="aff" rid="Aff75">75</xref></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>Kathryn A.</given-names></name><xref ref-type="aff" rid="Aff75">75</xref><xref ref-type="aff" rid="Aff89">89</xref></contrib><contrib contrib-type="author"><name><surname>Kidd</surname><given-names>Stephen P.</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name><surname>Grant</surname><given-names>Paul R.</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name><surname>Xu-McCrae</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="Aff61">61</xref></contrib><contrib contrib-type="author"><name><surname>Cox</surname><given-names>Alison</given-names></name><xref ref-type="aff" rid="Aff68">68</xref><xref ref-type="aff" rid="Aff90">90</xref></contrib><contrib contrib-type="author"><name><surname>Madona</surname><given-names>Pinglawathee</given-names></name><xref ref-type="aff" rid="Aff68">68</xref><xref ref-type="aff" rid="Aff90">90</xref></contrib><contrib contrib-type="author"><name><surname>Pond</surname><given-names>Marcus</given-names></name><xref ref-type="aff" rid="Aff68">68</xref><xref ref-type="aff" rid="Aff90">90</xref></contrib><contrib contrib-type="author"><name><surname>Randell</surname><given-names>Paul A.</given-names></name><xref ref-type="aff" rid="Aff68">68</xref><xref ref-type="aff" rid="Aff90">90</xref></contrib><contrib contrib-type="author"><name><surname>Withell</surname><given-names>Karen T.</given-names></name><xref ref-type="aff" rid="Aff91">91</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Cheryl</given-names></name><xref ref-type="aff" rid="Aff92">92</xref></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Clive</given-names></name><xref ref-type="aff" rid="Aff93">93</xref></contrib><contrib contrib-type="author"><name><surname>Denton-Smith</surname><given-names>Rebecca</given-names></name><xref ref-type="aff" rid="Aff94">94</xref></contrib><contrib contrib-type="author"><name><surname>Swindells</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="Aff94">94</xref></contrib><contrib contrib-type="author"><name><surname>Turnbull</surname><given-names>Robyn</given-names></name><xref ref-type="aff" rid="Aff94">94</xref></contrib><contrib contrib-type="author"><name><surname>Sloan</surname><given-names>Tim J.</given-names></name><xref ref-type="aff" rid="Aff95">95</xref></contrib><contrib contrib-type="author"><name><surname>Bosworth</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff61">61</xref></contrib><contrib contrib-type="author"><name><surname>Hutchings</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Pymont</surname><given-names>Hannah M.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Casey</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff96">96</xref></contrib><contrib contrib-type="author"><name><surname>Ratcliffe</surname><given-names>Liz</given-names></name><xref ref-type="aff" rid="Aff96">96</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Christopher R.</given-names></name><xref ref-type="aff" rid="Aff38">38</xref><xref ref-type="aff" rid="Aff97">97</xref></contrib><contrib contrib-type="author"><name><surname>Knight</surname><given-names>Bridget A.</given-names></name><xref ref-type="aff" rid="Aff38">38</xref><xref ref-type="aff" rid="Aff97">97</xref></contrib><contrib contrib-type="author"><name><surname>Haque</surname><given-names>Tanzina</given-names></name><xref ref-type="aff" rid="Aff56">56</xref></contrib><contrib contrib-type="author"><name><surname>Hart</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="Aff56">56</xref></contrib><contrib contrib-type="author"><name><surname>Irish-Tavares</surname><given-names>Dianne</given-names></name><xref ref-type="aff" rid="Aff56">56</xref></contrib><contrib contrib-type="author"><name><surname>Witele</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="Aff56">56</xref></contrib><contrib contrib-type="author"><name><surname>Mower</surname><given-names>Craig</given-names></name><xref ref-type="aff" rid="Aff57">57</xref></contrib><contrib contrib-type="author"><name><surname>Watson</surname><given-names>Louisa K.</given-names></name><xref ref-type="aff" rid="Aff57">57</xref></contrib><contrib contrib-type="author"><name><surname>Collins</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="Aff66">66</xref></contrib><contrib contrib-type="author"><name><surname>Eltringham</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="Aff66">66</xref></contrib><contrib contrib-type="author"><name><surname>Crudgington</surname><given-names>Dorian</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name><surname>Macklin</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name><surname>Iturriza-Gomara</surname><given-names>Miren</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Lucaci</surname><given-names>Anita O.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>McClure</surname><given-names>Patrick C.</given-names></name><xref ref-type="aff" rid="Aff98">98</xref></contrib><on-behalf-of>for the Metadata curation, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Carlile</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name><surname>Holmes</surname><given-names>Nadine</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name><surname>Moore</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name><surname>Storey</surname><given-names>Nathaniel</given-names></name><xref ref-type="aff" rid="Aff75">75</xref></contrib><contrib contrib-type="author"><name><surname>Rooke</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="Aff59">59</xref></contrib><contrib contrib-type="author"><name><surname>Yebra</surname><given-names>Gonzalo</given-names></name><xref ref-type="aff" rid="Aff59">59</xref></contrib><contrib contrib-type="author"><name><surname>Craine</surname><given-names>Noel</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Perry</surname><given-names>Malorie</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Alikhan</surname><given-names>Nabil-Fareed</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Bridgett</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Cook</surname><given-names>Kate F.</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Fearn</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Goudarzi</surname><given-names>Salman</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Lyons</surname><given-names>Ronan A.</given-names></name><xref ref-type="aff" rid="Aff99">99</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Haldenby</surname><given-names>Sam T.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><on-behalf-of>for the Metadata curation, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Davies</surname><given-names>Robert M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Metadata curation, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Batra</surname><given-names>Rahul</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Blane</surname><given-names>Beth</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Spyer</surname><given-names>Moira J.</given-names></name><xref ref-type="aff" rid="Aff19">19</xref><xref ref-type="aff" rid="Aff20">20</xref><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Perminder</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff100">100</xref></contrib><contrib contrib-type="author"><name><surname>Yavus</surname><given-names>Mehmet</given-names></name><xref ref-type="aff" rid="Aff48">48</xref><xref ref-type="aff" rid="Aff101">101</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Rachel J.</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Mahanama</surname><given-names>Adhyana I. K.</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Samaraweera</surname><given-names>Buddhini</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Girgis</surname><given-names>Sophia T.</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Hansford</surname><given-names>Samantha E.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Green</surname><given-names>Angie</given-names></name><xref ref-type="aff" rid="Aff76">76</xref></contrib><contrib contrib-type="author"><name><surname>Bellis</surname><given-names>Katherine L.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Dorman</surname><given-names>Matthew J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Project administration, and samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Quick</surname><given-names>Joshua</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><on-behalf-of>for the Project administration, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Poplawski</surname><given-names>Radoslaw</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><on-behalf-of>for the Project administration, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Reynolds</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="Aff102">102</xref></contrib><contrib contrib-type="author"><name><surname>Mack</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Morriss</surname><given-names>Arthur</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Whalley</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Bindi</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Georgana</surname><given-names>Iliana</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Hosmillo</surname><given-names>Myra</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Pinckert</surname><given-names>Malte L.</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Stockton</surname><given-names>Joanne</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Henderson</surname><given-names>John H.</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name><surname>Hollis</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name><surname>Stanley</surname><given-names>William</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name><surname>Yew</surname><given-names>Wen C.</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name><surname>Myers</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Thornton</surname><given-names>Alicia</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Adams</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Annett</surname><given-names>Tara</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Asad</surname><given-names>Hibo</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Birchley</surname><given-names>Alec</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Coombes</surname><given-names>Jason</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>Johnathan M.</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Fina</surname><given-names>Laia</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Gatica-Wilcox</surname><given-names>Bree</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Gilbert</surname><given-names>Lauren</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Lee</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Hey</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Hilvers</surname><given-names>Ember</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Kumziene-Summerhayes</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>McKerr</surname><given-names>Caoimhe</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Powell</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Pugh</surname><given-names>Georgia</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Trotter</surname><given-names>Alexander J.</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Charlotte A.</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Kermack</surname><given-names>Leanne M.</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Foulkes</surname><given-names>Benjamin H.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Gallis</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Hornsby</surname><given-names>Hailey R.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Louka</surname><given-names>Stavroula F.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Pohare</surname><given-names>Manoj</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Wolverson</surname><given-names>Paige</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Peijun</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>MacIntyre-Cockett</surname><given-names>George</given-names></name><xref ref-type="aff" rid="Aff76">76</xref></contrib><contrib contrib-type="author"><name><surname>Trebes</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="Aff76">76</xref></contrib><contrib contrib-type="author"><name><surname>Moll</surname><given-names>Robin J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ferguson</surname><given-names>Lynne</given-names></name><xref ref-type="aff" rid="Aff103">103</xref></contrib><contrib contrib-type="author"><name><surname>Goldstein</surname><given-names>Emily J.</given-names></name><xref ref-type="aff" rid="Aff103">103</xref></contrib><contrib contrib-type="author"><name><surname>Maclean</surname><given-names>Alasdair</given-names></name><xref ref-type="aff" rid="Aff103">103</xref></contrib><contrib contrib-type="author"><name><surname>Tomb</surname><given-names>Rachael</given-names></name><xref ref-type="aff" rid="Aff103">103</xref></contrib><on-behalf-of>for the Samples and logistics, and sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Starinskij</surname><given-names>Igor</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><on-behalf-of>for the Samples and logistics, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Thomson</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Southgate</surname><given-names>Joel</given-names></name><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Kraemer</surname><given-names>Moritz U. G.</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name><surname>Raghwani</surname><given-names>Jayna</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name><surname>Zarebski</surname><given-names>Alex E.</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name><surname>Boyd</surname><given-names>Olivia</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Geidelberg</surname><given-names>Lily</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Illingworth</surname><given-names>Chris J.</given-names></name><xref ref-type="aff" rid="Aff64">64</xref></contrib><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="Aff64">64</xref></contrib><contrib contrib-type="author"><name><surname>Pascall</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff64">64</xref></contrib><contrib contrib-type="author"><name><surname>Vattipally</surname><given-names>Sreenu</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Freeman</surname><given-names>Timothy M.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Sharon N.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Lindsey</surname><given-names>Benjamin B.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Tovar-Corona</surname><given-names>Jaime M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Sequencing and analysis, and software and analysis tools</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Cox</surname><given-names>MacGregor</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><on-behalf-of>for the Sequencing and analysis, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Abudahab</surname><given-names>Khalil</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff46">46</xref></contrib><contrib contrib-type="author"><name><surname>Menegazzo</surname><given-names>Mirko</given-names></name><xref ref-type="aff" rid="Aff46">46</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Ben E. W.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff46">46</xref></contrib><contrib contrib-type="author"><name><surname>Yeats</surname><given-names>Corin A.</given-names></name><xref ref-type="aff" rid="Aff46">46</xref></contrib><contrib contrib-type="author"><name><surname>Mukaddas</surname><given-names>Afrida</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Wright</surname><given-names>Derek W.</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>de Oliveira Martins</surname><given-names>Leonardo</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Colquhoun</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>Verity</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>McCrone</surname><given-names>J. T.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Medd</surname><given-names>Nathan</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Scher</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Keatley</surname><given-names>Jon-Paul</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Software and analysis tools, and visualization</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Curran</surname><given-names>Tanya</given-names></name><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><name><surname>Morgan</surname><given-names>Sian</given-names></name><xref ref-type="aff" rid="Aff77">77</xref></contrib><contrib contrib-type="author"><name><surname>Maxwell</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Ken</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Eldirdiri</surname><given-names>Sahar</given-names></name><xref ref-type="aff" rid="Aff88">88</xref></contrib><contrib contrib-type="author"><name><surname>Kenyon</surname><given-names>Anita</given-names></name><xref ref-type="aff" rid="Aff88">88</xref></contrib><contrib contrib-type="author"><name><surname>Holmes</surname><given-names>Alison H.</given-names></name><xref ref-type="aff" rid="Aff68">68</xref><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name><surname>Price</surname><given-names>James R.</given-names></name><xref ref-type="aff" rid="Aff68">68</xref><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name><surname>Wyatt</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="Aff104">104</xref></contrib><contrib contrib-type="author"><name><surname>Mather</surname><given-names>Alison E.</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Skvortsov</surname><given-names>Timofey</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Hartley</surname><given-names>John A.</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><on-behalf-of>for the Leadership and supervision</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Guest</surname><given-names>Martyn</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Kitchen</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Merrick</surname><given-names>Ian</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Munn</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Bertolusso</surname><given-names>Beatrice</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name><surname>Lynch</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name><surname>Vernet</surname><given-names>Gabrielle</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name><surname>Kirk</surname><given-names>Stuart</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name><surname>Wastnedge</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="Aff50">50</xref></contrib><contrib contrib-type="author"><name><surname>Stanley</surname><given-names>Rachael</given-names></name><xref ref-type="aff" rid="Aff79">79</xref></contrib><contrib contrib-type="author"><name><surname>Idle</surname><given-names>Giles</given-names></name><xref ref-type="aff" rid="Aff105">105</xref></contrib><contrib contrib-type="author"><name><surname>Bradley</surname><given-names>Declan T.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref><xref ref-type="aff" rid="Aff104">104</xref></contrib><contrib contrib-type="author"><name><surname>Poyner</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="Aff97">97</xref></contrib><contrib contrib-type="author"><name><surname>Mori</surname><given-names>Matilde</given-names></name><xref ref-type="aff" rid="Aff106">106</xref></contrib><on-behalf-of>for the Metadata curation</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Owen</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Wright</surname><given-names>Victoria</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name><surname>Brooks</surname><given-names>Ellena</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Churcher</surname><given-names>Carol M.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Fragakis</surname><given-names>Mireille</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Galai</surname><given-names>Katerina</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Jermy</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Judges</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>McManus</surname><given-names>Georgina M.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Kim S.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Westwick</surname><given-names>Elaine</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Attwood</surname><given-names>Stephen W.</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name><surname>Bolt</surname><given-names>Frances</given-names></name><xref ref-type="aff" rid="Aff68">68</xref><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>Alisha</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>De Lacy</surname><given-names>Elen</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Downing</surname><given-names>Fatima</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Edwards</surname><given-names>Sue</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Meadows</surname><given-names>Lizzie</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Jeremiah</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Nikki</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><on-behalf-of>for the Project administration</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Charalampous</surname><given-names>Themoula</given-names></name><xref ref-type="aff" rid="Aff16">16</xref><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Amita</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Berry</surname><given-names>Louise</given-names></name><xref ref-type="aff" rid="Aff85">85</xref></contrib><contrib contrib-type="author"><name><surname>Boswell</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="Aff85">85</xref></contrib><contrib contrib-type="author"><name><surname>Fleming</surname><given-names>Vicki M.</given-names></name><xref ref-type="aff" rid="Aff85">85</xref></contrib><contrib contrib-type="author"><name><surname>Howson-Wells</surname><given-names>Hannah C.</given-names></name><xref ref-type="aff" rid="Aff85">85</xref></contrib><contrib contrib-type="author"><name><surname>Joseph</surname><given-names>Amelia</given-names></name><xref ref-type="aff" rid="Aff85">85</xref></contrib><contrib contrib-type="author"><name><surname>Khakh</surname><given-names>Manjinder</given-names></name><xref ref-type="aff" rid="Aff85">85</xref></contrib><contrib contrib-type="author"><name><surname>Lister</surname><given-names>Michelle M.</given-names></name><xref ref-type="aff" rid="Aff85">85</xref></contrib><contrib contrib-type="author"><name><surname>Bird</surname><given-names>Paul W.</given-names></name><xref ref-type="aff" rid="Aff86">86</xref></contrib><contrib contrib-type="author"><name><surname>Fallon</surname><given-names>Karlie</given-names></name><xref ref-type="aff" rid="Aff86">86</xref></contrib><contrib contrib-type="author"><name><surname>Helmer</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff86">86</xref></contrib><contrib contrib-type="author"><name><surname>McMurray</surname><given-names>Claire L.</given-names></name><xref ref-type="aff" rid="Aff86">86</xref></contrib><contrib contrib-type="author"><name><surname>Odedra</surname><given-names>Mina</given-names></name><xref ref-type="aff" rid="Aff86">86</xref></contrib><contrib contrib-type="author"><name><surname>Shaw</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="Aff86">86</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Julian W.</given-names></name><xref ref-type="aff" rid="Aff86">86</xref></contrib><contrib contrib-type="author"><name><surname>Willford</surname><given-names>Nicholas J.</given-names></name><xref ref-type="aff" rid="Aff86">86</xref></contrib><contrib contrib-type="author"><name><surname>Blakey</surname><given-names>Victoria</given-names></name><xref ref-type="aff" rid="Aff87">87</xref></contrib><contrib contrib-type="author"><name><surname>Raviprakash</surname><given-names>Veena</given-names></name><xref ref-type="aff" rid="Aff87">87</xref></contrib><contrib contrib-type="author"><name><surname>Sheriff</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="Aff87">87</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Lesley-Anne</given-names></name><xref ref-type="aff" rid="Aff87">87</xref></contrib><contrib contrib-type="author"><name><surname>Feltwell</surname><given-names>Theresa</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Bedford</surname><given-names>Luke</given-names></name><xref ref-type="aff" rid="Aff107">107</xref></contrib><contrib contrib-type="author"><name><surname>Cargill</surname><given-names>James S.</given-names></name><xref ref-type="aff" rid="Aff108">108</xref></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>Warwick</given-names></name><xref ref-type="aff" rid="Aff108">108</xref></contrib><contrib contrib-type="author"><name><surname>Moore</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="Aff109">109</xref></contrib><contrib contrib-type="author"><name><surname>Stonehouse</surname><given-names>Susanne</given-names></name><xref ref-type="aff" rid="Aff109">109</xref></contrib><contrib contrib-type="author"><name><surname>Atkinson</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff75">75</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jack C. D.</given-names></name><xref ref-type="aff" rid="Aff75">75</xref></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Divya</given-names></name><xref ref-type="aff" rid="Aff75">75</xref></contrib><contrib contrib-type="author"><name><surname>Alcolea</surname><given-names>Adela</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff100">100</xref></contrib><contrib contrib-type="author"><name><surname>Ohemeng-Kumi</surname><given-names>Natasha</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff100">100</xref></contrib><contrib contrib-type="author"><name><surname>Ramble</surname><given-names>John</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff100">100</xref></contrib><contrib contrib-type="author"><name><surname>Sehmi</surname><given-names>Jasveen</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff100">100</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Rebecca</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name><surname>Chatterton</surname><given-names>Wendy</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name><surname>Pusok</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name><surname>Everson</surname><given-names>William</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>Castigador</surname><given-names>Anibolina</given-names></name><xref ref-type="aff" rid="Aff110">110</xref></contrib><contrib contrib-type="author"><name><surname>Macnaughton</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="Aff110">110</xref></contrib><contrib contrib-type="author"><name><surname>El Bouzidi</surname><given-names>Kate</given-names></name><xref ref-type="aff" rid="Aff111">111</xref></contrib><contrib contrib-type="author"><name><surname>Lampejo</surname><given-names>Temi</given-names></name><xref ref-type="aff" rid="Aff111">111</xref></contrib><contrib contrib-type="author"><name><surname>Sudhanva</surname><given-names>Malur</given-names></name><xref ref-type="aff" rid="Aff111">111</xref></contrib><contrib contrib-type="author"><name><surname>Breen</surname><given-names>Cassie</given-names></name><xref ref-type="aff" rid="Aff112">112</xref></contrib><contrib contrib-type="author"><name><surname>Sluga</surname><given-names>Graciela</given-names></name><xref ref-type="aff" rid="Aff91">91</xref></contrib><contrib contrib-type="author"><name><surname>Ahmad</surname><given-names>Shazaad S. Y.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff113">113</xref></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>Ryan P.</given-names></name><xref ref-type="aff" rid="Aff113">113</xref></contrib><contrib contrib-type="author"><name><surname>Machin</surname><given-names>Nicholas W.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff113">113</xref></contrib><contrib contrib-type="author"><name><surname>Binns</surname><given-names>Debbie</given-names></name><xref ref-type="aff" rid="Aff65">65</xref></contrib><contrib contrib-type="author"><name><surname>James</surname><given-names>Victoria</given-names></name><xref ref-type="aff" rid="Aff65">65</xref></contrib><contrib contrib-type="author"><name><surname>Blacow</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><contrib contrib-type="author"><name><surname>Coupland</surname><given-names>Lindsay</given-names></name><xref ref-type="aff" rid="Aff79">79</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Louise</given-names></name><xref ref-type="aff" rid="Aff74">74</xref></contrib><contrib contrib-type="author"><name><surname>Barton</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="Aff93">93</xref></contrib><contrib contrib-type="author"><name><surname>Padgett</surname><given-names>Debra</given-names></name><xref ref-type="aff" rid="Aff93">93</xref></contrib><contrib contrib-type="author"><name><surname>Scott</surname><given-names>Garren</given-names></name><xref ref-type="aff" rid="Aff93">93</xref></contrib><contrib contrib-type="author"><name><surname>Cross</surname><given-names>Aidan</given-names></name><xref ref-type="aff" rid="Aff114">114</xref></contrib><contrib contrib-type="author"><name><surname>Mirfenderesky</surname><given-names>Mariyam</given-names></name><xref ref-type="aff" rid="Aff114">114</xref></contrib><contrib contrib-type="author"><name><surname>Greenaway</surname><given-names>Jane</given-names></name><xref ref-type="aff" rid="Aff94">94</xref></contrib><contrib contrib-type="author"><name><surname>Cole</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="Aff105">105</xref></contrib><contrib contrib-type="author"><name><surname>Clarke</surname><given-names>Phillip</given-names></name><xref ref-type="aff" rid="Aff95">95</xref></contrib><contrib contrib-type="author"><name><surname>Duckworth</surname><given-names>Nichola</given-names></name><xref ref-type="aff" rid="Aff95">95</xref></contrib><contrib contrib-type="author"><name><surname>Walsh</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff95">95</xref></contrib><contrib contrib-type="author"><name><surname>Bicknell</surname><given-names>Kelly</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name><surname>Impey</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name><surname>Wyllie</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name><surname>Hopes</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bishop</surname><given-names>Chloe</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chalker</surname><given-names>Vicki</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gifford</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Molnar</surname><given-names>Zoltan</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Auckland</surname><given-names>Cressida</given-names></name><xref ref-type="aff" rid="Aff97">97</xref></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>Cariad</given-names></name><xref ref-type="aff" rid="Aff48">48</xref><xref ref-type="aff" rid="Aff101">101</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Kate</given-names></name><xref ref-type="aff" rid="Aff48">48</xref><xref ref-type="aff" rid="Aff101">101</xref></contrib><contrib contrib-type="author"><name><surname>Partridge</surname><given-names>David G.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref><xref ref-type="aff" rid="Aff101">101</xref></contrib><contrib contrib-type="author"><name><surname>Raza</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="Aff48">48</xref><xref ref-type="aff" rid="Aff101">101</xref></contrib><contrib contrib-type="author"><name><surname>Baker</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="Aff57">57</xref></contrib><contrib contrib-type="author"><name><surname>Bonner</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="Aff57">57</xref></contrib><contrib contrib-type="author"><name><surname>Essex</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff57">57</xref></contrib><contrib contrib-type="author"><name><surname>Murray</surname><given-names>Leanne J.</given-names></name><xref ref-type="aff" rid="Aff57">57</xref></contrib><contrib contrib-type="author"><name><surname>Lawton</surname><given-names>Andrew I.</given-names></name><xref ref-type="aff" rid="Aff115">115</xref></contrib><contrib contrib-type="author"><name><surname>Burton-Fanning</surname><given-names>Shirelle</given-names></name><xref ref-type="aff" rid="Aff66">66</xref></contrib><contrib contrib-type="author"><name><surname>Payne</surname><given-names>Brendan A. I.</given-names></name><xref ref-type="aff" rid="Aff66">66</xref></contrib><contrib contrib-type="author"><name><surname>Waugh</surname><given-names>Sheila</given-names></name><xref ref-type="aff" rid="Aff66">66</xref></contrib><contrib contrib-type="author"><name><surname>Gomes</surname><given-names>Andrea N.</given-names></name><xref ref-type="aff" rid="Aff116">116</xref></contrib><contrib contrib-type="author"><name><surname>Kimuli</surname><given-names>Maimuna</given-names></name><xref ref-type="aff" rid="Aff116">116</xref></contrib><contrib contrib-type="author"><name><surname>Murray</surname><given-names>Darren R.</given-names></name><xref ref-type="aff" rid="Aff116">116</xref></contrib><contrib contrib-type="author"><name><surname>Ashfield</surname><given-names>Paula</given-names></name><xref ref-type="aff" rid="Aff117">117</xref></contrib><contrib contrib-type="author"><name><surname>Dobie</surname><given-names>Donald</given-names></name><xref ref-type="aff" rid="Aff117">117</xref></contrib><contrib contrib-type="author"><name><surname>Ashford</surname><given-names>Fiona</given-names></name><xref ref-type="aff" rid="Aff78">78</xref></contrib><contrib contrib-type="author"><name><surname>Best</surname><given-names>Angus</given-names></name><xref ref-type="aff" rid="Aff78">78</xref></contrib><contrib contrib-type="author"><name><surname>Crawford</surname><given-names>Liam</given-names></name><xref ref-type="aff" rid="Aff78">78</xref></contrib><contrib contrib-type="author"><name><surname>Cumley</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="Aff78">78</xref></contrib><contrib contrib-type="author"><name><surname>Mayhew</surname><given-names>Megan</given-names></name><xref ref-type="aff" rid="Aff78">78</xref></contrib><contrib contrib-type="author"><name><surname>Megram</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="Aff78">78</xref></contrib><contrib contrib-type="author"><name><surname>Mirza</surname><given-names>Jeremy</given-names></name><xref ref-type="aff" rid="Aff78">78</xref></contrib><contrib contrib-type="author"><name><surname>Moles-Garcia</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="Aff78">78</xref></contrib><contrib contrib-type="author"><name><surname>Percival</surname><given-names>Benita</given-names></name><xref ref-type="aff" rid="Aff78">78</xref></contrib><contrib contrib-type="author"><name><surname>Ensell</surname><given-names>Leah</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Lowe</surname><given-names>Helen L.</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Maftei</surname><given-names>Laurentiu</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Mondani</surname><given-names>Matteo</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Chaloner</surname><given-names>Nicola J.</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Cogger</surname><given-names>Benjamin J.</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Easton</surname><given-names>Lisa J.</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Huckson</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Lowdon</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Malone</surname><given-names>Cassandra S.</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Munemo</surname><given-names>Florence</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Mutingwende</surname><given-names>Manasa</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Nicodemi</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Podplomyk</surname><given-names>Olga</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Somassa</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Beggs</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff118">118</xref></contrib><contrib contrib-type="author"><name><surname>Richter</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="Aff118">118</xref></contrib><contrib contrib-type="author"><name><surname>Cormie</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Dias</surname><given-names>Joana</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Forrest</surname><given-names>Sally</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Higginson</surname><given-names>Ellen E.</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Maes</surname><given-names>Mailis</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Jamie</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Davidson</surname><given-names>Rose K.</given-names></name><xref ref-type="aff" rid="Aff53">53</xref></contrib><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>Kathryn A.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Turtle</surname><given-names>Lance</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Keeley</surname><given-names>Alexander J.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Ball</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="Aff98">98</xref></contrib><contrib contrib-type="author"><name><surname>Byaruhanga</surname><given-names>Timothy</given-names></name><xref ref-type="aff" rid="Aff98">98</xref></contrib><contrib contrib-type="author"><name><surname>Chappell</surname><given-names>Joseph G.</given-names></name><xref ref-type="aff" rid="Aff98">98</xref></contrib><contrib contrib-type="author"><name><surname>Dey</surname><given-names>Jayasree</given-names></name><xref ref-type="aff" rid="Aff98">98</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>Jack D.</given-names></name><xref ref-type="aff" rid="Aff98">98</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Emily J.</given-names></name><xref ref-type="aff" rid="Aff98">98</xref></contrib><contrib contrib-type="author"><name><surname>Fanaie</surname><given-names>Arezou</given-names></name><xref ref-type="aff" rid="Aff119">119</xref></contrib><contrib contrib-type="author"><name><surname>Hilson</surname><given-names>Rachel A.</given-names></name><xref ref-type="aff" rid="Aff119">119</xref></contrib><contrib contrib-type="author"><name><surname>Yaze</surname><given-names>Geraldine</given-names></name><xref ref-type="aff" rid="Aff119">119</xref></contrib><on-behalf-of>for the Samples and logistics</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Afifi</surname><given-names>Safiah</given-names></name><xref ref-type="aff" rid="Aff77">77</xref></contrib><contrib contrib-type="author"><name><surname>Beer</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff77">77</xref></contrib><contrib contrib-type="author"><name><surname>Maksimovic</surname><given-names>Joshua</given-names></name><xref ref-type="aff" rid="Aff77">77</xref></contrib><contrib contrib-type="author"><name><surname>Masters</surname><given-names>Kathryn McCluggage</given-names></name><xref ref-type="aff" rid="Aff77">77</xref></contrib><contrib contrib-type="author"><name><surname>Spellman</surname><given-names>Karla</given-names></name><xref ref-type="aff" rid="Aff77">77</xref></contrib><contrib contrib-type="author"><name><surname>Bresner</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Fuller</surname><given-names>William</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Marchbank</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Workman</surname><given-names>Trudy</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Shelest</surname><given-names>Ekaterina</given-names></name><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name><surname>Debebe</surname><given-names>Johnny</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name><surname>Sang</surname><given-names>Fei</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name><surname>Zamudio</surname><given-names>Marina Escalera</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name><surname>Francois</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name><surname>Gutierrez</surname><given-names>Bernardo</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name><surname>Vasylyeva</surname><given-names>Tetyana I.</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name><surname>Flaviani</surname><given-names>Flavia</given-names></name><xref ref-type="aff" rid="Aff120">120</xref></contrib><contrib contrib-type="author"><name><surname>Ragonnet-Cronin</surname><given-names>Manon</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Smollett</surname><given-names>Katherine L.</given-names></name><xref ref-type="aff" rid="Aff73">73</xref></contrib><contrib contrib-type="author"><name><surname>Broos</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Mair</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Nichols</surname><given-names>Jenna</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Nomikou</surname><given-names>Kyriaki</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Tong</surname><given-names>Lily</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Tsatsani</surname><given-names>Ioulia</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>O&#x2019;Brien</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff121">121</xref></contrib><contrib contrib-type="author"><name><surname>Rushton</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="Aff121">121</xref></contrib><contrib contrib-type="author"><name><surname>Sanderson</surname><given-names>Roy</given-names></name><xref ref-type="aff" rid="Aff121">121</xref></contrib><contrib contrib-type="author"><name><surname>Perkins</surname><given-names>Jon</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><contrib contrib-type="author"><name><surname>Cotton</surname><given-names>Seb</given-names></name><xref ref-type="aff" rid="Aff50">50</xref></contrib><contrib contrib-type="author"><name><surname>Gallagher</surname><given-names>Abbie</given-names></name><xref ref-type="aff" rid="Aff50">50</xref></contrib><contrib contrib-type="author"><name><surname>Allara</surname><given-names>Elias</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Pearson</surname><given-names>Clare</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Bibby</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Dabrera</surname><given-names>Gavin</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ellaby</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gallagher</surname><given-names>Eileen</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hubb</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lackenby</surname><given-names>Angie</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Manesis</surname><given-names>Nikos</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mbisa</surname><given-names>Tamyo</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Platt</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Twohig</surname><given-names>Katherine A.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Morgan</surname><given-names>Mari</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Aydin</surname><given-names>Alp</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Baker</surname><given-names>David J.</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Foster-Nyarko</surname><given-names>Ebenezer</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Prosolek</surname><given-names>Sophie J.</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Rudder</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Baxter</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Carvalho</surname><given-names>S&#xED;lvia F.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Lavin</surname><given-names>Deborah</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Mariappan</surname><given-names>Arun</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Radulescu</surname><given-names>Clara</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Aditi</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Miao</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Morcrette</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="Aff97">97</xref></contrib><contrib contrib-type="author"><name><surname>Bayzid</surname><given-names>Nadua</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Cotic</surname><given-names>Marius</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Balcazar</surname><given-names>Carlos E.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Gallagher</surname><given-names>Michael D.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Maloney</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Stanton</surname><given-names>Thomas D.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Williamson</surname><given-names>Kathleen A.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Manley</surname><given-names>Robin</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Michelsen</surname><given-names>Michelle L.</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Sambles</surname><given-names>Christine M.</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Studholme</surname><given-names>David J.</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Warwick-Dugdale</surname><given-names>Joanna</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Eccles</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Gemmell</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Gregory</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>Margaret</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Nelson</surname><given-names>Charlotte</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Rainbow</surname><given-names>Lucille</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Vamos</surname><given-names>Edith E.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Webster</surname><given-names>Hermione J.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Whitehead</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Wierzbicki</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name><surname>Angyal</surname><given-names>Adrienn</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Green</surname><given-names>Luke R.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Whiteley</surname><given-names>Max</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Bronner</surname><given-names>Iraad F.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Farr</surname><given-names>Ben W.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lensing</surname><given-names>Stefanie V.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>McCarthy</surname><given-names>Shane A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Quail</surname><given-names>Michael A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Redshaw</surname><given-names>Nicholas M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Thurston</surname><given-names>Scott A. J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Sequencing and analysis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rowe</surname><given-names>Will</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Gaskin</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Le-Viet</surname><given-names>Thanh</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Liddle</surname><given-names>Jennifier</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Software and analysis tools</on-behalf-of></contrib-group></collab>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8314-8497</contrib-id>
          <name>
            <surname>Birney</surname>
            <given-names>Ewan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6268-8937</contrib-id>
          <name>
            <surname>Volz</surname>
            <given-names>Erik</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2842-3406</contrib-id>
          <name>
            <surname>Funk</surname>
            <given-names>Sebastian</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5023-0176</contrib-id>
          <name>
            <surname>Kwiatkowski</surname>
            <given-names>Dominic</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chand</surname>
            <given-names>Meera</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1122-4416</contrib-id>
          <name>
            <surname>Martincorena</surname>
            <given-names>Inigo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1152-370X</contrib-id>
          <name>
            <surname>Barrett</surname>
            <given-names>Jeffrey C.</given-names>
          </name>
          <address>
            <email>jb26@sanger.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6709-963X</contrib-id>
          <name>
            <surname>Gerstung</surname>
            <given-names>Moritz</given-names>
          </name>
          <address>
            <email>moritz.gerstung@ebi.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.225360.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9709 7726</institution-id><institution>European Molecular Biology Laboratory, </institution><institution>European Bioinformatics Institute EMBL-EBI, </institution></institution-wrap>Hinxton, UK </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.10306.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 0606 5382</institution-id><institution>Wellcome Sanger Institute, </institution></institution-wrap>Hinxton, UK </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.451388.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1795 1830</institution-id><institution>The Francis Crick Institute, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.271308.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 5909 016X</institution-id><institution>Public Health England, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.8991.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0425 469X</institution-id><institution>London School of Hygiene &amp; Tropical Medicine, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>The Big Data Institute, Nuffield Department of Medicine, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.7445.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id><institution>MRC Centre for Global Infectious Disease Analysis, Jameel Institute for Disease and Emergency Analytics, </institution><institution>Imperial College London, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.420545.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0489 3985</institution-id><institution>Guy&#x2019;s and St Thomas&#x2019; NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution>Division for AI in Oncology, </institution><institution>German Cancer Research Centre DKFZ, </institution></institution-wrap>Heidelberg, Germany </aff>
        <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution>Department of Medicine, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff>
        <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.4701.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0728 6636</institution-id><institution>Centre for Enzyme Innovation, </institution><institution>University of Portsmouth, </institution></institution-wrap>Portsmouth, UK </aff>
        <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.4701.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0728 6636</institution-id><institution>School of Pharmacy &amp; Biomedical Sciences, </institution><institution>University of Portsmouth, </institution></institution-wrap>Portsmouth, UK </aff>
        <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.5600.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 5670</institution-id><institution>Cardiff University, </institution></institution-wrap>Cardiff, UK </aff>
        <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.439475.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 6360 002X</institution-id><institution>Public Health Wales, </institution></institution-wrap>Cardiff, UK </aff>
        <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.6572.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7486</institution-id><institution>Institute of Microbiology and Infection, </institution><institution>University of Birmingham, </institution></institution-wrap>Birmingham, UK </aff>
        <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.13097.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2322 6764</institution-id><institution>King&#x2019;s College London, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution>University of Edinburgh, </institution></institution-wrap>Edinburgh, UK </aff>
        <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.420545.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0489 3985</institution-id><institution>Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, </institution><institution>Guy&#x2019;s and St Thomas&#x2019; NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.52996.31</institution-id><institution-id institution-id-type="ISNI">0000 0000 8937 2257</institution-id><institution>University College London Hospitals NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.439749.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0612 2754</institution-id><institution>Advanced Pathogen Diagnostics Unit, </institution><institution>University College London Hospital, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>Great Ormond Street Institute of Child Health, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="GRID">grid.24029.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0383 8386</institution-id><institution>Department of Infectious Diseases and Microbiology, </institution><institution>Cambridge University Hospitals NHS Foundation Trust, </institution></institution-wrap>Cambridge, UK </aff>
        <aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution>Division of Virology, Department of Pathology, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff>
        <aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="GRID">grid.430506.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0465 4079</institution-id><institution>University Hospital Southampton NHS Foundation Trust, </institution></institution-wrap>Southampton, UK </aff>
        <aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="GRID">grid.5491.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9297</institution-id><institution>School of Health Sciences, </institution><institution>University of Southampton, </institution></institution-wrap>Southampton, UK </aff>
        <aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="GRID">grid.5491.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9297</institution-id><institution>School of Medicine, </institution><institution>University of Southampton, </institution></institution-wrap>Southampton, UK </aff>
        <aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>Division of Infection and Immunity, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="GRID">grid.12477.37</institution-id><institution-id institution-id-type="ISNI">0000000121073784</institution-id><institution>University of Brighton, </institution></institution-wrap>Brighton, UK </aff>
        <aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="GRID">grid.264200.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 8546 682X</institution-id><institution>Institute for Infection and Immunity, </institution><institution>St George&#x2019;s University of London, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="GRID">grid.451349.e</institution-id><institution>Infection Care Group, </institution><institution>St George&#x2019;s University Hospitals NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="GRID">grid.301713.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0393 3981</institution-id><institution>MRC&#x2013;University of Glasgow Centre for Virus Research, </institution></institution-wrap>Glasgow, UK </aff>
        <aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution>University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff>
        <aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="GRID">grid.4777.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0374 7521</institution-id><institution>Queen&#x2019;s University Belfast, </institution></institution-wrap>Belfast, UK </aff>
        <aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="GRID">grid.440172.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0376 9309</institution-id><institution>Blackpool Teaching Hospitals NHS Foundation Trust, </institution></institution-wrap>Blackpool, UK </aff>
        <aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="GRID">grid.9481.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0412 8669</institution-id><institution>Hull University Teaching Hospitals NHS Trust, </institution></institution-wrap>Hull, UK </aff>
        <aff id="Aff36"><label>36</label>University Hospitals Dorset NHS Foundation Trust, Poole, UK </aff>
        <aff id="Aff37"><label>37</label><institution-wrap><institution-id institution-id-type="GRID">grid.511096.a</institution-id><institution>University Hospitals Sussex NHS Foundation Trust, </institution></institution-wrap>Worthing, UK </aff>
        <aff id="Aff38"><label>38</label><institution-wrap><institution-id institution-id-type="GRID">grid.8391.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8024</institution-id><institution>University of Exeter, </institution></institution-wrap>Exeter, UK </aff>
        <aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="GRID">grid.412915.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9565 2378</institution-id><institution>Belfast Health &amp; Social Care Trust, </institution></institution-wrap>Belfast, UK </aff>
        <aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="GRID">grid.4563.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8868</institution-id><institution>Deep Seq, School of Life Sciences, Queens Medical Centre, </institution><institution>University of Nottingham, </institution></institution-wrap>Nottingham, UK </aff>
        <aff id="Aff41"><label>41</label><institution-wrap><institution-id institution-id-type="GRID">grid.270474.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 8610 0379</institution-id><institution>East Kent Hospitals University NHS Foundation Trust, </institution></institution-wrap>Canterbury, UK </aff>
        <aff id="Aff42"><label>42</label><institution-wrap><institution-id institution-id-type="GRID">grid.9759.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2232 2818</institution-id><institution>University of Kent, </institution></institution-wrap>Canterbury, UK </aff>
        <aff id="Aff43"><label>43</label><institution-wrap><institution-id institution-id-type="GRID">grid.42629.3b</institution-id><institution-id institution-id-type="ISNI">0000000121965555</institution-id><institution>Hub for Biotechnology in the Built Environment, </institution><institution>Northumbria University, </institution></institution-wrap>Newcastle upon Tyne, UK </aff>
        <aff id="Aff44"><label>44</label><institution-wrap><institution-id institution-id-type="GRID">grid.42629.3b</institution-id><institution-id institution-id-type="ISNI">0000000121965555</institution-id><institution>Northumbria University, </institution></institution-wrap>Newcastle upon Tyne, UK </aff>
        <aff id="Aff45"><label>45</label><institution-wrap><institution-id institution-id-type="GRID">grid.42629.3b</institution-id><institution-id institution-id-type="ISNI">0000000121965555</institution-id><institution>NU-OMICS, </institution><institution>Northumbria University, </institution></institution-wrap>Newcastle upon Tyne, UK </aff>
        <aff id="Aff46"><label>46</label><institution-wrap><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Centre for Genomic Pathogen Surveillance, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff>
        <aff id="Aff47"><label>47</label><institution-wrap><institution-id institution-id-type="GRID">grid.271308.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 5909 016X</institution-id><institution>Public Health England, Cambridge, </institution></institution-wrap>Cambridge, UK </aff>
        <aff id="Aff48"><label>48</label><institution-wrap><institution-id institution-id-type="GRID">grid.11835.3e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9262</institution-id><institution>University of Sheffield, </institution></institution-wrap>Sheffield, UK </aff>
        <aff id="Aff49"><label>49</label><institution-wrap><institution-id institution-id-type="GRID">grid.418709.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0456 1761</institution-id><institution>Portsmouth Hospitals University NHS Trust, </institution></institution-wrap>Portsmouth, UK </aff>
        <aff id="Aff50"><label>50</label><institution-wrap><institution-id institution-id-type="GRID">grid.39489.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0388 0742</institution-id><institution>NHS Lothian, </institution></institution-wrap>Edinburgh, UK </aff>
        <aff id="Aff51"><label>51</label><institution-wrap><institution-id institution-id-type="GRID">grid.413301.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0523 9342</institution-id><institution>NHS Greater Glasgow and Clyde, </institution></institution-wrap>Glasgow, UK </aff>
        <aff id="Aff52"><label>52</label><institution-wrap><institution-id institution-id-type="GRID">grid.40368.39</institution-id><institution-id institution-id-type="ISNI">0000 0000 9347 0159</institution-id><institution>Quadram Institute Bioscience, </institution></institution-wrap>Norwich, UK </aff>
        <aff id="Aff53"><label>53</label><institution-wrap><institution-id institution-id-type="GRID">grid.8273.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 1092 7967</institution-id><institution>University of East Anglia, </institution></institution-wrap>Norwich, UK </aff>
        <aff id="Aff54"><label>54</label><institution-wrap><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff>
        <aff id="Aff55"><label>55</label><institution-wrap><institution-id institution-id-type="GRID">grid.439351.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0498 6997</institution-id><institution>Hampshire Hospitals NHS Foundation Trust, </institution></institution-wrap>Basingstoke, UK </aff>
        <aff id="Aff56"><label>56</label><institution-wrap><institution-id institution-id-type="GRID">grid.437485.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0439 3380</institution-id><institution>Royal Free London NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff57"><label>57</label><institution-wrap><institution-id institution-id-type="GRID">grid.440194.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 4647 6776</institution-id><institution>South Tees Hospitals NHS Foundation Trust, </institution></institution-wrap>Middlesbrough, UK </aff>
        <aff id="Aff58"><label>58</label><institution-wrap><institution-id institution-id-type="GRID">grid.4701.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0728 6636</institution-id><institution>School of Biological Sciences, </institution><institution>University of Portsmouth, </institution></institution-wrap>Portsmouth, UK </aff>
        <aff id="Aff59"><label>59</label><institution-wrap><institution-id institution-id-type="GRID">grid.508718.3</institution-id><institution>Public Health Scotland, </institution></institution-wrap>Edinburgh, UK </aff>
        <aff id="Aff60"><label>60</label><institution-wrap><institution-id institution-id-type="GRID">grid.271308.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 5909 016X</institution-id><institution>Health Services Laboratories, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff61"><label>61</label><institution-wrap><institution-id institution-id-type="GRID">grid.413964.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0399 7344</institution-id><institution>Heartlands Hospital, </institution></institution-wrap>Birmingham, UK </aff>
        <aff id="Aff62"><label>62</label><institution-wrap><institution-id institution-id-type="GRID">grid.10025.36</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8470</institution-id><institution>University of Liverpool, </institution></institution-wrap>Liverpool, UK </aff>
        <aff id="Aff63"><label>63</label><institution-wrap><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Department of Zoology, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff>
        <aff id="Aff64"><label>64</label><institution-wrap><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution>MRC Biostatistics Unit, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff>
        <aff id="Aff65"><label>65</label><institution-wrap><institution-id institution-id-type="GRID">grid.439664.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 863X</institution-id><institution>Microbiology Department, </institution><institution>Buckinghamshire Healthcare NHS Trust, </institution></institution-wrap>Aylesbury, UK </aff>
        <aff id="Aff66"><label>66</label><institution-wrap><institution-id institution-id-type="GRID">grid.420004.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 2244</institution-id><institution>The Newcastle upon Tyne Hospitals NHS Foundation Trust, </institution></institution-wrap>Newcastle upon Tyne, UK </aff>
        <aff id="Aff67"><label>67</label><institution-wrap><institution-id institution-id-type="GRID">grid.11914.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0721 1626</institution-id><institution>University of St Andrews, </institution></institution-wrap>St Andrews, UK </aff>
        <aff id="Aff68"><label>68</label><institution-wrap><institution-id institution-id-type="GRID">grid.417895.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0693 2181</institution-id><institution>Imperial College Healthcare NHS Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff69"><label>69</label><institution-wrap><institution-id institution-id-type="GRID">grid.7445.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id><institution>NIHR Health Protection Research Unit in HCAI and AMR, </institution><institution>Imperial College London, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff70"><label>70</label><institution-wrap><institution-id institution-id-type="GRID">grid.24029.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0383 8386</institution-id><institution>Cambridge University Hospitals NHS Foundation Trust, </institution></institution-wrap>Cambridge, UK </aff>
        <aff id="Aff71"><label>71</label>Department of Microbiology, South West London Pathology, London, UK </aff>
        <aff id="Aff72"><label>72</label><institution-wrap><institution-id institution-id-type="GRID">grid.440486.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 8958 011X</institution-id><institution>Betsi Cadwaladr University Health Board, </institution></institution-wrap>Wrexham, UK </aff>
        <aff id="Aff73"><label>73</label>Institute of Biodiversity, Animal Health &amp; Comparative Medicine, Glasgow, UK </aff>
        <aff id="Aff74"><label>74</label><institution-wrap><institution-id institution-id-type="GRID">grid.436599.4</institution-id><institution-id institution-id-type="ISNI">0000 0000 9416 9237</institution-id><institution>Norfolk County Council, </institution></institution-wrap>Norfolk, UK </aff>
        <aff id="Aff75"><label>75</label><institution-wrap><institution-id institution-id-type="GRID">grid.424537.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 5902 9895</institution-id><institution>Great Ormond Street Hospital for Children NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff76"><label>76</label><institution-wrap><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff>
        <aff id="Aff77"><label>77</label><institution-wrap><institution-id institution-id-type="GRID">grid.273109.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0111 258X</institution-id><institution>Cardiff and Vale University Health Board, </institution></institution-wrap>Cardiff, UK </aff>
        <aff id="Aff78"><label>78</label><institution-wrap><institution-id institution-id-type="GRID">grid.6572.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7486</institution-id><institution>Turnkey Laboratory, </institution><institution>University of Birmingham, </institution></institution-wrap>Birmingham, UK </aff>
        <aff id="Aff79"><label>79</label><institution-wrap><institution-id institution-id-type="GRID">grid.240367.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0445 7876</institution-id><institution>Norfolk and Norwich University Hospitals NHS Foundation Trust, </institution></institution-wrap>Norwich, UK </aff>
        <aff id="Aff80"><label>80</label>Royal Brompton and Harefield Hospitals, London, UK </aff>
        <aff id="Aff81"><label>81</label><institution-wrap><institution-id institution-id-type="GRID">grid.470208.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0415 9545</institution-id><institution>The Queen Elizabeth Hospital King&#x2019;s Lynn NHS Foundation Trust, </institution></institution-wrap>King&#x2019;s Lynn, UK </aff>
        <aff id="Aff82"><label>82</label><institution-wrap><institution-id institution-id-type="GRID">grid.507529.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 8610 0651</institution-id><institution>Whittington Health NHS Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff83"><label>83</label><institution-wrap><institution-id institution-id-type="GRID">grid.439436.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 7289</institution-id><institution>Barking, Havering and Redbridge University Hospitals NHS Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff84"><label>84</label><institution-wrap><institution-id institution-id-type="GRID">grid.17236.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 0728 4630</institution-id><institution>Bournemouth University, </institution></institution-wrap>Bournemouth, UK </aff>
        <aff id="Aff85"><label>85</label><institution-wrap><institution-id institution-id-type="GRID">grid.240404.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0440 1889</institution-id><institution>Clinical Microbiology Department, Queens Medical Centre, </institution><institution>Nottingham University Hospitals NHS Trust, </institution></institution-wrap>Nottingham, UK </aff>
        <aff id="Aff86"><label>86</label><institution-wrap><institution-id institution-id-type="GRID">grid.269014.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 0435 9078</institution-id><institution>Clinical Microbiology, </institution><institution>University Hospitals of Leicester NHS Trust, </institution></institution-wrap>Leicester, UK </aff>
        <aff id="Aff87"><label>87</label><institution-wrap><institution-id institution-id-type="GRID">grid.412907.9</institution-id><institution>County Durham and Darlington NHS Foundation Trust, </institution></institution-wrap>Durham, UK </aff>
        <aff id="Aff88"><label>88</label><institution-wrap><institution-id institution-id-type="GRID">grid.415192.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0400 5589</institution-id><institution>Department of Microbiology, </institution><institution>Kettering General Hospital, </institution></institution-wrap>Kettering, UK </aff>
        <aff id="Aff89"><label>89</label><institution-wrap><institution-id institution-id-type="GRID">grid.139534.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0372 5777</institution-id><institution>Barts Health NHS Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff90"><label>90</label><institution-wrap><institution-id institution-id-type="GRID">grid.511221.4</institution-id><institution>North West London Pathology, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff91"><label>91</label><institution-wrap><institution-id institution-id-type="GRID">grid.439813.4</institution-id><institution-id institution-id-type="ISNI">0000 0000 8822 7920</institution-id><institution>Maidstone and Tunbridge Wells NHS Trust, </institution></institution-wrap>Maidstone, UK </aff>
        <aff id="Aff92"><label>92</label><institution-wrap><institution-id institution-id-type="GRID">grid.416187.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0400 8130</institution-id><institution>Microbiology, </institution><institution>Royal Oldham Hospital, </institution></institution-wrap>Oldham, UK </aff>
        <aff id="Aff93"><label>93</label><institution-wrap><institution-id institution-id-type="GRID">grid.507531.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0484 7081</institution-id><institution>North Cumbria Integrated Care NHS Foundation Trust, </institution></institution-wrap>Carlisle, UK </aff>
        <aff id="Aff94"><label>94</label><institution-wrap><institution-id institution-id-type="GRID">grid.487275.b</institution-id><institution>North Tees and Hartlepool NHS Foundation Trust, </institution></institution-wrap>Stockton on Tees, UK </aff>
        <aff id="Aff95"><label>95</label>Path Links, Northern Lincolnshire and Goole NHS Foundation Trust, Grimsby, UK </aff>
        <aff id="Aff96"><label>96</label><institution-wrap><institution-id institution-id-type="GRID">grid.415490.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2177 007X</institution-id><institution>Queen Elizabeth Hospital, </institution></institution-wrap>Birmingham, UK </aff>
        <aff id="Aff97"><label>97</label><institution-wrap><institution-id institution-id-type="GRID">grid.419309.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0495 6261</institution-id><institution>Royal Devon and Exeter NHS Foundation Trust, </institution></institution-wrap>Exeter, UK </aff>
        <aff id="Aff98"><label>98</label><institution-wrap><institution-id institution-id-type="GRID">grid.4563.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8868</institution-id><institution>Virology, School of Life Sciences, Queens Medical Centre, </institution><institution>University of Nottingham, </institution></institution-wrap>Nottingham, UK </aff>
        <aff id="Aff99"><label>99</label><institution-wrap><institution-id institution-id-type="GRID">grid.4827.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0658 8800</institution-id><institution>Swansea University, </institution></institution-wrap>Swansea, UK </aff>
        <aff id="Aff100"><label>100</label>Viapath, Guy&#x2019;s and St Thomas&#x2019; NHS Foundation Trust, and King&#x2019;s College Hospital NHS Foundation Trust, London, UK </aff>
        <aff id="Aff101"><label>101</label><institution-wrap><institution-id institution-id-type="GRID">grid.31410.37</institution-id><institution-id institution-id-type="ISNI">0000 0000 9422 8284</institution-id><institution>Sheffield Teaching Hospitals NHS Foundation Trust, </institution></institution-wrap>Sheffield, UK </aff>
        <aff id="Aff102"><label>102</label><institution-wrap><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution>Cambridge Stem Cell Institute, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff>
        <aff id="Aff103"><label>103</label><institution-wrap><institution-id institution-id-type="GRID">grid.413301.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0523 9342</institution-id><institution>West of Scotland Specialist Virology Centre, </institution><institution>NHS Greater Glasgow and Clyde, </institution></institution-wrap>Glasgow, UK </aff>
        <aff id="Aff104"><label>104</label><institution-wrap><institution-id institution-id-type="GRID">grid.454053.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0494 5490</institution-id><institution>Public Health Agency, </institution></institution-wrap>Belfast, UK </aff>
        <aff id="Aff105"><label>105</label><institution-wrap><institution-id institution-id-type="GRID">grid.451090.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0642 1330</institution-id><institution>Northumbria Healthcare NHS Foundation Trust, </institution></institution-wrap>Newcastle upon Tyne, UK </aff>
        <aff id="Aff106"><label>106</label><institution-wrap><institution-id institution-id-type="GRID">grid.5491.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9297</institution-id><institution>University of Southampton, </institution></institution-wrap>Southampton, UK </aff>
        <aff id="Aff107"><label>107</label><institution-wrap><institution-id institution-id-type="GRID">grid.507581.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0033 9432</institution-id><institution>East Suffolk and North Essex NHS Foundation Trust, </institution></institution-wrap>Colchester, UK </aff>
        <aff id="Aff108"><label>108</label><institution-wrap><institution-id institution-id-type="GRID">grid.439656.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0466 4605</institution-id><institution>East Sussex Healthcare NHS Trust, </institution></institution-wrap>St Leonards-on-Sea, UK </aff>
        <aff id="Aff109"><label>109</label><institution-wrap><institution-id institution-id-type="GRID">grid.476396.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0403 3782</institution-id><institution>Gateshead Health NHS Foundation Trust, </institution></institution-wrap>Gateshead, UK </aff>
        <aff id="Aff110"><label>110</label><institution-wrap><institution-id institution-id-type="GRID">grid.487226.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1793 1581</institution-id><institution>Isle of Wight NHS Trust, </institution></institution-wrap>Newport, UK </aff>
        <aff id="Aff111"><label>111</label><institution-wrap><institution-id institution-id-type="GRID">grid.429705.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0489 4320</institution-id><institution>King&#x2019;s College Hospital NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff112"><label>112</label>Liverpool Clinical Laboratories, Liverpool, UK </aff>
        <aff id="Aff113"><label>113</label><institution-wrap><institution-id institution-id-type="GRID">grid.498924.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0430 9101</institution-id><institution>Manchester University NHS Foundation Trust, </institution></institution-wrap>Manchester, UK </aff>
        <aff id="Aff114"><label>114</label><institution-wrap><institution-id institution-id-type="GRID">grid.439355.d</institution-id><institution-id institution-id-type="ISNI">0000 0000 8813 6797</institution-id><institution>North Middlesex University Hospital NHS Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff115"><label>115</label>Southwest Pathology Services, Taunton, UK </aff>
        <aff id="Aff116"><label>116</label><institution-wrap><institution-id institution-id-type="GRID">grid.5072.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0304 893X</institution-id><institution>The Royal Marsden NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff117"><label>117</label><institution-wrap><institution-id institution-id-type="GRID">grid.439674.b</institution-id><institution-id institution-id-type="ISNI">0000 0000 9830 7596</institution-id><institution>The Royal Wolverhampton NHS Trust, </institution></institution-wrap>Wolverhampton, UK </aff>
        <aff id="Aff118"><label>118</label><institution-wrap><institution-id institution-id-type="GRID">grid.6572.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7486</institution-id><institution>University of Birmingham, </institution></institution-wrap>Birmingham, UK </aff>
        <aff id="Aff119"><label>119</label><institution-wrap><institution-id institution-id-type="GRID">grid.416955.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0400 4949</institution-id><institution>Watford General Hospital, </institution></institution-wrap>Watford, UK </aff>
        <aff id="Aff120"><label>120</label>Guy&#x2019;s and St Thomas&#x2019; Biomedical Research Centre, London, UK </aff>
        <aff id="Aff121"><label>121</label><institution-wrap><institution-id institution-id-type="GRID">grid.1006.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0462 7212</institution-id><institution>Newcastle University, </institution></institution-wrap>Newcastle, UK </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>10</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>14</day>
        <month>10</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2021</year>
      </pub-date>
      <volume>600</volume>
      <issue>7889</issue>
      <fpage>506</fpage>
      <lpage>511</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>5</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>9</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2021, corrected publication 2022</copyright-statement>
        <license>
          <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x2019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">The evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus leads to new variants that warrant timely epidemiological characterization. Here we use the dense genomic surveillance data&#xA0;generated by the COVID-19 Genomics UK Consortium to reconstruct the dynamics of 71 different lineages in each of 315 English local authorities between September 2020 and June 2021. This analysis reveals a series of subepidemics that peaked in early autumn 2020, followed by a jump in transmissibility of the B.1.1.7/Alpha lineage. The Alpha variant grew when other lineages declined during the second national lockdown and regionally tiered restrictions between November and December 2020. A third more stringent national lockdown suppressed the Alpha variant and eliminated nearly all other lineages in early 2021. Yet a series of variants (most of which contained the spike E484K mutation) defied these trends and persisted at moderately increasing proportions. However, by accounting for sustained introductions, we found that the transmissibility of these variants is unlikely to have exceeded the transmissibility of the Alpha variant. Finally, B.1.617.2/Delta was repeatedly introduced in England and grew rapidly in early summer 2021, constituting approximately 98% of sampled SARS-CoV-2 genomes on 26 June 2021.</p>
      </abstract>
      <abstract id="Abs2" abstract-type="web-summary">
        <p id="Par2">A study of the evolution of the SARS-CoV-2 virus in England between September 2020 and June 2021 finds that interventions capable of containing previous variants were insufficient to stop the more transmissible Alpha and Delta variants.</p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
        <title>Subject terms</title>
        <kwd>Evolutionary genetics</kwd>
        <kwd>Viral infection</kwd>
        <kwd>Epidemiology</kwd>
        <kwd>SARS-CoV-2</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s), under exclusive licence to Springer Nature Limited 2021</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Main</title>
      <p id="Par3">The SARS-CoV-2 virus accumulates approximately 24 point mutations per year, or 0.3 mutations per viral generation<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref></sup>. Most of these mutations appear to be evolutionarily neutral but, as the SARS-CoV-2 epidemic spread around the world during spring 2020, it became apparent that the virus is continuing to adapt to its human host. An initial sign was the emergence and global spread of the spike protein variant D614G in the second quarter of 2020. Epidemiological analyses estimated that this mutation, which defines the B.1 lineage, confers a 20% transmissibility advantage over the original A lineage that was isolated in Wuhan, China<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>.</p>
      <p id="Par4">A broad range of lineages have been defined since that can be used to track SARS-CoV-2 transmission across the globe<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. For example, B.1.177/EU-1 emerged in Spain in early summer 2020 and spread across Europe through travel<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Subsequently, four variants of concern (VOCs) have been identified by the WHO and other public health authorities: the B.1.351/Beta lineage was discovered in South Africa<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, where it spread rapidly in late 2020. The B.1.1.7/Alpha lineage was first observed in Kent in September 2020 (ref. <sup><xref ref-type="bibr" rid="CR9">9</xref></sup>) from where it swept through the United Kingdom and large parts of the world due to a 50&#x2013;60% increase<sup><xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR13">13</xref></sup> in transmissibility. P.1/Gamma originated in Brazil<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup> and has spread throughout South America. Most recently, B.1.617.2/Delta was associated with a large surge of coronavirus disease 2019 (COVID-19) in India in April 2021 and subsequently around the world.</p>
    </sec>
    <sec id="Sec2">
      <title>Epidemiology of SARS-CoV-2 in England</title>
      <p id="Par5">In the United Kingdom, by late June 2021 the COVID-19 Genomics UK Consortium (COG-UK) had sequenced close to 600,000 viral samples. These data have enabled a detailed reconstruction of the dynamics of the first wave of the epidemic in the United Kingdom between February and August 2020 (ref. <sup><xref ref-type="bibr" rid="CR16">16</xref></sup>). Here we leverage a subset of those data&#x2014;genomic surveillance data generated at the Wellcome Sanger Institute&#x2014;to characterize the growth rates and geographical spread of different SARS-CoV-2 lineages and reconstruct how newly emerging variants changed the course of the epidemic.</p>
      <p id="Par6">Our data cover England between 1 September 2020 and 26 June 2021, encompassing three epidemic waves and two national lockdowns (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). In this time period, we sequenced 281,178 viral genomes, corresponding to an average of 7.2% (281,178/3,894,234) of all of the positive tests from PCR testing for the wider population, ranging from 5% in winter 2020 to 38% in early summer 2021, and filtered to remove cases that were associated with international travel (<xref rid="Sec10" ref-type="sec">Methods</xref> and Extended Data Fig. <xref rid="Fig6" ref-type="fig">1a, b</xref>). Overall, a total of 328 SARS-CoV-2 lineages were identified using the PANGO lineage definition<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. As some of these lineages were only rarely and intermittently detected, we collapsed these on the basis of the underlying phylogenetic tree into a set of 71 lineages for modelling (Fig. <xref rid="Fig1" ref-type="fig">1b&#x2013;d</xref> and Supplementary Tables <xref rid="MOESM4" ref-type="media">1</xref> and <xref rid="MOESM4" ref-type="media">2</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>SARS-CoV-2 surveillance sequencing in England between September 2020 and June 2021.</title><p><bold>a</bold>, Positive Pillar 2 SARS-CoV-2 tests in England. <bold>b</bold>, The relative frequency of 328 different PANGO lineages, representing approximately 7.2% of the tests shown in <bold>a</bold>. <bold>c</bold>, Positive tests (row 1) and the frequency of 4 major lineages (rows 2&#x2013;5) across 315 English lower tier local authorities. <bold>d</bold>, The absolute frequency of sequenced genomes mapped to 71 PANGO lineages. The blue areas in the pie charts are proportional to the fraction of LTLAs in which a given lineage was observed.</p><p><xref rid="MOESM5" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41586_2021_4069_Fig1_HTML" id="d32e8204"/></fig></p>
      <p id="Par7">These data reveal a diversity of lineages in the fall of 2020 followed by sweeps of the Alpha and Delta variants (Fig. <xref rid="Fig1" ref-type="fig">1b</xref> and Supplementary Tables <xref rid="MOESM4" ref-type="media">2</xref> and <xref rid="MOESM4" ref-type="media">3</xref>). Figure <xref rid="Fig1" ref-type="fig">1c</xref> shows the geographical distribution of cases and of different lineages, studied at the level of 315 English lower tier local authorities (LTLAs), administrative regions with approximately 100,000&#x2013;200,000 inhabitants.</p>
    </sec>
    <sec id="Sec3">
      <title>Modelling the dynamics of SARS-CoV-2</title>
      <p id="Par8">We developed a Bayesian statistical model that tracks the fraction of genomes from different lineages in each LTLA in each week and fits the daily total number of positive Pillar 2 tests (<xref rid="Sec10" ref-type="sec">Methods</xref> and Extended Data Fig. <xref rid="Fig7" ref-type="fig">2</xref>). The multivariate logistic regression model is conceptually similar to previous approaches in its estimation of relative growth rates<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. It accounts for differences in the epidemiological dynamics between LTLAs, and enables the introduction of new lineages (Fig. <xref rid="Fig2" ref-type="fig">2a&#x2013;c</xref>). Despite the sampling noise in a given week, the fitted proportions recapitulate the observed proportions of genomes as revealed by 35 example LTLAs covering the geography of England (Fig. <xref rid="Fig2" ref-type="fig">2b, c</xref> and Supplementary Notes&#xA0;<xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM1" ref-type="media">2</xref>). The quality of fit is confirmed by different probabilistic model selection criteria (Extended Data Fig. <xref rid="Fig8" ref-type="fig">3</xref>) and also evident at the aggregated regional level (Extended Data Fig. <xref rid="Fig9" ref-type="fig">4</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Spatiotemporal model of 71 SARS-CoV-2 lineages in 315 English LTLAs between September 2020 and June 2021.</title><p><bold>a</bold>, The average growth rates for 71 lineages. Data are median&#x2009;&#xB1;&#x2009;95% CI. <bold>b</bold>, Lineage-specific relative frequency for 35 selected LTLAs, arranged by longitude and latitude to geographically cover England. <bold>c</bold>, Fitted lineage-specific relative frequency for the same LTLAs as in <bold>b</bold>. <bold>d</bold>, Fitted lineage-specific incidence for the same LTLAs as in <bold>b</bold>.</p><p><xref rid="MOESM6" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41586_2021_4069_Fig2_HTML" id="d32e8286"/></fig></p>
      <p id="Par9">Although the relative growth rate of each lineage is modelled as identical across LTLAs, the local viral proportions change dynamically due to the timing and rate of introduction of different lineages. The model also calculates total and lineage-specific local incidences and time-dependent growth rates and approximate reproduction numbers&#xA0;<italic>R</italic><sub><italic>t</italic></sub> by negative binomial spline fitting of the number of daily positive PCR tests (<xref rid="Sec10" ref-type="sec">Methods</xref>, Fig. <xref rid="Fig2" ref-type="fig">2d</xref> and Extended Data Fig. <xref rid="Fig7" ref-type="fig">2c</xref>). Together, this enables a quantitative reconstruction of different periods of the epidemic, which we will discuss in chronological order.</p>
    </sec>
    <sec id="Sec4">
      <title>Multiple subepidemics in autumn 2020</title>
      <p id="Par10">Autumn 2020 was characterized by a surge of cases&#x2014;concentrated in the north of England&#x2014;that peaked in November, triggering a second national lockdown (Fig. <xref rid="Fig1" ref-type="fig">1a, c</xref>). This second wave initially featured B.1 and B.1.1 sublineages, which were slightly more prevalent in the south and north of England, respectively (Fig. <xref rid="Fig2" ref-type="fig">2b, c</xref>). Yet, the proportion of B.1.177 and its geographically diverse sublineages steadily increased across LTLAs from around 25% at the beginning of September to 65% at the end of October. This corresponds to a growth rate of between 8% (growth per 5.1&#x2009;d; 95% confidence interval (CI)&#x2009;=&#x2009;7&#x2013;9%) and 12% (95% CI&#x2009;=&#x2009;11&#x2013;13%) greater than that of B.1 or B.1.1. The trend of B.1.177 expansion relative to B.1 persisted throughout January (Extended Data Fig. <xref rid="Fig10" ref-type="fig">5a</xref>) and involved a number of monophyletic sublineages that arose in the UK, and similar patterns were observed in Denmark<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> (Extended Data Fig. <xref rid="Fig10" ref-type="fig">5b</xref>). Such behaviour cannot easily be explained by international travel, which was the major factor in the initial spread of B.1. throughout Europe in summer 2020 (ref. <sup><xref ref-type="bibr" rid="CR7">7</xref></sup>). However, the underlying biological mechanism is unclear as the characteristic A222V spike variant is not believed to confer a growth advantage<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p>
    </sec>
    <sec id="Sec5">
      <title>The spread of Alpha during restrictions</title>
      <p id="Par11">The subsequent third wave from December 2020 to February 2021 was almost exclusively driven by Alpha/B.1.1.7, as described previously<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. The rapid sweep of Alpha was due to an estimated transmissibility advantage of 1.52 compared with B.1.1 (growth per 5.1&#x2009;d; 95% CI&#x2009;=&#x2009;1.50&#x2013;1.55; Fig. <xref rid="Fig2" ref-type="fig">2a</xref>), assuming an unchanged generation interval distribution<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. The growth advantage is thought to stem, at least in part, from spike mutations that facilitate ACE2 receptor binding (N501Y)<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup> and furin cleavage (P681H)<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Alpha grew during a period of restrictions, which proved to be insufficient to contain its spread (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Growth of B.1.1.7/Alpha and other lineages in relation to lockdown restrictions between November 2020 and March 2021.</title><p><bold>a</bold>, Maps and dates of national and regional restrictions in England. Second national lockdown: closed hospitality businesses; contacts&#x2009;&#x2264;&#x2009;2, outdoors only; open schools; reasonable excuse needed for leaving home<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Tier 1: private indoor gatherings of &#x2264;6 persons. Tier 2: as tier 1 plus restricted hospitality services; gatherings of &#x2264;6 in public outdoor places. Tier 3: as tier 2 plus most hospitality businesses closed. Tier 4: as tier 3 but single outdoor contact. Third national lockdown: closed schools with the exception of key workers. <bold>b</bold>, Local lineage-specific <italic>R</italic><sub><italic>t</italic></sub> values for Alpha and the average <italic>R</italic><sub><italic>t</italic></sub> value (growth per 5.1&#x2009;d) of all of the other lineages in the same periods. <bold>c</bold>, <italic>R</italic><sub><italic>t</italic></sub> values from <italic>n&#x2009;</italic>=&#x2009;315 LTLA shown in <bold>b</bold>. The&#xA0;box centre horizontal line indicates the median, box limits show the quartiles, the whiskers extend to 1.5&#xD7; the interquartile range. <bold>d</bold>, Total and lineage-specific incidence (top) and <italic>R</italic><sub><italic>t</italic></sub> values (bottom) for six selected LTLAs during the period of restrictions. <bold>e</bold>, Crude lineage-specific fold changes (odds ratios) in Alpha and other lineages across the second (orange) and third national lockdown (red).</p><p><xref rid="MOESM7" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41586_2021_4069_Fig3_HTML" id="d32e8434"/></fig></p>
      <p id="Par12">The second national lockdown from 5 November to 1 December 2020 successfully reduced the total number of cases, but this masked a lineage-specific increase (<italic>R</italic><sub><italic>t</italic></sub>&#x2009;&gt;&#x2009;1; defined as growth per 5.1&#x2009;d) in Alpha and a simultaneous decrease in other hitherto dominant lineages (<italic>R</italic><sub><italic>t</italic></sub>&#x2009;&lt;&#x2009;1) in 78% (246/315) of LTLAs<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> (Fig. <xref rid="Fig3" ref-type="fig">3b, c</xref>). This pattern of Alpha-specific growth during lockdown is supported by a model-agnostic analysis of raw case numbers and proportions of Alpha genomes (Fig. <xref rid="Fig3" ref-type="fig">3e</xref>).</p>
      <p id="Par13">Three levels of regionally tiered restrictions were introduced in December 2020 (ref. <sup><xref ref-type="bibr" rid="CR24">24</xref></sup>) (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). The areas under different tiers of restrictions visibly and quantitatively coincide with the resulting local <italic>R</italic><sub><italic>t</italic></sub> values, with greater <italic>R</italic><sub><italic>t</italic></sub> values in areas with lower restrictions (Fig. <xref rid="Fig3" ref-type="fig">3a&#x2013;c</xref>).The reopening caused a surge of cases across all tiers with <italic>R</italic><sub><italic>t</italic></sub>&#x2009;&gt;&#x2009;1, which is also evident in selected time series (Fig. <xref rid="Fig3" ref-type="fig">3d</xref>). As Alpha cases surged, more areas were placed under tier 3 restrictions, and stricter tier 4 restrictions were introduced. Nevertheless, Alpha continued to grow (<italic>R</italic><sub><italic>t</italic></sub>&#x2009;&gt;&#x2009;1) in most areas, presumably driven by increased social interaction over Christmas (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>).</p>
      <p id="Par14">After the peak of 72,088 daily cases on 29 December 2020 (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>), a third national lockdown was announced on 4 January 2021 (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). The lockdown and increasing immunity derived from infection and increasing vaccination<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> led to a sustained contraction of the epidemic to approximately 5,500 daily cases by 8 March, when restrictions began to be lifted by reopening schools (further steps of easing occurred on 12 April and 17 May). In contrast to the second national lockdown 93% (296/315) of LTLAs exhibited a contraction in both Alpha and other lineages (Fig. <xref rid="Fig3" ref-type="fig">3e</xref>).</p>
    </sec>
    <sec id="Sec6">
      <title>Elimination of lineages in early 2021</title>
      <p id="Par15">The lineage-specific rates of decline during the third national lockdown and throughout March 2021 resulted in large differences in lineage-specific incidence. Cases of Alpha contracted nationally from a peak of around 50,000 daily new cases to approximately 2,750 on 1 April 2021 (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). At the same time, B.1.177&#x2014;the most prevalent lineage in November 2020&#x2014;fell to less than an estimated 10 cases per day. Moreover, the incidence of most other lineages present in autumn 2020 was well below 1 after April 2021, implying that the majority of them have been eliminated. The number of observed distinct PANGO lineages declined from a peak of 137 to only 22 in the first week of April 2021 (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). Although this may be attributed in part to how PANGO lineages were defined, we note that the period of contraction did not replenish the genetic diversity lost due to the selective sweep by Alpha (Extended Data Fig. <xref rid="Fig11" ref-type="fig">6</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Elimination of SARS-CoV-2 lineages during spring 2021.</title><p><bold>a</bold>, Modelled lineage-specific incidence in England. The colours resemble major lineages as indicated and shades thereof indicate the respective sublineages. <bold>b</bold>, The observed number of PANGO lineages per week.</p><p><xref rid="MOESM8" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41586_2021_4069_Fig4_HTML" id="d32e8550"/></fig></p>
    </sec>
    <sec id="Sec7">
      <title>Refractory variants with E484K mutations</title>
      <p id="Par16">Parallel to the elimination of many formerly dominant SARS-CoV-2 lineages, a number of new variants were imported or emerged (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). These include the VOCs B.1.351/Beta and P.1/Gamma, which carry the spike variant N501Y that is also found in B.1.1.7/Alpha and a similar pair of mutations (K417N/T and E484K) that were each shown to reduce the binding affinity of antibodies from vaccine-derived or convalescent sera<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref ref-type="bibr" rid="CR29">29</xref></sup> . The ability to escape from previous immunity is consistent with the epidemiology of Beta in South Africa<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> and especially the surge of Gamma in Manaus<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. The variants B.1.525/Eta, B.1.526/Iota, B.1.1.318 and P.2/Zeta also harbour E484K spike mutations as per their lineage definition, and sublineages of Alpha and A.23.1 that acquired E484K were found in England (Fig. <xref rid="Fig5" ref-type="fig">5a, b</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><title>Dynamics of E484K variants and Delta between January and June 2021.</title><p><bold>a</bold>, The observed relative frequency of other lineages (light grey), Alpha/B.1.1.7 (dark grey), E484K variants (orange) and Delta/B.1.617.2 (brown). <bold>b</bold>, The observed and modelled relative frequency of variants in England. <bold>c</bold>, The total and relative lineage-specific incidence in four selected LTLAs. For <bold>b</bold> and <bold>c</bold>, the shaded areas indicate the 95% CIs. <bold>d</bold>, Estimated UK clade numbers (numbers in square parentheses represent minimum and maximum numbers) and sizes. <bold>e</bold>, Crude growth rates (odds ratios) of Delta and Alpha between April and June 2021, as in Fig. <xref rid="Fig3" ref-type="fig">3e</xref>. <bold>f</bold>, Lineage-specific <italic>R</italic><sub><italic>t</italic></sub> values of <italic>n&#x2009;</italic>=&#x2009;315 LTLA in the same period, defined as in Fig. <xref rid="Fig3" ref-type="fig">3c</xref>. <bold>g</bold>, Changes in the average transmissibility across 315 LTLAs during the study period.</p><p><xref rid="MOESM9" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41586_2021_4069_Fig5_HTML" id="d32e8637"/></fig></p>
      <p id="Par17">The proportion of these E484K-containing variants was consistently 0.3&#x2013;0.4% from January to early April 2021. A transient rise, especially of the Beta and Gamma variants, was observed in May 2021 (Fig. <xref rid="Fig5" ref-type="fig">5a, b</xref>). Yet, the dynamics were largely stochastic and characterized by a series of individual and localized outbreaks, possibly curtailed by local surge testing efforts against Beta and Gamma variants (Fig. <xref rid="Fig5" ref-type="fig">5c</xref>). Consistent with the transient nature of these outbreaks, the estimated growth rates of these variants were typically lower than Alpha (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>).</p>
      <p id="Par18">Sustained imports from international travel were a critical driving mechanism behind the observed number of non-Alpha cases. A phylogeographical analysis establishing the most parsimonious sets of monophyletic and exclusively domestic clades, which can be interpreted as individual introductions, confirmed that A.23.1 with E484K (1 clade) probably has a domestic origin as no genomes of the same clade were observed internationally (<xref rid="Sec10" ref-type="sec">Methods</xref>, Fig. <xref rid="Fig5" ref-type="fig">5d</xref> and Extended Data Fig. <xref rid="Fig12" ref-type="fig">7</xref>). The estimated number of introductions was lowest for B.1.1.318 (3 introductions, range&#x2009;=&#x2009;1&#x2013;6), and highest for Beta (49 introductions, range&#x2009;=&#x2009;45&#x2013;58) and Eta (30 introductions, range&#x2009;=&#x2009;18&#x2013;34). Although our data exclude genomes sampled directly from travellers, these repeated introductions show that the true rate of transmission is lower than the observed increase in the number of surveillance genomes.</p>
    </sec>
    <sec id="Sec8">
      <title>The rise of Delta from April to June 2021</title>
      <p id="Par19">The B.1.617.1/Kappa and B.1.617.2/Delta lineages, which were first detected in India in 2020, first appeared in English surveillance samples in March 2021. In contrast to other VOCs, Delta/Kappa do not contain N501Y or E484K mutations, but their L452R mutation may reduce antibody recognition<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and P681R enhances furin cleavage<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>, similar to the P681H mutation of Alpha. The frequency of Delta, which harbours further spike mutations of unknown function, increased rapidly and reached levels of 98% (12,474/12,689) on 26 June 2021 (Fig. <xref rid="Fig5" ref-type="fig">5a, b</xref>). Although initially constrained to a small number of large local clusters, such as in Bolton, in May 2021 (Fig. <xref rid="Fig5" ref-type="fig">5c</xref>), Delta was detected in all LTLAs by 26 June 2021 (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). The sweep of Delta occurred at a rate of around 59% (growth per 5.1&#x2009;d, CI&#x2009;=&#x2009;53&#x2013;66) higher than Alpha with minor regional variation (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>, Extended Data Fig. <xref rid="Fig9" ref-type="fig">4e</xref> and Supplementary Table <xref rid="MOESM4" ref-type="media">4</xref>).</p>
      <p id="Par20">The rapid rise of Delta contrasts with Kappa, which grew more slowly despite being introduced at a similar time and into a similar demographic background (Figs. <xref rid="Fig2" ref-type="fig">2a</xref> and <xref rid="Fig5" ref-type="fig">5b</xref>). This is also evident in the phylogeographical analysis (based on data as of 1 May 2021). The 224 genomes of Delta derive from larger clades (23 introductions, range&#x2009;=&#x2009;6&#x2013;40; around 10 genomes for every introduction) compared with the 80 genomes of Kappa (17 introductions, range&#x2009;=&#x2009;15&#x2013;31; around 3&#x2013;4 genomes per introduction) and also other variants (Fig. <xref rid="Fig5" ref-type="fig">5d</xref> and Extended Data Fig. <xref rid="Fig13" ref-type="fig">8</xref>). The AY.1 lineage, derived from Delta and containing an additional K417N mutation, appeared only transiently (Fig. <xref rid="Fig5" ref-type="fig">5b</xref>).</p>
      <p id="Par21">The sustained domestic growth of Delta and its international spread<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> relative to the Alpha lineage are the first evidence of a biological growth advantage. The causes appear to be a combination of increased transmissibility and immune evasion. Evidence for higher transmissibility includes the fast growth in younger unvaccinated age groups, reports of elevated secondary attack rates<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> and a higher viral load<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Furthermore, vaccine efficacy against infection by Delta is diminished, depending on the type of vaccine<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>, and reinfection is more frequent<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, both supported by experimental research demonstrating the reduced antibody neutralization of Delta by vaccine-derived and convalescent sera<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>.</p>
      <p id="Par22">The higher growth rate of Delta&#x2014;combined with gradual reopening and proceeding vaccination&#x2014;repeated the dichotomous pattern of lineage-specific decline and growth, although now with declining Alpha (<italic>R</italic><sub><italic>t</italic></sub>&#x2009;&lt;&#x2009;1) and growing Delta (<italic>R</italic><sub><italic>t</italic></sub>&#x2009;&gt;&#x2009;1; Fig. <xref rid="Fig5" ref-type="fig">5e, f</xref>). Overall, we estimate that the spread of more transmissible variants between August 2020 and early summer 2021 increased the average growth rate of circulating SARS-CoV-2 in England by a factor of 2.39 (95% CI&#x2009;=&#x2009;2.25&#x2013;2.42; Fig. <xref rid="Fig5" ref-type="fig">5g</xref>). Thus, previously effective interventions may prove to be insufficient to contain newly emerging and more transmissible variants.</p>
    </sec>
    <sec id="Sec9" sec-type="discussion">
      <title>Discussion</title>
      <p id="Par23">Our dense genomic surveillance analysis identified lineages that consistently grew faster than others in each local authority and, therefore, at the same time, under the same restrictions and in a comparable population. This pinpointed a series of variants with elevated transmissibility, in broad agreement with other reports<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. However, a number of limitations exist. The growth rates of rare new variants are stochastic due to introductions and superspreading. Local outbreaks of the Beta and Gamma variants triggered asymptomatic surge testing, which may have reduced their spread. Furthermore, transmission depends both on the viral variant and the immunity of the host population, which changed from less than 20% to over 90% in the study period<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. This will influence the growth rates of variants with immune evasion capabilities over time. The effect of immunity is currently not modelled, but may become more important in the future as SARS-CoV-2 becomes endemic. Further limitations are discussed in the Limitations section&#xA0;of the&#xA0;<xref rid="Sec10" ref-type="sec">Methods</xref>.</p>
      <p id="Par24">The third and fourth waves in England were each caused by more transmissible variants, which outgrew restrictions that were sufficient to suppress previous variants. During the second national lockdown, Alpha grew despite falling numbers for other lineages and, similarly, Delta took hold in April and May when cases of Alpha were declining. The fact that such growth was initially masked by the falling cases of dominant lineages highlights the need for dense genomic surveillance and rapid analysis to devise optimal and timely control strategies. Such surveillance should ideally be global as, even though Delta was associated with a large wave of cases in India, its transmissibility remained unclear at the time due to a lack of systematic genomic surveillance data.</p>
      <p id="Par25">The 2.4-fold increase in growth rate during the study period as a result of new variants is also likely to have consequences for the future course of the pandemic. If this increase in growth rate was explained solely by higher transmissibility, it would raise the basic reproduction number <italic>R</italic><sub>0</sub> from a value of around 2.5&#x2013;3 in spring 2020 (ref. <sup><xref ref-type="bibr" rid="CR40">40</xref></sup>) to the range of 6&#x2013;7 for Delta. This is likely to spur new waves of the epidemic in countries that have to date been able to control the epidemic despite low vaccination rates, and it may exacerbate the situation elsewhere. Although the exact herd-immunity threshold depends on contact patterns and the distribution of immunity across age groups<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>, it is worth considering that Delta may increase the threshold to values around 0.85. Given current estimates of vaccine efficacy<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup> this would require nearly 100% vaccination coverage. Even though more than 90% of adults had antibodies against SARS-CoV-2 (ref. <sup><xref ref-type="bibr" rid="CR39">39</xref></sup>) and close to 70% had received two doses of vaccination, England saw rising Delta variant cases in the first weeks of July 2021. It can therefore be expected that other countries with high vaccination coverage are also likely to experience rising cases when restrictions are lifted.</p>
      <p id="Par26">SARS-CoV-2 is likely to continue its evolutionary adaptation process to humans<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. To date, variants with considerably higher transmissibility have had strongest positive selection, and swept through England during the 10 months of this investigation. However, the possibility that an increasingly immune population may now select for variants with better immune escape highlights the need for continued systematic and, ideally, global genomic surveillance.</p>
    </sec>
    <sec id="Sec10" sec-type="materials|methods">
      <title>Methods</title>
      <sec id="Sec11">
        <title>Pillar 2 SARS-CoV-2 testing data</title>
        <p id="Par27">Publicly available daily SARS-CoV-2 test result data from testing for the wider population outside the National Health Service (Pillar 2 newCasesBySpecimenDate) were downloaded from <ext-link ext-link-type="uri" xlink:href="https://coronavirus.data.gov.uk/">https://coronavirus.data.gov.uk/</ext-link> spanning the date range from 1 September 2020 to 30 June 2021 for 315 English LTLAs (downloaded on 20 July 2021). These data are mostly positive PCR tests, with about 4% of results from lateral flow tests without PCR confirmation. In this dataset, the City of London is merged with Hackney, and the Isles of Scilly are merged with Cornwall due to their small number of inhabitants, thereby reducing the number of English LTLAs from 317 to 315. Population data for each LTLA were downloaded from the Office of National Statistics (ONS; <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland">https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland</ext-link>).</p>
      </sec>
      <sec id="Sec12">
        <title>SARS-CoV-2 surveillance sequencing</title>
        <p id="Par28">In total, 281,178 tests (September 2020 to June 2021) were collected as part of random surveillance of positive tests of residents of England from four Pillar 2 Lighthouse laboratories. The samples were collected between 1 September 2020 and 26 June 2021. A random selection of samples was taken, after excluding those that were known to be taken during quarantine of recent travellers, and samples from targeted and local surge testing efforts. The available metadata made this selection imperfect, but these samples should be an approximately random selection of infections in England during this time period, and the large sample size makes our subsequent inferences robust.</p>
        <p id="Par29">We amplified RNA extracts from these tests with <italic>C</italic><sub>t</sub>&#x2009;&lt;&#x2009;30 using the ARTIC amplicon protocol (<ext-link ext-link-type="uri" xlink:href="https://www.protocols.io/workspaces/coguk/publications">https://www.protocols.io/workspaces/coguk/publications</ext-link>). We sequenced 384-sample pools on Illumina NovaSeq, and produced consensus fasta sequences according to the ARTIC nextflow processing pipeline (<ext-link ext-link-type="uri" xlink:href="https://github.com/connor-lab/ncov2019-artic-nf">https://github.com/connor-lab/ncov2019-artic-nf</ext-link>). Lineage assignments were made using Pangolin<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>, according to the latest lineage definitions at the time, except for B.1.617, which we reanalysed after the designation of sublineages B.1.617.1, B.1.617.2 and B.1.617.3. Lineage prevalence was computed from 281,178 genome sequences. The genomes were mapped to the same 315 English LTLAs as for the testing data described above. Mapping was performed from outer postcodes to LTLA, which can introduce some misassignment to neighbouring LTLAs. Furthermore, lineages in each LTLA were aggregated to counts per week for a total of 43 weeks, defined beginning on Sunday and ending on Saturday.</p>
        <p id="Par30">Finally, the complete set of 328 SARS-CoV-2 PANGO lineages was collapsed into <italic>l</italic>&#x2009;=&#x2009;71 lineages using the underlying phylogenetic tree, such that each resulting lineage constituted at least 100 genomes, unless the lineage has been designated a VOC, variant under investigation (VUI) or variant in monitoring by Public Health England<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>.</p>
      </sec>
      <sec id="Sec13">
        <title>Spatiotemporal genomic surveillance model</title>
        <p id="Par31">A hierarchical Bayesian model was used to fit local incidence data in a given day in each local authority and jointly estimate the relative historical prevalence and transmission parameters. In the following, <italic>t</italic> denotes time and is measured in days. We use the convention that bold lowercase symbols, such as <bold>b</bold>, indicate vectors.</p>
      </sec>
      <sec id="Sec14">
        <title>Motivation</title>
        <p id="Par32">Suppose that <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{x}}}^{{\prime} }(t)=({\bf{b}}+{r}_{0}(t))\cdot {\bf{x}}(t)$$\end{document}</tex-math><mml:math id="M2"><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="bold">x</mml:mi></mml:mrow></mml:mrow><mml:mo>&#x2032;</mml:mo></mml:msup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="bold">b</mml:mi></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo><mml:mo>&#x22C5;</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="bold">x</mml:mi></mml:mrow></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq1.gif"/></alternatives></inline-formula> &#x2009;describes the ordinary differential equation (ODE) for the viral dynamics for a set of <italic>l</italic> different lineages. Here <italic>r</italic><sub><italic>0</italic></sub>(<italic>t</italic>) is a scalar time-dependent logarithmic growth rate that is thought to reflect lineage-independent transmission determinants, which changes over time in response to behaviour, non-pharmaceutical interventions (NPIs) and immunity. This reflects a scenario in which the lineages differ only in terms of the intensity of transmission, but not the intergeneration time distribution. The ODE is solved by <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{x}}(t)={{\rm{e}}}^{{\bf{c}}+{\bf{b}}t+{\int }_{{t}_{0}}^{t}{r}_{0}(t){\rm{d}}t}={{\rm{e}}}^{{\bf{c}}+{\bf{b}}t}\nu (t)$$\end{document}</tex-math><mml:math id="M4"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">x</mml:mi></mml:mrow></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">c</mml:mi></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="bold">b</mml:mi></mml:mrow></mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mo>&#x222B;</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">c</mml:mi></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="bold">b</mml:mi></mml:mrow></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mi>&#x3BD;</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq2.gif"/></alternatives></inline-formula>. The term <italic>&#x3BD;</italic>(<italic>t</italic>) contributes the same factor to each lineage and therefore drops from the relative proportions of lineages <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{p}}(t)=\frac{{\bf{x}}(t)}{\sum {\bf{x}}(t)}\propto {{\rm{e}}}^{{\bf{c}}+{\bf{b}}t}$$\end{document}</tex-math><mml:math id="M6"><mml:mi mathvariant="bold">p</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="bold">x</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>&#x2211;</mml:mo><mml:mi mathvariant="bold">x</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>&#x221D;</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold">c</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="bold">b</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq3.gif"/></alternatives></inline-formula>.</p>
        <p id="Par33">In the given model, the lineage prevalence <bold>p</bold>(<italic>t</italic>) follows a multinomial logistic-linear trajectory. Moreover, the total incidence factorizes into <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\boldsymbol{\mu }}(t)=\nu (t)\sum {{\rm{e}}}^{{\bf{c}}+{\bf{b}}t}$$\end{document}</tex-math><mml:math id="M8"><mml:mi mathvariant="bold">&#x3BC;</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi>&#x3BD;</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#x2211;</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">c</mml:mi></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="bold">b</mml:mi></mml:mrow></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq4.gif"/></alternatives></inline-formula>, which provides a basis to separately estimate the total incidence <bold><italic>&#xB5;</italic></bold>(<italic>t</italic>) from Pillar 2 test data and lineage-specific prevalence <bold>p</bold>(<italic>t</italic>) from genomic surveillance data (which are taken from a varying proportion of positive tests). By using the equations above, one can subsequently calculate lineage-specific estimates by multiplying <bold><italic>&#xB5;</italic></bold>(<italic>t</italic>) with the respective genomic proportions <bold>p</bold>(<italic>t</italic>).</p>
      </sec>
      <sec id="Sec15">
        <title>Incidence</title>
        <p id="Par34">In the following text, we describe a flexible semi-parametric model of the incidence. Let <bold><italic>&#xB5;</italic></bold>(<italic>t</italic>) be the expected daily number of positive Pillar 2 tests and <italic>s</italic> the population size in each of 315 LTLAs. Denote <inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\boldsymbol{\lambda }}(t)=\,\log \,{\boldsymbol{\mu }}(t)-\,\log (s)$$\end{document}</tex-math><mml:math id="M10"><mml:mi mathvariant="bold">&#x3BB;</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>log</mml:mi><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="bold">&#x3BC;</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#x2212;</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>log</mml:mi><mml:mo>(</mml:mo><mml:mi>s</mml:mi><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq5.gif"/></alternatives></inline-formula> the logarithmic daily incidence per capita at time <italic>t</italic> in each of the 315 LTLAs.</p>
        <p id="Par35">Suppose <italic>f</italic>(<italic>t</italic>) is the daily number of new infections caused by the number of people infected at time <italic>t</italic>. As new cases are noticed and tested only after a delay <italic>u</italic> with distribution <italic>g</italic>, the observed number of cases <italic>f</italic>&#x200A;&#x200A;&#x200A;<sup>*</sup>(<italic>t</italic>) will be given by the convolution<disp-formula id="Equa"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${f}^{\ast }(t)={\int }_{0}^{{\rm{\infty }}}g(u)f(t-u){\rm{d}}u=(g\ast f)(t).$$\end{document}</tex-math><mml:math id="M12" display="block"><mml:msup><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x2217;</mml:mo></mml:mrow></mml:msup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mo>&#x222B;</mml:mo><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">&#x221E;</mml:mi></mml:mrow></mml:msubsup><mml:mi>g</mml:mi><mml:mo>(</mml:mo><mml:mi>u</mml:mi><mml:mo>)</mml:mo><mml:mi>f</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mi>u</mml:mi><mml:mo>)</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow><mml:mi>u</mml:mi><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mi>g</mml:mi><mml:mo>&#x2217;</mml:mo><mml:mi>f</mml:mi><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="41586_2021_4069_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par36">The time from infection to test is given by the incubation time plus the largely unknown distribution of the time from symptoms to test, which, in England, was required to take place within 5&#x2009;d of symptom onset. To account for these factors, the log normal incubation time distribution from ref. <sup><xref ref-type="bibr" rid="CR46">46</xref></sup> is scaled by the equivalent of changing the mean by 2&#x2009;d. The convolution shifts cases approximately 6&#x2009;d into the future and also spreads them out according to the width of <italic>g</italic> (Extended Data Fig. <xref rid="Fig7" ref-type="fig">2a</xref>).</p>
        <p id="Par37">To parametrize the short- and longer-term changes of the logarithmic incidence <inline-formula id="IEq6"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\boldsymbol{\lambda }}(t)$$\end{document}</tex-math><mml:math id="M14"><mml:mi mathvariant="bold">&#x3BB;</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq6.gif"/></alternatives></inline-formula>, we use a combination of <italic>h</italic> weekly and <italic>k</italic>&#x2009;&#x2212;&#x2009;<italic>h</italic> monthly cubic basis splines <inline-formula id="IEq7"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{f}}(t)=({f}_{1}(t),\ldots ,{f}_{k}(t)).$$\end{document}</tex-math><mml:math id="M16"><mml:mi mathvariant="bold">f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>&#x2026;</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq7.gif"/></alternatives></inline-formula> The knots of the <italic>h</italic> weekly splines uniformly tile the observation period except for the last 6 weeks.</p>
        <p id="Par38">Each spline basis function is convolved with the time to test distribution <italic>g</italic>, <inline-formula id="IEq90"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{f}}}^{\ast }(t)=({f}_{1}^{\ast }(t),\ldots ,{f}_{k}^{\ast }(t))$$\end{document}</tex-math><mml:math id="M18"><mml:msup><mml:mrow><mml:mi mathvariant="bold">f</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x2217;</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>&#x2217;</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>&#x2026;</mml:mi><mml:mo>,</mml:mo><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x2217;</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq90.gif"/></alternatives></inline-formula> as outlined above and used to fit the logarithmic incidence. The derivatives of the original basis <bold>f</bold>&#x2032;(<italic>t</italic>) are used to calculate the underlying growth rates and <italic>R</italic><sub><italic>t</italic></sub> values, as shown further below. The convolved spline basis <bold>f</bold>*(<italic>t</italic>) is used to fit the per capita incidence in each LTLA as (Extended Data Fig. <xref rid="Fig7" ref-type="fig">2b</xref>):<disp-formula id="Equb"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\boldsymbol{\lambda }}(t)={\bf{B}}\times {{\bf{f}}}^{\ast }(t).$$\end{document}</tex-math><mml:math id="M20" display="block"><mml:mrow><mml:mi mathvariant="bold">&#x3BB;</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mo>&#xD7;</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">f</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mo>&#x2217;</mml:mo></mml:mrow></mml:msup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="41586_2021_4069_Article_Equb.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par39">This implies that fitting the incidence function for each of the <italic>m</italic> local authorities is achieved by a suitable choice of coefficients <inline-formula id="IEq9"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{B}}\in {{\mathbb{R}}}^{m\times k}$$\end{document}</tex-math><mml:math id="M22"><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mo>&#x2208;</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>&#xD7;</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq9.gif"/></alternatives></inline-formula>, that is one coefficient for each spline function for each of the LTLAs. The parameters&#xA0;<bold>B</bold> have a univariate normal prior distribution each, which reads for LTLA <italic>i</italic> and spline <italic>j</italic>:<disp-formula id="Equc"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{B}}}_{i,j}\sim N(0,{\sigma }_{j}).$$\end{document}</tex-math><mml:math id="M24" display="block"><mml:msub><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&#x223C;</mml:mo><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>&#x3C3;</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="41586_2021_4069_Article_Equc.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par40">The s.d. of the prior regularizes the amplitude of the splines and is chosen as <inline-formula id="IEq10"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\sigma }_{j}=0.2$$\end{document}</tex-math><mml:math id="M26"><mml:msub><mml:mrow><mml:mi>&#x3C3;</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq10.gif"/></alternatives></inline-formula> &#x2009;for weekly splines and <inline-formula id="IEq11"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\sigma }_{j}=1$$\end{document}</tex-math><mml:math id="M28"><mml:msub><mml:mrow><mml:mi>&#x3C3;</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq11.gif"/></alternatives></inline-formula> &#x2009;for monthly splines. This choice was found to reduce the overall variance resulting from the high number of weekly splines, meant to capture rapid changes in growth rates, but which can lead to instabilities particularly at the end of the time series, when not all effects of changes in growth rates are observed yet. The less regularized monthly splines reflect trends on the scale of several weeks and are therefore subject to less noise.</p>
        <p id="Par41">Finally, we introduce a term accounting for periodic differences in weekly testing patterns (there are typically 30% lower specimens taken on weekends; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>):<disp-formula id="Equ110"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathop{{\boldsymbol{\mu }}}\limits^{ \sim }={\boldsymbol{\mu }}(t)\cdot \delta (t),$$\end{document}</tex-math><mml:math id="M30" display="block"><mml:mrow><mml:mover><mml:mrow><mml:mi mathvariant="bold">&#x3BC;</mml:mi></mml:mrow><mml:mo>~</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="bold">&#x3BC;</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#x22C5;</mml:mo><mml:mi>&#x3B4;</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math><graphic xlink:href="41586_2021_4069_Article_Equ110.gif" position="anchor"/></alternatives></disp-formula>where the scalar <inline-formula id="IEq12"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\delta (t)=\delta (t-i\times 7)\,{\rm{\forall }}i\in {\mathbb{N}}$$\end{document}</tex-math><mml:math id="M32"><mml:mi>&#x3B4;</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi>&#x3B4;</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mi>i</mml:mi><mml:mo>&#xD7;</mml:mo><mml:mn>7</mml:mn><mml:mo>)</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">&#x2200;</mml:mi><mml:mi>i</mml:mi><mml:mo>&#x2208;</mml:mo><mml:mrow><mml:mi mathvariant="double-struck">N</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq12.gif"/></alternatives></inline-formula> and prior distribution <inline-formula id="IEq13"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\delta (t)\sim {\rm{L}}{\rm{o}}{\rm{g}}{\rm{N}}{\rm{o}}{\rm{r}}{\rm{m}}{\rm{a}}{\rm{l}}(0,1)$$\end{document}</tex-math><mml:math id="M34"><mml:mi>&#x3B4;</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#x223C;</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq13.gif"/></alternatives></inline-formula> for <inline-formula id="IEq14"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t=1,\ldots ,6$$\end{document}</tex-math><mml:math id="M36"><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x2026;</mml:mi><mml:mo>,</mml:mo><mml:mn>6</mml:mn></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq14.gif"/></alternatives></inline-formula> and <inline-formula id="IEq15"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\delta (0)=1$$\end{document}</tex-math><mml:math id="M38"><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq15.gif"/></alternatives></inline-formula>.</p>
        <p id="Par42">The total incidence was fitted to the observed number of positive daily tests&#xA0;<bold>X</bold> by a negative binomial with a dispersion <inline-formula id="IEq16"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\omega =10$$\end{document}</tex-math><mml:math id="M40"><mml:mi>&#x3C9;</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq16.gif"/></alternatives></inline-formula>. The overdispersion buffers against non-Poissonian uncorrelated fluctuations in the number of daily tests.<disp-formula id="Eque"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{X}}(t)\sim {\rm{N}}{\rm{B}}(\mathop{{\boldsymbol{\mu }}}\limits^{ \sim }(t),\omega ).$$\end{document}</tex-math><mml:math id="M42" display="block"><mml:mrow><mml:mi mathvariant="bold">X</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#x223C;</mml:mo><mml:mrow><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mover><mml:mrow><mml:mi mathvariant="bold">&#x3BC;</mml:mi></mml:mrow><mml:mo>~</mml:mo></mml:mover></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>,</mml:mo><mml:mi>&#x3C9;</mml:mi><mml:mo>)</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="41586_2021_4069_Article_Eque.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par43">The equation above assumes that all elements of <bold>X</bold>(<italic>t</italic>) are independent, conditional on&#xA0;<inline-formula id="IEq39"><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\tilde{{\boldsymbol{\mu }}}(t)$$\end{document}</tex-math><mml:math id="M44"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi mathvariant="bold">&#x3BC;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold">&#x2DC;</mml:mi></mml:mrow></mml:mover><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq39.gif"/></alternatives></inline-formula>.</p>
      </sec>
      <sec id="Sec16">
        <title>Growth rates and <italic>R</italic><sub><italic>t</italic></sub> values</title>
        <p id="Par44">A convenient consequence of the spline basis of <inline-formula id="IEq18"><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\log ({\boldsymbol{\mu }})={\boldsymbol{\lambda }}$$\end{document}</tex-math><mml:math id="M46"><mml:mi>log</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi mathvariant="bold">&#x3BC;</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi mathvariant="bold">&#x3BB;</mml:mi></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq18.gif"/></alternatives></inline-formula>, is that the delay-adjusted daily logarithmic&#xA0;growth rate <bold>r</bold>(<italic>t</italic>) =&#xA0;<bold>&#x3BB;&#x2032;</bold>(<italic>t</italic>)&#xA0;of the local epidemic simplifies to:<disp-formula id="Equf"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{r}}(t)={\bf{B}}\times {{\bf{f}}}^{{\prime} }(t),$$\end{document}</tex-math><mml:math id="M48" display="block"><mml:mi mathvariant="bold">r</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="bold">B</mml:mi></mml:mrow><mml:mo>&#xD7;</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold">f</mml:mi></mml:mrow><mml:mo>&#x2032;</mml:mo></mml:msup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math><graphic xlink:href="41586_2021_4069_Article_Equf.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq115"><alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{f}}}_{j}^{{\prime} }(t)$$\end{document}</tex-math><mml:math id="M50"><mml:msubsup><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">f</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mo>&#x2032;</mml:mo></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq115.gif"/></alternatives></inline-formula> represents the first derivative of the <italic>j</italic>th cubic spline basis function.</p>
        <p id="Par45">To express the daily growth rate as an approximate reproductive number <italic>R</italic><sub><italic>t</italic></sub>, one needs to consider the distribution of the intergeneration time, which is assumed to be gamma distributed with mean 6.3&#x2009;d (<italic>&#x3B1;</italic>&#x2009;=&#x2009;2.29, <italic>&#x3B2;</italic>&#x2009;=&#x2009;0.36)<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. The <italic>R</italic><sub><italic>t</italic></sub> value can be expressed as a Laplace transform of the intergeneration time distribution<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Effectively, this shortens the relative time period because the exponential dynamics put disproportionally more weight on stochastically early transmissions over late ones. For reasons of simplicity and being mindful also of the uncertainties of the intergeneration time distribution, we approximate <italic>R</italic><sub><italic>t</italic></sub> values by multiplying the logarithmic growth rates with a value of <inline-formula id="IEq20"><alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bar{\tau }}_{{\rm{e}}}$$\end{document}</tex-math><mml:math id="M52"><mml:msub><mml:mrow><mml:mover accent="true"><mml:mi>&#x3C4;</mml:mi><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq20.gif"/></alternatives></inline-formula> = 5.1&#x2009;d, which was found to be a reasonable approximation to the convolution required to calculate <italic>R</italic><sub><italic>t</italic></sub> values (denoted here by the lower case symbol <inline-formula id="IEq21"><alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\boldsymbol{\rho }}(t)$$\end{document}</tex-math><mml:math id="M54"><mml:mrow><mml:mi mathvariant="bold">&#x3C1;</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq21.gif"/></alternatives></inline-formula> in line with our convention for vector-variate symbols and to avoid confusion with the epidemiological growth rate <italic>r</italic><sub><italic>t</italic></sub>),<disp-formula id="Equg"><alternatives><tex-math id="M55">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\log ({\boldsymbol{\rho }}(t))\approx \frac{{\rm{d}}\,\log ({\boldsymbol{\mu }}(t))}{{\rm{d}}t}{\bar{\tau }}_{{\rm{e}}}={\bf{r}}(t){\bar{\tau }}_{{\rm{e}}}$$\end{document}</tex-math><mml:math id="M56" display="block"><mml:mi>log</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="bold">&#x3C1;</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo><mml:mo>&#x2248;</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow><mml:mspace width="thinmathspace"/><mml:mi>log</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="bold">&#x3BC;</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>&#x3C4;</mml:mi><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="bold">r</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>&#x3C4;</mml:mi><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msub></mml:math><graphic xlink:href="41586_2021_4069_Article_Equg.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par46">Thus, the overall growth rate scaled to an effective inter generation time of 5.1&#x2009;d can be readily derived from the derivatives of the spline basis and the corresponding coefficients. The values derived from the approach are in very close agreement with those of the method of ref. <sup><xref ref-type="bibr" rid="CR48">48</xref></sup>, but shifted according to the typical delay from infection to test (Extended Data Fig. <xref rid="Fig7" ref-type="fig">2b</xref>).</p>
      </sec>
      <sec id="Sec17">
        <title>Genomic prevalence</title>
        <p id="Par47">The dynamics of the relative frequency&#xA0;<bold>P</bold><italic>(t)</italic> of each lineage was modelled using a logistic-linear model in each LTLA, as described above. The logistic prevalence of each lineage in each LTLA is defined as <inline-formula id="IEq22"><alternatives><tex-math id="M57">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{L}}(t)={\rm{l}}{\rm{o}}{\rm{g}}{\rm{i}}{\rm{t}}({\bf{P}}(t))$$\end{document}</tex-math><mml:math id="M58"><mml:mrow><mml:mi mathvariant="bold">L</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="bold">P</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq22.gif"/></alternatives></inline-formula>. This is modelled using the piecewise linear expression<disp-formula id="Equh"><alternatives><tex-math id="M59">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{L}}(t)={\bf{C}}+{\bf{b}}\cdot {{\bf{t}}}_{+},$$\end{document}</tex-math><mml:math id="M60" display="block"><mml:mrow><mml:mi mathvariant="bold">L</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="bold">C</mml:mi></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="bold">b</mml:mi></mml:mrow></mml:mrow><mml:mo>&#x22C5;</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">t</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math><graphic xlink:href="41586_2021_4069_Article_Equh.gif" position="anchor"/></alternatives></disp-formula>where <bold>b</bold> may be interpreted as a lineage-specific growth advantage and <bold>C</bold> as an offset term of dimension (LTLA&#x2009;&#xD7;&#x2009;lineages). Time <inline-formula id="IEq23"><alternatives><tex-math id="M61">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{t}}}_{+}$$\end{document}</tex-math><mml:math id="M62"><mml:msub><mml:mrow><mml:mi mathvariant="bold">t</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq23.gif"/></alternatives></inline-formula> is measured since introduction <bold>t</bold><sub>0</sub> and is defined as<disp-formula id="Equi"><alternatives><tex-math id="M63">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{t}}}_{+}=t-{{\bf{t}}}_{0}\,{\rm{i}}{\rm{f}}\,t &gt; {{\bf{t}}}_{0}\,{\rm{e}}{\rm{l}}{\rm{s}}{\rm{e}}-{\rm{\infty }}$$\end{document}</tex-math><mml:math id="M64" display="block"><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">t</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">t</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mspace width="1em"/><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:mrow><mml:mspace width=".25em"/><mml:mi>t</mml:mi><mml:mo>&gt;</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="bold">t</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mspace width=".25em"/><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mi mathvariant="normal">&#x221E;</mml:mi></mml:math><graphic xlink:href="41586_2021_4069_Article_Equi.gif" position="anchor"/></alternatives></disp-formula>and accounts for the fact that lineages can be entirely absent prior to a stochastically distributed time period preceding their first observation. This is because, in the absence of such a term, the absence of a lineage prior to the point of observation can only be explained by a higher growth rate compared with the preceding lineages, which may not necessarily be the case. As the exact time of introduction is generally unknown, a stochastic three-week period of <inline-formula id="IEq24"><alternatives><tex-math id="M65">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{t}}}_{0}\sim {\rm{Unif}}(-14,0)+{{\bf{t}}}_{0}^{{\rm{obs}}}$$\end{document}</tex-math><mml:math id="M66"><mml:msub><mml:mrow><mml:mi mathvariant="bold">t</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#x223C;</mml:mo><mml:mi mathvariant="normal">Unif</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>14</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold">t</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">obs</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq24.gif"/></alternatives></inline-formula>prior to the first observation <inline-formula id="IEq25"><alternatives><tex-math id="M67">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{t}}}_{0}^{{\rm{obs}}}$$\end{document}</tex-math><mml:math id="M68"><mml:msubsup><mml:mrow><mml:mi mathvariant="bold">t</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">obs</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq25.gif"/></alternatives></inline-formula> was chosen.</p>
        <p id="Par48">As the inverse logit transformation projects onto the <italic>l</italic>&#x2009;&#x2212;&#x2009;1 dimensional simplex <inline-formula id="IEq26"><alternatives><tex-math id="M69">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${S}_{l-1}$$\end{document}</tex-math><mml:math id="M70"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq26.gif"/></alternatives></inline-formula> and therefore loses one degree of freedom, B.1.177 was set as a baseline with<disp-formula id="Equj"><alternatives><tex-math id="M71">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{L}}}_{\cdot ,0}(t)=0.$$\end{document}</tex-math><mml:math id="M72" display="block"><mml:msub><mml:mrow><mml:mi mathvariant="bold">L</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x22C5;</mml:mo><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo></mml:math><graphic xlink:href="41586_2021_4069_Article_Equj.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par49">The offset parameters <italic>C</italic> are modelled across LTLAs as independently distributed multivariate normal random variables with a lineage-specific mean <bold>c</bold> and covariance <inline-formula id="IEq27"><alternatives><tex-math id="M73">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Sigma =10\cdot {I}_{l-1}$$\end{document}</tex-math><mml:math id="M74"><mml:mi mathvariant="normal">&#x3A3;</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn><mml:mo>&#x22C5;</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq27.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq28"><alternatives><tex-math id="M75">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}_{l-1}$$\end{document}</tex-math><mml:math id="M76"><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq28.gif"/></alternatives></inline-formula> denotes an <inline-formula id="IEq29"><alternatives><tex-math id="M77">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$(l-1)\times (l-1)$$\end{document}</tex-math><mml:math id="M78"><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>l</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>&#xD7;</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>l</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq29.gif"/></alternatives></inline-formula> identity matrix. The lineage-specific parameters growth rate <bold>b</bold> and average offset <bold>c</bold> are modelled using IID Normal prior distributions<disp-formula id="Equk"><alternatives><tex-math id="M79">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{b}}\sim N(0,0.2)$$\end{document}</tex-math><mml:math id="M80" display="block"><mml:mi mathvariant="bold">b</mml:mi><mml:mo>&#x223C;</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.2</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:math><graphic xlink:href="41586_2021_4069_Article_Equk.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equl"><alternatives><tex-math id="M81">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{c}}\sim N(-10,5)$$\end{document}</tex-math><mml:math id="M82" display="block"><mml:mi mathvariant="bold">c</mml:mi><mml:mo>&#x223C;</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:math><graphic xlink:href="41586_2021_4069_Article_Equl.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par50">The time-dependent relative prevalence&#xA0;<bold>P</bold>(t) of SARS-CoV2 lineages was fitted to the number of weekly genomes&#xA0;<bold>Y</bold>(t) in each LTLA by a Dirichlet-multinomial distribution with expectation <inline-formula id="IEq30"><alternatives><tex-math id="M83">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\mathbb{E}}[{\bf{Y}}(t)]\approx {\bf{P}}(t)\cdot {\bf{G}}(t)$$\end{document}</tex-math><mml:math id="M84"><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi mathvariant="bold">Y</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>]</mml:mo><mml:mo>&#x2248;</mml:mo><mml:mrow><mml:mi mathvariant="bold">P</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#x22C5;</mml:mo><mml:mrow><mml:mi mathvariant="bold">G</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq30.gif"/></alternatives></inline-formula> where&#xA0;<bold>G</bold>(t) are the total number of genomes sequenced from each LTLA in each week. For LTLA&#xA0;<italic>i</italic>, this is defined as:<disp-formula id="Equm"><alternatives><tex-math id="M85">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{Y}}}_{i,\cdot }(t)\sim {\rm{D}}{\rm{i}}{\rm{r}}{\rm{M}}{\rm{u}}{\rm{l}}{\rm{t}}({\alpha }_{0}+{{\boldsymbol{\alpha }}}_{1}{{\bf{P}}}_{i,\cdot }(t),{{\bf{G}}}_{i}(t)).$$\end{document}</tex-math><mml:math id="M86" display="block"><mml:msub><mml:mrow><mml:mi mathvariant="bold">Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mo>&#x22C5;</mml:mo></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#x223C;</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>&#x3B1;</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mi mathvariant="bold">&#x3B1;</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="bold">P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mo>&#x22C5;</mml:mo></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">G</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo><mml:mo>.</mml:mo></mml:math><graphic xlink:href="41586_2021_4069_Article_Equm.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par51">The scalar parameter <inline-formula id="IEq31"><alternatives><tex-math id="M87">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\boldsymbol{\alpha }}}_{0}=0.01$$\end{document}</tex-math><mml:math id="M88"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">&#x3B1;</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq31.gif"/></alternatives></inline-formula> can be interpreted as a weak prior with expectation 1/<italic>n</italic>, making the model less sensitive to the introduction of single new lineages, which can otherwise exert a very strong effect. Furthermore, the array <inline-formula id="IEq32"><alternatives><tex-math id="M89">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\boldsymbol{\alpha }}}_{1}=\frac{{\rm{cases}}}{2}$$\end{document}</tex-math><mml:math id="M90"><mml:msub><mml:mrow><mml:mi mathvariant="bold">&#x3B1;</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">cases</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq32.gif"/></alternatives></inline-formula> increases the variance to account for the fact that, especially at high sequencing coverage (genomes&#x2009;&#x2248;&#x2009;cases), cases and therefore genomes are likely to be correlated and overdispersed as they may derive from a single transmission event. Other choices such as <inline-formula id="IEq33"><alternatives><tex-math id="M91">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\boldsymbol{\alpha }}}_{1}=1,000$$\end{document}</tex-math><mml:math id="M92"><mml:msub><mml:mi mathvariant="bold">&#x3B1;</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>000</mml:mn></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq33.gif"/></alternatives></inline-formula>, which make the model converge to a standard multinomial, leave the conclusions qualitatively unchanged. This model aspect is illustrated in Extended Data Fig. <xref rid="Fig7" ref-type="fig">2c</xref>.</p>
      </sec>
      <sec id="Sec18">
        <title>Lineage-specific incidence and growth rates</title>
        <p id="Par52">From the two definitions above it follows that the lineage-specific incidence is given by multiplying the total incidence in each LTLA <bold>&#xB5;</bold>(<italic>t</italic>) with the corresponding lineage frequency estimate&#xA0;<bold>P</bold>(<italic>t</italic>)for lineage <italic>j</italic> at each time point</p>
        <p id="Par53"><inline-formula id="IEq34"><alternatives><tex-math id="M93">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{M}}}_{\cdot ,j}(t)={\boldsymbol{\mu }}(t)\cdot {{\bf{P}}}_{\cdot ,j}(t)$$\end{document}</tex-math><mml:math id="M94"><mml:msub><mml:mrow><mml:mi mathvariant="bold">M</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x22C5;</mml:mo><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="bold">&#x3BC;</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#x22C5;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">P</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x22C5;</mml:mo><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq34.gif"/></alternatives></inline-formula> for <inline-formula id="IEq35"><alternatives><tex-math id="M95">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j=0,\ldots ,l-1$$\end{document}</tex-math><mml:math id="M96"><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x2026;</mml:mi><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq35.gif"/></alternatives></inline-formula></p>
        <p id="Par54">Further corresponding lineage-specific <italic>R</italic><sub><italic>t</italic></sub> values <bold>R</bold>(<italic>t</italic>) in each LTLA can be calculated from the lineage-agnostic average <italic>R</italic><sub><italic>t</italic></sub> value <bold>&#x3C1;</bold>(<italic>t</italic>) and the lineage proportions <bold>P</bold>(<italic>t</italic>) as<disp-formula id="Equn"><alternatives><tex-math id="M97">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\log {\bf{R}}(t)=\,\log \,{\boldsymbol{\rho }}(t)+{\bar{\tau }}_{{\rm{e}}}({\bf{b}}-{\bf{P}}(t)\times {\bf{b}})$$\end{document}</tex-math><mml:math id="M98" display="block"><mml:mi>log</mml:mi><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>log</mml:mi><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="bold">&#x3C1;</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>&#x3C4;</mml:mi><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="bold">b</mml:mi></mml:mrow></mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mrow><mml:mi mathvariant="bold">P</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#xD7;</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="bold">b</mml:mi></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:math><graphic xlink:href="41586_2021_4069_Article_Equn.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par55">By adding the log-transformed growth rate fold changes <bold>b</bold> and subtracting the average log-transformed growth rate change <inline-formula id="IEq36"><alternatives><tex-math id="M99">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\bf{P}}(t)\times {\bf{b}}$$\end{document}</tex-math><mml:math id="M100"><mml:mrow><mml:mi mathvariant="bold">P</mml:mi></mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#xD7;</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="bold">b</mml:mi></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq36.gif"/></alternatives></inline-formula>, it follows that <inline-formula id="IEq37"><alternatives><tex-math id="M101">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{R}}}_{i,\cdot }(t)={{\bf{R}}}_{i,0}(t){{\rm{e}}}^{{\bar{\tau }}_{{\rm{e}}}{\bf{b}}}$$\end{document}</tex-math><mml:math id="M102"><mml:msub><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mo>&#x22C5;</mml:mo></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>&#x3C4;</mml:mi><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mrow><mml:mi mathvariant="bold">b</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq37.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq38"><alternatives><tex-math id="M103">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{R}}}_{i,0}(t)$$\end{document}</tex-math><mml:math id="M104"><mml:msub><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq38.gif"/></alternatives></inline-formula> is the <italic>R</italic><sub><italic>t</italic></sub> value of the reference lineage <italic>j</italic>&#x2009;=&#x2009;0 (for which <inline-formula id="IEq100"><alternatives><tex-math id="M105">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\bf{b}}}_{0}=0$$\end{document}</tex-math><mml:math id="M106"><mml:msub><mml:mrow><mml:mi mathvariant="bold">b</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq100.gif"/></alternatives></inline-formula>) in LTLA <italic>i</italic>. It follows that all other lineage-specific the <italic>R</italic><sub><italic>t</italic></sub> values are proportional to this baseline at any given point in time with factor <inline-formula id="IEq40"><alternatives><tex-math id="M107">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\rm{e}}}^{{\bar{\tau }}_{{\rm{e}}}{\bf{b}}}$$\end{document}</tex-math><mml:math id="M108"><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mi>&#x3C4;</mml:mi><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="bold">b</mml:mi></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41586_2021_4069_Article_IEq40.gif"/></alternatives></inline-formula>.</p>
      </sec>
      <sec id="Sec19">
        <title>Inference</title>
        <p id="Par56">The model was implemented in numpyro<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup> and fitted using stochastic variational inference<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Guide functions were multivariate normal distributions for each row (corresponding to an LTLA) of&#xFEFF; <bold>B</bold>,&#x2009;<bold>C</bold> to preserve the correlations across lineages and time as well as for (<bold>b</bold>,&#x2009;<bold>c</bold>) to also model correlations between growth rates and typical introduction.</p>
      </sec>
      <sec id="Sec20">
        <title>Phylogeographic analyses</title>
        <p id="Par57">To infer VOC introduction events into the UK and corresponding clade sizes, we investigated VOC genome sequences from GISAID (<ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org/">https://www.gisaid.org/</ext-link>) available from any country. We downloaded multiple sequence alignments of genome sequences with the release dates 17 April 2021 (for the analysis of the lineages A.23.1, B.1.1.318, B.1.351 andB.1.525) and 5 May 2021 (for the analysis of the B.1.617 sublineages). We next extracted a subalignment from each lineage (according to the 1 April 2021 version of PANGOlin for the 17 April 2021 alignment and the 23 April 2021 version of PANGOlin for the 5 May 2021 alignment) and, for each subalignment, we inferred a phylogeny through maximum likelihood using FastTree2 (v.2.1.11)<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> with the default options and GTR substitution model<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>.</p>
        <p id="Par58">On each VOC/VUI phylogeny, we inferred the minimum and maximum number of introductions of the considered SARS-CoV-2 lineage into the UK compatible with a parsimonious migration history of the ancestors of the considered samples; we also measured clade sizes for one specific example parsimonious migration history. We counted only introduction events into the UK that resulted in at least one descendant from the set of UK samples that we considered in this work for our hierarchical Bayesian model; similarly, we measured clade sizes by the number of UK samples considered here included in such clades. Multiple occurrences of identical sequences were counted as separate cases, as this helped us to identify rapid SARS-CoV-2 spread.</p>
        <p id="Par59">When using parsimony, we considered only migration histories along a phylogenetic tree that are parsimonious in terms of the number of migration events from and to the UK (in practice, we collapse all of the non-UK locations into a single one). Furthermore, as SARS-CoV-2 phylogenies present substantial numbers of polytomies, that is, phylogenetic nodes where the tree topology cannot be reconstructed due to a lack of mutation events on certain branches, we developed a tailored dynamic programming approach to efficiently integrate over all possible splits of polytomies and over all possible parsimonious migration histories. The idea of this method is somewhat similar to typical Bayesian phylogeographic inference<sup><xref ref-type="bibr" rid="CR54">54</xref></sup> in that it enables us to at least in part integrate over phylogenetic uncertainty and uncertainty in migration history; however, it also represents a very simplified version of these analyses, more so than ref. <sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, as it considers most of the phylogenetic tree as fixed, ignores sampling times and uses parsimony instead of a likelihood-based approach. Parsimony is expected to represent a good approximation in the context of SARS-CoV-2, due to the shortness (both in time and substitutions) of the phylogenetic branches considered<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>. The main advantage of our approach is that, owing to the dynamic programming implementation, it is more computationally efficient than Bayesian alternatives, as the most computationally demanding step is the inference of the maximum likelihood phylogenetic tree. This enables us to infer plausible ranges for numbers of introduction events for large datasets and to quickly update our analyses as new sequences become available. The other advantage of this approach is that it enables us to easily customize the analysis and to focus on inferred UK introductions that result in at least one UK surveillance sample, while still making use of non-surveillance UK samples to inform the inferred phylogenetic tree and migration history. Note that possible biases due to uneven sequencing rates across the world<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> apply to our approach as well as other popular phylogeographic methods. Our approach works by traversing the maximum likelihood tree starting from the terminal nodes and ending at the root (postorder traversal). Here, we define a &#x2018;UK clade&#x2019; as a maximal subtree of the total phylogeny for which all terminal nodes are from the UK, all internal nodes are inferred to be from the UK and at least one terminal node is a UK surveillance sample; the size of a UK clade is defined as the number of UK surveillance samples in it. At each node, using values already calculated for all children nodes (possibly more than two children in the case of a multifurcation), we calculate the following quantities: (1) the maximum and minimum number of possible descendant UK clades of the current node, over the space of possible parsimonious migration histories, and conditional on the current node being UK or non-UK; (2) the number of migration events compatible with a parsimonious migration history in the subtree below the current node, and conditional on the current node being UK or non-UK; (3) the size so far of the UK clade the current node is part of, conditional on it being UK; and (4) a sample of UK clade sizes for the subtree below the node. To calculate these quantities, for each internal node, and conditional on each possible node state (UK or non-UK), we consider the possible scenarios of having 0 of 1 migration events between the internal node and its children nodes (migration histories with more than 1 migration event between the node and its children are surely not parsimonious in our analysis and can be ignored).</p>
        <p id="Par60">To confirm the results of our analyses based on parsimony, we also used the new Bayesian phylogenetic approach Thorney BEAST<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> (<ext-link ext-link-type="uri" xlink:href="https://beast.community/thorney_beast">https://beast.community/thorney_beast</ext-link>) for VOCs for which it was computationally feasible, that is, excluding B.1.351. For each VOC, we used in Thorney BEAST the same topology inferred with FastTree2 as for our parsimony analysis; we also used treetime<sup><xref ref-type="bibr" rid="CR57">57</xref></sup> v.0.8.2 to estimatea timed tree and branch divergences for use in Thorney BEAST. We used a two-state (UK and non-UK) migration model<sup><xref ref-type="bibr" rid="CR54">54</xref></sup> of migration to infer introductions into the UK but again counted, from the posteriorsample trees, only UK clades with at least one UK surveillance sample.We used a Skygrid<sup><xref ref-type="bibr" rid="CR58">58</xref></sup> tree coalescent prior with six time intervals. The comparison of parsimony and Bayesian estimates is shown in Extended Data Fig. <xref rid="Fig13" ref-type="fig">8d</xref>.</p>
      </sec>
      <sec id="Sec21">
        <title>ONS infection survey analysis</title>
        <p id="Par61">Data from the cross-sectional infection survey were downloaded from <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/30april2021">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/30april2021</ext-link>.</p>
        <p id="Par62">Comparison of ONS incidence estimates with hospitalization, case and death rates was conducted by estimating infection trajectories separately from observed cases, hospitalizations and deaths<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>, convolving them with estimated PCR detection curves<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>, and dividing the resulting PCR prevalence estimates by the estimated prevalence from the ONS Community Infection Survey at the midpoints of the two-week intervals over which prevalence was reported in the survey.</p>
      </sec>
      <sec id="Sec22">
        <title>Maps</title>
        <p id="Par63">Maps were plotted using LTLA shapefiles (<ext-link ext-link-type="uri" xlink:href="https://geoportal.statistics.gov.uk/datasets/69dc11c7386943b4ad8893c45648b1e1">https://geoportal.statistics.gov.uk/datasets/69dc11c7386943b4ad8893c45648b1e1</ext-link>), sourced from the ONS, which is licensed under the Open Government Licence v.3.0.</p>
      </sec>
      <sec id="Sec23">
        <title>Limitations</title>
        <p id="Par64">A main limitation of the analysis is that the transmission model is deterministic, whereas the spread of variants is a stochastic process. Although the logistic growth assumption is a consistent estimator of the average transmission dynamics, individual outbreaks may deviate from these averages and therefore produce unreliable estimates.</p>
        <p id="Par65">Stochastic growth effects are accounted for only in terms of (uncorrelated) overdispersion and the offset at the time of the introduction. For these reasons, the estimated growth rates may not accurately reflect the viral transmissibility, especially at a low prevalence. It is therefore important to assess whether consistent growth patterns in multiple independent areas are observed. We note that the posterior distribution of the growth rates of rare variants tends to be biased to the baseline due to the centred prior.</p>
        <p id="Par66">In its current form, the model accounts for only a single introduction event per LTLA. Although this problem is in part alleviated by the high spatial resolution, which spreads introductions across 315 LTLAs, it is important to investigate whether sustained introductions inflate the observed growth rates, as in the case of the Delta variant or other VOCs and VUIs. This can be achieved by a more detailed phylogeographic assessment and through the assessment of monophyletic sublineages.</p>
        <p id="Par67">Furthermore, there is no explicit transmission modelled from one LTLA to another. As each introduction is therefore modelled separately, this makes the model conservative in ascertaining elevated transmission as single observed cases across different LTLAs can be explained by their introduction.</p>
        <p id="Par68">The inferred growth rates also cannot identify a particular mechanism of altered transmission. Biological mechanisms include a higher viral load, longer infectivity or greater susceptibility. Lineages could potentially differ by their intergeneration time, which would lead to nonlinear scaling. Here we did not find convincing evidence in incidence data for such effects, in contrast to previous reports<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. However, contact-tracing data indicate that the intergeneration time may be shortening for more transmissible lineages such as Delta<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR62">62</xref></sup>. Cases of the Beta and Gamma VOCs may have been more intensely contact traced and triggered asymptomatic surge testing in some postcode areas. This may have reduced the observed growth rates relative to other lineages.</p>
        <p id="Par69">Lineages, such as Beta, Gamma or Delta also differ in their ability to evade previous immunity. As immunity changes over time, this might lead to a differential growth advantage over time. It is therefore advisable to assess whether a growth advantage is constant over periods in which immunity changes considerably.</p>
        <p id="Par70">A further limitation underlies the nature of lineage definition and assignment. The PANGO lineage definition<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> assigns lineages to geographical clusters, which have by definition expanded, and this can induce a certain survivor bias, often followed by winner&#x2019;s curse. Another issue results from the fact that very recent variants may not be classified as a lineage despite having grown, which can inflate the growth rate of ancestral lineages over sublineages.</p>
        <p id="Par71">As the total incidence is modelled on the basis of the total number of positive PCR tests, it may be influenced by testing capacity; the total number of tests approximately tripled between September 2020 and March 2021. This can potentially lead to a time trend in recorded cases and therefore baseline <italic>R</italic><sub><italic>t</italic></sub> values if the access to testing changed, for example, by too few tests being available tests during periods of high incidence, or changes to the eligibility to intermittently test with fewer symptoms. Generally, the observed incidence was in good agreement with representative cross-sectional estimates from the ONS<sup><xref ref-type="bibr" rid="CR63">63</xref>,<xref ref-type="bibr" rid="CR64">64</xref></sup>, except for a period of peak incidence from late December 2020 to January 2021 (Extended Data Fig. <xref rid="Fig6" ref-type="fig">1d</xref>). Values after 8 March 2021 need to be interpreted with caution as Pillar 2 PCR testing was supplemented by lateral flow devices, which increased the number of daily tests to more than 1.5&#x2009;million. Positive cases were usually confirmed by PCR and counted only once.</p>
        <p id="Par72">The modelled curves are smoothed over intervals of approximately 7&#x2009;d using cubic splines, creating the possibility that later time points influence the period of investigation and cause a certain waviness of the <italic>R</italic><sub><italic>t</italic></sub> value pattern. An alternative parameterization using piecewise linear basis functions per week (that is, constant <italic>R</italic><sub><italic>t</italic></sub> values per week) leaves the overall conclusions and extracted parameters broadly unchanged.</p>
      </sec>
      <sec id="Sec24">
        <title>Ethical approval</title>
        <p id="Par73">This study was performed as part of surveillance for COVID-19 under the auspices of Section 251 of the National Health Service Act 2006. It therefore did not require individual patient consent or ethical approval. The COG-UK study protocol was approved by the Public Health England Research Ethics Governance Group.</p>
      </sec>
      <sec id="Sec25">
        <title>Reporting summary</title>
        <p id="Par74">Further information on research design is available in the&#xA0;<xref rid="MOESM2" ref-type="media">Nature Research Reporting Summary</xref> linked to this paper.</p>
      </sec>
    </sec>
    <sec id="Sec26" sec-type="materials|methods">
      <title>Online content</title>
      <p id="Par75">Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-021-04069-y.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41586_2021_4069_MOESM1_ESM.pdf"><label>Supplementary Notes</label><caption><p>Supplementary Notes 1&#x2013;3.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41586_2021_4069_MOESM2_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41586_2021_4069_MOESM3_ESM.pdf"><caption><p>Peer Review File</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41586_2021_4069_MOESM4_ESM.xlsx"><label>Supplementary Tables</label><caption><p>Supplementary Tables 1&#x2013;4.</p></caption></media></supplementary-material>
</p>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec27">
          <title>Extended data figures and tables</title>
          <p id="Par77">
<fig id="Fig6"><label>Extended Data Fig. 1</label><caption><title>SARS-CoV-2 surveillance sequencing in England between September 2020 and June 2021.</title><p><bold>a</bold>. Local monthly coverage across 315 LTLAs. <bold>b</bold>. Weekly coverage of genomic surveillance sequencing. <bold>c</bold>. Hospitalization, case and infection fatality rates relative to ONS prevalence. Dots denote mean estimates and error bars 95% CIs.</p></caption><graphic position="anchor" xlink:href="41586_2021_4069_Fig6_ESM" id="d32e11742"/></fig>
</p>
          <p id="Par78">
<fig id="Fig7"><label>Extended Data Fig. 2</label><caption><title>Genomic surveillance model of total incidence and lineage-specific frequencies.</title><p><bold>a</bold>. Cubic basis splines (top row) are convolved with the infection to test distribution (row 2 and 3) and used to fit the log incidence in a LTLA and its corresponding derivatives (growth rates; bottom row). <bold>b</bold>. Example incidence (top row), logarithmic incidence with individual convolved basis functions (dashed lines, row 2), growth rate with individual spline basis derivatives (dashed lines, row 3) and resulting (case) reproduction numbers (growth rate per 5.1d) from our approach (GenomicSurveillance) and estimates by EpiEstim<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>, shifted by 10d to approximate a case reproduction number. <bold>c</bold>. The relative frequencies of 62 different lineages are modelled using piecewise multinomial logistic regression. The linear logits are modelled to jump stochastically within 21d prior to first observation to account for the effects of new introductions. Shown are the logits of 5 selected lineages in two different LTLAs.</p></caption><graphic position="anchor" xlink:href="41586_2021_4069_Fig7_ESM" id="d32e11768"/></fig>
</p>
          <p id="Par79">
<fig id="Fig8"><label>Extended Data Fig. 3</label><caption><title>Genomic surveillance model selection.</title><p><bold>a</bold>. Model loss in terms of the ELBO objective function and the model hyperparameters alpha0 and alpha1 (see&#xA0;<xref rid="Sec10" ref-type="sec">Methods</xref>). <bold>b</bold>. Model deviance (calculated as &#x2212;2 x log pointwise predictive density) with respect to the model hyperparameters &#x3B1;<sub>0</sub>&#xA0;and &#x3B1;<sub>1</sub>&#xA0;(see&#xA0;<xref rid="Sec10" ref-type="sec">Methods</xref>). <bold>c</bold>. Mean squared error (MSE) of modelled weekly proportions of highly prevalent lineages with respect to the model parameters &#xA0;&#x3B1;<sub>0</sub>&#xA0;and &#xA0;&#x3B1;<sub>1</sub>&#xA0;(see&#xA0;<xref rid="Sec10" ref-type="sec">Methods</xref>). <bold>d</bold>. Same as in <bold>c</bold>, but for lineages exhibiting low frequencies (VOCs).</p></caption><graphic position="anchor" xlink:href="41586_2021_4069_Fig8_ESM" id="d32e11818"/></fig>
</p>
          <p id="Par80">
<fig id="Fig9"><label>Extended Data Fig. 4</label><caption><title>Spatiotemporal model of 71 SARS-CoV-2 lineages in 315 English LTLAs between September 2020 and June 2021.</title><p><bold>a</bold>. Regional lineage specific relative frequency of lineages contributing more than 50 genomes during the time period shown. Dots denote observed data, lines the fits aggregated to each region. <bold>b</bold>. Same as <bold>a</bold>, but on a log scale. <bold>c</bold>. Same data as in a, shown as stacked bar charts. Colours resemble major lineages as indicated and shadings thereof indicate sublineages. <bold>d</bold>. Same fits as in <bold>a</bold>, shown as stacked segments. <bold>e</bold>. Average growth rates for 71 SARS-Cov2 lineages estimated in different regions in England. Dots denote median estimates and error bars 95% CIs.</p></caption><graphic position="anchor" xlink:href="41586_2021_4069_Fig9_ESM" id="d32e11853"/></fig>
</p>
          <p id="Par81">
<fig id="Fig10"><label>Extended Data Fig. 5</label><caption><title>Relative growth of B.1.177.</title><p><bold>a</bold>. Lineage-specific relative frequency data in England, excluding B.1.1.7 and other VOCs/VUIs (Category Other includes: A, A.18, A.20, A.23, A.25, A.27, A.28, B, B.29, B.40, None). Colours resemble major lineages as indicated and shadings thereof indicate sublineages. <bold>b</bold>. Lineage-specific relative frequency data in Denmark, excluding B.1.1.7 and other VOCs/VUIs. Colours resemble major lineages as indicated and shadings thereof indicate sublineages.</p></caption><graphic position="anchor" xlink:href="41586_2021_4069_Fig10_ESM" id="d32e11872"/></fig>
</p>
          <p id="Par82">
<fig id="Fig11"><label>Extended Data Fig. 6</label><caption><title>Genomic diversity of the SARS-CoV-2 epidemic.</title><p>Shown is the entropy (blue), total number of observed Pango lineages (grey, divided by 4), as well as the proportion of B.1.1.7 (orange, right axis). The sweep of B.1.1.7 causes an intermittent decline of genomic diversity as measured by the entropy.</p></caption><graphic position="anchor" xlink:href="41586_2021_4069_Fig11_ESM" id="d32e11886"/></fig>
</p>
          <p id="Par83">
<fig id="Fig12"><label>Extended Data Fig. 7</label><caption><title>Global phylogenetic trees of selected VOCs/VUIs.</title><p>English surveillance and other (targeted and quarantine) samples are highlighted respectively orange and red.</p></caption><graphic position="anchor" xlink:href="41586_2021_4069_Fig12_ESM" id="d32e11900"/></fig>
</p>
          <p id="Par84">
<fig id="Fig13"><label>Extended Data Fig. 8</label><caption><title>Global phylogenetic trees of B.1.617 sublineages.</title><p><bold>a</bold>, <bold>b and c</bold>. English surveillance and other (targeted and quarantine) samples are highlighted respectively orange and red. The trees of B.1.617.1 and B.1.617.2 are rooted. <bold>d</bold>. Number of UK introductions inferred by parsimony (minimum and maximum numbers) and by Thorney BEAST (95% posterior CI) for each VOC.</p></caption><graphic position="anchor" xlink:href="41586_2021_4069_Fig13_ESM" id="d32e11922"/></fig>
</p>
        </sec>
        <sec id="Sec29">
          <title>Source data</title>
          <p id="Par86">
<media position="anchor" xlink:href="41586_2021_4069_MOESM5_ESM.xlsx" id="MOESM5"><caption><p>Source Data Fig. 1</p></caption></media>
<media position="anchor" xlink:href="41586_2021_4069_MOESM6_ESM.xlsx" id="MOESM6"><caption><p>Source Data Fig. 2</p></caption></media>
<media position="anchor" xlink:href="41586_2021_4069_MOESM7_ESM.xlsx" id="MOESM7"><caption><p>Source Data Fig. 3</p></caption></media>
<media position="anchor" xlink:href="41586_2021_4069_MOESM8_ESM.xlsx" id="MOESM8"><caption><p>Source Data Fig. 4</p></caption></media>
<media position="anchor" xlink:href="41586_2021_4069_MOESM9_ESM.xlsx" id="MOESM9"><caption><p>Source Data Fig. 5</p></caption></media>
</p>
        </sec>
      </app>
    </app-group>
    <fn-group>
      <fn>
        <p><bold>Peer review information</bold>
<italic>Nature</italic> thanks Tulio De Oliveira, Philippe Lemey and Matthew Scotch for their contribution to the peer review of this work. Peer reviewer reports are available.</p>
      </fn>
      <fn>
        <p><bold>Publisher&#x2019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>Lists of authors and their affiliations appear online</p>
      </fn>
      <fn>
        <p>
          <bold>Change history</bold>
        </p>
        <p>6/7/2022</p>
        <p>A Correction to this paper has been published: 10.1038/s41586-022-04887-8</p>
      </fn>
    </fn-group>
    <sec>
      <title>Extended data</title>
      <p>is available for this paper at 10.1038/s41586-021-04069-y.</p>
    </sec>
    <sec>
      <title>Supplementary information</title>
      <p>The online version contains supplementary material available at 10.1038/s41586-021-04069-y.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank E. Allara (Cambridge) and G. Whitton (Sanger) for providing outer postcodes to LTLA mappings; R. Beale for comments and J. McCrone for setting up Thorney Beast analysis; all of the contributors who submitted genome sequences to GISAID (acknowledgement tables for individual sequences are provided at GitHub; <ext-link ext-link-type="uri" xlink:href="https://github.com/NicolaDM/phylogeographySARS-CoV-2">https://github.com/NicolaDM/phylogeographySARS-CoV-2</ext-link>); and our colleagues at EMBL-EBI, the Wellcome Sanger Institute and COG-UK for discussions and comments on this manuscript. COG-UK is supported by funding from the Medical Research Council (MRC), part of UK Research &amp; Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. Additional sequence generation was funded by the Department of Health and Social Care. H.S.V., J.P.G. and M.G. are supported by a grant from the Department of Health and Social Care. A.W.J., E.B. and M.G. are beneficiaries from grant NNF17OC0027594 from the Novo Nordisk Foundation. E.V. is supported by Wellcome Trust grant 220885/Z/20/Z. T.S. is supported by grant 210918/Z/18/Z, and J.H. and S.F. by grant 210758/Z/18/Z from the Wellcome Trust. H.S.V., N.D.M., A.W.J., N.G., E.B. and M.G. are supported by EMBL.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>H.S.V. and M.G. developed the analysis code, which H.S.V. implemented with input from A.W.J.; H.S.V. created most of the figures. M.S. analysed, annotated and aggregated viral genome data. N.D.M. conducted phylogeographic analyses supervised by N.G.; T.S., R.G., M.S. and H.S.V. developed the interactive spatiotemporal viewer. T.N., F.S., I.H., R.A., C.A., S.G., D.J., I.J., C.S., J.S., T.S. and M.S. analysed genomic surveillance data under the supervision of D.K., M.C., I.M. and J.C.B.; J.H. and S.F. analysed ONS data and helped with epidemiological modelling and data interpretation. E.V. analysed growth rates and helped with data interpretation. E.B. and J.P.G. supervised H.S.V. and helped with data interpretation. J.C.B. and M.G. supervised the analysis with advice from I.M.; M.G., H.S.V., M.S., N.D.M., T.S., I.M. and J.C.B. wrote the manuscript with input from all of the co-authors.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>Open access funding provided by Deutsches Krebsforschungszentrum (DKFZ).</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>PCR test data are publicly available online (<ext-link ext-link-type="uri" xlink:href="https://coronavirus.data.gov.uk/">https://coronavirus.data.gov.uk/</ext-link>). A filtered, privacy conserving version of the lineage&#x2013;LTLA&#x2013;week dataset is publicly available online (<ext-link ext-link-type="uri" xlink:href="https://covid19.sanger.ac.uk/downloads">https://covid19.sanger.ac.uk/downloads</ext-link>) and enables strong reproduction of our results, despite a small number of cells having been suppressed to avoid disclosure. Full SARS-CoV-2 genome data and geolocations can be obtained under controlled access from <ext-link ext-link-type="uri" xlink:href="https://www.cogconsortium.uk/data/">https://www.cogconsortium.uk/data/</ext-link>. Application for full data access requires a description of the planned analysis and can be initiated at coguk_DataAccess@medschl.cam.ac.uk. The data and a version of the analysis with fewer lineages can be interactively explored at <ext-link ext-link-type="uri" xlink:href="https://covid19.sanger.ac.uk">https://covid19.sanger.ac.uk</ext-link>.&#xA0;<xref rid="Sec29" ref-type="sec">Source data</xref> are provided with this paper.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Code availability</title>
      <p>The genomic surveillance model is implemented in Python and available at GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/gerstung-lab/genomicsurveillance">https://github.com/gerstung-lab/genomicsurveillance</ext-link>) and as a PyPI package (genomicsurveillance).&#xA0;Specific code for the analyses of this study can be found as individual Google colab notebooks in the same repository. These were run using Python v.3.7.1 (packages: matplotlib (v.3.4.1), numpy (v.1.20.2), pandas (v.1.2.3), scikit-learn (v.0.19.1), scipy (v.1.6.2), seaborn (v.0.11.1), jax (v.0.2.8), genomicsurveillance (v.0.4.0), numpyro (v.0.4.0)). The phylogeographic analyses were performed using Thorney Beast (v.0.1.1) and <ext-link ext-link-type="uri" xlink:href="https://github.com/NicolaDM/phylogeographySARS-CoV-2">https://github.com/NicolaDM/phylogeographySARS-CoV-2</ext-link>. Code for the ONS infection survey analysis is available at GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/jhellewell14/ons_severity_estimates">https://github.com/jhellewell14/ons_severity_estimates</ext-link>).</p>
    </notes>
    <notes id="FPar1" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par76">E.B. is a paid consultant of Oxford Nanopore.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">Rambaut, A. <italic>Phylogenetic Analysis of nCoV-2019 Genomes</italic> (Virological, 2020); <ext-link ext-link-type="uri" xlink:href="https://virological.org/t/phylodynamic-analysis-176-genomes-6-mar-2020/356">https://virological.org/t/phylodynamic-analysis-176-genomes-6-mar-2020/356</ext-link></mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="other">Nextstrain Team <italic>Genomic Epidemiology of Novel Coronavirus&#x2014;Global Subsampling</italic> (Nextstrain, 2020); <ext-link ext-link-type="uri" xlink:href="https://nextstrain.org/ncov/global?l=clock">https://nextstrain.org/ncov/global?l=clock</ext-link></mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hadfield</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nextstrain: real-time tracking of pathogen evolution</article-title>
          <source>Bioinformatics</source>
          <year>2018</year>
          <volume>34</volume>
          <fpage>4121</fpage>
          <lpage>4123</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/bty407</pub-id>
          <pub-id pub-id-type="pmid">29790939</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volz</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity</article-title>
          <source>Cell</source>
          <year>2021</year>
          <volume>184</volume>
          <fpage>64</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2020.11.020</pub-id>
          <pub-id pub-id-type="pmid">33275900</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rambaut</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology</article-title>
          <source>Nat. Microbiol.</source>
          <year>2020</year>
          <volume>5</volume>
          <fpage>1403</fpage>
          <lpage>1407</lpage>
          <pub-id pub-id-type="doi">10.1038/s41564-020-0770-5</pub-id>
          <pub-id pub-id-type="pmid">32669681</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="other">O&#x2019;Toole, &#xC1;. et al. <italic>Global Report Investigating Novel Coronavirus Haplotypes</italic><ext-link ext-link-type="uri" xlink:href="https://cov-lineages.org/global_report.html">https://cov-lineages.org/global_report.html</ext-link> (2021).</mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hodcroft</surname>
              <given-names>EB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Spread of a SARS-CoV-2 variant through Europe in the summer of 2020</article-title>
          <source>Nature</source>
          <year>2021</year>
          <volume>595</volume>
          <fpage>707</fpage>
          <lpage>712</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-021-03677-y</pub-id>
          <pub-id pub-id-type="pmid">34098568</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="other">Tegally, H., Wilkinson, E., Lessells, R.J. et al. Sixteen novel lineages of SARS-CoV-2 in South Africa. <italic>Nat. Med.</italic><bold>27</bold>, 440&#x2013;446 (2021).</mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="other">Rambaut, A. et al. <italic>Preliminary Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in the UK Defined by a Novel Set of Spike Mutations</italic> (Virological, 2020); <ext-link ext-link-type="uri" xlink:href="https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563">https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563</ext-link></mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="other">Volz, E., Mishra, S., Chand, M. et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. <italic>Nature</italic><bold>593</bold>, 266&#x2013;269 (2021).</mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="other">Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. <italic>Science</italic><bold>372</bold>, eabg3055 (2021).</mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="other">O&#x2019;Toole, &#xC1;. et al. <italic>Tracking the International Spread of SARS-CoV-2 Lineages B.1.1.7 and B.1.351/501Y-V2</italic> (Virological, 2021); <ext-link ext-link-type="uri" xlink:href="https://virological.org/t/tracking-the-international-spread-of-sars-cov-2-lineages-b-1-1-7-and-b-1-351-501y-v2/592">https://virological.org/t/tracking-the-international-spread-of-sars-cov-2-lineages-b-1-1-7-and-b-1-351-501y-v2/592</ext-link></mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Washington</surname>
              <given-names>NL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States</article-title>
          <source>Cell</source>
          <year>2021</year>
          <volume>184</volume>
          <fpage>2587</fpage>
          <lpage>2594</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2021.03.052</pub-id>
          <pub-id pub-id-type="pmid">33861950</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="other">Faria, N. R. et al. <italic>Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in Manaus: Preliminary Findings</italic> (Virological, 2021); <ext-link ext-link-type="uri" xlink:href="https://www.icpcovid.com/sites/default/files/2021-01/Ep%20102-1%20Genomic%20characterisation%20of%20an%20emergent%20SARS-CoV-2%20lineage%20in%20Manaus%20Genomic%20Epidemiology%20-%20Virological.pdf">https://www.icpcovid.com/sites/default/files/2021-01/Ep%20102-1%20Genomic%20characterisation%20of%20an%20emergent%20SARS-CoV-2%20lineage%20in%20Manaus%20Genomic%20Epidemiology%20-%20Virological.pdf</ext-link></mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="other">Faria, N. R. et al. Genomics and Epidemiology of the P.1 SARS-CoV-2 Lineage in Manaus, Brazil. <italic>Science</italic><bold>372</bold>, 815&#x2013;21 (2021).</mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>du Plessis</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK</article-title>
          <source>Science</source>
          <year>2021</year>
          <volume>371</volume>
          <fpage>708</fpage>
          <lpage>712</lpage>
          <pub-id pub-id-type="doi">10.1126/science.abf2946</pub-id>
          <pub-id pub-id-type="pmid">33419936</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="other">Danish Covid-19 Genome Consortium <italic>Genomic Overview of SARS-CoV-2 in Denmark</italic> (2021); <ext-link ext-link-type="uri" xlink:href="https://www.covid19genomics.dk/statistics">https://www.covid19genomics.dk/statistics</ext-link></mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kraemer</surname>
              <given-names>MUG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence</article-title>
          <source>Science</source>
          <year>2021</year>
          <volume>373</volume>
          <fpage>889</fpage>
          <lpage>895</lpage>
          <pub-id pub-id-type="doi">10.1126/science.abj0113</pub-id>
          <pub-id pub-id-type="pmid">34301854</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="other">Park, S. W. et al Roles of generation-interval distributions in shaping relative epidemic strength, speed, and control of new SARS-CoV-2 variants. Preprint at <italic>medRxiv</italic>10.1101/2021.05.03.21256545 (2021).</mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Starr</surname>
              <given-names>TN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding</article-title>
          <source>Cell</source>
          <year>2020</year>
          <volume>182</volume>
          <fpage>1295</fpage>
          <lpage>1310</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2020.08.012</pub-id>
          <pub-id pub-id-type="pmid">32841599</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="other">Zahradn&#xED;k, J., Marciano, S., Shemesh, M. et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. <italic>Nat. Microbiol.</italic><bold>6</bold>, 1188&#x2013;1198 (2021).</mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <mixed-citation publication-type="other">Brown, J. C. et al. Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape. Preprint at <italic>bioRxiv</italic>10.1101/2021.02.24.432576 (2021).</mixed-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="other">V&#xF6;hringer, H. et al. <italic>Lineage-specific Growth of SARS-CoV-2 B.1.1.7 During the English National Lockdown</italic> (Virological, 2020); <ext-link ext-link-type="uri" xlink:href="https://virological.org/t/lineage-specific-growth-of-sars-cov-2-b-1-1-7-during-the-english-national-lockdown/575/2">https://virological.org/t/lineage-specific-growth-of-sars-cov-2-b-1-1-7-during-the-english-national-lockdown/575/2</ext-link></mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="other">The Health Protection (Coronavirus, Restrictions) (All Tiers) (England) Regulations 2020. <italic>Wikipedia</italic><ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/w/index.php?title=The_Health_Protection_(Coronavirus,_Restrictions)_(All_Tiers)_(England)_Regulations_2020&amp;oldid=1014831173">https://en.wikipedia.org/w/index.php?title=The_Health_Protection_(Coronavirus,_Restrictions)_(All_Tiers)_(England)_Regulations_2020&amp;oldid=1014831173</ext-link> (2021).</mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <mixed-citation publication-type="other">Steel, K. &amp; Davies, B. <italic>Coronavirus (COVID-19) Infection Survey, Antibody and Vaccination Data for the UK</italic> (ONS, 2021); <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveyantibodydatafortheuk/28april2021">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveyantibodydatafortheuk/28april2021</ext-link></mixed-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <mixed-citation publication-type="other">Greaney, A. J. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. <italic>Cell Host &amp; Microbe</italic><bold>29</bold>, 463-476 (2021).</mixed-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greaney</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition</article-title>
          <source>Cell Host Microbe</source>
          <year>2021</year>
          <volume>29</volume>
          <fpage>44</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chom.2020.11.007</pub-id>
          <pub-id pub-id-type="pmid">33259788</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera</article-title>
          <source>Cell</source>
          <year>2021</year>
          <volume>184</volume>
          <fpage>2348</fpage>
          <lpage>2361</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2021.02.037</pub-id>
          <pub-id pub-id-type="pmid">33730597</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Planas</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies</article-title>
          <source>Nat. Med.</source>
          <year>2021</year>
          <volume>27</volume>
          <fpage>917</fpage>
          <lpage>924</lpage>
          <pub-id pub-id-type="doi">10.1038/s41591-021-01318-5</pub-id>
          <pub-id pub-id-type="pmid">33772244</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="other">Peacock, T. P. et al. The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin. Preprint at <italic>bioRxiv</italic>10.1101/2021.05.28.446163 (2021).</mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campbell</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021</article-title>
          <source>Euro Surveill.</source>
          <year>2021</year>
          <volume>26</volume>
          <fpage>2100509</fpage>
          <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2021.26.24.2100509</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <mixed-citation publication-type="other"><italic>Investigation of Novel SARS-CoV-2 Variants of Concern</italic> Technical briefing 10 (Public Health England, 2021); <ext-link ext-link-type="uri" xlink:href="https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201">https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201</ext-link></mixed-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <mixed-citation publication-type="other">Li, B. et al. Viral infection and transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant. Preprint at <italic>medRxiv</italic>10.1101/2021.07.07.21260122 (2021).</mixed-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <mixed-citation publication-type="other">Nasreen, S. et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. Preprint at <italic>medRxiv</italic>10.1101/2021.06.28.21259420 (2021).</mixed-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopez Bernal</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant</article-title>
          <source>N. Engl. J. Med.</source>
          <year>2021</year>
          <volume>385</volume>
          <fpage>585</fpage>
          <lpage>594</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa2108891</pub-id>
          <pub-id pub-id-type="pmid">34289274</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <mixed-citation publication-type="other"><italic>Investigation of Novel SARS-CoV-2 Variants of Concern</italic> Technical briefing 19 (Public Health England, 2021); <ext-link ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1005517/Technical_Briefing_19.pdf">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1005517/Technical_Briefing_19.pdf</ext-link></mixed-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <mixed-citation publication-type="other">Ferreira, I. et al. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. Preprint at <italic>bioRxiv</italic>10.1101/2021.05.08.443253 (2021).</mixed-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wall</surname>
              <given-names>EC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination</article-title>
          <source>Lancet</source>
          <year>2021</year>
          <volume>397</volume>
          <fpage>2331</fpage>
          <lpage>2333</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(21)01290-3</pub-id>
          <pub-id pub-id-type="pmid">34090624</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <mixed-citation publication-type="other">Steel, K. &amp; Haughton, P. <italic>Coronavirus (COVID-19) Infection Survey, Antibody and Vaccination Data, UK</italic> (ONS, 2021); <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyantibodyandvaccinationdatafortheuk/21july2021">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyantibodyandvaccinationdatafortheuk/21july2021</ext-link></mixed-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <mixed-citation publication-type="other">Anderson, R. et al. <italic>Reproduction Number (R) and Growth Rate (r) of the COVID-19 Epidemic in the UK: Methods of Estimation, Data Sources, Causes of Heterogeneity, and use as a Guide in Policy Formulation</italic> (The Royal Society, 2020).</mixed-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Britton</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ball</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Trapman</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2</article-title>
          <source>Science</source>
          <year>2020</year>
          <volume>369</volume>
          <fpage>846</fpage>
          <lpage>849</lpage>
          <pub-id pub-id-type="doi">10.1126/science.abc6810</pub-id>
          <pub-id pub-id-type="pmid">32576668</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Funk</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination</article-title>
          <source>BMC Med.</source>
          <year>2019</year>
          <volume>17</volume>
          <fpage>180</fpage>
          <pub-id pub-id-type="doi">10.1186/s12916-019-1413-7</pub-id>
          <pub-id pub-id-type="pmid">31551070</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hodgson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Flasche</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kucharski</surname>
              <given-names>AJ</given-names>
            </name>
            <collab>CMMID COVID-19 Working Group</collab>
          </person-group>
          <article-title>The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant</article-title>
          <source>Euro Surveill.</source>
          <year>2021</year>
          <volume>26</volume>
          <fpage>2100428</fpage>
          <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2021.26.20.2100428</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Dorp</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Houldcroft</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Richard</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Balloux</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>COVID-19, the first pandemic in the post-genomic era</article-title>
          <source>Curr. Opin. Virol.</source>
          <year>2021</year>
          <volume>50</volume>
          <fpage>40</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1016/j.coviro.2021.07.002</pub-id>
          <pub-id pub-id-type="pmid">34352474</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <mixed-citation publication-type="other"> The Health Protection (Coronavirus, Restrictions) (England) (No. 4) Regulations 2020. <italic>Wikipedia</italic><ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/w/index.php?title=The_Health_Protection_(Coronavirus,_Restrictions)_(England)_(No._4)_Regulations_2020&amp;oldid=1014701607">https://en.wikipedia.org/w/index.php?title=The_Health_Protection_(Coronavirus,_Restrictions)_(England)_(No._4)_Regulations_2020&amp;oldid=1014701607</ext-link> (2021).</mixed-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bi</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study</article-title>
          <source>Lancet Infect. Dis.</source>
          <year>2020</year>
          <volume>20</volume>
          <fpage>911</fpage>
          <lpage>919</lpage>
          <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30287-5</pub-id>
          <pub-id pub-id-type="pmid">32353347</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallinga</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lipsitch</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>How generation intervals shape the relationship between growth rates and reproductive numbers</article-title>
          <source>Proc. Biol. Sci.</source>
          <year>2007</year>
          <volume>274</volume>
          <fpage>599</fpage>
          <lpage>604</lpage>
          <pub-id pub-id-type="pmid">17476782</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cori</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ferguson</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cauchemez</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A new framework and software to estimate time-varying reproduction numbers during epidemics</article-title>
          <source>Am. J. Epidemiol.</source>
          <year>2013</year>
          <volume>178</volume>
          <fpage>1505</fpage>
          <lpage>1512</lpage>
          <pub-id pub-id-type="doi">10.1093/aje/kwt133</pub-id>
          <pub-id pub-id-type="pmid">24043437</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <mixed-citation publication-type="other">Bingham, E. et al. Pyro: deep universal probabilistic programming. Preprint at <ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/1810.09538">http://arxiv.org/abs/1810.09538</ext-link> (2018).</mixed-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <mixed-citation publication-type="other">Phan, D., Pradhan, N. &amp; Jankowiak, M. Composable effects for flexible and accelerated probabilistic programming in NumPyro. Preprint at <ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/1912.11554">http://arxiv.org/abs/1912.11554</ext-link> (2019).</mixed-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoffman</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Blei</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Paisley</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Stochastic variational inference</article-title>
          <source>J. Mach. Learn. Res.</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>1303</fpage>
          <lpage>1347</lpage>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Price</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Dehal</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Arkin</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
          <article-title>FastTree 2&#x2014;approximately maximum-likelihood trees for large alignments</article-title>
          <source>PLoS ONE</source>
          <year>2010</year>
          <volume>5</volume>
          <fpage>e9490</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0009490</pub-id>
          <pub-id pub-id-type="pmid">20224823</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tavar&#xE9;</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Some probabilistic and statistical problems in the analysis of DNA sequences</article-title>
          <source>Lect. Math. Life Sci.</source>
          <year>1986</year>
          <volume>17</volume>
          <fpage>57</fpage>
          <lpage>86</lpage>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lemey</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rambaut</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Drummond</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Suchard</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Bayesian phylogeography finds its roots</article-title>
          <source>PLoS Comput. Biol.</source>
          <year>2009</year>
          <volume>5</volume>
          <fpage>e1000520</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pcbi.1000520</pub-id>
          <pub-id pub-id-type="pmid">19779555</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Maio</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>C-H</given-names>
            </name>
            <name>
              <surname>O&#x2019;Reilly</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>New routes to phylogeography: a bayesian structured coalescent approximation</article-title>
          <source>PLoS Genet.</source>
          <year>2015</year>
          <volume>11</volume>
          <fpage>e1005421</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pgen.1005421</pub-id>
          <pub-id pub-id-type="pmid">26267488</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turakhia</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ultrafast Sample placement on Existing tRees (UShER) enables real-time phylogenetics for the SARS-CoV-2 pandemic</article-title>
          <source>Nat. Genet.</source>
          <year>2021</year>
          <volume>53</volume>
          <fpage>809</fpage>
          <lpage>816</lpage>
          <pub-id pub-id-type="doi">10.1038/s41588-021-00862-7</pub-id>
          <pub-id pub-id-type="pmid">33972780</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sagulenko</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Puller</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Neher</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>TreeTime: maximum-likelihood phylodynamic analysis</article-title>
          <source>Virus Evol.</source>
          <year>2018</year>
          <volume>4</volume>
          <fpage>vex042</fpage>
          <pub-id pub-id-type="doi">10.1093/ve/vex042</pub-id>
          <pub-id pub-id-type="pmid">29340210</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gill</surname>
              <given-names>MS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Improving Bayesian population dynamics inference: a coalescent-based model for multiple loci</article-title>
          <source>Mol. Biol. Evol.</source>
          <year>2013</year>
          <volume>30</volume>
          <fpage>713</fpage>
          <lpage>724</lpage>
          <pub-id pub-id-type="doi">10.1093/molbev/mss265</pub-id>
          <pub-id pub-id-type="pmid">23180580</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <mixed-citation publication-type="other">Sherratt, K. et al. Exploring surveillance data biases when estimating the reproduction number: with insights into subpopulation transmission of COVID-19 in England. <italic>Philos. Trans. Royal Soc. B</italic><bold>376</bold>10.1098/RSTB.2020.0283 (2021).</mixed-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abbott</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Estimating the time-varying reproduction number of SARS-CoV-2 using national and subnational case counts</article-title>
          <source>Wellcome Open Res.</source>
          <year>2020</year>
          <volume>5</volume>
          <fpage>112</fpage>
          <pub-id pub-id-type="doi">10.12688/wellcomeopenres.16006.1</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hellewell</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections</article-title>
          <source>BMC Med.</source>
          <year>2021</year>
          <volume>19</volume>
          <fpage>106</fpage>
          <pub-id pub-id-type="doi">10.1186/s12916-021-01982-x</pub-id>
          <pub-id pub-id-type="pmid">33902581</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <mixed-citation publication-type="other">Hart, W. S. et al. Inference of SARS-CoV-2 generation times using UK household data. Preprint at <italic>medRxiv</italic>10.1101/2021.05.27.21257936 (2021).</mixed-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pouwels</surname>
              <given-names>KB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey</article-title>
          <source>Lancet Publ. Health</source>
          <year>2021</year>
          <volume>6</volume>
          <fpage>e30</fpage>
          <lpage>e38</lpage>
          <pub-id pub-id-type="doi">10.1016/S2468-2667(20)30282-6</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <mixed-citation publication-type="other">Donnarumma, K. S. <italic>Coronavirus (COVID-19) Infection Survey, UK</italic> (ONS, 2021); <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/23april2021">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/23april2021</ext-link></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">6011</journal-id>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33299182</article-id>
      <article-id pub-id-type="pmc">8110206</article-id>
      <article-id pub-id-type="doi">10.1038/s41586-020-3032-z</article-id>
      <article-id pub-id-type="manuscript">NIHMS1684558</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>H1 histones control the epigenetic landscape by local chromatin compaction</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Willcockson</surname>
            <given-names>Michael A.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Healton</surname>
            <given-names>Sean E.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Weiss</surname>
            <given-names>Cary N.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bartholdy</surname>
            <given-names>Boris A.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Botbol</surname>
            <given-names>Yair</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mishra</surname>
            <given-names>Laxmi N.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sidhwani</surname>
            <given-names>Dhruv S.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wilson</surname>
            <given-names>Tommy J.</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinto</surname>
            <given-names>Hugo B.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maron</surname>
            <given-names>Maxim I.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Skalina</surname>
            <given-names>Karin A.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Toro</surname>
            <given-names>Laura Norwood</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>Jie</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Chul-Hwan</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
          <xref ref-type="aff" rid="A6">6</xref>
          <xref ref-type="aff" rid="A15">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hou</surname>
            <given-names>Harry</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yusufova</surname>
            <given-names>Nevin</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meydan</surname>
            <given-names>Cem</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Osunsade</surname>
            <given-names>Adewola</given-names>
          </name>
          <xref ref-type="aff" rid="A10">10</xref>
          <xref ref-type="aff" rid="A11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>David</surname>
            <given-names>Yael</given-names>
          </name>
          <xref ref-type="aff" rid="A10">10</xref>
          <xref ref-type="aff" rid="A11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cesarman</surname>
            <given-names>Ethel</given-names>
          </name>
          <xref ref-type="aff" rid="A12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Melnick</surname>
            <given-names>Ari M.</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sidoli</surname>
            <given-names>Simone</given-names>
          </name>
          <xref ref-type="aff" rid="A13">13</xref>
          <xref ref-type="aff" rid="A16">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garcia</surname>
            <given-names>Benjamin A.</given-names>
          </name>
          <xref ref-type="aff" rid="A13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Edelmann</surname>
            <given-names>Winfried</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Macian</surname>
            <given-names>Fernando</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Skoultchi</surname>
            <given-names>Arthur I.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="CR1" ref-type="corresp">&#x2709;</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Cell Biology, Albert Einstein College of Medicine, New York, NY, USA</aff>
      <aff id="A2"><label>2</label>Department of Pathology, Albert Einstein College of Medicine, New York, NY, USA</aff>
      <aff id="A3"><label>3</label>Department of Neurology, Columbia University College of Physicians and Surgeons, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, USA</aff>
      <aff id="A4"><label>4</label>Department of Biochemistry, Albert Einstein College of Medicine, New York, NY, USA</aff>
      <aff id="A5"><label>5</label>Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY, USA</aff>
      <aff id="A6"><label>6</label>Howard Hughes Medical Institute, Chevy Chase, MD, USA</aff>
      <aff id="A7"><label>7</label>Cell &amp; Molecular Biology Graduate Program, Weill Cornell Medicine, New York, NY, USA</aff>
      <aff id="A8"><label>8</label>Division of Hematology/Oncology, Department of Medicine, Biochemistry, Weill Cornell Medicine, New York, NY, USA</aff>
      <aff id="A9"><label>9</label>Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA</aff>
      <aff id="A10"><label>10</label>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
      <aff id="A11"><label>11</label>Tri-Institutional PhD Program in Chemical Biology, New York, NY, USA</aff>
      <aff id="A12"><label>12</label>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA</aff>
      <aff id="A13"><label>13</label>Department of Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Smilow Center for Translational Research, Philadelphia, PA, USA</aff>
      <aff id="A14"><label>14</label>Present address: Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA</aff>
      <aff id="A15"><label>15</label>Present address: Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea</aff>
      <aff id="A16"><label>16</label>Present address: Department of Biochemistry, Albert Einstein College of Medicine, New York, NY, USA</aff>
      <aff id="A17"><label>17</label>These authors contributed equally: Michael A. Willcockson, Sean E. Healton, Cary N. Weiss, Boris A. Bartholdy</aff>
      <author-notes>
        <fn fn-type="con" id="FN1">
          <p id="P1"><bold>Author contributions</bold> S.E.H., C.N.W., M.A.W., B.A.B. and A.I.S. conceived of and designed the study. S.E.H., C.N.W., B.A.B. and M.A.W. performed the experiments. Y.B. performed transplantation and in vivo proliferation experiments, analysed T cell populations and performed ELISAs. L.N.M. performed immunoblots, in vitro chromatin reconstitution, histone methyltransferase assays and sucrose gradient fractionations. D.S.S. analysed CAGE data and performed histone extractions from mouse tissues. M.I.M. performed in vitro interaction assays. K.A.S. analysed T cell progenitors. H.B.P. performed cell cycle analysis. N.Y. and C.M. performed Hi-C experiments. A.M.M. and E.C. supervised N.Y. and provided expert advice. C.-H.L. provided purified PRC2&#x2013;AEBP2 complex. A.O. and Y.D. provided purified mutant and wild-type H1.2 protein for use in histone methyltransferase assays. T.J.W. designed the NRLfinder tool. J.Z., L.N.T., H.H. and W.E. helped generate the H1cTKO mouse strain and J.Z. supervised the mouse colony. F.M. provided expert advice regarding T cell biology and experimentation. B.A.G. and S.S. performed mass spectrometry and helped analyse the mass spectrometry data. B.A.B. and M.A.W. performed computational analyses. S.E.H., C.N.W., M.A.W. and A.I.S. wrote the manuscript.</p>
        </fn>
        <corresp id="CR1"><label>&#x2709;</label><bold>Correspondence and requests for materials</bold> should be addressed to A.I.S., <email>arthur.skoultchi@einsteinmed.org</email></corresp>
        <fn fn-type="COI-statement" id="FN4">
          <p id="P72"><bold>Competing interests</bold> The authors declare no competing interests.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>5</day>
        <month>5</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>09</day>
        <month>12</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>01</day>
        <month>7</month>
        <year>2021</year>
      </pub-date>
      <volume>589</volume>
      <issue>7841</issue>
      <fpage>293</fpage>
      <lpage>298</lpage>
      <!--elocation-id from pubmed: 10.1038/s41586-020-3032-z-->
      <permissions>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://www.nature.com/reprints</ali:license_ref>
          <license-p><bold>Reprints and permissions information</bold> is available at <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/reprints">http://www.nature.com/reprints</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="ABS1">
        <p id="P2">H1 linker histones are the most abundant chromatin-binding proteins<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. In vitro studies indicate that their association with chromatin determines nucleosome spacing and enables arrays of nucleosomes to fold into more compact chromatin structures. However, the in vivo roles of H1 are poorly understood<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. Here we show that the local density of H1 controls the balance of repressive and active chromatin domains by promoting genomic compaction. We generated a conditional triple-H1-knockout mouse strain and depleted H1 in haematopoietic cells. H1 depletion in T cells leads to de-repression of T cell activation genes, a process that mimics normal T cell activation. Comparison of chromatin structure in normal and H1-depleted CD8<sup>+</sup> T cells reveals that H1-mediated chromatin compaction occurs primarily in regions of the genome containing higher than average levels of H1: the chromosome conformation capture (Hi-C) B compartment and regions of the Hi-C A compartment marked by PRC2. Reduction of H1 stoichiometry leads to decreased H3K27 methylation, increased H3K36 methylation, B-to-A-compartment shifting and an increase in interaction frequency between compartments. In vitro, H1 promotes PRC2-mediated H3K27 methylation and inhibits NSD2-mediated H3K36 methylation. Mechanistically, H1 mediates these opposite effects by promoting physical compaction of the chromatin substrate. Our results establish H1 as a critical regulator of gene silencing through localized control of chromatin compaction, 3D genome organization and the epigenetic landscape.</p>
      </abstract>
    </article-meta>
  </front>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <?properties manuscript?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">6011</journal-id>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">35545674</article-id>
      <article-id pub-id-type="pmc">9377328</article-id>
      <article-id pub-id-type="doi">10.1038/s41586-022-04722-0</article-id>
      <article-id pub-id-type="manuscript">NIHMS1823962</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Iram</surname>
            <given-names>Tal</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="CR1" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kern</surname>
            <given-names>Fabian</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kaur</surname>
            <given-names>Achint</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Myneni</surname>
            <given-names>Saket</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Morningstar</surname>
            <given-names>Allison R.</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shin</surname>
            <given-names>Heather</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garcia</surname>
            <given-names>Miguel A.</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yerra</surname>
            <given-names>Lakshmi</given-names>
          </name>
          <xref rid="A6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Palovics</surname>
            <given-names>Robert</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Andrew C.</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hahn</surname>
            <given-names>Oliver</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>Nannan</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shuken</surname>
            <given-names>Steven R.</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Haney</surname>
            <given-names>Michael s.</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lehallier</surname>
            <given-names>Benoit</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Iyer</surname>
            <given-names>Manasi</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>Jian</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zetterberg</surname>
            <given-names>Henrik</given-names>
          </name>
          <xref rid="A8" ref-type="aff">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Keller</surname>
            <given-names>Andreas</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A9" ref-type="aff">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zuchero</surname>
            <given-names>J. Bradley</given-names>
          </name>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wyss-Coray</surname>
            <given-names>Tony</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A10" ref-type="aff">10</xref>
          <xref rid="CR1" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</aff>
      <aff id="A2"><label>2</label>Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, California, USA</aff>
      <aff id="A3"><label>3</label>Chair for Clinical Bioinformatics, Saarland University, 66123 Saarbr&#xFC;cken, Germany.</aff>
      <aff id="A4"><label>4</label>Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Saarland University Campus E8.1, Saarbr&#xFC;cken, Germany.</aff>
      <aff id="A5"><label>5</label>Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA 94305, USA.</aff>
      <aff id="A6"><label>6</label>Palo Alto Veterans Institute for Research, Palo Alto, CA 94304</aff>
      <aff id="A7"><label>7</label>Department of Chemistry, Stanford University, Stanford, CA, USA</aff>
      <aff id="A8"><label>8</label>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xF6;lndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xF6;lndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK</aff>
      <aff id="A9"><label>9</label>Center for Bioinformatics, Saarland Informatics Campus, 66123 Saarbr&#xFC;cken, Germany.</aff>
      <aff id="A10"><label>10</label>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, California, USA.</aff>
      <author-notes>
        <fn fn-type="con" id="FN1">
          <p id="P1"><bold>Author contributions:</bold> T.I. and T.W.-C. conceptualized the study. T.I. performed all surgical procedures. A.Ka., S.M., H.S and T.I. performed and analyzed histology and cell culture experiments. A.Ka., L.Y., J.L. and T.I. designed and performed behavior experiments. S.M. performed SLAMseq experiments which were designed and analyzed by F.K. and T.I. A.R.M. and T.I. performed nuclei sorting and RNAseq experiments with guidance from N.L. and O.H. F.K. and T.I. analyzed the datasets. M.A.G. isolated mouse SRF-floxed OPCs and M.I. and M.S.H. assisted with cell culture experiments. A.C.Y., A.R.M., and T.I. preformed labeled CSF and Fgf17 experiments. S.R.S. assisted with CSF collection. R.P. and B.L. assisted with bioinformatic analysis. H.Z. provided human CSF samples. T.I. wrote the manuscript with input from all authors, T.I. and F.K. designed manuscript figures, J.B.Z. and T.W.-C. edited the manuscript. A.Ke., J.B.Z. and T.W.-C. supervised the work.</p>
        </fn>
        <corresp id="CR1"><label>*</label>Correspondence to <email>twc@stanford.edu</email> or <email>tal.iram@stanford.edu</email></corresp>
        <fn fn-type="COI-statement" id="FN2">
          <p id="P130"><bold>Competing interests:</bold> T.W.-C. and T.I. are co-inventors on a patent application related to the work published in this paper (STDU2-39617.101, S21-153 - METHODS AND COMPOSITIONS FOR IMPROVED MEMORY IN THE AGING). HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>6</day>
        <month>8</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>5</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>11</day>
        <month>11</month>
        <year>2022</year>
      </pub-date>
      <volume>605</volume>
      <issue>7910</issue>
      <fpage>509</fpage>
      <lpage>515</lpage>
      <abstract id="ABS1">
        <p id="P2">Recent understanding of how the systemic environment shapes the brain throughout life has led to numerous intervention strategies to slow brain ageing <sup><xref rid="R1" ref-type="bibr">1</xref>&#x2013;<xref rid="R3" ref-type="bibr">3</xref></sup>. Cerebrospinal fluid (CSF) makes up the immediate environment of brain cells providing them with nourishing compounds <sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup>. We discovered that infusing young CSF directly into aged brains improves memory function. Unbiased transcriptome analysis of the hippocampus identified oligodendrocytes to be most responsive to this rejuvenated CSF environment. We further revealed that young CSF boosts oligodendrocyte progenitor cell (OPC) proliferation and differentiation in the aged hippocampus and in primary OPC cultures. Using SLAMseq to metabolically label nascent mRNA, we identified serum response factor (SRF), a transcription factor that drives actin cytoskeleton rearrangement, as a mediator of OPC proliferation following young CSF exposure. With age, SRF expression decreases in hippocampal OPCs, and the pathway is induced by acute young CSF injection. We screened for potential SRF activators in CSF and found that fibroblast growth factor 17 (Fgf17) infusion is sufficient to induce OPC proliferation and long-term memory consolidation in aged mice while Fgf17 blockade impairs cognition in young mice. These findings demonstrate the rejuvenating power of young CSF and identify Fgf17 as a key target to restore oligodendrocyte function in the ageing brain.</p>
      </abstract>
    </article-meta>
  </front>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">35523247</article-id>
      <article-id pub-id-type="pmc">9279144</article-id>
      <article-id pub-id-type="publisher-id">4830</article-id>
      <article-id pub-id-type="doi">10.1038/s41586-022-04830-x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Omicron infection enhances Delta antibody immunity in vaccinated persons</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7565-7400</contrib-id>
          <name>
            <surname>Khan</surname>
            <given-names>Khadija</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Karim</surname>
            <given-names>Farina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cele</surname>
            <given-names>Sandile</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reedoy</surname>
            <given-names>Kajal</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5736-664X</contrib-id>
          <name>
            <surname>San</surname>
            <given-names>James Emmanuel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lustig</surname>
            <given-names>Gila</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tegally</surname>
            <given-names>Houriiyah</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6681-8329</contrib-id>
          <name>
            <surname>Rosenberg</surname>
            <given-names>Yuval</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bernstein</surname>
            <given-names>Mallory</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jule</surname>
            <given-names>Zesuliwe</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ganga</surname>
            <given-names>Yashica</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ngcobo</surname>
            <given-names>Nokuthula</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mazibuko</surname>
            <given-names>Matilda</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mthabela</surname>
            <given-names>Ntombifuthi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mhlane</surname>
            <given-names>Zoey</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mbatha</surname>
            <given-names>Nikiwe</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miya</surname>
            <given-names>Yoliswa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Giandhari</surname>
            <given-names>Jennifer</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ramphal</surname>
            <given-names>Yajna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Naidoo</surname>
            <given-names>Taryn</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sivro</surname>
            <given-names>Aida</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Samsunder</surname>
            <given-names>Natasha</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kharsany</surname>
            <given-names>Ayesha B. M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Amoako</surname>
            <given-names>Daniel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bhiman</surname>
            <given-names>Jinal N.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manickchund</surname>
            <given-names>Nithendra</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abdool Karim</surname>
            <given-names>Quarraisha</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Magula</surname>
            <given-names>Nombulelo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abdool Karim</surname>
            <given-names>Salim S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gray</surname>
            <given-names>Glenda</given-names>
          </name>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hanekom</surname>
            <given-names>Willem</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0243-7455</contrib-id>
          <name>
            <surname>von Gottberg</surname>
            <given-names>Anne</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
          <xref ref-type="aff" rid="Aff14">14</xref>
        </contrib>
        <contrib contrib-type="author" id="IAu1">
          <collab>COMMIT-KZN Team<contrib-group><contrib contrib-type="author"><name><surname>Harrichandparsad</surname><given-names>Rohen</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Herbst</surname><given-names>Kobus</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Jeena</surname><given-names>Prakash</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Khoza</surname><given-names>Thandeka</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kl&#xF8;verpris</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Leslie</surname><given-names>Alasdair</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Madansein</surname><given-names>Rajhmun</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Marakalala</surname><given-names>Mohlopheni</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Moshabela</surname><given-names>Mosa</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Naidoo</surname><given-names>Kogie</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ndhlovu</surname><given-names>Zaza</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name><surname>Ndung&#x2019;u</surname><given-names>Thumbi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff18">18</xref><xref ref-type="aff" rid="Aff25">25</xref><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Nyamande</surname><given-names>Kennedy</given-names></name><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Vinod</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name><surname>Smit</surname><given-names>Theresa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Steyn</surname><given-names>Adrie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff29">29</xref></contrib></contrib-group></collab>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1641-2299</contrib-id>
          <name>
            <surname>Milo</surname>
            <given-names>Ron</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6336-7489</contrib-id>
          <name>
            <surname>Gosnell</surname>
            <given-names>Bernadett I.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0926-710X</contrib-id>
          <name>
            <surname>Lessells</surname>
            <given-names>Richard J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8719-4028</contrib-id>
          <name>
            <surname>Moore</surname>
            <given-names>Penny L.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff8">8</xref>
          <xref ref-type="aff" rid="Aff15">15</xref>
          <xref ref-type="aff" rid="Aff16">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Oliveira</surname>
            <given-names>Tulio</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
          <xref ref-type="aff" rid="Aff17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6191-4023</contrib-id>
          <name>
            <surname>Moosa</surname>
            <given-names>Mahomed-Yunus S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8571-2004</contrib-id>
          <name>
            <surname>Sigal</surname>
            <given-names>Alex</given-names>
          </name>
          <address>
            <email>alex.sigal@ahri.org</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff18">18</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.488675.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 8337 9561</institution-id><institution>Africa Health Research Institute, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>School of Laboratory Medicine and Medical Sciences, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff3"><label>3</label>KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.428428.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 5938 4248</institution-id><institution>Centre for the AIDS Programme of Research in South Africa, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.11956.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2214 904X</institution-id><institution>Centre for Epidemic Response and Innovation, </institution><institution>School of Data Science and Computational Thinking, Stellenbosch University, </institution></institution-wrap>Stellenbosch, South Africa </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.13992.30</institution-id><institution-id institution-id-type="ISNI">0000 0004 0604 7563</institution-id><institution>Department of Plant and Environmental Sciences, </institution><institution>Weizmann Institute of Science, </institution></institution-wrap>Rehovot, Israel </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>Department of Medical Microbiology, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.416657.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0630 4574</institution-id><institution>National Institute for Communicable Diseases of the National Health Laboratory Service, </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.21729.3f</institution-id><institution-id institution-id-type="ISNI">0000000419368729</institution-id><institution>Department of Epidemiology, Mailman School of Public Health, </institution><institution>Columbia University, </institution></institution-wrap>New York, NY USA </aff>
        <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>Department of Internal Medicine, Nelson R. Mandela School of Medicine, </institution><institution>University of Kwa-Zulu Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.415021.3</institution-id><institution-id institution-id-type="ISNI">0000 0000 9155 0024</institution-id><institution>South African Medical Research Council, </institution></institution-wrap>Cape Town, South Africa </aff>
        <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>Division of Infection and Immunity, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>School of Pathology, Faculty of Health Sciences, </institution><institution>University of Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>SAMRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, </institution><institution>University of the Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.7836.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1151</institution-id><institution>Institute of Infectious Disease and Molecular Medicine, </institution><institution>University of Cape Town, </institution></institution-wrap>Cape Town, South Africa </aff>
        <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution>Department of Global Health, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA USA </aff>
        <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.418159.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0491 2699</institution-id><institution>Max Planck Institute for Infection Biology, </institution></institution-wrap>Berlin, Germany </aff>
        <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>Department of Neurosurgery, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff20"><label>20</label>South African Population Research Infrastructure Network, Durban, South Africa </aff>
        <aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>Department of Paediatrics and Child Health, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="GRID">grid.5254.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0674 042X</institution-id><institution>Department of Immunology and Microbiology, </institution><institution>University of Copenhagen, </institution></institution-wrap>Copenhagen, Denmark </aff>
        <aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>Department of Cardiothoracic Surgery, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>College of Health Sciences, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="GRID">grid.461656.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0489 3491</institution-id><institution>Ragon Institute of MGH, MIT and Harvard, </institution></institution-wrap>Boston, MA USA </aff>
        <aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>Department of Pulmonology and Critical Care, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>Department of Neurology, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="GRID">grid.265892.2</institution-id><institution-id institution-id-type="ISNI">0000000106344187</institution-id><institution>Division of Infectious Diseases, </institution><institution>University of Alabama at Birmingham, </institution></institution-wrap>Birmingham, AL USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>6</day>
        <month>5</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>6</day>
        <month>5</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2022</year>
      </pub-date>
      <volume>607</volume>
      <issue>7918</issue>
      <fpage>356</fpage>
      <lpage>359</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>1</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>5</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2022</copyright-statement>
        <license>
          <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x2019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">The extent to which Omicron infection<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR9">9</xref></sup>, with or without previous vaccination, elicits protection against the previously dominant Delta (B.1.617.2) variant is unclear. Here we measured the neutralization capacity against variants of severe acute respiratory syndrome coronavirus 2 in 39 individuals in South Africa infected with the Omicron sublineage BA.1 starting at a median of 6 (interquartile range 3&#x2013;9) days post symptom onset and continuing until last follow-up sample available,&#xA0;a median of 23 (interquartile range 19&#x2013;27) days post symptoms to allow BA.1-elicited neutralizing immunity time to develop. Fifteen participants were vaccinated with Pfizer's BNT162b2 or Johnson &amp; Johnson's Ad26.CoV2.S and had BA.1 breakthrough infections, and 24 were unvaccinated. BA.1 neutralization increased from a geometric mean 50% focus reduction neutralization test&#xA0;titre of 42 at enrolment to 575 at the last follow-up time point (13.6-fold) in vaccinated participants and from 46 to 272 (6.0-fold) in unvaccinated participants. Delta virus neutralization also increased, from 192 to 1,091 (5.7-fold) in vaccinated participants and from 28 to 91 (3.0-fold) in unvaccinated participants. At the last time point, unvaccinated individuals infected with BA.1 had low absolute levels of neutralization for the non-BA.1 viruses and&#xA0;2.2-fold lower BA.1 neutralization, 12.0-fold lower Delta neutralization, 9.6-fold lower Beta variant neutralization, 17.9-fold lower ancestral virus neutralization and 4.8-fold lower Omicron sublineage BA.2 neutralization relative to vaccinated individuals&#xA0;infected with BA.1. These results indicate that hybrid immunity formed by vaccination and Omicron BA.1 infection should be protective against Delta and other variants. By contrast, infection with Omicron BA.1 alone offers limited cross-protection despite moderate enhancement.</p>
      </abstract>
      <abstract id="Abs2" abstract-type="web-summary">
        <p id="Par2">A study quantifying the neutralization of severe acute respiratory syndrome coronavirus 2&#xA0;variants in individuals infected with Omicron/BA.1&#xA0;shows that vaccinated individuals previously infected with Omicron have enhanced protection against reinfection with current variants,&#xA0;\including Omicron/BA.2, while Omicron/BA.1&#xA0;infected unvaccinated individuals&#xA0;have limited protection.</p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
        <title>Subject terms</title>
        <kwd>SARS-CoV-2</kwd>
        <kwd>Viral infection</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s), under exclusive licence to Springer Nature Limited 2022</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Main</title>
      <p id="Par3">The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in November 2021 in South Africa and Botswana<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>, has been shown by us<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> and others<sup><xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR9">9</xref></sup> to have extensive but incomplete escape from neutralizing immunity elicited by vaccines and previous infection, with boosted individuals showing better neutralization. In South Africa, Omicron infections led to a lower incidence of severe disease relative to other variants<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>, although this can be at least partly explained by pre-existing immunity<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. The first Omicron sublineage to appear was BA.1, which was supplanted by the BA.2 sublineage in many countries<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p>
      <p id="Par4">How Omicron BA.1 infection will interact with vaccination to protect against the previously dominant Delta variant, emerging variants such as BA.2 and other variants is still unclear. We isolated live Omicron BA.1, Omicron BA.2, ancestral, Beta and Delta viruses and neutralized viruses with plasma from participants enrolled and longitudinally sampled during the Omicron BA.1 infection wave in South Africa, with all participants having a confirmed diagnosis of SARS-CoV-2 by quantitative PCR. To quantify neutralization, we used a live virus neutralization assay and calculated the focus reduction neutralization test (FRNT<sub>50</sub>) titre, the inverse of the plasma dilution required for 50% neutralization, as measured by the reduction in the number of infection foci. We enrolled 41 participants who reported symptoms from late November 2021 to January 2022. We successfully sequenced the infecting virus in 26 participants, and all sequences corresponded to Omicron BA.1 (Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>). Two participants had advanced human immunodeficiency virus (HIV) disease on the basis of a low CD4 count (&lt;200&#x2009;cells&#x2009;&#x3BC;l<sup>&#x2212;1</sup> throughout the study) and unsuppressed HIV infection, and we excluded these participants because&#xA0;of our previous data showing an atypical response to SARS-CoV-2 in advanced HIV disease<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Extended Data Table <xref rid="Tab2" ref-type="table">2</xref> summarizes the characteristics of the remaining 39 participants.</p>
      <p id="Par5">Of the 39 participants, 27 were admitted to hospital because of coronavirus disease 2019&#xA0;symptoms. Seven required supplemental oxygen and one died. Fifteen participants were vaccinated and had a breakthrough Omicron BA.1 infection. The median time post vaccination was 139 days (interquartile range (IQR) 120&#x2013;178), a time interval that would predict considerable waning of the vaccine-elicited immune response<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, which may have contributed to the breakthrough infections. Eight participants were vaccinated with two doses of Pfizer's BNT162b2 and seven were vaccinated with Johnson &amp; Johnson's Ad26.CoV2.S (six with a single dose and one with two doses; Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>). The length of hospital stay was shorter in the vaccinated (3.5&#x2009;days) relative to unvaccinated (8&#x2009;days; Extended Data Table <xref rid="Tab2" ref-type="table">2</xref>) participants. Three participants self-reported having a previous SARS-CoV-2 infection (Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
      <p id="Par6">Participants were sampled at enrolment at a median of 6&#x2009;days (IQR 3&#x2013;9&#x2009;days) after symptom onset, and again at weekly follow-up visits that were attended as practicable because of the Christmas holidays in South Africa. The last follow-up visit was a median of 23&#x2009;days (IQR 19&#x2013;27&#x2009;days) post-symptom onset (Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>). Examining neutralization at all available time points per study participant showed that neutralization of the Omicron BA.1 variant increased substantially in most participants from enrolment to the time of the last follow-up (Extended Data Fig. <xref rid="Fig4" ref-type="fig">1</xref>), consistent with developing a neutralizing antibody response to Omicron BA.1 infection. We therefore analysed neutralization at enrolment (baseline for the study) and the last follow-up visit to quantify the increase in neutralization capacity after Omicron infection.</p>
      <p id="Par7">We observed that Omicron BA.1 neutralization increased in vaccinated individuals from a low geometric mean titre (GMT) FRNT<sub>50</sub> of 42 at the enrolment visit to 575 at the last follow-up visit about 2 to 3&#x2009;weeks later, a 13.6-fold change (95%&#x2009;CI confidence interval (CI) 3.7&#x2013;50.2; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). The samples from unvaccinated participants at the study baseline neutralized Omicron BA.1 at a similar starting level of 46 and reached a final level of 272 at the last follow-up, a 6.0-fold increase (95%&#x2009;CI 2.2&#x2013;16.1; Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). Neutralization of the Delta virus also increased during this period. At enrolment, neutralization capacity against the Delta virus was 192 and reached a final level of 1,091 at the last follow-up&#xA0;visit in vaccinated participants, a 5.7-fold increase (95%&#x2009;CI 1.7&#x2013;18.4; Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). Unvaccinated participants had lower Delta neutralization at baseline with Delta virus FRNT<sub>50</sub>&#x2009;=&#x2009;28, and reached FRNT<sub>50</sub>&#x2009;=&#x2009;91, a 3.2-fold increase (95%&#x2009;CI 1.3&#x2013;8.1; Fig. <xref rid="Fig1" ref-type="fig">1d</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Enhancement of Delta neutralization by Omicron infection.</title><p><bold>a</bold>,<bold>b</bold>, Neutralization of the Omicron BA.1 virus over time for <italic>n</italic>&#x2009;=&#x2009;15 vaccinated (<bold>a</bold>) and <italic>n</italic>&#x2009;=&#x2009;24 unvaccinated (<bold>b</bold>) participants infected with Omicron BA.1. <bold>c</bold>,<bold>d</bold>, Neutralization of the Delta virus over time for the same vaccinated (<italic>n</italic>&#x2009;=&#x2009;15; <bold>c</bold>) and unvaccinated (<italic>n</italic>&#x2009;=&#x2009;24; <bold>d</bold>) participants as in <bold>a</bold>,<bold>b</bold>. For each participant, the sample collected at the initial enrolment visit (median 6 days post symptom onset) was compared with that collected at the last follow-up visit (median 23 days post symptom onset). The neutralization capacity per participant was determined in two independent experiments, and the numbers&#xA0;and horizontal bars are GMTs over all participants per group of the reciprocal plasma dilution (FRNT<sub>50</sub>) resulting in 50% neutralization. The fold change was calculated by dividing the GMT from the follow-up by the GMT from the enrolment visit. The dashed line is the most concentrated plasma tested. The <italic>P</italic> values were determined by a left-sided Wilcoxon rank sum test measuring the significance of the increase; **<italic>P</italic>&#x2009;=&#x2009;0.01&#x2013;0.001; NS, not significant. The exact <italic>P</italic> values are 0.0012 (<bold>a</bold>), 0.0081 (<bold>b</bold>), 0.0021 (<bold>c</bold>) and 0.11 (<bold>d</bold>).</p><p><xref rid="MOESM2" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41586_2022_4830_Fig1_HTML" id="d32e1144"/></fig></p>
      <p id="Par8">We next compared Omicron BA.1 to Omicron BA.2, Delta, Beta (ref.&#x2009;<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>) and ancestral virus neutralization at the last available follow-up visit in three sets of paired experiments, each comparing Omicron BA.2, Delta or ancestral and Beta virus neutralization to Omicron BA.1 neutralization. The range of Omicron BA.1 neutralization shown in Fig. <xref rid="Fig2" ref-type="fig">2a</xref> for different experiments (FRNT<sub>50</sub>&#x2009;=&#x2009;516 to 646 for vaccinated samples and 266 to 271 for unvaccinated samples) is the result of experimental variation. BA.2 neutralization was moderately and not significantly lower relative to BA.1 neutralization in both vaccinated and unvaccinated participants. Testing only participants with sequence-confirmed Omicron BA.1 infection gave a similar result (Extended Data Fig. <xref rid="Fig5" ref-type="fig">2</xref>). The trend for the other variants and the ancestral virus was that neutralization was higher relative to Omicron BA.1 in vaccinated participants but lower relative to Omicron BA.1 in unvaccinated participants, although the differences were mostly not significant (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). As a result of the relatively moderate fold change, higher participant numbers would probably be required to&#xA0;make the trends statistically significant.<fig id="Fig2"><label>Fig. 2</label><caption><title>Gap in neutralizing immunity between vaccinated and unvaccinated participants infected with Omicron BA.1.</title><p><bold>a</bold>, Neutralization of Omicron BA.2, Beta, Delta and ancestral (with the D614G substitution) viruses compared to the Omicron BA.1 virus at the last available follow-up time point in <italic>n</italic>&#x2009;=&#x2009;15 vaccinated or <italic>n</italic>&#x2009;=&#x2009;24 unvaccinated participants infected with Omicron BA.1. The neutralization capacity per participant was determined in two independent experiments, and the numbers and horizontal bars&#xA0;are GMT FRNT<sub>50</sub>. The fold change was calculated by dividing the larger by the smaller GMT. The dashed line is the most concentrated plasma tested. The <italic>P</italic> values were determined by a two-sided Wilcoxon rank sum test; *<italic>P</italic>&#x2009;=&#x2009;0.05&#x2013;0.01; NS, not significant. The exact <italic>P</italic> values (vaccinated/unvaccinated) are: 0.22/0.087 for BA.2, 0.36/0.071 for Beta, 0.15/0.25 for Delta and 0.014/0.20 for ancestral. <bold>b</bold>, Comparison of the neutralization capacity against the Omicron BA.1, Omicron BA.2, Beta, Delta and ancestral (D614G) viruses in vaccinated (<italic>n</italic>&#x2009;=&#x2009;15) versus unvaccinated (<italic>n</italic>&#x2009;=&#x2009;24) participants infected with Omicron BA.1. The neutralization capacity per participant was determined in two independent experiments for all strains except for Omicron BA.1, for which six experiments were available and were used in the calculation. The points represent GMT FRNT<sub>50</sub> per group and the error bars are GMT 95% CIs. The <italic>P</italic> values were determined by a two-sided Wilcoxon rank sum test; *<italic>P</italic>&#x2009;=&#x2009;0.05&#x2013;0.01; **<italic>P</italic>&#x2009;=&#x2009;0.01&#x2013;0.001; ***<italic>P</italic>&#x2009;=&#x2009;0.001&#x2013;0.0001. The exact <italic>P</italic> values are 0.025 (BA.1), 0.0026 (BA.2), 4.1&#x2009;&#xD7;&#x2009;10<sup>&#x2212;4</sup> (Beta), 0.0012 (Delta) and 3.3&#x2009;&#xD7;&#x2009;10<sup>&#x2212;4</sup> (ancestral).</p><p><xref rid="MOESM2" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41586_2022_4830_Fig2_HTML" id="d32e1232"/></fig></p>
      <p id="Par9">The comparison of the other variants to Omicron BA.1 within the vaccinated or unvaccinated group&#xA0;does not indicate the differences in neutralization capacity elicited by Omicron BA.1 between the vaccinated and unvaccinated participants. We therefore compared neutralization of each variant between the vaccinated and unvaccinated groups at the last time point directly (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). The smallest difference between vaccinated and unvaccinated participants was in neutralization of Omicron BA.1, the infecting variant, with the vaccinated participants showing 2.2-fold higher neutralization. For the other variants, neutralization was higher in vaccinated participants by a factor of 4.8-fold for Omicron BA.2, 9.6-fold for Beta, 12.0-fold for Delta and 17.9-fold for ancestral (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). All differences were significant, and the 95% CIs for the GMT FRNT<sub>50</sub> of vaccinated and unvaccinated participants did not overlap for BA.2, Beta, Delta or ancestral virus neutralization (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). For the unvaccinated participants, the absolute neutralization capacity against the BA.2, Beta, Delta and ancestral viruses was low<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, with GMT FRNT<sub>50</sub> being about or below FRNT<sub>50</sub>&#x2009;=&#x2009;100 (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>).</p>
      <p id="Par10">We also tested neutralization of Omicron BA.1 by Delta-variant-elicited immunity. We collected 18 plasma samples from 14 participants (including pre-vaccination and post-vaccination samples from 4 participants) previously infected in the Delta variant wave in South Africa, 8 of whom were vaccinated either before or after infection (Extended Data Table <xref rid="Tab3" ref-type="table">3</xref>). Confirming previously reported results<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, we observed similar escape of Omicron BA.1 from Delta-elicited immunity across all samples tested, manifested as a 22.5-fold decrease (95%&#x2009;CI 14.4&#x2013;35.0) in Omicron BA.1 neutralization compared to Delta virus neutralization (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Escape of Omicron virus from Delta-infection-elicited immunity.</title><p>Neutralization of Delta compared to the Omicron BA.1 virus by Delta-infection-elicited plasma immunity in vaccinated and unvaccinated participants. A total of 18 samples were tested from <italic>n</italic>&#x2009;=&#x2009;14 participants infected during the Delta infection wave in South Africa. The neutralization capacity per participant was determined in two independent experiments, and the numbers and horizontal bars&#xA0;are GMT FRNT<sub>50</sub>. The fold change was calculated by dividing the larger by the smaller GMT.&#xA0;The dashed line is the most concentrated plasma tested. ****<italic>P</italic>&#x2009;=&#x2009;3.2&#x2009;&#xD7;&#x2009;10<sup>&#x2212;7</sup> as determined by a two-sided Wilcoxon rank sum test.</p><p><xref rid="MOESM2" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41586_2022_4830_Fig3_HTML" id="d32e1298"/></fig></p>
      <p id="Par11">The large fold drop in Delta-infection-elicited neutralization capacity against Omicron BA.1 contrasts with the moderate and nonsignificant fold drops, or even fold increases, in neutralization of other variants relative to Omicron BA.1 in individuals infected with Omicron BA.1. However, in unvaccinated individuals, even though fold drops in neutralization were moderate and nonsignificant, the absolute levels of neutralization of the other variants, and of Omicron BA.1 itself, were low and on a similar scale to the cross-neutralization capacity against Omicron in Delta-infection-elicited immunity. This is consistent with other recently reported results<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, and possibly indicates that Omicron is poorly immunogenic. In agreement with recent reports<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>, our observations show moderately and nonsignificantly lower neutralization of BA.2 by BA.1-elicited immunity. The results explain epidemiological observations showing that Omicron BA.2 reinfection is relatively rare soon after Omicron BA.1 infection<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>.</p>
      <p id="Par12">Our results may be supportive of a scenario in which hybrid immunity formed by Omicron infection combined with vaccination protects as well or better against reinfection with variants such as Delta relative to reinfection with Omicron itself. By contrast, unvaccinated participants infected with Omicron BA.1 only,&#xA0;have low neutralization capacity against the Omicron BA.2, Beta, Delta and ancestral viruses.</p>
      <p id="Par13">Limitations of this study include heterogeneity in participant immune history, including two vaccination types and one boost. On the basis of the high seroprevalence observed in South Africa<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>, some participants may also have had unreported previous infection. However, including two vaccine types did not mask the differences between vaccinated and unvaccinated participants, and the low levels of neutralization in unvaccinated participants against the ancestral, Beta and Delta viruses (the dominant strains in the preceding South African infection waves) support the notion that these participants were either not previously infected, or that immunity has waned completely. Participants were also mostly hospitalized, which may not be typical of Omicron infection<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. Increased disease severity has been shown to lead to higher anti-SARS-CoV-2 antibody titres<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. This should help in the detection of the neutralization response, but whether it would affect the trend we observed is unclear. Omicron infection is unlikely benign to the extent that hospitalization is an outlier outcome: in the USA, the number of individuals with coronavirus disease 2019 who died in the Omicron wave was similar to the number who died in the Delta wave<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Neutralizing immunity may have increased further in some participants had we sampled later: the neutralizing capacity did not plateau at the last time point in 8 of the 24 (33%) unvaccinated participants (participants 10, 14, 21, 27, 30, 31, 34 and 38; Extended Data Fig. <xref rid="Fig4" ref-type="fig">1</xref>) and 6 of the 15 (40%) vaccinated participants (participants 4, 6, 15, 16, 25 and 26). Therefore, the temporal dynamics give no clear indication that the immunity in the unvaccinated participants was delayed and would have reached similar levels to that of vaccinated participants if sampled later. However, the consequences of waning immunity several months post Omicron infection should be investigated.</p>
      <p id="Par14">The gap in immunity between unvaccinated individuals infected with Omicron BA.1 and vaccinated individuals with BA.1 breakthrough infection is concerning. Especially as immunity wanes, unvaccinated individuals post Omicron infection are likely to have poor cross-protection against existing and possibly emerging SARS-CoV-2 variants, despite acquiring some neutralizing immunity to the infecting Omicron BA.1 sub-lineage&#xA0;variant. The implication may be that Omicron&#xA0;BA.1 infection alone is not sufficient for protection and vaccination should be administered even in areas with a high prevalence of Omicron infection to protect against other variants.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Informed consent and ethics</title>
        <p id="Par15">Blood samples and the Delta isolate were obtained after written informed consent from adults with PCR-confirmed SARS-CoV-2 infection who were enrolled in a prospective cohort study at the Africa Health Research Institute approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal (reference BREC/00001275/2020). Omicron BA.1 was isolated from a residual swab sample for SARS-CoV-2&#xA0;where isolation from the sample was&#xA0;approved by the University of the Witwatersrand Human Research Ethics Committee (HREC; reference M210752). The sample to isolate Omicron BA.2 was collected after written informed consent as part of the study &#x201C;COVID-19 transmission and natural history in KwaZulu-Natal, South Africa: Epidemiological Investigation to Guide Prevention and Clinical Care&#x201D; of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and isolation from the sample&#xA0;approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal (reference BREC/00001195/2020, BREC/00003106/2021).</p>
      </sec>
      <sec id="Sec4">
        <title>Reagent availability</title>
        <p id="Par16">Virus isolates and the cell line are available from the corresponding author. A Biosafety Level 3 facility is required for laboratories receiving live SARS-CoV-2.</p>
      </sec>
      <sec id="Sec5">
        <title>Whole-genome sequencing, genome assembly and phylogenetic analysis</title>
        <p id="Par17">RNA was extracted on an automated Chemagic 360 instrument, using the CMG-1049 kit (Perkin Elmer). The RNA was stored at &#x2212;80&#x2009;&#xB0;C before use. Libraries for whole-genome sequencing were prepared using either the Oxford Nanopore Midnight protocol with Rapid Barcoding or the Illumina COVIDseq Assay. For the Illumina COVIDseq assay, the libraries were prepared according to the manufacturer&#x2019;s protocol. Briefly, amplicons were tagmented, followed by indexing using the Nextera UD Indexes Set A. Sequencing libraries were pooled, normalized to 4&#x2009;nM and denatured with 0.2&#x2009;N sodium acetate. An 8&#x2009;pM sample library was spiked with 1% PhiX (PhiX Control v3 adaptor-ligated library used as a control). We sequenced libraries on a 500-cycle v2 MiSeq Reagent Kit on the Illumina MiSeq instrument (Illumina). On the Illumina NextSeq 550 instrument, sequencing was performed using the Illumina COVIDSeq protocol (Illumina), an amplicon-based next-generation sequencing approach. The first-strand synthesis was carried using random hexamer primers from Illumina, and the synthesized cDNA underwent two separate multiplex PCR reactions. The pooled PCR-amplified products were processed for tagmentation and adaptor ligation using IDT for Illumina Nextera UD Indexes. Further enrichment and cleanup was performed as per protocols provided by the manufacturer (Illumina). Pooled samples were quantified using a Qubit 3.0 or 4.0 fluorometer (Invitrogen) through the Qubit dsDNA High Sensitivity Assay according to the manufacturer&#x2019;s instructions. The fragment sizes were analysed using TapeStation 4200 (Invitrogen). The pooled libraries were further normalized to 4&#x2009;nM concentration and 25&#x2009;&#x3BC;l of each normalized pool containing unique index adaptor sets was combined in a new tube. The final library pool was denatured and neutralized with 0.2&#x2009;N sodium hydroxide and 200&#x2009;mM Tris-HCl (pH&#x2009;7), respectively. A 1.5&#x2009;pM sample library was spiked with 2% PhiX. Libraries were loaded onto a 300-cycle NextSeq 500/550 HighOutput Kit v2 and run on the Illumina NextSeq 550 instrument (Illumina). For Oxford Nanopore sequencing, the Midnight primer kit was used: cDNA synthesis was performed on the extracted RNA using LunaScript RT mastermix (New England BioLabs) followed by gene-specific multiplex PCR using the Midnight Primer pools that produce 1,200-base-pair amplicons that overlap to cover the 30-kb SARS-CoV-2 genome. Amplicons from each pool were pooled and used neat for barcoding with the Oxford Nanopore Rapid Barcoding kit as per the manufacturer&#x2019;s protocol. Barcoded samples were pooled and bead purified. After the bead cleanup, the library was loaded on a prepared R9.4.1 flow cell. A GridION X5 or MinION sequencing run was initiated using MinKNOW software with the base-call setting switched off. We assembled paired-end and nanopore.fastq reads using Genome Detective 1.132 (<ext-link ext-link-type="uri" xlink:href="https://www.genomedetective.com">https://www.genomedetective.com</ext-link>), which was updated for the accurate assembly and variant calling of tiled primer amplicon Illumina or Oxford Nanopore reads, and the Coronavirus Typing Tool. For Illumina assembly, the GATK HaploTypeCaller &#x2013;min-pruning 0 argument was added to increase mutation calling sensitivity near sequencing gaps. For Nanopore, low-coverage regions with poor alignment quality (&lt;85% variant homogeneity) near sequencing/amplicon ends were masked to be robust against primer drop-out experienced in the spike gene, and the sensitivity for detecting short inserts using a region-local global alignment of reads was increased. In addition, we also used the wf_artic (ARTIC SARS-CoV-2) pipeline as built using the nextflow workflow framework. In some instances, mutations were confirmed visually with .bam files using Geneious software V2020.1.2 (Biomatters). The reference genome used throughout the assembly process was <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NC_045512.2">NC_045512.2</ext-link> (numbering equivalent to <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gquery/?term=MN908947.3">MN908947.3</ext-link>). For lineage classification, we used the widespread dynamic lineage classification method from the Phylogenetic Assignment of Named Global Outbreak Lineages software suite (<ext-link ext-link-type="uri" xlink:href="https://github.com/hCoV-2019/pangolin">https://github.com/hCoV-2019/pangolin</ext-link>).</p>
      </sec>
      <sec id="Sec6">
        <title>Cells</title>
        <p id="Par18">Vero E6 cells (originally ATCC CRL-1586, obtained from Cellonex in South Africa) were propagated in complete growth medium consisting of Dulbecco's modified Eagle medium with 10% fetal bovine serum (Hyclone) containing 10&#x2009;mM HEPES, 1&#x2009;mM sodium pyruvate, 2&#x2009;mM <sc>l</sc>-glutamine and 0.1&#x2009;mM nonessential amino acids (Sigma-Aldrich). Vero E6 cells were passaged every 3&#x2013;4&#x2009;days. The H1299-E3 cell line (H1299 originally from ATCC as CRL-5803) was propagated in growth medium consisting of complete Roswell Park Memorial Institute 1640 medium with 10% fetal bovine serum containing 10&#x2009;mM HEPES, 1&#x2009;mM sodium pyruvate, 2&#x2009;mM <sc>l</sc>-glutamine and 0.1&#x2009;mM nonessential amino acids. Cells were passaged every second day. The H1299-E3 (H1299-ACE2, clone E3) cell line was derived from H1299 as described in our previous work<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>.&#xA0;Cell lines were not&#xA0;authenticated. Cell lines tested negative for mycoplasma contamination.</p>
      </sec>
      <sec id="Sec7">
        <title>Virus expansion</title>
        <p id="Par19">All work with live virus was performed in Biosafety Level 3 containment using protocols for SARS-CoV-2 approved by the Africa Health Research Institute Biosafety Committee. ACE2-expressing H1299-E3 cells were seeded at 4.5&#x2009;&#xD7;&#x2009;10<sup>5</sup> cells in a 6-well plate well and incubated for 18&#x2013;20&#x2009;h. After one Dulbecco's phosphate-buffered saline (PBS) wash, the subconfluent cell monolayer was inoculated with 500&#x2009;&#x3BC;l universal transport medium diluted 1:1 with growth medium filtered through a 0.45-&#x3BC;m filter. Cells were incubated for 1&#x2009;h. Wells were then filled with 3&#x2009;ml complete growth medium. After 4 days of infection (completion of passage 1 (P1)), cells were trypsinized, centrifuged at 300&#x2009;RCF for 3&#x2009;min and resuspended in 4&#x2009;ml growth medium. All cells from the P1&#xA0;infection&#xA0;were added to Vero E6 cells that had been seeded at 2&#x2009;&#xD7;&#x2009;10<sup>5</sup>&#x2009;cells&#x2009;ml<sup>&#x2212;1</sup>, 20&#x2009;ml total, 18&#x2013;20&#x2009;h earlier in a T75 flask for cell-to-cell infection. The coculture of ACE2-expressing H1299-E3 and Vero E6 cells was incubated for 1&#x2009;h, and the flask was filled with 20&#x2009;ml of complete growth medium and incubated for 4&#x2009;days. The viral supernatant from this culture (passage 2 (P2) stock) was used for experiments.</p>
      </sec>
      <sec id="Sec8">
        <title>Live virus neutralization assay</title>
        <p id="Par20">H1299-E3 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day pre-infection. Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500&#x2009;RCF for 10&#x2009;min and stored at &#x2212;80&#x2009;&#xB0;C. Aliquots of plasma samples were heat-inactivated at 56&#x2009;&#xB0;C for 30&#x2009;min and clarified by centrifugation at 10,000&#x2009;RCF for 5&#x2009;min. Virus stocks were used at approximately 50&#x2013;100 focus-forming units per microwell and added to diluted plasma. Antibody&#x2013;virus mixtures were incubated for 1&#x2009;h at 37&#x2009;&#xB0;C, 5%&#x2009;CO<sub>2</sub>. Cells were infected with 100&#x2009;&#x3BC;l of the virus&#x2013;antibody mixtures for 1&#x2009;h, and then 100&#x2009;&#x3BC;l of a 1&#xD7; Roswell Park Memorial Institute 1640 (Sigma-Aldrich, R6504), 1.5% carboxymethylcellulose (Sigma-Aldrich, C4888) overlay was added without removing the inoculum. Cells were fixed 18&#x2009;h after infection using 4% paraformaldehyde (Sigma-Aldrich) for 20&#x2009;min. Foci were stained with a rabbit anti-spike monoclonal antibody (BS-R2B12, GenScript A02058) at 0.5&#x2009;&#x3BC;g&#x2009;ml<sup>&#x2212;1</sup> in a permeabilization buffer containing 0.1% saponin (Sigma-Aldrich), 0.1% BSA (Sigma-Aldrich) and 0.05% Tween-20 (Sigma-Aldrich) in PBS. Plates were incubated with primary antibody overnight at 4&#x2009;&#xB0;C, and then washed with wash buffer containing 0.05% Tween-20 in PBS. Secondary goat anti-rabbit antibody conjugated to horseradish peroxidase (Abcam ab205718) was added at 1&#x2009;&#x3BC;g&#x2009;ml<sup>&#x2212;1</sup> and incubated for 2&#x2009;h at room temperature with shaking. TrueBlue peroxidase substrate (SeraCare 5510-0030) was then added at 50&#x2009;&#x3BC;l per well and incubated for 20&#x2009;min at room temperature. Plates were imaged in an ImmunoSpot Ultra-V S6-02-6140 Analyzer ELISPOT instrument with BioSpot Professional built-in image analysis (Cellular Technology&#xA0;Limited).</p>
      </sec>
      <sec id="Sec9">
        <title>Statistics and fitting</title>
        <p id="Par21">Statistical methods were not&#xA0;used to predetermine sample size, and blinding and randomization were not used. All statistics and fitting were performed using custom code in MATLAB v.2019b. Neutralization data were fitted to:</p>
        <p id="Par22">
<inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\rm{Tx}}=1/1+(D/{{\rm{ID}}}_{50}).$$\end{document}</tex-math><mml:math id="M2"><mml:mrow><mml:mi mathvariant="normal">Tx</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>D</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">ID</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="41586_2022_4830_Article_IEq1.gif"/></alternatives></inline-formula>
</p>
        <p id="Par23">Here Tx is the number of foci normalized to the number of foci in the absence of plasma on the same plate at dilution <italic>D</italic>, and ID<sub>50</sub> is the plasma dilution giving 50% neutralization. FRNT<sub>50</sub>&#x2009;=&#x2009;1/ID<sub>50</sub>. Values of FRNT<sub>50</sub>&#x2009;&lt;&#x2009;1 are set to 1 (undiluted), the lowest measurable value. We note that the most concentrated plasma dilution was 1:25 and therefore FRNT<sub>50</sub>&#x2009;&lt;&#x2009;25 data were extrapolated. To calculate CIs, FRNT<sub>50</sub> or fold change in FRNT<sub>50</sub> per participant was log transformed and the arithmetic mean plus 2&#x2009;s.d. and the arithmetic mean minus 2&#x2009;s.d. were calculated for the log-transformed values. These were exponentiated to obtain the upper and lower 95% CIs on the geometric mean FRNT<sub>50</sub> or the fold change in FRNT<sub>50</sub> geometric means.</p>
      </sec>
      <sec id="Sec10">
        <title>Reporting summary</title>
        <p id="Par24">Further information on research design is available in the&#xA0;<xref rid="MOESM1" ref-type="media">Nature Research Reporting Summary</xref> linked to this paper.</p>
      </sec>
    </sec>
    <sec id="Sec11" sec-type="materials|methods">
      <title>Online content</title>
      <p id="Par25">Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-022-04830-x.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41586_2022_4830_MOESM1_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
</p>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec12">
          <title>Extended data figures and tables</title>
          <p id="Par28">
<fig id="Fig4"><label>Extended Data Fig. 1</label><caption><title>Longitudinal Omicron/BA.1 and Delta neutralization capacity in Omicron/BA.1 infected participants.</title><p>Neutralization of Omicron (blue) and Delta (red) at all study visits. Participant number is as in Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>. Top three rows are participants vaccinated with Pfizer BNT162b2 (n&#x2009;=&#x2009;8) or Johnson and Johnson Ad26.CoV2.S (n&#x2009;=&#x2009;7) and bottom five rows are unvaccinated participants (n&#x2009;=&#x2009;24). X-axis is the time post-symptom onset when sample was collected, and y-axis is neutralization as FRNT<sub>50</sub>. Dashed line is the most concentrated plasma tested (LOQ, limit of quantification below which FRNT<sub>50</sub> values are extrapolated). All participants recovered except participant 29, who died.</p></caption><graphic position="anchor" xlink:href="41586_2022_4830_Fig4_ESM" id="d32e1628"/></fig>
</p>
          <p id="Par29">
<fig id="Fig5"><label>Extended Data Fig. 2</label><caption><title>Fold-drop in BA.2 versus BA.1 neutralization in all and sequence confirmed samples.</title><p>Neutralization of Omicron BA.2 compared to BA.1 in participants described in Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>, excluding participant 14 for technical reasons and participants 40 and 41 because of advanced HIV disease. Left panel shows neutralization capacity in all n&#x2009;=&#x2009;38 participants and right panel shows neutralization capacity for n&#x2009;=&#x2009;25 participants where infection was successfully sequenced and determined to be BA.1. Dashed line is the most concentrated plasma tested. p-values were 0.077 for all and 0.15 for BA.1 sequence confirmed participants as determined by a two-sided Wilcoxon rank sum test. ns, not significant.</p></caption><graphic position="anchor" xlink:href="41586_2022_4830_Fig5_ESM" id="d32e1645"/></fig>
</p>
          <p id="Par30">
<table-wrap id="Tab1"><label>Extended Data Table 1</label><caption><p>Characteristics of Omicron/BA.1 infected participants</p></caption><graphic position="anchor" xlink:href="41586_2022_4830_Tab1_ESM" id="d32e1657"><caption><p>Characteristics of Omicron/BA.1 infected participants</p></caption></graphic><table-wrap-foot><p>Ct enrol.: qPCR cycle threshold for SARS-CoV-2 at enrollment. Symptoms to enrol.: time between symptoms onset and study enrolment. Symp. to last follow-up: time between symptoms onset and last follow-up visit. Max CD4: maximum CD4 count per microliter blood across all study visits. Supp O<sub>2</sub>: participant required supplemental oxygen during the study. Hosp.: participant hospitalized during the study. UND: Undetectable Ct. N/A: Not available; sequencing failed, usually due to insufficient virus substrate. *Reported previous infection. **Boosted with Ad26.CoV2.S in Nov-2021. ***Participants with persistent low CD4 count and uncontrolled HIV viremia indicative of advanced HIV disease and immune suppression. Excluded from analysis. <sup>$</sup>Deceased.</p></table-wrap-foot></table-wrap>
</p>
          <p id="Par31">
<table-wrap id="Tab2"><label>Extended Data Table 2</label><caption><p>Summary characteristics of Omicron/BA.1 infected participants</p></caption><graphic position="anchor" xlink:href="41586_2022_4830_Tab2_ESM" id="d32e1682"><caption><p>Summary characteristics of Omicron/BA.1 infected participants</p></caption></graphic><table-wrap-foot><p>Values are median (IQR). Hospital stay calculated to last inpatient study visit.</p></table-wrap-foot></table-wrap>
</p>
          <p id="Par32">
<table-wrap id="Tab3"><label>Extended Data Table 3</label><caption><p>Characteristics of Delta infected participants</p></caption><graphic position="anchor" xlink:href="41586_2022_4830_Tab3_ESM" id="d32e1701"><caption><p>Characteristics of Delta infected participants</p></caption></graphic><table-wrap-foot><p>*Asymptomatic, date of diagnostic swab used instead of symptoms onset. Ct enrol: qPCR cycle threshold for SARS-CoV-2 at enrollment. UND: undetectable. Pre: sample taken pre-vaccination. Post: sample taken post-vaccination for participants with a pre-vaccination sample. N/A: not available.</p></table-wrap-foot></table-wrap>
</p>
        </sec>
        <sec id="Sec14">
          <title>Source data</title>
          <p id="Par34">
<media position="anchor" xlink:href="41586_2022_4830_MOESM2_ESM.xlsx" id="MOESM2"><caption><p>Source Data Figs. 1&#x2013;3</p></caption></media>
</p>
        </sec>
      </app>
    </app-group>
    <fn-group>
      <fn>
        <p><bold>Publisher&#x2019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>These authors contributed equally: Khadija Khan, Farina Karim</p>
      </fn>
      <fn>
        <p>A list of authors and their affiliations appears at the end of the paper</p>
      </fn>
    </fn-group>
    <sec>
      <title>Extended data</title>
      <p>is available for this paper at 10.1038/s41586-022-04830-x.</p>
    </sec>
    <sec>
      <title>Supplementary information</title>
      <p>The online version contains supplementary material available at 10.1038/s41586-022-04830-x.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>This study was supported by the Bill and Melinda Gates award INV-018944 (A.Sigal), the National Institutes of Health award R01 AI138546 (A.Sigal), South African Medical Research Council awards including 6084COAP2020 (A.Sigal, T.d.O. and P.L.M.), the UK Foreign, Commonwealth and Development Office and the Wellcome Trust (grant number 221003/Z/20/Z; P.L.M.). P.L.M. is also supported by the South African Research Chairs Initiative of the Department of Science and Innovation and the NRF (grant number 98341). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>A.Sigal., K.K. and F.K. conceived the study and designed the study and experiments. A.v.G., Q.A.K., S.S.A.K., G.L., A.Sivro and N.S. identified and provided virus samples. M.-Y.S.M., F.K., B.I.G., M.B., K.K., T.N., M.M., N.&#x2009;Mthabela, Z.M., N.N., Y.M., N.&#x2009;Mbatha, N.&#x2009;Manickchund, N.&#x2009;Magula, Z.J., K.R. and Y.G. set up and managed the cohort and cohort data. K.K., Z.J., K.R., S.C., H.T., J.E.S., Y.G., J.G., Y. Ramphal, A.B.M.K., D.A. and J.N.B. performed experiments and sequence analysis with input from A.Sigal, T.d.O., R.J.L. and J.N.B.,&#xA0;A.Sigal, K.K., F.K., R.M. and Y. Rosenberg interpreted data with input from M.-Y.S.M., G.G., S.S.A.K., W.H., T.d.O., N.&#x2009;Magula, R.J.L. and P.L.M.,&#xA0;A.Sigal, K.K., G.L., F.K. and M.B. prepared the manuscript with input from all authors.</p>
    </notes>
    <notes notes-type="peer-review">
      <title>Peer review</title>
      <sec id="FPar1">
        <title>Peer review information</title>
        <p id="Par26"><italic>Nature</italic> thanks the anonymous reviewers for their contribution to the peer review of this work.</p>
      </sec>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>Sequences of outgrown Omicron sublineages have been deposited in GISAID&#xA0;(<ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org/">https://www.gisaid.org/</ext-link>) with accessions EPI_ISL_7886688 (Omicron BA.1), EPI_ISL_9082893 (Omicron BA.2)&#xA0;and&#xA0;EPI_ISL_602626.1 (ancestral/D614G). Delta&#xA0;(EPI_ISL_3118687)&#xA0;and Beta&#xA0;(EPI_ISL_678615) isolates have been described previously<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Raw images of the data are available upon reasonable request.&#xA0;<xref rid="Sec14" ref-type="sec">Source data</xref> are provided with this paper.</p>
    </notes>
    <notes id="FPar2" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par27">The authors declare no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <italic>Nature</italic>10.1038/s41586-021-04387-1 (2021).</mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andrews</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant</article-title>
          <source>N. Engl. J. Med.</source>
          <year>2022</year>
          <volume>386</volume>
          <fpage>1532</fpage>
          <lpage>1546</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa2119451</pub-id>
          <pub-id pub-id-type="pmid">35249272</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cao</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies</article-title>
          <source>Nature</source>
          <year>2022</year>
          <volume>602</volume>
          <fpage>657</fpage>
          <lpage>663</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-021-04385-3</pub-id>
          <pub-id pub-id-type="pmid">35016194</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dejnirattisai</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses</article-title>
          <source>Cell</source>
          <year>2022</year>
          <volume>185</volume>
          <fpage>467</fpage>
          <lpage>484</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2021.12.046</pub-id>
          <pub-id pub-id-type="pmid">35081335</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dejnirattisai</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum</article-title>
          <source>Lancet</source>
          <year>2022</year>
          <volume>399</volume>
          <fpage>234</fpage>
          <lpage>236</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(21)02844-0</pub-id>
          <pub-id pub-id-type="pmid">34942101</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia-Beltran</surname>
              <given-names>WF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant</article-title>
          <source>Cell</source>
          <year>2022</year>
          <volume>185</volume>
          <fpage>457</fpage>
          <lpage>466</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2021.12.033</pub-id>
          <pub-id pub-id-type="pmid">34995482</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="other">Lu, L. et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. <italic>Clin. Infect. Dis.</italic>10.1093/cid/ciab1041 (2021).</mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Planas</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Considerable escape of SARS-CoV-2 Omicron to antibody neutralization</article-title>
          <source>Nature</source>
          <year>2022</year>
          <volume>602</volume>
          <fpage>671</fpage>
          <lpage>675</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-021-04389-z</pub-id>
          <pub-id pub-id-type="pmid">35016199</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>VanBlargan</surname>
              <given-names>LA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies</article-title>
          <source>Nat. Med.</source>
          <year>2022</year>
          <volume>28</volume>
          <fpage>490</fpage>
          <lpage>495</lpage>
          <pub-id pub-id-type="doi">10.1038/s41591-021-01678-y</pub-id>
          <pub-id pub-id-type="pmid">35046573</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="other">Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. <italic>Nature</italic>10.1038/d41586-021-03832-5 (2021).</mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="other">Davies, M.-A. et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. <italic>Trop. Med. Int. Health</italic>10.1111/tmi.13752 (2022).</mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolter</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study</article-title>
          <source>Lancet</source>
          <year>2022</year>
          <volume>399</volume>
          <fpage>437</fpage>
          <lpage>446</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(22)00017-4</pub-id>
          <pub-id pub-id-type="pmid">35065011</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sigal</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Milder disease with Omicron: is it the virus or the pre-existing immunity?</article-title>
          <source>Nat. Rev. Immunol.</source>
          <year>2022</year>
          <volume>22</volume>
          <fpage>69</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="doi">10.1038/s41577-022-00678-4</pub-id>
          <pub-id pub-id-type="pmid">35046570</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="other">Lyngse, F. P. et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish households. Preprint at <italic>medRxiv</italic>10.1101/2022.01.28.22270044 (2022).</mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cele</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape</article-title>
          <source>Cell Host Microbe</source>
          <year>2022</year>
          <volume>30</volume>
          <fpage>154</fpage>
          <lpage>162</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chom.2022.01.005</pub-id>
          <pub-id pub-id-type="pmid">35120605</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldberg</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Waning immunity after the BNT162b2 vaccine in Israel</article-title>
          <source>N. Engl. J. Med.</source>
          <year>2021</year>
          <volume>385</volume>
          <fpage>e85</fpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa2114228</pub-id>
          <pub-id pub-id-type="pmid">34706170</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cele</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma</article-title>
          <source>Nature</source>
          <year>2021</year>
          <volume>593</volume>
          <fpage>142</fpage>
          <lpage>146</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-021-03471-w</pub-id>
          <pub-id pub-id-type="pmid">33780970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="other">Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <italic>Nat. Med.</italic><bold>27,</bold> 1205&#x2013;1211 (2021).</mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>R&#xF6;ssler</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Riepler</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bante</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>von Laer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kimpel</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons</article-title>
          <source>N. Engl. J. Med.</source>
          <year>2022</year>
          <volume>386</volume>
          <fpage>698</fpage>
          <lpage>700</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc2119236</pub-id>
          <pub-id pub-id-type="pmid">35021005</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Servellita</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants</article-title>
          <source>Cell</source>
          <year>2022</year>
          <volume>185</volume>
          <fpage>1539</fpage>
          <lpage>1548</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2022.03.019</pub-id>
          <pub-id pub-id-type="pmid">35429436</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="other">Yu, J. et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. <italic>N. Engl. J. Med.</italic><bold>386</bold>, 1579&#x2013;1580 (2022).</mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <mixed-citation publication-type="other">Richardson, S. I. et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. <italic>Cell Host Microbe</italic>10.1016/j.chom.2022.03.029 (2022).</mixed-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="other">Chemaitelly, H. et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. Preprint at <italic>medRxiv</italic>10.1101/2022.02.24.22271440 (2022).</mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="other">Stegger, M. et al. Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection. Preprint at <italic>medRxiv</italic>10.1101/2022.02.19.22271112 (2022).</mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <mixed-citation publication-type="other">Khan, K. et al. Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV. <italic>Clin. Infect. Dis.</italic>10.1093/cid/ciab1008 (2021).</mixed-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <mixed-citation publication-type="other">Madhi, S. A. et al. Population immunity and Covid-19 severity with Omicron Variant in South Africa. <italic>N. Engl. J. Med.</italic>10.1056/NEJMoa2119658 (2022).</mixed-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sigal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Milo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jassat</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Estimating disease severity of Omicron and Delta SARS-CoV-2 infections</article-title>
          <source>Nat. Rev. Immunol.</source>
          <year>2022</year>
          <volume>22</volume>
          <fpage>267</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="doi">10.1038/s41577-022-00720-5</pub-id>
          <pub-id pub-id-type="pmid">35414124</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Age, disease severity and ethnicity influence humoral responses in a multi-ethnic COVID-19 cohort</article-title>
          <source>Viruses</source>
          <year>2021</year>
          <volume>13</volume>
          <fpage>786</fpage>
          <pub-id pub-id-type="doi">10.3390/v13050786</pub-id>
          <pub-id pub-id-type="pmid">33925055</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">35042229</article-id>
      <article-id pub-id-type="pmc">8942855</article-id>
      <article-id pub-id-type="publisher-id">4411</article-id>
      <article-id pub-id-type="doi">10.1038/s41586-022-04411-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Viana</surname>
            <given-names>Raquel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3821-4592</contrib-id>
          <name>
            <surname>Moyo</surname>
            <given-names>Sikhulile</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3551-3458</contrib-id>
          <name>
            <surname>Amoako</surname>
            <given-names>Daniel G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Tegally</surname>
            <given-names>Houriiyah</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Scheepers</surname>
            <given-names>Cathrine</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5230-6760</contrib-id>
          <name>
            <surname>Althaus</surname>
            <given-names>Christian L.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Anyaneji</surname>
            <given-names>Ugochukwu J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bester</surname>
            <given-names>Phillip A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0830-9630</contrib-id>
          <name>
            <surname>Boni</surname>
            <given-names>Maciej F.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chand</surname>
            <given-names>Mohammed</given-names>
          </name>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Choga</surname>
            <given-names>Wonderful T.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Colquhoun</surname>
            <given-names>Rachel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Davids</surname>
            <given-names>Michaela</given-names>
          </name>
          <xref ref-type="aff" rid="Aff14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3898-9494</contrib-id>
          <name>
            <surname>Deforche</surname>
            <given-names>Koen</given-names>
          </name>
          <xref ref-type="aff" rid="Aff15">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Doolabh</surname>
            <given-names>Deelan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0352-6289</contrib-id>
          <name>
            <surname>du Plessis</surname>
            <given-names>Louis</given-names>
          </name>
          <xref ref-type="aff" rid="Aff17">17</xref>
          <xref ref-type="aff" rid="Aff18">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1318-5994</contrib-id>
          <name>
            <surname>Engelbrecht</surname>
            <given-names>Susan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff19">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0373-2093</contrib-id>
          <name>
            <surname>Everatt</surname>
            <given-names>Josie</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Giandhari</surname>
            <given-names>Jennifer</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5849-7326</contrib-id>
          <name>
            <surname>Giovanetti</surname>
            <given-names>Marta</given-names>
          </name>
          <xref ref-type="aff" rid="Aff20">20</xref>
          <xref ref-type="aff" rid="Aff21">21</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hardie</surname>
            <given-names>Diana</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
          <xref ref-type="aff" rid="Aff22">22</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hill</surname>
            <given-names>Verity</given-names>
          </name>
          <xref ref-type="aff" rid="Aff13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4926-6216</contrib-id>
          <name>
            <surname>Hsiao</surname>
            <given-names>Nei-Yuan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
          <xref ref-type="aff" rid="Aff22">22</xref>
          <xref ref-type="aff" rid="Aff23">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4413-2569</contrib-id>
          <name>
            <surname>Iranzadeh</surname>
            <given-names>Arash</given-names>
          </name>
          <xref ref-type="aff" rid="Aff24">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4672-5915</contrib-id>
          <name>
            <surname>Ismail</surname>
            <given-names>Arshad</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Joseph</surname>
            <given-names>Charity</given-names>
          </name>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Joseph</surname>
            <given-names>Rageema</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Koopile</surname>
            <given-names>Legodile</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4817-4029</contrib-id>
          <name>
            <surname>Kosakovsky Pond</surname>
            <given-names>Sergei L.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff25">25</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8838-7147</contrib-id>
          <name>
            <surname>Kraemer</surname>
            <given-names>Moritz U. G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kuate-Lere</surname>
            <given-names>Lesego</given-names>
          </name>
          <xref ref-type="aff" rid="Aff26">26</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Laguda-Akingba</surname>
            <given-names>Oluwakemi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27">27</xref>
          <xref ref-type="aff" rid="Aff28">28</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lesetedi-Mafoko</surname>
            <given-names>Onalethatha</given-names>
          </name>
          <xref ref-type="aff" rid="Aff29">29</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0926-710X</contrib-id>
          <name>
            <surname>Lessells</surname>
            <given-names>Richard J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lockman</surname>
            <given-names>Shahin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff30">30</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lucaci</surname>
            <given-names>Alexander G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff25">25</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maharaj</surname>
            <given-names>Arisha</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2129-527X</contrib-id>
          <name>
            <surname>Mahlangu</surname>
            <given-names>Boitshoko</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maponga</surname>
            <given-names>Tongai</given-names>
          </name>
          <xref ref-type="aff" rid="Aff19">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mahlakwane</surname>
            <given-names>Kamela</given-names>
          </name>
          <xref ref-type="aff" rid="Aff19">19</xref>
          <xref ref-type="aff" rid="Aff31">31</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Makatini</surname>
            <given-names>Zinhle</given-names>
          </name>
          <xref ref-type="aff" rid="Aff32">32</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marais</surname>
            <given-names>Gert</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
          <xref ref-type="aff" rid="Aff22">22</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maruapula</surname>
            <given-names>Dorcas</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Masupu</surname>
            <given-names>Kereng</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matshaba</surname>
            <given-names>Mogomotsi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff33">33</xref>
          <xref ref-type="aff" rid="Aff34">34</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mayaphi</surname>
            <given-names>Simnikiwe</given-names>
          </name>
          <xref ref-type="aff" rid="Aff35">35</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mbhele</surname>
            <given-names>Nokuzola</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mbulawa</surname>
            <given-names>Mpaphi B.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff36">36</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mendes</surname>
            <given-names>Adriano</given-names>
          </name>
          <xref ref-type="aff" rid="Aff14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mlisana</surname>
            <given-names>Koleka</given-names>
          </name>
          <xref ref-type="aff" rid="Aff37">37</xref>
          <xref ref-type="aff" rid="Aff38">38</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mnguni</surname>
            <given-names>Anele</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mohale</surname>
            <given-names>Thabo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moir</surname>
            <given-names>Monika</given-names>
          </name>
          <xref ref-type="aff" rid="Aff39">39</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moruisi</surname>
            <given-names>Kgomotso</given-names>
          </name>
          <xref ref-type="aff" rid="Aff26">26</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mosepele</surname>
            <given-names>Mosepele</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff40">40</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Motsatsi</surname>
            <given-names>Gerald</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Motswaledi</surname>
            <given-names>Modisa S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff41">41</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mphoyakgosi</surname>
            <given-names>Thongbotho</given-names>
          </name>
          <xref ref-type="aff" rid="Aff36">36</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Msomi</surname>
            <given-names>Nokukhanya</given-names>
          </name>
          <xref ref-type="aff" rid="Aff42">42</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mwangi</surname>
            <given-names>Peter N.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10">10</xref>
          <xref ref-type="aff" rid="Aff43">43</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Naidoo</surname>
            <given-names>Yeshnee</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ntuli</surname>
            <given-names>Noxolo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nyaga</surname>
            <given-names>Martin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10">10</xref>
          <xref ref-type="aff" rid="Aff43">43</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Olubayo</surname>
            <given-names>Lucier</given-names>
          </name>
          <xref ref-type="aff" rid="Aff23">23</xref>
          <xref ref-type="aff" rid="Aff24">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pillay</surname>
            <given-names>Sureshnee</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Radibe</surname>
            <given-names>Botshelo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ramphal</surname>
            <given-names>Yajna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2441-3868</contrib-id>
          <name>
            <surname>Ramphal</surname>
            <given-names>Upasana</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>San</surname>
            <given-names>James E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Scott</surname>
            <given-names>Lesley</given-names>
          </name>
          <xref ref-type="aff" rid="Aff44">44</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shapiro</surname>
            <given-names>Roger</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff30">30</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>Lavanya</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smith-Lawrence</surname>
            <given-names>Pamela</given-names>
          </name>
          <xref ref-type="aff" rid="Aff26">26</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stevens</surname>
            <given-names>Wendy</given-names>
          </name>
          <xref ref-type="aff" rid="Aff44">44</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Strydom</surname>
            <given-names>Amy</given-names>
          </name>
          <xref ref-type="aff" rid="Aff14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Subramoney</surname>
            <given-names>Kathleen</given-names>
          </name>
          <xref ref-type="aff" rid="Aff32">32</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tebeila</surname>
            <given-names>Naume</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tshiabuila</surname>
            <given-names>Derek</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tsui</surname>
            <given-names>Joseph</given-names>
          </name>
          <xref ref-type="aff" rid="Aff17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van Wyk</surname>
            <given-names>Stephanie</given-names>
          </name>
          <xref ref-type="aff" rid="Aff39">39</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6931-7191</contrib-id>
          <name>
            <surname>Weaver</surname>
            <given-names>Steven</given-names>
          </name>
          <xref ref-type="aff" rid="Aff25">25</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wibmer</surname>
            <given-names>Constantinos K.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wilkinson</surname>
            <given-names>Eduan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff39">39</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wolter</surname>
            <given-names>Nicole</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
          <xref ref-type="aff" rid="Aff45">45</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zarebski</surname>
            <given-names>Alexander E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zuze</surname>
            <given-names>Boitumelo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goedhals</surname>
            <given-names>Dominique</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10">10</xref>
          <xref ref-type="aff" rid="Aff46">46</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0254-7910</contrib-id>
          <name>
            <surname>Preiser</surname>
            <given-names>Wolfgang</given-names>
          </name>
          <xref ref-type="aff" rid="Aff19">19</xref>
          <xref ref-type="aff" rid="Aff31">31</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Treurnicht</surname>
            <given-names>Florette</given-names>
          </name>
          <xref ref-type="aff" rid="Aff32">32</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Venter</surname>
            <given-names>Marietje</given-names>
          </name>
          <xref ref-type="aff" rid="Aff14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0125-1226</contrib-id>
          <name>
            <surname>Williamson</surname>
            <given-names>Carolyn</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
          <xref ref-type="aff" rid="Aff22">22</xref>
          <xref ref-type="aff" rid="Aff23">23</xref>
          <xref ref-type="aff" rid="Aff47">47</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8797-2667</contrib-id>
          <name>
            <surname>Pybus</surname>
            <given-names>Oliver G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6354-4003</contrib-id>
          <name>
            <surname>Bhiman</surname>
            <given-names>Jinal</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Glass</surname>
            <given-names>Allison</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff48">48</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martin</surname>
            <given-names>Darren P.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff23">23</xref>
          <xref ref-type="aff" rid="Aff47">47</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4337-3707</contrib-id>
          <name>
            <surname>Rambaut</surname>
            <given-names>Andrew</given-names>
          </name>
          <xref ref-type="aff" rid="Aff13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gaseitsiwe</surname>
            <given-names>Simani</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>von Gottberg</surname>
            <given-names>Anne</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
          <xref ref-type="aff" rid="Aff45">45</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3027-5254</contrib-id>
          <name>
            <surname>de Oliveira</surname>
            <given-names>Tulio</given-names>
          </name>
          <address>
            <email>tulio@sun.ac.za</email>
          </address>
          <xref ref-type="aff" rid="Aff6">6</xref>
          <xref ref-type="aff" rid="Aff39">39</xref>
          <xref ref-type="aff" rid="Aff49">49</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.511132.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0500 3622</institution-id><institution>Lancet Laboratories, </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.462829.3</institution-id><institution>Botswana Harvard AIDS Institute Partnership, </institution><institution>Botswana Harvard HIV Reference Laboratory, </institution></institution-wrap>Gaborone, Botswana </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Harvard T.H. Chan School of Public Health, </institution></institution-wrap>Boston, MA USA </aff>
        <aff id="Aff4"><label>4</label>Botswana Presidential COVID-19 Taskforce, Gaborone, Botswana </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.416657.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0630 4574</institution-id><institution>National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R. Mandela School of Medicine, </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>South African Medical Research Council Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, </institution><institution>University of the Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.5734.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0726 5157</institution-id><institution>Institute of Social and Preventive Medicine, </institution><institution>University of Bern, </institution></institution-wrap>Bern, Switzerland </aff>
        <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.416657.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0630 4574</institution-id><institution>Division of Virology, </institution><institution>National Health Laboratory Service, </institution></institution-wrap>Bloemfontein, South Africa </aff>
        <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.412219.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2284 638X</institution-id><institution>Division of Virology, </institution><institution>University of the Free State, </institution></institution-wrap>Bloemfontein, South Africa </aff>
        <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.29857.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2097 4281</institution-id><institution>Center for Infectious Disease Dynamics, Department of Biology, </institution><institution>Pennsylvania State University, </institution></institution-wrap>University Park, PA USA </aff>
        <aff id="Aff12"><label>12</label>Diagnofirm Medical Laboratories, Gaborone, Botswana </aff>
        <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution>Institute of Evolutionary Biology, </institution><institution>University of Edinburgh, </institution></institution-wrap>Edinburgh, UK </aff>
        <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.49697.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 2298</institution-id><institution>Zoonotic Arbo and Respiratory Virus Program, Centre for Viral Zoonoses, Department of Medical Virology, </institution><institution>University of Pretoria, </institution></institution-wrap>Pretoria, South Africa </aff>
        <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.508029.6</institution-id><institution>Emweb, </institution></institution-wrap>Herent, Belgium </aff>
        <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.7836.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1151</institution-id><institution>Division of Medical Virology, Faculty of Health Sciences, </institution><institution>University of Cape Town, </institution></institution-wrap>Cape Town, South Africa </aff>
        <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Department of Zoology, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff>
        <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.5801.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2156 2780</institution-id><institution>Department of Biosystems Science and Engineering, </institution><institution>ETH Zurich, </institution></institution-wrap>Zurich, Switzerland </aff>
        <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.11956.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2214 904X</institution-id><institution>Division of Medical Virology, Faculty of Medicine and Health Sciences, </institution><institution>Stellenbosch University, Tygerberg, </institution></institution-wrap>Cape Town, South Africa </aff>
        <aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.418068.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 0931</institution-id><institution>Laboratorio de Flavivirus, </institution><institution>Fundacao Oswaldo Cruz, </institution></institution-wrap>Rio de Janeiro, Brazil </aff>
        <aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.8430.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 4888</institution-id><institution>Laborat&#xF3;rio de Gen&#xE9;tica Celular e Molecular, </institution><institution>Universidade Federal de Minas Gerais, </institution></institution-wrap>Belo Horizonte, Brazil </aff>
        <aff id="Aff22"><label>22</label>Division of Virology, NHLS Groote Schuur Laboratory, Cape Town, South Africa </aff>
        <aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="GRID">grid.497864.0</institution-id><institution>Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), </institution></institution-wrap>Cape Town, South Africa </aff>
        <aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="GRID">grid.7836.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1151</institution-id><institution>Division of Computational Biology, Faculty of Health Sciences, </institution><institution>University of Cape Town, </institution></institution-wrap>Cape Town, South Africa </aff>
        <aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="GRID">grid.264727.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2248 3398</institution-id><institution>Institute for Genomics and Evolutionary Medicine, Department of Biology, </institution><institution>Temple University, </institution></institution-wrap>Philadelphia, PA USA </aff>
        <aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="GRID">grid.415807.f</institution-id><institution>Health Services Management, </institution><institution>Ministry of Health and Wellness, </institution></institution-wrap>Gaborone, Botswana </aff>
        <aff id="Aff27"><label>27</label>NHLS Port Elizabeth Laboratory, Port Elizabeth, South Africa </aff>
        <aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="GRID">grid.412870.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 0447 7939</institution-id><institution>Faculty of Health Sciences, </institution><institution>Walter Sisulu University, </institution></institution-wrap>Mthatha, South Africa </aff>
        <aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="GRID">grid.415807.f</institution-id><institution>Public Health Department, Integrated Disease Surveillance and Response, </institution><institution>Ministry of Health and Wellness, </institution></institution-wrap>Gaborone, Botswana </aff>
        <aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Immunology and Infectious Diseases, </institution><institution>Harvard T.H. Chan School of Public Health, Boston, </institution></institution-wrap>MA, USA </aff>
        <aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="GRID">grid.417371.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0635 423X</institution-id><institution>NHLS Tygerberg Laboratory, </institution><institution>Tygerberg Hospital, </institution></institution-wrap>Cape Town, South Africa </aff>
        <aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="GRID">grid.414707.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0364 9292</institution-id><institution>Department of Virology, </institution><institution>Charlotte Maxeke Johannesburg Academic Hospital, </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="GRID">grid.463139.a</institution-id><institution>Botswana-Baylor Children&#x2019;s Clinical Centre of Excellence, </institution></institution-wrap>Gaborone, Botswana </aff>
        <aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, TX USA </aff>
        <aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="GRID">grid.49697.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 2298</institution-id><institution>Department of Medical Virology, </institution><institution>University of Pretoria, </institution></institution-wrap>Pretoria, South Africa </aff>
        <aff id="Aff36"><label>36</label><institution-wrap><institution-id institution-id-type="GRID">grid.415807.f</institution-id><institution>National Health Laboratory, Health Services Management, </institution><institution>Ministry of Health and Wellness, </institution></institution-wrap>Gaborone, Botswana </aff>
        <aff id="Aff37"><label>37</label><institution-wrap><institution-id institution-id-type="GRID">grid.416657.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0630 4574</institution-id><institution>National Health Laboratory Service (NHLS), </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff38"><label>38</label><institution-wrap><institution-id institution-id-type="GRID">grid.428428.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 5938 4248</institution-id><institution>Centre for the AIDS Programme of Research in South Africa (CAPRISA), </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="GRID">grid.11956.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2214 904X</institution-id><institution>Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational Thinking, </institution><institution>Stellenbosch University, </institution></institution-wrap>Stellenbosch, South Africa </aff>
        <aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="GRID">grid.7621.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0635 5486</institution-id><institution>Department of Medicine, Faculty of Medicine, </institution><institution>University of Botswana, </institution></institution-wrap>Gaborone, Botswana </aff>
        <aff id="Aff41"><label>41</label><institution-wrap><institution-id institution-id-type="GRID">grid.7621.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0635 5486</institution-id><institution>Department of Medical Laboratory Sciences, School of Allied Health Professions, Faculty of Health Sciences, </institution><institution>University of Botswana, </institution></institution-wrap>Gaborone, Botswana </aff>
        <aff id="Aff42"><label>42</label><institution-wrap><institution-id institution-id-type="GRID">grid.16463.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 0723 4123</institution-id><institution>Discipline of Virology, School of Laboratory Medicine and Medical Sciences and National Health Laboratory Service (NHLS), </institution><institution>University of KwaZulu-Natal, </institution></institution-wrap>Durban, South Africa </aff>
        <aff id="Aff43"><label>43</label><institution-wrap><institution-id institution-id-type="GRID">grid.412219.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2284 638X</institution-id><institution>Next Generation Sequencing Unit, Division of Virology, Faculty of Health Sciences, </institution><institution>University of the Free State, </institution></institution-wrap>Bloemfontein, South Africa </aff>
        <aff id="Aff44"><label>44</label><institution-wrap><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>Department of Molecular Medicine and Haematology, </institution><institution>University of the Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff45"><label>45</label><institution-wrap><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>School of Pathology, Faculty of Health Sciences, </institution><institution>University of the Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff46"><label>46</label>PathCare Vermaak, Pretoria, South Africa </aff>
        <aff id="Aff47"><label>47</label><institution-wrap><institution-id institution-id-type="GRID">grid.7836.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1151</institution-id><institution>Institute of Infectious Disease and Molecular Medicine, </institution><institution>University of Cape Town, </institution></institution-wrap>Cape Town, South Africa </aff>
        <aff id="Aff48"><label>48</label><institution-wrap><institution-id institution-id-type="GRID">grid.11951.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1135</institution-id><institution>Department of Molecular Pathology, School of Pathology, Faculty of Health Sciences, </institution><institution>University of the Witwatersrand, </institution></institution-wrap>Johannesburg, South Africa </aff>
        <aff id="Aff49"><label>49</label><institution-wrap><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution>Department of Global Health, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>7</day>
        <month>1</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>7</day>
        <month>1</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2022</year>
      </pub-date>
      <volume>603</volume>
      <issue>7902</issue>
      <fpage>679</fpage>
      <lpage>686</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>12</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>1</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2022</copyright-statement>
        <license>
          <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x2019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">The SARS-CoV-2 epidemic in southern Africa has been characterized by three distinct waves. The first was associated with a mix of SARS-CoV-2 lineages, while the second and third waves were driven by the Beta&#xA0;(B.1.351) and Delta&#xA0;(B.1.617.2) variants, respectively<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref></sup>. In November 2021, genomic surveillance teams in South Africa and Botswana detected a new SARS-CoV-2 variant associated with a rapid resurgence of infections in Gauteng province, South Africa. Within three days of the first genome being uploaded, it was designated a variant of concern (Omicron, B.1.1.529) by the World Health Organization and, within three weeks, had been identified in 87 countries. The Omicron variant is exceptional for carrying over 30 mutations in the spike glycoprotein, which are predicted to influence antibody neutralization and spike function<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Here we describe the genomic profile and early transmission dynamics of Omicron, highlighting the rapid spread in regions with high levels of population immunity.</p>
      </abstract>
      <abstract id="Abs2" abstract-type="web-summary">
        <p id="Par2">The genomic profile and early transmission dynamics of the Omicron strain of SARS-CoV-2.</p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
        <title>Subject terms</title>
        <kwd>Molecular evolution</kwd>
        <kwd>Epidemiology</kwd>
        <kwd>SARS-CoV-2</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s), under exclusive licence to Springer Nature Limited 2022</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Main</title>
      <p id="Par3">Since the onset of the COVID-19 pandemic in December 2019, variants of SARS-CoV-2 have emerged repeatedly. Some variants have spread worldwide and made major contributions to the cyclical infection waves that occur asynchronously in different regions. Between October and December 2020, the world witnessed the emergence of the first variants of concern (VOCs). These variants exhibited increased transmissibility and/or immune evasion properties that threatened global efforts to control the pandemic. Although the Alpha&#xA0;(B.1.1.7), Beta and Gamma VOCs<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup> that emerged during this time disseminated globally and drove epidemic resurgences in many different countries, it was the highly transmissible Delta variant that subsequently displaced all of the other VOCs in most regions of the world<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. During its spread, the Delta variant evolved into multiple sublineages<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, some of which demonstrated signs of having a growth advantage in certain locations<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, prompting speculation that the next VOC to drive a resurgence of infections would probably be derived from Delta. In October 2021, while Delta was continuing to exhibit high levels of transmission in the Northern Hemisphere, a large Delta wave was subsiding in southern Africa. The culmination of this wave coincided with the emergence of a new SARS-CoV-2 variant that, within days of its near-simultaneous discovery in four individuals in Botswana, a traveller from South Africa in Hong Kong and 54 individuals in South Africa, was designated by the World Health Organization&#xA0;(WHO) as Omicron&#x2014;the fifth VOC of SARS-CoV-2. Since then and the beginning of 2022, over 100,000 genomes of Omicron have been produced as Omicron has started to dominate SARS-CoV-2 infections in the world.</p>
    </sec>
    <sec id="Sec2">
      <title>Epidemic dynamics and detection of Omicron</title>
      <p id="Par4">The three distinct epidemic waves of SARS-CoV-2 experienced by southern African countries were each driven by different variants: the first between June and August 2020 by descendants of the B.1 lineage<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>; the second between November 2020 and February 2021 by the Beta VOC<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>; and the third between May and September 2021 by the Delta VOC<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>, with an estimated 2&#x2013;5% of third-wave cases in South Africa attributed to the C.1.2 lineage<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Serosurveys conducted before the Delta wave suggested high levels of exposure to SARS-CoV-2 (40&#x2013;60%) in South Africa<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>, and the estimated seroprevalence was &gt;70% in Gauteng on the basis of a population-based survey that was conducted between October and December 2021 (ref. <sup><xref ref-type="bibr" rid="CR13">13</xref></sup>). The weeks following the third wave in South Africa, between 10 October and 15 November 2021, were marked by lower levels of transmission, as indicated by a low incidence of reported COVID-19 cases (100&#x2013;200 new cases per day) and low (&lt;2%) test positivity rates (Fig. <xref rid="Fig1" ref-type="fig">1a&#x2013;c</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Detection of Omicron variant.</title><p><bold>a</bold>, The progression of daily reported cases in South Africa from March 2020 to December 2021. The 7-day rolling average of daily case numbers is coloured by the inferred proportion of variants responsible for the infections, as calculated by genomic surveillance data on GISAID. <bold>b</bold>, Timeline of Omicron detection in Botswana and South Africa. Bars represent the number of Omicron genomes shared per day, according to the date they were uploaded to GISAID; the line represents the 7-day moving average of daily new cases in South Africa. BHHRL, Botswana Harvard HIV Reference Laboratory; BW, Botswana;&#xA0;NGS-SA, Network for Genomic Surveillance in South Africa; SA, South Africa. <bold>c</bold>, Weekly progression of average daily cases per 100,000 individuals, test positivity rates, proportion of SGTF tests (on the TaqPath COVID-19 PCR assay) and genomic prevalence of Omicron in nine provinces of South Africa for five weeks from 31 October to 4 December 2021. Note that, because of heterogeneous use of the TaqPath PCR assay across provinces, the proportion of SGTF tests illustrated for the Eastern Cape province in weeks of 14&#x2013;20 November and 21&#x2013;27 November 2021 are based on only 2 and 4 data points, respectively. Genomic prevalence here is equivalent to the proportion of weekly surveillance sequences genotyped as being Omicron.</p></caption><graphic xlink:href="41586_2022_4411_Fig1_HTML" id="d32e1575"/></fig></p>
      <p id="Par5">A rapid increase in COVID-19 cases was observed from the middle of November 2021 in Gauteng province, the economic hub of South Africa containing the cities of Tshwane (Pretoria) and Johannesburg. Specifically, rising case numbers and test positivity rates were first noticed in Tshwane, initially associated with outbreaks in higher-education settings. This resurgence of cases was accompanied by an increasing frequency of <italic>S</italic>-gene target failure (SGTF) during TaqPath-based diagnostic PCR testing: a phenomenon that was previously observed with the Alpha variant due to a deletion at amino acid positions 69 and 70 (&#x2206;69&#x2013;70) in the SARS-CoV-2 spike protein<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Given the low prevalence of Alpha in South Africa (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>), targeted whole-genome sequencing of these specimens was prioritized.</p>
      <p id="Par6">On 19 November 2021, sequencing results from a batch of 8 SGTF samples collected between 14 and 16 November 2021 indicated that all were of a new and genetically distinct lineage of SARS-CoV-2. Further rapid sequencing identified the same variant in 29 out of 32 routine diagnostic samples from multiple locations in Gauteng province, indicating the widespread circulation of this new variant by the second week of November. Crucially, this rise immediately preceded a sharp increase in reported case numbers (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>, Extended Data Fig. <xref rid="Fig5" ref-type="fig">1</xref>). In the following four days, the presence of this lineage was confirmed by sequencing in another two provinces&#x2014;KwaZulu-Natal and the Western Cape (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>).</p>
      <p id="Par7">Concurrently, in Gaborone, Botswana (&lt;360&#x2009;km from Tshwane), four genomes generated from samples collected on 11 November 2021 and sequenced on 17&#x2013;18 November 2021 as part of weekly surveillance displayed an unusual set of mutations. These were reported to the Botswana Ministry of Health and Wellness on 22 November 2021 as unusual sequences that were linked to a group of visitors (non-residents) on a diplomatic mission. The sequences were uploaded to GISAID<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup> on 23 November 2021, and it became apparent that they belonged to a new lineage. A further 15 genomically confirmed cases (not epidemiologically linked to the first four) were identified within the same week from various other locations in Botswana. All of these either had travel links from South Africa, or were contacts of someone with travel links.</p>
      <p id="Par8">On 24 November 2021, these SARS-CoV-2 genomes from both South Africa and Botswana were designated as belonging to a new PANGO lineage (B.1.1.529)<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, which was later divided into sublineages aliased BA.1 (the main clade), BA.2 and BA.3. On 26 November 2021, the lineage was designated a VOC and named Omicron by the WHO on the recommendation of the Technical Advisory Group on SARS-CoV-2 Virus Evolution<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. By the first week of December 2021, Omicron was causing a rapid and sustained increase in cases in South Africa and Botswana (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>, Extended Data Fig. <xref rid="Fig6" ref-type="fig">2</xref> (for Botswana)). In Gauteng, weekly test positivity rates increased from &lt;1% in the week beginning 31 October, to 16% in the week beginning 21 November 2021, and to 35% in the week beginning 28 November, concurrent with an exponential rise in COVID-19 incidence (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>, Extended Data Fig. <xref rid="Fig5" ref-type="fig">1</xref>). Nationally, daily case numbers exceeded 22,000 (84% of the peak of the previous wave of infections) by 9 December 2021. At the same time, the proportion of TaqPath PCR tests with SGTF increased rapidly in all provinces of South Africa, reaching ~90% nationally by the week beginning 21 November 2021, strongly indicating that the fourth wave was being driven by Omicron&#x2014;an indication that has now been confirmed by virus genome sequencing in all provinces (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). Similarly, Botswana experienced a sharp increase in cases, doubling every 2&#x2013;3 days during late November to early December 2021, transitioning from a 7-day moving average of &lt;10 cases per 100,000 individuals to above 25 cases per 100,000 individuals in less than 10 days (Extended Data Fig. <xref rid="Fig6" ref-type="fig">2</xref>).</p>
      <p id="Par9">By 16 December 2021, Omicron had been detected in 87 countries, both in samples from travellers returning from southern Africa, and in samples from routine community testing (Extended Data Fig. <xref rid="Fig7" ref-type="fig">3</xref>) and, by 1 January 2022, over 100,000 genomes had been produced from over 100 countries and Omicron was becoming the dominant VOC in the world.</p>
    </sec>
    <sec id="Sec3">
      <title>Evolutionary origins of Omicron</title>
      <p id="Par10">To determine when and where Omicron probably originated, we analysed all 686 available Omicron genomes (including 248 from southern Africa and 438 from elsewhere in the world) retrieved from GISAID (date of access, 7 December 2021)<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>, in the context of a global reference set of representative SARS-CoV-2 genomes (<italic>n</italic>&#x2009;=&#x2009;12,609) collected between December 2019 and November 2021. Preliminary maximum-likelihood phylogenies identified the Omicron&#xA0;BA.1 sequences as a monophyletic clade rooted within the B.1.1 lineage (Nextstrain clade 20B), with no clear basal progenitor (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). Importantly, the BA.1 cluster is highly phylogenetically distinct from any known VOCs or variants of interest (VOIs) and from any other lineages that are known to be circulating in southern Africa (such as C.1.2) (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). More recently, two related lineages have emerged (BA.2 and BA.3), both sharing many, but not all of the characteristic mutations of BA.1 and both having many unique mutations of their own (Extended Data Fig. <xref rid="Fig8" ref-type="fig">4a, b</xref>). While BA.2 and BA.3 are evolutionarily linked to BA.1 in that they all branch off of the same B.1.1 node without obvious progenitors, the three sublineages evolved independently from one another along separate branches (Extended Data Fig. <xref rid="Fig8" ref-type="fig">4c, d</xref>). The earliest specimens of BA.2 and BA.3 were both sampled after the earliest known BA.1 in South Africa (8 November 2021 at the time of writing), on 17 November 2021 in Tshwane (Gauteng) and on 18 November 2021 in a neighbouring province (North West), respectively. We primarily focus here on the BA.1 lineage, which is rapidly spreading in multiple countries around the world and is the lineage that was first officially designated as the Omicron VOC.<fig id="Fig2"><label>Fig. 2</label><caption><title>Evolution of Omicron.</title><p><bold>a</bold>, Time-resolved maximum likelihood phylogeny of 13,295 SARS-CoV-2 genomes; 9,944 of these are from Africa (denoted with tip point circle shapes). Alpha, Beta and Delta VOCs and the C.1.2 lineage, recently circulating in South Africa, are denoted in black, brown, green and blue, respectively. The newly identified SARS-CoV-2 Omicron variant is shown in pink. Genomes of other lineages are shown in grey. <bold>b</bold>, Time-resolved maximum clade credibility phylogeny of the Omicron cluster of southern African genomes (<italic>n</italic>&#x2009;=&#x2009;553), with locations indicated. The posterior distribution of the TMRCA is also shown. <bold>c</bold>, Spatiotemporal reconstruction of the spread of the Omicron variant in southern Africa with an inset of Gauteng province. Circles represent nodes of the maximum clade credibility phylogeny, coloured according to their inferred time of occurrence (scale in the top panel). Shaded areas represent the 80% HPD interval and depict the uncertainty of the phylogeographical estimates for each node. Solid curved lines denote the links between nodes and the directionality of movement is anticlockwise along the curve. EC, Eastern Cape; FS, Free State; GP, Gauteng; KZN, KwaZulu-Natal; LP, Limpopo; MP, Mpumalanga; NC, Northern Cape; NW, North West; WC, Western Cape.</p></caption><graphic xlink:href="41586_2022_4411_Fig2_HTML" id="d32e1691"/></fig></p>
      <p id="Par11">Time-calibrated Bayesian phylogenetic analysis of all BA.1 assigned genomes from southern Africa (as of 11 December 2021, <italic>n</italic>&#x2009;=&#x2009;553) estimated the time at which the most recent common ancestor (TMRCA) of the analysed BA.1 lineage sequences existed to be 9 October 2021 (95% highest posterior density (HPD) 30 September&#x2013;20 October) with a per-day exponential growth rate of 0.137 (95% HPD&#x2009;=&#x2009;0.099&#x2013;0.175) reflecting a doubling time of 5.1 days (95% HPD&#x2009;=&#x2009;4.0&#x2013;7.0) (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). These estimates are robust to whether the evolutionary rate is estimated from the data or fixed to previously estimated values (Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>). Limiting the analysis to genomes from Gauteng province only yields a faster growth rate estimate with a doubling time of 2.8 days (95% HPD&#x2009;=&#x2009;2.1&#x2013;4.2) (Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>). Using a phylodynamic model that accounts for variable genome sampling through time (birth&#x2013;death skyline model (BDSKY)<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>) yields a doubling time of BA.1-assigned genomes from South Africa and Botswana (<italic>n</italic>&#x2009;=&#x2009;552) of 3.9 (95% HPD&#x2009;=&#x2009;3.5&#x2013;4.3) days with an effective reproduction number (<italic>R</italic><sub>e</sub>) of 2.79 (95% HPD&#x2009;=&#x2009;2.60&#x2013;2.97) during the period from early November to early December. The BDSKY-estimated <italic>R</italic><sub>e</sub> for the Gauteng province dataset is 3.86 (95% HPD&#x2009;=&#x2009;3.43&#x2013;4.29) and 3.61 (95% HPD&#x2009;=&#x2009;3.20&#x2013;4.02) for the 3-epoch and 4-epoch model, respectively (Extended Data Tables <xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab5" ref-type="table">5</xref>). Spatiotemporal phylogeographic analysis indicates that the BA.1 variant spread from the Gauteng province of South Africa to seven of the eight other provinces and to two regions of Botswana from late October to late November 2021, and shows evidence of more recent transmission within and between other South African provinces (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>). However, this does not imply that Omicron originated in Gauteng and these phylogeographic inferences could change as further genomic data accumulate from other locations.</p>
    </sec>
    <sec id="Sec4">
      <title>Molecular profile of Omicron</title>
      <p id="Par12">Compared with Wuhan-Hu-1, BA.1 carries 15 mutations in the spike receptor-binding domain (RBD) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>), five of which (G339D, N440K, S477N, T478K and N501Y) have been shown individually to enhance bind to human ACE2 (hACE2)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Seven of the RBD mutations (K417N, G446S, E484A, Q493R, G496S, Q498R and N501Y) are expected to have moderate to strong effects on the binding of at least three out of the four major classes of RBD-targeted neutralizing antibodies<sup><xref ref-type="bibr" rid="CR21">21</xref>&#x2013;<xref ref-type="bibr" rid="CR23">23</xref></sup>. These RBD mutations coupled with four amino acid substitutions (A67V, T95I, G142D and L212I), three deletions (69&#x2013;70, 143&#x2013;145 and 211) and an insertion (EPE between 214 and 215) in the N-terminal domain (NTD)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> are predicted to underlie the substantially reduced sensitivity of Omicron to neutralization by anti-SARS-CoV-2 antibodies induced by either infection or vaccination<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>. These mutations also involve key structural epitopes that are targeted by some of the currently authorized monoclonal antibodies, particularly bamlanivimab + etesevimab and casirivimab + imdevimab<sup><xref ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref ref-type="bibr" rid="CR29">29</xref></sup>. Preliminary analysis suggests that, although the spike mutations involve a number of T cell and B cell epitopes, the majority of epitopes (&gt;70%) remain unaffected<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>.<fig id="Fig3"><label>Fig. 3</label><caption><title>Molecular profile of BA.1.</title><p><bold>a</bold>, Amino&#xA0;acid mutations on the spike gene of the BA.1 variant. <bold>b</bold>, The structure of the SARS-CoV-2 spike trimer, showing a single spike protomer in cartoon view. The NTD, RBD, subdomains 1 and 2, and the S2 protein are shown in cyan, yellow, pink, and green, respectively. The red spheres indicate the alpha carbon positions for each omicron variant residue. NTD-specific loop insertions/deletions are shown in red, with the original loop shown in transparent black.</p></caption><graphic xlink:href="41586_2022_4411_Fig3_HTML" id="d32e1791"/></fig></p>
      <p id="Par13">Omicron also has a cluster of three mutations (H655Y, N679K and P681H) adjacent to the S1/S2 furin cleavage site (FCS) that are likely to enhance spike protein cleavage and fusion with host cells<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup> and that could also contribute to enhanced transmissibility<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> (Extended Data Fig. <xref rid="Fig9" ref-type="fig">5</xref>).</p>
      <p id="Par14">Outside of the spike protein, a deletion in nsp6 (del105&#x2013;107), in the same region as deletions seen in Alpha, Beta, Gamma and Lambda, may have a role in evasion of innate immunity<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, and the double mutation in nucleocapsid (R203K and G204R)&#x2014;which is also present in Alpha, Gamma and C.1.2&#x2014;has been associated with enhanced infectivity in human lung cells<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>.</p>
    </sec>
    <sec id="Sec5">
      <title>Recombination analysis</title>
      <p id="Par15">Given the large number of mutations differentiating BA.1, BA.2 and BA.3 from other known SARS-CoV-2 lineages, it was considered plausible that (1) all of these lineages might have descended from a common recombinant ancestor; (2) one or more of the BA lineages might have originated through recombination between a virus in one of the other BA lineages and a virus in a non-BA lineage; or (3) one of the BA lineages may have originated through recombination between viruses in the other two BA lineages. We tested these hypotheses using a variety of recombination detection approaches (implemented using GARD<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, 3SEQ<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> and RDP5 (ref. <sup><xref ref-type="bibr" rid="CR38">38</xref></sup>)) to identify potential signals of recombination in sequence datasets containing the BA.1, BA.2 and BA.3 sequences together with sequences representative of global SARS-CoV-2 genomic diversity.</p>
      <p id="Par16">Potential evidence of a single recombination event involving BA.1, BA.2 and BA3 was identified by 3SEQ (<italic>P</italic>&#x2009;=&#x2009;0.03), GARD (delta c-AIC&#x2009;=&#x2009;20) and RDP5 (GENECONV <italic>P</italic>&#x2009;=&#x2009;0.027; RDP <italic>P</italic>&#x2009;=&#x2009;0.006) within the NTD encoding region of spike. The most likely breakpoint locations for this recombination event were 21690 for the 5&#x2032; breakpoint (high likelihood interval between 15716 and 21761) and 22198 for the 3&#x2032; breakpoint (high likelihood interval between 22197 and 22774). However, these analyses could not reliably identify which of BA.1, BA.2 or BA.3 was the recombinant. Phylogenetic analysis of the genome regions bounded by these breakpoints (genome coordinates 1&#x2013;21689, 21690&#x2013;22198 and 22199&#x2013;29903) potentially supported (1) BA.1 having acquired the NTD encoding region of BA.3 through recombination, (2) BA.3 having acquired the NTD-encoding region of BA.1 through recombination or (3) BA.2 having acquired the NTD-encoding region of a non-BA lineage virus through recombination (Extended Data Fig. <xref rid="Fig10" ref-type="fig">6</xref>).</p>
      <p id="Par17">Although we found weak statistical and phylogenetic evidence of one of BA.1, BA.2 or BA.3 being recombinant, we found no evidence that the MRCA of the BA.1, BA.2 and BA.3 lineages was recombinant. However, note that recombination tests in general will not have sufficient statistical power to reliably identify evidence of individual recombination events that result in transfers of less than ~5 contiguous polymorphic nucleotide sites between genomes<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>. Furthermore, if BA.1, BA.2 and/or BA.3 are the products of a series of multiple partially overlapping recombination events occurring across multiple temporally clustered replication cycles, the complex patterns of nucleotide variation that might result could be extremely difficult to interpret as recombination using the methods applied here<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>.</p>
    </sec>
    <sec id="Sec6">
      <title>Selection analysis of Omicron</title>
      <p id="Par18">The large numbers of mutations seen in the BA.1, BA.2 and BA.3 lineage sequences may have accrued at an accelerated pace under the influence of positive selection. To test for evidence of this, we applied a selection analysis pipeline to all of the available sequences designated as BA.1, BA.2 and BA.3 in GISAID as of 20 December 2021. We ran selection screens individually on BA.1, BA.2 and BA.3 sequences, according to a previously described procedure<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. We downsampled alignments of individual protein-encoding regions to obtain a median of 110 genetically unique BA.1 sequences, 3 BA.2 sequences, 2.5 BA.3 sequences and around 100 other unique sequences for each gene/open reading frame (ORF) from a representative collection of other SARS-CoV-2 lineages (used as background sequences to contextualize evolution within the Omicron subclade).</p>
      <p id="Par19">Given that the BA.1 lineage has 1,000-fold more sequences than BA.2 and BA.3, we performed the most detailed analysis on it. We detected evidence of gene-wide positive selection (using the BUSTED method<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>) acting on 11 genes&#xA0;or&#xA0;ORFs since the ancestral BA.1 lineage split from the B.1.1 lineage: <italic>M</italic> gene (<italic>P</italic>&#x2009;=&#x2009;0.002), <italic>N</italic> gene (<italic>P</italic>&#x2009;=&#x2009;0.006), <italic>nsp3</italic> (<italic>P</italic>&#x2009;=&#x2009;0.05), <italic>S</italic> gene, exonuclease,&#xA0;<italic>RdRp</italic>,&#xA0;methyltransferase, helicase, <italic>ORF7a</italic>, <italic>ORF6</italic> and <italic>ORF3a</italic> (<italic>P</italic>&#x2009;&lt;&#x2009;0.0001 for all tests). In all ten genes, this selection was strong (ratio of non-synonymous to synonymous substitutions&#xA0;(d<italic>N</italic>/d<italic>S</italic>)&#xA0;&gt;&#x2009;5) and occurred in bursts (&#x2264;6% of branch&#x2013;site combinations selected). The branch separating BA.1 from its most recent B.1.1 ancestor had the most prominent selection signal (which was strongest in the <italic>S</italic> gene, with evidence for nine positively selected sites along this branch<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>), strongly supporting the hypothesis that adaptive evolution had a substantial role in the mutational divergence of Omicron from other B.1.1 SARS-CoV-2 lineages. Relative to the intensity of selection evident within the background B.1.1 lineages, selection in five genes was probably significantly intensified in the BA.1 lineage: <italic>S</italic> gene (intensification factor <italic>K</italic>&#x2009;=&#x2009;2.1, <italic>P</italic>&#x2009;&lt;&#x2009;0.0001<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>), exonuclease (<italic>K</italic>&#x2009;=&#x2009;3.50, <italic>P</italic>&#x2009;=&#x2009;0.0009), <italic>nsp6</italic> (<italic>K</italic>&#x2009;=&#x2009;2.4, <italic>P</italic>&#x2009;=&#x2009;0.03), <italic>RdRp</italic> (<italic>K</italic>&#x2009;=&#x2009;1.14, <italic>P</italic>&#x2009;=&#x2009;0.02) and <italic>M</italic> (<italic>K</italic>&#x2009;=&#x2009;4.6, <italic>P</italic>&#x2009;&lt;&#x2009;0.0001).</p>
      <p id="Par20">Among 1,546 codon sites that are polymorphic among the BA.1 sequences analysed, 45 were found to have experienced episodic positive selection since BA.1 split from the B.1.1 lineage<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> (MEME <italic>P</italic>&#x2009;&#x2264;&#x2009;0.01; Extended Data Table <xref rid="Tab2" ref-type="table">2</xref>) . Twenty-three (51%) of these codon sites are in the <italic>S</italic> gene, thirteen of which contain BA.1-lineage-defining mutations (that is, these selection signals reflect mutations that occurred within the ancestral Omicron lineage). The three positively selected codon sites that did not correspond to sites of lineage-defining mutations (<italic>S</italic>, 346; <italic>S</italic>, 452; and <italic>S</italic>, 701) are particularly notable as these are attributable to mutations that have occurred since the MRCA of the analysed BA.1 sequences. The mutations driving the positive selection signals at these three sites in the Omicron <italic>S</italic> gene converge on mutations seen in other VOCs or VOIs (R346K in Mu, L452R in Delta, and A701V in Beta and Iota). The A701V mutation, the precise impact of which is currently unknown, is one of 19 in a proposed &#x2018;501Y-lineage spike meta-signature&#x2019; comprising the set of mutations that were most adaptive during the evolution of the Alpha, Beta and Gamma VOC lineages<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Furthermore, both R346K and L452R are known to affect antibody binding<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> and both of the codon sites at which these mutations occur display evidence of directional selection (using the FADE method<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>). These selective patterns suggest that, during its current rapid spread, BA.1 may be undergoing additional evolution to modify its neutralization profile.</p>
      <p id="Par21">As the numbers of available BA.2 and BA.3 sequences are much lower than for BA.1, the power to perform selection detection was much reduced and not possible for some genomic regions. Nonetheless, there was a strong signal of selection on the <italic>S</italic> gene (<italic>P</italic>&#x2009;&lt;&#x2009;0.0001 for BA.2 and <italic>P</italic>&#x2009;=&#x2009;0.05 for BA.3) and selective pressures on this gene in the BA.2 clade were intensified relative to reference SARS-CoV-2 isolates (<italic>K</italic>&#x2009;=&#x2009;6.25, <italic>P</italic>&#x2009;=&#x2009;0.005). Within BA.2 sequences, positive selection was detectable on five sites in the <italic>S</italic> gene (371, 376, 405, 477 and 505&#x2014;all clade defining sites) as well on two sites in the <italic>M</italic> gene (19 and 63&#x2014;both clade-defining sites). Within BA.3 sequences, positive selection was detectable on four sites in the <italic>S</italic> gene (67, 371, 477 and 505&#x2014;all clade-defining sites) as well on two sites in the <italic>N</italic> gene (13 and 413&#x2014;both clade defining sites).</p>
    </sec>
    <sec id="Sec7">
      <title>Transmissibility and immune evasion</title>
      <p id="Par22">We estimated that Omicron had a growth advantage of 0.24 (95% CI&#x2009;=&#x2009;0.16&#x2013;0.33) per day over Delta in Gauteng, South Africa (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). This corresponds to a 5.4-fold (95% CI&#x2009;=&#x2009;3.1&#x2013;10.1) weekly increase in cases compared with Delta. The growth advantage of Omicron is likely to be mediated by (1) an increase relative to other variants in its intrinsic transmissibility, (2) an increase relative to other variants in its ability to infect, and be transmitted from, previously infected and vaccinated individuals; or (3) both.<fig id="Fig4"><label>Fig. 4</label><caption><title>Growth of Omicron in Gauteng, South Africa, and the relationship between potential increase in transmissibility and immune evasion.</title><p><bold>a</bold>, Omicron rapidly outcompeted Delta in November 2021. Model fits are based on a multinomial logistic regression. Dots represent the weekly proportions of variants. <bold>b</bold>, The relationship between the potential increase in transmissibility and immune evasion strongly depends on the assumed level of current population immunity against Delta that is afforded by previous infections during earlier epidemic waves and/or vaccination (<italic>&#x3A9;</italic>). <bold>c</bold>&#x2013;<bold>e</bold>, The relationship for a population immunity of 40% (<bold>c</bold>), 60% (<bold>d</bold>) and 80% (<bold>e</bold>) against infection and transmission with Delta. The dark vertical dashed line indicates equal transmissibility of Omicron compared to Delta. The shaded areas correspond to the 95% CIs of the model estimates.</p></caption><graphic xlink:href="41586_2022_4411_Fig4_HTML" id="d32e2092"/></fig></p>
      <p id="Par23">The predicted combination of transmissibility and immune evasion for Omicron strongly depends on the assumed level of current population immunity against infection by, and transmission of, the competing variant Delta that is afforded by previous infections with Beta, Delta and other strains during the three previous epidemic waves in South Africa, and/or vaccination (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). For moderate levels of population immunity against Delta (<italic>&#x3A9;</italic>&#x2009;=&#x2009;0.4), immune evasion alone cannot explain the observed growth advantage of Omicron (Fig. <xref rid="Fig4" ref-type="fig">4c</xref>). For medium levels of immunity against Delta (<italic>&#x3A9;</italic>&#x2009;=&#x2009;0.6), very high levels of immune evasion could explain the observed growth advantage without an additional increase in transmissibility (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>). For high levels of population immunity against Delta (<italic>&#x3A9;</italic>&#x2009;=&#x2009;0.8), even moderate levels of immune evasion (~25&#x2013;50%) can explain the observed growth advantage without an additional increase in transmissibility (Fig. <xref rid="Fig4" ref-type="fig">4e</xref>). The results of seroprevalence studies and vaccination coverage (&#x223C;40% of the adult population in South Africa) suggest that the proportion of the population with potential immunity against Delta and earlier variants is probably above 60% (refs. <sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>). We therefore argue that the population level of protective immunity against Delta acquired during previous epidemic waves is high, and that partial immune evasion is a major driver for the observed dynamics of Omicron in South Africa. This notion is supported by recent findings that show an increased risk of SARS-CoV-2 reinfection associated with the emergence of Omicron in South Africa<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> and the initial results from neutralization assays<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. However, in addition to immune evasion, an increase or decrease in the transmissibility of Omicron compared with Delta cannot be ruled out.</p>
      <p id="Par24">There are a number of limitations to this analysis. First, we estimated the growth advantage of Omicron based on early sequence data only. These data could be biased due to targeted sequencing of SGTF samples and stochastic effects (such as superspreading) in a low-incidence setting, which can lead to overestimates of the growth advantage and, consequently, of the increased transmissibility and immune evasion. Second, without reliable estimates of the level of protective immunity against Delta in South Africa, we cannot obtain precise estimates of transmissibility or immune evasion of Omicron.</p>
    </sec>
    <sec id="Sec8" sec-type="conclusion">
      <title>Conclusion</title>
      <p id="Par25">Strong genomic surveillance systems in South Africa and Botswana enabled the identification of Omicron within a week of observing a resurgence in cases in Gauteng province. Immediate notification of the WHO and early designation as a VOC has stimulated global scientific efforts and has given other countries time to prepare their response. Omicron is now driving a fourth wave of the SARS-CoV-2 epidemic in southern Africa, and is spreading rapidly in several other countries. Genotypic and phenotypic data suggest that Omicron has the capacity for substantial evasion of neutralizing antibody responses, and modelling suggests that immune evasion could be a major driver of the observed transmission dynamics. Close monitoring of the spread of Omicron in countries outside southern Africa will be necessary to better understand its transmissibility and the capacity of this variant to evade post-infection and vaccine-elicited immunity. Neutralizing antibodies are only one component of the immune protection from vaccines and prior infection, and the cellular immune response is predicted to be less affected by the mutations in Omicron. Vaccination therefore remains critical to protect those who have the highest risk of severe disease and death. The emergence and rapid spread of Omicron poses a threat to the world and a particular threat in Africa, where fewer than one in ten people are fully vaccinated.</p>
    </sec>
    <sec id="Sec9" sec-type="materials|methods">
      <title>Methods</title>
      <sec id="Sec10">
        <title>Epidemiological dynamics</title>
        <p id="Par26">We analysed daily cases of SARS-CoV-2 in South Africa up to 14 December 2021 from publicly released data provided by the National Department of Health and the National Institute for Communicable Diseases. This was accessible through the repository of the Data Science for Social Impact Research Group at the University of Pretoria (<ext-link ext-link-type="uri" xlink:href="https://github.com/dsfsi/covid19za">https://github.com/dsfsi/covid19za</ext-link>)<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. The National Department of Health releases daily updates on the number of confirmed new cases, deaths and recoveries, with a breakdown by province. Daily case numbers for Botswana were obtained through Our World in Data (OWID) COVID-19 data repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/owid/covid-19-data">https://github.com/owid/covid-19-data</ext-link>). We obtained test positivity data from weekly reports from the National Institute for Communicable Diseases (NICD)<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Data to calculate the proportion of positive TaqPath COVID-19 PCR tests (Thermo Fisher Scientific) with SGTF in South Africa was obtained from the National Health Laboratory Service and Lancet Laboratories. Test positivity data for Botswana was obtained from the National Health Laboratory up to 6 December 2021. All data visualization was generated through the ggplot package in R<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>.</p>
      </sec>
      <sec id="Sec11">
        <title>SARS-CoV-2 sampling</title>
        <p id="Par27">As part of the NGS-SA, seven sequencing hubs in South Africa receive randomly selected samples for sequencing every week according to approved protocols at each site<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. These samples include remnant nucleic acid extracts or remnant nasopharyngeal and oropharyngeal swab samples from routine diagnostic SARS-CoV-2 PCR testing from public and private laboratories in South Africa. In response to a focal resurgence of COVID-19 in the City of Tshwane Metropolitan Municipality in Gauteng province in November, we enriched our routine sampling with additional samples from the affected area, including initial targeted sequencing of SGTF samples. In Botswana, all public and private laboratories submit randomly selected residual nasopharyngeal and oropharyngeal PCR positive samples weekly to the National Health Laboratory (NHL) and the Botswana Harvard HIV Reference Laboratory (BHHRL) for sequencing.</p>
      </sec>
      <sec id="Sec12">
        <title>Ethical statement</title>
        <p id="Par28">The genomic surveillance in South Africa was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC/00001510/2020), the University of the Witwatersrand Human Research Ethics Committee (HREC) (M180832), Stellenbosch University HREC (N20/04/008_COVID-19), University of Cape Town HREC (383/2020), University of Pretoria HREC (H101/17) and the University of the Free State Health Sciences Research Ethics Committee (UFS-HSD2020/1860/2710). The genomic sequencing in Botswana was conducted as part of the national vaccine roll-out plan and was approved by the Health Research and Development Committee (Health Research Ethics body, HRDC#00948 and HRDC#00904). Individual participant consent was not required for the genomic surveillance. This requirement was waived by the Research Ethics Committees.</p>
      </sec>
      <sec id="Sec13">
        <title>Ion Torrent Genexus Integrated Sequencer methodology for rapid whole-genome sequencing of SARS-CoV-2</title>
        <p id="Par29">Viral RNA was extracted using the MagNA Pure 96 DNA and Viral Nucleic Acid kit on the automated MagNA Pure 96 system (Roche Diagnostics) according to the manufacturer&#x2019;s instructions. Extracts were then screened by quantitative PCR to acquire the mean cycle threshold (<italic>C</italic><sub>t</sub>) values for the SARS-CoV-2 <italic>N</italic> and <italic>ORF1ab</italic> genes using the TaqMan 2019-nCoV assay kit v1 (Thermo Fisher Scientific) on the ViiA7 Real-time PCR system (Thermo Fisher Scientific) according to the manufacturer&#x2019;s instructions. Extracts were sorted into batches of <italic>n</italic>&#x2009;=&#x2009;8 within a C<sub><italic>t</italic></sub> range difference of 5 for a maximum of two batches per run. Extracts with &lt;200 copies were sequenced using the low viral titre protocol. Next-generation sequencing was performed using the Ion AmpliSeq SARS-CoV-2 Research Panel on the Ion Torrent Genexus Integrated Sequencer (Thermo Fisher Scientific), which combines automated cDNA synthesis, library preparation, templating preparation and sequencing within 24&#x2009;h. The Ion Ampliseq SARS-CoV-2 Research Panel consists of two primer pools targeting 237 amplicons tiled across the SARS-CoV-2 genome providing &gt;99% coverage of the SARS-CoV-2 genome (~30&#x2009;kb) and an additional five primer pairs targeting human expression controls. The SARS-CoV-2 amplicons range from 125&#x2009;bp to 275&#x2009;bp in length. TRINITY was used for de novo assembly and the Iterative Refinement Meta-Assembler (IRMA) was used for genome assisted assembly as well as FastQC for quality checks.</p>
      </sec>
      <sec id="Sec14">
        <title>Whole-genome sequencing and genome assembly</title>
        <p id="Par30">RNA was extracted on an automated Chemagic 360 instrument, using the CMG-1049 kit (Perkin Elmer). The RNA was stored at &#x2212;80&#x2009;&#xB0;C before use. Libraries for whole-genome sequencing were prepared using either the Oxford Nanopore Midnight protocol with Rapid Barcoding or the Illumina COVIDseq Assay.</p>
        <sec id="Sec15">
          <title>Illumina Miseq/NextSeq</title>
          <p id="Par31">For the Illumina COVIDseq assay, the libraries were prepared according to the manufacturer&#x2019;s protocol. In brief, amplicons were tagmented, followed by indexing using the Nextera UD Indexes Set A. Sequencing libraries were pooled, normalized to 4&#x2009;nM and denatured with 0.2&#x2009;N sodium acetate. A 8&#x2009;pM sample library was spiked with 1% PhiX (PhiX Control v3 adaptor-ligated library used as a control). We sequenced libraries using the 500-cycle v2 MiSeq Reagent Kit on the Illumina MiSeq instrument (Illumina). On the Illumina NextSeq 550 instrument, sequencing was performed using the Illumina COVIDSeq protocol (Illumina), an amplicon-based next-generation sequencing approach. The first-strand synthesis was performed using random hexamers primers from Illumina and the synthesized cDNA underwent two separate multiplex PCR reactions. The pooled PCR amplified products were processed for tagmentation and adapter ligation using IDT for Illumina Nextera UD Indexes. Further enrichment and clean-up was performed according to protocols provided by the manufacturer (Illumina). Pooled samples were quantified using the Qubit 3.0 or 4.0 fluorometer (Invitrogen) and the Qubit dsDNA High Sensitivity assay kit according to the manufacturer&#x2019;s instructions. The fragment sizes were analysed using the TapeStation 4200 (Invitrogen). The pooled libraries were further normalized to 4&#x2009;nM concentration, and 25&#x2009;&#x3BC;l of each normalized pool containing unique index adapter sets was combined into a new tube. The final library pool was denatured and neutralized with 0.2&#x2009;N sodium hydroxide and 200&#x2009;mM Tris-HCl (pH&#x2009;7), respectively. Sample library (1.5&#x2009;pM) was spiked with 2% PhiX. Libraries were loaded onto a 300-cycle NextSeq 500/550 HighOutput Kit v2 and run on the Illumina NextSeq 550 instrument (Illumina).</p>
        </sec>
        <sec id="Sec16">
          <title>Midnight protocol</title>
          <p id="Par32">For Oxford Nanopore sequencing, the Midnight primer kit was used as described previously<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. cDNA synthesis was performed on the extracted RNA using the LunaScript RT mastermix (New England BioLabs) followed by gene-specific multiplex PCR using the Midnight primer pools, which produce 1,200&#x2009;bp amplicons that overlap to cover the 30&#x2009;kb SARS-CoV-2 genome. Amplicons from each pool were pooled and used neat for barcoding with the Oxford Nanopore Rapid Barcoding kit according to the manufacturer&#x2019;s protocol. Barcoded samples were pooled and bead-purified. After the bead clean-up, the library was loaded on a prepared R9.4.1 flow-cell. A GridION X5 or MinION sequencing run was initiated using MinKNOW software with the base-call setting switched off.</p>
        </sec>
        <sec id="Sec17">
          <title>Genome assembly</title>
          <p id="Par33">We assembled paired-end and Nanopore .fastq reads using Genome Detective v.1.132 (<ext-link ext-link-type="uri" xlink:href="https://www.genomedetective.com">https://www.genomedetective.com</ext-link>), which was updated for the accurate assembly and variant calling of tiled primer amplicon Illumina or Oxford Nanopore reads, and the Coronavirus Typing Tool<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. For Illumina assembly, the GATK HaploTypeCaller --min-pruning 0 argument was added to increase mutation calling sensitivity near sequencing gaps. For Nanopore, low-coverage regions with poor alignment quality (&lt;85% variant homogeneity) near sequencing/amplicon ends were masked to be robust against primer drop-out experienced in the spike gene, and the sensitivity for detecting short inserts using a region-local global alignment of reads was increased. We also used the wf_artic (ARTIC SARS-CoV-2) pipeline as built using the Nextflow workflow framework<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. In some instances, mutations were confirmed visually with .bam files using Geneious v.2020.1.2 (Biomatters). The reference genome used throughout the assembly process was <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NC_045512.2">NC_045512.2</ext-link> (numbering equivalent to <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3">MN908947.3</ext-link>).</p>
          <p id="Par34">Raw reads from the Illumina COVIDSeq protocol were assembled using the Exatype NGS SARS-CoV-2 pipeline v.1.6.1 (<ext-link ext-link-type="uri" xlink:href="https://sars-cov-2.exatype.com/">https://sars-cov-2.exatype.com/</ext-link>). This pipeline performs quality control on reads and then maps the reads to a reference using Examap. The reference genome used throughout the assembly process was <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NC_045512.2">NC_045512.2</ext-link> (accession number: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3">MN908947.3</ext-link>).</p>
          <p id="Par35">Several of the initial Ion Torrent genomes contained a number of frameshifts, which caused unknown variant calls. Manual inspection revealed that these were probably sequencing errors resulting in mis-assembled regions (probably due to the known error profile of Ion Torrent sequencers)<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. To resolve this, the raw reads from the IonTorrent platform were assembled using the SARSCoV2 RECoVERY (Reconstruction of Coronavirus Genomes &amp; Rapid Analysis) pipeline implemented in the Galaxy instance ARIES (<ext-link ext-link-type="uri" xlink:href="https://aries.iss.it">https://aries.iss.it</ext-link>). This pipeline fixed the observed frameshifts, confirming that they were artefacts of mis-assembly; this subsequently resolved the variant calls. The Exatype and RECoVERY pipelines each produce a consensus sequence for each sample. These consensus sequences were manually inspected and polished using Aliview v.1.27 (<ext-link ext-link-type="uri" xlink:href="http://ormbunkar.se/aliview/">http://ormbunkar.se/aliview/</ext-link>).</p>
          <p id="Par36">All of the sequences were deposited in GISAID (<ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org/">https://www.gisaid.org/</ext-link>)<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>, and the GISAID accession identifiers are included in Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>. Raw reads for our sequences have also been deposited at the NCBI Sequence Read Archive (BioProject: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA784038">PRJNA784038</ext-link>).</p>
          <p id="Par37">The number and position of the Omicron mutations has affected a number of primers and caused primer drop-outs across a range of sequencing protocols, especially within the RBD (<ext-link ext-link-type="uri" xlink:href="https://primer-monitor.neb.com/lineages">https://primer-monitor.neb.com/lineages</ext-link>). These primer drop-outs have resulted in a number of genomes missing stretches of the RBD, and can affect estimates of mutation prevalence and the determination of the true set of lineage-defining mutations. Given this, .bam files of all initial genomes were inspected using IG Viewer to confirm mutation calls where reference calls were suspected to be from low coverage at primer dropout sites<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>.</p>
        </sec>
        <sec id="Sec18">
          <title>Lineage classification</title>
          <p id="Par38">We used the widespread dynamic lineage classification method from the Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN) software suite (<ext-link ext-link-type="uri" xlink:href="https://github.com/hCoV-2019/pangolin">https://github.com/hCoV-2019/pangolin</ext-link>)<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. This is aimed at identifying the most epidemiologically important lineages of SARS-CoV-2 at the time of analysis, enabling researchers to monitor the epidemic in a particular geographical region. For the Omicron variant described in this study, the corresponding PANGO lineage designation is BA.1 (lineages v.1.2.106). When first characterized, the lineage was designated B.1.1.529, but the emergence of three sibling lineages to Omicron resulted in the split into sublineages (B.1.1.529.1, B.1.1.529.2 and B.1.1.529.3, aliased as BA.1, BA.2 and BA.3). BA.1 contains all the genomes with the original mutational constellation that was designated as Omicron and, at time of writing, is the dominant sublineage.</p>
        </sec>
        <sec id="Sec19">
          <title>Recombination testing</title>
          <p id="Par39">To test for the possibility that the Omicron lineage (including BA.1, BA.2 and BA.3) is a recombinant of other SARS-CoV-2 lineages, we used a global subsample of sequences spanning January 2021 to August 2021. Using the NCBI SARS-CoV-2 Data hub<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>, we constructed a dataset containing 221 sequences by randomly sampling five sequences from each month for each continent. No Oceania samples were available from July or August, and no South American sequences were available from July 2021 (ref. <sup><xref ref-type="bibr" rid="CR61">61</xref></sup>). These sequences were aligned together with a set of five high-quality BA.1, six BA.2 and one BA.3 sequences (representing the known diversity of these clades on 5 December 2021) using MAFFT<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> with the default settings. Whereas 3SEQ<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> and RDP5 (ref. <sup><xref ref-type="bibr" rid="CR38">38</xref></sup>) were used to analyse this dataset, a subsample of the 39 most divergent sequences from the dataset was analysed using the GARD recombination detection method<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. As none of these recombination detection methods normally use potentially informative deletion patterns, deletions in these alignments were recoded as nucleotide substitutions (one substitution per contiguous run of deleted nucleotides). Furthermore, to minimize multiple testing issues, BA.1, BA.2 and BA.3 were tested for evidence of recombination among one another using individual sequences from each of these lineages (CERI-KRISP-K032254, EPI_ISL_7190366 and EPI_ISL_7526186, respectively) together with the Wuhan-Hu-1 sequence (which served as a reference point for rooting the four taxon phylogeny). The default program settings were used throughout for recombination analyses, with the exception of RDP5 analysis, in which sequences were treated as linear and the window sizes for the SiScan and BootScan methods (two of the seven recombination detection methods applied in RDP5) were changed to 2,000 nucleotides.</p>
        </sec>
        <sec id="Sec20">
          <title>Selection analyses</title>
          <p id="Par40">We investigated the nature and extent of selective forces acting on BA.1, BA.2 and BA.3 genes encoding individual protein products (respectively, a median of 110, 3 and 2.5 unique BA.1, BA.2 and BA.3 sequences per protein product encoding genome region). A subset of publicly available sequences (from the Virus Pathogen Database and Analysis Resource (ViPR); <ext-link ext-link-type="uri" xlink:href="https://www.viprbrc.org/">https://www.viprbrc.org/</ext-link>) was included as background sequences to contextualize selection signals detectable within the BA.1, BA.2 and BA.3 lineages at the levels of complete protein product encoding regions, and individual codons (a median of ~100 sequences per protein coding region). Sequences were selected, quality-checked, aligned, and processed for BUSTED, RELAX, MEME, FADE, FEL and BGM selection analyses (all implemented in HyPhy v.2.5.33)<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> using the automated RASCL pipeline as outlined previously<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>.</p>
        </sec>
        <sec id="Sec21">
          <title>Structure modelling</title>
          <p id="Par41">We modelled the spike protein on the basis of the Protein Data Bank coordinate set <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb7A94/pdb">7A94</ext-link>, showing the first step of the spike protein trimer activation with one RBD domain in the up position, bound to the human ACE2 receptor<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>. We used Pymol (The PyMOL Molecular Graphics System, v.2.2.0) for visualization.</p>
        </sec>
        <sec id="Sec22">
          <title>Phylogenetic analysis</title>
          <p id="Par42">All sequences on GISAID<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup> designated Omicron (<italic>n</italic>&#x2009;=&#x2009;686; date of access: 7 December 2021) were analysed against a globally representative reference set of SARS-CoV-2 genotypes (<italic>n</italic>&#x2009;=&#x2009;12,609) spanning the entire genetic diversity observed since the start of the pandemic. In brief, the reference set included: (1) all genomes from Africa assigned to PANGO lineage B.1.1 or any of its descendents, excluding those belonging to a VOC clade; (2) a representative subsampling of global data from the publicly maintained global build of Nexstrain (<ext-link ext-link-type="uri" xlink:href="https://nextstrain.org/ncov/gisaid/global">https://nextstrain.org/ncov/gisaid/global</ext-link>); and (3) the top thirty BLAST hits when querying GISAID BLAST for BA.1 and BA.2 sequences. This sampling scheme ensures that we analyse Omicron against the closest variants of the virus. Omicron and reference sequences were aligned using Nextalign<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. A maximum-likelihood tree topology was inferred in FastTree<sup><xref ref-type="bibr" rid="CR66">66</xref></sup> under the following parameters: a General Time Reversible model of nucleotide substitution and a total of 100 bootstrap replicates<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. The resulting maximum-likelihood tree topology was transformed into a time-calibrated phylogeny in which branches along the tree were scaled in calendar time using TreeTime<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>. The resulting tree was then visualized and annotated in ggtree in R<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. Additional BA.2 (<italic>n</italic>&#x2009;=&#x2009;148) and BA.3 (<italic>n</italic>&#x2009;=&#x2009;19) sequences were added to the above phylogeny after review to clarify the evolutionary relationship between BA.1, BA.2 and BA.3 (Extended Data Fig. <xref rid="Fig8" ref-type="fig">4c, d</xref>).</p>
        </sec>
        <sec id="Sec23">
          <title>Time-calibrated BEAST analysis</title>
          <p id="Par43">To estimate a time-scale and growth rate from the genome sequencing data, BEAST (v.1.10.4)<sup><xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup> was used to sample phylogenetic trees under an exponential growth coalescent model using a strict molecular clock. All BA.1-assigned genomes from South Africa and Botswana (as of 11 December 2021) were included, with some lower coverage genomes removed, leaving a total of 553 genomes. The single South African BA.2 genome (CERI-KRISP-K032307, EPI_ISL_6795834) was included to help to stabilize the root of the BA.1 clade but the exponential growth coalescent model was applied only to BA.1 (a constant population size coalescent was used for the rest of the tree). The rate of molecular evolution was estimated from the data. Two runs of 100&#x2009;million iterations were compared to assess convergence, and then post-burnin samples were pooled to summarize parameter estimates.</p>
        </sec>
        <sec id="Sec24">
          <title>Birth&#x2013;death phylogenetic analysis</title>
          <p id="Par44">We analysed the full South Africa and Botswana dataset (<italic>n</italic>&#x2009;=&#x2009;552, all BA.1 assigned), and the reduced dataset containing only Gauteng province genomes (<italic>n</italic>&#x2009;=&#x2009;277) using the serially sampled birth&#x2013;death skyline (BDSKY) model<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, implemented in BEAST2 (v.2.5.2)<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. To allow for changes in genomic sampling intensity shortly after the discovery of the new lineage, we allowed the sampling proportion to vary with time while keeping all other models parameters constant over the study period. The choice of prior distributions for the model parameters is summarized in Extended Data Table <xref rid="Tab3" ref-type="table">3</xref>.</p>
          <p id="Par45">For each analysis, we used an HKY substitution model and a strict clock model with a fixed clock rate of 0.75&#x2009;&#xD7;&#x2009;10<sup>&#x2212;3</sup> and 1.1&#x2009;&#xD7;&#x2009;10<sup>&#x2212;3</sup> substitutions per site per year (s.s.y.) for the full South Africa and Botswana dataset, and Gauteng province-only dataset, respectively. To allow for comparisons with the exponential growth coalescent model, we also repeated the analyses with clock rates fixed at those estimated from the coalescent analyses (1.2&#x2009;&#xD7;&#x2009;10<sup>&#x2212;3</sup> and 0.3&#x2009;&#xD7;&#x2009;10<sup>&#x2212;3</sup>&#x2009;s.s.y.). The mean duration of infectiousness was fixed at 10 days<sup><xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR74">74</xref></sup>. The effective reproduction number, <italic>R</italic><sub>e</sub>, was assumed to be constant through time. The sampling proportion was assumed to be 0 before the collection time of the oldest sample and allowed to change at fixed times that were approximately equidistantly spaced between the oldest sample and the most recent sample. For Markov chain Monte Carlo (MCMC) analyses of the full South Africa and Botswana dataset, the maximum clade credibility tree from the exponential growth coalescent model was used as the starting tree. We kept the tree topology fixed, estimating only internal node heights.</p>
          <p id="Par46">To assess the robustness of our estimates of <italic>R</italic><sub>e</sub> under different assumptions of temporal variations in the sampling proportion, we repeated the analyses with 3 instead of 4 equidistant change-time points. All of the other model parameters and priors were kept the same.</p>
          <p id="Par47">For each analysis, we ran two independent chains of 100&#x2009;million MCMC steps and sampled parameters every 10,000 steps. We used Tracer (v.1.7)<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> to evaluate MCMC convergence for each of the individual chains (effective sample size (ESS)&#x2009;&gt;&#x2009;200), which were then combined using LogCombiner to obtain the final posterior distribution after removing 10% of each chain as burn-in. The results were analysed using the bdskytools package in R (<ext-link ext-link-type="uri" xlink:href="https://github.com/laduplessis/bdskytools">https://github.com/laduplessis/bdskytools</ext-link>).</p>
          <p id="Par48">The resulting estimates for the time of the most recent common ancestor, exponential growth rate and doubling time are summarized in Extended Data Tables <xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab5" ref-type="table">5</xref>. With fixed clock rates of 0.75&#x2009;&#xD7;&#x2009;10<sup>&#x2212;3</sup> and 1.1&#x2009;&#xD7;&#x2009;10<sup>&#x2212;3</sup>&#x2009;s.s.y. for the full South Africa and Botswana dataset and Gauteng province-only dataset, respectively, the 3-epoch and 4-epoch BDSKY models resulted in similar estimates of the effective reproduction number, <italic>R</italic><sub>e</sub>, for both datasets: 2.74 (95% HPD&#x2009;=&#x2009;2.56&#x2013;2.92) and 2.79 (95% HPD&#x2009;=&#x2009;2.60&#x2013;2.97) for the South Africa and Botswana dataset, and 3.86 (95% HPD&#x2009;=&#x2009;3.43&#x2013;4.29) and 3.61 (95% HPD&#x2009;=&#x2009;3.20&#x2013;4.02) for the Gauteng province-only dataset. Using a faster clock rate led to more recent common ancestors and higher estimates of the effective reproduction number and growth rate.</p>
          <p id="Par49">We examined the sensitivity of our estimates to different assumptions regarding the average duration of infectiousness by repeating the analysis of the South Africa and Botswana dataset with different fixed values of the becoming non-infectious rate: 52.1 per year and 26.1 per year, which translate to an infectious period of 7 and 14 days, respectively. These values were selected as plausible bounds based on the infectious period of asymptomatic cases and the time from symptom onset to two negative RT&#x2013;PCR tests<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. The 4-epoch model was used with a fixed clock rate of 0.75&#x2009;&#xD7;&#x2009;10<sup>&#x2212;3</sup>&#x2009;s.s.y. in these analyses. For each analysis, we ran three independent chains of 35&#x2009;million MCMC steps and sampled parameters every 10,000 steps. We used Tracer (v.1.7)<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> to evaluate MCMC convergence for each of the individual chains (ESS&#x2009;&gt;&#x2009;200), which were then combined using LogCombiner to obtain the final posterior distribution after removing 10% of each chain as burn-in.</p>
          <p id="Par50">The results from the sensitivity analyses showed that our estimates are largely robust to alternative assumptions about the infectious period. On doubling of the mean duration of infectiousness from 7 to 14 days, the TMRCA remained mostly the same (10 October 2021 (95% HPD&#x2009;=&#x2009;2 October&#x2013;17 October) compared with 11 October 2021 (95% HPD&#x2009;=&#x2009;3 October&#x2013;17 October), while the doubling time shifted from 4.4 (95% HPD&#x2009;=&#x2009;3.9&#x2013;5.0) days to 3.5 (95% HPD&#x2009;=&#x2009;3.2&#x2013;3.9) days. This change in the doubling time is partially explained by differing estimates of the sampling proportion. For most of the epochs, the sampling proportion increases with the doubling time to explain the same number of sequences observed in each instance, that is, if we assume a shorter average duration of infectiousness, then we infer a slower transmission of which a greater proportion of sequences has been sampled.</p>
        </sec>
        <sec id="Sec25">
          <title>Phylogeographic analysis</title>
          <p id="Par51">MCMC analyses were run in duplicate in BEAST (v.1.10.4)<sup><xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup> for a total of 100&#x2009;million iterations sampling every 10,000 steps in the chain. Convergence of runs was assessed in Tracer (v.1.7.1)<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> based on high effective sample sizes (&gt;200) and good mixing in the chains. Maximum clade credibility trees for each run were summarized in TreeAnnotator after discarding the first 10% of the chain as burn in. Finally, the spatiotemporal dispersal of Omicron was mapped using the R package seraphim<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>.</p>
        </sec>
        <sec id="Sec26">
          <title>Estimating transmission advantage</title>
          <p id="Par52">We analysed 805 SARS-CoV-2 sequences from Gauteng, South Africa, that were uploaded to GISAID with sample collection dates from 1 September to 1 December 2021 (ref. <sup><xref ref-type="bibr" rid="CR15">15</xref></sup>). We used a multinomial logistic regression model to estimate the growth advantage of Omicron compared with Delta at the time point at which the proportion of Omicron reached 50% (refs. <sup><xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR78">78</xref></sup>). We fitted the model using the multinom function of the nnet package and estimated the growth advantage using the package emmeans in R.</p>
          <p id="Par53">The difference in the net growth rates (that is, the growth advantage) between a variant (Omicron) and the wild type (Delta) can be expressed as follows:<sup><xref ref-type="bibr" rid="CR79">79</xref></sup><disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\rho =(1+\tau )\beta (S+{\epsilon }(1-S))-\beta S,$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mi>&#x3C1;</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>&#x3C4;</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mi>&#x3B2;</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="italic">&#x3F5;</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:mi>S</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mi>&#x3B2;</mml:mi><mml:mi>S</mml:mi><mml:mo>,</mml:mo></mml:math><graphic xlink:href="41586_2022_4411_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>where <italic>&#x3C4;</italic> is the increase of the intrinsic transmissibility, <italic>&#x3F5;</italic> is the level of immune evasion, <italic>&#x3B2;</italic> is the transmission rate of the wild type and <italic>S</italic> is the proportion of the population that is susceptible to the wild type. This relationship can be algebraically solved for <italic>&#x3C4;</italic> and <italic>&#x3F5;</italic>. We further define <italic>R</italic><sub>w</sub>&#x2009;=&#x2009;<italic>&#x3B2;SD</italic> as the effective reproduction number of the wild-type with <italic>D</italic> being the generation time. <italic>&#x3A9;</italic>&#x2009;=&#x2009;1&#x2009;&#x2212;&#x2009;<italic>S</italic> corresponds to the proportion of the population with protective immunity against infection and subsequent transmission with the wild type.</p>
          <p id="Par54">We estimated <italic>&#x3F5;</italic> for different levels of <italic>&#x3C4;</italic> and <italic>&#x3A9;</italic>. To propagate the uncertainty, we constructed 95% credible intervals (CIs) of the estimates from 10,000 parameter samples of <italic>&#x3C1;</italic>, <italic>D</italic> and <italic>R</italic><sub>w</sub>. We assumed <italic>D</italic> to be normally distributed with a mean of 5.2 days and a s.d. of 0.8 days (ref. <sup><xref ref-type="bibr" rid="CR80">80</xref></sup>). We sampled from publicly available estimates of the daily <italic>R</italic><sub>w</sub> based on confirmed cases during the early growth phase of Omicron in South Africa (1 October&#x2013;31 October 2021; range&#x2009;=&#x2009;0.78&#x2013;0.85) (<ext-link ext-link-type="uri" xlink:href="https://github.com/covid-19-Re">https://github.com/covid-19-Re</ext-link>)<sup><xref ref-type="bibr" rid="CR81">81</xref></sup>.</p>
        </sec>
      </sec>
      <sec id="Sec27">
        <title>Reporting summary</title>
        <p id="Par55">Further information on research design is available in the&#xA0;<xref rid="MOESM2" ref-type="media">Nature Research Reporting Summary</xref> linked to this paper.</p>
      </sec>
    </sec>
    <sec id="Sec28" sec-type="materials|methods">
      <title>Online content</title>
      <p id="Par56">Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-022-04411-y.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41586_2022_4411_MOESM1_ESM.xlsx"><caption><p>Supplementary Table 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41586_2022_4411_MOESM2_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41586_2022_4411_MOESM3_ESM.pdf"><caption><p>Peer Review File</p></caption></media></supplementary-material>
</p>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec29">
          <title>Extended data figures and tables</title>
          <p id="Par59">
<fig id="Fig5"><label>Extended Data Fig. 1</label><caption><title>Progression of daily recorded cases and variant proportions in Gauteng (A), KwaZulu-Natal (B) and Western Cape (C) provinces between October and December 2021.</title><p>A sharp increase in the 7-day rolling average of the number of cases is observed in all three of the biggest provinces in South Africa at the emergence of the Omicron variant.</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Fig5_ESM" id="d32e2926"/></fig>
</p>
          <p id="Par60">
<fig id="Fig6"><label>Extended Data Fig. 2</label><caption><title>Epidemic Progression in Botswana.</title><p><bold>A</bold>) Epidemic and variant dynamics in Botswana from May 2020 to December 2021, with the 7-day rolling average of the number of recorded cases coloured by the proportion of variants as inferred by genomic surveillance data available on GISAID. At the end of November 2021, a big Delta-driven wave was coming to its end and an Omicron wave was starting at the end of November 2021. <bold>B</bold>) Trends in testing numbers and positivity rates in Botswana between October and December 2021, showing a sharp increase in positivity rate mid-November 2021.</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Fig6_ESM" id="d32e2945"/></fig>
</p>
          <p id="Par61">
<fig id="Fig7"><label>Extended Data Fig. 3</label><caption><title>Global distribution of Omicron.</title><p>(<bold>A</bold>) Detection of Omicron globally. Shown are the locations for which Omicron genomes have been deposited on GISAID as of December 16, 2021. Those labelled as &#x201C;reported&#x201D; referred to the country from which Omicron has been reported to the WHO but there is currently no sequencing data available in GISAID, all data comes from GISAID and the WHO weekly epidemiology report Edition 70 dated December 14, 2021 (<ext-link ext-link-type="uri" xlink:href="https://reliefweb.int/sites/reliefweb.int/files/resources/20211207_Weekly_Epi_Update_69-%281%29.pdf">https://reliefweb.int/sites/reliefweb.int/files/resources/20211207_Weekly_Epi_Update_69-%281%29.pdf</ext-link>). Countries are coloured according to the number of genomes deposited with warmer colours representing more genomes. (<bold>B</bold>) Omicron transmission globally. Shown are countries for which Omicron sequencing data is available on GISAID. Proportions of sequences are coloured according to sampling strategy or additional host/location information from either travel history, targeted sequencing (specifically for SGTF, vaccine breakthroughs, outbreaks, contact tracing or other reasons), routine surveillance or unknown if no information has been provided. Countries are ordered by the number of sequences available on GISAID as of December 16, 2021.</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Fig7_ESM" id="d32e2970"/></fig>
</p>
          <p id="Par62">
<fig id="Fig8"><label>Extended Data Fig. 4</label><caption><title>Related Lineages BA.2 and BA.3 Molecular Profile and Evolutionary Origins.</title><p><bold>A</bold>) Amino-acid mutations on the spike gene of the BA.2 <bold>B</bold>) Amino-acid mutations on the spike gene of the BA.3 <bold>C</bold>) Raw maximum likelihood phylogeny of 13,462 SARS-CoV-2 genomes, including 148 BA.2 and 19 BA.3. The newly identified SARS-CoV-2 Omicron variant is shown in colour versus grey for all other lineages. <bold>D</bold>) A zoomed-in view of the Omicron clade showing the evolutionary relationship between BA.1, BA.2 and BA.3.</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Fig8_ESM" id="d32e2995"/></fig>
</p>
          <p id="Par63">
<fig id="Fig9"><label>Extended Data Fig. 5</label><caption><title>BA.1 spike mutations shared with other VOC/VOIs.</title><p>All spike mutations seen in BA.1 are listed at the top in red and coloured according to prevalence. Prevalence was calculated by number of mutation detections / total number of sequences. However, primer drop-outs have affected the RBD region spanning K417N, N440K and G446S, and so it is likely that these mutations may actually be more prevalent than indicated here. For the VOC/VOIs only mutations that are shared with Omicron and seen in &#x2265;50% of the respective VOC/VOI sequences are shown and are coloured according to Nextstrain clade. The mutations listed at the bottom are shaded according to known immune escape (blue), enhanced infectivity (green) or for unknown/unconfirmed impact (red).</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Fig9_ESM" id="d32e3009"/></fig>
</p>
          <p id="Par64">
<fig id="Fig10"><label>Extended Data Fig. 6</label><caption><title>Maximum-likelihood trees (inferred with RAxML v8.2.12<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>) for genome regions bounding the consensus recombination breakpoints detected in lineages BA.1, BA.2 and BA.3<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>.</title><p>The trees include SARS-CoV-2 genome sequences sampled in 2021 (N&#x2009;=&#x2009;221) together with 13 sequences representing the BA.1, BA.2 and BA.3 lineages. Whereas in trees for regions 1 and 3 BA.2 and BA.3 cluster together with high bootstrap support, BA.1 is a well-supported albeit more distantly related sibling lineage. The a 897nt region 2 segment (encoding the N-terminal domain of spike) includes 67 polymorphic sites with a maximum 8nt difference between strains, showing little bootstrap support for any sibling or clade relationships except the membership of certain viruses in WHO-designated clades (Lambda, Omicron, Gamma). Despite Omicron lineages BA.1 and BA.3 clustering with certain Delta and Eta viruses and Omicron BA.2 clustering with a distinct set of Delta viruses (all on the basis of several key nucleotide positions), trees based on region 2 show no statistical support for the three Omicron lineages having distinct evolutionary origins. Bootstrap values are shown on branches with relevant values magnified for readability. All trees were rooted on the Wuhan-Hu-1 sequence.</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Fig10_ESM" id="d32e3031"/></fig>
</p>
          <p id="Par65">
<table-wrap id="Tab1"><label>Extended Data Table 1</label><caption><p>Parameter estimates from BEAST for the full South Africa and Botswana dataset and the reduced data set of only Gauteng Province genomes</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Tab1_ESM" id="d32e3043"><caption><p>Parameter estimates from BEAST for the full South Africa and Botswana dataset and the reduced data set of only Gauteng Province genomes</p></caption></graphic><table-wrap-foot><p>95% HPD intervals in parentheses.</p></table-wrap-foot></table-wrap>
</p>
          <p id="Par66">
<table-wrap id="Tab2"><label>Extended Data Table 2</label><caption><p>Sites in the BA.1 sequences that have been subject to episodic diversifying selection</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Tab2_ESM" id="d32e3062"><caption><p>Sites in the BA.1 sequences that have been subject to episodic diversifying selection</p></caption></graphic></table-wrap>
</p>
          <p id="Par67">
<table-wrap id="Tab3"><label>Extended Data Table 3</label><caption><p>Prior distributions used for the BDSKY analyses</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Tab3_ESM" id="d32e3078"><caption><p>Prior distributions used for the BDSKY analyses</p></caption></graphic><table-wrap-foot><p>The becoming non-infectious rate was fixed to 36.5/year which corresponds to a mean infectious period of 10 days. A less informative prior for the sampling proportion was used for the Gauteng Province only dataset to allow for the possibility of a higher province-specific sampling proportion.</p></table-wrap-foot></table-wrap>
</p>
          <p id="Par68">
<table-wrap id="Tab4"><label>Extended Data Table 4</label><caption><p>Time of most recent common ancestor, exponential growth rate and doubling time estimates for the full South Africa and Botswana dataset and the reduced dataset of only Gauteng Province genomes under the 3-epoch BDSKY model in which the sampling proportion was allowed to change at 3 equidistantly spaced time points</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Tab4_ESM" id="d32e3097"><caption><p>Time of most recent common ancestor, exponential growth rate and doubling time estimates for the full South Africa and Botswana dataset and the reduced dataset of only Gauteng Province genomes under the 3-epoch BDSKY model in which the sampling proportion was allowed to change at 3 equidistantly spaced time points</p></caption></graphic><table-wrap-foot><p>95% HPD intervals in parentheses.</p></table-wrap-foot></table-wrap>
</p>
          <p id="Par69">
<table-wrap id="Tab5"><label>Extended Data Table 5</label><caption><p>Time of most recent common ancestor, exponential growth rate and doubling time estimates for the full South Africa and Botswana dataset and the reduced dataset of only Gauteng Province genomes under the 4-epoch BDSKY model in which the sampling proportion was allowed to change at 4 equidistantly spaced time points</p></caption><graphic position="anchor" xlink:href="41586_2022_4411_Tab5_ESM" id="d32e3117"><caption><p>Time of most recent common ancestor, exponential growth rate and doubling time estimates for the full South Africa and Botswana dataset and the reduced dataset of only Gauteng Province genomes under the 4-epoch BDSKY model in which the sampling proportion was allowed to change at 4 equidistantly spaced time points</p></caption></graphic><table-wrap-foot><p>95% HPD intervals in parentheses.</p></table-wrap-foot></table-wrap>
</p>
        </sec>
      </app>
    </app-group>
    <fn-group>
      <fn>
        <p><bold>Publisher&#x2019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>These authors contributed equally: Raquel Viana, Sikhulile Moyo, Daniel G. Amoako, Houriiyah Tegally, Cathrine Scheepers</p>
      </fn>
      <fn>
        <p>These authors jointly supervised this work: Simani Gaseitsiwe, Anne von Gottberg, Tulio de Oliveira</p>
      </fn>
    </fn-group>
    <sec>
      <title>Extended data</title>
      <p>is available for this paper at 10.1038/s41586-022-04411-y.</p>
    </sec>
    <sec>
      <title>Supplementary information</title>
      <p>The online version contains supplementary material available at 10.1038/s41586-022-04411-y.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank L. de Gouveia, A. Buys, C. Fourie, N. Duma, M. Ndlovu and other members of the NICD Centre for Respiratory Diseases and Meningitis and Sequencing Core Facility; N. Govender, G. Ntshoe, A. Moipone Shonhiwa, D. Muganhiri, I. Matiea, E. Mathatha, F. Gavhi, T. Mashudu Lamola, M. Makhubele, M. Matjokotja, S. Mdleleni, M. Makhubela from the national SARS-CoV-2 NICD surveillance team for NMCSS case data; F. Mckenna, T. Graham Bell, N. Munava, S. Kwenda, M. Raza Bano and J. Khosa from NICD IT for NMCSS case and test data (in particular, SGTF data); and the following people from the diagnostic laboratories for their assistance: K. Reddy, L. Gounder and C. Naicker from NHLS Inkosi Albert Luthuli Central Hospital Laboratory, S. Korsman from the NHLS Groote Schuur Laboratory, and A. Enoch at NHLS Green Point Laboratory; the staff at the global laboratories who generated and made public the SARS-CoV-2 sequences (through GISAID) used as reference dataset in this study (a complete list of individual contributors of sequences is provided in Supplementary Table <xref rid="Tab1" ref-type="table">1</xref>). The research reported in this publication was supported by the Strategic Health Innovation Partnerships Unit of the South African Medical Research Council, with funds received from the South African Department of Science and Innovation. Sequencing activities at KRISP and CERI were supported in part by the WHO, the National Institutes of Health (NIH) (U01 AI151698) for the United World Antivirus Research Network (UWARN), and the Rockefeller Foundation (grants 2021 HTH 017 and 2020 HTH 062).&#xA0;C.L.A. received funding from the European Union&#x2019;s Horizon 2020 research and innovation programme, project EpiPose (no. 101003688). D.P.M. was funded by the Wellcome Trust (222574/Z/21/Z). R.C. and A.R. acknowledge support from the Wellcome Trust (Collaborators Award 206298/Z/17/Z, ARTIC network) and A.R. from the European Research Council (no. 725422, ReservoirDOCS). V.H. was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (grant no. BB/M010996/1). A.E.Z., J.T., M.U.G.K. and O.G.P. acknowledge support from the Oxford Martin School. M.U.G.K. acknowledges support from the Rockefeller Foundation, Google.org, and the European Horizon 2020 programme MOOD (no. 874850). M.V. and the members of the Zoonotic Arbo and Respiratory Virus Program, UP was funded through the ANDEMIA G7 Global Health Concept: contributions to improvement of International Health, COVID-19 funds through the Robert Koch Institute. The genomic sequencing at UCT/NHLS is funded from the South African Medical Research Council and Department of Science and Innovation; and by the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), which is supported by core funding from the Wellcome Trust (203135/Z/16/Z and 222754). C.W. and J.B. are funded by the EDCTP (RADIATES Consortium; RIA2020EF-3030). Sequencing activities at the NICD were supported by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response; a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention (no. 5U01IP001048-05-00); the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a subaward from the Bill and Melinda Gates Foundation grant no. INV-018978; the UK Foreign, Commonwealth and Development Office and Wellcome (no. 221003/Z/20/Z); the South African Medical Research Council (SHIPNCD 76756); the UK Department of Health and Social Care, managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project. The genomic sequencing in Botswana was supported by the Foundation for Innovative New Diagnostics and Fogarty International Center (5D43TW009610), NIH (5K24AI131924-04; 5K24AI131928-05) and support from the Botswana government through the Ministry of Health &amp; Wellness and Presidential COVID-19 Task Force. S.&#xA0;Moyo. was supported in part by the Bill &amp; Melinda Gates Foundation (036530).&#xA0;Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>Genomic data generation: R.V., S.&#xA0;Moyo, D.G.A., H.T., C.S., J.G., J.E., S.G., W.T.C., D.M., B.Z., B.R., L.K., R.S., S.L., M.B.M., P.S.-L., M.&#xA0;Matshaba, M.&#xA0;Mosepele, K.&#xA0;Masupu, A.&#xA0;Mnguni, A.&#xA0;Ismail, B.M., M.S.M., J.E.S., N.N., G.&#xA0;Motsatsi., S.P., G. Marais,&#xA0;T.&#xA0;Mohale, U.R., Y.N., C.W., S.E., T.&#xA0;Maponga, W.P., L.&#xA0;Singh, U.J.A., M.&#xA0;Moir, S.v.W., D.T., K.D., D.H., D.D., R.J., A.&#xA0;Iranzadeh, D.G., P.A.B, M.N., P.N.M. and J.B. Sample collection and metadata curation: R.V., S.&#xA0;Moyo, D.G.A., A.&#xA0;Mendes, A.S., M.D., S.&#xA0;Mayaphi, W.T.C., D.M., P.S.-L., M.C., C.J., L.K.-L., O.L.-A., K.&#xA0;Mahlakwane, N.T., N.-Y.H., N.&#xA0;Msomi, K.&#xA0;Moruisi, A.S., A.&#xA0;Maharaj, M.D., Z.M., O.L.-M., Y.R., K.S., D.G., P.A.B., F.T. and M.V. Data analysis: H.T., C.S., R.J.L., N.W., J.E., A.R., C.L.A., E.W., C.K.W., D.P.M., V.H., R.C., J.E.S., M.G., S.P., A.G.L., S.W., M.F.B., A.E.Z., J.T., L.d.P., M.U.G.K. and O.G.P. Study design and data interpretation: R.V., S.&#xA0;Moyo, D.G.A., R.J.L., A.R., C.L.A., S.G., M.&#xA0;Matshaba, M.&#xA0;Mosepele, K.&#xA0;Mlisana, L.K.-L., O.L.-M., M.S.M., K.&#xA0;Moruisi, C.W., L.d.P., O.G.P., A.G., F.T., M.V., J.B., A.v.G. and T.d.O. Manuscript writing: S.&#xA0;Moyo, H.T., R.J.L., J.G., J.E., A.R., C.L.A., E.W., D.P.M., J.B., A.v.G. and T.d.O. All of the authors reviewed the manuscript.</p>
    </notes>
    <notes notes-type="peer-review">
      <title>Peer review</title>
      <sec id="FPar1">
        <title>Peer review information</title>
        <p id="Par57"><italic>Nature</italic> thanks Katia Koelle, Tommy Tsan-Yuk Lam and Michael Worobey for their contribution to the peer review of this work. Peer reviewer reports are available.</p>
      </sec>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>All SARS-CoV-2 whole-genome sequences produced by NGS-SA are deposited in the GISAID sequence database and are publicly available subject to the terms and conditions of the GISAID database. The GISAID accession numbers of sequences used in the phylogenetic analysis, including Omicron and global references, are provided in the Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>. Raw reads for our sequences have also been deposited at the NCBI Sequence Read Archive (SRA) (BioProject: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA784038">PRJNA784038</ext-link>). Other raw data for this study are provided as a supplementary dataset at our GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/krisp-kwazulu-natal/SARSCoV2_Omicron_Southern_Africa">https://github.com/krisp-kwazulu-natal/SARSCoV2_Omicron_Southern_Africa</ext-link>). The reference SARS-CoV-2 genome (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3">MN908947.3</ext-link>) was downloaded from the NCBI database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/">https://www.ncbi.nlm.nih.gov/</ext-link>). Other publicly available data used in this study are as follows: NCBI SARS-CoV-2 Data Hub (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sars-cov-2/">https://www.ncbi.nlm.nih.gov/sars-cov-2/</ext-link>), Protein Data Bank coordinate set <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb7A94/pdb">7A94</ext-link> (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>), Nexstrain global build (<ext-link ext-link-type="uri" xlink:href="https://nextstrain.org/ncov/gisaid/global">https://nextstrain.org/ncov/gisaid/global</ext-link>), Covid-19 Re repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/covid-19-Re">https://github.com/covid-19-Re</ext-link>), daily Covid-19 case numbers from the Data Science for Social Impact Research Group at the University of Pretoria (<ext-link ext-link-type="uri" xlink:href="https://github.com/dsfsi/covid19za">https://github.com/dsfsi/covid19za</ext-link>), daily case numbers from OWID (<ext-link ext-link-type="uri" xlink:href="https://github.com/owid/covid-19-data">https://github.com/owid/covid-19-data</ext-link>) and the Virus Pathogen Database and Analysis Resource (ViPR) (<ext-link ext-link-type="uri" xlink:href="https://www.viprbrc.org/">https://www.viprbrc.org/</ext-link>).</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Code availability</title>
      <p>All input files (such as raw data for figures, alignments or XML files), along with all resulting output files and scripts used in the present study are publicly shared at GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/krisp-kwazulu-natal/SARSCoV2_Omicron_Southern_Africa">https://github.com/krisp-kwazulu-natal/SARSCoV2_Omicron_Southern_Africa</ext-link>).</p>
    </notes>
    <notes id="FPar2" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par58">The authors declare no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tegally</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sixteen novel lineages of SARS-CoV-2 in South Africa</article-title>
          <source>Nat. Med.</source>
          <year>2021</year>
          <volume>27</volume>
          <fpage>440</fpage>
          <lpage>446</lpage>
          <pub-id pub-id-type="pmid">33531709</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tegally</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Detection of a SARS-CoV-2 variant of concern in South Africa</article-title>
          <source>Nature</source>
          <year>2021</year>
          <volume>592</volume>
          <fpage>438</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="pmid">33690265</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="other">Tegally, H. et al. Rapid replacement of the Beta variant by the Delta variant in South Africa. Preprint at <italic>medRxiv</italic>10.1101/2021.09.23.21264018 (2021).</mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="other">Martin, D. P. et al. Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function. Preprint at <italic>bioRxiv</italic>10.1101/2022.01.14.476382 (2022).</mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faria</surname>
              <given-names>NR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil</article-title>
          <source>Science</source>
          <year>2021</year>
          <volume>372</volume>
          <fpage>815</fpage>
          <lpage>821</lpage>
          <pub-id pub-id-type="pmid">33853970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhar</surname>
              <given-names>MS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India</article-title>
          <source>Science</source>
          <year>2021</year>
          <volume>374</volume>
          <fpage>995</fpage>
          <lpage>999</lpage>
          <pub-id pub-id-type="pmid">34648303</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="other">New A. Y. <italic>Lineages&#x2014;Pango Network</italic>; <ext-link ext-link-type="uri" xlink:href="https://www.pango.network/new-ay-lineages/">https://www.pango.network/new-ay-lineages/</ext-link> (2021).</mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="other">Eales, O. et al. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2. Preprint at <italic>medRxiv</italic>10.1101/2021.12.17.21267925 (2021).</mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilkinson</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa</article-title>
          <source>Science</source>
          <year>2021</year>
          <volume>374</volume>
          <fpage>423</fpage>
          <lpage>431</lpage>
          <pub-id pub-id-type="pmid">34672751</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="other">Scheepers, C. et al. The continuous evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations of concern and global detection. Preprint at <italic>medRxiv</italic>10.1101/2021.08.20.21262342 (2021).</mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kleynhans</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SARS-CoV-2 seroprevalence in a rural and urban household cohort during first and second waves of infections, South Africa, July 2020-March 2021</article-title>
          <source>Emerg. Infect. Dis.</source>
          <year>2021</year>
          <volume>27</volume>
          <fpage>3020</fpage>
          <lpage>3029</lpage>
          <pub-id pub-id-type="pmid">34477548</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="other">Vermeulen, M. et al. Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021. Preprint at <italic>Research Square</italic>10.21203/rs.3.rs-690372/v1 (2021).</mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="other">Madhi, S. et al. Population immunity and Covid-19 severity with Omicron variant in South Africa. <italic>New Engl. J. Med.</italic>10.1056/NEJMoa2119658 (2022).</mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volz</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England</article-title>
          <source>Nature</source>
          <year>2021</year>
          <volume>593</volume>
          <fpage>266</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="pmid">33767447</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>McCauley</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>GISAID: global initiative on sharing all influenza data&#x2014;from vision to reality</article-title>
          <source>Euro Surveill.</source>
          <year>2017</year>
          <volume>22</volume>
          <fpage>30494</fpage>
          <pub-id pub-id-type="pmid">28382917</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elbe</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Buckland-Merrett</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Data, disease and diplomacy: GISAID&#x2019;s innovative contribution to global health</article-title>
          <source>Glob. Chall.</source>
          <year>2017</year>
          <volume>1</volume>
          <fpage>33</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">31565258</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rambaut</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology</article-title>
          <source>Nat. Microbiol.</source>
          <year>2020</year>
          <volume>5</volume>
          <fpage>1403</fpage>
          <lpage>1407</lpage>
          <pub-id pub-id-type="pmid">32669681</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="other">WHO. <italic>Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern</italic>; <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/statements/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern">https://www.who.int/news-room/statements/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern</ext-link> (2021).</mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stadler</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>K&#xFC;hnert</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bonhoeffer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Drummond</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Birth-death skyline plot reveals temporal changes of epidemic spread in HIV and hepatitis C virus (HCV)</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <year>2013</year>
          <volume>110</volume>
          <fpage>228</fpage>
          <lpage>233</lpage>
          <pub-id pub-id-type="pmid">23248286</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Starr</surname>
              <given-names>TN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding</article-title>
          <source>Cell</source>
          <year>2020</year>
          <volume>182</volume>
          <fpage>1295</fpage>
          <lpage>1310</lpage>
          <pub-id pub-id-type="pmid">32841599</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greaney</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies</article-title>
          <source>Nat. Commun.</source>
          <year>2021</year>
          <volume>12</volume>
          <fpage>4196</fpage>
          <pub-id pub-id-type="pmid">34234131</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greaney</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Complete mapping of mutations to the SARS-CoV-2 Spike receptor-binding domain that escape antibody recognition</article-title>
          <source>Cell Host Microbe</source>
          <year>2021</year>
          <volume>29</volume>
          <fpage>44</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="pmid">33259788</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greaney</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies</article-title>
          <source>Cell Host Microbe</source>
          <year>2021</year>
          <volume>29</volume>
          <fpage>463</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="pmid">33592168</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCallum</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2</article-title>
          <source>Cell</source>
          <year>2021</year>
          <volume>184</volume>
          <fpage>2332</fpage>
          <lpage>2347</lpage>
          <pub-id pub-id-type="pmid">33761326</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <mixed-citation publication-type="other">Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <italic>Nature</italic><bold>602</bold>, 54&#x2013;656 (2022).</mixed-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <mixed-citation publication-type="other">Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <italic>Nature</italic><bold>602</bold>, 671-675 (2022).</mixed-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Starr</surname>
              <given-names>TN</given-names>
            </name>
            <name>
              <surname>Greaney</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Dingens</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Bloom</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016</article-title>
          <source>Cell Rep. Med.</source>
          <year>2021</year>
          <volume>2</volume>
          <fpage>100255</fpage>
          <pub-id pub-id-type="pmid">33842902</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Starr</surname>
              <given-names>TN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prospective mapping of viral mutations that escape antibodies used to treat COVID-19</article-title>
          <source>Science</source>
          <year>2021</year>
          <volume>371</volume>
          <fpage>850</fpage>
          <lpage>854</lpage>
          <pub-id pub-id-type="pmid">33495308</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <mixed-citation publication-type="other">Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. <italic>Nature</italic><bold>602</bold>, 657&#x2013;663 (2022).</mixed-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="other">Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. <italic>Nature</italic>10.1038/s41586-022-04460-3 (2022).</mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <mixed-citation publication-type="other">Brown, J. C. et al. Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape. Preprint at <italic>BioRxiv</italic>10.1101/2021.02.24.432576 (2021).</mixed-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <mixed-citation publication-type="other">Saito, A. et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. <italic>Nature</italic><bold>602</bold>, 300&#x2013;306 (2022).</mixed-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mlcochova</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion</article-title>
          <source>Nature</source>
          <year>2021</year>
          <volume>599</volume>
          <fpage>114</fpage>
          <lpage>119</lpage>
          <pub-id pub-id-type="pmid">34488225</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>DP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages</article-title>
          <source>Cell</source>
          <year>2021</year>
          <volume>184</volume>
          <fpage>5189</fpage>
          <lpage>5200</lpage>
          <pub-id pub-id-type="pmid">34537136</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2</article-title>
          <source>Cell Host Microbe</source>
          <year>2021</year>
          <volume>29</volume>
          <fpage>1788</fpage>
          <lpage>1801</lpage>
          <pub-id pub-id-type="pmid">34822776</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kosakovsky Pond</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Posada</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gravenor</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Woelk</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Frost</surname>
              <given-names>SDW</given-names>
            </name>
          </person-group>
          <article-title>GARD: a genetic algorithm for recombination detection</article-title>
          <source>Bioinformatics</source>
          <year>2006</year>
          <volume>22</volume>
          <fpage>3096</fpage>
          <lpage>3098</lpage>
          <pub-id pub-id-type="pmid">17110367</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lam</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Ratmann</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Boni</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Improved algorithmic complexity for the 3SEQ recombination detection algorithm</article-title>
          <source>Mol. Biol. Evol.</source>
          <year>2018</year>
          <volume>35</volume>
          <fpage>247</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="pmid">29029186</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>DP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>RDP5: a computer program for analyzing recombination in, and removing signals of recombination from, nucleotide sequence datasets</article-title>
          <source>Virus Evol.</source>
          <year>2021</year>
          <volume>7</volume>
          <fpage>veaa087</fpage>
          <pub-id pub-id-type="pmid">33936774</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boni</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Posada</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>An exact nonparametric method for inferring mosaic structure in sequence triplets</article-title>
          <source>Genetics</source>
          <year>2007</year>
          <volume>176</volume>
          <fpage>1035</fpage>
          <lpage>1047</lpage>
          <pub-id pub-id-type="pmid">17409078</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Posada</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Crandall</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of methods for detecting recombination from DNA sequences: computer simulations</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>13757</fpage>
          <lpage>13762</lpage>
          <pub-id pub-id-type="pmid">11717435</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van der Walt</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rapid host adaptation by extensive recombination</article-title>
          <source>J. Gen. Virol.</source>
          <year>2009</year>
          <volume>90</volume>
          <fpage>734</fpage>
          <lpage>746</lpage>
          <pub-id pub-id-type="pmid">19218220</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wisotsky</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Kosakovsky Pond</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Shank</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Muse</surname>
              <given-names>SV</given-names>
            </name>
          </person-group>
          <article-title>Synonymous site-to-site substitution rate variation dramatically inflates false positive rates of selection analyses: ignore at your own peril</article-title>
          <source>Mol. Biol. Evol.</source>
          <year>2020</year>
          <volume>37</volume>
          <fpage>2430</fpage>
          <lpage>2439</lpage>
          <pub-id pub-id-type="pmid">32068869</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>MD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Less is more: an adaptive branch-site random effects model for efficient detection of episodic diversifying selection</article-title>
          <source>Mol. Biol. Evol.</source>
          <year>2015</year>
          <volume>32</volume>
          <fpage>1342</fpage>
          <lpage>1353</lpage>
          <pub-id pub-id-type="pmid">25697341</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wertheim</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Murrell</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Kosakovsky Pond</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Scheffler</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>RELAX: detecting relaxed selection in a phylogenetic framework</article-title>
          <source>Mol. Biol. Evol.</source>
          <year>2015</year>
          <volume>32</volume>
          <fpage>820</fpage>
          <lpage>832</lpage>
          <pub-id pub-id-type="pmid">25540451</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murrell</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Detecting individual sites subject to episodic diversifying selection</article-title>
          <source>PLoS Genet.</source>
          <year>2012</year>
          <volume>8</volume>
          <fpage>e1002764</fpage>
          <pub-id pub-id-type="pmid">22807683</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kosakovsky Pond</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Poon</surname>
              <given-names>AFY</given-names>
            </name>
            <name>
              <surname>Leigh Brown</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Frost</surname>
              <given-names>SDW</given-names>
            </name>
          </person-group>
          <article-title>A maximum likelihood method for detecting directional evolution in protein sequences and its application to influenza A virus</article-title>
          <source>Mol. Biol. Evol.</source>
          <year>2008</year>
          <volume>25</volume>
          <fpage>1809</fpage>
          <lpage>1824</lpage>
          <pub-id pub-id-type="pmid">18511426</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <mixed-citation publication-type="other">Pulliam, J. R. C. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. Preprint at <italic>medRxiv</italic>10.1101/2021.11.11.21266068 (2021).</mixed-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <mixed-citation publication-type="other">R&#xF6;ssler, A., Riepler, L., Bante, D., Laer, D. von &amp; Kimpel, J. SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons. <italic>New Engl. J. Med.</italic><bold>386</bold>, 698&#x2013;700(2022).</mixed-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <mixed-citation publication-type="other">Marivate, V. &amp; Combrink, H. M. Use of available data to inform the COVID-19 outbreak in South Africa: a case study. <italic>Data Sci. J.</italic><bold>19</bold>, 19 (2020).</mixed-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <mixed-citation publication-type="other">Marivate, V. et al. Coronavirus disease (COVID-19) case data&#x2014;South Africa. <italic>Zenodo</italic>10.5281/zenodo.3819126 (2020).</mixed-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <mixed-citation publication-type="other">NICD. <italic>Weekly Testing Summary</italic>; <ext-link ext-link-type="uri" xlink:href="https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/weekly-testing-summary/">https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/weekly-testing-summary/</ext-link> (accessed 22 December 2021).</mixed-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wickham</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>ggplot2</article-title>
          <source>WIREs Comp. Stat.</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>180</fpage>
          <lpage>185</lpage>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Msomi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mlisana</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>A genomics network established to respond rapidly to public health threats in South Africa</article-title>
          <source>Lancet Microbe</source>
          <year>2020</year>
          <volume>1</volume>
          <fpage>e229</fpage>
          <lpage>e230</lpage>
          <pub-id pub-id-type="pmid">32838349</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <mixed-citation publication-type="other">Freed, N. &amp; Silander, O. SARS-CoV2 genome sequencing protocol (1200bp amplicon &#x201C;midnight&#x201D; primer set, using Nanopore Rapid kit). <italic>Protocols.io</italic>10.17504/protocols.io.bwyppfvn (2021).</mixed-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cleemput</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomes</article-title>
          <source>Bioinformatics</source>
          <year>2020</year>
          <volume>36</volume>
          <fpage>3552</fpage>
          <lpage>3555</lpage>
          <pub-id pub-id-type="pmid">32108862</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <mixed-citation publication-type="other">Wright, C. &amp; Parker, M. epi2me-labs/wf-artic: ARTIC SARS-CoV-2 workflow and reporting (GitHub); <ext-link ext-link-type="uri" xlink:href="https://github.com/epi2me-labs/wf-artic#readme">https://github.com/epi2me-labs/wf-artic#readme</ext-link> (2021).</mixed-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bragg</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Butler</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Hugenholtz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tyson</surname>
              <given-names>GW</given-names>
            </name>
          </person-group>
          <article-title>Shining a light on dark sequencing: characterising errors in Ion Torrent PGM data</article-title>
          <source>PLoS Comput. Biol.</source>
          <year>2013</year>
          <volume>9</volume>
          <fpage>e1003031</fpage>
          <pub-id pub-id-type="pmid">23592973</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>JT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Integrative genomics viewer</article-title>
          <source>Nat. Biotechnol.</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>24</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="pmid">21221095</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hatcher</surname>
              <given-names>EL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Virus Variation Resource&#x2014;improved response to emergent viral outbreaks</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2017</year>
          <volume>45</volume>
          <fpage>D482</fpage>
          <lpage>D490</lpage>
          <pub-id pub-id-type="pmid">27899678</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <mixed-citation publication-type="other">National Library of Medicine. <italic>NCBI Virus: SARS-CoV-2 Data Hub</italic>; <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&amp;VirusLineage_ss=SARS-CoV-2,%20taxid:2697049">https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&amp;VirusLineage_ss=SARS-CoV-2,%20taxid:2697049</ext-link> (accessed 1 December 2021).</mixed-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <mixed-citation publication-type="other">Boni, M. covid19-omicron-origins-recombination (GitHub); <ext-link ext-link-type="uri" xlink:href="https://github.com/bonilab/covid19-omicron-origins-recombination/blob/main/4%20GS5%20plus%20Canada%20Outlier%20Lineage/4.2%20aligned_mafft_addfrag_wref/aligned_234.shortnames.afa">https://github.com/bonilab/covid19-omicron-origins-recombination/blob/main/4%20GS5%20plus%20Canada%20Outlier%20Lineage/4.2%20aligned_mafft_addfrag_wref/aligned_234.shortnames.afa</ext-link> (2021).</mixed-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katoh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Misawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kuma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Miyata</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2002</year>
          <volume>30</volume>
          <fpage>3059</fpage>
          <lpage>3066</lpage>
          <pub-id pub-id-type="pmid">12136088</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kosakovsky Pond</surname>
              <given-names>SL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HyPhy 2.5&#x2014;a customizable platform for evolutionary hypothesis testing using phylogenies</article-title>
          <source>Mol. Biol. Evol.</source>
          <year>2020</year>
          <volume>37</volume>
          <fpage>295</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="pmid">31504749</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benton</surname>
              <given-names>DJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Receptor binding and priming of the Spike protein of SARS-CoV-2 for membrane fusion</article-title>
          <source>Nature</source>
          <year>2020</year>
          <volume>588</volume>
          <fpage>327</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="pmid">32942285</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aksamentov</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Roemer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hodcroft</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Neher</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Nextclade: clade assignment, mutation calling and quality control for viral genomes</article-title>
          <source>J. Open Source Softw.</source>
          <year>2021</year>
          <volume>6</volume>
          <fpage>3773</fpage>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Price</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Dehal</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Arkin</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
          <article-title>FastTree 2&#x2014;approximately maximum-likelihood trees for large alignments</article-title>
          <source>PLoS ONE</source>
          <year>2010</year>
          <volume>5</volume>
          <fpage>e9490</fpage>
          <pub-id pub-id-type="pmid">20224823</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Felsenstein</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Confidence limits on phylogenies: an approach using the bootstrap</article-title>
          <source>Evolution</source>
          <year>1985</year>
          <volume>39</volume>
          <fpage>783</fpage>
          <lpage>791</lpage>
          <pub-id pub-id-type="pmid">28561359</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sagulenko</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Puller</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Neher</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>TreeTime: maximum-likelihood phylodynamic analysis</article-title>
          <source>Virus Evol.</source>
          <year>2018</year>
          <volume>4</volume>
          <fpage>vex042</fpage>
          <pub-id pub-id-type="pmid">29340210</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Using ggtree to visualize data on tree-like structures</article-title>
          <source>Curr. Protoc. Bioinform.</source>
          <year>2020</year>
          <volume>69</volume>
          <fpage>e96</fpage>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suchard</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10</article-title>
          <source>Virus Evol.</source>
          <year>2018</year>
          <volume>4</volume>
          <fpage>vey016</fpage>
          <pub-id pub-id-type="pmid">29942656</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drummond</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Suchard</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rambaut</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Bayesian phylogenetics with BEAUti and the BEAST 1.7</article-title>
          <source>Mol. Biol. Evol.</source>
          <year>2012</year>
          <volume>29</volume>
          <fpage>1969</fpage>
          <lpage>1973</lpage>
          <pub-id pub-id-type="pmid">22367748</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bouckaert</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>BEAST 2.5: an advanced software platform for Bayesian evolutionary analysis</article-title>
          <source>PLoS Comput. Biol.</source>
          <year>2019</year>
          <volume>15</volume>
          <fpage>e1006650</fpage>
          <pub-id pub-id-type="pmid">30958812</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benvenuto</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The global spread of 2019-nCoV: a molecular evolutionary analysis</article-title>
          <source>Pathog. Glob. Health</source>
          <year>2020</year>
          <volume>114</volume>
          <fpage>64</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="pmid">32048560</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Byrne</surname>
              <given-names>AW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases</article-title>
          <source>BMJ Open</source>
          <year>2020</year>
          <volume>10</volume>
          <fpage>e039856</fpage>
          <pub-id pub-id-type="pmid">32759252</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rambaut</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Drummond</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Baele</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Suchard</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Posterior summarization in Bayesian phylogenetics using tracer 1.7</article-title>
          <source>Syst. Biol.</source>
          <year>2018</year>
          <volume>67</volume>
          <fpage>901</fpage>
          <lpage>904</lpage>
          <pub-id pub-id-type="pmid">29718447</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dellicour</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Faria</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Lemey</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pybus</surname>
              <given-names>OG</given-names>
            </name>
          </person-group>
          <article-title>SERAPHIM: studying environmental rasters and phylogenetically informed movements</article-title>
          <source>Bioinformatics</source>
          <year>2016</year>
          <volume>32</volume>
          <fpage>3204</fpage>
          <lpage>3206</lpage>
          <pub-id pub-id-type="pmid">27334476</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>NG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England</article-title>
          <source>Science</source>
          <year>2021</year>
          <volume>372</volume>
          <fpage>eabg3055</fpage>
          <pub-id pub-id-type="pmid">33658326</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campbell</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021</article-title>
          <source>Euro Surveill.</source>
          <year>2021</year>
          <volume>26</volume>
          <fpage>2100509</fpage>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <mixed-citation publication-type="other">Althaus, C. L. et al. A tale of two variants: spread of SARS-CoV-2 variants Alpha in Geneva, Switzerland, and Beta in South Africa. Preprint at <italic>medRxiv</italic>10.1101/2021.06.10.21258468 (2021).</mixed-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ganyani</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020</article-title>
          <source>Euro Surveill.</source>
          <year>2020</year>
          <volume>25</volume>
          <fpage>2000257</fpage>
        </element-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <mixed-citation publication-type="other">Huisman, J. S. et al. Estimation and worldwide monitoring of the effective reproductive number of SARS-CoV-2. Preprint at <italic>medRxiv</italic>10.1101/2020.11.26.20239368 (2020).</mixed-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stamatakis</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies</article-title>
          <source>Bioinformatics</source>
          <year>2014</year>
          <volume>30</volume>
          <fpage>1312</fpage>
          <lpage>1313</lpage>
          <pub-id pub-id-type="pmid">24451623</pub-id>
        </element-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boni</surname>
              <given-names>MF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic</article-title>
          <source>Nat. Microbiol.</source>
          <year>2020</year>
          <volume>5</volume>
          <fpage>1408</fpage>
          <lpage>1417</lpage>
          <pub-id pub-id-type="pmid">32724171</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">35585235</article-id>
      <article-id pub-id-type="pmc">9159944</article-id>
      <article-id pub-id-type="publisher-id">4730</article-id>
      <article-id pub-id-type="doi">10.1038/s41586-022-04730-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>MCM complexes are barriers that restrict cohesin-mediated loop extrusion</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7975-2245</contrib-id>
          <name>
            <surname>Dequeker</surname>
            <given-names>Bart J. H.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0110-3709</contrib-id>
          <name>
            <surname>Scherr</surname>
            <given-names>Matthias J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5496-0638</contrib-id>
          <name>
            <surname>Brand&#xE3;o</surname>
            <given-names>Hugo B.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4408-6577</contrib-id>
          <name>
            <surname>Gassler</surname>
            <given-names>Johanna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Powell</surname>
            <given-names>Sean</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gaspar</surname>
            <given-names>Imre</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Flyamer</surname>
            <given-names>Ilya M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5250-3556</contrib-id>
          <name>
            <surname>Lalic</surname>
            <given-names>Aleksandar</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>Wen</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9478-3928</contrib-id>
          <name>
            <surname>Stocsits</surname>
            <given-names>Roman</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4945-6415</contrib-id>
          <name>
            <surname>Davidson</surname>
            <given-names>Iain F.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2820-3195</contrib-id>
          <name>
            <surname>Peters</surname>
            <given-names>Jan-Michael</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1279-7841</contrib-id>
          <name>
            <surname>Duderstadt</surname>
            <given-names>Karl E.</given-names>
          </name>
          <address>
            <email>duderstadt@biochem.mpg.de</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0785-5410</contrib-id>
          <name>
            <surname>Mirny</surname>
            <given-names>Leonid A.</given-names>
          </name>
          <address>
            <email>leonid@mit.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6564-7484</contrib-id>
          <name>
            <surname>Tachibana</surname>
            <given-names>Kiku&#xEB;</given-names>
          </name>
          <address>
            <email>tachibana@biochem.mpg.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.473822.8</institution-id><institution-id institution-id-type="ISNI">0000 0005 0375 3232</institution-id><institution>Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), </institution><institution>Vienna BioCenter (VBC), </institution></institution-wrap>Vienna, Austria </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.418615.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0491 845X</institution-id><institution>Structure and Dynamics of Molecular Machines, </institution><institution>Max Planck Institute of Biochemistry (MPIB), </institution></institution-wrap>Martinsried, Germany </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Harvard Program in Biophysics, </institution><institution>Harvard University, </institution></institution-wrap>Cambridge, MA USA </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.418615.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0491 845X</institution-id><institution>Department of Totipotency, </institution><institution>Max Planck Institute of Biochemistry (MPIB), </institution></institution-wrap>Martinsried, Germany </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution>MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine (IGMM), </institution><institution>University of Edinburgh, </institution></institution-wrap>Edinburgh, UK </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.473822.8</institution-id><institution-id institution-id-type="ISNI">0000 0005 0375 3232</institution-id><institution>Research Institute of Molecular Pathology (IMP), </institution><institution>Vienna BioCenter (VBC), </institution></institution-wrap>Vienna, Austria </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.6936.a</institution-id><institution-id institution-id-type="ISNI">0000000123222966</institution-id><institution>Department of Physics, </institution><institution>Technical University of Munich, </institution></institution-wrap>Garching, Germany </aff>
        <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.116068.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2341 2786</institution-id><institution>Department of Physics, </institution><institution>Massachusetts Institute of Technology (MIT), </institution></institution-wrap>Cambridge, MA USA </aff>
        <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.185669.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0507 3954</institution-id><institution>Present Address: Illumina Inc., </institution></institution-wrap>San Diego, CA USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>5</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>5</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2022</year>
      </pub-date>
      <volume>606</volume>
      <issue>7912</issue>
      <fpage>197</fpage>
      <lpage>203</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>10</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>6</day>
          <month>4</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2022</copyright-statement>
        <license>
          <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x2019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">Eukaryotic genomes are compacted into loops and topologically associating domains (TADs)<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref></sup>, which contribute to transcription, recombination and genomic stability<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>. Cohesin extrudes DNA into loops that are thought to lengthen until CTCF boundaries are encountered<sup><xref ref-type="bibr" rid="CR6">6</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref></sup>. Little is known about whether loop extrusion is impeded by DNA-bound machines. Here we show that the minichromosome maintenance (MCM) complex is a barrier that restricts loop extrusion in G1 phase. Single-nucleus Hi-C (high-resolution chromosome conformation capture) of mouse zygotes reveals that MCM loading reduces CTCF-anchored loops and decreases TAD boundary insulation, which suggests that loop extrusion is impeded before reaching CTCF. This effect extends to HCT116 cells, in which MCMs affect the number of CTCF-anchored loops and gene expression. Simulations suggest that MCMs are abundant, randomly positioned and partially permeable barriers. Single-molecule imaging shows that MCMs are physical barriers that frequently constrain cohesin translocation in vitro. Notably, chimeric yeast MCMs that contain a cohesin-interaction motif from human MCM3 induce cohesin pausing, indicating that MCMs are &#x2018;active&#x2019; barriers with binding sites. These findings raise the possibility that cohesin can arrive by loop extrusion at MCMs, which determine the genomic sites at which sister chromatid cohesion is established. On the basis of in vivo, in silico and in vitro data, we conclude that distinct loop extrusion barriers shape the three-dimensional genome.</p>
      </abstract>
      <abstract id="Abs2" abstract-type="web-summary">
        <p id="Par2">Single-nucleus Hi-C of embryos, polymer simulations and single-molecule imaging collectively reveal that MCM&#xA0;complexes influence genome folding and gene expression by impeding DNA loop extrusion.</p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
        <title>Subject terms</title>
        <kwd>Chromosomes</kwd>
        <kwd>Nuclear organization</kwd>
        <kwd>Computational biology and bioinformatics</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s), under exclusive licence to Springer Nature Limited 2022</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Main</title>
      <p id="Par3">Eukaryotic genomes are folded into loops that are generated by structural maintenance of chromosomes (SMC) proteins, including cohesin and condensin complexes (reviewed previously<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>). Structures that emerge through loop extrusion are detected by Hi-C experiments. The extrusion process is hypothesized to form progressively larger loops until cohesin encounters a barrier and/or is released by Wapl (refs. <sup><xref ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR11">11</xref></sup>). The predominant barrier to loop extrusion in vertebrates is CTCF (ref. <sup><xref ref-type="bibr" rid="CR12">12</xref></sup>), which has an instructive role in establishing extrusion-mediated structures that are visible in Hi-C<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. However, the loop extrusion machinery encounters other obstacles on chromatin, such as nucleosomes and other protein complexes. Although RNA polymerases are moving barriers for condensin translocation in bacteria<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and affect cohesin translocation in eukaryotes<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>, it remains unknown how SMCs can extrude loops on &#x2018;busy&#x2019; eukaryotic chromosomes that are bound by a myriad of proteins. Whether other DNA-bound proteins can influence three-dimensional genome architecture in eukaryotes is not known, and could be critical for understanding their function.</p>
      <p id="Par4">The minichromosome maintenance (MCM) complex is an abundant macromolecular machine that is essential for DNA replication in eukaryotes and archaea<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. MCM2&#x2013;MCM7 complexes (hereafter MCM) are loaded at replication origins by the origin recognition complex (ORC), Cdc6 and Cdt1 to form the pre-replication complex during mitosis and G1 phase<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. The head-to-head double MCM hexamer topologically entraps double-stranded DNA and is catalytically inactive as a helicase until the initiation of DNA replication<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Notably, 10&#x2013;100-fold more MCMs are loaded onto chromatin than are needed for S-phase progression. This is referred to as the &#x2018;MCM paradox&#x2019;<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. One hypothesis to explain this phenomenon is that surplus complexes mark dormant origins that fire under conditions such as DNA damage checkpoint activation<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Surplus MCMs have been shown to protect against DNA breaks by reducing replication fork speed<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Whether they have any functional consequences in G1 phase remains unclear. Given the abundance of MCMs, their long residence time on chromatin<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> (more than 6&#x2009;h) and their comparable size<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> (13&#x2009;nm) to the FtsK helicase (12.5&#x2009;nm) (Extended Data Fig. <xref rid="Fig5" ref-type="fig">1</xref>) that can push cohesin on DNA in vitro<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, we asked whether MCMs are obstacles to cohesin-mediated loop extrusion and in this way influence genome architecture.</p>
    </sec>
    <sec id="Sec2">
      <title>MCMs impede CTCF-anchored loops</title>
      <p id="Par5">To test this hypothesis, we used the oocyte-to-zygote transition to investigate whether MCM loss affects loop extrusion. Oocytes are female germ cells that divide meiotically and, after fertilization, generate one-cell embryos (zygotes). These contain maternal and paternal pronuclei, the chromatin of which is organized into cohesin-dependent loops and TADs<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. Although zygotes are limited by paucity of material, they offer advantages for: (1) studying MCM loading on newly assembled paternal chromatin; (2) deciphering haplotype-resolved chromatin organization; (3) manipulating the assembly of the pre-replication complex without interfering with cell-cycle progression, as there is no DNA replication between meiosis I and II; and (4) disentangling direct from indirect effects because of transcriptional inactivity<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>.</p>
      <p id="Par6">To generate zygotes that are deficient in chromatin-bound MCMs, we interfered with the Cdt1-mediated loading pathway. Cdt1 deposits MCMs onto chromatin, and this reaction is inhibited by geminin, a target of the anaphase-promoting complex/cyclosome (APC/C)<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> (Extended Data Fig. <xref rid="Fig6" ref-type="fig">2a</xref>). Mutation of geminin&#x2019;s destruction box generates a non-degradable version (geminin(L26A)) that inhibits the Cdt1-mediated loading of MCMs in G1 phase<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> (Extended Data Fig. <xref rid="Fig6" ref-type="fig">2a</xref>). To achieve this, mouse oocytes were microinjected with mRNA encoding an injection marker GFP with or without geminin(L26A) (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Metaphase II eggs were fertilized in vitro and zygotes were analysed in G1 phase (Extended Data Fig. <xref rid="Fig6" ref-type="fig">2c</xref>). Geminin(L26A) expression did not grossly affect the abundance of Scc1 and CTCF (Extended Data Fig. <xref rid="Fig6" ref-type="fig">2e, f</xref>). By contrast, few or no chromatin-bound MCMs were detected and EdU was not incorporated in zygotes expressing geminin(L26A) (referred to as &#x2018;MCM loss&#x2019;) (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>, Extended Data Fig. <xref rid="Fig6" ref-type="fig">2b, d</xref>), demonstrating the efficient inhibition of MCM loading.<fig id="Fig1"><label>Fig. 1</label><caption><title>Chromatin-bound MCMs impede loop and TAD formation in G1-phase zygotes.</title><p><bold>a</bold>, Germinal vesicle (GV)-stage oocytes were injected with geminin(L26A) mRNA and metaphase II eggs were fertilized in vitro. Maternal and paternal pronuclei were extracted for snHi-C. <bold>b</bold>, Representative images of immunofluorescence staining of chromatin-bound MCM2 in wild-type (WT) and MCM-loss G1-phase zygotes. DNA is stained with DAPI. Scale bars, 10&#x2009;&#xB5;m. <bold>c</bold>, Comparison of contacts detected in snHi-C versus bulk Hi-C. Contact probability curves, <italic>P</italic><sub>c</sub>(<italic>s</italic>), provide insights into chromatin compaction. <bold>d</bold>, Average loops and TADs for wild-type and MCM-loss chromatin in G1 phase. The data shown are based on <italic>n</italic> (WT, maternal)&#x2009;=&#x2009;13, <italic>n</italic> (WT, paternal)&#x2009;=&#x2009;16, <italic>n</italic> (MCM&#xA0;loss, maternal)&#x2009;=&#x2009;16, <italic>n</italic> (MCM&#xA0;loss, paternal)&#x2009;=&#x2009;15, from 4 independent experiments using 4&#x2013;6 females&#xA0;for each experiment. Heat maps were normalized to an equal number of <italic>cis</italic> contacts. <bold>e</bold>, <italic>P</italic><sub>c</sub>(<italic>s</italic>) curves for wild-type and MCM-loss conditions. <bold>f</bold>, Insulation scores at TAD borders.</p></caption><graphic xlink:href="41586_2022_4730_Fig1_HTML" id="d32e663"/></fig></p>
      <p id="Par7">Using this approach, we generated MCM-loss and control zygotes, isolated maternal and paternal pronuclei in G1 phase and performed single-nucleus Hi-C (snHi-C) (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). The sparsity of snHi-C data precluded de novo calling of loops (referred to as &#x2018;peaks&#x2019;), which represent contacts between CTCF-bound loci. Instead, we used 12,000 loop coordinates from mouse embryonic fibroblast Hi-C data that report on cohesin-dependent contacts in zygotes<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). Notably, MCM loss resulted in an increase in aggregate peaks and aggregate TADs (referred to as &#x2018;peaks&#x2019; and &#x2018;TADs&#x2019;) in maternal chromatin and an even stronger increase in paternal chromatin (Fig. <xref rid="Fig1" ref-type="fig">1d</xref>, Extended Data Fig. <xref rid="Fig7" ref-type="fig">3a&#x2013;c</xref>), which will be focused on hereafter. The increase in peak strengths after MCM loss could reflect higher CTCF occupancy, but this could not explain the barrier effect seen in vitro (see Fig. <xref rid="Fig4" ref-type="fig">4d</xref>). Alternatively, it could reflect increased access of cohesin to CTCF sites, owing to changes in either loop extrusion (potentially caused by barrier loss) or transcription. There were few transcriptomic differences between control and MCM-loss zygotes (Extended Data Fig. <xref rid="Fig8" ref-type="fig">4a, b</xref>). We conclude that MCMs hinder the formation of CTCF-anchored loops and TADs largely independently of changes in gene expression.</p>
      <p id="Par8">To find out whether cohesin is responsible for the increase in snHi-C peak strength caused by MCM loss, we used a conditional genetic knockout approach based on Cre recombinase under control of the <italic>Zp3</italic> promoter to delete floxed alleles of the cohesin subunit <italic>Scc1</italic> in oocytes<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. We expressed geminin(L26A) in <italic>Scc1</italic><sup><italic>&#x394;/&#x394;</italic></sup> oocytes isolated from <italic>Scc1</italic><sup><italic>fl/fl</italic></sup>
<italic>(Tg)Zp3</italic>-Cre females and generated maternal <italic>Scc1</italic> knockout zygotes (<italic>Scc1</italic><sup><italic>&#x394;(m)/+(p)</italic></sup>) (Extended Data Fig. <xref rid="Fig8" ref-type="fig">4c</xref>). Loops and TADs were undetectable in <italic>Scc1</italic><sup><italic>&#x394;(m)/+(p)</italic></sup> zygotes, as reported previously<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, and remained undetectable if MCM loading was prevented (Extended Data Fig. <xref rid="Fig8" ref-type="fig">4d</xref>). We conclude that MCMs interfere with cohesin-dependent chromatin structures.</p>
      <p id="Par9">To determine how MCMs affect chromatin organization, we examined the contact probability <italic>P</italic><sub>c</sub>(<italic>s</italic>) as a function of genomic distance (<italic>s</italic>) (Fig. <xref rid="Fig1" ref-type="fig">1e</xref>, Extended Data Fig. <xref rid="Fig7" ref-type="fig">3d, e</xref>). The position of the &#x2018;shoulder&#x2019; on the <italic>P</italic><sub>c</sub>(<italic>s</italic>) curve is informative of the mean size of extruded loops<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> (Extended Data Fig. <xref rid="Fig7" ref-type="fig">3f</xref>). Of note, MCM loss has little effect on the <italic>P</italic><sub>c</sub>(<italic>s</italic>) curve below 1&#x2009;Mb (Fig. <xref rid="Fig1" ref-type="fig">1e</xref>); this is reminiscent of CTCF loss<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>, and suggests that the mean size of extruded loops is largely unaffected. However, the effect of CTCF loss on &#x2018;peaks&#x2019; is opposite to that of MCM loss. We reasoned that if MCMs impede formation of CTCF-mediated structures, then MCM loss should lead to increased CTCF peaks and increased insulation of TAD boundaries, as observed (Fig. <xref rid="Fig1" ref-type="fig">1f</xref>). These effects on chromatin organization are consistent with a mechanism in which MCMs impede loop extrusion by altering loop positioning without considerably changing their sizes.</p>
      <p id="Par10">We tested whether CTCF and MCM together determine the strengths of peaks and TAD boundary insulation. We expressed geminin(L26A) in CTCF-knockdown oocytes isolated from <italic>(Tg)Zp3-CTCFdsRNA</italic> females and generated maternal CTCF-knockdown zygotes<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>, Extended Data Fig. <xref rid="Fig9" ref-type="fig">5a</xref>). CTCF knockdown without or with MCM perturbation resulted in a loss of loops and TADs (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>, Extended Data Fig. <xref rid="Fig9" ref-type="fig">5b</xref>); this shows that CTCF is essential for these structures in zygotes. Knockdown of CTCF caused a weakening of TAD boundary insulation and did not grossly change <italic>P</italic><sub>c</sub>(<italic>s</italic>) curves below 1&#x2009;Mb (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>, Extended Data Fig. <xref rid="Fig9" ref-type="fig">5c&#x2013;e</xref>). The lack of TAD organization after knockdown of CTCF, irrespective of MCMs, suggests that MCMs have no instructive function for establishing position-specific boundaries. This is consistent with MCMs being largely located in different positions in different cells<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>.<fig id="Fig2"><label>Fig. 2</label><caption><title>MCMs impede CTCF-anchored loops and function independently of Wapl.</title><p><bold>a</bold>, CTCF-knockdown oocytes from <italic>(Tg)Zp3-dsCTCF</italic> females were injected with geminin(L26A) mRNA and eggs were fertilized to generate zygotes for snHi-C analysis in G1 phase. <bold>b</bold>, Average loops and TADs for wild-type, CTCF-knockdown and CTCF-knockdown&#x2009;+&#x2009;MCM loss for paternal chromatin in G1. Data are based on <italic>n</italic> (WT, paternal)&#x2009;=&#x2009;12, <italic>n</italic> (CTCF&#xA0;knockdown, paternal)&#x2009;=&#x2009;8 and <italic>n</italic>(CTCF&#xA0;knockdown +&#x2009;MCM loss, paternal)&#x2009;=&#x2009;8 nuclei, from 4 independent experiments using 4&#x2013;6 females for each genotype. Heat maps were normalized to an equal number of <italic>cis</italic> contacts. <bold>c</bold>, Insulation scores at TAD borders for paternal chromatin. <bold>d</bold>, <italic>Wapl</italic><sup><italic>&#x394;/&#x394;</italic></sup> oocytes from <italic>Wapl</italic><sup><italic>fl/fl</italic></sup> (<italic>Tg</italic>)<italic>Zp3</italic>-Cre&#xA0;females were injected with geminin(L26A) mRNA and eggs were fertilized to generate zygotes for snHi-C analysis in G1 phase. <bold>e</bold>, Average loops and TADs for control (wild type), <italic>Wapl</italic><sup><italic>&#x394;</italic></sup> and <italic>Wapl</italic><sup><italic>&#x394;</italic></sup>&#x2009;+&#x2009;MCM loss for paternal chromatin in G1. Data shown are based on <italic>n</italic> (WT, paternal)&#x2009;=&#x2009;20, <italic>n</italic> (<italic>Wapl</italic><sup><italic>&#x394;</italic></sup>, paternal)&#x2009;=&#x2009;11, <italic>n</italic> (<italic>Wapl</italic><sup><italic>&#x394;</italic></sup>&#x2009;+&#x2009;MCM loss, paternal)&#x2009;=&#x2009;9 nuclei, from 4 independent experiments using 4&#x2013;6 females for each genotype. Control samples are wild type (this study) pooled with <italic>Wapl</italic><sup><italic>fl</italic></sup> samples (published previously<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>). Heat maps were normalized to an equal number of <italic>cis</italic> contacts. <bold>f</bold>, Insulation scores at TAD borders for paternal chromatin.</p></caption><graphic xlink:href="41586_2022_4730_Fig2_HTML" id="d32e954"/></fig></p>
      <p id="Par11">We considered an alternative possibility that MCMs affect loops by functioning with Wapl in releasing cohesin from chromatin. This is based on the similar effects on Hi-C peak and TAD strengths after <italic>Wapl</italic> knockout and MCM loss<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2e</xref>). If Wapl and MCMs function together, then their co-depletion would be expected to resemble individual depletions. If they function independently, then co-depletion could have synergistic effects. To distinguish between these, we expressed geminin(L26A) in <italic>Wapl</italic><sup><italic>&#x394;/&#x394;</italic></sup> oocytes isolated from <italic>Wapl</italic><sup><italic>fl/fl</italic></sup>
<italic>(Tg)Zp3</italic>-Cre females and generated maternal <italic>Wapl</italic> knockout zygotes<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> (<italic>Wapl</italic><sup><italic>&#x394;(m)/+(p)</italic></sup>) (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>). Combined MCM loss and <italic>Wapl</italic> knockout strongly increased peak and TAD strengths over the individual conditions (Fig. <xref rid="Fig2" ref-type="fig">2e</xref>, Extended Data Fig. <xref rid="Fig10" ref-type="fig">6a&#x2013;d</xref>), suggesting that they function through separate mechanisms. The combined loss increased TAD boundary insulation, suggesting that MCMs restrict loop extrusion also when cohesin residence time is increased (Fig. <xref rid="Fig2" ref-type="fig">2f</xref>, Extended Data Fig. <xref rid="Fig10" ref-type="fig">6b</xref>).</p>
    </sec>
    <sec id="Sec3">
      <title>MCMs are semi-permeable barriers</title>
      <p id="Par12">We introduced MCMs as randomly located permeable extrusion barriers into polymer models of loop extrusion (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). Polymer simulations identified parameters, including the permeability of MCMs, such that the peak strengths and <italic>P</italic><sub>c</sub>(<italic>s</italic>) curves of paternal chromatin can be quantitatively reproduced (Fig. <xref rid="Fig3" ref-type="fig">3b, d</xref>, Extended Data Fig. <xref rid="Fig10" ref-type="fig">6e&#x2013;h</xref>, <xref rid="MOESM1" ref-type="media">Supplementary Figs. 2&#x2013;5</xref>). In the model, cohesin extrudes loops and is stopped at CTCF sites (around 50% of encounters)<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> and MCMs (around 20% of encounters, for an estimated density of 1 MCM per 75&#x2009;kb) (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). If MCM density is lower in zygotes, then blocking will occur more frequently (more than 20%) (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). The predicted semi-permeability of MCMs could explain how CTCF-anchored loops are generated in the presence of MCMs in G1 phase.<fig id="Fig3"><label>Fig. 3</label><caption><title>Simulation model of MCMs as a random barrier to cohesin loop extrusion.</title><p><bold>a</bold>, A quantitative model for loop extrusion by cohesin and interactions with CTCF and MCMs. Cohesin (yellow) extrudes loops. On encountering barriers such as CTCF sites (green triangles), MCMs (red hexagons) or other cohesins, extrusion can be blocked. Cohesins may bypass some CTCFs and MCMs, but not others; the choice to bypass an MCM or CTCF site is stochastic and varies in time. <bold>b</bold>&#x2013;<bold>d</bold>, For paternal chromatin simulations, we assume that CTCF stalls cohesin around 45% of the time, as measured in mouse embryonic stem cells<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, and that MCMs stall cohesin 20% of the time. <bold>b</bold>, Peak strengths for simulated paternal chromatin under various perturbations for TADs of 300&#x2009;kb average length. <bold>c</bold>, Matrix of peak strengths in the wild type, showing a linear trade-off between MCM density and its ability to pause cohesin. AU, arbitrary units. <bold>d</bold>, The simulated contact probability decay curve <italic>P</italic><sub>c</sub>(<italic>s</italic>) for the MCM-loss condition is well matched with experimental data. <bold>e</bold>, Model summarizing the finding that chromatin-bound MCMs can function as barriers for loop extrusion in G1 phase.</p></caption><graphic xlink:href="41586_2022_4730_Fig3_HTML" id="d32e1100"/></fig></p>
      <p id="Par13">Our model provides a rationale for the seemingly contradictory ability of MCM to reduce CTCF&#x2013;CTCF peak strength without strongly affecting the mean size of extruded loops. A peak emerges if cohesin extrudes all chromatin between a pair of CTCFs into loops. A random barrier prevents cohesin from extruding all chromatin between CTCFs, leaving an unextruded gap<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> (Fig. <xref rid="Fig3" ref-type="fig">3e</xref>). The effect of random barriers on the average loop size is, however, marginal (less than 15%) if barriers are sufficiently permeable or sparse (one per TAD of around 300&#x2009;kb). This is an unexpected effect of random barriers on features of chromosome organization.</p>
    </sec>
    <sec id="Sec4">
      <title>MCMs affect transcription and loops</title>
      <p id="Par14">As these findings were obtained in zygotes, we tested whether MCMs also impede loop extrusion in somatic cells. To directly degrade MCMs, we treated G1-synchronized HCT116 cells carrying auxin-inducible degron MCM2-mAID alleles with dimethyl sulfoxide (DMSO) or auxin<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> (Extended Data Figs. <xref rid="Fig11" ref-type="fig">7a&#x2013;g</xref>, <xref rid="Fig12" ref-type="fig">8a&#x2013;f</xref>). Treatment with auxin reduced chromatin-bound MCM2 and MCM4 without grossly affecting the abundance of CTCF and cohesin (Extended Data Figs. <xref rid="Fig11" ref-type="fig">7c</xref>, <xref rid="Fig12" ref-type="fig">8c</xref>). Acute MCM degradation resulted in the differential expression of 229 genes (Extended Data Fig. <xref rid="Fig12" ref-type="fig">8l, m</xref>), which is comparable to the effects of acute CTCF degradation<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Hi-C data showed a moderate increase in aggregate peak strengths in MCM-depleted versus control cells (Extended Data Fig. <xref rid="Fig11" ref-type="fig">7d, e</xref>). To confirm this result using another method, we performed Micro-C and found that MCM depletion results in a moderate but genome-wide and significant (<italic>P</italic>&#x2009;=&#x2009;1.87&#x2009;&#xD7;&#x2009;10<sup>&#x2212;70</sup>) increase in the peak strength (Extended Data Fig. <xref rid="Fig12" ref-type="fig">8d, g&#x2013;i</xref>). Notably, de novo peak calling identified a greater number of loops in MCM-depleted cells, consistent with loop extrusion reaching CTCF sites more frequently (Extended Data Fig. <xref rid="Fig12" ref-type="fig">8j, k</xref>). The effects show the same directionality but are much more subtle than in zygotes and cannot be explained solely by RNA polymerase in somatic cells (Extended Data Fig. <xref rid="Fig12" ref-type="fig">8n, o</xref>). On the basis of the consistent increases in loop strengths and numbers after MCM degradation, we conclude that MCMs impede the formation of CTCF-anchored loops in somatic cells.</p>
    </sec>
    <sec id="Sec5">
      <title>MCMs block cohesin translocation</title>
      <p id="Par15">The most parsimonious interpretation of the effects of MCM loss on genome architecture is that MCMs interfere with loop extrusion by forming randomly located barriers. To directly test this, we established an MCM &#x2018;roadblock assay&#x2019; for passive translocation of cohesin using total internal reflection fluorescence microscopy that detects real-time cohesin&#x2013;MCM interactions at the single-molecule level. Origin licensing was reconstituted from purified components in a stepwise manner on origin-containing DNA molecules<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). Loading of yeast MCM and double-hexamer formation&#x2014;a hallmark of proper origin licensing&#x2014;was observed in the presence of ORC, Cdc6 and Cdt1 (ref. <sup><xref ref-type="bibr" rid="CR41">41</xref></sup>) (Extended Data Fig. <xref rid="Fig13" ref-type="fig">9a</xref>). Cohesin was introduced in low-salt conditions, followed by a high-salt wash to select for fully loaded MCMs<sup><xref ref-type="bibr" rid="CR41">41</xref>&#x2013;<xref ref-type="bibr" rid="CR43">43</xref></sup>. To mimic intracellular conditions, experiments were imaged in physiological salt conditions, promoting cohesin translocation on fast timescales<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> (Extended Data Fig. <xref rid="Fig13" ref-type="fig">9b</xref>, <xref rid="MOESM6" ref-type="media">Supplementary Video 1</xref>). The cohesin diffusion coefficient remained unchanged in the presence of MCMs (Extended Data Fig. <xref rid="Fig13" ref-type="fig">9c</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>MCMs are barriers for cohesin translocation in vitro.</title><p><bold>a</bold>, Principle of a single-molecule cohesin translocation assay on licensed DNA. MCM is loaded onto DNA by the licensing factors ORC, Cdc6 and Cdt1, followed by cohesin. A high-salt wash removes licensing factors and intermediates from DNA. Cohesin translocation is visualized at physiological salt conditions (0.15&#x2009;M NaCl) without free protein and buffer flow. <bold>b</bold>, <bold>c</bold>, Representative kymographs of translocating cohesin on licensed DNA. Origin-bound MCM (<bold>b</bold>) and MCM<sup>Mcm3-YDF</sup> (<bold>c</bold>) are efficient barriers for cohesin translocation. <bold>d</bold>, Probability of translocating cohesin bypassing the origin in the absence or in the presence of MCM or MCM<sup>Mcm3-YDF</sup>, calculated from 74, 162 or 79 molecules with 12,175, 15,348 or 9,455 visualized encounters, respectively. <bold>e</bold>, Cohesin translocation pauses at MCM in a YDF-disordered-region-dependent manner. Fraction of cohesin pausing of the total observation time in the absence or in the presence of MCM or MCM<sup>Mcm3-YDF</sup>. Data in <bold>d</bold>, <bold>e</bold> are depicted as mean within a 95% confidence interval (generated by bootstrapping). <italic>P</italic> values were determined by Kruskal&#x2013;Wallis test followed by Dunn&#x2019;s post-hoc test.</p></caption><graphic xlink:href="41586_2022_4730_Fig4_HTML" id="d32e1248"/></fig></p>
      <p id="Par16">Direct visualization of cohesin encounters with MCMs revealed constrained cohesin translocation with a fourfold reduction in origin passage (Fig. <xref rid="Fig4" ref-type="fig">4b, d</xref>, Extended Data Fig. <xref rid="Fig13" ref-type="fig">9d&#x2013;g</xref>, Supplementary Videos&#xA0;<xref rid="MOESM7" ref-type="media">2</xref>, <xref rid="MOESM8" ref-type="media">3</xref>). Similar results were obtained at higher salt concentrations (Extended Data Figs. <xref rid="Fig13" ref-type="fig">9c</xref>, <xref rid="Fig14" ref-type="fig">10a&#x2013;f</xref>, Supplementary Videos&#xA0;<xref rid="MOESM9" ref-type="media">4</xref>&#x2013;<xref rid="MOESM11" ref-type="media">6</xref>). A subpopulation of cohesin molecules were unable to pass origins even once during the 220-s imaging window (67/162; Fig. <xref rid="Fig4" ref-type="fig">4b</xref>, Extended Data Fig. <xref rid="Fig13" ref-type="fig">9d</xref>). By contrast, origin passage&#xA0;was unimpeded in the absence of MCMs (72/74; Extended Data Fig. <xref rid="Fig13" ref-type="fig">9b</xref>). The observed permeability of MCMs is lower than that predicted by simulations, which could be a result of different conditions from loop extrusion in vivo. It will be important in future studies to test whether MCMs halt loop extrusion, which requires a combined assay that has thus far not been established owing to&#xA0;different reaction conditions in vitro. We conclude that MCMs are physical barriers to cohesin translocation and may occasionally be bypassed.</p>
      <p id="Par17">Finally, we tested whether mammalian MCMs are stronger barriers&#xA0;than yeast MCMs to cohesin translocation. Unlike yeast Mcm3, human MCM3 contains a 19-amino-acid disordered region containing a YDF motif that is sufficient to bind STAG2&#x2013;SCC1 cohesin in vitro<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. The same motif mediates an interaction between CTCF and STAG2&#x2013;SCC1 (ref. <sup><xref ref-type="bibr" rid="CR44">44</xref></sup>). As there is no established human origin licensing assay, we modified the yeast assay to load a chimeric MCM complex containing a &#x2018;humanized&#x2019; MCM3 subunit (MCM-YDF). We found that cohesin bypasses MCM-YDF slightly less frequently compared to MCM, suggesting that its barrier strength is comparable to that of yeast MCMs (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>). Notably, we observed frequent pausing of cohesin upon encountering MCM-YDF (Fig. <xref rid="Fig4" ref-type="fig">4c</xref>, Extended Data Fig. <xref rid="Fig13" ref-type="fig">9h, i</xref>), with pauses accounting for 43% of the total observation time on average (Fig. <xref rid="Fig4" ref-type="fig">4e</xref>). These pauses were much less frequent (6.4%) in the presence of MCMs lacking YDF, which suggests that pausing reflects a molecular docking of cohesin to the YDF region.</p>
    </sec>
    <sec id="Sec6" sec-type="discussion">
      <title>Discussion</title>
      <p id="Par18">We have identified MCM complexes as barriers for loop extrusion on the basis of in vivo, in silico and in vitro data. MCMs are members of a new class of randomly positioned and cell-cycle-phase-specific barriers that impede the formation of CTCF-anchored loops and TADs. A key question is which features determine whether a protein impedes loop extrusion. Nanoparticles larger than the diameter of SMC complexes can be bypassed by extruding SMC complexes<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>, suggesting that size is not the sole determinant. Unlike those permeable roadblocks, MCMs have two distinguishing features that can promote barrier function. MCMs bind DNA in a topological manner. Although the mechanism of bypassing obstacles is not known, it is conceivable that a topological engagement of proteins around DNA could interfere with cohesin binding to DNA to &#x2018;swing over&#x2019; a protein<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Consistent with this, cohesin that topologically entraps sister chromatids restricts loop extrusion mediated by other cohesin complexes in oocytes<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>. In addition, the YDF disordered region alters the outcome of cohesin&#x2013;MCM collisions from blocking to pausing, which suggests that MCMs are active chemical barriers with binding sites rather than passive physical barriers.</p>
      <p id="Par19">The finding that MCMs are barriers to loop extrusion provides a different perspective on the body of knowledge on MCMs and cohesin loading. MCMs recruit cohesin to pre-replication complexes in <italic>Xenopus</italic> extracts<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup> and promote cohesin loading during DNA replication in human cells<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. These studies proposed that MCMs have a role in loading cohesin; that is, capturing cohesin from nucleoplasm and converting it from a freely diffusive into a DNA-bound state. Our work raises the possibility that cohesin could arrive at an MCM site by loop extrusion, where it is either blocked, passes by or pauses. Extruding cohesin pausing at MCMs could potentially be converted into a topologically binding complex that establishes cohesion after passage of the DNA replication fork (Extended Data Fig. <xref rid="Fig14" ref-type="fig">10g</xref>). A similar conversion of DNA binding mode has recently been proposed at CTCF sites<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Our idea distinguishes cohesin loading by MCMs from the arrival of cohesin at MCM sites by loop extrusion.</p>
      <p id="Par20">Given the evolutionary conservation of MCMs, it is possible that replicative helicases might be ancestral barriers in species that lack CTCF-anchored loops, such as <italic>Drosophila</italic>, in which the establishment of TADs during embryonic development coincides with a switch in replication origin usage<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Finally, our data suggest that the &#x2018;MCM paradox&#x2019; has consequences for chromatin organization and gene expression, which might have relevance for human pathologies such as Meier&#x2013;Gorlin syndrome that are linked to mutations in the MCM loading pathway<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>.</p>
    </sec>
    <sec id="Sec7" sec-type="materials|methods">
      <title>Methods</title>
      <sec id="Sec8">
        <title>Animals</title>
        <p id="Par21">The mice used in this work were bred and maintained in agreement with the authorizing committee according to the Austrian Animal Welfare law and the guidelines of the International Guiding Principles for Biomedical Research Involving Animals (CIOMS, the Council for International Organizations of Medical Sciences). Mice were housed in individually ventilated cages under a 14-h light&#x2013;10-h dark cycle at an ambient temperature of 22&#x2009;&#xB0;C&#x2009;&#xB1;&#x2009;1&#x2009;&#xB0;C and humidity of 55%&#x2009;&#xB1;&#x2009;5% with continuous access to food and water. Mice were housed in groups (maximum four males per cage and maximum five females per cage). All mice were bred in the IMBA animal facility. Wild-type, <italic>Scc1</italic><sup><italic>fl/fl</italic></sup> and <italic>Scc1</italic><sup><italic>Myc/+</italic></sup> mice were bred on a mixed background (B6, 129, Sv). <italic>Wapl</italic><sup><italic>fl/fl</italic></sup> and <italic>Zp3-dsCTCF</italic> mice were bred on a primarily C57BL/6J background. <italic>Zp3-dsCTCF</italic> mice were maintained by breeding <italic>Zp3-dsCTCF</italic> males with C57BL/6J females. Experimental <italic>Scc1</italic><sup><italic>fl/fl</italic></sup> and <italic>Wapl</italic><sup><italic>fl/fl</italic></sup> mice were obtained by mating of homozygous floxed females with homozygous floxed males carrying <italic>Tg(Zp3Cre)</italic><sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Experimental <italic>Scc1</italic><sup><italic>Myc/+</italic></sup> mice were obtained by intercrossing heterozygous <italic>Scc1</italic><sup><italic>Myc/+</italic></sup> mice. Experimental <italic>Zp3-dsCTCF</italic> mice were maintained by breeding <italic>Zp3-dsCTCF</italic> males with C57BL/6J females.</p>
      </sec>
      <sec id="Sec9">
        <title>Collection and in vitro culture of mouse oocytes</title>
        <p id="Par22">Ovaries were dissected from sexually mature female mice, which were euthanized by cervical dislocation. Fully grown germinal vesicle (GV) oocytes from 2&#x2013;5-month-old females were isolated by physical disaggregation of ovaries with hypodermic needles. GV oocytes were cultured in M2 medium supplemented with 0.2&#x2009;mM of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX, Sigma-Aldrich) at 37&#x2009;&#xB0;C. Mature oocytes were selected according to appearance (size, central nucleus, smooth zona pellucida) and cultured in M16 medium supplemented with IBMX in an incubator at 37&#x2009;&#xB0;C and 5% CO<sub>2</sub>. Oocytes were cultivated in approximately 40-&#xB5;l drops covered with paraffin oil (NidOil).</p>
      </sec>
      <sec id="Sec10">
        <title>Microinjection</title>
        <p id="Par23">GV oocytes were microinjected with in-vitro-transcribed mRNA dissolved in RNAse-free water (mMessage mMachine T3 kit, Ambion). The following mRNA concentrations were injected: 2.3&#x2009;pmol hGeminin(L26A) and 0.2&#x2009;pmol GFP. Microinjection was performed in approximately 20-&#xB5;l drops of M2 (0.2&#x2009;mM IBMX) covered with mineral oil (Sigma-Aldrich) using a Pneumatic PicoPump (World Precision Instruments) and hydraulic micromanipulator (Narishige) mounted onto a Zeiss Axiovert 200 microscope equipped with a 10&#xD7;/0.3 EC plan-neofluar and 40&#xD7;/0.6 LD Apochromat objective. Injected oocytes were cultured for 2&#x2009;h and then released from IBMX inhibition by washing in M16 to resume meiosis.</p>
      </sec>
      <sec id="Sec11">
        <title>In vitro maturation and in vitro fertilization</title>
        <p id="Par24">Oocyte collection and culturing was performed as described above but M2 and M16 media were supplemented with 20% FBS (Gibco) and 6&#x2009;mg&#x2009;ml<sup>&#x2212;1</sup> fetuin (Sigma-Aldrich). After microinjection and IBMX release as described above, GV oocytes were subsequently incubated at 37&#x2009;&#xB0;C and in low-oxygen conditions (5% CO<sub>2</sub>, 5% O<sub>2</sub>, 90% N<sub>2</sub>) to initiate in vitro maturation to metaphase II (MII) eggs. Next, MII eggs were in vitro fertilized 10.5&#x2013;12&#x2009;h after release of IBMX. Sperm was isolated from the cauda epididymis and vas deferens of stud males (2&#x2013;5 months old) and capacitated in fertilization medium (Cook Austria GmbH) in a tilted cell culture dish for at least 30&#x2009;min before incubation with MII eggs. For in vitro fertilization of wild-type, <italic>Scc1</italic><sup><italic>fl/fl</italic></sup> (<italic>Tg</italic>)<italic>Zp3</italic>-Cre and <italic>Zp3-dsCTCF</italic> oocytes, sperm was obtained from B6CBAF1 males, whereas sperm of C57BL/6J males was used for in vitro fertilization of&#xA0;<italic>Wapl</italic><sup><italic>fl/fl</italic></sup> (<italic>Tg</italic>)<italic>Zp3</italic>-Cre&#xA0;oocytes. Zygotes were scored by the formation of visible pronuclei at 5&#x2009;h after fertilization.</p>
      </sec>
      <sec id="Sec12">
        <title>In situ fixation, immunofluorescence staining and imaging</title>
        <p id="Par25">Zygotes were pulsed with 1&#x2009;mM 5-ethynyl-2&#x2032;-deoxyuridine (EdU) (Invitrogen) before in situ fixation to check the time frame of G1 phase. To check for DNA replication, zygotes were fixed in G2 after continuous incubation in the presence of EdU. Oocytes and zygotes were stripped from their zona pellucida by using acidic Tyrode&#x2019;s solution (Sigma-Aldrich) before in situ fixation in 4% paraformaldehyde (PFA) (in phosphate-buffered saline (PBS)) for 30&#x2009;min at room temperature, followed by permeabilization in 0.2% Triton X-100 in PBS (PBSTX) for 30&#x2009;min at room temperature. EdU-pulsed cells were processed according to the manual of the Click-iT EdU Alexa Fluor 647 imaging kit (Invitrogen). Blocking was performed using 10% goat serum (Dako) in PBSTX for 1&#x2009;h at room temperature or at 4&#x2009;&#xB0;C overnight. Cells were incubated with primary antibodies for 2.5&#x2009;h at room temperature or at 4&#x2009;&#xB0;C overnight. The following primary antibodies were used: anti-MCM2 (1:500; BD Transduction Laboratories, 610701), anti-CTCF (1:250, Peters Laboratory, A992), anti-MYC (1:500, Millipore, 05-724). After washing in blocking solution three times for at least 20&#x2009;min, cells were incubated with goat anti-mouse Alexa Fluor 488 (1:500, Invitrogen, A11029), donkey anti-rabbit Alexa Fluor 568 (1:500, Invitrogen, A10042) or goat anti-mouse Alexa Fluor 647 (1:500, Invitrogen, A-21235) secondary antibodies for 1&#x2009;h at room temperature. The excess of secondary antibody was removed by washing three times in 0.2% PBSTX for at least 20&#x2009;min, which was followed by a short PBS wash and submerging for 20&#x2009;min in Vectashield with DAPI (Vector Labs). Cells were mounted in Vectashield with DAPI using imaging spacers (Sigma-Aldrich) to preserve three-dimensional integrity. Detection of chromatin-bound MCM2 required pre-extraction before fixation and was performed as described previously<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. In short, the zona pellucida was not removed and zygotes were incubated in ice-cold extraction buffer (50&#x2009;mM NaCl, 3&#x2009;mM MgCl<sub>2</sub>, 300&#x2009;mM sucrose, 25&#x2009;mM HEPES, 0.5% Triton X-100) for 7&#x2009;min on ice, followed by three short washes in ice-cold extraction buffer without Triton X-100. In situ fixation and immunofluorescence was performed as described above. To avoid zona pellucida collapse, cells were submerged in increasing Vectashield concentrations before final mounting. Image acquisition was performed on a Zeiss LSM780 or LSM880 confocal microscope using a plan-apochromat 63&#xD7;/1.4 oil immersion objective. Image analysis was performed in Fiji/ImageJ. Mean intensity was measured within a defined nuclear area of each zygote. To measure nuclear signal over background, images were first deconvoluted by Huygens Professional (SVI) followed by segmentation into nuclei and surrounding cytoplasm using a custom ImageJ macro.</p>
      </sec>
      <sec id="Sec13">
        <title>Cell culture and synchronization</title>
        <p id="Par26">HCT116 cells were cultured as previously described<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. In brief, cells were cultured in McCoy&#x2019;s 5A medium (Thermo Fisher Scientific) supplemented with 10% FBS (Gibco), 2&#x2009;mM <sc>l</sc>-glutamine (Invitrogen) and 10% penicillin&#x2013;streptomycin solution (Sigma-Aldrich). Cells were grown in an incubator at 37&#x2009;&#xB0;C with 5% CO<sub>2</sub>. MCM2&#x2013;mAID degradation was induced by addition of 500&#x2009;&#xB5;M 3-indoleacetic acid (Sigma-Aldrich) for 6&#x2009;h. To synchronize cells in G1 for Hi-C analysis, a 2&#x2009;mM thymidine arrest was followed by release into fresh medium for 6&#x2009;h. Subsequently, nocodazole was added for 5&#x2009;h, followed by shake-off of prometaphase cells and release in fresh medium for 4&#x2009;h. Cells were fixed for Hi-C, microscopy and fluorescence-activated cell sorting (FACS). Cell-cycle profiling was performed using propidium iodide staining. For G1 FACS, cells were synchronized with a double-thymidine arrest&#x2013;release followed by release into fresh medium for 12&#x2009;h. Four hours before sorting, Hoechst 33342 (Sigma) was added to the medium at a concentration of 0.2&#x2009;&#xB5;g&#x2009;ml<sup>&#x2212;1</sup>. For the triptolide (Trp) experiment, 4&#x2009;h before sorting, triptolide (Sigma) at 1&#x2009;&#xB5;M was added. Live-cell sorting was performed with the BD FACS Aria II flow cytometry instrument. The following gating strategy was used: gating for cells with SSC-A versus FSC-A, excluding doublets with FSC-H versus FSC-A, selecting Hoechst 33342-stained cells with HOECHST-W versus HOECHST-A gating and Count versus HOECHST-A to select to select the G1 population. To avoid S-phase cell contamination, only cells in the left part of the G1 peak were collected (red dashed box in Extended Data Fig. <xref rid="Fig12" ref-type="fig">8</xref>) (see&#xA0;<xref rid="MOESM1" ref-type="media">Supplementary Fig. 6</xref> for the gating strategy).</p>
      </sec>
      <sec id="Sec14">
        <title>Chromatin fractionation and protein detection</title>
        <p id="Par27">Fractionation was performed as previous described<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. In brief, cells were extracted in a buffer consisting of 20&#x2009;mM Tris&#x2013;HCl (pH 7.5), 100&#x2009;mM NaCl, 5&#x2009;mM MgCl, 2&#x2009;mM NaF, 10% glycerol, 0.2% NP40, 20&#x2009;mM &#x3B2;-glycerophosphate, 0.5&#x2009;mM DTT and protease inhibitor cocktail (Complete EDTA-free, Roche). Chromatin pellets and supernatant were separated and collected by centrifugation at 1,700<italic>g</italic> for 5&#x2009;min. The chromatin pellets were washed three times with the same buffer. Protein concentration was measured using a Bradford assay. Proteins were separated through SDS&#x2013;PAGE on a Bolt 4&#x2013;12% Bis-Tris Plus Gel (Invitrogen) and transferred to a nitrocellulose membrane. After overnight blocking with 5% skimmed milk in TBS-T at 4&#x2009;&#xB0;C, the membrane was incubated with primary antibodies for 2.5&#x2009;h at room temperature. The following antibodies were used: anti-MCM2 (1:5,000; BD Transduction Laboratories, 610701), anti-MCM4 (1:5,000; Abcam, ab4459), anti-H3 (1:2,000; Cell Signaling, 97155), anti-GAPDH(1:2,500; Millipore, MAB374), anti-CTCF (1:1,000, Peters Laboratory, A992), anti-PCNA (1:500, Santa Cruz, PC10), anti-SCC1 (1:1,000, Millipore, 05-908) and anti-Pol II 8WG16 (1:500, Santa Cruz, sc-56767). Goat anti-mouse immunoglobulins&#x2013;HRP (1:500, Dako, P0447) and goat anti-rabbit immunoglobulins&#x2013;HRP (1:500, Dako, P0448) secondary antibodies were used to detect primary antibodies. Detection was performed using Immobilon Forte Western HRP Substrate (Merck) with a ChemiDoc imaging system (Bio-Rad).</p>
      </sec>
      <sec id="Sec15">
        <title>snHi-C</title>
        <p id="Par28">snHi-C was carried out as previously described<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>. Pronuclei of wild-type, <italic>Scc1</italic><sup><italic>&#x394;/&#x394;</italic></sup>, <italic>Wapl</italic><sup><italic>&#x394;/&#x394;</italic></sup> and <italic>Zp3-dsCTCF</italic> zygotes were fixed around 1.5&#x2009;h after visualization of pronuclei (corresponding to 6&#x2013;6.5&#x2009;h after fertilization) and therefore are expected to be in G1 phase of the cell cycle. No blinding or randomization was used for handling of the cells. In brief, isolated pronuclei were fixed in 2% PFA for 15&#x2009;min, transferred to microwell plates (Sigma, M0815) and then lysed on ice in lysis buffer (10&#x2009;mM Tris-HCl pH 8.0, 10&#x2009;mM NaCl, 0.5% (v/v) NP-40 substitute (Sigma), 1% (v/v) Triton X-100 (Sigma), 1&#xD7; Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific)) for at least 30&#x2009;min. After a brief PBS wash, the pronuclei were incubated in 1&#xD7; NEB3 buffer (New England Biolabs) with 0.6% SDS at 37&#x2009;&#xB0;C for 2&#x2009;h with shaking in a humidified atmosphere. The pronuclei were then washed once in 1&#xD7; DpnII buffer (New England Biolabs) with 1&#xD7; bovine serum albumin (BSA) (New England Biolabs) and further digested overnight with 5&#x2009;U DpnII (New England Biolabs) at 37&#x2009;&#xB0;C in a humidified atmosphere. After a brief PBS wash and a wash through 1&#xD7; ligation buffer (Thermo Fisher Scientific), the pronuclei were then ligated with 5&#x2009;U T4 ligase (Thermo Fisher Scientific) at 16&#x2009;&#xB0;C for 4.5&#x2009;h with rotation (50&#x2009;rpm), followed by 30&#x2009;min ligation at room temperature. Next, whole-genome amplification was performed using the illustra GenomiPhi V2 DNA amplification kit (GE Healthcare). In brief, the pronuclei were transferred to 0.2-ml PCR tubes in 3&#x2009;&#xB5;l sample buffer covered with mineral oil (Sigma-Aldrich) and were de-cross-linked at 65&#x2009;&#xB0;C overnight. Then, the pronuclei were lysed by adding 1.5&#x2009;&#xB5;l lysis solution (600&#x2009;mM KOH, 10&#x2009;mM EDTA, 100&#x2009;mM DTT) and incubated for 10 min at 30&#x2009;&#xB0;C, followed by neutralization with the addition of 1.5&#x2009;&#xB5;l neutralization solution (4 vol 1&#x2009;M Tris HCl, pH 8.0; 1 vol 3&#x2009;M HCl). Whole-genome amplification was carried out by addition of 4&#x2009;&#xB5;l sample buffer, 9&#x2009;&#xB5;l reaction buffer and 1&#x2009;&#xB5;l enzyme mixture and incubation at 30&#x2009;&#xB0;C for 4&#x2009;h followed by heat activation at 65&#x2009;&#xB0;C for 10&#x2009;min. High-molecular-weight DNA was purified using AMPure XP beads (Beckman Coulter, 1.8:1.0 beads:DNA ratio) and 1&#x2009;&#xB5;g DNA was sonicated to approximately 300&#x2013;1,300-bp fragments using the E220 Focused-Ultrasonicator (Covaris). The sonicated DNA was purified with a PCR purification kit (Qiagen) and used to prepare Illumina libraries with the NEB Next Ultra Library Prep kit (Illumina). Libraries were sequenced on the HiSeq 2500 v4 with 125-bp paired-end reads (at the VBCF NGS unit) or on the NextSeq high-output lane with 75-bp paired-end reads (at the MPIB NGS core facility).</p>
      </sec>
      <sec id="Sec16">
        <title>snHi-C data analysis</title>
        <p id="Par29">snHi-C data were processed and analysed similarly to a previous report<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> and as previously described in<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>. In brief, the reads of each sample were mapped to the mm9 genome with bwa and processed by the pairtools framework (<ext-link ext-link-type="uri" xlink:href="https://pairtools.readthedocs.io/en/latest/">https://pairtools.readthedocs.io/en/latest/</ext-link>) into pairs files. These data were subsequently converted into COOL files by the cooler package and used a container for Hi-C contact maps.</p>
        <p id="Par30">Loops were analysed by summing up snHi-C contact frequencies for loop coordinates of over 12,000 loops identified using the Hi-C data from wild-type mouse embryonic fibroblasts published previously<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>.We removed the effect of distance dependence by averaging 20&#x2009;&#xD7;&#x2009;20 matrices surrounding the loops and dividing the final result by similarly averaged control matrices. Control matrices were obtained by averaging 20&#x2009;&#xD7;&#x2009;20 matrices centred on the locations of randomly shifted positions of known loops (shifts ranged from 100 to 1,100&#x2009;kb with 100 shifts for each loop). For display and visual consistency with the loop strength quantification, we set the backgrounds levels of interaction to 1. The background is defined as the top left 6&#x2009;&#xD7;&#x2009;6 and the bottom right 6&#x2009;&#xD7;&#x2009;6 submatrices. To quantify the loop strength, the average signal in the middle 6&#x2009;&#xD7;&#x2009;6 submatrix is divided by the average signal in the top left and bottom right (at the same distance from the main diagonal) 6&#x2009;&#xD7;&#x2009;6 submatrices. Weighted statistics were calculated using the weights package in R (<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=weights">https://CRAN.R-project.org/package=weights</ext-link>).</p>
        <p id="Par31">For average TAD analysis, we used published TAD coordinates for the CH12-LX mouse cell line<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. We averaged Hi-C maps of all TADs and their neighbouring regions, chosen to be of the same length as the TAD, after rescaling each TAD to a 90&#x2009;&#xD7;&#x2009;90 matrix. For visualization, the contact probability of these matrices was rescaled to follow a shallow power law with distance (&#x2212;0.25 scaling). TAD strength was quantified using contact probability normalized snHi-C data. In Python notation, if <italic>M</italic> is the 90&#x2009;&#xD7;&#x2009;90 TAD numpy array (where numpy is np) and <italic>L</italic>&#x2009;=&#x2009;90 is the length of the matrix, then TAD_strength&#x2009;=&#x2009;box1/box2, where box1&#x2009;=&#x2009;0.5 * np.sum(M[0:L//3, L//3:2*L//3]) + 0.5 * np.sum(M[L//3:2*L// 3,2*L//3:L]); and box2&#x2009;=&#x2009;np.sum(M[L//3:2*L//3,L//3:2*L//3]).</p>
        <p id="Par32">To calculate the insulation score, we computed the sum of read counts within a sliding 40-kb-by-40-kb diamond. The diamond was positioned such that the &#x2018;tip&#x2019; touched the main axis of the snHi-C map corresponding to a &#x2018;self-interaction&#x2019;. As snHi-C maps are not iteratively corrected, we normalized all insulation profiles by the score of the minimum insulation and then subtracted 1. This way, the insulation/domain boundary is at 0 and has a minimum of 0.</p>
        <p id="Par33">Contact probability <italic>P</italic><sub>c</sub>(<italic>s</italic>) curves were computed from 10-kb binned snHi-C data. We divided the linear genomic separations into logarithmic bins with a factor of 1.3. Data within these log-spaced bins (at distance, <italic>s</italic>) were averaged to produce the value of <italic>P</italic><sub>c</sub>(<italic>s</italic>). Both <italic>P</italic><sub>c</sub>(<italic>s</italic>) curves and their log-space slopes are shown following a Gaussian smoothing (using the scipy.ndimage.filters.gaussian_smoothing1d function with radius 0.8). Both the <italic>y</italic> axis (that is, log(<italic>P</italic><sub>c</sub>(<italic>s</italic>)) and the <italic>x</italic> axis (that is, log[<italic>s</italic>]) were smoothed. The average loop size was determined by studying the derivative of the <italic>P</italic><sub>c</sub>(<italic>s</italic>) curve in log&#x2013;log space; that is, the slope of log(<italic>P</italic><sub>c</sub>(<italic>s</italic>)). The location of the maximum of the derivative curve (that is, the position of the smallest slope) closely matches the average length of extruded loops.</p>
      </sec>
      <sec id="Sec17">
        <title>Hi-C library preparation and sequencing</title>
        <p id="Par34">Hi-C was performed largely as described previously<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> with minor modifications. In brief, around 5&#x2009;&#xD7;&#x2009;10<sup>6</sup> HCT116 cells were cross-linked in 1% formaldehyde for 10 min at room temperature, snap-frozen and stored at &#x2212;80&#x2009;&#xB0;C. After permeabilization in lysis buffer (0.2% Igepal, 10 mM Tris-HCl pH 8.0, 10&#x2009;mM NaCl, 1&#xD7; Halt Protease inhibitor cocktail) nuclei were isolated in 0.3% SDS in NEBuffer 3 at 62&#x2009;&#xB0;C for 10&#x2009;min. SDS was quenched with 1% Triton X-100 at 37&#x2009;&#xB0;C for 1&#x2009;h, then the nuclei were pelleted and resuspended in 250&#x2009;&#x3BC;l DpnII buffer with 600&#x2009;U DpnII (New England Biolabs) at 37&#x2009;&#xB0;C. After overnight digestion, 200&#x2009;U DpnII was added followed by 2&#x2009;h more incubation. Then, nuclei were spun down and resuspended in fill-in mix (biotin-14-dATP (Thermo Fisher Scientific), dCTP, dGTP and dTTP (Thermo Fisher Scientific), Klenow Polymerase (NEB), 1&#xD7; NEB 2 buffer) for 1.5&#x2009;h at 37&#x2009;&#xB0;C with rotation. After ligation at room temperature for 4&#x2009;h with T4 ligase (NEB), the nuclei were pelleted, resuspended in 200&#x2009;&#xB5;l H<sub>2</sub>O and digested with proteinase K for 30&#x2009;min at 55&#x2009;&#xB0;C in the presence of 1% SDS. NaCl was added to a final concentration of 1.85&#x2009;M before cross-links were reversed at 65&#x2009;&#xB0;C overnight. After ethanol precipitation and a 70%&#x2013;80% ethanol wash, DNA was resuspended in 10&#x2009;mM Tris EDTA, transferred to a Covaris microtube (Covaris) and sheared to approximately 300&#x2013;1,300-bp fragments on the E220 Focused-Ultrasonicator (Covaris). DNA was then bound to Dynabeads MyOne Streptavidin C1 beads (Thermo Fisher Scientific) for biotin pull-down. Beads were resuspended in H<sub>2</sub>O used for library preparation with the NEBNext Ultra II Library Prep kit for Illumina (NEB). Beads were then washed four times using Tween wash buffer (5&#x2009;mM Tris-HCl, 1&#x2009;M NaCl, 0.5&#x2009;mM EDTA, 0.05% Tween20) and DNA was eluted using 95% formamide, 10&#x2009;mM EDTA at 65&#x2009;&#xB0;C for 2&#x2009;min. After precipitation, DNA was washed with 70&#x2013;80% ethanol and resuspended in H<sub>2</sub>O. The finished libraries were sequenced on the NovaSeq 6000 system (Illumina) with 100-bp paired-end reads (at the VBCF NGS unit) or on the NextSeq high-output lane (Illumina) with 75-bp paired-end reads (at the MPIB NGS core facility).</p>
      </sec>
      <sec id="Sec18">
        <title>Micro-C library preparation and sequencing</title>
        <p id="Par35">The Micro-C libraries were prepared using the Dovetail Micro-C Kit following the manufacturer&#x2019;s protocol. In brief, the chromatin was fixed with disuccinimidyl glutarate (DSG) and formaldehyde in the nucleus. The cross-linked chromatin was then digested in situ using micrococcal nuclease (MNase). After digestion, the cells were lysed with SDS to extract the chromatin fragments and the chromatin fragments were bound to chromatin capture beads. Next, the chromatin ends were repaired and ligated to a biotinylated bridge adapter followed by proximity ligation of adapter-containing ends. After proximity ligation, the cross-links were reversed, the associated proteins were degraded and the purified DNA was converted into a sequencing library using Illumina-compatible adaptors. Biotinylated molecules were pulled down on streptavidin beads before PCR amplification. The library was sequenced on the NextSeq high-output lane (Illumina) with 75-bp paired-end reads (at the MPIB NGS core facility).</p>
      </sec>
      <sec id="Sec19">
        <title>Hi-C and Micro-C data analysis</title>
        <p id="Par36">Hi-C and Micro-C data processing was performed using distiller&#x2014;a nextflow-based pipeline (<ext-link ext-link-type="uri" xlink:href="https://github.com/open2c/distiller-nf">https://github.com/open2c/distiller-nf</ext-link>)<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Reads were mapped to the hg38 reference genome with default settings except dedup/max_mismatch_bp=0. Multiresolution cooler files<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> generated by distiller were used for visualization in HiGlass<sup><xref ref-type="bibr" rid="CR57">57</xref></sup> and in the downstream analyses.</p>
        <p id="Par37">For downstream analysis, we used quaich (<ext-link ext-link-type="uri" xlink:href="https://github.com/open2c/quaich">https://github.com/open2c/quaich</ext-link>), a new snakemake pipeline for Hi-C postprocessing. It uses cooltools (<ext-link ext-link-type="uri" xlink:href="https://github.com/open2c/cooltools">https://github.com/open2c/cooltools</ext-link>)<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>, chromosight<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> and coolpup.py<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> to perform compartment and insulation analysis, peak annotation and pileups, respectively. The config file we used is available here: <ext-link ext-link-type="uri" xlink:href="https://gist.github.com/Phlya/5c2d0688610ebc5236d5aa7d0fd58adb">https://gist.github.com/Phlya/5c2d0688610ebc5236d5aa7d0fd58adb</ext-link>.</p>
        <p id="Par38">We annotated peaks of enriched contact frequency in untreated HCT116 cells from a previous report<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> using chromosight at 5&#x2009;kb resolution with default parameters. Then we used this annotation to quantify the strength of Hi-C peaks in our datasets using pileups at 5&#x2009;kb resolution. Similarly, valleys of insulation score at 10&#x2009;kb resolution with a window of 500&#x2009;kb (and prominence over 0.1) were identified in the same published dataset and filtered to remove those that don&#x2019;t disappear after cohesin depletion (or don&#x2019;t become at least fivefold weaker) to identify cohesin-dependent domain boundaries. These were used to quantify changes in insulation in our datasets. Neighbouring insulation valleys were joined together to form TADs; regions longer than 1.5&#x2009;Mb were ignored. TAD coordinates were used for rescaled pileup analysis<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> to quantify their strength in our datasets. De novo peaks were called using Mustache<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>.</p>
        <p id="Par39">To investigate whether the increase in loop strength occurs genome wide, we split all loop calls into 1&#x2009;Mb bins, using the coordinate of the centre of the loops. Then for each bin, we created pileups normalized to the global chromosome arm-wide expected level of interactions, using coolpuppy at 5&#x2009;kb resolution with 100&#x2009;kb flanks. In addition, each pileup (105&#x2009;&#xD7;&#x2009;105&#x2009;kb) was normalized to the mean value of the top left and bottom right 3&#x2009;&#xD7;&#x2009;3 pixels, to remove variability in local background between different regions of the genome. Then the mean of the central 3&#x2009;&#xD7;&#x2009;3 square of the pileup was used as the measure of normalized loop strength for this bin. Having done this for both MCM2-depleted and control cells, we plotted the result as a histogram of log<sub>2</sub> ratio between the two, to investigate whether the overall distribution of scores is shifted between the two conditions.</p>
      </sec>
      <sec id="Sec20">
        <title>RNA sequencing (RNA-seq) of G1 zygotes</title>
        <p id="Par40">For each replicate, a pool of 10 G1 zygotes were lysed, total RNA was extracted and cDNA was synthesized using the SMART-Seq v4 Ultra Low Input RNA Kit (Takara Bio Europe). Sequencing libraries were prepared with the Nextera XT DNA Library Preparation Kit for Illumina. Libraries were sequenced on the HiSeq 2500 v4 (Illumina) with 50-bp single-end reads at the VBCF NGS unit.</p>
      </sec>
      <sec id="Sec21">
        <title>RNA-seq of tissue culture cells</title>
        <p id="Par41">Total RNA from HCT116 cells was isolated using a lysis step based on guanidine thiocyanate (adapted from a previous study<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> and using magnetic beads (GE Healthcare, 65152105050450). mRNA sequencing libraries were prepared from 1&#x2009;&#xB5;g total RNA using NEBNext Poly(A) mRNA Magnetic Isolation Module (E7490) and NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (E7760). Paired-end sequencing was performed on Illumina NextSeq 500 (2&#x2009;&#xD7;&#x2009;43-bp reads). A total of six samples were multiplexed and sequenced on a NextSeq 500/550 High Output Kit v2.5 (75 Cycles) at the MPIB NGS core facility. BCL raw data were converted to FASTQ data and demultiplexed by bcl2fastq.</p>
      </sec>
      <sec id="Sec22">
        <title>RNA-seq analysis</title>
        <p id="Par42">FASTQ files from sequencing mouse G1 zygotes or the human HCT116 cell line were pseudoaligned to the mm10 or hg38 releases of the <italic>Mus musculus</italic> or <italic>Homo sapiens</italic> genomes, respectively, using Kallisto with 100 bootstraps<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>. The resulting abundance measures were analysed in R to generate PCA plots<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> (factoextra) and a heat map of the correlation matrix (heatmap.2)<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. To find differentially expressed transcripts we used the Wald test for Sleuth model (sleuth) in R. Gene ontology (GO) term enrichment of molecular functions of up- and downregulated genes were carried out using ShinyGO (<ext-link ext-link-type="uri" xlink:href="http://bioinformatics.sdstate.edu/go/">http://bioinformatics.sdstate.edu/go/</ext-link>).</p>
        <p id="Par43">The changes in the chromatin contact frequencies that occurred upon MCM depletion around the TSS of differentially expressed (DE), non-differentially expressed (non-DE) and non-expressed genes were analysed&#xA0;by aggregating the number of contacts as determined in Micro-C experiments with 5&#x2009;kb resolution. The number of contacts was normalized with LOESS using HICcompare in R, and ensemble analysis of the four expression categories (upregulated, <italic>n</italic>&#x2009;=&#x2009;164; downregulated, <italic>n</italic>&#x2009;=&#x2009;65; non-DE, <italic>n</italic>&#x2009;=&#x2009;916; non-expressed, <italic>n</italic>&#x2009;=&#x2009;1,000) was carried out in distance bins of 0&#x2013;5&#x2009;kb, 5&#x2013;25&#x2009;kb, 25&#x2013;250&#x2009;kb, 250&#x2013;1,000&#x2009;kb and over 1,000&#x2009;kb up- and downstream of the TSS. The mean change of contact frequencies in each bin for every category was calculated by averaging the auxin versus DMSO treatment ratios of the normalized sum of contacts. All of the mean contact frequency changes were tested against the non-DE TSS control using the non-parametric Kruskal&#x2013;Wallis test followed by pairwise Wilcoxon (Mann&#x2013;Whitney <italic>U</italic>) test.</p>
        <p id="Par44">All plots were compiled with ggplot2 in R.</p>
      </sec>
      <sec id="Sec23">
        <title>Protein expression and purification</title>
        <sec id="Sec24">
          <title>Cohesin</title>
          <p id="Par45">Human recombinant cohesin<sup>STAG1, SCC1-Halo</sup> was purified and fluorescently labelled with Janelia Fluor 549 HaloTag (Promega) as previously described<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>.</p>
        </sec>
        <sec id="Sec25">
          <title>ORC and Cdc6</title>
          <p id="Par46"><italic>Saccharomyces cerevisiae</italic> recombinant ORC and Cdc6 were purified as previously described<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>.</p>
        </sec>
        <sec id="Sec26">
          <title>SFP synthase</title>
          <p id="Par47">SFP synthase was purified essentially as previously described<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>.</p>
        </sec>
        <sec id="Sec27">
          <title>Cdt1&#x2013;MCM and Cdt1&#x2013;MCM<sup>Mcm3-YDF</sup></title>
          <p id="Par48">To generate fluorescently labelled <italic>S. cerevisiae</italic> recombinant Cdt1&#x2013;MCM, the <italic>S. cerevisiae</italic> strain ySA4 was generated. In brief, a ybbR and 3&#xD7;Flag tag were fused to the N and C terminus of Mcm6, respectively, generating Cdt1&#x2013;MCM<sup>ybbR-Mcm6</sup>. The chimeric MCM complex containing a humanized Mcm3 subunit (Cdt1&#x2013;MCM<sup>Mcm3-YDF, ybbR-Mcm6</sup>) was expressed in strain yMS1, which was generated by further modification of ySA4. For this, the corresponding region in <italic>S. cerevisiae</italic> Mcm3 was replaced by the 19-amino-acid disordered region that contains a YDF motif present in human MCM3<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>, using CRISPR&#x2013;Cas9-based genome editing essentially as previously described<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. To target <italic>S. cerevisiae</italic> Mcm3, the following guide sequence was used: 5&#x2032;-TATAATGTCACCGCTTCCTG-3&#x2032;. The homologous repair template (synthesized by Eurofins Genomics) encoding the 19-amino-acid disordered region containing the YDF motif (underlined) was: 5&#x2032;-ACTCCAAGAAGGTCAACGGCATCTTCCGTTAATGCCACGCCATCGTCAGCACGCAGAATATTACGTTTTCAAGATGACGAACAGAACGCTGGTGAAGAC<underline>GATGGGGATTCATACGACCCCTATGACTTCAGTGACACAGAGGAGGAAATGCCTCAA</underline>AGGCTTCAACTGGGGTTGAGAGTGTCTCCAAGACGTAGAGAACATCTTCACGCACCTGAGGAAGGTTCGTCGGGACCTCTTACCGAGGTCGGTACTCCA-3&#x2032;. Notably, this strategy allowed the modification of all Mcm3 alleles (confirmed by sequencing) and thus ensured the complete absence of wild-type Mcm3 in the subsequent preparation. Strain yMS1 grew comparably to the parental strain ySA4, confirming that the YDF motif did not alter the MCM function.</p>
          <p id="Par49">Cells were grown in 6&#x2009;l YP medium supplemented with 2% (v/v) raffinose at 30&#x2009;&#xB0;C. At an optical density at 600&#x2009;nm (OD<sub>600&#x2009;nm</sub>) of 1.2, cells were arrested at G1 by adding &#x3B1;-factor to a final concentration of 150&#x2009;ng&#x2009;ml<sup>&#x2212;1</sup> for 3&#x2009;h. Subsequently, protein expression was induced by the addition of 2 % (v/v) galactose. After 4&#x2009;h, cells were collected and washed once with cold MilliQ water + 0.3&#x2009;mM PMSF and once with buffer A (100&#x2009;mM HEPES-KOH, pH 7.6, 0.8&#x2009;M sorbitol, 10&#x2009;mM Mg(OAc)<sub>2</sub>, 0.75&#x2009;M potassium glutamate (KGlu)). Finally, cells were resuspended in 1 packed cell volume of buffer A + 1&#x2009;mM DTT supplemented with a protease inhibitor cocktail (2&#x2009;&#xB5;M pepstatin, 2&#x2009;&#xB5;M leupeptin, 1&#x2009;mM PMSF,1&#x2009;mM benzamidine, 1&#x2009;&#xB5;g&#x2009;ml<sup>&#x2212;1</sup> aprotinin) and frozen dropwise in liquid N<sub>2</sub>. Frozen cells were lysed in a freezer mill (SPEX) and lysed cell powder was resuspended in 1 packed cell volume buffer B (45&#x2009;mM HEPES-KOH, pH 7.6, 0.02 % (v/v) Nonidet P40 Substitute, 5&#x2009;mM Mg(OAc)<sub>2</sub>, 10 % (v/v) glycerol, 1&#x2009;mM ATP, 1&#x2009;mM DTT) + 300&#x2009;mM KGlu. All subsequent purification steps were performed at 4&#x2009;&#xB0;C unless stated otherwise. The lysate was cleared by ultracentrifugation at 235,000<italic>g</italic> for 60&#x2009;min. Soluble lysate was incubated with 0.5&#x2009;ml bed volume (BV) Anti-Flag M2 affinity gel (Sigma) equilibrated with buffer B + 300&#x2009;mM KGlu for 3&#x2009;h. The resin was washed twice with 20 BV buffer B + 300&#x2009;mM KGlu and twice with 20 BV buffer B + 100&#x2009;mM KGlu. Protein was eluted with buffer B + 100&#x2009;mM KGlu + 0.5&#x2009;mg&#x2009;ml<sup>&#x2212;1</sup> 3&#xD7;Flag peptide.</p>
          <p id="Par50">For site-specific labelling, Cdt1-MCM<sup>ybbR-Mcm6</sup> or Cdt1-MCM<sup>Mcm3-YDF, ybbR-Mcm6</sup> was incubated with SFP-Synthase and LD655-CoA (Lumidyne Technologies) at a 1:3:6 molar ratio for 2&#x2009;h at 30&#x2009;&#xB0;C in buffer B + 100&#x2009;mM KGlu, 10&#x2009;mM MgCl<sub>2</sub>. Labelled protein was further purified on a Superdex 200 increase 10/300 gel filtration column (GE Healthcare) equilibrated in buffer B + 100&#x2009;mM potassium acetate (KOAc). Protein-containing fractions were pooled, concentrated with a MWCO 50000 Amicon Ultra Centrifugal Filter unit (Merck) and stored in aliquots at &#x2212;80&#x2009;&#xB0;C. The labelling efficiency was estimated to be around 90% from the extinction coefficients of Cdt1-MCM and LD655.</p>
        </sec>
      </sec>
      <sec id="Sec28">
        <title>Single-molecule imaging</title>
        <p id="Par51">Single-molecule assays were performed using an RM21 micromirror TIRF microscope (Mad City Labs) built in a similar manner to that previously described<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> with an Apo N TIRF 60&#xD7; oil-immersion TIRF objective (NA 1.49, Olympus). Janelia Fluor 532 and LD655 were excited with a 532&#x2009;nm and 637&#x2009;nm laser (OBIS 532&#x2009;nm LS 120&#x2009;mW and OBIS 637&#x2009;nm LX 100&#x2009;mW, Coherent), respectively at a frame rate of around 6&#x2009;fps. Residual scattered light from excitation was removed with a ZET532/640m emission filter (Chroma). Emission light was split at 635&#x2009;nm (T635lpxr, Chroma) and recorded as dual-view with an iXon Ultra 888 EMCCD camera (Andor). All microscope parts were controlled using Micromanager v1.4 (ref. <sup><xref ref-type="bibr" rid="CR71">71</xref></sup>) and custom Beanshell scripts.</p>
      </sec>
      <sec id="Sec29">
        <title>Preparation of PEG&#x2013;biotin microscope slides</title>
        <p id="Par52">Glass coverslips (22 &#xD7; 22&#x2009;mm, Marienfeld) were cleaned in a plasma cleaner (Zepto, Diener Electronic) and subsequently incubated in 2% (v/v) 3-aminopropyltriethoxysilane (Roth) in acetone for 5&#x2009;min. Silanized coverslips were washed with ddH<sub>2</sub>O, dried and incubated at 110&#x2009;&#xB0;C for 30&#x2009;min. Slides were covered with a fresh solution of 0.1&#x2009;M NaHCO<sub>3</sub> containing 0.4% (w/v) biotin&#x2013;PEG-SC-5000 and 15% (w/v) mPEG-SC-5000 (Laysan Bio) and incubated overnight. Functionalized slides were washed with ddH<sub>2</sub>O, dried and incubated again overnight in a fresh biotin&#x2013;PEG/mPEG solution. Slides were finally washed, dried and stored under vacuum.</p>
      </sec>
      <sec id="Sec30">
        <title>DNA substrate for single-molecule imaging</title>
        <p id="Par53">To generate pMSuperCos-ARS1, first, a 21&#x2009;kb genomic DNA fragment of bacteriophage lambda (NEB) was flanked by a unique XbaI (position 0) and NotI restriction site on either end and cloned into a pSuperCos1 backbone (Stratagene). Second, the yeast origin ARS1 was inserted at a BamHI site around position 5.3&#x2009;kb within the 21&#x2009;kb genomic DNA fragment.</p>
        <p id="Par54">To produce the DNA substrate for single-molecule imaging, pMSuperCos-ARS1 was isolated from DH5&#x3B1; using a Plasmid Maxi Kit (Qiagen). One hundred micrograms of plasmid was digested with 100&#x2009;U NotI-HF and XbaI (NEB) for 7&#x2009;h at 37&#x2009;&#xB0;C. The resulting 21,202&#x2009;bp ARS1-DNA fragment was separated from the SuperCos1 backbone on a 10&#x2013;40 % sucrose gradient. DNA handles were prepared by annealing oligonucleotides MS_200/201 MS202/203 (see&#xA0;<xref rid="MOESM5" ref-type="media">Supplementary Table 2</xref> for oligonucleotide sequences) in equimolar amounts in 30&#x2009;mM HEPES, pH 7.5, 100&#x2009;mM KOAc by heating to 95&#x2009;&#xB0;C for 5&#x2009;min and cooling to 4&#x2009;&#xB0;C at &#x2212;1&#x2009;&#xB0;C per min. Annealed handles were mixed with the purified 21&#x2009;kb ARS1-DNA at a molar ratio of 15:1 and ligated with T4 DNA Ligase in 1&#xD7; T4 ligase buffer (both NEB) at 16&#x2009;&#xB0;C overnight. Free handles were removed on a Sephacryl S-1000 SF Tricorn 10/300 gel filtration column (GE Healthcare) equilibrated in 10&#x2009;mM Tris, pH 8, 300&#x2009;mM NaCl, 1&#x2009;mM EDTA. Peak fractions were pooled, ethanol precipitated and reconstituted in TE buffer. Final DNA was stored in aliquots at &#x2212;80&#x2009;&#xB0;C. Note that the final linear DNA is functionalized with biotin at a NotI site and an 18-bp single-stranded DNA overhang at an XbaI site that is used for orientation specific doubly tethering.</p>
        <sec id="Sec31">
          <title>Flow cell preparation</title>
          <p id="Par55">A functionalized PEG&#x2013;biotin slide was incubated with blocking buffer (20&#x2009;mM Tris-HCl, pH 7.5, 50&#x2009;mM NaCl, 2&#x2009;mM EDTA, 0.2&#x2009;mg&#x2009;ml&#x2212;1 BSA, 0.025 % (v/v) Tween20) + 0.2&#x2009;mg&#x2009;ml<sup>&#x2212;1</sup> streptavidin (Sigma) for 30&#x2009;min. A flow cell was assembled by placing a polydimethylsiloxane block on top to generate a 0.5&#x2009;mm wide and 0.1&#x2009;mm high flow channel and a polyethylene tube (inner diameter 0.58&#x2009;mm) was inserted at either end.</p>
          <p id="Par56">DNA was introduced to the flow cell at 5&#x2009;pM in blocking buffer and incubated for 15&#x2009;min in the absence of buffer flow to allow binding to the slide surface. To doubly tether DNA, the flow lane was flushed with 100&#x2009;&#xB5;M oligonucleotide MS_204 (see&#xA0;<xref rid="MOESM5" ref-type="media">Supplementary Table 2</xref> for oligonucleotide sequences) in blocking buffer at 100&#x2009;&#xB5;l per min.</p>
        </sec>
      </sec>
      <sec id="Sec32">
        <title>Single-molecule sliding assay</title>
        <p id="Par57">Helicase loading was achieved by introducing 0.25&#x2009;nM ORC, 4&#x2009;nM Cdc6 and 10&#x2009;nM Cdt1&#x2013;MCM<sup>ybbR-LD655-Mcm6</sup> or Cdt1&#x2013;MCM<sup>Mcm3-YDF, ybbR-LD655-Mcm6</sup> in licensing buffer (30&#x2009;mM HEPES-KOH, pH 7.6, 8&#x2009;mM Mg(OAc)<sub>2</sub>, 0.1&#x2009;mg&#x2009;ml<sup>&#x2212;1</sup> BSA, 0.05 % (v/v) Tween20) + 200&#x2009;mM KOAc, 5&#x2009;mM DTT, 3&#x2009;mM ATP to a prepared flow cell and incubating for 25&#x2009;min. Cohesin loading and sliding was essentially performed as previously described<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Cohesin<sup>STAG1, SCC1-Halo-JF546</sup> (0.7&#x2009;nM) was incubated with licensed DNA in cohesin binding buffer (35&#x2009;mM Tris, pH 7.5, 25&#x2009;mM NaCl, 25&#x2009;mM KCl, 1&#x2009;mM MgCl<sub>2</sub>, 10% (v/v) glycerol, 0.1&#x2009;mg&#x2009;ml<sup>&#x2212;1</sup> BSA, 0.003 (v/v) Tween20, 1&#x2009;mM DTT, 0.2&#x2009;mM ATP) for 10&#x2009;min. To remove free protein, DNA-bound licensing factors and MCM loading intermediates, the flow cell was washed with licensing buffer + 500&#x2009;mM NaCl, 1&#x2009;mM DTT, 0.6&#x2009;mM ATP supplemented with an oxygen scavenging system (1&#x2009;mM Trolox, 2.5&#x2009;mM PCA, 0.21&#x2009;U&#x2009;ml<sup>&#x2212;1</sup> PCD (all Sigma))<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. Imaging was either started directly (high-salt condition) or after lowering the salt concentration to 150&#x2009;mM NaCl (physiological salt condition) in an otherwise identical buffer to that described for the high-salt condition. DNA was post-stained with 50&#x2009;nM SYTOX Orange (Thermo Fisher Scientific) in the same buffer that was used during imaging.</p>
      </sec>
      <sec id="Sec33">
        <title>Single-molecule data analysis</title>
        <p id="Par58">Single-molecule data were analysed in Fiji using the Molecule Archive Suite (Mars) plug-in (<ext-link ext-link-type="uri" xlink:href="https://github.com/duderstadt-lab/">https://github.com/duderstadt-lab/</ext-link>)<sup><xref ref-type="bibr" rid="CR74">74</xref></sup> and custom Python scripts. In brief, all doubly tethered DNA molecules containing cohesin were chosen for analysis. Cohesin and MCM were tracked individually and merged with DNA to determine their position on the same DNA molecule. Pauses during cohesin translocation were determined by fitting cohesin trajectories (position on DNA versus time) with the kinetic change point algorithm<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> with the following settings: confidence value 0.6; global sigma 300 base pairs (bps)/s. Subsequently, resulting segments with rates lower than 200&#x2009;bps per s, standard deviations of less than 30 bps per s and length greater than 1&#x2009;s were classified as pause segments. If two adjacent segments were classified as pauses and the end and start position on DNA of the first and second pause segment, respectively, were within 1&#x2009;kb, these segments were merged to one pause segment. The fraction of cohesin pausing reported was determined by calculating the cumulative time of all pause segments divided by the total observation time. These pauses were excluded when calculating cohesin&#x2013;MCM passing probabilities and diffusion coefficients (see below).</p>
        <p id="Par59">The probability of cohesin passing MCM was addressed as follows: Frames in which cohesin colocalized with MCM (median position) within less than thresh1 were classified as encounter. Upon an encounter, if cohesin passed MCM in the consecutive frame by at least thresh2, the encounter was determined as successful bypassing. All remaining frames (distance&#x2009;&gt;&#x2009;thresh1 to MCM) were further evaluated for MCM passing as described above, and in addition counted as an encounter with successful bypassing. DNA molecules with cohesin only were analysed the same way using the theoretical ARS1 position on DNA. All frames within the cohesin trajectory that were part of a translocation pause were excluded from this analysis and instead classified as one encounter with failed bypassing. To account for different resolution at different extensions, two dynamic thresholds, thresh1 and thresh2, were set to 1.5&#x2009;kb and 0.5&#x2009;kb at the mean DNA extension of all DNA molecules and adjusted for the individual length of the DNA molecule (Extended Data Fig. <xref rid="Fig13" ref-type="fig">9g</xref>).</p>
        <p id="Par60">MCM photobleaching steps were defined as abrupt drops in fluorescence intensity and detected using the kinetic change point algorithm<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>.</p>
        <p id="Par61">Diffusion coefficients (<italic>D</italic>) were calculated with:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D=\frac{ &lt; x{ &gt; }^{2}}{2t},$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>&lt;</mml:mo><mml:mi>x</mml:mi><mml:msup><mml:mrow><mml:mo>&gt;</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:math><graphic xlink:href="41586_2022_4730_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par62">in which &lt;<italic>x</italic>&gt;<sup>2</sup> is the mean square displacement in kb<sup>2</sup> and <italic>t</italic> is the time in s.</p>
        <p id="Par63">All kymographs were generated using Fiji. For this, individual DNA ends were fitted with subpixel localization and the kymograph was generated along the connecting line. Individual DNA molecules doubly tethered with different extension to the slide surface and as a consequence, kymographs differ in pixel heights. These length differences were accounted for throughout all of the analysis steps described above.</p>
      </sec>
      <sec id="Sec34">
        <title>Loop extrusion simulations and contact map generation</title>
        <sec id="Sec35">
          <title>Simulations overview</title>
          <p id="Par64">We introduced MCMs into polymer models of loop extrusion<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>), as randomly located extrusion barriers. Both CTCF and MCM barriers stall cohesin with some probability (CTCF 50%; ref. <sup><xref ref-type="bibr" rid="CR38">38</xref></sup>) but allow bypassing, consistent with single-molecule experiments (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>). By sweep parameters (processivity and linear density of cohesin, and density and permeability of MCM;&#xA0;Supplementary Figs. 2&#x2013;5), we found a narrow range of values for each condition such that the peak strengths and paternal <italic>P</italic><sub>c</sub>(<italic>s</italic>) curves can be simultaneously reproduced (Fig. <xref rid="Fig3" ref-type="fig">3b, d</xref>,&#xA0;Extended Data Fig. 6e&#x2013;h,&#xA0;Supplementary Figs. 2&#x2013;5). The simulations suggest that in&#xA0;wild-type&#xA0;conditions, cohesins extrude 110&#x2013;130-kb loops and have a density of around 1 per 300&#x2009;kb. MCM permeability was essential to achieve the increase in peak strength without strongly affecting the average loop size after MCM loss; in this regime, there is a linear trade-off between the MCM density and permeability (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). Using MCM densities (one per 30&#x2013;150&#x2009;kb) experimentally measured in other cell types (see below), cohesins should bypass MCMs in around 60&#x2013;90% of encounters.</p>
        </sec>
        <sec id="Sec36">
          <title>Time steps and lattice set-up</title>
          <p id="Par65">We use a fixed-time-step Monte Carlo algorithm as in previous work<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. We define the chromosome as a lattice of <italic>L</italic>&#x2009;=&#x2009;10,000 sites, in which each lattice site corresponds to 2&#x2009;kb of DNA. Loop extruding factors (LEFs) are represented as two motor subunits, which move bidirectionally away from one another one lattice site at a time. When LEFs encounter one another, we assume that they cannot bypass each other as is typical for cohesin simulations<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. The ends of the chromosome (that is, the first and last lattice sites) are considered boundaries to LEF translocation; this way, LEFs cannot &#x2018;walk off&#x2019; the chromosome.</p>
        </sec>
        <sec id="Sec37">
          <title>CTCF and MCM boundary elements</title>
          <p id="Par66">To simulate TADs, we specify that every 150th lattice site is a CTCF site. In this way, our simulated 20&#x2009;Mb chromosome segment is composed of 66 TADs each of size 300&#x2009;kb. CTCF sites may stall the translocation of a LEF subunit with a probability of 0.45. This stalling probability is chosen within the experimental estimates of 15%&#x2013;50% fractional occupancy of CTCF sites via ChIP&#x2013;seq and microscopy<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. For simulations mimicking the &#x2018;control&#x2019; and &#x2018;Wapl&#x2019; depletion conditions (that is, where MCM is present on the genome), we also add random extrusion barriers to our lattice to mimic the presence of MCMs. For our parameter sweep, we add 33, 66, 132, 264, 528 barriers (that is, representing MCMs) randomly dispersed in the 20&#x2009;Mb chromosome segment; this corresponds to a density of 1 MCM complex per 600&#x2009;kb, 300&#x2009;kb, 150&#x2009;kb, 75&#x2009;kb, 37.5&#x2009;kb, respectively. The MCM barriers are fixed in place for the duration of a simulation. Like the CTCFs, the MCM barriers can also stall LEF translocation. A randomly translocating LEF subunit will be stalled at an MCM site with a probability of 0.0001, 0.05, 0.2, 0.4 or 0.8 (meaning that LEFs can bypass between around 20&#x2013;100% of MCM sites). For both CTCF and MCM lattice sites, &#x2018;stalling&#x2019; a LEF subunit is a permanent event that prevents further movement of that subunit. Stalling events are only resolved after dissociation of the LEF from the lattice. For simulations in which there is &#x2018;MCM loss&#x2019;, we set the total number of random MCM barriers to zero but keep the CTCF lattice sites the same. All results presented in this paper are from an average over 25 different random distributions of MCMs (that is, 25 simulation runs were performed for each condition).</p>
        </sec>
        <sec id="Sec38">
          <title>LEF separations and processivity</title>
          <p id="Par67">For our simulations of&#xA0;&#x2018;control&#x2019; and &#x2018;MCM-loss&#x2019; conditions, the default LEF processivity was 90&#x2009;kb, and the default LEF separation was 300&#x2009;kb. For our simulations of the &#x2018;<italic>Wapl</italic><sup><italic>&#x394;</italic></sup>&#x2019; and &#x2018;<italic>Wapl</italic><sup><italic>&#x394;</italic></sup>&#x2009;+&#x2009;MCM loss&#x2019; conditions, the LEF processivity was 130&#x2009;kb, and the separations were 180&#x2009;kb. The approximately 50% increase in density after Wapl depletion is supported by quantitative immunofluorescence data indicating there is a modest enrichment of cohesin after removal of Wapl<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p>
        </sec>
        <sec id="Sec39">
          <title>Association and dissociation rates</title>
          <p id="Par68">All simulations are performed with fixed numbers of extruders. The dissociation rate is ultimately tied to the &#x2018;processivity&#x2019; of the LEF, which is the average distance in kb (or lattice sites) that the LEF travels before dissociating. We allow LEFs to randomly associate to at any lattice position after a dissociation event.</p>
        </sec>
        <sec id="Sec40">
          <title>Loop extrusion equilibration steps</title>
          <p id="Par69">We compute 10,000 initialization steps for each simulation before creating any contact maps. This ensures that the loop statistics have reached a steady-state. Subsequent loop configurations were sampled every 100 simulation steps to generate contact maps. We sampled from at least 2,500 different LEF configurations (that is, 100 configurations from 25 different simulations) to generate contact probability decay curves and perform aggregate peak analysis (see below).</p>
        </sec>
        <sec id="Sec41">
          <title>Contact maps</title>
          <p id="Par70">We generated contact maps semi-analytically, which uses a Gaussian approximation to calculate contact probability maps directly from the positions of LEFs. This approach was developed previously<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> and used to simulate bacterial Hi-C maps. We note that as the density of cohesins is sufficiently low in the zygotes (that is, the processivity and separation ratio is close to or less than 1), and as the contact probability scaling exponent up to 10&#x2009;Mb is close to &#x2212;1.5 in the absence of cohesins<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, we are justified in using the Gaussian approximation to generate contact maps. To generate the <italic>P</italic><sub>c</sub>(<italic>s</italic>) curves, we use at least 9,000,000 random samples of the contact probability; these samples were taken from varying genomic positions and relative separations within the simulated 20&#x2009;Mb of chromosome and averaged using logarithmically spaced bins (factor of 1.3). To generate the equivalent of the aggregate peak analysis for contact enrichments at CTCF sites, we used at least 144,000,000 random samples of the contact probability from a 100&#x2009;kb by 100&#x2009;kb window centred on the CTCF sites. These 144,000,000 samples were distributed evenly between 64 TADs (there are 66 TADs, but we excluded the 2 TADs closest to the chromosome ends) and at least 2,500 LEF conformations. Control matrices for normalization were obtained as described above, but using a shifted window shifted by 150&#x2009;kb from the TAD boundaries. Aggregate peak analysis plots are shown coarse-grained to 20&#x2009;&#xD7;&#x2009;20 bins.</p>
        </sec>
        <sec id="Sec42">
          <title>Comparing simulated and experimental data</title>
          <p id="Par71">The criteria for comparing the experimental data and the simulated data were two-fold. First, we computed from snHi-C the corner peak strength above background; this was usually a number between 1 and 3 depending on the condition. Second, we computed the <italic>P</italic>(<italic>s</italic>) curves from experiments genome wide. However, we knew from previous studies<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>, that the effect of cohesin on <italic>P</italic>(<italic>s</italic>) typically only extends up to around 1&#x2009;Mb under normal conditions. Moreover, above 1&#x2009;Mb, the semi-analytical approach to generating contact maps becomes less reliable as non-equilibrium effects, chain topology, and chain swelling may start to have a role in the <italic>P</italic>(<italic>s</italic>) curve, which are not accounted for in our model<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Below 30&#x2009;kb, Hi-C data have been shown to contain artefacts and can vary significantly between different protocols. Thus, we restricted our comparisons to the range 30&#x2009;kb&#x2013;1&#x2009;Mb.</p>
          <p id="Par72">The criteria then for evaluating the goodness of a simulation, were to (1) obtain quantitative values for the corner peak strengths as close as possible to the experiments, preserving the correct relative ordering between various conditions (for example, in paternal zygotes, the corner peak strength from weakest to highest was: wild type, Wapl depletion, MCM depletion, MCM&#x2009;+&#x2009;Wapl depletion). We directly scored the goodness of the simulation by minimizing the absolute error between the simulated and experimental corner peak strengths. (2) Simultaneously, we evaluated the absolute values and shapes of the <italic>P</italic>(<italic>s</italic>) curves between 30&#x2009;kb&#x2013;1&#x2009;Mb. The goodness of <italic>P</italic>(<italic>s</italic>) fit was evaluated by visual agreement. Therefore, we used a combined approach to evaluate the match between experiments and simulations, in which the dot strength and <italic>P</italic>(<italic>s</italic>) curves were evaluated together.</p>
        </sec>
        <sec id="Sec43">
          <title>Estimation of chromatin-bound MCM density in mammalian cells</title>
          <p id="Par73">Using mass-spectrometry analysis, the copy number of each MCM subunit is estimated at around 670,000 in HeLa cells<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>, and quantitative immunoblotting shows that in late G1 phase around 45% of MCM2 is bound to chromatin<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. This leads to the estimate that around 301,500 MCMs are bound to the chromatin in late G1. Knowing that MCMs form double hexamers on chromatin and that the average genome size of HeLa cells is around 7.9&#x2009;&#xD7;&#x2009;10<sup>9</sup> (ref. <sup><xref ref-type="bibr" rid="CR79">79</xref></sup>), we estimate a density of 1 MCM double hexamer every approximately 52&#x2009;kb (7.9&#x2009;&#xD7;&#x2009;10<sup>9</sup>/(301,500/2)) (assuming a random distribution of MCMs).</p>
        </sec>
      </sec>
      <sec id="Sec44">
        <title>Reporting summary</title>
        <p id="Par74">Further information on research design is available in the&#xA0;<xref rid="MOESM2" ref-type="media">Nature Research Reporting Summary</xref> linked to this paper.</p>
      </sec>
    </sec>
    <sec id="Sec45" sec-type="materials|methods">
      <title>Online content</title>
      <p id="Par75">Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-022-04730-0.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41586_2022_4730_MOESM1_ESM.pdf"><label>Supplementary Information</label><caption><p>This file contains Supplementary Figures 1-6.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41586_2022_4730_MOESM2_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41586_2022_4730_MOESM3_ESM.pdf"><caption><p>Peer Review File</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41586_2022_4730_MOESM4_ESM.xlsx"><label>Supplementary Table 1</label><caption><p>Read statistics of Hi-C and micro-C replicates.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41586_2022_4730_MOESM5_ESM.xlsx"><label>Supplementary Table 2</label><caption><p>Oligonucleotide sequences used for the DNA substrate for single-molecule imaging.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41586_2022_4730_MOESM6_ESM.mov"><label>Supplementary Video 1</label><caption><p>Video showing translocating cohesin (green) on doubly tethered DNA (blue) in the absence of MCM at 0.15&#x2009;M NaCl (corresponds to kymograph in Extended Data Fig. 9b).</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="41586_2022_4730_MOESM7_ESM.mov"><label>Supplementary Video 2</label><caption><p>Video showing origin-bound MCM (magenta) as an efficient barrier for cohesin translocation (green) on doubly tethered DNA (blue) at 0.15&#x2009;M NaCl (corresponds to kymograph in Fig. 4b).</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="41586_2022_4730_MOESM8_ESM.mov"><label>Supplementary Video 3</label><caption><p>Video showing translocating cohesin (green) on doubly tethered DNA (blue) that occasionally can bypass origin-bound MCM (magenta) at 0.15 M NaCl (corresponds to kymograph in Extended Data Fig. 9e).</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="41586_2022_4730_MOESM9_ESM.mov"><label>Supplementary Video 4</label><caption><p>Video showing translocating cohesin (green) on doubly tethered DNA (blue) in the absence of MCM at 0.5 M NaCl (corresponds to kymograph in Extended Data Fig. 10b).</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="41586_2022_4730_MOESM10_ESM.mov"><label>Supplementary Video 5</label><caption><p>Video showing origin-bound MCM (magenta) as an efficient barrier for cohesin translocation (green) on doubly tethered DNA (blue) at 0.5 M NaCl (corresponds to kymograph in Extended Data Fig. 10c, left).</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="41586_2022_4730_MOESM11_ESM.mov"><label>Supplementary Video 6</label><caption><p>Video showing translocating cohesin (green) on doubly tethered DNA (blue) that occasionally can bypass origin-bound MCM (magenta) at 0.5 M NaCl (corresponds to kymograph in Extended Data Fig. 10d, left).</p></caption></media></supplementary-material>
</p>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec46">
          <title>Extended data figures and tables</title>
          <p id="Par78">
<fig id="Fig5"><label>Extended Data Fig. 1</label><caption><title>Dimensions of cohesin compared to the estimated size of the MCM2&#x2013;7 complex and the FtsK roadblock.</title><p>Size comparison between a schematic representation of the ring-shaped heterotrimeric cohesin (SMC1-SMC3-SCC1) with the MCM2&#x2013;7 double hexamer and the FtsK monohexamer. The size estimation of MCM2&#x2013;7 and FtsK was based on their crystal structure. PDB accessions codes for each protein are shown in parentheses.</p></caption><graphic position="anchor" xlink:href="41586_2022_4730_Fig5_ESM" id="d32e2491"/></fig>
</p>
          <p id="Par79">
<fig id="Fig6"><label>Extended Data Fig. 2</label><caption><title>Prevention of MCM loading in G1-synchronized zygotes.</title><p><bold>a</bold>, Expression of geminin(L26A), a non-degradable variant of geminin, prevents the recruitment of MCMs to chromatin in G1 phase by inhibiting the Cdt1-mediated loading pathway. <bold>b</bold>, Quantification of mean chromatin-bound MCM2 intensity in maternal and paternal pronuclei from wild type (WT, n&#x2009;=&#x2009;7) and MCM-loading inhibited (MCM loss, n&#x2009;=&#x2009;7) G1-phase zygotes from 1 experiment using 4 females. Representative image is shown in Fig. <xref rid="Fig1" ref-type="fig">1b</xref>. <bold>c</bold>, 5-ethynyl-2&#x2032;-deoxyuridine (EdU)-cultured zygotes collected at 6.5h post-fertilization do not incorporate EdU (0/12) and therefore have not yet entered S phase. Zygotes without EdU in the medium (no EdU) also don&#xB4;t incorporate EdU (0/6), while zygotes fixed at 12h post-fertilization show EdU-incorporation (7/7). Quantification of EdU intensity as signal over background shown for both maternal and paternal pronuclei from G1/no Edu (n&#x2009;=&#x2009;6), G1/EdU (n&#x2009;=&#x2009;12) and S/EdU (n&#x2009;=&#x2009;7) zygotes examined in 1 experiment using 6 females. <bold>d</bold>, Immunofluorescence analysis of WT (n&#x2009;=&#x2009;9) and MCM loss (n&#x2009;=&#x2009;11) zygotes from 1 experiment using 6 females that were cultured in continuous presence of EdU and collected at 14h post-fertilization (G2&#xA0;phase). Top, representative image. Bottom, quantification of EdU signal over background in maternal and paternal pronuclei. <bold>e</bold>, <bold>f</bold>, Immunofluorescence analysis of chromatin-bound CTCF (<bold>e</bold>) and SCC1-MYC (<bold>f</bold>) in WT (n&#x2009;=&#x2009;7 for CTCF, n&#x2009;=&#x2009;5 for SCC1-MYC) and MCM loss (n&#x2009;=&#x2009;8 for CTCF, n&#x2009;=&#x2009;7 for SCC1-MYC) G1-phase zygotes from 1 experiment for each staining using 5 females each. Left, representative image. Right, Quantification of CTCF and SCC1-MYC intensity as signal over background in maternal and paternal pronuclei. <italic>P</italic> values were determined by two-sided unpaired <italic>t</italic>-test (<bold>b</bold>, <bold>c</bold>, <bold>e</bold>, <bold>f</bold>) or by two-sided Mann-Whitney <italic>U</italic> test (<bold>d</bold>). Quantifications in panels b-f are depicted as mean &#xB1; s.d.; *, sperm head. <bold>&#x2020;</bold>, degraded polar body. DNA is stained with DAPI. Scale bars, 10&#x2009;&#xB5;m.</p></caption><graphic position="anchor" xlink:href="41586_2022_4730_Fig6_ESM" id="d32e2560"/></fig>
</p>
          <p id="Par80">
<fig id="Fig7"><label>Extended Data Fig. 3</label><caption><title>MCMs impede loops in G1 zygotes while having little effect on the <italic>P</italic><sub>c</sub>(<italic>s</italic>) curve in the range of cohesin-dependent contacts up to 1&#x2009;Mb.</title><p><bold>a</bold>, Peak strength of individual samples for wild type (WT) and MCM-loading inhibited (MCM loss) conditions, shown for maternal and paternal pronuclei. Size of the bullets corresponds to the number of cis 1kb+ contacts per sample (weights). Data are based on n(WT, maternal)&#x2009;=&#x2009;13, n(WT, paternal)&#x2009;=&#x2009;16, n(MCM&#xA0;loss, maternal)&#x2009;=&#x2009;16, n(MCM&#xA0;loss, paternal)&#x2009;=&#x2009;15, from 4 independent experiments using 4-6 females for each experiment (same samples as in Fig. <xref rid="Fig1" ref-type="fig">1d</xref>). Data presented as weighted mean &#xB1; s.d.; <italic>P</italic> values were calculated using weighted statistics (Methods). <bold>b</bold>, Aggregate peak analysis for intermediate (100-250kb) and long loops (&gt;250kb) in WT and MCM loss conditions for maternal and paternal pronuclei. Data are based on the same samples as in (<bold>a</bold>) and Fig. <xref rid="Fig1" ref-type="fig">1d</xref>. <bold>c</bold>, Aggregate peak analysis for WT and MCM loss conditions from a subset of 4, 8 and 12 samples, shown for maternal and paternal pronuclei. <bold>d</bold>, Contact probability P<sub>c</sub>(s) curve as a function of genomic distance (s). Cohesin is directly involved in shaping the P<sub>c</sub>(s) in the range up to 1&#x2009;Mb. The contact frequency in this region is decreased after cohesin depletion (<italic>Scc1</italic><sup><italic>&#x394;</italic></sup>) and is increased after enrichment of chromatin-bound cohesin (<italic>Wapl</italic><sup><italic>&#x394;</italic></sup>). <bold>e</bold>, Contact probability P<sub>c</sub>(s) curves from individual maternal and paternal pronuclei with average P<sub>c</sub>(s) (same as in Fig. <xref rid="Fig1" ref-type="fig">1e</xref>) in bold overlaid. <bold>f</bold>, Slopes of the P<sub>c</sub>(s) curves (depicted in Fig. <xref rid="Fig1" ref-type="fig">1e</xref>) as an indication for the average size of cohesin-extruded loops in WT and MCM loss conditions.</p></caption><graphic position="anchor" xlink:href="41586_2022_4730_Fig7_ESM" id="d32e2647"/></fig>
</p>
          <p id="Par81">
<fig id="Fig8"><label>Extended Data Fig. 4</label><caption><title>MCMs impede cohesin-dependent loops and TADs largely independently of transcriptional changes.</title><p><bold>a</bold>, Principal component analysis (PCA) of the transcriptomes of G1 wild type (G1_WT), G1 MCM-loading inhibited (G1_MCM loss) and G2 wild type (G2_WT) zygotes. <bold>b</bold>, Volcano plot showing statistical significance &#x2013;log<sub>10</sub> (FDR) versus fold change (log<sub>2</sub> fold change) for RNA-Seq data between WT and MCM loss conditions in G1 zygotes. Numbers indicate the number of transcripts significantly up- (right) or downregulated (left) after MCM loss at FDR&#x2009;=&#x2009;0.1. Dashed vertical lines indicate &#x2212;0.585 and +0.585 log<sub>2</sub> fold change in expression (1.5-fold decrease and increase in expression), respectively. <bold>c</bold>, <italic>Scc1</italic><sup><italic>&#x394;/&#x394;</italic></sup> oocytes from <italic>Scc1</italic><sup><italic>fl/fl</italic></sup>
<italic>(Tg)Zp3</italic>-Cre females were injected with geminin(L26A) mRNA and eggs were fertilized to generate maternal knockout <italic>Scc1</italic><sup><italic>&#x394;(m)/+(p)</italic></sup> zygotes for snHi-C analysis in G1 phase. Because most proteins are provided by the oocyte and the G1-phase zygote is practically transcriptionally inactive, these maternal knockout zygotes are depleted for Scc1<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. <bold>d</bold>, Aggregate peak and TAD analysis for <italic>Scc1</italic><sup><italic>fl</italic></sup> (WT), <italic>Scc1</italic><sup><italic>&#x394;</italic></sup> and <italic>Scc1</italic><sup><italic>&#x394;</italic></sup>&#xA0;+&#xA0;MCM loss. Maternal and paternal data are shown pooled together. Data are based on n(<italic>Scc1</italic><sup><italic>fl</italic></sup>)&#x2009;=&#x2009;26, n(<italic>Scc1</italic><sup><italic>&#x394;</italic></sup>)&#x2009;=&#x2009;42, and n(<italic>Scc1</italic><sup><italic>&#x394;</italic></sup>&#xA0;+&#xA0;MCM loss)&#x2009;=&#x2009;10 nuclei. Heat maps were normalized to an equal number of <italic>cis</italic> contacts. Control (<italic>Scc1</italic><sup><italic>fl</italic></sup>) samples and 38 Scc1-depleted samples (<italic>Scc1</italic><sup><italic>&#x394;</italic></sup>) were previously published<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>.</p></caption><graphic position="anchor" xlink:href="41586_2022_4730_Fig8_ESM" id="d32e2765"/></fig>
</p>
          <p id="Par82">
<fig id="Fig9"><label>Extended Data Fig. 5</label><caption><title>CTCF is required for loop and TAD formation in G1 zygotes.</title><p><bold>a</bold>, Immunofluorescence analysis of CTCF in wild type (n&#x2009;=&#x2009;5) and CTCF-depleted (n&#x2009;=&#x2009;12) surrounded nucleolus (SN) oocytes from 1 experiment using 2 females for each genotype. Left, representative images, DNA is stained with DAPI. Scale bars: 20&#x2009;&#xB5;m. Right, Quantification of CTCF intensity as signal over background. Data are presented as mean &#xB1; s.d.; <italic>P</italic> value was determined by two-sided unpaired <italic>t</italic>-test. <bold>b</bold>, Aggregate peak and TAD analysis for wild type (WT), CTCF-depleted (CTCF knockdown) and CTCF-depleted combined with prevention of MCM loading (CTCF knockdown&#xA0;+&#xA0;MCM loss)&#xA0;maternal chromatin in G1 zygotes. Data shown are based on n(WT, maternal)&#x2009;=&#x2009;12, n(CTCF knockdown, maternal)&#x2009;=&#x2009;12, n(CTCF knockdown&#xA0;+&#xA0;MCM loss, maternal)&#x2009;=&#x2009;10 nuclei, from 4 independent experiments using 4-6 females for each genotype. Heat maps were normalized to an equal number of <italic>cis</italic> contacts. <bold>c</bold>, Insulation scores at TAD borders for maternal nuclei. <bold>d</bold>, Average contact probability P<sub>c</sub>(s) curves for WT and CTCF knockdown conditions, shown separately for maternal and paternal nuclei. <bold>e</bold>, P<sub>c</sub>(s) curves for individual samples (maternal and paternal pronuclei) with average P<sub>c</sub>(s) (same as in <bold>d</bold>) in bold overlaid.</p></caption><graphic position="anchor" xlink:href="41586_2022_4730_Fig9_ESM" id="d32e2815"/></fig>
</p>
          <p id="Par83">
<fig id="Fig10"><label>Extended Data Fig. 6</label><caption><title>MCM restricts loop and TAD formation in maternal chromatin independently of Wapl-mediated cohesin release.</title><p><bold>a</bold>, Aggregate peak and TAD analysis for control (WT), <italic>Wapl</italic><sup><italic>&#x394;</italic></sup> and <italic>Wapl</italic><sup><italic>&#x394;</italic></sup>&#xA0;+&#xA0;MCM loss for maternal chromatin in G1 zygotes. Data shown are based on n(WT, maternal)&#x2009;=&#x2009;17, n(<italic>Wapl</italic><sup><italic>&#x394;</italic></sup>, maternal)&#x2009;=&#x2009;10, n(<italic>Wapl</italic><sup><italic>&#x394;</italic></sup>&#xA0;+&#xA0;MCM loss, maternal)&#x2009;=&#x2009;10, from 4 independent experiments using 4-6 females for each genotype. Control samples are WT (this study) pooled with <italic>Wapl</italic><sup><italic>fl</italic></sup> samples (published in<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>). <bold>b</bold>, Insulation scores at TAD borders for maternal nuclei. <bold>c</bold>, Average contact probability P<sub>c</sub>(s) curves for control (WT), <italic>Wapl</italic><sup><italic>&#x394;</italic></sup> and <italic>Wapl</italic><sup><italic>&#x394;</italic></sup>&#xA0;+&#xA0;MCM loss, shown separately for maternal and paternal nuclei. <bold>d</bold>, P<sub>c</sub>(s) curves for individual samples (maternal and paternal pronuclei) with average P<sub>c</sub>(s) (same as in panel c) in bold overlaid. <bold>e</bold>, Matrix of peak strengths, generated by polymer simulations, showing a linear trade-off between the MCM density and its ability to pause cohesins in <italic>Wapl</italic><sup><italic>&#x394;</italic></sup>. <bold>f</bold>&#x2013;<bold>g</bold>, Simulated contact probability decay curve P<sub>c</sub>(s) for WT (<bold>f</bold>), <italic>Wapl</italic><sup><italic>&#x394;</italic></sup> (<bold>g</bold>) and <italic>Wapl</italic><sup><italic>&#x394;</italic></sup>&#xA0;+&#xA0;MCM loss (<bold>h</bold>). The simulated P<sub>c</sub>(s) curve is well matched with the experimental data.</p></caption><graphic position="anchor" xlink:href="41586_2022_4730_Fig10_ESM" id="d32e2942"/></fig>
</p>
          <p id="Par84">
<fig id="Fig11"><label>Extended Data Fig. 7</label><caption><title>Moderate increase in aggregate peak strength after acute depletion of MCM in HCT116 cells using Hi-C.</title><p><bold>a</bold>, Schematic for G1 synchronization of HCT116 MCM2-mAID cells. <bold>b</bold>, Cell cycle profiles of asynchronous and G1-synchronized (Control/MCM depletion) HCT116 MCM2-mAID cells. <bold>c</bold>, Immunoblotting analysis of whole-cell lysate (W), supernatant (S) and chromatin (C) fraction for MCM2, MCM4, GAPDH and H3 from G1-synchronized HCT116 MCM2-mAID cells treated with DMSO (Control) or auxin (MCM depletion). GAPDH and H3 are used as loading controls for supernatant and chromatin fraction, respectively. Uncropped blots are displayed in&#xA0;<xref rid="MOESM1" ref-type="media">Supplementary Fig. 1</xref>. This experiment was repeated independently three more times with similar results. <bold>d</bold>, Hi-C contact matrices for control and MCM depletion conditions for the region 112,5-117,6 Mb on chromosome 12 at 10&#x2009;kb resolution. Increased corner peaks are denoted with an arrow. CTCF sites are depicted above the contact matrices. <bold>e</bold>, Average of total contact frequency for loops and TADs in aggregate peak and TAD analysis for control and MCM-depleted cells. <bold>f</bold>, Contact probability P<sub>c</sub>(s) curves for control and MCM depletion conditions. <bold>g</bold>, Insulation scores at TAD borders for control and MCM-depleted cells. Read statistics for Hi-C replicates can be found in&#xA0;<xref rid="MOESM4" ref-type="media">Supplementary Table 1</xref>.</p></caption><graphic position="anchor" xlink:href="41586_2022_4730_Fig11_ESM" id="d32e2986"/></fig>
</p>
          <p id="Par85">
<fig id="Fig12"><label>Extended Data Fig. 8</label><caption><title>Micro-C reveals a genome-wide increase in peak strength and in de novo loop number after acute depletion of MCM2 in HCT116 cells.</title><p><bold>a</bold>, Schematic for G1 synchronization of HCT116 MCM2-mAID cells before G1 FACs sorting. <bold>b</bold>, FACS-analysis of synchronized HCT116 MCM2-mAID cells. Only cells in the left part of the G1 peak were sorted and collected for Micro-C and RNA-seq to avoid contamination of S-phase cells (red dashed box). <bold>c</bold>,&#xA0;Immunoblotting analysis of whole-cell lysate (W), supernatant (S) and chromatin fraction (C) for MCM2, MCM4, CTCF, SCC1, PCNA, GAPDH and H3 from asynchronous and G1-sorted HCT116 MCM2-mAID cells treated with DMSO (Control) or auxin (MCM depletion). GAPDH and H3 are used as loading controls for the supernatant and chromatin fraction, respectively. Uncropped blots are displayed in&#xA0;<xref rid="MOESM1" ref-type="media">Supplementary Fig. 1</xref>. This experiment was repeated independently one more time with similar results. <bold>d</bold>, Micro-C contact matrices for the region 57 - 58.5 Mb on chromosome 15 at 10&#x2009;kb resolution in control vs MCM-depleted cells. <bold>e</bold>, P<sub>c</sub>(s) curves for control and MCM depletion conditions. <bold>f</bold>, Insulation scores at TAD borders for control and MCM-depleted cells. <bold>g</bold>, Average of the total contact frequency of loops in an aggregate peak analysis for two independent Micro-C replicates (middle and lower panel) and pooled dataset (upper panel) in control and MCM-depleted cells. <bold>h</bold>, Peak strengths for control and MCM-depleted cells over a range of genomic distances. <bold>i</bold>, Histogram showing the distribution of log<sub>2</sub> ratio of peak strengths in MCM-depleted and control cells within 1&#x2009;Mb bins across the whole genome, normalized to global and local background of interactions. Higher values indicate increase of peak strength after MCM depletion. Mean of the distribution is highly significantly different from 0 (one sample <italic>t</italic>-test), <italic>P</italic>&#x2009;=&#x2009;1.87&#x2009;&#xD7;&#x2009;10<sup>&#x2212;70</sup>. <bold>j</bold>, de novo called loops using Mustache over a range of genomic distances in control and MCM-depleted cells. <bold>k</bold>, Number of de novo loops (called with Mustache) in independent Hi-C and Micro-C experiments. All replicates were downsampled to 300 million total contacts. <bold>l</bold>, Volcano plot showing statistical significance &#x2013;log<sub>10</sub> (FDR) versus fold change (log<sub>2</sub> fold change) for RNA-seq data between MCM2-mAID expressing HCT116 cells treated with DMSO (Control) or auxin (MCM depletion). Numbers indicate the number of transcripts significantly up- (right) or downregulated (left) after MCM depletion at FDR&#x2009;=&#x2009;0.1. Dashed vertical lines indicate &#x2212;0.585 and +0.585 log<sub>2</sub> fold change in expression (1.5-fold decrease and increase in expression), respectively. RNA-seq libraries were generated in triplicate (independent replicates). <bold>m</bold>, Correlation between gene expression changes and relative change in chromatin contact frequencies around the transcriptional start sites (TSSs) after MCM loss. All mean contact frequency changes were tested against the non-DE TSS control using the non-parametric Kruskal-Wallis test followed by pairwise Wilcoxon (Mann-Whitney <italic>U</italic>) test. <bold>n</bold>, Immunoblotting analysis of whole-cell lysate (W), supernatant (S) and chromatin fraction (C) from asynchronous and G1-sorted HCT116 MCM2-mAID cells treated with triptolide (chromatin-bound RNA PolII degradation) and either DMSO (Control) or auxin (MCM depletion). H3 is used as loading control for the chromatin fraction. Uncropped blots are displayed in&#xA0;<xref rid="MOESM1" ref-type="media">Supplementary Fig. 1</xref>. This experiment was repeated independently one more time with similar results. <bold>o</bold>, Peak strengths for control, MCM-depleted, triptolide-treated (DMSO/trp) and triptolide-treated/MCM-depleted (MCM depletion/trp) cells over a range of genomic distances. Notes: Micro-C datasets (control/MCM depletion) are pooled replicates from two biologically independent Micro-C experiments, unless otherwise stated. Read statistics for Hi-C and Micro-C replicates can be found in&#xA0;<xref rid="MOESM4" ref-type="media">Supplementary Table 1</xref>.</p></caption><graphic position="anchor" xlink:href="41586_2022_4730_Fig12_ESM" id="d32e3084"/></fig>
</p>
          <p id="Par86">
<fig id="Fig13"><label>Extended Data Fig. 9</label><caption><title>Translocating cohesin can bypass MCM with reduced efficiency.</title><p><bold>a</bold>, MCM loads as double-hexamers at origins. Time traces of origin-bound MCM fluorescence intensity (purple) show two-step bleaching but less frequent also one and multi-step (black, fits by kinetic change point analysis) <bold>b</bold>, Representative kymograph of translocating cohesin in the absence of MCM at the origin. <bold>c</bold>, MCM does not alter observed cohesin translocation velocity. Box plots of cohesin diffusion coefficients in the absence (green) or presence (blue) of MCM at 150 or 500&#x2009;mM NaCl. The centre line displays median, box edges show quartiles 1&#x2013;3, and whiskers span quartiles 1&#x2013;3&#x2009;&#xB1;&#x2009;1.5&#x2009;&#xD7;&#x2009;interquartile range. <italic>P</italic> values were determined by two-sided Mann-Whitney <italic>U</italic> test. <bold>d</bold>, <bold>e</bold>, Representative kymographs of translocating cohesin in the presence of MCM at the origin. MCM is a&#xA0;strong barrier for cohesin translocation (<bold>d</bold>) with MCM passage observed infrequently (<bold>e</bold>) during a 220&#x2009;s interval. <bold>f</bold>, Multiple loaded MCMs do not increase the barrier strength for cohesin translocation. Photobleaching analysis confirm loaded MCM double-hexamers as main species. Data are depicted as mean within a 95 % confidence interval (generated by bootstrapping). <italic>P</italic> values were determined by Kruskal-Wallis test. <bold>g</bold>, Length distribution of doubly tethered DNA in pixels (px). The line represents a Gaussian fit. <bold>h</bold>, Cohesin translocation pauses at origins bound by MCM. Distribution of cohesin pause (green) and corresponding MCM (blue) positions on DNA. <bold>i</bold>, Representative kymographs of translocating cohesin showing frequent pausing after encountering MCM<sup>Mcm3-YDF</sup> at the origin. All data displayed (except in <bold>e</bold> and where specified in <bold>c</bold>) were imaged under physiological salt conditions (0.15&#x2009;M NaCl).</p></caption><graphic position="anchor" xlink:href="41586_2022_4730_Fig13_ESM" id="d32e3150"/></fig>
</p>
          <p id="Par87">
<fig id="Fig14"><label>Extended Data Fig. 10</label><caption><title>MCM is a barrier for cohesin translocation at a high salt concentration.</title><p><bold>a</bold>, Schematic principle of a single-molecule cohesin translocation assay on licensed DNA. MCM is loaded onto DNA in the&#xA0;presence of the licensing factors ORC and Cdc6, followed by cohesin as described in Fig. <xref rid="Fig4" ref-type="fig">4a</xref>. Subsequently, cohesin translocation is visualized at high salt concentration (0.5&#x2009;M NaCl) in the&#xA0;absence of free protein and buffer flow. <bold>b</bold>&#x2013;<bold>d</bold>, Representative kymographs of translocating cohesin on DNA in the absence (<bold>b</bold>) or presence of MCM at the origin (<bold>c</bold>, <bold>d</bold>). Origin-bound MCM is a strong barrier to cohesin translocation (<bold>c</bold>) with passage events occurring infrequently (<bold>d</bold>) during a 220&#x2009;s observation interval. <bold>e</bold>, MCM is a barrier for cohesin translocation at high salt concentration. Probability of translocating cohesin bypassing the origin in the absence or presence of MCM calculated from 40 or 64 molecules with 7802 or 9829 visualized encounters, respectively. <bold>f</bold>, Multiple loaded MCMs do not increase the barrier strength for cohesin translocation. Data in <bold>e</bold>, <bold>f</bold> are depicted as mean within a 95 % confidence interval (generated by bootstrapping). <italic>P values</italic> were determined by Kruskal-Wallis followed by Dunn&#x2019;s post-hoc test. All data displayed were imaged in the presence of 0.5&#x2009;M NaCl. <bold>g</bold>, Model showing that pausing of extruding cohesin at MCMs could promote sister-chromatid cohesion.</p></caption><graphic position="anchor" xlink:href="41586_2022_4730_Fig14_ESM" id="d32e3210"/></fig>
</p>
        </sec>
      </app>
    </app-group>
    <fn-group>
      <fn>
        <p><bold>Publisher&#x2019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>These authors contributed equally: Bart J. H. Dequeker, Matthias J. Scherr</p>
      </fn>
    </fn-group>
    <sec>
      <title>Extended data</title>
      <p>is available for this paper at 10.1038/s41586-022-04730-0.</p>
    </sec>
    <sec>
      <title>Supplementary information</title>
      <p>The online version contains supplementary material available at 10.1038/s41586-022-04730-0.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank M. S. Bartolomei for the <italic>(Tg)Zp3-dsCTCF</italic> mouse strain; M.&#xA0;T. Kanemaki for the <italic>MCM2-mAID</italic> HCT116 cell line; the D.&#xA0;Remus laboratory for generating the ySA4 MCM strain that was used in vitro single-molecule assays; Z. Lygerou for sharing the geminin(L26A)-GFP plasmid; U. Cramer and R. Hornberger for technical assistance in generating the MCM3&#x2013;YDF yeast strains; and H. C. Theu&#xDF;l and J. R. Wojciechowski for reviving <italic>(Tg)Zp3-dsCTCF</italic> embryos. Illumina sequencing was performed at the VBCF NGS unit and the MPIB NGS core facility (<ext-link ext-link-type="uri" xlink:href="http://www.vbcf.ac.at">http://www.vbcf.ac.at</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.biochem.mpg.de/7076201/NGS">https://www.biochem.mpg.de/7076201/NGS</ext-link>). B.J.H.D. is funded by the PhD program (DK) Chromosome Dynamics (W1238-B20), supported by the Austrian Science Fund (FWF). L.A.M. and H.B.B. acknowledge support from the National Institutes of Health Common Fund 4D Nucleome Program (DK107980) and the Human Frontier Science Program (HFSP RGP0057/2018). I.M.F. is supported by a Medical Research Council UK University Unit grant (MC_UU_00007/2). Research in the K.E.D. laboratory is supported by the European Research Council (ERC; ERC-StG-804098 ReplisomeBypass), the German Research Foundation (DFG, SFB863-111166240) and the Max Planck Society. Research in the J.-M.P. laboratory is supported by Boehringer Ingelheim, the Austrian Research Promotion Agency (Headquarter grant FFG-878286), the ERC (grant agreement no. 693949 and 101020558), HFSP (RGP0057/2018) and the Vienna Science and Technology Fund (grant LS19-029). Research in the K.T. laboratory is supported by the ERC (ERC-CoG-818556 TotipotentZygotChrom), HFSP (RGP0057/2018), the Herzfelder Foundation and FWF (P30613-B21), the Austrian Academy of Sciences and the Max Planck Society.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>K.T. conceived the project. B.J.H.D. supervised by K.T. performed snHi-C, Hi-C, Micro-C, RNA-seq and imaging experiments. H.B.B. developed and performed snHi-C data analysis and polymer simulations with L.A.M. M.J.S. supervised by K.E.D. performed single-molecule imaging and analysis. J.G. performed snHi-C and imaging experiments. S.P. performed snHi-C data analysis and RNA-seq analysis. I.G. performed RNA-seq analysis&#xA0;and contributed to imaging analysis.&#xA0;A.L. performed Micro-C experiments. J.G., S.P., I.G. and A.L. were supervised by K.T.&#xA0;I.M.F. performed Hi-C and Micro-C analysis. I.F.D. purified recombinant cohesin<sup>STAG1, SCC1-Halo</sup>.&#xA0;W.T. contributed to development of cell lines and R.S. to bioinformatic analyses. I.F.D.,&#xA0;W.T. and&#xA0;R.S. were supervised by J.-M.P. B.J.H.D., H.B.B., M.J.S., I.M.F. and I.G. prepared the figures. B.J.H.D., H.B.B., M.J.S., I.G., K.E.D., L.A.M. and K.T. wrote the manuscript with input from all authors.</p>
    </notes>
    <notes notes-type="peer-review">
      <title>Peer review</title>
      <sec id="FPar1">
        <title>Peer review information</title>
        <p id="Par76"><italic>Nature</italic> thanks the anonymous reviewers for their contribution to the peer review of this work.&#xA0;<xref rid="MOESM3" ref-type="media">Peer reviewer reports</xref> are available.</p>
      </sec>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>Open access funding provided by Max Planck Society.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>All sequencing data in support of the findings of this study have been deposited in the Gene Expression Omnibus (GEO) under the series accession numbers <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE196497">GSE196497</ext-link> (snHi-C and RNA-seq) and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE155971">GSE155971</ext-link> (Hi-C and Micro-C). The single-molecule video datasets supporting the findings in this study have been deposited at Zenodo with the following: 10.5281/zenodo.5911106 (high-salt experiments), 10.5281/zenodo.5911210 (physiological salt experiments) and 10.5281/zenodo.5911284 (YDF experiments). All data are also available from the authors upon request.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Code availability</title>
      <p>The snHi-C and single-molecule processing scripts are deposited at Zenodo under 10.5281/zenodo.5906351 and 10.5281/zenodo.5911644, respectively. The simulation codes are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/mirnylab/MCMs-as-random-barriers-to-loop-extrusion-paper">https://github.com/mirnylab/MCMs-as-random-barriers-to-loop-extrusion-paper</ext-link>.</p>
    </notes>
    <notes id="FPar2" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par77">The authors declare no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nora</surname>
              <given-names>EP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Spatial partitioning of the regulatory landscape of the X-inactivation centre</article-title>
          <source>Nature</source>
          <year>2012</year>
          <volume>485</volume>
          <fpage>381</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="doi">10.1038/nature11049</pub-id>
          <pub-id pub-id-type="pmid">22495304</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dixon</surname>
              <given-names>JR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Topological domains in mammalian genomes identified by analysis of chromatin interactions</article-title>
          <source>Nature</source>
          <year>2012</year>
          <volume>485</volume>
          <fpage>376</fpage>
          <lpage>380</lpage>
          <pub-id pub-id-type="doi">10.1038/nature11082</pub-id>
          <pub-id pub-id-type="pmid">22495300</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rao</surname>
              <given-names>SSP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping</article-title>
          <source>Cell</source>
          <year>2014</year>
          <volume>159</volume>
          <fpage>1665</fpage>
          <lpage>1680</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2014.11.021</pub-id>
          <pub-id pub-id-type="pmid">25497547</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuartero</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Control of inducible gene expression links cohesin to hematopoietic progenitor self-renewal and differentiation</article-title>
          <source>Nat. Immunol.</source>
          <year>2018</year>
          <volume>19</volume>
          <fpage>932</fpage>
          <lpage>941</lpage>
          <pub-id pub-id-type="doi">10.1038/s41590-018-0184-1</pub-id>
          <pub-id pub-id-type="pmid">30127433</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The fundamental role of chromatin loop extrusion in physiological V(D)J recombination</article-title>
          <source>Nature</source>
          <year>2019</year>
          <volume>573</volume>
          <fpage>600</fpage>
          <lpage>604</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-019-1547-y</pub-id>
          <pub-id pub-id-type="pmid">31511698</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davidson</surname>
              <given-names>IF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>DNA loop extrusion by human cohesin</article-title>
          <source>Science</source>
          <year>2019</year>
          <volume>366</volume>
          <fpage>1338</fpage>
          <lpage>1345</lpage>
          <pub-id pub-id-type="doi">10.1126/science.aaz3418</pub-id>
          <pub-id pub-id-type="pmid">31753851</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Finkelstein</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Human cohesin compacts DNA by loop extrusion</article-title>
          <source>Science</source>
          <year>2019</year>
          <volume>366</volume>
          <fpage>1345</fpage>
          <lpage>1349</lpage>
          <pub-id pub-id-type="doi">10.1126/science.aaz4475</pub-id>
          <pub-id pub-id-type="pmid">31780627</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Golfier</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Quail</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Brugu&#xE9;s</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Cohesin and condensin extrude DNA loops in a cell cycle-dependent manner</article-title>
          <source>eLife</source>
          <year>2020</year>
          <volume>9</volume>
          <fpage>e53885</fpage>
          <pub-id pub-id-type="doi">10.7554/eLife.53885</pub-id>
          <pub-id pub-id-type="pmid">32396063</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alipour</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Marko</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Self-organization of domain structures by DNA-loop-extruding enzymes</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2012</year>
          <volume>40</volume>
          <fpage>11202</fpage>
          <lpage>11212</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gks925</pub-id>
          <pub-id pub-id-type="pmid">23074191</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanborn</surname>
              <given-names>AL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chromatin extrusion explains key features of loop and domain formation in wild-type and engineered genomes</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <year>2015</year>
          <volume>112</volume>
          <fpage>E6456</fpage>
          <lpage>E6465</lpage>
          <pub-id pub-id-type="pmid">26499245</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fudenberg</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Formation of chromosomal domains by loop extrusion</article-title>
          <source>Cell Rep.</source>
          <year>2016</year>
          <volume>15</volume>
          <fpage>2038</fpage>
          <lpage>2049</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.085</pub-id>
          <pub-id pub-id-type="pmid">27210764</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hansen</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>CTCF as a boundary factor for cohesin-mediated loop extrusion: evidence for a multi-step mechanism</article-title>
          <source>Nucleus</source>
          <year>2020</year>
          <volume>11</volume>
          <fpage>132</fpage>
          <lpage>148</lpage>
          <pub-id pub-id-type="doi">10.1080/19491034.2020.1782024</pub-id>
          <pub-id pub-id-type="pmid">32631111</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davidson</surname>
              <given-names>IF</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>J-M</given-names>
            </name>
          </person-group>
          <article-title>Genome folding through loop extrusion by SMC complexes</article-title>
          <source>Nat. Rev. Mol. Cell Biol.</source>
          <year>2021</year>
          <volume>22</volume>
          <fpage>445</fpage>
          <lpage>464</lpage>
          <pub-id pub-id-type="doi">10.1038/s41580-021-00349-7</pub-id>
          <pub-id pub-id-type="pmid">33767413</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nora</surname>
              <given-names>EP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Targeted degradation of CTCF decouples local insulation of chromosome domains from genomic compartmentalization</article-title>
          <source>Cell</source>
          <year>2017</year>
          <volume>169</volume>
          <fpage>930</fpage>
          <lpage>944</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2017.05.004</pub-id>
          <pub-id pub-id-type="pmid">28525758</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brand&#xE3;o</surname>
              <given-names>HB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>RNA polymerases as moving barriers to condensin loop extrusion</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <year>2019</year>
          <volume>116</volume>
          <fpage>20489</fpage>
          <lpage>20499</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1907009116</pub-id>
          <pub-id pub-id-type="pmid">31548377</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heinz</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transcription elongation can affect genome 3D structure</article-title>
          <source>Cell</source>
          <year>2018</year>
          <volume>174</volume>
          <fpage>1522</fpage>
          <lpage>1536</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2018.07.047</pub-id>
          <pub-id pub-id-type="pmid">30146161</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Busslinger</surname>
              <given-names>GA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cohesin is positioned in mammalian genomes by transcription, CTCF and Wapl</article-title>
          <source>Nature</source>
          <year>2017</year>
          <volume>460</volume>
          <fpage>410</fpage>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deegan</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Diffley</surname>
              <given-names>JFX</given-names>
            </name>
          </person-group>
          <article-title>MCM: one ring to rule them all</article-title>
          <source>Curr. Opin. Struct. Biol.</source>
          <year>2016</year>
          <volume>37</volume>
          <fpage>145</fpage>
          <lpage>151</lpage>
          <pub-id pub-id-type="doi">10.1016/j.sbi.2016.01.014</pub-id>
          <pub-id pub-id-type="pmid">26866665</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hyrien</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>How MCM loading and spreading specify eukaryotic DNA replication initiation sites</article-title>
          <source>F1000Res.</source>
          <year>2016</year>
          <volume>5</volume>
          <fpage>2063</fpage>
          <pub-id pub-id-type="doi">10.12688/f1000research.9008.1</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Remus</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Diffley</surname>
              <given-names>JFX</given-names>
            </name>
          </person-group>
          <article-title>Eukaryotic DNA replication control: lock and load, then fire</article-title>
          <source>Curr. Opin. Cell Biol.</source>
          <year>2009</year>
          <volume>21</volume>
          <fpage>771</fpage>
          <lpage>777</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ceb.2009.08.002</pub-id>
          <pub-id pub-id-type="pmid">19767190</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Das</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pradhan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Narayan</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>MCM paradox: abundance of eukaryotic replicative helicases and genomic integrity</article-title>
          <source>Mol. Biol. Int.</source>
          <year>2014</year>
          <volume>2014</volume>
          <fpage>574850</fpage>
          <pub-id pub-id-type="doi">10.1155/2014/574850</pub-id>
          <pub-id pub-id-type="pmid">25386362</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ibarra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schwob</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>M&#xE9;ndez</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <year>2008</year>
          <volume>105</volume>
          <fpage>8956</fpage>
          <lpage>8961</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0803978105</pub-id>
          <pub-id pub-id-type="pmid">18579778</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sedlackova</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Equilibrium between nascent and parental MCM proteins protects replicating genomes</article-title>
          <source>Nature</source>
          <year>2020</year>
          <volume>587</volume>
          <fpage>297</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-020-2842-3</pub-id>
          <pub-id pub-id-type="pmid">33087936</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuipers</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Highly stable loading of Mcm proteins onto chromatin in living cells requires replication to unload</article-title>
          <source>J. Cell Biol.</source>
          <year>2011</year>
          <volume>192</volume>
          <fpage>29</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.201007111</pub-id>
          <pub-id pub-id-type="pmid">21220507</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structure of the eukaryotic MCM complex at 3.8 &#xC5;</article-title>
          <source>Nature</source>
          <year>2015</year>
          <volume>524</volume>
          <fpage>186</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="doi">10.1038/nature14685</pub-id>
          <pub-id pub-id-type="pmid">26222030</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stigler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>&#xC7;amdere</surname>
              <given-names>G&#xD6;</given-names>
            </name>
            <name>
              <surname>Koshland</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
          <article-title>Single-molecule imaging reveals a collapsed conformational state for DNA-bound cohesin</article-title>
          <source>Cell Rep.</source>
          <year>2016</year>
          <volume>15</volume>
          <fpage>988</fpage>
          <lpage>998</lpage>
          <pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.003</pub-id>
          <pub-id pub-id-type="pmid">27117417</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gassler</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A mechanism of cohesin-dependent loop extrusion organizes zygotic genome architecture</article-title>
          <source>EMBO J.</source>
          <year>2017</year>
          <volume>36</volume>
          <fpage>3600</fpage>
          <lpage>3618</lpage>
          <pub-id pub-id-type="doi">10.15252/embj.201798083</pub-id>
          <pub-id pub-id-type="pmid">29217590</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flyamer</surname>
              <given-names>IM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Single-nucleus Hi-C reveals unique chromatin reorganization at oocyte-to-zygote transition</article-title>
          <source>Nature</source>
          <year>2017</year>
          <volume>544</volume>
          <fpage>110</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="doi">10.1038/nature21711</pub-id>
          <pub-id pub-id-type="pmid">28355183</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aoki</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Worrad</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Regulation of transcriptional activity during the first and second cell cycles in the preimplantation mouse embryo</article-title>
          <source>Dev. Biol.</source>
          <year>1997</year>
          <volume>181</volume>
          <fpage>296</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="doi">10.1006/dbio.1996.8466</pub-id>
          <pub-id pub-id-type="pmid">9013938</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McGarry</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Kirschner</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Geminin, an inhibitor of DNA replication, is degraded during mitosis</article-title>
          <source>Cell</source>
          <year>1998</year>
          <volume>93</volume>
          <fpage>1043</fpage>
          <lpage>1053</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81209-X</pub-id>
          <pub-id pub-id-type="pmid">9635433</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wohlschlegel</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of eukaryotic DNA replication by geminin binding to Cdt1</article-title>
          <source>Science</source>
          <year>2000</year>
          <volume>290</volume>
          <fpage>2309</fpage>
          <lpage>2312</lpage>
          <pub-id pub-id-type="doi">10.1126/science.290.5500.2309</pub-id>
          <pub-id pub-id-type="pmid">11125146</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Silva</surname>
              <given-names>MCC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Wapl releases Scc1-cohesin and regulates chromosome structure and segregation in mouse oocytes</article-title>
          <source>J. Cell Biol.</source>
          <year>2020</year>
          <volume>219</volume>
          <fpage>e201906100</fpage>
          <pub-id pub-id-type="doi">10.1083/jcb.201906100</pub-id>
          <pub-id pub-id-type="pmid">32328639</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ladst&#xE4;tter</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tachibana-Konwalski</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>A surveillance mechanism ensures repair of DNA lesions during zygotic reprogramming</article-title>
          <source>Cell</source>
          <year>2016</year>
          <volume>167</volume>
          <fpage>1774</fpage>
          <lpage>1787</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2016.11.009</pub-id>
          <pub-id pub-id-type="pmid">27916276</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wutz</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Topologically associating domains and chromatin loops depend on cohesin and are regulated by CTCF, WAPL, and PDS5 proteins</article-title>
          <source>EMBO J.</source>
          <year>2017</year>
          <volume>36</volume>
          <fpage>3573</fpage>
          <lpage>3599</lpage>
          <pub-id pub-id-type="doi">10.15252/embj.201798004</pub-id>
          <pub-id pub-id-type="pmid">29217591</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wan</surname>
              <given-names>L-B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Maternal depletion of CTCF reveals multiple functions during oocyte and preimplantation embryo development</article-title>
          <source>Development</source>
          <year>2008</year>
          <volume>135</volume>
          <fpage>2729</fpage>
          <lpage>2738</lpage>
          <pub-id pub-id-type="doi">10.1242/dev.024539</pub-id>
          <pub-id pub-id-type="pmid">18614575</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genome-wide mapping of human DNA replication by optical replication mapping supports a stochastic model of eukaryotic replication</article-title>
          <source>Mol. Cell</source>
          <year>2021</year>
          <volume>81</volume>
          <fpage>2975</fpage>
          <lpage>2988</lpage>
          <pub-id pub-id-type="doi">10.1016/j.molcel.2021.05.024</pub-id>
          <pub-id pub-id-type="pmid">34157308</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haarhuis</surname>
              <given-names>JHI</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The cohesin release factor WAPL restricts chromatin loop extension</article-title>
          <source>Cell</source>
          <year>2017</year>
          <volume>169</volume>
          <fpage>693</fpage>
          <lpage>707</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2017.04.013</pub-id>
          <pub-id pub-id-type="pmid">28475897</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hansen</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Pustova</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Cattoglio</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tjian</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Darzacq</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>CTCF and cohesin regulate chromatin loop stability with distinct dynamics</article-title>
          <source>eLife</source>
          <year>2017</year>
          <volume>6</volume>
          <fpage>2848</fpage>
          <pub-id pub-id-type="doi">10.7554/eLife.25776</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Banigan</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>van den Berg</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Brand&#xE3;o</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Marko</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Mirny</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Chromosome organization by one-sided and two-sided loop extrusion</article-title>
          <source>eLife</source>
          <year>2020</year>
          <volume>9</volume>
          <fpage>e53558</fpage>
          <pub-id pub-id-type="doi">10.7554/eLife.53558</pub-id>
          <pub-id pub-id-type="pmid">32250245</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Natsume</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute inactivation of the replicative helicase in human cells triggers MCM8-9-dependent DNA synthesis</article-title>
          <source>Genes Dev.</source>
          <year>2017</year>
          <volume>31</volume>
          <fpage>816</fpage>
          <lpage>829</lpage>
          <pub-id pub-id-type="doi">10.1101/gad.297663.117</pub-id>
          <pub-id pub-id-type="pmid">28487407</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Remus</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Concerted loading of MCM2&#x2013;7 double hexamers around DNA during DNA replication origin licensing</article-title>
          <source>Cell</source>
          <year>2009</year>
          <volume>139</volume>
          <fpage>719</fpage>
          <lpage>730</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2009.10.015</pub-id>
          <pub-id pub-id-type="pmid">19896182</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evrin</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A double-hexameric MCM2&#x2013;7 complex is loaded onto origin DNA during licensing of eukaryotic DNA replication</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <year>2009</year>
          <volume>106</volume>
          <fpage>20240</fpage>
          <lpage>20245</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0911500106</pub-id>
          <pub-id pub-id-type="pmid">19910535</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <mixed-citation publication-type="other">Scherr, M. J., Abd Wahab, S., Remus, D. &amp; Duderstadt, K. E. Mobile origin-licensing factors confer resistance to conflicts with RNA polymerase. <italic>Cell Rep.</italic><bold>38</bold>, 110531 (2022).</mixed-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The structural basis for cohesin&#x2013;CTCF-anchored loops</article-title>
          <source>Nature</source>
          <year>2020</year>
          <volume>578</volume>
          <fpage>472</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="doi">10.1038/s41586-019-1910-z</pub-id>
          <pub-id pub-id-type="pmid">31905366</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <mixed-citation publication-type="other">Pradhan, B. et al. SMC complexes can traverse physical roadblocks bigger than their ring size. Preprint at <italic>bioRxiv</italic>10.1101/2021.07.15.452501 (2021).</mixed-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bauer</surname>
              <given-names>BW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cohesin mediates DNA loop extrusion by a &#x201C;swing and clamp&#x201D; mechanism</article-title>
          <source>Cell</source>
          <year>2021</year>
          <volume>184</volume>
          <fpage>5448</fpage>
          <lpage>5464</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2021.09.016</pub-id>
          <pub-id pub-id-type="pmid">34624221</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chatzidaki</surname>
              <given-names>EE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ovulation suppression protects against chromosomal abnormalities in mouse eggs at advanced maternal age</article-title>
          <source>Curr. Biol.</source>
          <year>2021</year>
          <volume>31</volume>
          <fpage>4038</fpage>
          <lpage>4051</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cub.2021.06.076</pub-id>
          <pub-id pub-id-type="pmid">34314679</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takahashi</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Yiu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Gygi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Walter</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Recruitment of <italic>Xenopus</italic> Scc2 and cohesin to chromatin requires the pre-replication complex</article-title>
          <source>Nat. Cell Biol.</source>
          <year>2004</year>
          <volume>6</volume>
          <fpage>991</fpage>
          <lpage>996</lpage>
          <pub-id pub-id-type="doi">10.1038/ncb1177</pub-id>
          <pub-id pub-id-type="pmid">15448702</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gillespie</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Scc2 couples replication licensing to sister chromatid cohesion in <italic>Xenopus</italic> egg extracts</article-title>
          <source>Curr. Biol.</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>1598</fpage>
          <lpage>1603</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cub.2004.07.053</pub-id>
          <pub-id pub-id-type="pmid">15341749</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kanchwala</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>MCM2&#x2013;7-dependent cohesin loading during S phase promotes sister-chromatid cohesion</article-title>
          <source>eLife</source>
          <year>2018</year>
          <volume>7</volume>
          <fpage>9906</fpage>
          <pub-id pub-id-type="doi">10.7554/eLife.33920</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <mixed-citation publication-type="other">Liu, Y. &amp; Dekker, J. Biochemically distinct cohesin complexes mediate positioned loops between CTCF sites and dynamic loops within chromatin domains. Preprint at <italic>bioRxiv</italic>10.1101/2021.08.24.457555 (2021).</mixed-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hug</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Grimaldi</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Kruse</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vaquerizas</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Chromatin architecture emerges during zygotic genome activation independent of transcription</article-title>
          <source>Cell</source>
          <year>2017</year>
          <volume>169</volume>
          <fpage>216</fpage>
          <lpage>2289</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2017.03.024</pub-id>
          <pub-id pub-id-type="pmid">28388407</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Munnik</surname>
              <given-names>SA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Meier&#x2013;Gorlin syndrome genotype&#x2013;phenotype studies: 35 individuals with pre-replication complex gene mutations and 10 without molecular diagnosis</article-title>
          <source>Eur. J. Hum. Genet.</source>
          <year>2012</year>
          <volume>20</volume>
          <fpage>598</fpage>
          <lpage>606</lpage>
          <pub-id pub-id-type="doi">10.1038/ejhg.2011.269</pub-id>
          <pub-id pub-id-type="pmid">22333897</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lewandoski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wassarman</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>GR</given-names>
            </name>
          </person-group>
          <article-title><italic>Zp3-cre</italic>, a transgenic mouse line for the activation or inactivation of loxP-flanked target genes specifically in the female germ line</article-title>
          <source>Curr. Biol.</source>
          <year>1997</year>
          <volume>7</volume>
          <fpage>148</fpage>
          <lpage>151</lpage>
          <pub-id pub-id-type="doi">10.1016/S0960-9822(06)00059-5</pub-id>
          <pub-id pub-id-type="pmid">9016703</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <mixed-citation publication-type="other">Goloborodko, A. et al. mirnylab/distiller-nf: v0.3.3 10.5281/zenodo.3350937 (Zenodo, 2019).</mixed-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdennur</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mirny</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Cooler: scalable storage for Hi-C data and other genomically labeled arrays</article-title>
          <source>Bioinformatics</source>
          <year>2020</year>
          <volume>36</volume>
          <fpage>311</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/btz540</pub-id>
          <pub-id pub-id-type="pmid">31290943</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerpedjiev</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HiGlass: web-based visual exploration and analysis of genome interaction maps</article-title>
          <source>Genome Biol.</source>
          <year>2018</year>
          <volume>19</volume>
          <fpage>125</fpage>
          <pub-id pub-id-type="doi">10.1186/s13059-018-1486-1</pub-id>
          <pub-id pub-id-type="pmid">30143029</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <mixed-citation publication-type="other">Venev, S. et al. mirnylab/cooltools: v0.3.2 10.5281/zenodo.3787004 (Zenodo, 2020).</mixed-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matthey-Doret</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Computer vision for pattern detection in chromosome contact maps</article-title>
          <source>Nat. Commun.</source>
          <year>2020</year>
          <volume>11</volume>
          <fpage>5795</fpage>
          <pub-id pub-id-type="doi">10.1038/s41467-020-19562-7</pub-id>
          <pub-id pub-id-type="pmid">33199682</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flyamer</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Illingworth</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Bickmore</surname>
              <given-names>WA</given-names>
            </name>
          </person-group>
          <article-title>Coolpup.py: versatile pile-up analysis of Hi-C data</article-title>
          <source>Bioinformatics</source>
          <year>2020</year>
          <volume>36</volume>
          <fpage>2980</fpage>
          <lpage>2985</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/btaa073</pub-id>
          <pub-id pub-id-type="pmid">32003791</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rao</surname>
              <given-names>SSP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cohesin loss eliminates all loop domains</article-title>
          <source>Cell</source>
          <year>2017</year>
          <volume>171</volume>
          <fpage>305</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2017.09.026</pub-id>
          <pub-id pub-id-type="pmid">28985562</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roayaei Ardakany</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gezer</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Lonardi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ay</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Mustache: multi-scale detection of chromatin loops from Hi-C and Micro-C maps using scale-space representation</article-title>
          <source>Genome Biol.</source>
          <year>2020</year>
          <volume>21</volume>
          <fpage>256</fpage>
          <pub-id pub-id-type="doi">10.1186/s13059-020-02167-0</pub-id>
          <pub-id pub-id-type="pmid">32998764</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boom</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rapid and simple method for purification of nucleic acids</article-title>
          <source>J. Clin. Microbiol.</source>
          <year>1990</year>
          <volume>28</volume>
          <fpage>495</fpage>
          <lpage>503</lpage>
          <pub-id pub-id-type="doi">10.1128/jcm.28.3.495-503.1990</pub-id>
          <pub-id pub-id-type="pmid">1691208</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bray</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Pimentel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Melsted</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pachter</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Near-optimal probabilistic RNA-seq quantification</article-title>
          <source>Nat. Biotechnol.</source>
          <year>2016</year>
          <volume>34</volume>
          <fpage>525</fpage>
          <lpage>527</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id>
          <pub-id pub-id-type="pmid">27043002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xEA;</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Josse</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Husson</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>FactoMineR: an R package for multivariate analysis</article-title>
          <source>J. Stat. Soft.</source>
          <year>2008</year>
          <volume>25</volume>
          <fpage>1</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="doi">10.18637/jss.v025.i01</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <mixed-citation publication-type="other">Warnes, G. R. et al. gplots: various R programming tools for plotting data. R version 3.0. 1 <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=gplots">https://CRAN.R-project.org/package=gplots</ext-link> (2016).</mixed-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frigola</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Remus</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mehanna</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Diffley</surname>
              <given-names>JFX</given-names>
            </name>
          </person-group>
          <article-title>ATPase-dependent quality control of DNA replication origin licensing</article-title>
          <source>Nature</source>
          <year>2013</year>
          <volume>495</volume>
          <fpage>339</fpage>
          <lpage>343</lpage>
          <pub-id pub-id-type="doi">10.1038/nature11920</pub-id>
          <pub-id pub-id-type="pmid">23474987</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Golan</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>Site-specific protein labeling by Sfp phosphopantetheinyl transferase</article-title>
          <source>Nat. Protoc.</source>
          <year>2006</year>
          <volume>1</volume>
          <fpage>280</fpage>
          <lpage>285</lpage>
          <pub-id pub-id-type="doi">10.1038/nprot.2006.43</pub-id>
          <pub-id pub-id-type="pmid">17406245</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laughery</surname>
              <given-names>MF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>New vectors for simple and streamlined CRISPR&#x2013;Cas9 genome editing in <italic>Saccharomyces cerevisiae</italic>: vectors for simple CRISPR&#x2013;Cas9 genome editing in yeast</article-title>
          <source>Yeast</source>
          <year>2015</year>
          <volume>32</volume>
          <fpage>711</fpage>
          <lpage>720</lpage>
          <pub-id pub-id-type="doi">10.1002/yea.3098</pub-id>
          <pub-id pub-id-type="pmid">26305040</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larson</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Design and construction of a multiwavelength, micromirror total internal reflectance fluorescence microscope</article-title>
          <source>Nat. Protoc.</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>2317</fpage>
          <lpage>2328</lpage>
          <pub-id pub-id-type="doi">10.1038/nprot.2014.155</pub-id>
          <pub-id pub-id-type="pmid">25188633</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edelstein</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Amodaj</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hoover</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vale</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Stuurman</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Computer control of microscopes using &#xB5;Manager</article-title>
          <source>Curr. Protoc. Mol. Biol.</source>
          <year>2010</year>
          <volume>92</volume>
          <fpage>14.20.1</fpage>
          <lpage>14.20.17</lpage>
          <pub-id pub-id-type="doi">10.1002/0471142727.mb1420s92</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davidson</surname>
              <given-names>IF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rapid movement and transcriptional re-localization of human cohesin on DNA</article-title>
          <source>EMBO J.</source>
          <year>2016</year>
          <volume>35</volume>
          <fpage>2671</fpage>
          <lpage>2685</lpage>
          <pub-id pub-id-type="doi">10.15252/embj.201695402</pub-id>
          <pub-id pub-id-type="pmid">27799150</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aitken</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Puglisi</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>An oxygen scavenging system for improvement of dye stability in single-molecule fluorescence experiments</article-title>
          <source>Biophys. J.</source>
          <year>2008</year>
          <volume>94</volume>
          <fpage>1826</fpage>
          <lpage>1835</lpage>
          <pub-id pub-id-type="doi">10.1529/biophysj.107.117689</pub-id>
          <pub-id pub-id-type="pmid">17921203</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <mixed-citation publication-type="other">Huisjes, N. M. et al. Mars, a molecule archive suite for reproducible analysis and reporting of single molecule properties from bioimages. Preprint at <italic>bioRxiv</italic>10.1101/2021.11.26.470105 (2021).</mixed-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hill</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>van Oijen</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Duderstadt</surname>
              <given-names>KE</given-names>
            </name>
          </person-group>
          <article-title>Detection of kinetic change points in piece-wise linear single molecule motion</article-title>
          <source>J. Chem. Phys.</source>
          <year>2018</year>
          <volume>148</volume>
          <fpage>123317</fpage>
          <pub-id pub-id-type="doi">10.1063/1.5009387</pub-id>
          <pub-id pub-id-type="pmid">29604840</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Banigan</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Mirny</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Loop extrusion: theory meets single-molecule experiments</article-title>
          <source>Curr. Opin. Cell Biol.</source>
          <year>2020</year>
          <volume>64</volume>
          <fpage>124</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ceb.2020.04.011</pub-id>
          <pub-id pub-id-type="pmid">32534241</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kulak</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Pichler</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Paron</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Nagaraj</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells</article-title>
          <source>Nat. Meth.</source>
          <year>2014</year>
          <volume>11</volume>
          <fpage>319</fpage>
          <lpage>324</lpage>
          <pub-id pub-id-type="doi">10.1038/nmeth.2834</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dimitrova</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Todorov</surname>
              <given-names>IT</given-names>
            </name>
            <name>
              <surname>Melendy</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Mcm2, but not Rpa, is a component of the mammalian early G1-phase prereplication complex</article-title>
          <source>J. Cell Biol.</source>
          <year>1999</year>
          <volume>146</volume>
          <fpage>709</fpage>
          <lpage>722</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.146.4.709</pub-id>
          <pub-id pub-id-type="pmid">10459007</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landry</surname>
              <given-names>JJM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The genomic and transcriptomic landscape of a HeLa cell line</article-title>
          <source>G3</source>
          <year>2013</year>
          <volume>3</volume>
          <fpage>1213</fpage>
          <lpage>1224</lpage>
          <pub-id pub-id-type="doi">10.1534/g3.113.005777</pub-id>
          <pub-id pub-id-type="pmid">23550136</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
